<SEC-DOCUMENT>0001737287-21-000022.txt : 20210505
<SEC-HEADER>0001737287-21-000022.hdr.sgml : 20210505
<ACCEPTANCE-DATETIME>20210505162409
ACCESSION NUMBER:		0001737287-21-000022
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210505
DATE AS OF CHANGE:		20210505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Allogene Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001737287
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				823562771
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38693
		FILM NUMBER:		21893728

	BUSINESS ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 457-2700

	MAIL ADDRESS:	
		STREET 1:		210 EAST GRAND AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>allo-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:d318bd7c-046b-4e7c-95c7-84b602262a02,g:436096e2-f446-4eef-a0b1-f01b7434d186,d:82c49afd4bcb4a2a8da74edcf15bc0ac--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:allo="http://allogene.com/20210331" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>allo-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8yLTEtMS0xLTA_00d45b22-f53d-4aa0-803f-e8a4c537a591">12-31</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8yLTEtMS0xLTA_94131f6d-e9da-41a9-bce1-3f28dd05012d">12-31</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8zLTEtMS0xLTA_92a95488-ee28-4273-af91-fa7190cf50f2">false</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8zLTEtMS0xLTA_ddd3edfd-facd-4945-b691-9519e416b2b5">false</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF80LTEtMS0xLTA_c114de0c-1602-4a81-bed2-463b7bf9aa23">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF80LTEtMS0xLTA_c802cef4-c995-4e5d-ae20-df6094565f90">0001737287</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF81LTEtMS0xLTA_27b9d347-209a-4aeb-af2a-1967013d8464">2021</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF81LTEtMS0xLTA_89c67530-abb5-4d24-827d-a57bfb62153d">2021</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF82LTEtMS0xLTA_2f4120d1-b81a-4520-b677-442399bb581f">Q1</ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF82LTEtMS0xLTA_fd84fb26-42c8-4809-8680-880a4a306736">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181NS9mcmFnOjE3ZDY1M2Q3YzUxOTQyN2Q5YzY3ZTkzNjJmZmE0MjAwL3RhYmxlOmEzODUyMmE0YzNkOTRjZWFhYzY5M2U2ZTE4NzJmM2M5L3RhYmxlcmFuZ2U6YTM4NTIyYTRjM2Q5NGNlYWFjNjkzZTZlMTg3MmYzYzlfMC0wLTEtMS0w_0047954c-8fd9-4279-a19c-74e76903725e">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181NS9mcmFnOjE3ZDY1M2Q3YzUxOTQyN2Q5YzY3ZTkzNjJmZmE0MjAwL3RhYmxlOmEzODUyMmE0YzNkOTRjZWFhYzY5M2U2ZTE4NzJmM2M5L3RhYmxlcmFuZ2U6YTM4NTIyYTRjM2Q5NGNlYWFjNjkzZTZlMTg3MmYzYzlfMC0wLTEtMS0w_328b8780-37a1-4bd6-a6a6-cc1a590a826d">allo:AccruedAndOtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="allo-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8bb0ce173a264ffb98a91df551b8de22_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia39d6a89bb844679938131a4168a79f8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bc1f891fbe4441687ad896e3591b769_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i2011b80082724645a7f1440247f631ed_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d8d5d7cc5e4b369dc02b51cc31ba63_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if62b8835b5894a97961539f08038f95b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f14c477d6247bcb8b315bd0a71ca2b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i964ffbd064624356a2ce6298cdba096c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c89cfc2f1df420e80df10b19bb7045c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fe5f193450e4e168c14067f2f2d182e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90d14178c6914d93a889ac3ed04c02a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e5769ae558548b8b8db13dd5a510d74_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6562b41725243958717d88b90e4728a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad89e42e666e4c46b385e97bc6797118_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ccf8d124ff499fbbabad09739a47b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic054bea3b59344829df6ae5dc931c60b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i313259e23cfb4a2ab8bd19b643ad78ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f4a1b7bf0a947fb8b63dca9e112a72b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c3252db9b543d6a7491e001ef77b45_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacc623b05c8141db83c3d25a61bcb2cf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c2a96affa64584ab33e6e2aa1a077b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62bda789cb6d4921af13cb46113d49d7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i571a727871624fde93fb27f4e770e678_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i989fb3c13e4c463ca87f71c224b0cb1d_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d9397e7db24081a8cb1f7febad8dfb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef8c73e705a4baa9efc6f53a2920a77_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i504c57fff4964e769a633e05ed2a8d01_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i344a99f050b64372885525e2c3a160e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1b5c9589324b51a5ac5e3aa31ea60e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12fb68b0dae4f7a91f55375717a8a56_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i165eea287dc54c3585c522f50f626b8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8935686a9046d6abb1898661b57010_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0ea4f1b6e1f4122bf000ec2f062663f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0e44b399f5c47039974adea069751e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f0f98344ea41ee89c1226f1ebfb886_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia444669c28534a2f916cca00d9a1084c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0453ee7dff14085ab6fbbaa87e73917_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b8ebc8cb37b496daa43a0b287fbcb06_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb31a0895811482e8e0345481a846bb5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1842dec3973f4c7fbaefb4e0b73af312_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8af6adb4d85d4284a8361787ad478d67_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib91dea83a7374424acc07bf7143a9de1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbf32eb5eb78476fbab5c4d927d70513_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e0375da1c3406a99fb9a733a7af9e2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1db911011e7478f95e414ea628f6000_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i639fb921dad04c38b75ac3f84cea54ce_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c77fed04674b399c499733307337a2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39b02d830004ca0ae7768a7ab1cfb0a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b8541c2de84111941a459c4cca9e41_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1f946978604abd96aacdf6511485f5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77f8b7841b54c16b57577533fef2ad5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b87df3539b4602a0cb77a894476522_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i190755c884ba4407a67755b5981209fb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425ece1b06434afbbb883c90e17bdb61_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3619adf51ab94510807b3324a8c3fb3e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if31b6a89951d44f89dbabea0393f7de8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0aa4add5f0548b1bbcfbe54905115be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib345026090ae4d7aaf20623437eda88e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb40fd0c453149bf89e2575d7dfd1a8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8693ce8adb3e4f87894764efa1dc1be6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27ee0888939a402dbc25013b3f240b0f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34403b8da4544edeb9bcf602d09ea7e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i925a07a2a5da4c4a954ec447c21627d9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94dd7dacb51143a7be602182537411c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36ca55f6d2d4f6e82521817fdfb9e12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22b516ddd68d487c9dc9976d12bdb980_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a51a763aa048458e78d279f2649278_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b7be258eff4efa93d6f7841ab564b8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3a8e946c7364e21ad7e16db6b94a4a4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98c4ad06e92445fdb0c7c1102056f114_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24de2ec1a8294b05a3fad113a1acd836_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e4e73bf01548db85151208211a884f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic62115cf799f465eb2f3b2b3d65a0c40_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ab2e4c6e7c24bac8d2935a6b6c36a9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc6467fc7c44ae18600b20b5a30e83e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8d696029864336acfec926937a4a09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie501860c6b9a4e07a7bb38b17e7be2b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087dace4c72a4178aadef0c41c9bb356_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i007c67785640431a9ade0b3cbec093e5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6376740830184eaa825958505c990d48_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f300d7009234b3da0340504d7e659a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81538cf0c097486badfa1786facbcdff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f071d9be3e64ae7909bb18979e547ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a1941e2894148b696f50b001c993d68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba50cbc018a4f96b6da7385f98c25c9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6758881023d4b35b0388e05d5360ed4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie50601403e82462a993279d9571f8647_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c98ae4709454667a0750d6459d7ac91_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c63d34d1bfe495ea11be0647eed83c7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ac0012f0854969a20a692346460384_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d90dd4d682d4d36a32874f3b745fcb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1d87e6eccd34d439d8a2297c843c8df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6974fc646add4195bfcc6857939ed0d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10370fc5f7e4e4e8a0c23adbcbc6922_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed9ef18264f4d15aa5462978b00b3bf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc7cbd26add4fff8fe2bc2d9c90f90d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407ac8a1e41242c9be72213ac2a23645_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1278a0a51b1640cdbb03fe0a13675240_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48368b1762a44efd868c61b94c87d3b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf55e9cbdb241bda666ae71bf9b4636_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c01076628f14533a22a6ed1bf7f645f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3809bdb24e4487867ca711c35faed6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5979e4ee83f743c18eb44a9e12a96a76_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:DevelopmentAndSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d63cc5b557e4a7781a31dbcd492270b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d689d0f8bd4b609f81b32837461df5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ieb0b77194500411893671236498c869e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie804f754091d4ee08b0012cf286c45ee_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94890323746341f2b456015e6973a164_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9bcc3e59ff0414e9e68d09f328231d1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ie6ce30503f7e4dcb8b48f3209ba957d1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88109eef01694d5087c4d4045520c227_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedead71724684d8c9198e3945bc63aad_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93e629aa48694adaba119d9561912c43_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076cc18b50ba412ca3242c4341c20664_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie316218928294928a89e52d1606777a9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63935ec464224be99ddd75ab04bfdab1_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8539bb2dda47de90067bfbe0969f59_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="allo:EquityInvestmentBasisAxis">allo:VotingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11005bc5a44b4d80a0ea4954488ea86b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifac376ffe9ed4e7b99c011fd45a31021_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8687e0cabd401c931e5f274bdb2016_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f77c63a834a4681b022dff5f2da6fe7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i019720c47c404ba483f76b9fc6e614e2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia54b21b65ef24f6cbdcf06ec5a9d9dd0_D20201006-20201006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-06</xbrli:startDate><xbrli:endDate>2020-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08db9380997d4d1b9f4e44201d651df9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f26d67082094c649f56c52d8b485753_I20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-14</xbrli:startDate><xbrli:endDate>2020-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i0af7e5161e0e4accbc495ed05d1832d0_I20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i087b1f988f50425c88274e63ae23612e_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1ff3e19d184af39773c955bf6f264f_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewal"><xbrli:measure>allo:renewal</xbrli:measure></xbrli:unit><xbrli:context id="i741a26ced88a4be9b88be81d60e87b12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0049318f88420fb355203ab4e399b1_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i413a4f8e6e7e4ee28ed209070c2b4426_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1c66efc41f41b3a6ae07c79e88874c_D20191101-20191101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e523f02887b4694813dc952ebe2a83d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie55d9fe72329461caf14cd949cf5f9f0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14bbb500f25447d69b2babcd02fb2d40_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b360877fd0487881046b793d288efa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9606d98985d4a4aa8219e4759fe5755_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib97658ccecf0407bb53a0ff5d41930f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15371b2572eb4bbab0588d744217e7b9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e50cc94898c4c38af402cdd90cb3431_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7851275aa1884775b7054b0238c07f90_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5060d1ddf0ff4c76a3852cdb609b01d6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f00168a0e94cdcb56ab6e3ec5a5938_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c39330288e480a82e92430adf135a6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14661dcd7bd04b018bb9677c345a8f5c_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0618c69e39949038145e2a090838f1f_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i769dd97badbb4b2f80e2f2bbbb9b5946_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231088853bd94ca78694266c68e382cd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e3200cd5ee4aec98b75df42cbd8a19_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i701ddf49607b425c93a8f1bcc7064cec_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if95eb4b787c74543b5067fc4b0661d0f_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ebc3e0c018541f4b70cf9419d86dfa9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f6335266109450ca23eec174e7cdcab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c6f84593b7d463c9ff60c7ca46e93bb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i722789689fd9475695feac4a92e9226f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158e95b9cb1646beabf8dfd28baec0fc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986898a7e34741d7954f86f9c33d1968_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1c8fe00fa14644bd319487f70e9221_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia418d380ade7488fa285afa3617ce316_D20180801-20180831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea9e93b01c9d476194a141c6b0fef19e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0bf2b2e4cd04570b9e804413fe277cb_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e4b9c96e43a4d7e97a39037a134b7e1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ea6b4be1364df5a17f2f871d780f18_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18038f78c8f7485c88a47821af555ffa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787d6c72d2aa4f58916999e0c3306ea9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec840582431407c876320ad99849824_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ffc5ac698f42a59f37c79159d75b55_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855de4b72ebc4f219d2f0aba2723cefd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ba8e4cb94c47d6b333c42599e31017_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41eacec9267f4e78b154a165573c48bc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadaf0078bc664e608b63092936b79aaf_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001737287</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMy0xLTEtMA_307edecc-1f63-4284-9b6f-669b07cf0d86 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMy0xLTEtMA_5e9f9b98-da28-4e8c-a81c-8427db4456b5 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMy0xLTEtMA_641c80ef-eff9-4b78-8e4a-43867ef01b17 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0zLTEtMS0w_f954bfd9-3ec4-49a1-8ed4-3603eb6c4420 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMy0xLTEtMA_032c8e48-834a-4336-8f3e-c82f3e031e8c id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMy0xLTEtMA_05d265ff-76ea-4f8b-a25a-bc8590153428 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMy0xLTEtMA_8a4279c2-3924-4726-9d6e-3ecc7f9022ce id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0zLTEtMS0w_86b80932-6046-4e43-b786-e789b1c5c394 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMy0xLTEtMA_858375b0-b7e6-44d0-aee2-5433ebd4d75e id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0zLTEtMS0w_35f3d49f-37b9-44b1-81b0-54756833a5c9 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMy0xLTEtMA_10341c22-77ed-49b5-81b9-e3fe143b6963 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMy0xLTEtMA_8aad1752-7abe-41ca-9395-682a129acf01 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMA_6dcd5482-5ea0-4e1a-9ece-14a8ed6ab7d8 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMy0xLTEtMA_f86ec844-b092-466f-875d-31a225500c6d id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMy0xLTEtMA_4270382f-5182-4bc8-9df9-42838675b91c id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0zLTEtMS0w_0912a133-4ef3-43bb-b0a1-210618ffe1fd id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMy0xLTEtMA_7d1df015-883b-43a9-bdf2-99712365fcd0 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMy0xLTEtMA_2ed3d9e1-6c63-413c-bb02-093ff5201ac8 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMy0xLTEtMA_8309ea67-a578-46de-b7fb-90ba2e3014f6 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMy0xLTEtMA_0195fc54-fdd9-4a59-ac0c-b5d33857f0c7 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0zLTEtMS0w_22241486-a7e9-49f8-a1f8-19cd00a4baa6 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMy0xLTEtMA_c57dc54d-b37a-4a7f-adfa-57966c63a2de id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMy0xLTEtMA_fc257be9-08cb-46b2-8838-a02f1641ffe1 id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0zLTEtMS0w_bc524264-0ca4-4835-99e7-d6ea5ec1348d id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0zLTEtMS0w_47b966a1-77f8-47e2-92a3-b44c18d3761b" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzMx_2d4c9d01-7ac3-4851-a63c-2e7d69651fdd">10-Q</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6NDcyZjFlMzFkMTQzNGM3ZjlhM2NlYmI2NjE1NWEwYTUvdGFibGVyYW5nZTo0NzJmMWUzMWQxNDM0YzdmOWEzY2ViYjY2MTU1YTBhNV8wLTAtMS0xLTA_685d2a33-4b7d-44f3-92be-24240afd608e">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8zODQ4MjkwNjk5NzI1_e7fdcb96-4996-4937-8e5e-3daa8551d0d5">March&#160;31, 2021</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6YTY5ZmU1ODZkYzYyNGIzNWFlNjFiNWNhNGQ0ZTY0OTQvdGFibGVyYW5nZTphNjlmZTU4NmRjNjI0YjM1YWU2MWI1Y2E0ZDRlNjQ5NF8wLTAtMS0xLTA_c738fe35-ee1f-44ad-8d49-6c414d2bab81">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI1_ec87dae7-30b2-4706-970c-455d7787a150">001-38693</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV80MjQ_982cd335-1bce-47c4-a856-dcc8da534d1d">Allogene Therapeutics, Inc.</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6YTEwMWU1ZmRkOGFmNDMyYjkwNjk4ZmI2ZDJmZGMzYzkvdGFibGVyYW5nZTphMTAxZTVmZGQ4YWY0MzJiOTA2OThmYjZkMmZkYzNjOV8wLTAtMS0xLTA_7954a52c-97eb-41c3-88d3-36ea939b9ad7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6YTEwMWU1ZmRkOGFmNDMyYjkwNjk4ZmI2ZDJmZGMzYzkvdGFibGVyYW5nZTphMTAxZTVmZGQ4YWY0MzJiOTA2OThmYjZkMmZkYzNjOV8wLTItMS0xLTA_d6172f5c-ef3c-4e30-b536-d2173c1858ff">82-3562771</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzIw_c1d90a5d-2c73-4783-86b2-ccc2ed5c8f19">210 East Grand Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzIy_9cc132a9-ed03-41d1-b073-afbd08fea6cd">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI5_3ce45342-4c04-4e4a-8acd-743824d61d4d">California</ix:nonNumeric> <ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI0_3e4dd881-d982-4906-9c65-6b16b9755a37">94080</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV83MTY_c12fbe58-5833-4406-a85b-61061607d4de">650</ix:nonNumeric>) <ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzMy_3ebffd2d-387a-43c9-8bf7-7303252f78ee">457-2700</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:30.131%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.133%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Former name, former address and former fiscal year, if changed since last report)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6ODI3ZjMyNzRiNjQxNDUzODg1MWY0OTYxNDFhNjUwODUvdGFibGVyYW5nZTo4MjdmMzI3NGI2NDE0NTM4ODUxZjQ5NjE0MWE2NTA4NV8xLTAtMS0xLTA_3e266546-b179-4980-8ef7-bfebcdf91ae7">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6ODI3ZjMyNzRiNjQxNDUzODg1MWY0OTYxNDFhNjUwODUvdGFibGVyYW5nZTo4MjdmMzI3NGI2NDE0NTM4ODUxZjQ5NjE0MWE2NTA4NV8xLTItMS0xLTA_ddf50e0c-45d7-4611-b31b-2a1822bf10dd">ALLO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6ODI3ZjMyNzRiNjQxNDUzODg1MWY0OTYxNDFhNjUwODUvdGFibGVyYW5nZTo4MjdmMzI3NGI2NDE0NTM4ODUxZjQ5NjE0MWE2NTA4NV8xLTQtMS0xLTA_063c10a7-83cc-4a40-bc63-bd2fbb5d05dc">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI3_1c9a9b1c-7236-440f-9e69-f8240374cced">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzMw_89f2255e-3d57-488f-923f-98eb3cc3e587">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6OGQzNjljYmVmYWVlNDFkMTkzZjU4MzMzYjc5MWI2N2EvdGFibGVyYW5nZTo4ZDM2OWNiZWZhZWU0MWQxOTNmNTgzMzNiNzkxYjY3YV8wLTAtMS0xLTA_ab8c192d-6220-41c5-ab6d-1a9b70772d96">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6OGQzNjljYmVmYWVlNDFkMTkzZjU4MzMzYjc5MWI2N2EvdGFibGVyYW5nZTo4ZDM2OWNiZWZhZWU0MWQxOTNmNTgzMzNiNzkxYjY3YV8xLTQtMS0xLTA_a7272428-5fed-4ced-aaa7-64f0f2026c1f">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6OGQzNjljYmVmYWVlNDFkMTkzZjU4MzMzYjc5MWI2N2EvdGFibGVyYW5nZTo4ZDM2OWNiZWZhZWU0MWQxOTNmNTgzMzNiNzkxYjY3YV8yLTEtMS0xLTA_bd166d0b-0dfd-49d9-b80f-c04930e093f9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#9744;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI4_66179782-fe55-4e4c-b7b3-06c22f954132">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div><span><br/></span></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of May&#160;3, 2021, the registrant had <ix:nonFraction unitRef="shares" contextRef="i8bb0ce173a264ffb98a91df551b8de22_I20210503" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMjUw_0895831c-acda-4aa7-8aa1-3d022a66ea8a">141,538,421</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page no.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_10">PART I:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_19">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_22">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_28">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_76">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_76">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_109">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_109">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_112">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_112">28</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_115">PART II:</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_115">OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_118">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_118">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_121">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_121">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_124">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_124">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_127">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_127">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_130">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_130">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_133">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_133">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_136">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_136">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_139">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_139">68</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I: FINANCIAL INFORMATION</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0xLTEtMS0w_be087a82-1132-4ead-93bc-7652a27e21bc">236,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0zLTEtMS0w_47b966a1-77f8-47e2-92a3-b44c18d3761b">183,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0xLTEtMS0w_129330e8-e857-4c1b-9f78-401588f654c1">462,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0zLTEtMS0w_35f3d49f-37b9-44b1-81b0-54756833a5c9">644,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0xLTEtMS0w_4967502f-b4f9-438e-9084-0e2f86feaf90">16,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0zLTEtMS0w_22241486-a7e9-49f8-a1f8-19cd00a4baa6">17,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0xLTEtMS0w_bcbcfd92-b310-4e25-b002-36ddd85cc3ec">716,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0zLTEtMS0w_f954bfd9-3ec4-49a1-8ed4-3603eb6c4420">845,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0xLTEtMS0w_6e281a81-c073-4e69-bc01-f47874174bba">264,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0zLTEtMS0w_bc524264-0ca4-4835-99e7-d6ea5ec1348d">204,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0xLTEtMS0w_7da97dc1-8517-4f00-b967-882fc98662fc">40,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0zLTEtMS0w_86b80932-6046-4e43-b786-e789b1c5c394">41,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0xLTEtMS0w_b224e7f8-d03b-4352-804b-af37d3c84df6">123,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0zLTEtMS0w_0912a133-4ef3-43bb-b0a1-210618ffe1fd">118,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMS0xLTEtMA_0d5f9d4d-3c92-454d-916e-197ee1ed990c">9,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMy0xLTEtMA_c57dc54d-b37a-4a7f-adfa-57966c63a2de">9,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMS0xLTEtMA_deace675-1d36-4423-896a-ab86d07ac2b1">6,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMy0xLTEtMA_2ed3d9e1-6c63-413c-bb02-093ff5201ac8">5,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMS0xLTEtMA_31ba4057-b60e-4732-9645-32aa30930cfe">19,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMy0xLTEtMA_307edecc-1f63-4284-9b6f-669b07cf0d86">3,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMS0xLTEtMA_15ed111c-8129-433d-a337-6971a98e9bd0">1,179,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMy0xLTEtMA_4270382f-5182-4bc8-9df9-42838675b91c">1,227,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMS0xLTEtMA_d62a88a2-fc86-467e-9537-658ebce6baa8">14,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMy0xLTEtMA_858375b0-b7e6-44d0-aee2-5433ebd4d75e">10,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMS0xLTEtMA_0b4454cc-9fbe-41a8-9690-09e06a5f60e7">39,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="allo:AccruedAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMy0xLTEtMA_05d265ff-76ea-4f8b-a25a-bc8590153428">44,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMS0xLTEtMjI_91417940-b86f-49dd-8820-655b3817ff48">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMjI_13761176-f72a-483a-b335-8ff7963fdc1d">38,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMS0xLTEtMA_3152015f-e64b-4215-afe4-4a73938b069c">54,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMA_6dcd5482-5ea0-4e1a-9ece-14a8ed6ab7d8">94,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMS0xLTEtMA_c44acc97-b8f2-4e08-add5-2a7488c7fc26">51,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMy0xLTEtMA_f86ec844-b092-466f-875d-31a225500c6d">50,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMS0xLTEtMA_aa36f01b-006a-4d9c-acfb-d96183609b39">2,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMy0xLTEtMA_7d1df015-883b-43a9-bdf2-99712365fcd0">3,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMS0xLTEtMA_55918b96-bbe1-4bba-897f-dc26a9331d89">109,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMy0xLTEtMA_032c8e48-834a-4336-8f3e-c82f3e031e8c">148,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Notes 6 and 7)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMS0xLTEtMA_a430e1be-0e29-4ba6-9210-f02c7620ee80"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMy0xLTEtMA_641c80ef-eff9-4b78-8e4a-43867ef01b17"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzIx_833aba23-2810-4b96-b241-cf6b427db633"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzIx_b6a62c7c-ec87-4075-9cd4-d003b04dc85c">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzM1_9f8fc5e6-f8a6-4ce7-88c9-edcd54b1e0fd"><ix:nonFraction unitRef="shares" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzM1_afd80ab3-0ead-4839-829f-ea506aa148bb">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_2b6fc218-8500-4435-b1b4-7634de09d431"><ix:nonFraction unitRef="shares" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_623c74b7-360c-4477-b02f-cb5b34b4d9a8"><ix:nonFraction unitRef="shares" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_747f8b54-9f5a-49fc-a212-4b45f47317e1"><ix:nonFraction unitRef="shares" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_abfc9e2f-b077-44e3-8df3-96193f1c7058">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares were issued and outstanding as of March 31, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMS0xLTEtMA_6174f0f6-27b0-4ef0-a149-8d7daf08cd4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMy0xLTEtMA_fc257be9-08cb-46b2-8838-a02f1641ffe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzE4_9eec1364-e641-43ba-aed4-966963fd48bd"><ix:nonFraction unitRef="usdPerShare" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzE4_c004c48a-ea4c-4bc8-8a9f-fa69a923b8cf">0.001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzMy_21e08519-fb7d-42d2-8ac6-9c1a3259a2b5"><ix:nonFraction unitRef="shares" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzMy_f05483b5-b015-4c2b-8b46-8ea10651765d">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March 31, 2021 and December 31, 2020; <ix:nonFraction unitRef="shares" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwMQ_4c27f3da-31d4-40be-9ef5-1c2de5218e04"><ix:nonFraction unitRef="shares" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwMQ_8c2490ad-c78c-418e-b3f9-c613330ba089">141,470,075</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwOA_9d93cedb-7927-42d4-b1e8-b27f1a4282bd"><ix:nonFraction unitRef="shares" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwOA_d74f9f1c-552a-40da-9339-a8489f2a4cb0">140,474,305</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMS0xLTEtMA_20fad735-1b84-4b6b-8208-61bcd43715d2">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMy0xLTEtMA_0195fc54-fdd9-4a59-ac0c-b5d33857f0c7">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMS0xLTEtMA_8225d449-4b8c-4a01-88c4-c5456d05f7f2">1,749,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMy0xLTEtMA_10341c22-77ed-49b5-81b9-e3fe143b6963">1,725,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMS0xLTEtMA_691a9365-60a1-4981-968e-dca9fdcd81de">679,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMy0xLTEtMA_8aad1752-7abe-41ca-9395-682a129acf01">646,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMS0xLTEtMA_e543b0d7-5cf1-4da4-834b-fee5c8102d3b">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMy0xLTEtMA_5e9f9b98-da28-4e8c-a81c-8427db4456b5">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMS0xLTEtMA_e7e57667-9380-43db-8bdd-28c9248f894c">1,069,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMy0xLTEtMA_8309ea67-a578-46de-b7fb-90ba2e3014f6">1,079,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMS0xLTEtMA_590a7cbe-5a77-437e-b0bb-7586315931f4">1,179,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMy0xLTEtMA_8a4279c2-3924-4726-9d6e-3ecc7f9022ce">1,227,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504" footnoteRole="http://www.xbrl.org/2003/role/footnote">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</ix:footnote></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:74.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.751%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.309%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMi0xLTEtMS02Njg_bc1263b4-915a-42e7-9991-640aeab390d6">38,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMi0zLTEtMS02Njg_c797f4c5-318e-403a-baa1-788dd2afde92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMy0xLTEtMS0w_18a48833-7d61-4b95-bee0-d6e270f92c39">55,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMy0zLTEtMS0w_ae2688d4-bc4e-433e-acff-3db254dd3e7a">42,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNC0xLTEtMS0w_f6b29deb-dbb6-49f8-bf86-e3d3d14d2369">16,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNC0zLTEtMS0w_5ee45197-edd3-4507-961f-c5ec24c4b055">15,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNS0xLTEtMS0w_05b11ead-eaed-4ca5-81a3-ea19550a143e">71,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNS0zLTEtMS0w_b7f39df8-3db4-4325-9485-cddcd509d3d2">57,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNi0xLTEtMS0w_22c06c38-9f52-46c2-986a-c470ced837dc">33,201</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNi0zLTEtMS0w_e4e4363b-25da-4a79-b969-13aef829c6b2">57,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOC0xLTEtMS0w_a8d39c8e-7715-49f1-8279-dee8777cb30c">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOC0zLTEtMS0w_d8b94d3b-6dbd-49a0-8c18-07c8c7936fbc">3,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOS0xLTEtMS0w_5d4616aa-08a2-4039-b731-3f79e1174219">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:OtherExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOS0zLTEtMS0w_d5b04d7b-1c07-4116-b3a8-6f87ddbad897">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTAtMS0xLTEtMA_9edc69a3-fa3f-4380-aa15-3425a34436b0">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTAtMy0xLTEtMA_38a16bfb-2ce5-4d5c-9d69-770f187300a0">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTMtMS0xLTEtMA_3f4e7362-4bfc-4b88-ab0a-80761c0f9fb0">33,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTMtMy0xLTEtMA_c64f04de-4d1b-45bd-8402-104151931228">54,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on available-for-sale investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTUtMS0xLTEtMA_140ed417-fcb2-4d99-939b-46e0a9b57c42">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTUtMy0xLTEtMA_ceab7f73-dab0-447e-90b9-92f02eec2f41">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTYtMS0xLTEtMA_39392653-2a30-46a8-ae9a-e301c1141f16">33,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTYtMy0xLTEtMA_6cc071d2-0cf4-4c77-ba8b-75202c1c1bcb">54,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTctMS0xLTEtMA_156734ee-6c5c-449b-acd2-d34233b0241d">0.25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTctMy0xLTEtMA_563ed89b-d947-4b1c-97af-754e873071b6">0.50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares used in computing net loss per share, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTgtMS0xLTEtMA_654b6994-2979-4559-b9ce-873606fe74d0">132,165,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTgtMy0xLTEtMA_47e5b9cd-0df7-43e1-9495-0ed0c4f6cde8">108,963,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.890%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5d8d5d7cc5e4b369dc02b51cc31ba63_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi0xLTEtMS0w_f1b34b7f-884f-4bc3-8d7c-ac24f7934484">140,474,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d8d5d7cc5e4b369dc02b51cc31ba63_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi0zLTEtMS0w_68e95bbd-329c-4526-9fba-6072cd6754d7">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if62b8835b5894a97961539f08038f95b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi01LTEtMS0w_c1cb4b49-594a-43c1-9b3f-55b40674ada8">1,725,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84f14c477d6247bcb8b315bd0a71ca2b_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi03LTEtMS0w_47c76a32-03a6-4500-b50b-32b64c6e71e2">646,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i964ffbd064624356a2ce6298cdba096c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi05LTEtMS0w_77c3bbb3-7525-407a-84be-8e3c992fb20c">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi0xMS0xLTEtMA_7141eaef-87f7-4eb3-a8bf-907cc6686a82">1,079,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy0xLTEtMS0w_2c940ee3-9a7c-4444-aad4-025ee22551c1">897,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy0zLTEtMS0w_20241d2e-b542-493c-9fee-528c83ada373">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy01LTEtMS0w_a8662677-4f95-4b6e-8861-efabf708fb63">4,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy0xMS0xLTEtMA_5aabc9a0-165c-4dba-be3c-e0e8dc1a094e">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNC01LTEtMS0w_52f522ec-6add-4fa0-afad-7acc7923b4b0">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNC0xMS0xLTEtMA_5506827d-fd49-4b08-aff8-763a84e24dba">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNS01LTEtMS0w_4101fd15-c09a-4d8a-b069-a0939062a121">16,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNS0xMS0xLTEtMA_1577d938-b26c-4631-a29c-497a00ed9b63">16,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNi0xLTEtMS0w_a8f503df-af8a-4ce4-9d3e-dd4847d2e218">98,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNi01LTEtMS0w_b861dfcf-27e8-4467-bd1d-a040c4f3b116">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNi0xMS0xLTEtMA_aac38992-9a4e-43a5-8481-f1543f0d1237">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c89cfc2f1df420e80df10b19bb7045c_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNy03LTEtMS0w_c699ced9-52e0-474a-bff2-9b3aab59c868">33,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNy0xMS0xLTEtMA_b9873f65-8b5f-4326-bc69-d64c020c5848">33,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fe5f193450e4e168c14067f2f2d182e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOC05LTEtMS0w_f49de07a-2e00-41fb-bc3f-8c94eb33e026">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOC0xMS0xLTEtMA_1070e1e9-f4fb-43f5-a96a-1e6e1f348a56">369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90d14178c6914d93a889ac3ed04c02a9_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS0xLTEtMS0w_a55da04e-48b1-4e79-9bf7-855f607ec315">141,470,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90d14178c6914d93a889ac3ed04c02a9_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS0zLTEtMS0w_9ce88efb-6dca-4dd1-a438-4550a6a9010e">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e5769ae558548b8b8db13dd5a510d74_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS01LTEtMS0w_b4c6037e-0408-491e-b50b-ccaec4d19748">1,749,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6562b41725243958717d88b90e4728a_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS03LTEtMS0w_312da796-aa49-476a-ba67-2f727b4b3817">679,358</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad89e42e666e4c46b385e97bc6797118_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS05LTEtMS0w_5bad1bf3-2816-4198-9104-14abc7ecd7c5">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS0xMS0xLTEtMA_a7f8327e-ceca-4e14-bfc4-e99e6f9b5514">1,069,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.890%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - December 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01ccf8d124ff499fbbabad09739a47b4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi0xLTEtMS0w_45994a9e-70b7-42b0-a99a-f6fd1d42afa6">124,267,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ccf8d124ff499fbbabad09739a47b4_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi0zLTEtMS0w_1c24a76f-a7f0-4c2e-97b7-74152a19af5c">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic054bea3b59344829df6ae5dc931c60b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi01LTEtMS0w_36fa0d8c-1e0b-4a0c-9d8d-33d2bae9eaec">1,023,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i313259e23cfb4a2ab8bd19b643ad78ea_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi03LTEtMS0w_2304e56f-8dd6-4407-8e9f-0078eaebcefc">396,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f4a1b7bf0a947fb8b63dca9e112a72b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi05LTEtMS0w_93d3f98a-fb4f-472f-99d5-baa42458c50d">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c3252db9b543d6a7491e001ef77b45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi0xMS0xLTEtMA_b221a4e1-29c0-443e-a252-1c0117ed6ded">629,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMy0xLTEtMS0w_0391318e-8880-4a8f-8537-05a3a99d669f">339,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMy01LTEtMS0w_ddd65c42-4406-4a92-8cfe-a6b12d936cf5">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMy0xMS0xLTEtMA_d14aa182-d00b-4cd3-9ff7-5844f8d0177e">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of early exercised common stock</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNC01LTEtMS0w_466a8939-a865-4311-96bf-afcebfb7861c">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNC0xMS0xLTEtMA_5f610947-d0c2-4dc1-9efb-fa1f759a7730">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNS01LTEtMS0w_b05aa790-5854-42dc-9fe0-463516c47344">14,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNS0xMS0xLTEtMA_a09287a2-da7f-47e7-a685-f8e4f51b96eb">14,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNi0xLTEtMS0w_16279507-0a9e-4e90-9982-85b3342dc2f8">84,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNi01LTEtMS0w_eadff80c-17e3-4712-9de8-a49a2aa361d5">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNi0xMS0xLTEtMA_ec4c4c99-88bf-4b5a-9a8c-49a03e7c09c9">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock from public offering, net of commissions and offering costs of $<ix:nonFraction unitRef="usd" contextRef="iacc623b05c8141db83c3d25a61bcb2cf_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0wLTEtMS0zNDEvdGV4dHJlZ2lvbjplYzdjNDRjZDkzYmY0MTdiYmY5YWNlYzgyNDllYTI0NF8zODQ4MjkwNjk3NDQ4_5ef1c35f-28b1-4506-ab5c-ded0cac9164f">0.3</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0xLTEtMS0xMjc_580d48c1-bd53-47ea-8210-9937c9046eae">570,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0zLTEtMS0xMjc_3a927305-6462-4e45-904a-252b508d5bca">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy01LTEtMS0xMjc_0fdc7287-8d48-4662-a5a7-b7cb7574851a">14,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0xMS0xLTEtMTI3_8ebc563b-bce1-41c2-9b7d-256e039eab3a">14,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4c2a96affa64584ab33e6e2aa1a077b_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfOS03LTEtMS0w_51811127-4cc4-41ae-a55c-4725a7d1bd71">54,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfOS0xMS0xLTEtMA_f97ddd10-7f39-4695-9592-486eb9d794bc">54,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on available-for-sale investments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62bda789cb6d4921af13cb46113d49d7_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTAtOS0xLTEtMA_233c58a3-290e-426b-bb79-593335a5819c">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTAtMTEtMS0xLTA_5716df9b-7a26-4ada-8513-5e9519f66eaa">465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance - March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i571a727871624fde93fb27f4e770e678_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtMS0xLTEtMA_db64fc4c-1da9-4cd8-92ca-2658cd0e5cb5">125,262,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i571a727871624fde93fb27f4e770e678_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtMy0xLTEtMA_6060fb4e-f62e-419f-98dc-4cd1b6d4c7df">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i989fb3c13e4c463ca87f71c224b0cb1d_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtNS0xLTEtMA_322ae224-1131-4d22-80d1-39d97c395daa">1,055,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3d9397e7db24081a8cb1f7febad8dfb_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtNy0xLTEtMA_ed5bc21b-122f-4551-9c4e-7889fa0f2a5d">450,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef8c73e705a4baa9efc6f53a2920a77_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtOS0xLTEtMA_bb5b1814-0aeb-45d4-9e89-3ac5c6dcf452">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504c57fff4964e769a633e05ed2a8d01_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtMTEtMS0xLTA_9fc031b4-f354-4347-b411-bfb0095dd1c8">606,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMy0xLTEtMS0w_30a095a5-90d2-459d-afbc-5970af3bfad3">33,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMy0zLTEtMS0w_986dd8ed-616d-4405-9b94-88b907cc0647">54,480</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNS0xLTEtMS0w_eab6f617-0175-442a-99f5-3322e8184bfd">16,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNS0zLTEtMS0w_63cb026a-348c-4c05-ac74-96db72080a3f">14,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of other intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNi0xLTEtMS0w_aba5c1ae-a0de-48ef-a34c-acbb2c433988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNi0zLTEtMS0w_70d63f55-493e-46dd-b0ac-e9ce3229f3f4">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNy0xLTEtMS0w_feb71e16-b658-41de-ba57-caf867425ed2">1,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNy0zLTEtMS0w_71ca78a3-2a23-45fd-863c-7e856139a0ef">1,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net amortization/accretion on investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOC0xLTEtMS0w_62f34e43-e864-4955-b7b9-50f9ecbf1ff8">1,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOC0zLTEtMS0w_d38557b4-d1df-40d4-a5fc-7220f7c0c7cf">207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash rent expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOS0xLTEtMS0w_dd489e89-faad-46cc-a8c1-9e4a0a26dd89">2,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:OperatingLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOS0zLTEtMS0w_6ba4468c-f7f9-4000-a674-63688bbc7a21">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share of losses from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" name="allo:IncomeLossFromCostMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTEtMS0xLTEtMA_fc82a76a-d675-418e-aafa-f9b0e868c890">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" name="allo:IncomeLossFromCostMethodInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTEtMy0xLTEtMA_b6bce23d-1bfe-4637-99a3-0186ec0b6fc2">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTMtMS0xLTEtMA_4294117e-8e8e-4ec2-a810-d22d2555dea0">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTMtMy0xLTEtMA_b7bcfb4f-0dfd-425d-bce7-09942c7987ec">2,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTQtMS0xLTEtMA_97882fdf-b802-4cda-aa7e-42ce47d9691d">799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTQtMy0xLTEtMA_1f2c12a8-c62b-4d7a-af40-f7ae643c29d7">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTUtMS0xLTEtMA_7fb22bf0-8987-4a95-a241-957449c33630">4,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTUtMy0xLTEtMA_6d2008fc-0a04-44eb-9118-2deffb46f03b">1,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMS0xLTEtMA_9253d575-7c12-4332-abeb-6551bda498ab">4,314</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMy0xLTEtMA_69bbca01-a9b4-4b73-9860-9b0f8587d5a4">3,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMS0xLTEtNzE2_ff9a05bd-19ea-4a68-acdb-5de7d99c7fc0">38,753</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMy0xLTEtNzE2_52dacf49-ac22-4e01-82a9-1758f52eacfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTctMS0xLTEtMA_6e1b0f3b-2ede-4a22-8fff-01535dd5f3c5">292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTctMy0xLTEtMA_145fabbe-a4b9-4810-921c-70ad32a15f1f">701</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTgtMS0xLTEtMA_0b8c3810-e283-49db-93ed-3eeec3b63c68">49,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTgtMy0xLTEtMA_cee101c3-e824-4989-825b-8ea26e11caa4">40,809</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjAtMS0xLTEtMA_8545f65c-8966-488f-84c0-91a7761763a8">6,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjAtMy0xLTEtMA_2886d68a-5de9-4a22-bc0b-c363077da46e">12,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of stock in equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjEtMS0xLTEtNzIx_4071eaf8-3f36-4a8c-b9e6-ce2d7b600f44">15,938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjEtMy0xLTEtNzIx_ea167afd-6f62-49dd-888d-84451b223b34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjItMS0xLTEtMA_4da6cb0c-9c7a-4f24-ad98-82112c63d824">268,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjItMy0xLTEtMA_d5bab684-d8d4-456b-9c30-65693da2e8e2">120,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjMtMS0xLTEtMA_59636cea-0d35-44fa-a839-bd6f1720cec6">149,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjMtMy0xLTEtMA_9308b5cf-cfc3-42a9-8416-1a7ff3de902d">123,015</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjQtMS0xLTEtMA_700c7988-c355-49a0-a63a-48e2982b1a1d">96,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjQtMy0xLTEtMA_8bc41eda-d5c4-4c74-8908-7c1751fa7cc6">15,007</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i344a99f050b64372885525e2c3a160e8_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjYtMS0xLTEtMA_66160138-b13c-4bad-a33f-c48c5f643484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1b5c9589324b51a5ac5e3aa31ea60e_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjYtMy0xLTEtMA_08f16fb6-8b60-4091-97d2-647670b10405">14,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjgtMS0xLTEtMA_30e6becc-843d-4fb4-84bc-bb5314d3349b">4,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjgtMy0xLTEtMA_81355331-3a34-43ee-9897-5858cab421da">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under the employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjktMS0xLTEtMA_62d31cfe-1209-43c2-9888-c1e7d429367b">1,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjktMy0xLTEtMA_a1e46ed7-05b6-46a2-ad68-90219d9bbef8">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzAtMS0xLTEtMA_0f0c8867-28d1-4ad6-9f74-a67f372407ae">6,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzAtMy0xLTEtMA_a46d8e1c-3509-4788-af9e-3eba6a897924">16,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzEtMS0xLTEtMA_e8075b15-d032-49b5-ac09-18aca8c87525">53,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzEtMy0xLTEtMA_b21519b8-0566-4f2c-839a-a50d59d46d73">39,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8212; beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzItMS0xLTEtMA_c5cdd762-dbd1-4bf6-af31-f1c3b41ce341">192,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c3252db9b543d6a7491e001ef77b45_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzItMy0xLTEtMA_803062cf-ae32-4ae0-985b-eb74021d6091">179,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash &#8212; end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzMtMS0xLTEtMA_9fd08174-e2b1-4327-aec0-b88db64fe74b">246,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i504c57fff4964e769a633e05ed2a8d01_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzMtMy0xLTEtMA_7dd00fe4-93f9-4a90-89a0-21ba4c51ab3a">140,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment purchases in accounts payable and accrued and other current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzUtMS0xLTEtMA_c0938901-8874-4007-991a-58f941781ff0">8,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzUtMy0xLTEtMA_2e536578-0e26-4254-bd95-0bdc0930f7c7">4,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized cloud computing costs included in accounts payable and accrued and other current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="allo:CapitalizedSoftwareCostsIncurredNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzYtMS0xLTEtNzMy_ff3fb11b-d2f2-4722-b0b3-d93afe25d7a8">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="allo:CapitalizedSoftwareCostsIncurredNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzYtMy0xLTEtNzMy_ed526169-8861-4818-b39d-58c849c133ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzctMS0xLTEtMA_6d744925-b437-4d0f-9817-0eac98bc8cd3">966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzctMy0xLTEtMA_c496da22-2ac9-4967-b2e8-ff2133d2a3bf">1,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts related to tenant improvement allowances</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzgtMS0xLTEtMA_36339926-c23b-4f2b-8704-e9dbef33fb18">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromTenantAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzgtMy0xLTEtMA_b7549fc9-13c8-4a31-9a34-d115e216dc2f">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ALLOGENE THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_31"></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zMS9mcmFnOjU5MjdkNWUxYmI1ZjRjY2I4NTIwOWIwYTkzZmEwYzIyL3RleHRyZWdpb246NTkyN2Q1ZTFiYjVmNGNjYjg1MjA5YjBhOTNmYTBjMjJfMzY2Nw_81f72516-7b53-4e04-a255-de54201c09d9" continuedAt="iaa2fc9631c0b4e40ae344f475aa3e72c" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="iaa2fc9631c0b4e40ae344f475aa3e72c" continuedAt="i80caa44bcc734fffbd4b7c1df67292e2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. The Company had cash and cash equivalents and investments of $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zMS9mcmFnOjU5MjdkNWUxYmI1ZjRjY2I4NTIwOWIwYTkzZmEwYzIyL3RleHRyZWdpb246NTkyN2Q1ZTFiYjVmNGNjYjg1MjA5YjBhOTNmYTBjMjJfMTg1Mw_2f7c8aea-5eb8-4c42-8d68-df6c00891b82">964.2</ix:nonFraction> million as of March&#160;31, 2021. Since inception through March&#160;31, 2021, the Company has incurred cumulative net losses of $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zMS9mcmFnOjU5MjdkNWUxYmI1ZjRjY2I4NTIwOWIwYTkzZmEwYzIyL3RleHRyZWdpb246NTkyN2Q1ZTFiYjVmNGNjYjg1MjA5YjBhOTNmYTBjMjJfMTk0NA_c9135747-0be9-405e-8805-3a23d46b83f7">679.4</ix:nonFraction> million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i80caa44bcc734fffbd4b7c1df67292e2">The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_34"></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAzMQ_038a4e64-55d4-4792-b547-9f827442ae7c" continuedAt="i6f02e22a922e4ab1bf9cb4696a6ee919" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i6f02e22a922e4ab1bf9cb4696a6ee919" continuedAt="i0cc15856ab134a5fa5d5988927a4fa8f"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAzMg_f3f3150a-b48a-4078-a89d-b0258db7dd49" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2021 and 2020, the condensed consolidated statements of stockholders&#8217; equity as of March&#160;31, 2021 and 2020, the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2021 and 2020, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2020, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 25, 2021.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAyNw_4d987479-e83d-47b0-b586-3071a5573a17" continuedAt="i985dc1cf1b8a4321812d566d21745f82" escape="true">Use of Estimates</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i0cc15856ab134a5fa5d5988927a4fa8f" continuedAt="i5c230bce363b46d79d4dc949ab5db930"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i985dc1cf1b8a4321812d566d21745f82">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</ix:continuation></span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="allo:ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAyOA_8c9cbf15-751f-4fb2-84ae-dabce6afcf34" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2021, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report, with the exception of revenue recognition related to the collaboration revenue recognized in the three months ended March 31, 2021 and the recently adopted accounting pronouncements in the section below.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfMzg0ODI5MDcyOTk2NA_92eb5568-b070-48e8-90da-fb4817bcdc11" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue may be generated through collaboration research and license agreements. The terms of these agreements may contain multiple deliverables which may include (i) grant of licenses, (ii) transfer of know-how, (iii) research and development activities, (iii) clinical manufacturing and, (iv) product supply. The payment terms of these agreements may include nonrefundable upfront fees, payments for research and development activities, payments based upon the achievement of certain milestones, royalty payments based on product sales derived from the collaboration, and payments for supplying product.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606, Revenue from Contracts with Customers (ASC 606). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that the Company determines should be accounted for under ASC 606, the Company assesses which activities in the collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. A performance obligation represents a promise in a contract to transfer a distinct good or service to a customer, which represents a unit of accounting in accordance with ASC 606. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once the Company has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. A portion of the consideration should be allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The total consideration which the Company expects to collect in exchange for the Company&#8217;s products is an estimate and may be fixed or variable. The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The transaction price is re-evaluated, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately. Revenue is recognized when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers. Funds received in advance are recorded as deferred revenue and are recognized as the related performance obligation is satisfied.</span></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="allo:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAzNA_79fbecfa-0bd2-49dd-95ad-e9191768a9b4" continuedAt="i11e0d53c415549aaa5be663a630f6c68" escape="true">Recently Adopted Accounting Pronouncements</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i5c230bce363b46d79d4dc949ab5db930"><div style="margin-top:6pt"><ix:continuation id="i11e0d53c415549aaa5be663a630f6c68"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standard Update No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarifies the interactions between Topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company adopted this standard on January 1, 2021 on a prospective basis. Adoption of the new guidance had no significant impact on the Company's condensed consolidated financial statements.</span></ix:continuation></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="allo:RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAyNA_a4e8741e-6b25-45fc-9c69-affb29326791" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_37"></div><div style="margin-top:18pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfOTA0_bca82606-799a-4dd7-9feb-c3df967a3c3a" continuedAt="id2243895ef364aa8b13e44535be6ed7b" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="id2243895ef364aa8b13e44535be6ed7b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="id12fb68b0dae4f7a91f55375717a8a56_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_31780b62-1e2d-432b-b991-af70f905a0e0"><ix:nonFraction unitRef="usd" contextRef="i165eea287dc54c3585c522f50f626b8b_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_b51faa19-39db-4d5d-b1d3-5a84fed659a0"><ix:nonFraction unitRef="usd" contextRef="i165eea287dc54c3585c522f50f626b8b_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_ca49c28c-570a-40c8-8dd0-af2cc2be7953"><ix:nonFraction unitRef="usd" contextRef="id12fb68b0dae4f7a91f55375717a8a56_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_e8783496-2c08-4d66-b48b-8391860c5ba9">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Level 3 assets or liabilities as of March&#160;31, 2021 and as of December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfOTAw_55ebb18f-4c4a-4b5c-a639-b65a73e31012" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8935686a9046d6abb1898661b57010_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC0xLTEtMS0w_40148f24-673d-4597-bf88-921eae637c60">176,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0ea4f1b6e1f4122bf000ec2f062663f_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC0zLTEtMS0w_b2c66fcd-8398-4080-84fb-176f627475a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e44b399f5c47039974adea069751e0_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC01LTEtMS0w_04b6e2b3-3b64-444f-a219-e7e624c3ffa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f0f98344ea41ee89c1226f1ebfb886_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC03LTEtMS0w_abc1eba8-75a9-44a0-8b47-e5fba09eb7f0">176,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia444669c28534a2f916cca00d9a1084c_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS0xLTEtMS0w_0785b18c-8d94-4933-b567-e93613bd3fb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0453ee7dff14085ab6fbbaa87e73917_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS0zLTEtMS0w_8c278e94-b197-48ab-aae1-a6f15e3dd67c">39,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8ebc8cb37b496daa43a0b287fbcb06_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS01LTEtMS0w_e3535208-e0d1-490b-a4b1-9208f0c7d8f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb31a0895811482e8e0345481a846bb5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS03LTEtMS0w_30ed9b75-4201-4249-965f-9413f9095200">39,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1842dec3973f4c7fbaefb4e0b73af312_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi0xLTEtMS0w_4f19b281-3995-4399-ad91-310a6c0a869d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8af6adb4d85d4284a8361787ad478d67_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi0zLTEtMS0w_091642f1-71ec-493a-89cb-09d0572f626e">221,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib91dea83a7374424acc07bf7143a9de1_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi01LTEtMS0w_ca95f857-c1ac-4ac2-8cc8-1250d91f2b8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf32eb5eb78476fbab5c4d927d70513_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi03LTEtMS0w_3d68f87a-b80c-4a98-937d-93bfbc2b4eb2">221,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e0375da1c3406a99fb9a733a7af9e2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy0xLTEtMS0w_19a77c47-5e71-4ab3-89ff-3a95c0b53b2d">390,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1db911011e7478f95e414ea628f6000_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy0zLTEtMS0w_26bd603e-5043-4551-b6b0-1882ac8abebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639fb921dad04c38b75ac3f84cea54ce_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy01LTEtMS0w_c1964722-6569-4060-b5eb-f2750ac7dfdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c77fed04674b399c499733307337a2_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy03LTEtMS0w_b5c08525-e78f-40a6-90b1-08d674871109">390,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39b02d830004ca0ae7768a7ab1cfb0a_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC0xLTEtMS0w_9087849f-e638-4ff6-ad71-cec0d816dc2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58b8541c2de84111941a459c4cca9e41_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC0zLTEtMS0w_7d9bd9ce-d3f4-42f2-93c0-f6c197cff171">75,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1f946978604abd96aacdf6511485f5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC01LTEtMS0w_543717c0-e6c8-4b37-a49d-8aabbfaa6f15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77f8b7841b54c16b57577533fef2ad5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC03LTEtMS0w_76e3340f-c928-4d8f-97cc-93d6aed51395">75,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73b87df3539b4602a0cb77a894476522_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS0xLTEtMS0w_152f9cf4-20ca-4f69-9bb4-36bdb66b5bdc">566,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190755c884ba4407a67755b5981209fb_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS0zLTEtMS0w_9e13d493-7fbb-4145-b9b6-8fedb69bbac7">336,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12fb68b0dae4f7a91f55375717a8a56_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS01LTEtMS0w_92d0af24-5608-4050-8913-f20415595fa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425ece1b06434afbbb883c90e17bdb61_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS03LTEtMS0w_13a33d09-59f4-43ce-9f0b-581ff763b429">903,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3619adf51ab94510807b3324a8c3fb3e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC0xLTEtMS0w_782a952c-be0e-4c7f-8925-b2cba4120e22">102,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31b6a89951d44f89dbabea0393f7de8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC0zLTEtMS0w_d224e4be-ec32-4aa3-8b65-792f113ffdc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0aa4add5f0548b1bbcfbe54905115be_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC01LTEtMS0w_a5927c79-084c-4297-a87d-15516ca50f41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib345026090ae4d7aaf20623437eda88e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC03LTEtMS0w_dc6004db-2a39-4bcf-923c-f4aff69c8621">102,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb40fd0c453149bf89e2575d7dfd1a8b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS0xLTEtMS0w_8fd397f6-e7c6-4b68-bf00-8c0ebdbb3a45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8693ce8adb3e4f87894764efa1dc1be6_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS0zLTEtMS0w_3b8bd89b-6773-4dd8-88c6-61f554ec3522">58,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ee0888939a402dbc25013b3f240b0f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS01LTEtMS0w_1f249d47-c763-448a-af05-2f8ab436a073">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34403b8da4544edeb9bcf602d09ea7e4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS03LTEtMS0w_1bfea288-b15e-4ef6-8e25-b4ac2807fe14">58,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i925a07a2a5da4c4a954ec447c21627d9_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi0xLTEtMS0w_4543ecf0-429f-49a6-bd35-01d634d2ee43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94dd7dacb51143a7be602182537411c1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi0zLTEtMS0w_e316203c-8f57-4d27-8770-de85246e8f8a">262,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36ca55f6d2d4f6e82521817fdfb9e12_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi01LTEtMS0w_b9f77dcf-1f5a-4cf5-a10c-f02ce5522269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22b516ddd68d487c9dc9976d12bdb980_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi03LTEtMS0w_088b10b5-5766-4fc3-b490-8e4b99052ec8">262,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a51a763aa048458e78d279f2649278_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy0xLTEtMS0w_c524ca80-c00e-4089-9b27-64a3ab885416">446,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b7be258eff4efa93d6f7841ab564b8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy0zLTEtMS0w_1eb676bd-16e6-47c0-be5b-ad852d1ba7a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a8e946c7364e21ad7e16db6b94a4a4_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy01LTEtMS0w_36e3f7e1-eea4-4488-96d4-6fbf830d10fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98c4ad06e92445fdb0c7c1102056f114_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy03LTEtMS0w_ce8c64b8-aebf-40c9-bbd0-1fd5502dcdc3">446,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24de2ec1a8294b05a3fad113a1acd836_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC0xLTEtMS0w_01aef45d-1bfb-4410-9000-fa2369df9491">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e4e73bf01548db85151208211a884f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC0zLTEtMS0w_85bbbe0e-2a6d-48e5-a184-181cfb05d87b">80,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic62115cf799f465eb2f3b2b3d65a0c40_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC01LTEtMS0w_67d5488d-3252-4e99-91ec-656d957787a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ab2e4c6e7c24bac8d2935a6b6c36a9d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC03LTEtMS0w_8edebc8c-1447-43e0-846e-2e118451674c">80,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc6467fc7c44ae18600b20b5a30e83e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS0xLTEtMS0w_98880587-f40f-430f-8bff-89f9b18238d6">549,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8d696029864336acfec926937a4a09_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS0zLTEtMS0w_762017b6-119b-461f-858e-95924d57ecf1">401,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i165eea287dc54c3585c522f50f626b8b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS01LTEtMS0w_26dee2c0-6886-4e2a-ac8b-fe6b6f2fca82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie501860c6b9a4e07a7bb38b17e7be2b3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS03LTEtMS0w_9770c2ac-d202-4a66-b87e-bc76ee59bb4b">950,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included within cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_43"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfOTYx_3e0b525e-c1ab-4d45-b248-b832c120f124" continuedAt="i2f0cc79e92c24ebaaeefd5c374efac86" escape="true">Financial Instruments</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i2f0cc79e92c24ebaaeefd5c374efac86"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfOTYy_5acf2024-bf73-499b-9f66-862428b27f90" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy0xLTEtMS0w_f3b23c9d-557a-4e4d-b5f8-fcaa72020505">176,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy0zLTEtMS0w_a9865f7b-aabd-4dff-9284-67415ae90e54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy01LTEtMS0w_2282b06e-d551-40dc-a9bf-016c8d6738e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy03LTEtMS0w_2d4c569f-fbc7-4752-a5ce-3d8984e80e15">176,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC0xLTEtMS0w_4534be32-f531-4c3e-8451-e4116d1b0052">39,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC0zLTEtMS0w_b1a05efe-291b-492a-80b1-700e5768d783">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC01LTEtMS0w_0ea6fece-3192-4e3b-94fc-a29ced34e47e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC03LTEtMS0w_5578cd3f-31f1-43b3-9dae-142f7007c4ae">39,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6376740830184eaa825958505c990d48_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS0xLTEtMS0w_cb394716-9cbd-47df-9536-32310a750872">221,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6376740830184eaa825958505c990d48_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS0zLTEtMS0w_423af8dc-27e3-4b2d-968b-aeb568eec155">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6376740830184eaa825958505c990d48_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS01LTEtMS0w_11022ea9-8de8-40fb-b27a-da94c319b95c">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6376740830184eaa825958505c990d48_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS03LTEtMS0w_b1473272-2ed2-4e1c-a354-27be486650bf">221,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi0xLTEtMS0w_9275b49a-2235-49eb-baec-f9f3013a143f">390,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi0zLTEtMS0w_1cef983e-5f6e-4b9d-9b71-5d06b64438a5">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi01LTEtMS0w_8ac7d32f-4c0d-4802-b5f6-7679e983e291">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi03LTEtMS0w_71845a1c-3dc0-464d-bd88-c6003b97420e">390,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy0xLTEtMS0w_17d99b63-7653-4321-874f-c696c330c275">75,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy0zLTEtMS0w_7eb39815-3d56-425f-8d34-ca0bba09a100">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy01LTEtMS0w_3fb1561e-3a79-4915-8928-f59994151490">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy03LTEtMS0w_2ce24be0-f5fc-4584-aebf-4471ba745a14">75,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC0xLTEtMS0w_a91f95b0-b32d-4d17-a8a9-818734799c46">903,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC0zLTEtMS0w_6d55251d-d56e-48bf-aaa0-8efa1e26bcb2">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC01LTEtMS0w_8e852753-145c-47e5-bae3-101537533e52">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC03LTEtMS0w_46f89f19-2fae-4d53-b69b-00885a53f605">903,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTEtNy0xLTEtMA_fc700a7d-b288-4ebd-ab10-b840a0ae7373">176,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTItNy0xLTEtMA_5f9b5ecb-0154-4ba5-af72-bfafeb3fbba6">462,716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTMtNy0xLTEtMA_8482b0a3-a0e8-41d1-b7ac-20f372831a46">264,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTQtNy0xLTEtMA_e3e7ff18-b46c-415d-9a94-0db032bd6d88">903,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81538cf0c097486badfa1786facbcdff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy0xLTEtMS0w_e923addf-3fed-462e-a868-9a7ff76b6fce">102,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81538cf0c097486badfa1786facbcdff_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy0zLTEtMS0w_b6338e17-3d8a-433e-bfcb-df3f306684e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81538cf0c097486badfa1786facbcdff_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy01LTEtMS0w_101640d8-7cce-44b9-8454-05992bb8af23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81538cf0c097486badfa1786facbcdff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy03LTEtMS0w_a4c25374-47be-4351-bc46-4700d247e8fe">102,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC0xLTEtMS0w_008b3780-1115-45e7-adfd-c54043d45c50">58,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC0zLTEtMS0w_ea36360f-a170-49e5-85ef-51a70de5659f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC01LTEtMS0w_03fea637-77fe-4652-bd80-70fbb53ab0f6">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC03LTEtMS0w_594e321a-a062-4384-bc76-74330ec6f721">58,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1941e2894148b696f50b001c993d68_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS0xLTEtMS0w_c1a60420-e543-42b8-a2ff-bf2c7fbc109e">262,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1941e2894148b696f50b001c993d68_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS0zLTEtMS0w_8443d7d6-347d-40dd-8c21-15699cecd1c9">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a1941e2894148b696f50b001c993d68_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS01LTEtMS0w_614735a5-6cb6-43e1-b38d-fe988e89eade">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a1941e2894148b696f50b001c993d68_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS03LTEtMS0w_a23d3d19-2767-41ed-a9b4-ee6da62844fc">262,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi0xLTEtMS0w_f02487b7-b051-4ea3-8910-cb54679e58df">446,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi0zLTEtMS0w_17c857d7-426f-4076-8701-4ce3f7eb05b6">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi01LTEtMS0w_1ee744fa-9042-434d-8517-19089bc2af9d">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi03LTEtMS0w_beea2117-70d5-4d0d-94f5-6c97c5dd359a">446,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy0xLTEtMS0w_1bd7d35d-3be2-4203-8574-90277733aaa4">80,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy0zLTEtMS0w_5f865957-6c25-4ff8-a50f-3dc591b059eb">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy01LTEtMS0w_afa42d45-e092-46fc-baaf-b97cc3d804a7">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy03LTEtMS0w_bcbd8213-2703-4e8b-985a-10cc524ba971">80,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC0xLTEtMS0w_5d5caafd-09b6-40ee-a310-ae50d0e5ddf3">950,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC0zLTEtMS0w_d9ee5276-b1c3-4100-b50e-8a436e524153">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC01LTEtMS0w_0fd89903-2b50-4c24-8215-dc4b0cb579b3">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC03LTEtMS0w_62ec0906-e010-4da1-b21a-08f4daa85fbb">950,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTEtNy0xLTEtMA_23a3035b-5974-4cec-9741-effe5c9ec4b0">102,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTItNy0xLTEtMA_00fb7216-3913-4ecb-b6be-2cc55b9d2e23">644,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTMtNy0xLTEtMA_c93224dd-254d-44c1-9566-d976a8db4d93">204,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="allo:CashEquivalentsAndShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTQtNy0xLTEtMA_b338f5fc-71e3-4d9b-a042-840db249bd9a">950,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021,&#160;the remaining contractual maturities of available-for-sale securities were less than <ix:nonNumeric contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" format="ixt-sec:duryear" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfMzEw_c0ae7875-5f1a-4c3b-9676-b8f83914bb59">3</ix:nonNumeric> years. There have been no significant realized losses on available-for-sale securities for the periods presented. As of March&#160;31, 2021, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more likely than not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#8217;s marketable securities are due to market factors. As of March 31, 2021 and December 31, 2020, securities with a fair value of <ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfMzg0ODI5MDY5ODgwMw_32e6d37d-dd62-4b5c-824d-9abd0b2b899e">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfMzg0ODI5MDY5ODc5MA_b04c1633-f1eb-44f5-bcc8-5fbabb5ac95c">5.0</ix:nonFraction>&#160;million respectively, were in a net unrealized loss position for more than 12 months. To date, the Company has not recorded any impairment charges on marketable securities.</span></div></ix:continuation><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_46"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RleHRyZWdpb246M2E0NmI0OTlmYjU0NGJkYzgyMTU3M2UyMDk3YTc4ODdfMTE1_00d9b715-8859-43f4-a98c-b8d59beed7ae" continuedAt="ieca83644871f4f79871df3130c8f945e" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="ieca83644871f4f79871df3130c8f945e" continuedAt="if105577a6ddd4902b67e333e705d5ab9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RleHRyZWdpb246M2E0NmI0OTlmYjU0NGJkYzgyMTU3M2UyMDk3YTc4ODdfMTE2_44004e0a-52c8-4c57-ba88-a8b7204b532e" continuedAt="iae29a4038725461cbea6292e8bed400a" escape="true">Property and Equipment consist of the following:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="if105577a6ddd4902b67e333e705d5ab9"><ix:continuation id="iae29a4038725461cbea6292e8bed400a"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie50601403e82462a993279d9571f8647_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMi0xLTEtMS0w_b899e155-127a-4c96-800d-94abd964a1c3">73,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c98ae4709454667a0750d6459d7ac91_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMi0zLTEtMS0w_66d8133b-0db0-4a69-8039-0bd9e6cfada8">68,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c63d34d1bfe495ea11be0647eed83c7_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMy0xLTEtMS0w_bec31451-dc1d-4eb2-ab18-4230c76ae6ee">31,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ac0012f0854969a20a692346460384_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMy0zLTEtMS0w_253b3441-aa5b-47ec-bcd1-17d641596216">31,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d90dd4d682d4d36a32874f3b745fcb9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNC0xLTEtMS0w_78b2d7ba-b253-426a-9e18-dc86b40777d6">25,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d87e6eccd34d439d8a2297c843c8df_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNC0zLTEtMS0w_63a1f621-69d8-4422-9f85-0d5c2ae3838d">23,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers equipment and purchased software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6974fc646add4195bfcc6857939ed0d3_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNS0xLTEtMS0w_c9ea5b0c-73dd-499c-b298-8cade2c43425">4,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10370fc5f7e4e4e8a0c23adbcbc6922_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNS0zLTEtMS0w_fc0b4f33-0c93-44e3-bb96-23786f4eb36c">4,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieed9ef18264f4d15aa5462978b00b3bf_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNi0xLTEtMS0w_aaf66043-707c-4c7a-b492-8d366b65d168">3,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc7cbd26add4fff8fe2bc2d9c90f90d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNi0zLTEtMS0w_8388c069-6939-46b2-b1e7-ab96b733e132">3,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNy0xLTEtMS0w_d0c7245b-d3b0-41a9-b39c-291dffc640ca">137,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNy0zLTEtMS0w_8ecd4aef-1aec-4461-a3a9-7a4c35456ad1">131,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOC0xLTEtMS0w_d0c32d29-358c-4b2c-86f5-9bfb72d4b2d2">14,825</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOC0zLTEtMS0w_8558a214-3bda-4833-bef3-2ff382fc4fca">12,908</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOS0xLTEtMS0w_b12f7ad7-dd5a-4907-9101-2d64a4a5258a">123,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOS0zLTEtMS0w_afc3eaf7-1b1b-4292-af72-912eb286b4b7">118,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:6pt"><span><br/></span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_49"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="allo:LicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTg4ODY_70170465-015f-41d1-bd54-25e6a46677a3" continuedAt="i80d1e5fc95734dfc88fe1132a853c5a0" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="i80d1e5fc95734dfc88fe1132a853c5a0" continuedAt="i383bc25b4d014cdca73b6a0ef41ac2f4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $<ix:nonFraction unitRef="usd" contextRef="i407ac8a1e41242c9be72213ac2a23645_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNzk3_46d77fa3-5fb6-4d41-b065-19cd8ba9c437">30.0</ix:nonFraction> million or $<ix:nonFraction unitRef="usd" contextRef="i1278a0a51b1640cdbb03fe0a13675240_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfODAz_38a2e1f2-acc7-4134-9f75-66250bb20059">60.0</ix:nonFraction> million, depending on the target, with aggregate potential regulatory and development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i1278a0a51b1640cdbb03fe0a13675240_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialRegulatoryAndDevelopmentMilestones" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfOTA0_255f63c6-0a16-418d-a449-c81122707eb4">840.0</ix:nonFraction> million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $<ix:nonFraction unitRef="usd" contextRef="i48368b1762a44efd868c61b94c87d3b4_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTM1OA_673d0a72-692e-4a46-a041-27af1de27752">325.0</ix:nonFraction> million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. <ix:nonFraction unitRef="usd" contextRef="i5cf55e9cbdb241bda666ae71bf9b4636_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="allo:MilestonePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY2MA_3e1963c1-2924-4518-aaec-2e05e09d8e7c"><ix:nonFraction unitRef="usd" contextRef="i48368b1762a44efd868c61b94c87d3b4_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="allo:MilestonePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY2MA_b46d6f31-bd13-4c25-ba93-261a62df11ec">No</ix:nonFraction></ix:nonFraction> milestone or royalty payments were made in the three months ended March&#160;31, 2021 and 2020 respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) <ix:nonNumeric contextRef="i7c01076628f14533a22a6ed1bf7f645f_D20210101-20210331" format="ixt-sec:duryear" name="allo:RoyaltyObligationPeriodFromDateOfFirstSale" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjMzMg_574d96eb-796e-4df4-aa03-6df386a00122">12</ix:nonNumeric> years from the first sale of such product in such country.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i383bc25b4d014cdca73b6a0ef41ac2f4" continuedAt="ifd6859d0c6f040c2bb323d0ee80547e0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i2d3809bdb24e4487867ca711c35faed6_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDYxMA_b0e2c895-7646-48b3-a4fe-20b274a61677">185.0</ix:nonFraction> million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i5979e4ee83f743c18eb44a9e12a96a76_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDc1MQ_5085354f-2c35-48c1-bb84-be9ed679a184">2.8</ix:nonFraction> billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs the Company incurred in connection with this agreement were recognized as research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and March&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i0d63cc5b557e4a7781a31dbcd492270b_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfODM0MQ_686ddb1c-a9c4-4cef-a934-c4ceff0ccf3f">5.0</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i62d689d0f8bd4b609f81b32837461df5_D20200101-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjc0ODc3OTA5NzAyMA_1adacbbd-3c4f-4159-afd2-0b00eed88398">zero</ix:nonFraction> costs were incurred related to the achievement of a clinical development milestone under this agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="ifd6859d0c6f040c2bb323d0ee80547e0" continuedAt="i153b8013053c457d9bbd3cd0ddea9df4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19, ALLO-501 and ALLO-501A in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for <ix:nonFraction unitRef="number" contextRef="ieb0b77194500411893671236498c869e_D20210101-20210331" decimals="2" name="allo:PercentageOfDevelopmentCostPayableByTheCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5MDQ_29eca72e-2310-4d6d-a8cd-6edd0ccf861c">60</ix:nonFraction>% of the specified development costs and Servier is responsible for the remaining <ix:nonFraction unitRef="number" contextRef="ieb0b77194500411893671236498c869e_D20210101-20210331" decimals="2" name="allo:PercentageOfDevelopmentCostPayableByCollaborationPartner" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5ODc_e575909f-bd36-4b3c-990a-1fc50b32548f">40</ix:nonFraction>% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="ie804f754091d4ee08b0012cf286c45ee_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTE2Mjg_764662f9-6eb6-42ef-9ef1-2e35051d4ad0">137.5</ix:nonFraction> million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $<ix:nonFraction unitRef="usd" contextRef="i94890323746341f2b456015e6973a164_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTE3NjA_9b4ba7c7-a754-483c-8462-1fda4b93b090">78.0</ix:nonFraction> million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $<ix:nonFraction unitRef="usd" contextRef="ib9bcc3e59ff0414e9e68d09f328231d1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTIyMjA_4090d77a-e1f8-41dd-a2a7-8ca51d802431">42.0</ix:nonFraction> million and &#8364;<ix:nonFraction unitRef="eur" contextRef="ie6ce30503f7e4dcb8b48f3209ba957d1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTIyMjc_713dc3c8-e8e8-4aeb-9bdf-589f4b734727">70.5</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="ie6ce30503f7e4dcb8b48f3209ba957d1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestoneReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTIyMzE_0701789f-3f7d-4447-9d88-4536184e7498">82.7</ix:nonFraction> million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i88109eef01694d5087c4d4045520c227_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjc0ODc3OTA5NzE3Nw_331a9104-636f-4e70-b6e0-8f38d3564167">3.9</ix:nonFraction> million  and $<ix:nonFraction unitRef="usd" contextRef="iedead71724684d8c9198e3945bc63aad_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjc0ODc3OTA5NzE4Mg_388d0742-51b4-43e8-9a04-a94e6dfeb16b">1.0</ix:nonFraction> million, respectively,&#160;of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. As of March&#160;31, 2021 and December&#160;31, 2020, amounts due from Servier of $<ix:nonFraction unitRef="usd" contextRef="i88109eef01694d5087c4d4045520c227_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY2MTIyOA_dfbf0daa-0793-4bb6-9a0c-4ba689016cbc">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i93e629aa48694adaba119d9561912c43_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTcxOQ_eb552932-aed1-4fee-a5a7-e5531179563c">3.8</ix:nonFraction> million, respectively, were recorded in other current assets in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Notch</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i153b8013053c457d9bbd3cd0ddea9df4" continuedAt="i2050293ebb1e40c5ad457fe9a26fb603"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $<ix:nonFraction unitRef="usd" contextRef="i076cc18b50ba412ca3242c4341c20664_I20191101" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTU5NDQ_88628b99-b778-4d96-ac76-1a27e9927f6f">10.0</ix:nonFraction>&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ie316218928294928a89e52d1606777a9_D20190101-20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTYxMjM_b1cd8145-6055-442e-b948-31f1aa51c62e">10</ix:nonFraction>&#160;million during the year ended December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $<ix:nonFraction unitRef="usd" contextRef="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTYyNTM_fc0053a3-e62d-4efc-abd8-cb94f945168c">5.0</ix:nonFraction>&#160;million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a <ix:nonFraction unitRef="number" contextRef="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTYzNTA_51583b07-fb98-4e34-98f8-c9764b82acad">25</ix:nonFraction>% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s Board of Directors. In February 2021, the Company made an additional $<ix:nonFraction unitRef="usd" contextRef="i63935ec464224be99ddd75ab04bfdab1_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTk4OQ_8b245ad8-9e85-4bbc-a14d-4eeaba073bb6">15.9</ix:nonFraction> million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was <ix:nonFraction unitRef="number" contextRef="i2d8539bb2dda47de90067bfbe0969f59_I20210228" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTk4MQ_dea8c621-a876-419d-9b18-30da2e67a0c3">20.7</ix:nonFraction>% on a voting interest basis. The Company did not have a controlling interest in Notch as of March 31, 2021, and continued to account for its investment in Notch as an equity method investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Notch Agreement, Notch will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i11005bc5a44b4d80a0ea4954488ea86b_I20210331" decimals="-4" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY3MTM_0c8ac0e1-8cb8-44f7-bc26-77c70eef83b7">7.25</ix:nonFraction>&#160;million upon achieving certain agreed research milestones, up to $<ix:nonFraction unitRef="usd" contextRef="ifac376ffe9ed4e7b99c011fd45a31021_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY3NzM_58571966-c1ec-490f-944f-de35ff978cd7">4.0</ix:nonFraction>&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i7b8687e0cabd401c931e5f274bdb2016_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="allo:AggregatePotentialMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY4Njc_34f81b1d-2bb7-4614-83a1-6cb623847dd7">283.0</ix:nonFraction>&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i2f77c63a834a4681b022dff5f2da6fe7_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationArrangementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTg3OTk_d4671c9b-5d4e-4203-b863-1135ced57091">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i019720c47c404ba483f76b9fc6e614e2_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationArrangementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTI2Nw_011a77c4-044f-4feb-ba59-362cee0612b5">0.3</ix:nonFraction> million, respectively, in collaboration costs as research and development expenses.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic Alliance with The University of Texas MD Anderson Cancer Center</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2020, the Company entered into a strategic <ix:nonNumeric contextRef="ia54b21b65ef24f6cbdcf06ec5a9d9dd0_D20201006-20201006" format="ixt-sec:durwordsen" name="allo:CollaborationAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQwOA_3337902f-99ed-4e28-ae19-bacd9f8f50c3">five-year</ix:nonNumeric> collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The Company and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company has committed up to $<ix:nonFraction unitRef="usd" contextRef="ia54b21b65ef24f6cbdcf06ec5a9d9dd0_D20201006-20201006" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationAgreementCommittedFunding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQxMA_020bbf8b-4261-43f4-b6ce-b3e84c8738ac">15.0</ix:nonFraction>&#160;million of funding for the duration of the agreement. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. The Company made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i08db9380997d4d1b9f4e44201d651df9_I20201231" decimals="-5" format="ixt:numdotdecimal" name="allo:CollaborationAgreementUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQyNQ_5fdd29b1-005d-4bfd-b515-a11085af0202">3.0</ix:nonFraction>&#160;million to MD Anderson in the year ended December 31, 2020. The Company is obligated to make further payments to MD Anderson each year upon the anniversary of the agreement effective date through the duration of the agreement term. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, among other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i2050293ebb1e40c5ad457fe9a26fb603"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture and License Agreement with Allogene Overland Biopharm (CY) Limited </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, the Company entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by the Company and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Share Purchase Agreement, the Company acquired Seed Preferred Shares in Allogene Overland representing <ix:nonFraction unitRef="number" contextRef="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ0Nw_2e96f81d-f6a8-4cea-8f40-9e341a56056f">49</ix:nonFraction>% of Allogene Overland's outstanding stock as partial consideration for the License Agreement, and Overland acquired Seed Preferred Shares representing <ix:nonFraction unitRef="number" contextRef="i9f26d67082094c649f56c52d8b485753_I20201214" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ2OA_17b4a9ec-5123-467a-84e2-3b6519a4f63b">51</ix:nonFraction>% of Allogene Overland's outstanding stock for $<ix:nonFraction unitRef="usd" contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214" decimals="-5" format="ixt:numdotdecimal" name="allo:UpfrontAndQuarterlyCashPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ1Mg_d6faeda1-fa33-430c-bf83-a71712a207da">117.0</ix:nonFraction>&#160;million in upfront and certain quarterly cash payments, to support operations of Allogene Overland. As of December 31, 2020, the Company and Overland are the sole equity holders in Allogene Overland. The Company received $<ix:nonFraction unitRef="usd" contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214" decimals="-6" format="ixt:numdotdecimal" name="allo:JointVentureCapitalSupportPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ3Mw_0b09187f-31c7-413f-8bda-96901b6fad72">40</ix:nonFraction>&#160;million from Allogene Overland as partial consideration for the License Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the License Agreement, the Company granted Allogene Overland an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell candidates directed at four targets, BCMA, CD70, FLT3, and DLL3, in the JV Territory. As consideration, the Company would also be entitled to additional regulatory milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214" decimals="-5" format="ixt:numdotdecimal" name="allo:MilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ4Ng_ee4d9952-9a8b-457b-bfe1-8a7b34f6161b">40.0</ix:nonFraction>&#160;million and, subject to certain conditions, tiered low-to-mid single-digit sales royalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promises that the Company concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and delivery of know-how, (2) the manufacturing license, related know-how and support, (3) if and when available know-how developed in future periods, and (4) participation in the joint steering committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Fixed consideration exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. Milestone fees were constrained and not included in the transaction price due to the uncertainties of research and development. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The shares of Series Seed Preferred Stock were accounted for as part of the Company&#8217;s joint venture and equity method accounting upon formation of the joint venture, and as such, were excluded from the transaction price. The Company determined that the initial transaction price consists of the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214" decimals="-6" format="ixt:numdotdecimal" name="allo:JointVentureCapitalSupportPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjUwMQ_392784ad-2984-4d6f-9755-6c6755976519">40.0</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price allocated to the license of intellectual property and delivery of know-how will be recognized upon grant of license and delivery of know-how. The transaction price allocated to (i) the manufacturing license, related know-how and support services, (ii) if and when available know-how developed in future periods, and (iii) participation in the joint steering committee, will be recognized over time as the services are delivered. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that Allogene Overland is a variable interest entity as of March 31, 2021 and December 31, 2020, respectively. The Company does not have the power to independently direct the activities which most significantly affect Allogene Overland's economic performance. Accordingly the Company did not consolidate Allogene Overland because the Company determined that it was not the primary beneficiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 the Company recognized $<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY2MDE1Ng_fe8dd224-5c98-486e-b851-b29b68939bbc">38.3</ix:nonFraction> million of collaboration revenue, primarily related to the license of intellectual property and delivery of the know-how performance obligation which was delivered in the first quarter of 2021.</span></div></ix:continuation><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_52"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY4OQ_20f1af12-5d9b-46cc-8baf-0d9dc4235a85" continuedAt="ie327dcfa1e4847418ee106edb4bdb8d3" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ie327dcfa1e4847418ee106edb4bdb8d3" continuedAt="i68486965dbbd4ce489da011cc8f9304c"><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately <ix:nonFraction unitRef="sqft" contextRef="i0af7e5161e0e4accbc495ed05d1832d0_I20180831" decimals="-3" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTkx_0aaf9bd2-6efc-42e1-bf67-7f3d004aedac">68,000</ix:nonFraction> square feet located in South San Francisco, California. The lease term is <ix:nonNumeric contextRef="i0af7e5161e0e4accbc495ed05d1832d0_I20180831" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMjY4_eeb09f85-8d60-4859-b127-ac1fdbfd0136">127</ix:nonNumeric> months beginning August 2018 through February 2029 with an option to extend the term for another <ix:nonNumeric contextRef="i0af7e5161e0e4accbc495ed05d1832d0_I20180831" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzYx_abaf5f5a-2788-4696-aab8-e6a7b72bdbd8">seven years</ix:nonNumeric> which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNTIw_227ae940-24b8-4c18-8ff4-d453dab68d29">5.0</ix:nonFraction> million of tenant improvement allowances. The rent payments began on March 1, 2019 after an abatement period. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i68486965dbbd4ce489da011cc8f9304c" continuedAt="i15a0a55a04b84d7ab1eaf1126ea7d620"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of <ix:nonFraction unitRef="sqft" contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfNewOfficeBuilding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNzYw_24e3d701-7cf6-4ec4-912d-a0e7e20c99da">14,943</ix:nonFraction> square feet located in South San Francisco, California. The lease term is <ix:nonNumeric contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfODM3_c8be7649-6ac2-43ac-a1b2-d0db997cd7a8">124</ix:nonNumeric> months beginning November 2018 through February 2029, with an option to extend the term for another <ix:nonNumeric contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfOTMz_c9cb49cd-5d69-47a5-89ba-92a2b62d2ba4">seven years</ix:nonNumeric> which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $<ix:nonFraction unitRef="usd" contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031" decimals="-5" name="allo:TenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTEzMA_e16a8cea-d308-4f7e-b830-b5c6afce8d32">0.8</ix:nonFraction> million. Rent payments began in November 2018. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company entered into a lease agreement for approximately <ix:nonFraction unitRef="sqft" contextRef="i087b1f988f50425c88274e63ae23612e_D20190201-20190228" decimals="-3" format="ixt:numdotdecimal" name="allo:AreaOfOperatingLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTI2MA_68cd4165-1f4a-4d8c-9796-eafbd2581c79">118,000</ix:nonFraction> square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of <ix:nonNumeric contextRef="i9c1ff3e19d184af39773c955bf6f264f_I20190228" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTM4MA_934eb55e-702f-4ba8-9187-c80e59ab70bb">188</ix:nonNumeric> months and commenced in November 2020. Upon certain conditions, the Company has <ix:nonFraction unitRef="renewal" contextRef="i087b1f988f50425c88274e63ae23612e_D20190201-20190228" decimals="INF" format="ixt-sec:numwordsen" name="allo:NumberOfOptionsToExtendLease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTQ3MA_fd20772a-e7f3-420f-9f80-2395a9f10ee3">two</ix:nonFraction> <ix:nonNumeric contextRef="i9c1ff3e19d184af39773c955bf6f264f_I20190228" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5Nw_37b21459-745e-4665-997b-d1edb252decc">ten-year</ix:nonNumeric> options to extend the lease, both of which are not reasonably assured of exercise. The Company is entitled to a tenant improvement allowance of&#160;$<ix:nonFraction unitRef="usd" contextRef="i9c1ff3e19d184af39773c955bf6f264f_I20190228" decimals="-5" name="allo:TenantImprovementAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTYxNg_08f73df9-edc2-4bb0-9a62-8c56aeb59926">2.9</ix:nonFraction> million for costs related to the design and construction of certain Company improvements and has received $<ix:nonFraction unitRef="usd" contextRef="i741a26ced88a4be9b88be81d60e87b12_I20210331" decimals="-5" format="ixt:numdotdecimal" name="allo:TenantImprovementAllowanceUtilizedToDate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzg0ODI5MDcwMjM3OA_236b53b5-eae4-4e9f-ba5e-40bb0a57b52d">2.7</ix:nonFraction>&#160;million of tenant improvement allowances up to March 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains letters of credit for the benefit of landlords which is disclosed as restricted cash in the condensed consolidated balance sheets. Restricted cash related to letters of credit due to landlords was $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTkyOQ_f01aaa02-8de1-4c22-8063-278027f65f57">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTkzNg_9a383dd1-38a5-4e24-a6a7-912a44e5f5c2">4.3</ix:nonFraction>&#160;million as of March&#160;31, 2021 and December&#160;31, 2020, respectively.</span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="allo:LiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5Ng_044acca2-784f-4a6e-bae8-13a065bdb148" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMi0yLTEtMS0w_95f2efe8-a4e6-40d6-babe-fa900fd07000">3,061</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMi00LTEtMS0w_d7096567-c4dd-420e-aebe-995bb0e6b830">2,974</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMy0yLTEtMS0w_c77a2e80-5c94-4246-8766-fe6ad1026ce1">51,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMy00LTEtMS0w_ba573571-8796-44ee-ae2e-96fbca8f9c17">50,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfNC0yLTEtMS0w_c401927c-5750-4cc1-83a7-35dc3f4347a7">54,686</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfNC00LTEtMS0w_d005770c-4761-448d-9be1-53e102eae088">53,783</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5Mw_25904f3a-f3ca-4cc7-b30f-6fba46096f0d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMi0yLTEtMS0w_b2b4acba-e875-4f48-98c5-70795a16d67d">1,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMi00LTEtMS0w_0f98ad67-0353-40c6-943f-8b8947dc5bcb">1,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMy0yLTEtMS0w_593008ce-5bc8-40ac-8c39-f196ea8b35f2">327</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMy00LTEtMS0w_b7247ae1-983c-49ae-b825-355384af7ca7">210</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfNC0yLTEtMS0w_a95b983d-b692-4299-bbe9-0e44e46bed2a">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfNC00LTEtMS0w_01288f1c-1e57-4816-b468-3511012e2612">2,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the three months ended March&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMjI5Nw_e77130f6-cc86-481a-afd5-a40b78eaf797">1.0</ix:nonFraction> million and was included in net cash used in operating activities in our condensed consolidated statements of cash flows. </span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5OA_e42508ec-baa4-4c43-8d7a-73bc1d02fe4e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undiscounted future lease payments under the lease agreements as of March&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2021 (remaining 9 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMS0yLTEtMS0w_05dcc7ae-e759-4d27-b82a-a5290e8fb1ca">5,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMi0yLTEtMS0w_d5810666-7b9b-4e6e-a7a6-86afc1848a24">7,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMy0yLTEtMS0w_cec51cdf-5481-44a0-a6a5-ccb9e66fe83c">8,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNC0yLTEtMS0w_643aa75b-14aa-42dc-9deb-1cddf45bd28b">8,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNS0yLTEtMS0w_ddf88de3-da45-4564-abc1-26e88985a929">8,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="allo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNi0yLTEtMS0w_90bf574f-c924-477b-9529-3e490c52e40d">48,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNy0yLTEtMS0w_2fb36098-c487-4ea9-ae19-e0f729a14ae8">86,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfOC0yLTEtMS0w_26273cc2-9c52-4ee2-a608-85a5c0372d66">31,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" name="allo:TenantImprovementAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfOS0yLTEtMS0w_1c8c57b8-80b1-4028-8c94-f7c9c7515b24">325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMTAtMi0xLTEtMA_61eb93a5-1892-4dee-a555-dde09bcfe242">54,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i15a0a55a04b84d7ab1eaf1126ea7d620"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discount rate used to determine the operating lease liability was&#160;<ix:nonFraction unitRef="number" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMjgzOA_e1744f99-38d8-4f85-ac70-0e8de89cf055">8.40</ix:nonFraction>%. As of&#160;March&#160;31, 2021, the weighted average remaining lease term for our operating leases is&#160;<ix:nonNumeric contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfOTM0NTg0ODg0MDg1Mw_3c41a5b6-572c-45c8-8802-48b9fa30f6fc">10.22</ix:nonNumeric> years.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, the Company entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at the Company's cell therapy manufacturing facility in Newark, California. The agreement has a term of <ix:nonNumeric contextRef="i6f0049318f88420fb355203ab4e399b1_I20200731" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseTermOfContract1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzI5MA_73d246f0-4ce1-49a7-a19d-1e9457d367cd">20</ix:nonNumeric> years and is expected to commence in the second quarter of 2021. The Company is obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by the Company will result in a termination payment due of approximately $<ix:nonFraction unitRef="usd" contextRef="i6f0049318f88420fb355203ab4e399b1_I20200731" decimals="-5" format="ixt:numdotdecimal" name="allo:LesseeFinanceLeasePaymentUponContractTermination" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzU4NQ_58cc8fd6-4637-4b7d-adb6-25fd8c215e7d">4.3</ix:nonFraction>&#160;million. In connection with the agreement, the Company maintains a letter of credit for the benefit of the service provider in the amount of $<ix:nonFraction unitRef="usd" contextRef="i413a4f8e6e7e4ee28ed209070c2b4426_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzcwNQ_5e26b1fb-c53b-4b66-869a-5580c101a3f6">4.3</ix:nonFraction>&#160;million which is disclosed as restricted cash in the condensed consolidated balance sheet as of March&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of March&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of March&#160;31, 2021, the Company had non-cancellable purchase commitments of $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY4Nw_f47537b0-a09f-4605-99d1-c651e350df91">4.1</ix:nonFraction>&#160;million.</span></div></ix:continuation><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_58"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNTUx_91a81bf6-2667-4a32-ad57-e6e7e668b60d" continuedAt="i9442a68c8b5747e2ab0cc8e032847e44" escape="true">Equity Method Investment</ix:nonNumeric></span></div><ix:continuation id="i9442a68c8b5747e2ab0cc8e032847e44"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notch Therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $<ix:nonFraction unitRef="usd" contextRef="i6b1c66efc41f41b3a6ae07c79e88874c_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMjg1_ae5eec99-e032-46fb-83a6-a2ddb911af30">5.1</ix:nonFraction>&#160;million which includes transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i6b1c66efc41f41b3a6ae07c79e88874c_D20191101-20191101" decimals="-5" format="ixt:numdotdecimal" name="allo:CostMethodInvestmentTransactionCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzI0_40e0f98c-057e-498d-a29b-1709b30bad88">0.1</ix:nonFraction>&#160;million, resulting in a <ix:nonFraction unitRef="number" contextRef="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzQz_2b14c934-7f77-472e-a75c-cb5804326378">25</ix:nonFraction>% ownership interest in Notch. In February 2021, the Company made a $<ix:nonFraction unitRef="usd" contextRef="i63935ec464224be99ddd75ab04bfdab1_D20210201-20210228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5OTUzNQ_82610b38-2016-428f-97e5-4a9d361dd14b">15.9</ix:nonFraction> million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was <ix:nonFraction unitRef="number" contextRef="i2d8539bb2dda47de90067bfbe0969f59_I20210228" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5OTcyMw_9bbba1d9-3571-4c53-a03f-c0b18e517c7d">20.7</ix:nonFraction>% on a voting interest basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total equity investment in Notch as of March&#160;31, 2021 and December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMTA5OTUxMTYzMDMzNQ_3dc256eb-b576-4783-b48a-5e05d4cefc40">19.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMTA5OTUxMTYzMDM1MA_db38dcc0-574d-4b1d-9b76-b308c0ba0b2b">3.7</ix:nonFraction> million, respectively, and the Company accounted for the investment using the equity method of accounting. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allogene Overland Biopharm (CY) Limited</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the License Agreement with Allogene Overland (see Note 6), the Company also entered into a Share Purchase Agreement and Shareholders' Agreement with the joint venture company under which it acquired shares of Allogene Overland&#8217;s Seed Preferred Shares representing a <ix:nonFraction unitRef="number" contextRef="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNDk0NzgwMjMyNjU5Mg_077441ae-53a3-4ed3-9464-7fde735a6f53">49</ix:nonFraction>% ownership interest as partial consideration for entering into a License Agreement which had a carrying value of <ix:nonFraction unitRef="usd" contextRef="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5ODgyOQ_499db0d7-5cec-42e3-9065-be872d8c2958">zero</ix:nonFraction>. The Company accounts for its investment in Allogene Overland as an equity method investment at carrying value. The Company's total equity investment in Allogene Overland was <ix:nonFraction unitRef="usd" contextRef="i6e523f02887b4694813dc952ebe2a83d_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNDk0NzgwMjMyNjU5Ng_01fc0b96-5f2e-45a6-a40c-4e02f5217b73"><ix:nonFraction unitRef="usd" contextRef="ie55d9fe72329461caf14cd949cf5f9f0_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNDk0NzgwMjMyNjU5Ng_0d46ce28-a856-4231-b24e-9b8a77f3db32">zero</ix:nonFraction></ix:nonFraction> as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The  Company&#8217;s equity investment in Allogene Overland as of March&#160;31, 2021 and December&#160;31, 2020 had a <ix:nonFraction unitRef="usd" contextRef="i6e523f02887b4694813dc952ebe2a83d_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5ODgzOA_8867cdd4-a60a-4d20-9e9a-4abfd6b034f9"><ix:nonFraction unitRef="usd" contextRef="ie55d9fe72329461caf14cd949cf5f9f0_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EquityMethodInvestmentQuotedMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5ODgzOA_d908d159-8a5b-4f20-a0d0-db21687ca21c">zero</ix:nonFraction></ix:nonFraction> carryover basis. Therefore, the Company did not account for its share of losses incurred by Allogene Overland. See Note 6 for further details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyMQ_e79fe5b8-5554-414c-93e8-27745c47d538" continuedAt="i1c29ba7c294a4555a0d62bdfa2473347" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i1c29ba7c294a4555a0d62bdfa2473347" continuedAt="i99b56b218c62423da9ebce19e3adcd5f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company adopted its 2018 Equity Incentive Plan (Prior 2018 Plan). The Prior 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#8217;s Board of Directors. In September 2018, the Board of Directors adopted a new amended and restated 2018 Equity Incentive Plan as a successor to and continuation of the Prior 2018 Plan, which became effective in October 2018 (the 2018 Plan), which authorized additional shares for issuance and provided for an automatic annual increase to the number of shares issuable under the 2018 Plan by an amount equal to <ix:nonFraction unitRef="number" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="INF" name="allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNzYz_6ddd5c12-11d7-4bc6-b52c-08e6dbe33cf4">5</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed <ix:nonNumeric contextRef="i14bbb500f25447d69b2babcd02fb2d40_D20210101-20210331" format="ixt-sec:duryear" name="allo:StockOptionGrantedPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfOTQy_fd418ff8-0f11-4fe5-8766-5ac7c00c2503">10</ix:nonNumeric> years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than <ix:nonFraction unitRef="number" contextRef="i14bbb500f25447d69b2babcd02fb2d40_D20210101-20210331" decimals="INF" name="allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTA3NQ_c6463d25-87ac-4551-97e1-48dd1644de89">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a <ix:nonNumeric contextRef="ic2b360877fd0487881046b793d288efa_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyMg_831e34f3-9bf7-4aab-9c0a-bde04fe03fc3">four-year</ix:nonNumeric> period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a <ix:nonNumeric contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyNQ_d805b16a-301c-4ec6-95bc-e32171a24d46">four-year</ix:nonNumeric> period but may be granted with different vesting terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTQwMQ_31426d0f-c8e3-416e-afb4-1cdb8c30245b">17,212,410</ix:nonFraction> shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyMw_d96f35a6-774b-41bf-88e7-62d0cfac1a20" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:42.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9606d98985d4a4aa8219e4759fe5755_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy0xLTEtMS0w_35f5602d-3387-4c9b-8ba5-da3ece833703">10,434,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9606d98985d4a4aa8219e4759fe5755_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy0zLTEtMS0w_92df33ca-a716-4bc8-9700-95e9fb2d7ac3">17.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib97658ccecf0407bb53a0ff5d41930f1_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy01LTEtMS0w_700e025d-a226-4b05-8915-0f80f59bd466">8.29</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9606d98985d4a4aa8219e4759fe5755_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy03LTEtMS0w_28b0b7f0-24da-411e-832c-995fac0f564b">93,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNC0xLTEtMS0w_f08511c1-e695-43b0-a3ac-4270dfb01377">1,617,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNC0zLTEtMS0w_b7bf0cc6-0491-4249-a462-96868ddbd2c9">34.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNS0xLTEtMS0w_ef3fdf46-b926-476f-b19a-0e135f12ae74">447,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNS0zLTEtMS0w_154ca88f-046a-400c-b626-ee07c770f0f1">8.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNi0xLTEtMS0w_caa880a8-fae4-4872-8115-9c28cc24acfe">496,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNi0zLTEtMS0w_1018bdb0-9a30-4261-80c6-e99b2111e10e">15.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy0xLTEtMS0w_632a0fbf-4925-44ec-b8ac-2bc8c3f60055">11,107,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy0zLTEtMS0w_1e08903e-5396-4bea-87fd-5c1d57c28754">20.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy01LTEtMS0w_2299a786-eefd-43bf-b219-ec29b0f51129">8.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy03LTEtMS0w_ab303b4a-8a7d-4461-a314-b94976af518b">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0xLTEtMS0w_56ffaf4a-8a6c-4e2e-bb72-cd690d0f482f"><ix:nonFraction unitRef="shares" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0xLTEtMS0w_7b8dd709-71fa-4bd3-9d70-c8068a683afa">7,423,034</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0zLTEtMS0w_3abec557-0e02-42cd-9756-f30b15e07bb7"><ix:nonFraction unitRef="usdPerShare" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0zLTEtMS0w_6cd3e5c4-9d99-4c74-b44a-603c37e11254">19.15</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC01LTEtMS0w_fb7cf964-96a7-432c-8d8e-84c5eafa9f68">8.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC03LTEtMS0w_fb332fad-8ba3-465a-baad-b40b73a9515f">120,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS0xLTEtMS0w_79296f64-f68f-4e29-883d-3c2b4bb24364">11,107,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS0zLTEtMS0w_1b6cb5eb-e73c-4255-a1ac-9a11a68c9375">20.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS01LTEtMS0w_6776f4ed-4241-4471-a58e-9da6584b158f">8.23</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS03LTEtMS0w_706c1772-1bc4-4fd0-84b7-1490218b4c05">166,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on March&#160;31, 2021. For the three months ended March&#160;31, 2021, the estimated weighted-average grant-date fair value of employee options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i4e50cc94898c4c38af402cdd90cb3431_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTk2Mg_13ca98fd-73a6-475d-a7c9-5d5715bb96d1">21.41</ix:nonFraction> per share. As of March&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i7851275aa1884775b7054b0238c07f90_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTk5Ng_388381b6-7d6b-4b59-8f64-c9bfabd2df1f">102.9</ix:nonFraction>&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i4e50cc94898c4c38af402cdd90cb3431_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMjE0NA_dcc77090-5766-40fd-813b-90a42ca98a62">2 years, 332 days</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIxOA_86fdbd7d-d877-4aee-988d-4b8a710beb6e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:67.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.195%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5060d1ddf0ff4c76a3852cdb609b01d6_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0xLTEtMS0wL3RleHRyZWdpb246M2Q4YTNkMzRiMGUzNGViMDk1MDhiMGJlZmJiMWU2YTVfNA_2f771285-af4d-4d86-9d46-b9e5a8689dbe">6.06</ix:nonNumeric> - <ix:nonNumeric contextRef="id0f00168a0e94cdcb56ab6e3ec5a5938_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0xLTEtMS0wL3RleHRyZWdpb246M2Q4YTNkMzRiMGUzNGViMDk1MDhiMGJlZmJiMWU2YTVfOQ_1c8fe72a-3c42-4b5e-beaa-f306113c5f70">6.08</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i25c39330288e480a82e92430adf135a6_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0zLTEtMS0wL3RleHRyZWdpb246MDJhYjVjMGFiYjc3NDViNGExZGFiZTljNzU5MWE2NTlfNA_a0c34740-bd09-494d-9751-e7e960a0ef05">6.07</ix:nonNumeric> - <ix:nonNumeric contextRef="i14661dcd7bd04b018bb9677c345a8f5c_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0zLTEtMS0wL3RleHRyZWdpb246MDJhYjVjMGFiYjc3NDViNGExZGFiZTljNzU5MWE2NTlfOQ_58c3fa10-5a03-40cb-8fe2-641aa038776a">6.09</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMy0xLTEtMS0wL3RleHRyZWdpb246YTgzNTA4NzczZTZiNDIyMzkzNDliN2QyZTdlOGVlM2JfNA_e29a7b5d-59cf-4566-8f28-2b94f8464146">70.80</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMy0zLTEtMS0w_f07081b0-8e37-4667-85fb-77de83b3a34a">71.42</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0xLTEtMS0wL3RleHRyZWdpb246NDc4ODMzZDVmYTgxNDM0NjlkNTA1MjA4NGZiMGY5NTBfNA_2351e3aa-e4a8-477c-b7a9-fbb892b53eed">0.60</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0xLTEtMS0wL3RleHRyZWdpb246NDc4ODMzZDVmYTgxNDM0NjlkNTA1MjA4NGZiMGY5NTBfOQ_a4edba89-42db-4eab-a19e-967d2f19d6c1">1.16</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0zLTEtMS0wL3RleHRyZWdpb246MDBjYmE5OTliM2M4NDg5ODk3NWEyN2MzYzQ1OGYxYjZfNA_fc772c8f-66e7-40d3-83c7-f14b822cea75">0.80</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0zLTEtMS0wL3RleHRyZWdpb246MDBjYmE5OTliM2M4NDg5ODk3NWEyN2MzYzQ1OGYxYjZfOQ_f5c0ebfe-36ca-4fdb-9ec7-7cd83fb91443">1.65</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNS0xLTEtMS0w_803ab3e5-11e3-45d7-bbdb-d5d1856e6f4a">0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNS0zLTEtMS0w_b4ea430b-213a-4170-9326-3584d7db74a9">0</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><ix:continuation id="i99b56b218c62423da9ebce19e3adcd5f"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNzY5NjU4MTM5OTcwOQ_58fbf565-f4bd-4efb-bc07-3ab94c028497">zero</ix:nonFraction>.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIxOQ_1f6f5dfe-ad6f-43c9-b0fa-008e7a6cc6c9" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes restricted stock unit activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value at Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Grant per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy0xLTEtMS0w_25dcd22e-5f76-469b-b39c-d146b4669aa7">2,493,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy0zLTEtMS0w_4ffc3200-a0a7-44a3-9844-78a57a25a907">26.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i769dd97badbb4b2f80e2f2bbbb9b5946_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy01LTEtMS0w_807ce759-4907-4d75-9df7-34f94d898d11">1.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy03LTEtMS0w_55bbc5d3-6b87-4373-b237-d60ea64c2566">62,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNC0xLTEtMS0w_07cafc7f-9ab5-40b7-afdb-389af001b55c">1,139,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNC0zLTEtMS0w_900c5091-d208-4558-ace2-c31023e0e9c7">33.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" format="ixt-sec:duryear" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNC01LTEtMS0w_251904ed-38de-4b0e-a206-3224eb04f94a">2.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNS0xLTEtMS0w_ea8c1713-4a79-4b9d-a013-53c64a44b11c">439,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNS0zLTEtMS0w_073ff20f-0967-44f8-94c3-02b7a7721672">23.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNi0xLTEtMS0w_91d7d9a0-a40a-4366-8315-82ff5bb03128">140,218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNi0zLTEtMS0w_9adabadf-439e-4262-b9bd-3aed9b348bde">25.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i231088853bd94ca78694266c68e382cd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy0xLTEtMS0w_27dcde55-6d68-4369-b1ec-b9bde5f9e812">3,053,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i231088853bd94ca78694266c68e382cd_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy0zLTEtMS0w_338f4e3f-9fb4-4646-88b6-69ea425001d6">29.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy01LTEtMS0w_3714a88b-e329-4047-8259-3a325c4e7d6a">2.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i231088853bd94ca78694266c68e382cd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy03LTEtMS0w_de12f607-a20e-4ef1-9dab-b1574c3b2c46">107,785</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i231088853bd94ca78694266c68e382cd_I20210331" decimals="INF" format="ixt:numdotdecimal" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC0xLTEtMS0w_27118ad5-6251-419a-9cc0-a2a43d52427c">3,053,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i231088853bd94ca78694266c68e382cd_I20210331" decimals="2" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC0zLTEtMS0w_641213f0-26f5-480a-8713-9c03992987b9">29.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" format="ixt-sec:duryear" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC01LTEtMS0w_eb90490a-7a2a-4306-93d0-314260cb97d9">2.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i231088853bd94ca78694266c68e382cd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC03LTEtMS0w_ff1d1248-e916-421a-926e-7ce919bc3264">107,785</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i231088853bd94ca78694266c68e382cd_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMzY0Nw_744c056a-da00-47ac-a424-7894880301c8">82.0</ix:nonFraction>&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMzgwNA_975a8c5f-28dd-448f-b30b-eeec099510d1">3 years, 88 days</ix:nonNumeric>.</span></div><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyNA_76bf6ea7-7dc1-420f-9f7b-812f0e5e7df8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f77c63a834a4681b022dff5f2da6fe7_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMi0xLTEtMS0w_3f50f097-f461-45a1-87e2-cb1ba3664696">7,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i019720c47c404ba483f76b9fc6e614e2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMi0zLTEtMS0w_9e7ee6c2-c499-4bf9-9dcb-c76167989421">6,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51e3200cd5ee4aec98b75df42cbd8a19_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMy0xLTEtMS0w_8270b588-504c-4006-9fdd-4379f5a53f28">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i701ddf49607b425c93a8f1bcc7064cec_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMy0zLTEtMS0w_3d808b63-9960-4140-be5d-71f153f319ab">7,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfNC0xLTEtMS0w_a131fb76-4a77-430d-81cf-60efa9df2bb4">16,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfNC0zLTEtMS0w_b4e99c70-8320-4515-8d64-de5e6bea0163">14,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercised Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows certain of its employees and its directors to exercise options granted under the Prior 2018 Plan and the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of March&#160;31, 2021 and December 31, 2020 there was $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNDc4Nw_21872964-5d53-4831-948e-92bba3cb7caa">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNDc5NA_0419d91a-f897-44c7-a978-cbc92d0dd30e">2.8</ix:nonFraction> million recorded in accrued and other liabilities and $<ix:nonFraction unitRef="usd" contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNDg0Mw_0947e532-4298-43d5-9111-7e9a4ca46e8e">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMjc0ODc3OTA3NjMwNg_0bbea527-4782-4bb0-b01d-d1dcf4b46ec5">1.1</ix:nonFraction> million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed consolidated financial statements since the exercise date but the shares which are subject to future vesting conditions are not included in the calculation of earnings per share.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfNDIxNA_168a8ef5-900c-43eb-a302-a894e8b7888d" continuedAt="i8e6a7123ce12411590774ec240e96394" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i8e6a7123ce12411590774ec240e96394"><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a license agreement with Allogene Overland, a corporate joint venture entity and related party (see Note 6). During the three months ending March 31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMjc0ODc3OTA3ODc2NA_fe8dd224-5c98-486e-b851-b29b68939bbc">38.3</ix:nonFraction> million of collaboration revenue from Allogene Overland under this arrangement.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for <ix:nonFraction unitRef="sqft" contextRef="if95eb4b787c74543b5067fc4b0661d0f_D20181201-20181231" decimals="0" format="ixt:numdotdecimal" name="allo:AreaOfOffice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMTMwOA_cc3d3aea-f86c-453e-abea-e32a94f37f51">1,293</ix:nonFraction> square feet of office space in Los Angeles, California for a <ix:nonNumeric contextRef="i0ebc3e0c018541f4b70cf9419d86dfa9_I20181231" format="ixt-sec:durwordsen" name="us-gaap:LessorOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfNDIxNQ_907c0f87-da3a-4a9e-bac2-5b49db0a6231">three year</ix:nonNumeric> term. On April 1, 2020, Bellco Capital Advisors Inc. assumed all rights, title, interests and obligations under the sublease from Bellco Capital LLC. The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc. The total right of use asset and associated liability recorded related to this related party lease was $<ix:nonFraction unitRef="usd" contextRef="i2f6335266109450ca23eec174e7cdcab_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMTc4NQ_330b200d-72da-4939-af66-cf6a248c95b2"><ix:nonFraction unitRef="usd" contextRef="i2f6335266109450ca23eec174e7cdcab_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMTc4NQ_8272f28e-bdbe-418d-a83c-4bbbc4faa55c">0.1</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6c6f84593b7d463c9ff60c7ca46e93bb_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0Mzc5Ng_ab5487f4-2b2e-4939-b7b1-4784635ff9e0"><ix:nonFraction unitRef="usd" contextRef="i6c6f84593b7d463c9ff60c7ca46e93bb_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0Mzc5Ng_c8017c14-7733-410b-87c2-dbcd0ea7d046">0.1</ix:nonFraction></ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $<ix:nonFraction unitRef="usd" contextRef="i722789689fd9475695feac4a92e9226f_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMjk3Mg_17f425c5-d267-404f-ae88-37e285f6440c">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i158e95b9cb1646beabf8dfd28baec0fc_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0NDU4MQ_9179ac35-3728-4add-8d29-20156481dc9e">0.1</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $<ix:nonFraction unitRef="usd" contextRef="i986898a7e34741d7954f86f9c33d1968_D20180801-20180831" decimals="INF" format="ixt:numdotdecimal" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMzYyMQ_a70c0847-bdea-4c5f-ba0c-61ed9fa1e77b">37,500</ix:nonFraction> per month in arrears commencing January 2020 and $<ix:nonFraction unitRef="usd" contextRef="i5a1c8fe00fa14644bd319487f70e9221_D20180801-20180831" decimals="INF" format="ixt:numdotdecimal" name="allo:RelatedPartyTransactionMonthlyPaymentsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMzY3Mw_80f87820-5388-446e-8b18-12b0451ccf9d">38,583</ix:nonFraction> per month in arrears commencing January 2021. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to <ix:nonFraction unitRef="number" contextRef="ia418d380ade7488fa285afa3617ce316_D20180801-20180831" decimals="INF" name="allo:RelatedPartyTransactionCompensationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMzgyMQ_a6a53196-10a9-4cfc-ab46-32633dfcb4c0">60</ix:nonFraction>% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $<ix:nonFraction unitRef="usd" contextRef="iea9e93b01c9d476194a141c6b0fef19e_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfNDEwNA_9f23b98a-ea8e-4865-a1bd-17fc2be242b0">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if0bf2b2e4cd04570b9e804413fe277cb_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0NDU4Ng_fdba8feb-1fc9-48fa-af33-7e0eece10f05">0.2</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_67"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182Ny9mcmFnOmJkMTNmMWI5ODllMDRmZTJiOWM2ODkxYmNhMmYyNjc1L3RleHRyZWdpb246YmQxM2YxYjk4OWUwNGZlMmI5YzY4OTFiY2EyZjI2NzVfMjAw_13aa7775-a362-46ac-855d-0a6bca94e6e1" continuedAt="ia70a2b7413f54a7a9e591f5086b430a4" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia70a2b7413f54a7a9e591f5086b430a4">The Company has a history of losses, and expects to record a loss in 2021. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</ix:continuation></span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_70"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RleHRyZWdpb246NTIxZjNjMjgxMTZlNDhjMDk2MGUxZGMwODRkNDNmMTVfMjIx_219bb92b-69f0-40e8-935e-7f9a219e3dd3" continuedAt="id98cdb42540c48e78a87298413c8389d" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="id98cdb42540c48e78a87298413c8389d"><ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RleHRyZWdpb246NTIxZjNjMjgxMTZlNDhjMDk2MGUxZGMwODRkNDNmMTVfMjIy_28ba6190-a155-4f10-823a-19bcd99988d5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e4b9c96e43a4d7e97a39037a134b7e1_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMi0xLTEtMS0w_254e8757-d2a8-442a-b896-8ee7897446b2">11,107,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2ea6b4be1364df5a17f2f871d780f18_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMi0zLTEtMS0w_c1702964-49ef-4305-bf94-65d0188fcbdb">11,627,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units subject to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18038f78c8f7485c88a47821af555ffa_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMy0xLTEtMS0w_2357c602-67f1-4489-a0e3-d6d4b2626a99">3,053,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i787d6c72d2aa4f58916999e0c3306ea9_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMy0zLTEtMS0w_3cd32f6d-0f36-4ca7-a531-96aaad7e344c">2,534,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieec840582431407c876320ad99849824_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNC0xLTEtMS0w_44086156-96d3-4862-83be-f4c6898c496b">258,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64ffc5ac698f42a59f37c79159d75b55_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNC0zLTEtMS0w_9de13edc-b9ce-46db-97c9-9259cc27885f">226,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Founder's shares of common stock subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i855de4b72ebc4f219d2f0aba2723cefd_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNS0xLTEtMS0w_44bd39b7-4518-47ef-850a-5a685238f338">6,057,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04ba8e4cb94c47d6b333c42599e31017_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNS0zLTEtMS0w_17adabaa-b0f6-4399-b776-76a6b9807b55">12,115,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41eacec9267f4e78b154a165573c48bc_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNi0xLTEtMS0w_3dc3a1c6-f9ef-4fe5-b89c-a868e799d677">1,423,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadaf0078bc664e608b63092936b79aaf_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNi0zLTEtMS0w_d2c1dacb-e2e4-4742-9a11-fc310c8cf6dd">2,678,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNy0xLTEtMS0w_eb743a7f-65c9-466c-8639-51e15c04ac1a">21,900,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNy0zLTEtMS0w_c242bb41-d7dc-45b7-a95a-24b5cf60c23f">29,182,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_73"></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183My9mcmFnOmNiODYzYTM1NWU4ODRlZWVhMmRkOTUxYmNkMjUwMzVmL3RleHRyZWdpb246Y2I4NjNhMzU1ZTg4NGVlZWEyZGQ5NTFiY2QyNTAzNWZfNTY1_8ff0ed93-3867-46b8-a6fa-3d7aad61eb30" continuedAt="ic4fb4831e3f04073bcc2330e41d7ddd7" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic4fb4831e3f04073bcc2330e41d7ddd7">None.</ix:continuation></span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December&#160;31, 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2020 (Annual Report), which was filed with the Securities and Exchange Commission (SEC) on February 25, 2021. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company&#8221;, &#8220;Allogene,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Allogene Therapeutics, Inc., and references to &#8220;Servier&#8221; collectively refer to Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to historical financial information, this discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; under Part II, Item 1A below. In some cases, you can identify forward-looking statements by terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements</span><span style="color:#32406b;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. We are developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Our engineered T cells are allogeneic, meaning they are derived from healthy donors for intended use in any patient, rather than from an individual patient for that patient&#8217;s use, as in the case of autologous T cells. We believe this key difference will enable us to deliver readily available treatments faster, more reliably, at greater scale, and to more patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a deep pipeline of allogeneic chimeric antigen receptor (CAR) T cell product candidates targeting multiple promising antigens in a host of hematological malignancies and solid tumors. Pursuant to the Exclusive Collaboration and License Agreement with Servier (Servier Agreement), we have exclusive rights to ALLO-501 and ALLO-501A, CAR T cell product candidates targeting CD19, in the United States, while Servier retains exclusive rights for these product candidates for all other countries. ALLO-501 and ALLO-501A use Cellectis S.A. (Cellectis) technologies under which Servier holds an exclusive worldwide license from Cellectis.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are sponsoring a Phase 1 clinical trial (the ALPHA trial) of ALLO-501 in patients with R/R non-Hodgkin lymphoma (NHL). We are also progressing the development of the second-generation version of ALLO-501, known as ALLO-501A. We have removed rituximab recognition domains in ALLO-501A, which we believe will potentially facilitate treatment of more patients, as rituximab is a typical part of a treatment regimen for a patient with NHL. We initiated a Phase 1/2 clinical trial for ALLO-501A (the ALPHA2 trial) in the second quarter of 2020. We plan to report updated data from the ALPHA trial and initial data from the ALPHA2 trial on May 19, 2021. We also plan to continue to progress the ALPHA and ALPHA2 trials and, subject to data, we plan to progress to the Phase 2 portion of the ALPHA2 trial by the end of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are progressing three programs targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. We initiated a Phase 1 clinical trial (the UNIVERSAL trial) of ALLO-715 in adult patients with R/R multiple myeloma in the third quarter of 2019 and presented initial clinical data at the American Society of Hematology annual meeting in December 2020. Based on preliminary clinical data, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-715 for the treatment of adult patients with R/R multiple myeloma after three or more prior lines of therapies.  RMAT does not change the standards for approval but may expedite the development or approval process. In January 2020, we entered into a clinical trial collaboration agreement with SpringWorks </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics, Inc. (SpringWorks) to evaluate ALLO-715 in combination with SpringWorks&#8217; investigational gamma secretase inhibitor, nirogacestat, in patients with R/R multiple myeloma. In the first quarter of 2021, we initiated this combination trial as part of the UNIVERSAL trial. Finally, we are advancing ALLO-605, an allogeneic CAR T cell product candidate targeting BCMA and our first product candidate to incorporate our TurboCAR technology. The FDA recently cleared our investigational new drug application (IND) to initiate a Phase 1 clinical trial (the IGNITE trial) of ALLO-605. We expect to initiate the IGNITE trial in mid-2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently initiated a Phase 1 clinical trial (the TRAVERSE trial) of ALLO-316, an allogeneic CAR T cell product candidate targeting CD70, in adult patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to enroll patients in the ALPHA trial, ALPHA2 trial, UNIVERSAL trial and TRAVERSE trial, however, enrollment of new patients in our trials and the ability to conduct patient follow-up is being adversely impacted by the COVID-19 pandemic. We have also limited the number of staff working at our facilities. The exact timing of delays and overall impact of the COVID-19 pandemic to our business, preclinical studies and clinical trials is currently unknown, and we are monitoring the pandemic as it continues to rapidly evolve.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have had significant operating losses. Our net losses were $33.0 million for the three months ended March&#160;31, 2021. As of March&#160;31, 2021, we had an accumulated deficit of $679.4 million.&#160;As of March&#160;31, 2021, we had $964.2 million in cash and cash equivalents and investments.&#160;We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses and general and administrative expenses will continue to increase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Research and Development and License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, we entered into an Asset Contribution Agreement (Pfizer Agreement) with Pfizer pursuant to which we acquired certain assets and assumed certain liabilities from Pfizer, including agreements with Cellectis and Servier as described below, and other intellectual property for the development and administration of CAR T cells for the treatment of cancer. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the Pfizer Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, Pfizer entered into a Research Collaboration and License Agreement with Cellectis. In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. In March 2019, we terminated the agreement with Cellectis and entered into a new license agreement with Cellectis. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further descriptions of the prior agreement with Cellectis and the new license agreement with Cellectis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, Pfizer entered into the Servier Agreement to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR products, including UCART19, in the United States with the option to obtain the rights over certain additional allogeneic anti-CD19 CAR product candidates and for allogeneic CAR T cell product candidates directed against one additional target. In April 2018, Pfizer assigned the agreement to us pursuant to the Pfizer Agreement. In October 2019, we agreed to waive our rights to the one additional target. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the Servier Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration and License Agreement with Notch</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2019, we entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted us an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in NHL, ALL and multiple myeloma. In addition, Notch has granted us an option to add certain specified targets to our exclusive license in exchange for an agreed upon per-target option fee.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to our exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. In connection with the execution of the Notch Agreement, we made an upfront payment to Notch of $10.0 million. In addition, we made a $5.0 million investment in Notch&#8217;s series seed convertible preferred stock, resulting in us having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In February 2021, we made an additional $15.9 million investment in Notch's Series A preferred stock. Immediately following this transaction, our share in Notch was 20.7% on a voting interest basis. See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the Notch Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Alliance with The University of Texas MD Anderson Cancer Center</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2020, we entered into a strategic five-year collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. See Note 6 to our consolidated financial statements included elsewhere in this report for further description of the agreement with MD Anderson.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Allogene Overland Biopharm (CY) Limited </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, we entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by us and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Share Purchase Agreement, we acquired Seed Preferred Shares in Allogene Overland representing 49% of Allogene Overland's outstanding stock as partial consideration for the License Agreement, and Overland acquired Seed Preferred Shares representing 51% of Allogene Overland's outstanding stock for $117.0&#160;million in upfront and certain quarterly cash payments, to support operations of Allogene Overland. As of March&#160;31, 2021, Allogene and Overland are the sole equity holders in Allogene Overland. The Company received $40 million from Allogene Overland as partial consideration for the License Agreement . </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the License Agreement, we granted Allogene Overland an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell candidates directed at four targets, BCMA, CD70, FLT3, and DLL3, in the JV Territory. As consideration, we would also be entitled to additional regulatory milestone payments of up to $40.0 million and, subject to certain conditions, tiered low-to-mid single-digit sales royalties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promises that we concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and delivery of know-how, (2) the manufacturing license, related know-how and support, (3) if and when available know-how developed in future periods, and (4) participation in the joint steering committee.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the transaction price, we evaluated all the payments to be received during the duration of the contract. Fixed consideration exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We constrain the estimated variable consideration when we assess it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. Milestone fees were constrained and not included in the transaction price due to the uncertainties of research and development. We re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The shares of Series Seed Preferred Stock were accounted for as part of our joint venture and equity method accounting upon formation of the joint venture, and as such, were excluded from the transaction price. We determined that the initial transaction price consists of the upfront payment of $40.0&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that we would charge for a performance obligation if it were sold separately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price allocated to the license of intellectual property and delivery of know-how will be recognized upon grant of license and delivery of know-how. The transaction price allocated to (i) the manufacturing license, related know-how and support services, (ii) if and when available know-how developed in future periods, and (iii) participation in the joint steering committee, will be recognized over time as the services are delivered. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied. We recognized $38.3 million of the upfront payment of $40.0 million as collaboration revenue for the quarter ending on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 to our condensed consolidated financial statements included elsewhere in this report for further description of the License Agreement and Share Purchase Agreement with Allogene Overland.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, our revenue has been exclusively generated from our collaboration and license agreement with Allogene Overland Biopharm (CY) limited (Allogene Overland). See Notes 2 and 6 to our financial statements appearing elsewhere in this Quarterly Report for more information related to our recognition of revenue and the Allogene Overland agreement.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may generate revenue from a combination of product sales, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval of them, our ability to generate future revenue, and our results of operations and financial position, will be materially adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to discovery efforts and preclinical and clinical development, and manufacturing of our product candidates. Research and development expenses for the three months ended March&#160;31, 2021 included costs associated with our clinical and preclinical stage pipeline candidates and research into newer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technologies. The most significant research and development expenses for the year relate to costs incurred for the development of our most advanced product candidates and include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred under agreements with our collaboration partners and third-party contract organizations, investigative clinical trial sites that conduct research and development activities on our behalf, and consultants;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">costs related to production of clinical materials, including fees paid for raw materials and to contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">laboratory and vendor expenses related to the execution of preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">employee-related expenses, which include salaries, benefits and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense and supplies; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">other significant research and development costs including overhead costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense all research and development costs in the periods in which they are incurred. We accrue for costs incurred as the services are being provided by monitoring the status of&#160;the project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to reimburse Servier for 60% of the costs associated with the prior development of UCART19, including for the CALM and PALL clinical trials of UCART19. We accrue for costs incurred by monitoring the status of the CALM and PALL clinical trials and the invoices received from Servier. We adjust our accrual as actual costs become known. Servier is required to reimburse us for 40% of the costs associated with the development of ALLO-501 and ALLO-501A.&#160;Collaboration expenses and cost reimbursement are recorded on a net basis as a research and development expense in our condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase in the future as&#160;our clinical programs progress and as we seek to initiate clinical trials of additional product candidates. The cost of advancing our manufacturing process as well as the cost of manufacturing product candidates for clinical trials are included in our research and development expense. We also expect to incur increased research and development expenses as we selectively identify and develop additional product candidates. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">biomarker analysis costs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost and timing of manufacturing for the trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the total number of cells that patients receive;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">potential additional safety monitoring or other studies requested by regulatory agencies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the duration of patient follow-up; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the efficacy and safety profile of the product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the probability of success for each product candidate will depend on numerous factors, including safety, efficacy, competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our product candidates are still in clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other staff-related costs, including stock-based compensation for options and restricted stock units granted. Other significant costs include costs relating to facilities and overhead costs, legal fees relating to corporate and patent matters, insurance, investor relations costs, fees for accounting and consulting services, information technology, and other general and administrative costs. General and administrative costs are expensed as incurred, and we accrue for services provided by third parties related to the above expenses by monitoring the status of services provided and receiving estimates from our service providers, and adjusting our accruals as actual costs become known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, potential commercialization of our product candidates and the increased costs of operating as a public company, including additional compliance-related expenses as a result of no longer being an emerging growth company. These increases are anticipated to include increased costs related to the hiring of additional personnel, developing commercial infrastructure, fees to outside consultants, lawyers and accountants, and increased costs associated with being a public company such as expenses related to services associated with maintaining compliance with Nasdaq listing rules and SEC requirements, insurance and investor relations costs.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net consists of interest earned on our cash, cash equivalents and investments, as well as investment gains and losses recognized during the period.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense consists of non-operating expenses, including our share of equity investments' net losses for the period.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2021 and 2020</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth our results of operations for the three months ended March&#160;31, 2021 and 2020 (dollars in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:51.741%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue - related party</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,683)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,482&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,017)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,015)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,480)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,465&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,015)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,480)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue - related party</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $38.3 million and zero for the three months ended March&#160;31, 2021 and 2020, respectively. The increase of $38.3 million was due to collaboration revenue recognized pursuant to the license agreement with Allogene Overland.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $55.2&#160;million and $42.0 million for the three months ended March&#160;31, 2021 and 2020, respectively. The increase of $13.1 million was driven primarily by an increase in personnel related costs of $6.6 million, of which $1.3 million was increased stock-based compensation expense, an increase in external costs relating to the advancement of our product candidates of $5.1 million, and an increase in building rent and facilities costs of $1.7 million, offset by a decrease in travel related costs of $0.1 million due to the impact of the COVID-19 pandemic.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $16.4&#160;million and $15.6 million for the three months ended March&#160;31, 2021 and 2020, respectively. The net increase of $0.7 million was primarily due to an increase in personnel related costs of $1.8 million, of which $1.3 million was increased stock-based compensation expense, offset by a decrease in business expenses and professional service fees of $0.7 million and a decrease in building rent and facilities costs of $0.3 million.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net was $0.5&#160;million and $3.3 million for the three months ended March&#160;31, 2021 and 2020, respectively. The decrease of $2.8 million was due to lower interest earned on our cash, cash equivalents and investments.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Plan of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have incurred significant net losses and negative cash flows from operations. As of March&#160;31, 2021, we had $964.2 million&#160;in cash and cash equivalents and investments. We anticipate that the aggregate of our current cash and cash equivalents and investments available for operations will enable us to maintain our operations for a period of at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations have been financed primarily by net proceeds from the sale and issuance of our convertible preferred stock, the issuance of convertible promissory notes, net proceeds from our IPO, our at-the-market (ATM) offerings, and our June 2020 underwritten public offering. In connection with our IPO in 2018, we sold an aggregate of 20,700,000 shares of our common stock (inclusive of 2,700,000 shares of common stock pursuant to the over-allotment option granted to the underwriters) at a price of $18.00 per share and received approximately $343.3 million in net proceeds. In November 2019, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">entered into a sales agreement with Cowen and Company, LLC (Cowen) under which we may from time to time issue and sell shares of our common stock through Cowen in ATM offerings for an aggregate offering price of up to $250.0 million. During the year ended December 31, 2020, we sold an aggregate of 848,663 shares of common stock in ATM offerings resulting in net proceeds of $26.2 million. As of March 31, 2021, $167.3 million remains available for sale under the sales agreement with Cowen.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, we sold 13,457,447 shares of our common stock, which included 1,755,319 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, in an underwritten public offering at a price of $47.00 per share, which resulted in net proceeds of approximately $595.7 million after deducting the underwriting discounts and commissions and other expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary use of cash is to fund construction projects for our manufacturing facility and operating expenses, which consist primarily of clinical manufacturing and research and development expenditures related to our lead product candidates, other research efforts, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are still in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain.&#160;Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise capital when needed, we will need to delay, reduce or terminate planned activities to reduce costs. Doing so will likely harm our ability to execute our business plans.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:6pt;margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:72.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,328)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,809)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,798&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,007)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,044&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,586&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,514&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,230)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, cash used in operating activities of $49.3 million was attributable to a net loss of $33.0 million, partially offset by non-cash charges of $23.0 million and an increase of $39.3 million in our net operating assets and liabilities. The non-cash charges consisted primarily of stock compensation expense of $16.8 million, non-cash rent expense of $2.0 million, depreciation of $1.9 million and net amortization and accretion on investment securities of $1.9 million. The change in operating assets and liabilities was primarily due to a $38.8 million decrease in deferred revenue, a $4.3 million decrease in accrued and other current liabilities, a $0.8 million increase in other long-term assets and a $0.3 million decrease in other long-term liabilities, offset by a $4.2 million increase in accounts payable and a $0.7 million decrease in prepaid expenses and other current assets.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, net cash used in investing activities of $96.8 million was related to cash provided by investment maturities of $268.2 million, offset by cash used in purchases of investments of $149.1 million, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash used in the purchase of stock in equity method investment of $15.9 million and cash used in the purchase of property and equipment of $6.5 million.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, cash provided by financing activities of $6.0 million was related to $4.1 million of cash provided by the issuance of common stock upon exercise of stock options and $2.0 million of cash provided by the sale of common stock through the employee stock purchase plan.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our contractual obligations and commitments as of December 31, 2020, please see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Contractual Obligation and Commitments&#8221; in our Annual Report.&#160;</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments primarily consist of obligations under our agreements with Pfizer, Cellectis, Servier and Notch. Under these agreements we are required to make milestone payments upon successful completion of certain regulatory and sales milestones on a target-by-target and country-by-country basis. The payment obligations under the license agreements are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and we will be required to make development milestone payments and royalty payments in connection with the sale of products developed under these agreements. As of March&#160;31, 2021, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales. For additional information regarding our agreements, see &#8220;&#8212;Our Research and Development and License Agreements&#8221; above.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have entered into agreements with third-party contract manufacturers for the manufacture and processing of certain of our product candidates for clinical testing purposes, and we have entered and will enter into other contracts in the normal course of business with contract research organizations for clinical trials and other vendors for other services and products for operating purposes. These agreements generally provide for termination or cancellation, other than for costs already incurred. As of March&#160;31, 2021, the Company had non-cancellable purchase commitments of $4.1&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at our manufacturing facility in Newark, California. The agreement has a term of 20 years and is expected to commence in the second quarter of 2021. We are obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by us will result in a termination payment due of approximately $4.3 million. In connection with the agreement, we maintain a letter of credit for the benefit of the service provider in the amount of $4.3 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have a Change in Control and Severance Plan that require the funding of specific payments, if certain events occur, such as a change of control and the termination of employment without cause.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the assumptions and estimates associated with accrued research and development expenditures and stock-based compensation have the most significant impact on our condensed consolidated financial statements. Therefore, we consider these to be our critical accounting policies and estimates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Operations&#8221; included in our Annual Report.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 2 to our unaudited condensed consolidated financial statements appearing under Part 1, Item 1 of this report for a discussion of new accounting standards and updates that may impact us.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate fluctuations.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and investments of $964.2 million as of March&#160;31, 2021 consist of bank deposits, money market funds and available-for-sale securities. Such interest-earning instruments carry a degree of interest rate risk; however, historical fluctuations in interest income have not been significant for us. A 10% change in the interest rates in effect on March&#160;31, 2021 would not have had a material effect on the fair market value of our cash equivalents and available-for-sale securities.</span></div><div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Rate Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration agreement with Servier requires collaboration payments for shared clinical development costs to be paid in Euros, and thus we face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. An adverse movement in foreign exchange rates could have an effect on payments due and made to our collaboration partner as well as other foreign suppliers and for license agreements. A 10% change in the applicable foreign exchange rates during the periods presented would not have had a material effect on our condensed consolidated financial statements. As of March&#160;31, 2021, we had $4.5 million of other receivables denominated in foreign currency.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_112"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of implementing new enterprise resource planning software, SAP, as part of a plan to integrate and upgrade our systems and processes. The implementation of this software is scheduled to continue in phases over a number of years. During the first quarter of 2021, we migrated certain areas of our business to SAP, including financial reporting, asset management, procurement, clinical inventory and warehouse management. As the phased implementation of this system occurs, we are experiencing certain changes to our processes and procedures which, in turn, result in changes to our internal control </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over financial reporting. While we expect SAP to strengthen our internal financial controls by automating certain manual processes and standardizing business processes and reporting, management will continue to evaluate and monitor our internal controls as processes and procedures in each of the affected areas evolve.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as discussed above, no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the three months ended March&#160;31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II-OTHER INFORMATION</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations, financial condition or cash flows.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">RISK FACTOR SUMMARY</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q and our other filings with the Securities and Exchange Commission (SEC) before making investment decisions regarding our common stock.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future. </span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us. </span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Gene-editing is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">The COVID-19 global pandemic is adversely impacting our business, including our preclinical studies and clinical trials.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We are heavily reliant on our partners for access to key gene editing technology for the manufacturing and development of our product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">Our business is highly dependent on the success of our lead product candidates. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We rely and will continue to rely on third parties to conduct our clinical trials and manufacture our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We rely on the availability of suitable donor material and other specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="margin-top:4pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-align:center;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:95%">RISK FACTORS</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020 (Annual Report), which was filed with the SEC on February 25, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company and investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. We are advancing an allogeneic CAR T platform of primarily early-stage product candidates and have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. For the year ended December 31, 2020, we reported a net loss of $250.2 million. For the quarter ended March 31, 2021, we reported a net loss of $33.0 million. As of March 31, 2021, we had an accumulated deficit of $679.4 million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our engineered allogeneic T cell platform. Because our allogeneic T cell product candidates are based on new technologies and will require the creation of inventory of mass-produced, off-the-shelf product, they will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with relapsed or refractory cancer and to treat potential side effects that may result from our product candidates can be significant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our engineered allogeneic T cell product candidates represent a novel approach to cancer treatment that creates significant challenges for us.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing a pipeline of allogeneic T cell product candidates that are engineered from healthy donor T cells to express CARs and are intended for use in any patient with certain cancers. Advancing these novel product candidates creates significant challenges for us, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">manufacturing our product candidates to our or regulatory specifications and in a timely manner to support our clinical trials, and, if approved, commercialization;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">sourcing clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">understanding and addressing variability in the quality of a donor&#8217;s T cells, which could ultimately affect our ability to produce product in a reliable and consistent manner and treat certain patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">educating medical personnel regarding the potential side effect profile of our product candidates, if approved, such as the potential adverse side effects related to cytokine release syndrome (CRS), neurotoxicity, graft-versus-host disease (GvHD), prolonged cytopenia and neutropenic sepsis;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">using medicines to preempt or manage adverse side effects of our product candidates, which may not adequately control the side effects and/or may have other safety risks or a detrimental impact on the efficacy of the treatment;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">conditioning patients with chemotherapy and ALLO-647 or other lymphodepletion agents in advance of administering our product candidates, which may increase the risk of infections and other adverse side effects;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">obtaining regulatory approval, as the U.S. Food and Drug Administration (FDA) and other regulatory authorities have limited experience with development of allogeneic T cell therapies for cancer; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gene-editing is a relatively new technology, and if we are unable to use this technology in our intended product candidates, our revenue opportunities will be materially limited.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cellectis&#8217;s TALEN technology involves a relatively new approach to gene editing, using sequence-specific DNA-cutting enzymes, or nucleases, to perform precise and stable modifications in the DNA of living-cells and organisms. Although Cellectis has generated nucleases for many specific gene sequences, it has not created nucleases for all gene sequences that we may seek to target, and Cellectis may have difficulty creating nucleases for other gene sequences that we may seek to target, which could limit the usefulness of this technology. This technology may also not be shown to be effective in clinical studies that Cellectis, we or other licensees of Cellectis technology may conduct, or may be associated with safety issues that may negatively affect our development programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For instance, gene-editing may create unintended changes to the DNA such as a non-target site gene-editing, a large deletion, or a DNA translocation, any of which could lead to oncogenesis. The gene-editing of our product candidates may also not be successful in limiting the risk of GvHD or premature rejection by the patient.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the gene-editing industry is rapidly developing, and our competitors may introduce new technologies that render our technology obsolete or less attractive. New technology could emerge at any point in the development cycle of our product candidates. As competitors use or develop new technologies, any failures of such technology could adversely impact our program. We also may be placed at a competitive disadvantage, and competitive pressures may force us to implement new technologies at a substantial cost. In addition, our competitors may have greater financial, technical and personnel resources that allow them to enjoy technological advantages and may in the future allow them to implement new technologies before we can. We cannot be certain that we will be able to implement technologies on a timely basis or at a cost that is acceptable to us. If we are unable to maintain technological advancements consistent with industry standards, our operations and financial condition may be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The COVID-19 global pandemic is adversely impacting our business, including our preclinical studies and clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or other outbreaks could adversely impact our business. As a result of the COVID-19 pandemic, or similar pandemics, and government response to pandemics, we have and may in the future experience disruptions that could severely impact our business, preclinical studies and clinical trials, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">halting or suspending enrollment in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays or difficulties in enrolling and retaining patients in our clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">interruption of key clinical trial activities, such as obtaining laboratory materials for collecting patient samples, clinical trial site data monitoring and efficacy, safety and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state or local governments, employers and others or interruption of clinical trial subject visits, which may impact the collection and integrity of subject data and clinical study endpoints;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical site initiation and recruiting clinical site investigators and clinical site staff; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">increased adverse events and deaths in our clinical trials due to COVID-19 related infections, which may result in increased complications due to immune suppression from our lymphodepletion regimen;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or being forced to quarantine; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays or disruptions in preclinical experiments and investigational new drug application-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations and vendors; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">interruption of, or delays in receiving, supplies of our raw materials or product candidates from our suppliers and contract manufacturing organizations (CMOs) due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, or due to prioritization of production for COVID-19 specific therapies or vaccines; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">limitations on employee resources that would otherwise be focused on advancing our business, including because of sickness of employees or their families, including executive officers and other key employees, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and local government response to the pandemic has included "shelter in place", "stay at home" and similar types of orders, which have limited travel and business operations in our locations, the location of our clinical trial sites, and the location of key vendors, including our CMOs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning the week of March 9, 2020, the majority of our workforce began working from home. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. While we, our clinical trials sites and certain of our vendors, including our CMOs, are currently exempt from the orders for certain essential operations, any of the applicable exemptions may be curtailed or revoked, which would further adversely impact our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable terms. Market and economic deterioration could also adversely impact our portfolio of corporate and government bonds.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and actions to contain the pandemic or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are heavily reliant on our partners for access to key gene editing technology for the manufacturing and development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A critical aspect to manufacturing allogeneic T cell product candidates involves gene editing the healthy donor T cells in an effort to avoid GvHD and to limit the patient&#8217;s immune system from attacking the allogeneic T cells. GvHD results when allogeneic T cells start recognizing the patient&#8217;s normal tissue as foreign. We use Cellectis&#8217;s TALEN gene-editing technology to inactivate a gene coding for TCR&#945;, a key component of the natural antigen receptor of T cells, to cause the engineered T cells to be incapable of recognizing foreign antigens. Accordingly, when injected into a patient, the intent is for the engineered T cell not to recognize the tissue of the patient as foreign and thus avoid attacking the patient&#8217;s tissue. In addition, we use TALEN gene editing to inactivate the CD52 gene in donor T cells, which codes for the target of an anti-CD52 monoclonal antibody. Anti-CD52 monoclonal antibodies deplete CD52 expressing T cells in patients while sparing therapeutic allogeneic T cells lacking CD52. By administering an anti-CD52 antibody prior to infusing our product candidates, we believe we have the potential to reduce the likelihood of a patient&#8217;s immune system from rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which the engineered allogeneic T cells can actively target and destroy the cancer cells. However, the antibody may not have the benefits that we anticipate and could have adverse effects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on an agreement with Cellectis for rights to use TALEN technology for 15 select cancer targets, including BCMA, FLT3, CD70, DLL3 and other targets included in our pipeline. We also rely on Cellectis, through our agreement with Servier, for rights to UCART19, ALLO-501 and ALLO-501A. We would need an additional license from Cellectis or access to other gene-editing technology to research and develop product candidates directed at targets not covered by our existing agreements with Cellectis and Servier. In addition, the Cellectis gene-editing technology may fail to produce viable product candidates. Moreover, both Servier and Cellectis may terminate our respective agreements in the event of a material breach of the agreements, or upon certain insolvency events. If our agreements were terminated or we required other gene editing technology, such a license or technology may not be available to us on reasonable terms, or at all, particularly given the limited number of alternative gene-editing technologies in the market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, pursuant to the Servier Agreement, we expect Servier to continue to support our clinical trials of ALLO-501 and ALLO-501A for the treatment of patients with R/R NHL. Should Servier become unable to continue providing its share of financial support for the ALLO-501 and ALLO-501A clinical trials, our expenses may be greater than we currently expect and we may have difficulty progressing our ongoing and planned clinical trials in a timely manner. Moreover, as the CALM and PALL clinical trials of UCART19 have completed, we are reliant on Servier for progressing a development strategy for ALL and any development strategy may face challenges, such as regulatory delays and unforeseen expenses if we consolidate programs. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research, development and manufacturing efforts on our engineered allogeneic T cell therapy and our future success depends on the successful development of this therapeutic approach. We are in the early stages of developing our platform and there can be no assurance that any development problems we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, since we are in the early stages of clinical development, we do not know the doses to be evaluated in pivotal trials or, if approved, commercially. Finding a suitable dose for our cell therapy product candidates as well as ALLO-647 may delay our anticipated clinical development timelines. In addition, our expectations with regard to our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also advancing product candidates against unexplored targets and with new technology.  For example, we are advancing ALLO-316 against a target, CD70, that has not been validated by any autologous CAR T therapies. ALLO-316 may have limited efficacy or have off-target toxicities. Since CD70 is found on activated T cells, ALLO-316 may also cause fratricide resulting in the loss of ALLO-316 cells or increase the risk of infections. In addition, our ALLO-605 product candidate is our first TurboCAR candidate that is designed to mimic cytokine signaling selectively within CAR T cells. Our TurboCAR product candidates may be more difficult to manufacture, which could delay the initiation of our Phase 1 clinical trial of ALLO-605, or not demonstrate any of the benefits that we expect. As potentially more potent, our TurboCAR product candidates may also increase the risk of adverse events, such as CRS and neurotoxicity. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The clinical study requirements of the FDA, European Medicines Agency (EMA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. We face additional challenges in obtaining regulatory approval for ALLO-647, which we use as part of our lymphodepletion regimen, and for which we would seek to obtain approval concurrently with approval of a CAR T cell product candidate. Approvals by the EMA and FDA for existing autologous CAR T therapies, such as Kymriah and Yescarta, may not be indicative of what these regulators may require for approval of our therapies. Also, while we expect reduced variability in our products candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability and the use of healthy donor material may create separate variability challenges for us. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates. Moreover, our product candidates may not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous CAR T therapies that have previously been approved. For instance, allogeneic product candidates may result in GvHD not experienced with autologous products. Even if we collect promising initial clinical data of our product candidates, longer-term data may reveal new adverse events or responses that are not durable. Unexpected clinical outcomes would significantly impact our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is highly dependent on the success of our lead product candidates. If we are unable to advance clinical development, obtain approval of and successfully commercialize our lead product candidates for the treatment of patients in approved indications, our business would be significantly harmed.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and future success depends on our ability to advance clinical development, obtain regulatory approval of, and then successfully commercialize, our lead product candidates, including ALLO-501A and ALLO-715. Because ALLO-501, ALLO-501A and ALLO-715 are among the first allogeneic products to be evaluated in the clinic, the failure of any such product candidate, or the failure of other allogeneic T cell therapies, including for reasons due to safety, efficacy or durability, may impede our ability to develop our product candidates, and significantly influence physicians&#8217; and regulators&#8217; opinions in regards to the viability of our entire pipeline of allogeneic T cell therapies. For instance, we are planning to progress to the Phase 2 portion of the ALPHA2 trial of ALLO-501A by the end of 2021. In order to do so, we will need to complete many objectives, such as continued enrollment in the ALPHA trial and ALPHA2 Phase 1 portion of the trial, timely patient follow-up, generation of positive Phase 1 data, advancement of cGMP manufacturing of ALLO-501A and approval from the FDA on any Phase 2 plan. If we are unable to achieve any of these objectives, we may not be able to advance to Phase 2 in a timely manner or at all, which would significantly harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates, including our lead product candidates, will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. In addition, because our other product candidates are based on similar technology as our lead product candidates, if any of the lead product candidates encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.*</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous CAR T therapies and those under development have shown frequent rates of CRS, neurotoxicity, serious infections, prolonged cytopenia and hypogammaglobulinemia, and adverse events have resulted in the death of patients. We expect similar adverse events for allogeneic CAR T product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our allogeneic CAR T cell product candidates may also cause unique adverse events related to the differences between the donor and patients, such as GvHD or infusion reactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we utilize a lymphodepletion regimen, which generally includes fludarabine, cyclophosphamide and ALLO-647, that may cause serious adverse events. For instance, because the regimen will cause a transient and sometimes prolonged immune suppression, patients will have an increased risk of infection, such as to COVID-19, that may be unable to be cleared by the patient and ultimately lead to death. Our lymphodepletion regimen has caused and may also cause prolonged cytopenia. We are also exploring various dosing strategies for lymphodepletion in our clinical trials, such as higher and lower dosing of ALLO-647 in combination with fludarabine and cyclophosphamide, which may increase the risk of serious adverse events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In our and Servier's clinical trials of allogeneic CAR T product candidates, the most common severe or life threatening adverse events resulted from serious infections, prolonged cytopenia, prolonged pancytopenia, hypokalemia, multiple organ dysfunction syndrome and neutropenic sepsis. As reported, patients have died from adverse events and future patients may also experience toxicity resulting in death.  For additional safety data, please see "Business--Product Pipeline and Development Strategy" in our Annual Report. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we treat and re-treat more patients with our product candidates in our clinical trials, new less common side effects may also emerge.  For instance, our allogeneic CAR T cell product candidates undergo gene engineering by using lentivirus and TALEN nucleases that can cause insertion, deletion, or chromosomal translocation. These changes can cause allogeneic CAR T cells to proliferate uncontrollably and may cause adverse events. In addition, we may combine the use of our product candidates with other investigational therapies that may cause separate adverse events or events related to the combination. For instance, we are advancing a combination of ALLO-715 and nirogacestat, a gamma secretase inhibitor, in a cohort in the UNIVERSAL trial. The most common adverse events relating to nirogacestat in prior trials have included diarrhea, nausea, fatigue, hypophosphatemia, vomiting, rash, cough, decreased appetite, pyrexia and hypokalemia. These or other adverse events could result in the suspension of therapy or otherwise adversely impact the UNIVERSAL trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. The data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell therapy are not normally encountered in the general patient population and by medical personnel. We have trained and expect to have to train medical personnel using CAR T cell product candidates to understand the side effect profile of our product candidates for both our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may harm our business, financial condition and prospects significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, including in any post-approval studies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for ongoing and any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial, interim and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publish initial, interim or preliminary data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For instance, we have published preliminary data from the ALPHA trial and UNIVERSAL trial, however such results are preliminary in nature, do not bear statistical significance and should not be viewed as predictive of ultimate success. It is possible that such results will not continue or may not be repeated in ongoing or future clinical trials of anti-CD19 or anti-BCMA CAR T cell product candidates or our other product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, initial, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to file INDs to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to submit INDs for additional product candidates in the future. We cannot be sure that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing of allogeneic CAR T cell therapy remains an emerging and evolving field. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be a focus of IND reviews, which may delay the clearance of INDs or IND amendments. For instance, we intend to optimize the manufacturing of our product candidates, including ALLO-501A, and regulatory authorities may require additional studies or clinical data to support the changes, which could delay our clinical trial timelines, including the Phase 2 portion of the ALPHA2 trial. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, IND amendment or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we submitted a standalone cross-reference IND for ALLO-647, which is being used as part of lymphodepletion in all our clinical trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our IND has been accepted, we have to update the IND for any new IND or IND amendment relating to our allogeneic CAR T cell product candidates and we plan to update the IND as we finalize pivotal manufacturing of ALLO-647 at one of our CMOs. Any regulatory issues related to the review of our ALLO-647 IND updates or to the development of ALLO-647 could delay development of our allogeneic CAR T cell product candidates and significantly affect our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if our trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical study can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">difficulty sourcing healthy donor material of sufficient quality and in sufficient quantity to meet our development needs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in reaching a consensus with regulatory agencies on study design;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in obtaining required institutional review board (IRB) approval at each clinical study site;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a new safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in recruiting suitable patients to participate in our clinical studies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">difficulty collaborating with patient groups and investigators;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">failure by our CROs, other third parties or us to adhere to clinical study requirements;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">failure to perform in accordance with the FDA&#8217;s good clinical practice (GCP) requirements or applicable regulatory guidelines in other countries;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">transfer of manufacturing processes to any new CMO or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in having patients complete participation in a study or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">patients dropping out of a study;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the cost of clinical studies of our product candidates being greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">clinical studies of our product candidates producing negative or inconclusive results, which may result in our deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials, including due to suppliers prioritizing COVID-19 specific treatments or vaccines; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing, including due to our CMOs or other vendors prioritizing COVID-19 specific treatments or vaccines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also increase the risk of certain of the events described above and delay our development timelines. Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Monitoring and managing toxicities in patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our ongoing and planned clinical trials of our product candidates, we contract or will contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. We also expect the centers using our product candidates, if approved, on a commercial basis could have similar difficulty in managing adverse events. Medicines used at centers to help manage adverse side effects of our product candidates may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. The COVID-19 pandemic, including the travel and business restrictions imposed by government authorities in response to the pandemic, have resulted in, and may continue to cause, reduced enrollment and may also create challenges to related clinical trial activities. In addition, the enrollment of patients depends on many factors, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the patient eligibility criteria defined in the protocol;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the proximity of patients to study sites;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the design of the trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our ability to obtain and maintain patient consents; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">the competition from approved products and from product candidates in other clinical trials; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we only need to conduct a limited number of manufacturing runs to generate clinical supply, the diversity of our supply is limited during clinical trials. As a result, some patients may have antibodies to certain donor specific antigens that may interact with our product candidates, which would render the patients ineligible for treatment.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, prior treatment with rituximab may interfere with ALLO-501 as ALLO-501 contains rituximab recognition domains. Since rituximab is a typical part of a treatment regimen for a patient with NHL, patient eligibility for the ALLO-501 trial may be limited. Patients may also undergo plasmapheresis to remove rituximab prior to infusion of ALLO-501, which may cause separate adverse effects. We have removed the rituximab recognition domains in the second generation of ALLO-501, known as ALLO-501A, which we believe will potentially facilitate treatment of patients who were recently treated with rituximab. However, ALLO-501A may not behave as expected and may be challenging to develop or manufacture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials will also compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic cell transplantation or autologous CAR T cell therapies, rather than enroll patients in our clinical trial, including if our product candidates have or are perceived to have additional safety or efficacy risks or if using our product candidates may affect insurance coverage of conventional therapies. Patients eligible for allogeneic CAR T cell therapies but ineligible for autologous CAR T cell therapies due to aggressive cancer and inability to wait for autologous CAR T cell therapies may be at greater risk for complications and death from therapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA often approves new therapies initially only for use in patients with R/R metastatic disease. We expect to initially seek approval of our product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment. There is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. We are also targeting a similar patient population as autologous CAR T product candidates, including approved autologous CAR T products. Our therapies may not be as safe and effective as autologous CAR T therapies and may only be approved for patients who are ineligible for autologous CAR T therapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of patients who have the cancers we are targeting, as well as the subset of patients with these cancers in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. For instance, we expect ALLO-501A to initially target a small patient population that suffers from R/R NHL. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our development strategy relies on incorporating an anti-CD52 monoclonal antibody as part of the lymphodepletion preconditioning regimen prior to infusing allogeneic CAR T cell product candidates.*</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize an anti-CD52 monoclonal antibody as part of a lymphodepletion regimen to be infused prior to infusing our product candidates. While we believe an anti-CD52 antibody may be able to reduce the likelihood of a patient&#8217;s immune system rejecting the engineered allogeneic T cells for a sufficient period of time to enable a window of persistence during which such engineered allogeneic T cells can actively target and destroy cancer cells, the antibody may not have the benefits that we anticipate and could have adverse effects. For instance, our lymphodepletion regimen, including using an anti-CD52 antibody, will cause a transient and sometimes prolonged immune suppression</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that is associated with an increased risk of infection, such as to COVID-19, that may be unable to be cleared by the patient and ultimately lead to death.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the prior CALM and PALL trials, a commercially available monoclonal antibody, alemtuzumab, that binds CD52 was used. Alemtuzumab is known to have risk of causing certain adverse events. In 2020, the EMA completed a pharmacovigilance review of alemtuzumab in the context of the treatment of multiple sclerosis following reports of immune-mediated conditions and problems affecting the heart and blood vessels, including fatal cases. The EMA recommended that alemtuzumab should not be used in patients with certain heart, circulation or bleeding disorders or in patients who have autoimmune disorders other than multiple sclerosis. The EMA also recommended that alemtuzumab only be given in a hospital with ready access to intensive care facilities and specialists who can manage serious adverse reactions. Based on the recommendations, we have added relevant new safety information to certain of our clinical trial documentation, including informed consent forms. Our product candidates will also continue to be administered at specialized centers, which are experienced at managing patients with advanced malignancies as well as toxicities associated with immunomodulatory therapies. We will continue to monitor any new safety information that will be reported or added to the product labels of alemtuzumab. If the EMA or other regulatory agencies further limit the use of alemtuzumab or anti-CD52 antibodies, our clinical program would be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To secure our own readily available source of anti-CD52 antibody, we are developing our own monoclonal anti-CD52 antibody, ALLO-647, which we are using in our clinical trials. ALLO-647 may cause serious adverse events that alemtuzumab may cause, including fatal adverse events, immune thrombocytopenia, glomerular nephropathies, thyroid disorders, autoimmune cytopenias, autoimmune hepatitis, hemophagocytic lymphohistiocytosis, acquired hemophilia and infections, stroke, and progressive multifocal leukoencephalopathy. In addition, we are exploring various dosing strategies for lymphodepletion in our clinical trials, such as higher and lower dosing of ALLO-647 in combination with fludarabine and cyclophosphamide, which may increase the risk of serious adverse events. See "Business--Product Pipeline and Development Strategy" in our Annual Report for information on safety events.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully develop and manufacture ALLO-647 in the timeframe we anticipate, or at all, or if regulatory authorities do not approve the use of ALLO-647 in combination with our allogeneic T cell product candidates, we may be unable to source alemtuzumab and our engineered allogeneic T cell product candidates may be less effective, which could result in delays in our product development efforts and/or the commercial potential of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to operate our own cell therapy manufacturing facility, which will require significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to achieve clinical or commercial manufacturing and cell processing on our own or at our CMO, including mass-producing off-the-shelf product to satisfy demands for any of our product candidates. While we believe the manufacturing and processing approaches are appropriate to support our clinical product development, we have limited experience in managing the allogeneic T cell engineering process, and our allogeneic processes may be more difficult or more expensive than the approaches taken by our competitors. We cannot be sure that the manufacturing processes employed by us or the technologies that we incorporate for manufacturing will result in T cells that will be safe and effective.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we entered into a lease for approximately 118,000 square feet to develop a state-of-the-art cell therapy manufacturing facility in Newark, California. While we expect to initiate manufacturing under current good manufacturing practices (cGMP) in the second half of 2021, any business interruptions or delays to our validation or commissioning efforts, securing equipment and raw materials, or obtaining appropriate regulatory or licensing approvals, in each case which may be more likely as a result of the COVID-19 pandemic, will delay our manufacturing timelines.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes in manufacturing of our product candidates currently in the clinic, including introducing product candidates manufactured at our facility into any ongoing clinical trials, will require that we meet certain regulatory conditions, such as establishing comparability with the product candidates manufactured at our CMO, and our inability to meet such conditions may result in a delay in using our manufacturing facility for production or extend our clinical trial timelines. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also do not yet have sufficient information to reliably estimate the cost of the clinical and commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. In addition, the ultimate clinical and any commercial dose and treatment regimen will affect our ability to scale and our costs per dose. For instance, because ALLO-715 may require a higher dose than ALLO-501A, it is possible that it may be more difficult to scale ALLO-715 production to meet any demand. As a result, we may never be able to develop a commercially viable product. The commercial manufacturing facility we build will also require FDA approval, which we may never obtain. Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP, and other government regulations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. The application of new regulatory guidelines or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our product candidates. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such supply may have to be discarded and our manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, our CMOs or any other of our or their vendors may fail to manage the logistics of storing and shipping our raw materials and product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in the inability to manufacture product, the loss of usable product or prevent or delay the delivery of product candidates to patients.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or in other markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to globally develop our product candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">differing regulatory requirements in foreign countries;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">differing standards for the conduct of clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">import and export requirements and restrictions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">difficulties staffing and managing foreign operations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">business interruptions resulting from the COVID-19 pandemic or other natural or man-made disasters, including earthquakes, tsunamis, fires or other medical epidemics, or geo-political actions, including war and terrorism.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These and other risks associated with our collaborations with Servier and Cellectis, each based in France, our collaboration with Notch Therapeutics Inc. (Notch), based in Canada, and our joint venture for China, Taiwan, South Korea and Singapore with Overland Pharmaceuticals (CY) Inc., may materially adversely affect our ability to attain or maintain profitable operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, engineered T cells face significant competition from multiple companies. Success of other therapies could impact our regulatory strategy and delay or prevent regulatory approval of our product candidates. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see &#8220;Item 1. Business&#8212;Competition&#8221; in our Annual Report.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Executive Chair, our President and Chief Executive Officer, our Chief Financial Officer, our Executive Vice President of Research &amp; Development and Chief Medical Officer, our Chief Technical Officer, and our General Counsel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct substantially all of our operations at our facilities in South San Francisco. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options and restricted stock unit (RSU) awards that vest over time. The value to employees of stock options and RSU awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 3, 2021, we had 276 full-time employees. As our development, manufacturing and commercialization plans and strategies develop, we have rapidly expanded our employee base and expect to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to build our organization and manage our employees has also been affected by the COVID-19 pandemic, as many of our staff are working from home on a part-time or full-time basis. The effects of the stay-at-home orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our development programs, regulatory and commercialization timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. We may also be subject to penalties or other liabilities if we mis-classify employees as consultants. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop, manufacture </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and commercialize our product candidates and, accordingly, may not achieve our research, development, manufacturing and commercialization goals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form or seek additional strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek additional strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we license products or acquire businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our agreements with Cellectis, Servier, Notch and SpringWorks require significant research and development that may not result in the development and commercialization of product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not realize the benefits of acquired assets or other strategic transactions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, including our acquisition of CAR T cell assets from Pfizer, licenses with Cellectis, Servier and Notch, joint venture with Overland Pharmaceuticals (CY) Inc. and any future strategic transactions depends on the risks and uncertainties involved including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt">unanticipated liabilities related to acquired companies or joint ventures;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">retention of key employees;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">increases in our expenses and reductions in our cash available for operations and other uses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">disruption in or termination of our relationships with collaborators or suppliers as a result of such a transaction; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">possible write-offs or impairment charges relating to acquired businesses or joint ventures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries. For instance, our joint venture with Overland Pharmaceuticals (CY) Inc. may face difficulties manufacturing or delivering our licensed product candidates in China, Taiwan, South Korea or Singapore, which could prevent any development or commercialization of our licensed product candidates in the region. The joint venture will also require significant financial support in the future by us or third parties, and any future financing of the joint venture would increase our expenses or dilute our ownership in the joint venture.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to spend a substantial amount of capital in the development and manufacture of our product candidates. We will need substantial additional financing to develop our products and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our products and initiate and complete registration trials for multiple products in multiple regions. Further, if approved, we will require significant additional amounts in order to launch and commercialize our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had $964.2 million in cash, cash equivalents and investments. Changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we presently plan. In any event, we will require additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our CROs, collaborators or other contractors or consultants, may fail or suffer security breaches.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our CROs, collaborators, and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, cybersecurity threats, and telecommunication and electrical failures. In addition, the COVID-19 pandemic has intensified our dependence on information technology systems as many of our critical business activities are currently being conducted remotely. A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, financial loss or otherwise compromise our confidential or proprietary information and disrupt our operations. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#8217; personal data could result in significant liability under state, federal, and international law and may cause a material adverse impact to our reputation, affect our ability to conduct our clinical trials and potentially disrupt our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny. Any failure by third-party providers to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, statutory, regulatory and policy changes, and business disruptions, such as those caused by the COVID-19 pandemic. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the business disruptions caused by the COVID-19 pandemic or cybersecurity attacks described above, our operations, and those of our CMOs, CROs, clinical trial sites and other contractors and consultants, could be subject to other disruptions, including those caused by earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to manufacture our product candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster or other business interruption. Our corporate headquarters and manufacturing facility are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information, price reporting, false claims and provider transparency. If our operations are found to be in violation of any of these laws that apply to us, we may be subject to significant civil, criminal and administrative penalties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal data in the European Union (EU) are governed by the General Data Protection Regulation (GDPR). The GDPR imposes stringent requirements for controllers and processors of personal data, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, California recently enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Known as the California Consumer Privacy Act (CPPA), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. As our business progresses, the CCPA may become applicable and significantly impact our business activities and exemplifies the vulnerability of our business to evolving regulatory environment related to personal data and protected health information.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">decreased demand for our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">injury to our reputation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">initiation of investigations by regulators;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the inability to commercialize any product candidate; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">a decline in our share price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. While we have obtained and expect to obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (Tax Act), as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), federal net operating losses incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal net operating losses in tax years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of our IPO in October 2018 and private placements and other transactions that have occurred since our incorporation, we may have experienced an &#8220;ownership change&#8221;. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. We anticipate incurring significant additional net losses for the foreseeable future, and our ability to utilize net operating loss carryforwards associated with any such losses to offset future taxable income may be limited to the extent we incur future ownership changes. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state net operating losses to offset taxable income in tax years beginning after 2019 and before 2023. As a result, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with good clinical practices (GCPs), which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.*</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are manufactured in the United States by our CMOs, and we manage all other aspects of the supply, including planning, CMO oversight, disposition and distribution logistics. In the past, Servier was responsible for UCART19 manufacturing, and experienced UCART19 supply issues that limited its ability to recruit new patients in the past. There can be no assurance that we will not experience supply or manufacturing issues in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are in the process of developing our own manufacturing facility for cell therapies, we must currently rely on outside vendors to manufacture supplies and process our product candidates. We do not have long-term agreements in place with CMOs for the manufacture of our cell therapies or of ALLO-647.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to contract with CMOs on acceptable terms or at all, our clinical development program would be delayed and our business would be significantly harmed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing and may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for any of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">Our third-party manufacturers could breach or terminate their agreement with us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Our CMOs may also be required to shutdown in response to the spread of COVID-19 or they may prioritize manufacturing for COVID-19 therapies or vaccines. In addition, our CMOs have certain responsibilities for storage of raw materials and in the past have lost or failed to adequately store our raw materials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional or future damage or loss of raw materials could materially impact our ability to manufacture and supply our product candidates. Each of these risks could delay our clinical trials, the approval, if any of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on donors of T cells to manufacture our product candidates, and if we do not obtain an adequate supply of T cells from qualified donors, development of those product candidates may be adversely impacted. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike autologous CAR T companies, we are reliant on receiving healthy donor material to manufacture our product candidates. Healthy donor T cells vary in type and quality, and this variation makes producing standardized product candidates more difficult and makes the development and commercialization pathway of those product candidates more uncertain. We have developed a screening process designed to enhance the quality and consistency of T cells used in the manufacture of our CAR T cell product candidates, but our screening process may fail to identify suitable donor material and we may discover failures with the material after production. We may also have to update our specifications for new risks that may emerge, such as to screen for new viruses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have strict specifications for donor material, which include specifications required by regulatory authorities. If we are unable to identify and obtain donor material that satisfy specifications, agree with regulatory authorities on appropriate specifications, or address variability in donor T cells, there may be inconsistencies in the product candidates we produce or we may be unable to initiate or continue ongoing clinical trials on the timelines we expect, which could harm our reputation and adversely impact our business and prospects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, vendors have in the past been unable to secure donor material during the COVID-19 pandemic due to government restrictions on business activity and travel. While we have donor material on hand, and our vendors are currently able to provide us with donor material, if the COVID-19 pandemic continues and our vendors are unable to secure donor material, we may no longer have sufficient donor material to manufacture our product candidates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates require many specialty raw materials, including viral vectors that deliver the CAR sequence and electroporation technology, some of which are manufactured by small companies with limited resources and experience to support a commercial product, and the suppliers may not be able to deliver raw materials to our specifications. We do not have contracts with many of the suppliers, and we may not be able to contract with them on acceptable terms, or at all. Many suppliers have curtailed their operations during the COVID-19 pandemic or focused their operations on supporting COVID-19 therapies and vaccines, and our ability to source raw materials has been impacted. Accordingly, we may experience delays in receiving, or fail to secure entirely, key raw materials to support clinical or commercial manufacturing. Certain raw materials also require third-party testing, and some of the testing service companies may not have capacity or be able to conduct the testing that we request.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also face competition for supplies from other cell therapy companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such competition may make it difficult for us to secure raw materials or the testing of such materials on commercially reasonable terms or in a timely manner.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some raw materials are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier, including to meet any regulatory requirements for such qualification, could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we and our suppliers&#8217; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a biologics license application (BLA) from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic T cell therapies for cancer. We may also request regulatory approval of future CAR-based product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">obtaining regulatory authorization to begin a trial, if applicable;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the availability of financial resources to commence and complete the planned trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">obtaining approval at each clinical trial site by an independent IRB;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:22.8pt">obtaining regulatory and other approvals to modify the conduct of a clinical trial;</span></div><div style="padding-left:27pt"><span><br/></span></div><div style="padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">recruiting suitable patients to participate in a trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">addressing any patient safety concerns that arise during the course of a trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">adding new clinical trial sites; or</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">manufacturing sufficient quantities of qualified materials under cGMPs and delivering product candidates for use in clinical trials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. The FDA&#8217;s review of our data of our ongoing clinical trials may, depending on the data, also result in the delay, suspension or termination of one or more of our clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affordable Care Act) to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty and could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that any of the product candidates we develop that is approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established gene therapy and cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are developing novel CAR T cell immunotherapy product candidates that are unique biological entities, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing gene therapy products and cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies (OTAT), formerly known as the Office of Cellular, Tissue and Gene Therapies (OCTGT), within its Center for Biologics Evaluation and Research (CBER) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials are also subject to review and oversight by an institutional biosafety committee (IBC), a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval of any of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Committee for Advanced Therapies (CAT) was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. In this regard, on May 28, 2014, the EMA issued a recommendation that UCART19 be considered a gene therapy product under Regulation (EC) No 1394/2007 on ATMPs. We believe our other product candidates may receive a similar recommendation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our CAR T cell immunotherapy product candidates is new, we may face even more cumbersome and complex regulations than those emerging for gene therapy products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when our ongoing and planned Phase 1 clinical trials are completed and, assuming positive data, we expect to advance to potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We expect registrational trials for ALLO-501A and ALLO-715 to be designed to evaluate the efficacy of the product candidate in an open-label, non-comparative, two-stage, pivotal, multicenter, single-arm clinical trial in patients who have exhausted available treatment options. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that our regulatory development plans will be sufficient for submission of a BLA. For example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the molecular similarities between ALLO-501 and ALLO-501A, we may have additional difficulties progressing any clinical trial of ALLO-501A, if emerging data from the clinical trial of ALLO-501 have safety or other issues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. We believe our accelerated approval strategy is warranted given the limited alternatives for patients with R/R cancers, but the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility and may not approve our manufacturing process or facility; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to obtain regulatory approval for ALLO-647 in a timely manner or at all, which could delay any approval or commercialization of our allogeneic T cell product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we are concurrently developing ALLO-647 to be used as part of the lymphodepletion regimen for our allogeneic CAR T cell product candidates, mapping a path for dual approval of ALLO-647 and any of our CAR T cell product candidates and coordinating concurrent review with different divisions of the FDA create additional regulatory uncertainty for us and may delay the development of our product candidates. We expect the Center for Drug Evaluation and Research division of the FDA to exercise authority over the regulatory approval of ALLO-647 while the CBER division will oversee the regulatory approval of our allogeneic CAR T cell product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect regulatory authorities will require us to demonstrate the safety of ALLO-647 and its contribution to the overall benefit to risk ratio of the lymphodepletion regimen, including through a cohort of patients that do not receive ALLO-647. If we are unable to meet any of the requirements of the regulatory authorities, we may be required to conduct additional clinical studies. We cannot be certain we will be able to successfully obtain regulatory approval of ALLO-647 in a timely manner or at all. Any delays to ALLO-647 approval could delay any approval or commercialization of our allogeneic CAR T cell product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regenerative Medicine Advanced Therapy designation may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.*</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-715 and may seek RMAT designation for additional product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our additional product candidates. RMAT designation does not change the FDA&#8217;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Some of our product candidates target indications that are not orphan indications. In addition, even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product candidates. In addition, given the novel nature of gene-editing and cell therapy technologies, governments may place import, export or other restrictions in order to retain control or limit the use of the technologies. For instance, any limits on exporting certain of our technology to China may adversely affect Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by us and Overland Pharmaceuticals (CY) Inc. Increased negative public opinion or more restrictive government regulations either in the United States or internationally, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for such product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of engineered T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect physicians in the large bone marrow transplant centers to be particularly important to the market acceptance of our products and we may not be able to educate them on the benefits of using our product candidates for many reasons. For example, certain of the product candidates that we will be developing target a cell surface marker that may be present on cancer cells as well as non-cancerous cells. It is possible that our product candidates may kill these non-cancerous cells, which may result in unacceptable side effects, including death. Additional factors will influence whether our product candidates are accepted in the market, including:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the clinical indications for which our product candidates are approved;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the potential and perceived advantages of our product candidates over alternative treatments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the prevalence and severity of any side effects;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">limitations or warnings contained in the labeling approved by the FDA;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the timing of market introduction of our product candidates as well as competitive products;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the cost of treatment in relation to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the effectiveness of our sales and marketing efforts.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.*</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. In particular, in 2010 the Affordable Care Act was enacted. The Affordable Care Act and its implementing regulations, among other things, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs and certain biologics, including our product candidates, under the Medicaid drug rebate program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid drug rebate program, extended the Medicaid drug rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research. Additionally, the Affordable Care Act allowed states to implement expanded eligibility criteria for Medicaid programs, imposed a new Medicare Part D coverage gap discount program, expanded the entities eligible for discounts under the Public Health Service pharmaceutical pricing program and implemented a new Patient-Centered Outcomes Research Institute. There have been legal and political challenges to certain aspects of the Affordable Care Act. The U.S. Supreme Court is currently reviewing the constitutionality of the Affordable Care Act, but it is unknown when a decision will be reached. On February 10, 2021, the Biden administration withdrew the federal government&#8217;s support for overturning the Affordable Care Act. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the Affordable Care Act, on January 28, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2021, President Biden issued an executive order to initiate a special enrollment period for the purposes of obtaining health insurance coverage through the Affordable Care Act marketplace, which began February 15, 2021 and will remain open through August 15, 2021. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is unclear how the Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability. Further, it is possible that additional government action is taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend substantially on our license agreements with Pfizer, Servier and Cellectis. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. For example, we are dependent on our license with Cellectis for gene-editing technology that is necessary to produce our engineered T cells. In addition, we are reliant on Servier in-licensing from Cellectis some of the intellectual property rights they are licensing to us, including certain intellectual property rights relating to ALLO-501 and ALLO-501A. To the extent these licensors fail to meet their obligations under their license agreements, which we are not in control of, we may lose the benefits of our license agreements with these licensors. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property that we have licensed, or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an exclusive collaboration with Servier to develop and commercialize certain anti-CD19 allogeneic T cell product candidates, including ALLO-501A, and we hold the commercial rights to these product candidates in the United States. We also have an exclusive worldwide license from Cellectis to its TALEN gene-editing technology for the development of allogeneic T cell product candidates directed against 15 different cancer antigens. Our collaboration with Servier gives us access to TALEN gene-editing technology for all product candidates under the Servier Agreement. Certain intellectual property which is covered by these agreements may have been developed with funding from the U.S. government. If so, our rights in this intellectual property may be subject to certain research and other rights of the government.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional patent applications have been filed, and we anticipate additional patent applications will be filed, both in the United States and in other countries, as appropriate. However, we cannot predict:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">if and when patents will issue;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Composition of matter patents for biological and pharmaceutical products such as CAR-based product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO) or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, for example through inter partes review (IPR) post-grant review or ex parte reexamination before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions, which may result in such patents being cancelled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. United States patent applications containing or that at any time contained a claim not entitled to a priority date before March 16, 2013 are subject to the &#8220;first to file&#8221; system implemented by the America Invents Act (2011).</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This first to file system will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For United States applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the United States patent laws, including new procedures for challenging patent applications and issued patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees, Allogene Overland and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. For example, we plan to transfer technology to Allogene Overland in certain developing countries, and we cannot be certain that we or Allogene Overland will be able to protect or enforce any proprietary rights in these countries. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. We are aware of several U.S. patents held by third parties relating to certain CAR compositions of matter and their methods of use. Generally, conducting clinical trials and other development activities in the United States is not considered an act of infringement. If and when any of our product candidates is approved by the FDA, third parties may then seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may be alleged to infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own, that we believe will facilitate the development of our product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put one or more of our pending patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The lives of our patents may not be sufficient to effectively protect our products and business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include IPR, ex parte re-examination and post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent U.S. Supreme Court rulings have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the 2013 case, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to protect our intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries where Allogene Overland may do business, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us or Allogene Overland to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock has been and may continue to be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock following our IPO in October 2018 has been and is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section, these factors include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the commencement, enrollment or results of our ongoing and planned clinical trials of our product candidates or any future clinical trials we or Servier may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our or Servier&#8217;s decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">adverse results or delays in clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our failure to commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">adverse developments concerning the manufacture or supply of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our inability to establish collaborations if needed;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">additions or departures of key scientific or management personnel;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">unanticipated serious safety concerns related to immuno-oncology or related to the use of our product candidates or pre-conditioning regimen;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our ability to effectively manage our growth;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the size and growth of our initial cancer target markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our ability to successfully treat additional types of cancers or at different stages;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our cash position;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">sales of our common stock by us or our stockholders in the future;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">ineffectiveness of our disclosure controls or internal controls;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">disagreements with our auditor or termination of an auditor engagement;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">significant business disruptions caused by natural or man-made disasters, such as the COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">general political and economic conditions; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the Nasdaq Global Select Market and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock, regardless of our actual operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to establish and maintain effective internal control over financial reporting could result in material misstatements in our financial statements, our failure to meet our reporting obligations and cause investors to lose confidence in our reported financial information, which in turn could cause the trading price of our common stock to decline</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining effective disclosure controls and procedures and internal controls over financial reporting are necessary for us to produce reliable financial statements. We are required, pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting.  We are also required to have our auditors formally attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 on an annual basis.  Complying with Section 404 requires a rigorous compliance program as well as adequate time and resources. We may not be able to complete our internal control evaluation, testing and any required remediation in a timely fashion. Additionally, if we or our auditors identify one or more material weaknesses in our internal control over financial reporting, we will not be able to assert that our internal controls are effective. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of implementing a new enterprise resource planning software as part of a plan to integrate and upgrade our systems and processes. The implementation of this new software is complex and its successful and timely implementation is not assured, requires significant capital expenditures, and can be disruptive to our business operations. Any failure to maintain or implement new or improved internal controls related to this new software implementation or otherwise could result in material weaknesses, result in material misstatements in our consolidated financial statements and cause us to fail to meet our reporting obligations. This could cause us to lose public confidence and could cause the trading price of our common stock to decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently anticipate that we will retain any future cash flow or earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">a requirement that special meetings of stockholders be called only by the chair of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global credit and financial markets have experienced extreme volatility and disruptions in the past, most recently as a result of the COVID-19 pandemic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These disruptions can result in severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds would also be adversely impacted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, including by any of our directors, officers or larger shareholders, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock could be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_124"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Proceeds from our Initial Public Offering of Common Stock</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced our IPO pursuant to registration statements on Form S-1 (File Nos.&#160;333-227333 and 333-227774) that were declared or became effective on October 10, 2018 and registered an aggregate of 20,700,000 shares of our common stock for sale at a public offering price of $18.00 per share and an aggregate gross offering price of $372.6 million. On October 10, 2018, we sold 18,000,000 shares of our common stock at a public offering price of $18.00 per share for an aggregate gross offering price of $324.0 million. An additional 2,700,000 shares were sold pursuant to the underwriters&#8217; option to purchase </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional shares with a public offering price of $18.00 per share for additional gross proceeds of $48.6 million. On October 15, 2018, we completed our IPO. Goldman Sachs&#160;&amp; Co. LLC, J.P. Morgan Securities LLC, Cowen and Company, LLC and Jefferies LLC acted as joint book-running managers for our IPO.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underwriting discounts and commissions for the offering totaled approximately $26.1 million. We incurred additional costs of approximately $3.2 million in offering expenses, which when added to the underwriting discounts and commissions paid by us, amounts to total fees and costs of approximately $29.3 million. Thus, net offering proceeds to us, after deducting underwriting discounts and commissions and offering costs, were approximately $343.3 million. No offering costs were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon receipt, the net proceeds from our IPO were held in cash and cash equivalents, primarily bank money market accounts. Through March 31, 2021, we have used $276.8 million of the net proceeds from our IPO. The net proceeds from our IPO are being used, together with our cash and cash equivalents, short-term and long-term investments, to fund continued advancement of our product pipeline, with the balance to be used to fund working capital and other general corporate purposes, which may include licensing, acquiring or investing in complementary businesses, technologies, products or assets.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_127"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description of document</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38693), filed with the SEC on October 15, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex31.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518299356/d622265dex32.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518290441/d548088dex41.htm">Form of Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on October 2, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1737287/000119312518273504/d548088dex42.htm">Investors Rights Agreement, dated April 6, 2018, as amended September 5, 2018, by and among the Registrant and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Registration Statement on Form S-1, as amended (File No. 333-227333), filed with the SEC on September 14, 2018).</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20210331xex311.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20210331xex312.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a-14(a)&#160;or Rule&#160;15d-14(a)&#160;of the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="allo-20210331xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document. </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i82c49afd4bcb4a2a8da74edcf15bc0ac_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i82c49afd4bcb4a2a8da74edcf15bc0ac_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ David Chang</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 5, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Eric Schmidt</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Schmidt, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>allo-20210331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4c0b22cd127d4fd8bb474adf9debd64f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Chang, M.D., Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Allogene Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; David Chang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.<br>President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>allo-20210331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i093c787f5e3a4c86a2d3cd046760b401_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Schmidt, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Allogene Therapeutics, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13(a)-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Eric Schmidt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Schmidt, Ph.D.<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>allo-20210331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1aa210952d4e4309b15dfccfb7e77571_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002&#160;</font></div><div style="margin-top:12pt;text-indent:47.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Allogene Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended March&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David Chang, M.D., Ph.D., President and Chief Executive Officer of the Company, and I, Eric Schmidt, Ph.D., Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge&#58;&#160;</font></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)&#59; and&#160;</font></div><div style="margin-top:12pt;padding-left:63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;</font></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; David Chang</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Chang, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 5, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Eric Schmidt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Schmidt, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="margin-top:12pt;text-indent:47.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Exchange Act or otherwise subject to the liability of Section&#160;18 of the Exchange Act. Such certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>allo-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d318bd7c-046b-4e7c-95c7-84b602262a02,g:436096e2-f446-4eef-a0b1-f01b7434d186-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:allo="http://allogene.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://allogene.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="allo-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://allogene.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://allogene.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://allogene.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://allogene.com/role/FairValueMeasurements">
        <link:definition>2105103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://allogene.com/role/FairValueMeasurementsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetail" roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail">
        <link:definition>2407402 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail">
        <link:definition>2408403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://allogene.com/role/FinancialInstruments">
        <link:definition>2109104 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://allogene.com/role/FinancialInstrumentsTables">
        <link:definition>2310302 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails">
        <link:definition>2411404 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAdditionalInformationDetails" roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails">
        <link:definition>2412405 - Disclosure - Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://allogene.com/role/BalanceSheetComponents">
        <link:definition>2113105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://allogene.com/role/BalanceSheetComponentsTables">
        <link:definition>2314303 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsDetails" roleURI="http://allogene.com/role/BalanceSheetComponentsDetails">
        <link:definition>2415406 - Disclosure - Balance Sheet Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://allogene.com/role/LicenseAgreements">
        <link:definition>2116106 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://allogene.com/role/LicenseAgreementsDetails">
        <link:definition>2417407 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://allogene.com/role/CommitmentsandContingencies">
        <link:definition>2118107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://allogene.com/role/CommitmentsandContingenciesTables">
        <link:definition>2319304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2420408 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseLiabilitiesDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails">
        <link:definition>2421409 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesLeaseCostsDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails">
        <link:definition>2422410 - Disclosure - Commitments and Contingencies - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails">
        <link:definition>2423411 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestment" roleURI="http://allogene.com/role/EquityMethodInvestment">
        <link:definition>2124108 - Disclosure - Equity Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentDetails" roleURI="http://allogene.com/role/EquityMethodInvestmentDetails">
        <link:definition>2425412 - Disclosure - Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://allogene.com/role/StockBasedCompensation">
        <link:definition>2126109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://allogene.com/role/StockBasedCompensationTables">
        <link:definition>2327305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2428413 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2429414 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsDetails" roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails">
        <link:definition>2430415 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpenseDetails" roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails">
        <link:definition>2432417 - Disclosure - Stock-Based Compensation - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://allogene.com/role/RelatedPartyTransactions">
        <link:definition>2133110 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2434418 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://allogene.com/role/IncomeTaxes">
        <link:definition>2135111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://allogene.com/role/NetLossPerShare">
        <link:definition>2136112 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://allogene.com/role/NetLossPerShareTables">
        <link:definition>2337306 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareDetails" roleURI="http://allogene.com/role/NetLossPerShareDetails">
        <link:definition>2438419 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://allogene.com/role/SubsequentEvents">
        <link:definition>2139113 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="allo_ResearchCollaborationAndLicenseAgreementMember" abstract="true" name="ResearchCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AreaOfOffice" abstract="false" name="AreaOfOffice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="allo_ComputerEquipmentAndPurchasedSoftwareMember" abstract="true" name="ComputerEquipmentAndPurchasedSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_LiabilitiesLesseeTableTextBlock" abstract="false" name="LiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_PercentageOfDevelopmentCostPayableByTheCompany" abstract="false" name="PercentageOfDevelopmentCostPayableByTheCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_PreClinicalDevelopmentMilestoneMember" abstract="true" name="PreClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" abstract="false" name="NumberOfSharesAsPercentageOfCommonSharesOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_UniversityOfTexasMDAndersonCancerCenterMember" abstract="true" name="UniversityOfTexasMDAndersonCancerCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayments" abstract="false" name="AggregatePotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CollaborationAgreementCommittedFunding" abstract="false" name="CollaborationAgreementCommittedFunding" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_OverlandPharmaceuticalsIncMember" abstract="true" name="OverlandPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" abstract="false" name="MaximumPaymentsRequiredPerProductAgainstSelectedTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AreaOfOperatingLease" abstract="false" name="AreaOfOperatingLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="allo_RelatedPartyTransactionMonthlyPaymentsInArrears" abstract="false" name="RelatedPartyTransactionMonthlyPaymentsInArrears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_LicenseAgreementsTextBlock" abstract="false" name="LicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_LicenseAndCollaborationAgreementMember" abstract="true" name="LicenseAndCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_EquityInvestmentBasisAxis" abstract="true" name="EquityInvestmentBasisAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_CapitalizedSoftwareCostsIncurredNotYetPaid" abstract="false" name="CapitalizedSoftwareCostsIncurredNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_EquityInvestmentBasisDomain" abstract="true" name="EquityInvestmentBasisDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PaymentsCommencingJanuary2020Member" abstract="true" name="PaymentsCommencingJanuary2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_PfizerIncMember" abstract="true" name="PfizerIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_NumberOfOptionsToExtendLease" abstract="false" name="NumberOfOptionsToExtendLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="allo_PaymentTermsAxis" abstract="true" name="PaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_IncomeLossFromCostMethodInvestment" abstract="false" name="IncomeLossFromCostMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_FounderSharesOfCommonStockMember" abstract="true" name="FounderSharesOfCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AggregatePotentialMilestoneReceivable" abstract="false" name="AggregatePotentialMilestoneReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CostMethodInvestmentTransactionCosts" abstract="false" name="CostMethodInvestmentTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_RelatedPartyTransactionCompensationPercentage" abstract="false" name="RelatedPartyTransactionCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" abstract="false" name="ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_PaymentTermsDomain" abstract="true" name="PaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_LesseeFinanceLeasePaymentUponContractTermination" abstract="false" name="LesseeFinanceLeasePaymentUponContractTermination" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" abstract="false" name="OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="allo_RoyaltyObligationPeriodFromDateOfFirstSale" abstract="false" name="RoyaltyObligationPeriodFromDateOfFirstSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" abstract="false" name="AggregatePotentialRegulatoryAndDevelopmentMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_BellcoCapitalLLCMember" abstract="true" name="BellcoCapitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_StockOptionGrantedPeriod" abstract="false" name="StockOptionGrantedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_AccruedAndOtherLiabilitiesCurrent" abstract="false" name="AccruedAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CollaborationArrangementExpense" abstract="false" name="CollaborationArrangementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AreaOfNewOfficeBuilding" abstract="false" name="AreaOfNewOfficeBuilding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="allo_NotchTherapeuticsIncMember" abstract="true" name="NotchTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SubleaseAgreementMember" abstract="true" name="SubleaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" abstract="false" name="RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_TenantImprovementAllowanceUtilizedToDate" abstract="false" name="TenantImprovementAllowanceUtilizedToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="allo_PaymentsCommencingJanuary2019Member" abstract="true" name="PaymentsCommencingJanuary2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ConsultingAgreementsMember" abstract="true" name="ConsultingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ServierMember" abstract="true" name="ServierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_TenantImprovementAllowance" abstract="false" name="TenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_TwoThousandEighteenPlanMember" abstract="true" name="TwoThousandEighteenPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_MilestoneTypeDomain" abstract="true" name="MilestoneTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" abstract="false" name="RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="allo_TwoRiverConsultingLLCMember" abstract="true" name="TwoRiverConsultingLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="allo_ClinicalRegulatoryAndCommercialMilestoneMember" abstract="true" name="ClinicalRegulatoryAndCommercialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_RegulatoryMilestoneMember" abstract="true" name="RegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AggregatePotentialMilestonePayable" abstract="false" name="AggregatePotentialMilestonePayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_NewarkMember" abstract="true" name="NewarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_AssetContributionAgreementMember" abstract="true" name="AssetContributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_VotingInterestMember" abstract="true" name="VotingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_EarlyExerciseOfStockOptionsMember" abstract="true" name="EarlyExerciseOfStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_SalesMilestoneMember" abstract="true" name="SalesMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_JointVentureCapitalSupportPayments" abstract="false" name="JointVentureCapitalSupportPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="allo_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CellectisSAMember" abstract="true" name="CellectisSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_DevelopmentAndSalesMember" abstract="true" name="DevelopmentAndSalesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_CollaborationAgreementUpfrontPayment" abstract="false" name="CollaborationAgreementUpfrontPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_AllogeneOverlandMember" abstract="true" name="AllogeneOverlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="allo_CashEquivalentsAndShortTermInvestments" abstract="false" name="CashEquivalentsAndShortTermInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_MilestoneTypeAxis" abstract="true" name="MilestoneTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="allo_UpfrontAndQuarterlyCashPayments" abstract="false" name="UpfrontAndQuarterlyCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" abstract="false" name="PercentageOfDevelopmentCostPayableByCollaborationPartner" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>allo-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d318bd7c-046b-4e7c-95c7-84b602262a02,g:436096e2-f446-4eef-a0b1-f01b7434d186-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_da79d556-92e9-4457-a10c-5bdf1e2c8405" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b590173-c16e-4428-9d08-37e740f3e51b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da79d556-92e9-4457-a10c-5bdf1e2c8405" xlink:to="loc_us-gaap_LiabilitiesCurrent_7b590173-c16e-4428-9d08-37e740f3e51b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32010154-ffcd-4a6a-b65e-0f93bb600ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da79d556-92e9-4457-a10c-5bdf1e2c8405" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32010154-ffcd-4a6a-b65e-0f93bb600ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d0295d3a-2b41-479c-ab0e-5820245f0b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_da79d556-92e9-4457-a10c-5bdf1e2c8405" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d0295d3a-2b41-479c-ab0e-5820245f0b0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a2a6e8c3-90fe-4abb-ac8f-a6756d5b9fc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b632f320-d662-4f9b-bac7-ff788e8d101d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a6e8c3-90fe-4abb-ac8f-a6756d5b9fc9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b632f320-d662-4f9b-bac7-ff788e8d101d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fbcaaea4-dd43-4dbc-a549-62f7a6ae59bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a6e8c3-90fe-4abb-ac8f-a6756d5b9fc9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fbcaaea4-dd43-4dbc-a549-62f7a6ae59bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a243e4a5-aefd-4f6b-b42f-73bec842ec33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a2a6e8c3-90fe-4abb-ac8f-a6756d5b9fc9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a243e4a5-aefd-4f6b-b42f-73bec842ec33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6da1aff0-2c3a-4a7b-97f2-e305ed7148e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a20859e6-a425-49e1-90e8-9a3102a97362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6da1aff0-2c3a-4a7b-97f2-e305ed7148e0" xlink:to="loc_us-gaap_PreferredStockValue_a20859e6-a425-49e1-90e8-9a3102a97362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5aa91f00-ea87-4c7f-808d-bdf7a5245547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6da1aff0-2c3a-4a7b-97f2-e305ed7148e0" xlink:to="loc_us-gaap_CommonStockValue_5aa91f00-ea87-4c7f-808d-bdf7a5245547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4be7f3b7-9686-4515-a939-17e62238a969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6da1aff0-2c3a-4a7b-97f2-e305ed7148e0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4be7f3b7-9686-4515-a939-17e62238a969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cec45b85-936d-42d4-8996-f8030ffbaab3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6da1aff0-2c3a-4a7b-97f2-e305ed7148e0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cec45b85-936d-42d4-8996-f8030ffbaab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5402ea7-2a17-4956-9b31-e086bc507843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6da1aff0-2c3a-4a7b-97f2-e305ed7148e0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e5402ea7-2a17-4956-9b31-e086bc507843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_667ad52d-b628-4197-8810-7abdf823314d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_70eac570-dae8-43e9-9af4-0418982673dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_667ad52d-b628-4197-8810-7abdf823314d" xlink:to="loc_us-gaap_Liabilities_70eac570-dae8-43e9-9af4-0418982673dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ef778dea-270d-49cd-9ab8-770bcd35ed20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_667ad52d-b628-4197-8810-7abdf823314d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ef778dea-270d-49cd-9ab8-770bcd35ed20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c95cdb3b-e378-4d13-9f69-b3b14e197dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_667ad52d-b628-4197-8810-7abdf823314d" xlink:to="loc_us-gaap_StockholdersEquity_c95cdb3b-e378-4d13-9f69-b3b14e197dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11ee9935-1a47-4ae4-a897-884bf7d9b332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11ee9935-1a47-4ae4-a897-884bf7d9b332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_dd606e03-f652-4feb-b5c4-a1d22ed88ff1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_dd606e03-f652-4feb-b5c4-a1d22ed88ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a6e78290-b1a6-429c-93c2-a9410b8c42b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a6e78290-b1a6-429c-93c2-a9410b8c42b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_c2911b13-b809-4731-ab90-63adf35833b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_c2911b13-b809-4731-ab90-63adf35833b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e5777ef3-f404-45cf-a75d-4ec7cabb3695" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e5777ef3-f404-45cf-a75d-4ec7cabb3695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d999985c-0d78-4b81-ae51-a4c15847ac49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:to="loc_us-gaap_AssetsCurrent_d999985c-0d78-4b81-ae51-a4c15847ac49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f57b765b-ebc8-4e75-bc80-32b9fe1af001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5c8063e0-7667-4279-ae66-55eab4092f26" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f57b765b-ebc8-4e75-bc80-32b9fe1af001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_82cf0555-21a6-4aab-b116-215349f5c87d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0c0c7429-4c0b-4ed6-b4e9-e78fe625acfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cf0555-21a6-4aab-b116-215349f5c87d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_0c0c7429-4c0b-4ed6-b4e9-e78fe625acfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_8d17cfa1-1876-4fbc-a4a0-e4cfbed5ba98" xlink:href="allo-20210331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cf0555-21a6-4aab-b116-215349f5c87d" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_8d17cfa1-1876-4fbc-a4a0-e4cfbed5ba98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9918ef77-efc0-4344-878a-456e441c85d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_82cf0555-21a6-4aab-b116-215349f5c87d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9918ef77-efc0-4344-878a-456e441c85d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4e90dd1-366b-48f7-9262-f0575f48ca99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06da2b57-4582-4957-9460-28a4d53a7b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4e90dd1-366b-48f7-9262-f0575f48ca99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_06da2b57-4582-4957-9460-28a4d53a7b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_936f2462-1148-4395-a3c3-0cbfeb2c3d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c4e90dd1-366b-48f7-9262-f0575f48ca99" xlink:to="loc_us-gaap_NetIncomeLoss_936f2462-1148-4395-a3c3-0cbfeb2c3d99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d0ab6bab-e69c-44fa-a0d6-dbc7bce29fde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54f4c4c3-f9a5-48fe-b34d-d4c2355bd1a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d0ab6bab-e69c-44fa-a0d6-dbc7bce29fde" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_54f4c4c3-f9a5-48fe-b34d-d4c2355bd1a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_66666478-4ff2-454b-9697-48a7e2ba7f00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d0ab6bab-e69c-44fa-a0d6-dbc7bce29fde" xlink:to="loc_us-gaap_OperatingExpenses_66666478-4ff2-454b-9697-48a7e2ba7f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ba4a300-80b1-4fbe-9686-e25e6e3d18b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d54e058b-caa1-4fc2-a90d-3bfdd17b136d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1ba4a300-80b1-4fbe-9686-e25e6e3d18b7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d54e058b-caa1-4fc2-a90d-3bfdd17b136d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_606484fd-6333-422a-bc05-9e24b79742dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1ba4a300-80b1-4fbe-9686-e25e6e3d18b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_606484fd-6333-422a-bc05-9e24b79742dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f0a698d0-4614-4326-aa24-c078886ce6f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2490d71c-d9f6-44cd-a4c5-bee65abff546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f0a698d0-4614-4326-aa24-c078886ce6f3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2490d71c-d9f6-44cd-a4c5-bee65abff546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_fe2ce40b-ef92-4d9c-b5aa-2e0ea8af6330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_f0a698d0-4614-4326-aa24-c078886ce6f3" xlink:to="loc_us-gaap_OtherExpenses_fe2ce40b-ef92-4d9c-b5aa-2e0ea8af6330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d3b77b5f-fa1a-470a-b2b5-b49e3e165ca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4935cf9a-d79c-4f47-b43f-b43d7a901cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d3b77b5f-fa1a-470a-b2b5-b49e3e165ca7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4935cf9a-d79c-4f47-b43f-b43d7a901cfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7234d307-4abd-416b-b7f0-b9cbd29d9476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d3b77b5f-fa1a-470a-b2b5-b49e3e165ca7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7234d307-4abd-416b-b7f0-b9cbd29d9476" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aae2e3f4-7372-4734-aab9-fda700e47a67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b02904c8-afcc-4580-900f-984eed721eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aae2e3f4-7372-4734-aab9-fda700e47a67" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b02904c8-afcc-4580-900f-984eed721eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d57de66b-0667-458a-8476-daacc78c417c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aae2e3f4-7372-4734-aab9-fda700e47a67" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d57de66b-0667-458a-8476-daacc78c417c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_93f41c11-a627-4248-b0b5-a7f459b7b039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aae2e3f4-7372-4734-aab9-fda700e47a67" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_93f41c11-a627-4248-b0b5-a7f459b7b039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d2d6497a-68dd-4c2e-ab7f-d3d26dae3aec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_aae2e3f4-7372-4734-aab9-fda700e47a67" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_d2d6497a-68dd-4c2e-ab7f-d3d26dae3aec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2bb79a1-cf8b-4793-90eb-e57179339e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_54b9d9d7-7e9f-4652-8525-ff2d9b37d4cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2bb79a1-cf8b-4793-90eb-e57179339e35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_54b9d9d7-7e9f-4652-8525-ff2d9b37d4cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f8efea43-bef2-4b6e-b878-020f4a301ffb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2bb79a1-cf8b-4793-90eb-e57179339e35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f8efea43-bef2-4b6e-b878-020f4a301ffb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d9af12d6-43be-4eb1-ad6f-dd5b29c0fd79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f2bb79a1-cf8b-4793-90eb-e57179339e35" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d9af12d6-43be-4eb1-ad6f-dd5b29c0fd79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d0aab9da-d038-4780-a2ce-4567a72ebeed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d0aab9da-d038-4780-a2ce-4567a72ebeed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_38fca13f-57c1-4b58-ad97-7a6132077629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_OperatingLeaseExpense_38fca13f-57c1-4b58-ad97-7a6132077629" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9752a26c-e795-401f-96ca-b0231c23144b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9752a26c-e795-401f-96ca-b0231c23144b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3205f04f-9cd4-47d2-bf37-42c012903a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_3205f04f-9cd4-47d2-bf37-42c012903a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_9afaeaf0-a5cf-4ec0-9d13-f7f25819db6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_9afaeaf0-a5cf-4ec0-9d13-f7f25819db6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3ba4f587-2601-4248-801c-e42bec4e5663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_Depreciation_3ba4f587-2601-4248-801c-e42bec4e5663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6a7a151c-8227-472c-b833-245847555873" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6a7a151c-8227-472c-b833-245847555873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3b187731-dfc1-4efa-8d84-1f4f06f87822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3b187731-dfc1-4efa-8d84-1f4f06f87822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c2fc4a7a-38da-4dd6-a9d7-89e57017c915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_ProfitLoss_c2fc4a7a-38da-4dd6-a9d7-89e57017c915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_599e62bf-17cd-43ce-900f-cfca7a58aa7a" xlink:href="allo-20210331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_599e62bf-17cd-43ce-900f-cfca7a58aa7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_07e03e2c-53bc-48e8-9dfc-0d8e91e290d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_ShareBasedCompensation_07e03e2c-53bc-48e8-9dfc-0d8e91e290d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c4fcd4ab-1256-4c50-b498-d3dab2a99556" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_c4fcd4ab-1256-4c50-b498-d3dab2a99556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1f309ad6-4f64-46bc-adc7-778b6fe5e671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b289da5d-abde-438e-9b8e-3da2385690bb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1f309ad6-4f64-46bc-adc7-778b6fe5e671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f44417a3-1314-4689-9d5e-d6ae74b03b3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f251d8ba-4fd2-4882-aa56-ad7456ff627b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f44417a3-1314-4689-9d5e-d6ae74b03b3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f251d8ba-4fd2-4882-aa56-ad7456ff627b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69e0273c-ab5c-4c8d-a125-033c8f36f6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f44417a3-1314-4689-9d5e-d6ae74b03b3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69e0273c-ab5c-4c8d-a125-033c8f36f6de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e7bc597-dd61-4a2b-bf3a-c4b301d09f99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f44417a3-1314-4689-9d5e-d6ae74b03b3c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5e7bc597-dd61-4a2b-bf3a-c4b301d09f99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="allo-20210331.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#DescriptionofBusinessDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb76fe62-832b-4311-baa5-ef77f095b78f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c11501c6-8562-488c-86cc-5225104af728" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb76fe62-832b-4311-baa5-ef77f095b78f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c11501c6-8562-488c-86cc-5225104af728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0c92fc4a-f5b1-4cd1-a778-177a4b31b5ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb76fe62-832b-4311-baa5-ef77f095b78f" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0c92fc4a-f5b1-4cd1-a778-177a4b31b5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_9766c577-147c-433e-8196-b9d24be66792" xlink:href="allo-20210331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb76fe62-832b-4311-baa5-ef77f095b78f" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_9766c577-147c-433e-8196-b9d24be66792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b974c459-04b6-491c-85ab-b7a4aa9d6dfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fb76fe62-832b-4311-baa5-ef77f095b78f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b974c459-04b6-491c-85ab-b7a4aa9d6dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_acc322a8-cfea-4bce-8b73-b0b0d4035135" xlink:href="allo-20210331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ac0bffdb-9964-4000-8d01-375d96f22d80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_acc322a8-cfea-4bce-8b73-b0b0d4035135" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ac0bffdb-9964-4000-8d01-375d96f22d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8c205f3a-857f-44c3-b2d7-39784778fa11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_acc322a8-cfea-4bce-8b73-b0b0d4035135" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8c205f3a-857f-44c3-b2d7-39784778fa11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d93fee2b-ca5b-403c-b8f2-0008bc104f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments_acc322a8-cfea-4bce-8b73-b0b0d4035135" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d93fee2b-ca5b-403c-b8f2-0008bc104f5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponentsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a9bb7ced-4fec-4a6f-a13d-b4efa4ef5c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8aeff33a-cd5e-4a8f-8b41-89b42c7098a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a9bb7ced-4fec-4a6f-a13d-b4efa4ef5c7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8aeff33a-cd5e-4a8f-8b41-89b42c7098a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3c875716-0a51-4a90-a896-2fd8a0e3a297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_a9bb7ced-4fec-4a6f-a13d-b4efa4ef5c7f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3c875716-0a51-4a90-a896-2fd8a0e3a297" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:type="simple" xlink:href="allo-20210331.xsd#LicenseAgreements"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#LicenseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_175fa396-c666-46b8-9e03-c1a004cd74f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9cdd3c09-aeac-4ed9-86d9-e73f51ca808d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_175fa396-c666-46b8-9e03-c1a004cd74f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9cdd3c09-aeac-4ed9-86d9-e73f51ca808d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_65ba63e4-dffc-455a-8424-15c5f5e8cc39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_175fa396-c666-46b8-9e03-c1a004cd74f2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_65ba63e4-dffc-455a-8424-15c5f5e8cc39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d59f5506-dab3-4dfa-9cd4-68d9ce80412b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_49785d3c-2567-4066-b654-70ca8f7e25de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d59f5506-dab3-4dfa-9cd4-68d9ce80412b" xlink:to="loc_us-gaap_OperatingLeaseCost_49785d3c-2567-4066-b654-70ca8f7e25de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0ef57894-8091-46c5-a042-bd923425a0f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_d59f5506-dab3-4dfa-9cd4-68d9ce80412b" xlink:to="loc_us-gaap_VariableLeaseCost_0ef57894-8091-46c5-a042-bd923425a0f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f0dc266-17fc-4c33-b93b-0d91d9a76914" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5fc2a2c5-9f86-46ff-8047-4d2a20f892b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f0dc266-17fc-4c33-b93b-0d91d9a76914" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5fc2a2c5-9f86-46ff-8047-4d2a20f892b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c54a0621-1bf6-4ecb-befd-045116802470" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f0dc266-17fc-4c33-b93b-0d91d9a76914" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c54a0621-1bf6-4ecb-befd-045116802470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bcf983ab-df32-4c7f-b4a2-6f88dc5eeecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f0dc266-17fc-4c33-b93b-0d91d9a76914" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bcf983ab-df32-4c7f-b4a2-6f88dc5eeecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8dc4bd7-c7b0-48a6-8788-2ae2fee2f877" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f0dc266-17fc-4c33-b93b-0d91d9a76914" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c8dc4bd7-c7b0-48a6-8788-2ae2fee2f877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_83a277b4-d5bc-450c-a5ed-b8d666d6e59b" xlink:href="allo-20210331.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f0dc266-17fc-4c33-b93b-0d91d9a76914" xlink:to="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_83a277b4-d5bc-450c-a5ed-b8d666d6e59b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74db85c2-2255-468e-a472-4fb009a4db1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3f0dc266-17fc-4c33-b93b-0d91d9a76914" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74db85c2-2255-468e-a472-4fb009a4db1c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20210331.xsd#EquityMethodInvestment"/>
  <link:calculationLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#EquityMethodInvestmentDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20210331.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShare"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShareTables"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20210331.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>allo-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d318bd7c-046b-4e7c-95c7-84b602262a02,g:436096e2-f446-4eef-a0b1-f01b7434d186-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended" id="i7304c033f190498d9320fa404a1f8684_CoverPage"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i43b878cdf2eb43749c8a06a131bfbe2e_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i9b6a9a869e4440d8af8006c353063dca_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="ia409ac873e5e40d1bf6bd62fbeb7509a_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="id7714598ef7c45d0bbb4d00c9eda2b30_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8dd1849-5022-4a1b-bf24-0567c7ddf4c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8dd1849-5022-4a1b-bf24-0567c7ddf4c7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bcd57e76-3a82-4e73-91f1-fb7f0f866284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bcd57e76-3a82-4e73-91f1-fb7f0f866284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b91f773b-d89c-43e2-9a5a-5e5fae44085f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockholdersEquity_b91f773b-d89c-43e2-9a5a-5e5fae44085f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4f0c9650-ffcd-4473-9b15-98a7f84d1e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4f0c9650-ffcd-4473-9b15-98a7f84d1e21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a5b09925-8155-44be-b54d-639b0448cb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a5b09925-8155-44be-b54d-639b0448cb05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6067b7b4-ba94-4f86-81d8-f161ed875e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6067b7b4-ba94-4f86-81d8-f161ed875e71" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_da17b32c-fb09-48d2-80e9-d0ce2946bbad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_da17b32c-fb09-48d2-80e9-d0ce2946bbad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_317040ca-9984-4a10-96ab-4c4c7237a177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_317040ca-9984-4a10-96ab-4c4c7237a177" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_627a87f7-cec2-40a9-8c1a-6537a109bc70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_627a87f7-cec2-40a9-8c1a-6537a109bc70" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7b0c215-823e-460d-a978-c6da86d79cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7b0c215-823e-460d-a978-c6da86d79cda" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72c5a01c-210b-40d7-88a7-48e759b62e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72c5a01c-210b-40d7-88a7-48e759b62e04" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_703b6cde-a23a-40b3-8cc6-c4bc7487c9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_NetIncomeLoss_703b6cde-a23a-40b3-8cc6-c4bc7487c9ff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_16e8c9f6-4fab-4676-9048-c24d125cb694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_16e8c9f6-4fab-4676-9048-c24d125cb694" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ac83154d-2288-4016-8fbb-5d4240752ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1aed2397-46b3-455b-8af9-c30bd819f500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_26cd98f1-6ffd-412b-8fef-fc19ef5231d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c8dd1849-5022-4a1b-bf24-0567c7ddf4c7" xlink:to="loc_us-gaap_StatementTable_26cd98f1-6ffd-412b-8fef-fc19ef5231d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58acf216-9990-4c25-a989-c983b9140057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_26cd98f1-6ffd-412b-8fef-fc19ef5231d8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58acf216-9990-4c25-a989-c983b9140057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_58acf216-9990-4c25-a989-c983b9140057_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58acf216-9990-4c25-a989-c983b9140057" xlink:to="loc_us-gaap_EquityComponentDomain_58acf216-9990-4c25-a989-c983b9140057_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58acf216-9990-4c25-a989-c983b9140057" xlink:to="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e4103dcf-3bbc-40e6-8b62-fb9c3fd0c485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_CommonStockMember_e4103dcf-3bbc-40e6-8b62-fb9c3fd0c485" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a94a0e21-88f5-4df8-ba7c-203305b52f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a94a0e21-88f5-4df8-ba7c-203305b52f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_46501c1f-8bc0-4351-9ad5-48bd19c2e2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_RetainedEarningsMember_46501c1f-8bc0-4351-9ad5-48bd19c2e2f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e123bd84-6def-4ebc-9141-b0cb6ce2b805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e123bd84-6def-4ebc-9141-b0cb6ce2b805" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="ie5204a46b1174a5796df760a88c77b27_CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ed593d8-252a-4d76-b9ed-bf1ae9ee27a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_479fc892-2918-4eea-a851-d087877acd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ed593d8-252a-4d76-b9ed-bf1ae9ee27a7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_479fc892-2918-4eea-a851-d087877acd70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_62068877-476d-449f-82bb-f77e3f3d1f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3ed593d8-252a-4d76-b9ed-bf1ae9ee27a7" xlink:to="loc_us-gaap_StatementTable_62068877-476d-449f-82bb-f77e3f3d1f97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dc4c9456-8eab-4ba5-b63c-63b6ded700a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_62068877-476d-449f-82bb-f77e3f3d1f97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dc4c9456-8eab-4ba5-b63c-63b6ded700a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc4c9456-8eab-4ba5-b63c-63b6ded700a6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dc4c9456-8eab-4ba5-b63c-63b6ded700a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dc4c9456-8eab-4ba5-b63c-63b6ded700a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3698b717-7e14-4bcc-8c7e-79cb0077b24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dc4c9456-8eab-4ba5-b63c-63b6ded700a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3698b717-7e14-4bcc-8c7e-79cb0077b24a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PublicOfferingMember_75963937-0606-4d36-8d95-b2a2136ca173" xlink:href="allo-20210331.xsd#allo_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3698b717-7e14-4bcc-8c7e-79cb0077b24a" xlink:to="loc_allo_PublicOfferingMember_75963937-0606-4d36-8d95-b2a2136ca173" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i5a1bb0b4090a4d64adf3373068418056_CondensedConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c00ded5e-2386-4beb-b003-e71b6f2e950c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_ProfitLoss_c00ded5e-2386-4beb-b003-e71b6f2e950c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_660e1c23-1d34-41aa-b6c8-8c68cccdfb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_ShareBasedCompensation_660e1c23-1d34-41aa-b6c8-8c68cccdfb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3953d7d9-761d-4836-baa8-3d6b301e8c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3953d7d9-761d-4836-baa8-3d6b301e8c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a1a2f616-cfaa-4e2e-9313-c5e79f79e331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_Depreciation_a1a2f616-cfaa-4e2e-9313-c5e79f79e331" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d165e9ee-bd40-4679-888f-f6e17a6823f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d165e9ee-bd40-4679-888f-f6e17a6823f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_63fa8f56-d4ec-48b0-911b-c4f09bd6a876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_OperatingLeaseExpense_63fa8f56-d4ec-48b0-911b-c4f09bd6a876" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_573df315-fd68-4400-903f-ef82c540a764" xlink:href="allo-20210331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_573df315-fd68-4400-903f-ef82c540a764" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ddda67ae-8d31-4e7f-96ac-ff84906ea075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ddda67ae-8d31-4e7f-96ac-ff84906ea075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ab3b097b-74ad-4271-b8b9-495a44be8888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ab3b097b-74ad-4271-b8b9-495a44be8888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f18d776-327d-4d7b-a72d-fb173cf662e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f18d776-327d-4d7b-a72d-fb173cf662e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d4d0c06d-34d7-40d2-a0e9-1c53ee4382f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d4d0c06d-34d7-40d2-a0e9-1c53ee4382f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_96553124-963d-4c24-8573-b2dd7fdbe188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_96553124-963d-4c24-8573-b2dd7fdbe188" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cdf3c3ba-c598-4f32-bda6-a7eba556504a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cdf3c3ba-c598-4f32-bda6-a7eba556504a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_83057f45-82f9-498c-8348-a913f4631ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_83057f45-82f9-498c-8348-a913f4631ee9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4bd50efa-f173-4569-9d87-e8b0a0e32628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4bd50efa-f173-4569-9d87-e8b0a0e32628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3f263091-de42-4d2e-8be7-c07f866f204c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3f263091-de42-4d2e-8be7-c07f866f204c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6788e5f6-28cc-427a-8f2f-4f402d58b88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6788e5f6-28cc-427a-8f2f-4f402d58b88b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_628593db-01b9-4741-adea-2ba22d6fa798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_628593db-01b9-4741-adea-2ba22d6fa798" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b3dc4423-6ade-4197-8376-08c5889ebb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b3dc4423-6ade-4197-8376-08c5889ebb44" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51ac13a6-4789-438e-b402-341c5260f8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51ac13a6-4789-438e-b402-341c5260f8af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dd433d80-d359-48fd-9909-6a720dc1d34f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dd433d80-d359-48fd-9909-6a720dc1d34f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_97ad82d9-331e-4430-aba2-4c35fc15a29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_ProceedsFromStockPlans_97ad82d9-331e-4430-aba2-4c35fc15a29c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35fdd5b1-3868-4a20-9601-2caeccf2df15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35fdd5b1-3868-4a20-9601-2caeccf2df15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_016cff8b-577c-4e1d-acab-b8dd8f511ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_016cff8b-577c-4e1d-acab-b8dd8f511ddb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e66fc2b-c008-4816-87d9-86dfa97b2e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e66fc2b-c008-4816-87d9-86dfa97b2e1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbbae4a7-8d30-43a1-a783-c4aa7e57bee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_931bade3-ae3e-4436-84bd-e5506d823422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_931bade3-ae3e-4436-84bd-e5506d823422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CapitalizedSoftwareCostsIncurredNotYetPaid_a1f15d5d-9b33-4d7f-85c3-f23c00029c50" xlink:href="allo-20210331.xsd#allo_CapitalizedSoftwareCostsIncurredNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:to="loc_allo_CapitalizedSoftwareCostsIncurredNotYetPaid_a1f15d5d-9b33-4d7f-85c3-f23c00029c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_481c9a48-f279-4c0f-8019-a2b2cf48eae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:to="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_481c9a48-f279-4c0f-8019-a2b2cf48eae3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_3b6ec3c2-b4c6-40f8-bd5c-16c0dd1691c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_3b6ec3c2-b4c6-40f8-bd5c-16c0dd1691c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c332e066-41dd-41e8-bae1-bde7b39c2b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_StatementTable_c332e066-41dd-41e8-bae1-bde7b39c2b8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16707766-ca82-497f-8329-54920182ca73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c332e066-41dd-41e8-bae1-bde7b39c2b8b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16707766-ca82-497f-8329-54920182ca73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16707766-ca82-497f-8329-54920182ca73_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16707766-ca82-497f-8329-54920182ca73" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16707766-ca82-497f-8329-54920182ca73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ac7534b-47cf-4d21-9f33-0a4cd6a5cc28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16707766-ca82-497f-8329-54920182ca73" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ac7534b-47cf-4d21-9f33-0a4cd6a5cc28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AtTheMarketOfferingMember_67f26bed-b63c-4d6d-b863-eeba36d3bfd9" xlink:href="allo-20210331.xsd#allo_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ac7534b-47cf-4d21-9f33-0a4cd6a5cc28" xlink:to="loc_allo_AtTheMarketOfferingMember_67f26bed-b63c-4d6d-b863-eeba36d3bfd9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="allo-20210331.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusiness" xlink:type="extended" id="iaa8a5640e9a54266b5703e376d133440_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="ib24b5c50d9a84886b7da00c4cbea3bf8_DescriptionofBusinessDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i13c102a9d22b486b95537a3babb085da_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i656b368bbbd845799c88ee28df4403ad_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended" id="i0a109245e1d14d2598afc6202c181591_FairValueMeasurements"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i96409d23b8574eb6984a7c073f405f37_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended" id="i898bf6a453504c7a8eb2d20454a416f1_FairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_799d8a5e-a763-40f9-bc5a-eb56e2d4f28e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_799d8a5e-a763-40f9-bc5a-eb56e2d4f28e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a52d3582-7594-4eb5-bd64-67ce01b2e634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_a52d3582-7594-4eb5-bd64-67ce01b2e634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a39d659a-ba6d-4ef7-925c-1d700b0827f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a39d659a-ba6d-4ef7-925c-1d700b0827f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a39d659a-ba6d-4ef7-925c-1d700b0827f6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a39d659a-ba6d-4ef7-925c-1d700b0827f6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a39d659a-ba6d-4ef7-925c-1d700b0827f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb724b00-9432-440c-a5c7-a914fce4515b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a39d659a-ba6d-4ef7-925c-1d700b0827f6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb724b00-9432-440c-a5c7-a914fce4515b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5c6c70d9-2ace-49da-8654-02cc867a1e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb724b00-9432-440c-a5c7-a914fce4515b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5c6c70d9-2ace-49da-8654-02cc867a1e3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_982450ff-7447-496b-9ca7-e669920f46e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_982450ff-7447-496b-9ca7-e669920f46e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_982450ff-7447-496b-9ca7-e669920f46e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_982450ff-7447-496b-9ca7-e669920f46e9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_982450ff-7447-496b-9ca7-e669920f46e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7108536-aa90-46bb-b4e6-b909220e9450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_982450ff-7447-496b-9ca7-e669920f46e9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7108536-aa90-46bb-b4e6-b909220e9450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_17b21882-0d8c-4bf4-8864-f22d40feccd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7108536-aa90-46bb-b4e6-b909220e9450" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_17b21882-0d8c-4bf4-8864-f22d40feccd3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended" id="ib54d4411cd9d4f679f220be6c16c91e9_FairValueMeasurementsFinancialAssetsandLiabilitiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae572329-236d-4660-8d74-636825355475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_920355c2-b1ee-470f-b6d9-26599464ff71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae572329-236d-4660-8d74-636825355475" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_920355c2-b1ee-470f-b6d9-26599464ff71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae572329-236d-4660-8d74-636825355475" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a2cb88e7-ac67-4d15-84ed-56526e5b25bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a2cb88e7-ac67-4d15-84ed-56526e5b25bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2cb88e7-ac67-4d15-84ed-56526e5b25bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a2cb88e7-ac67-4d15-84ed-56526e5b25bc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a2cb88e7-ac67-4d15-84ed-56526e5b25bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_785684ba-8e29-4131-8733-dbc4f8f1b90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a2cb88e7-ac67-4d15-84ed-56526e5b25bc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_785684ba-8e29-4131-8733-dbc4f8f1b90b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b9f35a2-cf82-4936-bd31-67814b5040dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_785684ba-8e29-4131-8733-dbc4f8f1b90b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b9f35a2-cf82-4936-bd31-67814b5040dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_721cc81e-4779-4e0c-887d-d16b71ffcd89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_721cc81e-4779-4e0c-887d-d16b71ffcd89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_721cc81e-4779-4e0c-887d-d16b71ffcd89_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_721cc81e-4779-4e0c-887d-d16b71ffcd89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_721cc81e-4779-4e0c-887d-d16b71ffcd89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_721cc81e-4779-4e0c-887d-d16b71ffcd89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d02eb711-94cb-4de0-a7e3-69667f32844c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d02eb711-94cb-4de0-a7e3-69667f32844c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c3fc8c7-bb7c-43ca-9966-35111746d595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c3fc8c7-bb7c-43ca-9966-35111746d595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ef8e9b17-fb65-44c5-ba54-1580615009e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ef8e9b17-fb65-44c5-ba54-1580615009e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2452a9b8-d705-431d-8d86-80b9eefc1bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2452a9b8-d705-431d-8d86-80b9eefc1bed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2452a9b8-d705-431d-8d86-80b9eefc1bed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2452a9b8-d705-431d-8d86-80b9eefc1bed" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2452a9b8-d705-431d-8d86-80b9eefc1bed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2452a9b8-d705-431d-8d86-80b9eefc1bed" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d251a136-fded-4c41-b83c-404e10eeae36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d251a136-fded-4c41-b83c-404e10eeae36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_04c72e35-657f-4785-93ed-12ec1fe5ffdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_CommercialPaperMember_04c72e35-657f-4785-93ed-12ec1fe5ffdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8e8207aa-d048-4940-8656-0e0f33dc6bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8e8207aa-d048-4940-8656-0e0f33dc6bf3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_87121086-8bfc-4ecd-8ee5-e83375e999ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_87121086-8bfc-4ecd-8ee5-e83375e999ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_42b1a7ba-6176-4574-99f8-24ea3a8586da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_42b1a7ba-6176-4574-99f8-24ea3a8586da" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended" id="ic248b944cef54f42ab4a0e11d11b3aa9_FinancialInstruments"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended" id="ia79e4d215fac408087cbf51526fed21d_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended" id="i657c0e9159ff42798edf01b5d2c3f041_FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5d29abe-d8fe-4411-8afd-4b5c1b577c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5d29abe-d8fe-4411-8afd-4b5c1b577c4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d6f32951-ac7c-475a-b5bf-a9861fb5d3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d6f32951-ac7c-475a-b5bf-a9861fb5d3bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_858dadf9-60fd-4917-b785-9e2d7d29e706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_858dadf9-60fd-4917-b785-9e2d7d29e706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55457637-379b-4e0a-b915-18b034a56859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55457637-379b-4e0a-b915-18b034a56859" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_0fa44c8d-2a51-421c-98ab-1036aee3dfc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_0fa44c8d-2a51-421c-98ab-1036aee3dfc2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_27bc62ad-08fe-47ab-b6e5-c633e39baa24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_27bc62ad-08fe-47ab-b6e5-c633e39baa24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8a82668f-2c63-468f-98ab-e6b352423de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8a82668f-2c63-468f-98ab-e6b352423de5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_c483611b-200e-434f-953b-8bde6f9796f4" xlink:href="allo-20210331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_c483611b-200e-434f-953b-8bde6f9796f4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_de2565e5-86e9-4a6a-9fbf-ab7a9b510993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_de2565e5-86e9-4a6a-9fbf-ab7a9b510993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ab03da9f-5205-46eb-8a98-e316c400607a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_de2565e5-86e9-4a6a-9fbf-ab7a9b510993" xlink:to="loc_us-gaap_InvestmentTypeAxis_ab03da9f-5205-46eb-8a98-e316c400607a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ab03da9f-5205-46eb-8a98-e316c400607a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_ab03da9f-5205-46eb-8a98-e316c400607a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ab03da9f-5205-46eb-8a98-e316c400607a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_ab03da9f-5205-46eb-8a98-e316c400607a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c4a13aed-0a67-4738-bb4e-5d9c566daa60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c4a13aed-0a67-4738-bb4e-5d9c566daa60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_065492eb-6920-43d9-9a0a-30ea9ca02e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_CommercialPaperMember_065492eb-6920-43d9-9a0a-30ea9ca02e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6391e269-179c-4599-84b0-0dc226b50dba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6391e269-179c-4599-84b0-0dc226b50dba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_db714e09-f4b3-48d3-bdef-f61686a9a183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_db714e09-f4b3-48d3-bdef-f61686a9a183" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_317b771f-07c9-4cf7-ba23-2ef5163ed990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_317b771f-07c9-4cf7-ba23-2ef5163ed990" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended" id="i31215ebaed0b41ad92d0a83b791d704f_FinancialInstrumentsAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponents" xlink:type="extended" id="i8de65e3d5b7445d8aaef24b731038bd3_BalanceSheetComponents"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="extended" id="i943109702cf34be1b32f49251ce0f411_BalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponentsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="extended" id="i868fea65bc9c4fa5a3acd92878be1349_BalanceSheetComponentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1d1a78ec-af17-4793-b0d4-85e1039df6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1d1a78ec-af17-4793-b0d4-85e1039df6c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b145819a-7880-43b9-a632-3958b55a5c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b145819a-7880-43b9-a632-3958b55a5c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5cef12a0-1a78-4aeb-9754-f0df2e8d9ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5cef12a0-1a78-4aeb-9754-f0df2e8d9ac8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3badc6dc-85f4-457a-b9b8-24bfe58d41e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3badc6dc-85f4-457a-b9b8-24bfe58d41e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4776690c-03f6-44d0-85be-ced542f59a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3badc6dc-85f4-457a-b9b8-24bfe58d41e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4776690c-03f6-44d0-85be-ced542f59a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4776690c-03f6-44d0-85be-ced542f59a84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4776690c-03f6-44d0-85be-ced542f59a84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4776690c-03f6-44d0-85be-ced542f59a84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4776690c-03f6-44d0-85be-ced542f59a84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d0c73dc0-9bc0-473c-9e30-3a97d24b98f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_us-gaap_ConstructionInProgressMember_d0c73dc0-9bc0-473c-9e30-3a97d24b98f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3a9cff22-5887-4330-a371-8c5023daf5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3a9cff22-5887-4330-a371-8c5023daf5e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_9d0707eb-1578-4f55-84b4-f00266e22ff0" xlink:href="allo-20210331.xsd#allo_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_allo_LaboratoryEquipmentMember_9d0707eb-1578-4f55-84b4-f00266e22ff0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_8c70bea4-f30d-492d-b12d-e0c75404cb81" xlink:href="allo-20210331.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_8c70bea4-f30d-492d-b12d-e0c75404cb81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e88f34b7-4878-49be-8683-be2772789563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e88f34b7-4878-49be-8683-be2772789563" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:type="simple" xlink:href="allo-20210331.xsd#LicenseAgreements"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended" id="i173f3e3774074a3986729a89928ade1f_LicenseAgreements"/>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended" id="i3b067ab972864b11886d6d92bf5e6e4b_LicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_2dcdf222-5eff-43af-b6f1-822aee24b127" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialMilestonePayments_2dcdf222-5eff-43af-b6f1-822aee24b127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_9b1595b2-f598-473c-8d30-368234d81fb7" xlink:href="allo-20210331.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_9b1595b2-f598-473c-8d30-368234d81fb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_e9990fd9-a26c-4bd2-9f39-ae612bf82dbb" xlink:href="allo-20210331.xsd#allo_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_MilestonePayments_e9990fd9-a26c-4bd2-9f39-ae612bf82dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_8dcd6dfa-ce44-49af-a5c1-8a62a5cc3632" xlink:href="allo-20210331.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_8dcd6dfa-ce44-49af-a5c1-8a62a5cc3632" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_504557fc-2eff-43e4-a937-db990b0a88f4" xlink:href="allo-20210331.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_504557fc-2eff-43e4-a937-db990b0a88f4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7402e9c1-772c-4162-bb9b-e969c7dd207c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7402e9c1-772c-4162-bb9b-e969c7dd207c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_7af660ae-3b93-40fa-9550-58b5910635b8" xlink:href="allo-20210331.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_7af660ae-3b93-40fa-9550-58b5910635b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_786cbf34-f071-47d3-9ffc-f7cc521cd324" xlink:href="allo-20210331.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_786cbf34-f071-47d3-9ffc-f7cc521cd324" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_82eb7901-9a8a-4784-b9ff-2d96fe8762fb" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_8e6f48e0-dba1-4ffd-a741-21ddf367795f" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_8e6f48e0-dba1-4ffd-a741-21ddf367795f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc93d439-b7a5-4ec8-936d-029f4ee38d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc93d439-b7a5-4ec8-936d-029f4ee38d47" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_68438af7-a627-436e-9669-7d040d10dd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_DueFromRelatedParties_68438af7-a627-436e-9669-7d040d10dd93" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_d8f4dd3c-bd1a-446f-adc7-60822cbdcb32" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_d8f4dd3c-bd1a-446f-adc7-60822cbdcb32" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_cd2b9db6-4352-43ba-9338-fcc93f9c6b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_cd2b9db6-4352-43ba-9338-fcc93f9c6b90" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0b9167ae-d8ea-410f-9741-79b656de6d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0b9167ae-d8ea-410f-9741-79b656de6d90" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_776f95fd-dbed-4860-a25c-87f5a7af8e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_776f95fd-dbed-4860-a25c-87f5a7af8e61" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_330b5034-4f28-4b48-9e0e-f106bd7c6939" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialMilestonePayable_330b5034-4f28-4b48-9e0e-f106bd7c6939" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense_39b1f098-c6d9-433f-94bd-1171c2be74bd" xlink:href="allo-20210331.xsd#allo_CollaborationArrangementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationArrangementExpense_39b1f098-c6d9-433f-94bd-1171c2be74bd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementTerm_7aa1f508-8b2c-4aaf-9239-85a08ae591ed" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationAgreementTerm_7aa1f508-8b2c-4aaf-9239-85a08ae591ed" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementCommittedFunding_8a09d8d1-b318-4a4e-b4b5-6f4415d21670" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementCommittedFunding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationAgreementCommittedFunding_8a09d8d1-b318-4a4e-b4b5-6f4415d21670" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UpfrontAndQuarterlyCashPayments_351a1d2a-774d-41fd-a32a-0cc94b80e18d" xlink:href="allo-20210331.xsd#allo_UpfrontAndQuarterlyCashPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_UpfrontAndQuarterlyCashPayments_351a1d2a-774d-41fd-a32a-0cc94b80e18d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_JointVentureCapitalSupportPayments_3e0ff9fe-744c-4a55-8c89-b539940417a3" xlink:href="allo-20210331.xsd#allo_JointVentureCapitalSupportPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_JointVentureCapitalSupportPayments_3e0ff9fe-744c-4a55-8c89-b539940417a3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f43d4a0-2de1-4f9c-913d-31f43e5d5100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f43d4a0-2de1-4f9c-913d-31f43e5d5100" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6af6bd3-9975-4932-ba63-1493b6791093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6af6bd3-9975-4932-ba63-1493b6791093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d6af6bd3-9975-4932-ba63-1493b6791093_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6af6bd3-9975-4932-ba63-1493b6791093" xlink:to="loc_us-gaap_RelatedPartyDomain_d6af6bd3-9975-4932-ba63-1493b6791093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6af6bd3-9975-4932-ba63-1493b6791093" xlink:to="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_5aa099c2-de1e-4e5f-bb8e-422bcecf2c25" xlink:href="allo-20210331.xsd#allo_PfizerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_PfizerIncMember_5aa099c2-de1e-4e5f-bb8e-422bcecf2c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_c590e001-cf4e-46e1-84a4-c266d2a48a24" xlink:href="allo-20210331.xsd#allo_CellectisSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_CellectisSAMember_c590e001-cf4e-46e1-84a4-c266d2a48a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_1ad4c86c-9254-4417-8701-2336e5f12df9" xlink:href="allo-20210331.xsd#allo_ServierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_ServierMember_1ad4c86c-9254-4417-8701-2336e5f12df9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_b99f45bc-0dba-40c0-87fe-75b363b787d9" xlink:href="allo-20210331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_NotchTherapeuticsIncMember_b99f45bc-0dba-40c0-87fe-75b363b787d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis_9f2e1333-868f-44e0-b405-486b7784413c" xlink:href="allo-20210331.xsd#allo_MilestoneTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_allo_MilestoneTypeAxis_9f2e1333-868f-44e0-b405-486b7784413c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_9f2e1333-868f-44e0-b405-486b7784413c_default" xlink:href="allo-20210331.xsd#allo_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_MilestoneTypeAxis_9f2e1333-868f-44e0-b405-486b7784413c" xlink:to="loc_allo_MilestoneTypeDomain_9f2e1333-868f-44e0-b405-486b7784413c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_f91ae83d-6945-4e34-a498-666534f038eb" xlink:href="allo-20210331.xsd#allo_MilestoneTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_MilestoneTypeAxis_9f2e1333-868f-44e0-b405-486b7784413c" xlink:to="loc_allo_MilestoneTypeDomain_f91ae83d-6945-4e34-a498-666534f038eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember_41a2e0f7-da74-4655-893c-a30add606ef0" xlink:href="allo-20210331.xsd#allo_DevelopmentAndSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_MilestoneTypeDomain_f91ae83d-6945-4e34-a498-666534f038eb" xlink:to="loc_allo_DevelopmentAndSalesMember_41a2e0f7-da74-4655-893c-a30add606ef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1214c4c8-8da8-4897-b3aa-3db750ca4362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1214c4c8-8da8-4897-b3aa-3db750ca4362" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1214c4c8-8da8-4897-b3aa-3db750ca4362_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1214c4c8-8da8-4897-b3aa-3db750ca4362" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1214c4c8-8da8-4897-b3aa-3db750ca4362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1214c4c8-8da8-4897-b3aa-3db750ca4362" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_8b51aa12-3d2f-4450-8632-4f2312955c1c" xlink:href="allo-20210331.xsd#allo_AssetContributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_AssetContributionAgreementMember_8b51aa12-3d2f-4450-8632-4f2312955c1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_50763141-3169-4d77-8db8-ec2d7c064478" xlink:href="allo-20210331.xsd#allo_RegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_RegulatoryMilestoneMember_50763141-3169-4d77-8db8-ec2d7c064478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_79ed0a2f-8ea1-4b88-a384-343c75a41c1b" xlink:href="allo-20210331.xsd#allo_SalesMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_SalesMilestoneMember_79ed0a2f-8ea1-4b88-a384-343c75a41c1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_368b000e-f9b6-4cc8-9681-b8b65c4649a5" xlink:href="allo-20210331.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_368b000e-f9b6-4cc8-9681-b8b65c4649a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_e1f4f0e0-5e79-4bde-b3da-cd5490edee10" xlink:href="allo-20210331.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_e1f4f0e0-5e79-4bde-b3da-cd5490edee10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0ec1d97-a1bc-44d8-a697-1b5535ff7053" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_srt_RangeAxis_a0ec1d97-a1bc-44d8-a697-1b5535ff7053" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0ec1d97-a1bc-44d8-a697-1b5535ff7053_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a0ec1d97-a1bc-44d8-a697-1b5535ff7053" xlink:to="loc_srt_RangeMember_a0ec1d97-a1bc-44d8-a697-1b5535ff7053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a0ec1d97-a1bc-44d8-a697-1b5535ff7053" xlink:to="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df994e21-ccef-4de3-b8dc-f4092d43230e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:to="loc_srt_MinimumMember_df994e21-ccef-4de3-b8dc-f4092d43230e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_264d1999-bb07-482e-8797-c1242b04bbb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:to="loc_srt_MaximumMember_264d1999-bb07-482e-8797-c1242b04bbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7fc3f1c-af86-40f2-bedd-17e3211aac42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7fc3f1c-af86-40f2-bedd-17e3211aac42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7fc3f1c-af86-40f2-bedd-17e3211aac42_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7fc3f1c-af86-40f2-bedd-17e3211aac42" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7fc3f1c-af86-40f2-bedd-17e3211aac42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7fc3f1c-af86-40f2-bedd-17e3211aac42" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_48dba038-8304-497f-bb69-0f84fa66667f" xlink:href="allo-20210331.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_48dba038-8304-497f-bb69-0f84fa66667f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_d8fa55f9-f998-4e75-9514-8227ccc3fe3f" xlink:href="allo-20210331.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_d8fa55f9-f998-4e75-9514-8227ccc3fe3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_a193943e-57c4-4c45-9c78-6eaf9a21f4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:to="loc_us-gaap_CorporateJointVentureMember_a193943e-57c4-4c45-9c78-6eaf9a21f4dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_57d946b9-77fb-4251-b2c4-99e9e2827ef3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_57d946b9-77fb-4251-b2c4-99e9e2827ef3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_57d946b9-77fb-4251-b2c4-99e9e2827ef3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_57d946b9-77fb-4251-b2c4-99e9e2827ef3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_57d946b9-77fb-4251-b2c4-99e9e2827ef3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_57d946b9-77fb-4251-b2c4-99e9e2827ef3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_7434236f-428a-48f4-9caa-af3d8045ed97" xlink:href="allo-20210331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:to="loc_allo_NotchTherapeuticsIncMember_7434236f-428a-48f4-9caa-af3d8045ed97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_00cb4181-ae0e-4158-af5a-f7cc90b6a110" xlink:href="allo-20210331.xsd#allo_AllogeneOverlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:to="loc_allo_AllogeneOverlandMember_00cb4181-ae0e-4158-af5a-f7cc90b6a110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_018c70f3-9074-488d-a3f1-de95b21d6abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_018c70f3-9074-488d-a3f1-de95b21d6abb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_018c70f3-9074-488d-a3f1-de95b21d6abb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_018c70f3-9074-488d-a3f1-de95b21d6abb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_018c70f3-9074-488d-a3f1-de95b21d6abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b3cb9d07-81d3-45bf-a3d6-d93c17dfdfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_018c70f3-9074-488d-a3f1-de95b21d6abb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b3cb9d07-81d3-45bf-a3d6-d93c17dfdfc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea2c606e-689f-4f48-bc71-3ceef71a8c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3cb9d07-81d3-45bf-a3d6-d93c17dfdfc9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea2c606e-689f-4f48-bc71-3ceef71a8c5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_srt_CounterpartyNameAxis_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5dd11f58-4a22-47c2-8691-316205ee65ba" xlink:href="allo-20210331.xsd#allo_UniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:to="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5dd11f58-4a22-47c2-8691-316205ee65ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_db34fc03-90c5-44c2-9608-232bb8e50da8" xlink:href="allo-20210331.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_db34fc03-90c5-44c2-9608-232bb8e50da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_014623fa-c687-4813-b902-0f6ba5b94690" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_dei_LegalEntityAxis_014623fa-c687-4813-b902-0f6ba5b94690" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_014623fa-c687-4813-b902-0f6ba5b94690_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_014623fa-c687-4813-b902-0f6ba5b94690" xlink:to="loc_dei_EntityDomain_014623fa-c687-4813-b902-0f6ba5b94690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_83a93301-9a83-47d6-9340-1de6b59bc19e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_014623fa-c687-4813-b902-0f6ba5b94690" xlink:to="loc_dei_EntityDomain_83a93301-9a83-47d6-9340-1de6b59bc19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_cb624de9-a7d3-4c3e-84ed-833fb3c05ad8" xlink:href="allo-20210331.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_83a93301-9a83-47d6-9340-1de6b59bc19e" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_cb624de9-a7d3-4c3e-84ed-833fb3c05ad8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_ec618e43-6eaa-4a62-86b7-75e5a793421f" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_allo_EquityInvestmentBasisAxis_ec618e43-6eaa-4a62-86b7-75e5a793421f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_ec618e43-6eaa-4a62-86b7-75e5a793421f_default" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_EquityInvestmentBasisAxis_ec618e43-6eaa-4a62-86b7-75e5a793421f" xlink:to="loc_allo_EquityInvestmentBasisDomain_ec618e43-6eaa-4a62-86b7-75e5a793421f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_9dfcd326-32da-4143-8a05-90f01d327838" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_EquityInvestmentBasisAxis_ec618e43-6eaa-4a62-86b7-75e5a793421f" xlink:to="loc_allo_EquityInvestmentBasisDomain_9dfcd326-32da-4143-8a05-90f01d327838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_00299f67-691b-4b5c-b374-51c5bc3943d3" xlink:href="allo-20210331.xsd#allo_VotingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_EquityInvestmentBasisDomain_9dfcd326-32da-4143-8a05-90f01d327838" xlink:to="loc_allo_VotingInterestMember_00299f67-691b-4b5c-b374-51c5bc3943d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended" id="i0484786c51c84560ad7e71051b976363_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="ib395333c784a4e3d9b2ffbe295d6f724_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="id53fbbc710f247f0a6ed0e4129b9baef_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_74a07988-c9a4-4e0b-b8e4-ad5b34868bbc" xlink:href="allo-20210331.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_AreaOfNewOfficeBuilding_74a07988-c9a4-4e0b-b8e4-ad5b34868bbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_cec7efc8-5e79-4b08-8ccf-d3bcf6d3feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_cec7efc8-5e79-4b08-8ccf-d3bcf6d3feb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c2d399c5-bde9-4237-ad3a-5b7e3eb2b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c2d399c5-bde9-4237-ad3a-5b7e3eb2b26f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_4498f032-2204-45bd-b94a-3a281102d0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_TenantImprovements_4498f032-2204-45bd-b94a-3a281102d0ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowance_fdaede7e-f9ca-43b1-83d4-2931842a96eb" xlink:href="allo-20210331.xsd#allo_TenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_TenantImprovementAllowance_fdaede7e-f9ca-43b1-83d4-2931842a96eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease_9ca3785f-1a79-4e0d-b089-2c06313fb6fe" xlink:href="allo-20210331.xsd#allo_AreaOfOperatingLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_AreaOfOperatingLease_9ca3785f-1a79-4e0d-b089-2c06313fb6fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease_7934fdca-bb16-46cc-8ab5-5fc6fbb948b2" xlink:href="allo-20210331.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_NumberOfOptionsToExtendLease_7934fdca-bb16-46cc-8ab5-5fc6fbb948b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowanceUtilizedToDate_3c11e541-9f60-4b75-99fe-0aca842fc406" xlink:href="allo-20210331.xsd#allo_TenantImprovementAllowanceUtilizedToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_TenantImprovementAllowanceUtilizedToDate_3c11e541-9f60-4b75-99fe-0aca842fc406" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_34d272dc-ad55-4bf0-80da-af0e10fa7555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_34d272dc-ad55-4bf0-80da-af0e10fa7555" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_49f7cbd2-eddb-4f4f-89b5-cb51ae9df87d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_OperatingLeasePayments_49f7cbd2-eddb-4f4f-89b5-cb51ae9df87d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e035da91-b38b-4765-ae4e-fd5e91eb4692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e035da91-b38b-4765-ae4e-fd5e91eb4692" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80598219-d517-4669-93c3-8b7bde20453d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80598219-d517-4669-93c3-8b7bde20453d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_928c0d96-7b8e-4f9c-abea-6b0f475fe629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_928c0d96-7b8e-4f9c-abea-6b0f475fe629" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_ddac809c-48fd-497b-9388-98f6a1c4ff38" xlink:href="allo-20210331.xsd#allo_LesseeFinanceLeasePaymentUponContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_ddac809c-48fd-497b-9388-98f6a1c4ff38" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_004d51b0-46a2-40ea-b51d-a4de8d9e8fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_004d51b0-46a2-40ea-b51d-a4de8d9e8fa4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_17085a3f-c3b5-421f-9bc3-56513cfeb620" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:to="loc_srt_StatementGeographicalAxis_17085a3f-c3b5-421f-9bc3-56513cfeb620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_17085a3f-c3b5-421f-9bc3-56513cfeb620_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_17085a3f-c3b5-421f-9bc3-56513cfeb620" xlink:to="loc_srt_SegmentGeographicalDomain_17085a3f-c3b5-421f-9bc3-56513cfeb620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eb2312b1-e1b7-4d60-abd4-98dfa1ffbaed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_17085a3f-c3b5-421f-9bc3-56513cfeb620" xlink:to="loc_srt_SegmentGeographicalDomain_eb2312b1-e1b7-4d60-abd4-98dfa1ffbaed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_5474e327-49bb-4bc2-9d14-0da4fc9dd483" xlink:href="allo-20210331.xsd#allo_NewarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_eb2312b1-e1b7-4d60-abd4-98dfa1ffbaed" xlink:to="loc_allo_NewarkMember_5474e327-49bb-4bc2-9d14-0da4fc9dd483" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c908c58e-1807-46d8-8fed-85f5500447bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:to="loc_us-gaap_CreditFacilityAxis_c908c58e-1807-46d8-8fed-85f5500447bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c908c58e-1807-46d8-8fed-85f5500447bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c908c58e-1807-46d8-8fed-85f5500447bb" xlink:to="loc_us-gaap_CreditFacilityDomain_c908c58e-1807-46d8-8fed-85f5500447bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_624eb3bd-2d8e-474b-96a7-dc0c11115e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c908c58e-1807-46d8-8fed-85f5500447bb" xlink:to="loc_us-gaap_CreditFacilityDomain_624eb3bd-2d8e-474b-96a7-dc0c11115e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_258e74c0-6016-4bf0-9987-830baf558966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_624eb3bd-2d8e-474b-96a7-dc0c11115e54" xlink:to="loc_us-gaap_LetterOfCreditMember_258e74c0-6016-4bf0-9987-830baf558966" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended" id="ie08cd788a47c449b9fb7b76c499ec262_CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended" id="i76ef1ec850b145b7999fdfc2cedbec4f_CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended" id="ic7bf8f8dd570471a953f0a63d9265fff_CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20210331.xsd#EquityMethodInvestment"/>
  <link:definitionLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended" id="ib01ed7e6f7374cf28b4d08e859497721_EquityMethodInvestment"/>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#EquityMethodInvestmentDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended" id="icfda65b1796848efa91ad36e5d6bcd94_EquityMethodInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_d9d85536-ef2c-4ef6-808a-a3beeb4b8f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_d9d85536-ef2c-4ef6-808a-a3beeb4b8f3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_66306d6e-bbb8-48db-ba5a-25674e0d3b8e" xlink:href="allo-20210331.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_66306d6e-bbb8-48db-ba5a-25674e0d3b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90e2cd9e-8019-4a96-8d8f-eb10a75c55a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90e2cd9e-8019-4a96-8d8f-eb10a75c55a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f06457c1-1d0c-4c7e-850a-d8b946be77b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f06457c1-1d0c-4c7e-850a-d8b946be77b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491ceff7-ec05-4dce-a1e4-82b9a8fcaa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491ceff7-ec05-4dce-a1e4-82b9a8fcaa95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bdbdaf16-04ae-4808-991c-2b87af85c574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bdbdaf16-04ae-4808-991c-2b87af85c574" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7115884-6b98-4b19-b350-9e8a59800e56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7115884-6b98-4b19-b350-9e8a59800e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a7115884-6b98-4b19-b350-9e8a59800e56_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7115884-6b98-4b19-b350-9e8a59800e56" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a7115884-6b98-4b19-b350-9e8a59800e56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7115884-6b98-4b19-b350-9e8a59800e56" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_fd5a1c29-9ca7-41b0-ae6d-0b229892fd64" xlink:href="allo-20210331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:to="loc_allo_NotchTherapeuticsIncMember_fd5a1c29-9ca7-41b0-ae6d-0b229892fd64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_5f24b940-d09e-4af0-9b82-7ceee382f134" xlink:href="allo-20210331.xsd#allo_AllogeneOverlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:to="loc_allo_AllogeneOverlandMember_5f24b940-d09e-4af0-9b82-7ceee382f134" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:to="loc_allo_EquityInvestmentBasisAxis_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f_default" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_EquityInvestmentBasisAxis_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f" xlink:to="loc_allo_EquityInvestmentBasisDomain_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_b1ba84fb-1884-49f8-ad14-3c5929a059d2" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_EquityInvestmentBasisAxis_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f" xlink:to="loc_allo_EquityInvestmentBasisDomain_b1ba84fb-1884-49f8-ad14-3c5929a059d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_b1ac76d6-aa65-487d-a349-2f1e015520dc" xlink:href="allo-20210331.xsd#allo_VotingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_EquityInvestmentBasisDomain_b1ba84fb-1884-49f8-ad14-3c5929a059d2" xlink:to="loc_allo_VotingInterestMember_b1ac76d6-aa65-487d-a349-2f1e015520dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended" id="id0535fb845494a1d9a450df59d48a439_StockBasedCompensation"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended" id="ic8344c441f694eb690ae0c25f6b922f6_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="i9d8eafaeda8b41d3a97ac66a4de23607_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_5c5b8c46-95f0-4aeb-9ecd-236d189986fe" xlink:href="allo-20210331.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_5c5b8c46-95f0-4aeb-9ecd-236d189986fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_80f73494-5212-45c3-93fe-571e70af7603" xlink:href="allo-20210331.xsd#allo_StockOptionGrantedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_allo_StockOptionGrantedPeriod_80f73494-5212-45c3-93fe-571e70af7603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_2a8606b2-6143-460e-addb-15d22b659469" xlink:href="allo-20210331.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_2a8606b2-6143-460e-addb-15d22b659469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c508fe06-7dfa-4a32-b900-2e7cabc1990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c508fe06-7dfa-4a32-b900-2e7cabc1990b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_49477be7-32e3-46b9-b727-807a2bec4a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_49477be7-32e3-46b9-b727-807a2bec4a34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3b4d85c-f10f-412c-967b-0be4b7f71e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3b4d85c-f10f-412c-967b-0be4b7f71e05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3a79c9ad-fb18-4ddb-8c1c-9921e6a2924b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3a79c9ad-fb18-4ddb-8c1c-9921e6a2924b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1a373fcb-2160-4930-b2b5-d47a21ef91cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1a373fcb-2160-4930-b2b5-d47a21ef91cf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_4a22bc51-9b13-4477-a6df-54abadf86d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_4a22bc51-9b13-4477-a6df-54abadf86d74" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_72d3863b-bc42-4c05-a5b6-f5e7fd0b7223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_72d3863b-bc42-4c05-a5b6-f5e7fd0b7223" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f160f767-690c-49c2-8aa0-a8eb9a04815f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:to="loc_srt_RangeAxis_f160f767-690c-49c2-8aa0-a8eb9a04815f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f160f767-690c-49c2-8aa0-a8eb9a04815f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f160f767-690c-49c2-8aa0-a8eb9a04815f" xlink:to="loc_srt_RangeMember_f160f767-690c-49c2-8aa0-a8eb9a04815f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ff3ca20-da10-4319-b27e-1e4d1cc6e4fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f160f767-690c-49c2-8aa0-a8eb9a04815f" xlink:to="loc_srt_RangeMember_8ff3ca20-da10-4319-b27e-1e4d1cc6e4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40b78914-1ab4-4911-b11b-132b53cbecd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8ff3ca20-da10-4319-b27e-1e4d1cc6e4fc" xlink:to="loc_srt_MaximumMember_40b78914-1ab4-4911-b11b-132b53cbecd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_504def74-190c-467d-98b0-bd7aaa5128bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:to="loc_us-gaap_AwardTypeAxis_504def74-190c-467d-98b0-bd7aaa5128bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_504def74-190c-467d-98b0-bd7aaa5128bc_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_504def74-190c-467d-98b0-bd7aaa5128bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_504def74-190c-467d-98b0-bd7aaa5128bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_504def74-190c-467d-98b0-bd7aaa5128bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b2cf2b5e-12ef-4c23-948f-16db90447507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:to="loc_us-gaap_StockOptionMember_b2cf2b5e-12ef-4c23-948f-16db90447507" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_31867914-06b5-4443-be35-d79c502d724b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_31867914-06b5-4443-be35-d79c502d724b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2cf43dc9-1354-4740-bf8e-ffdaa4b6ec28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2cf43dc9-1354-4740-bf8e-ffdaa4b6ec28" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i6b7d96793df14fc8b7356bbff5305b69_StockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_001805f0-989d-4a9b-9f58-382bcf123999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_001805f0-989d-4a9b-9f58-382bcf123999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac86c3bc-d653-42f6-91c5-15c50e1a9b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac86c3bc-d653-42f6-91c5-15c50e1a9b9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3caf71bb-7411-4fba-94fb-2a9f2d5435b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3caf71bb-7411-4fba-94fb-2a9f2d5435b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c50c4663-bc04-4670-8250-b053010ca751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c50c4663-bc04-4670-8250-b053010ca751" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cf3ae28b-c9b5-4c55-8af9-fb1c366348f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7326b133-42fb-4b90-aaec-6f107219f69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7326b133-42fb-4b90-aaec-6f107219f69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9bab7fbc-67e3-4ae2-9efa-95f2c0ce1856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9bab7fbc-67e3-4ae2-9efa-95f2c0ce1856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d165d68-b1b6-422b-8a4a-e86ac1736155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d165d68-b1b6-422b-8a4a-e86ac1736155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eca74c80-d751-414a-9472-97209bafdf4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eca74c80-d751-414a-9472-97209bafdf4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40117a56-c760-4001-b11b-4b53a9815dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40117a56-c760-4001-b11b-4b53a9815dbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20ad7ce8-51e8-42a3-b7a0-65d13613ff9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20ad7ce8-51e8-42a3-b7a0-65d13613ff9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9cabc6b-2a9f-437c-8606-b7c1bcdec593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_be1a245a-b3a9-4dc4-b910-0831567967cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_be1a245a-b3a9-4dc4-b910-0831567967cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_667e0644-8a02-4e47-8113-eb1eeee35dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_667e0644-8a02-4e47-8113-eb1eeee35dcd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f8acf051-c27b-4de1-80f7-ca5671cc8cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f8acf051-c27b-4de1-80f7-ca5671cc8cf8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8a66d25f-627a-4cba-967a-5b04ec4eef4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8a66d25f-627a-4cba-967a-5b04ec4eef4e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_552d5929-2b5c-4329-ba8d-b3d8ec8d5993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_552d5929-2b5c-4329-ba8d-b3d8ec8d5993" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ab1d5f39-4c11-4f88-a0d2-699c8474b37e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ab1d5f39-4c11-4f88-a0d2-699c8474b37e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1195acb-98d9-4389-806c-dc6624bfad7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1195acb-98d9-4389-806c-dc6624bfad7f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_247c2e73-5c36-4f87-b1b4-4662bbe3de0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_247c2e73-5c36-4f87-b1b4-4662bbe3de0b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740ddeb0-b6de-49e9-ab20-4580ece16377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740ddeb0-b6de-49e9-ab20-4580ece16377" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_55d1186c-7bc9-48d9-a006-e5a928360c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740ddeb0-b6de-49e9-ab20-4580ece16377" xlink:to="loc_us-gaap_AwardTypeAxis_55d1186c-7bc9-48d9-a006-e5a928360c7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55d1186c-7bc9-48d9-a006-e5a928360c7f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_55d1186c-7bc9-48d9-a006-e5a928360c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55d1186c-7bc9-48d9-a006-e5a928360c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480107c7-e6ea-434c-828c-ecde1297b2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_55d1186c-7bc9-48d9-a006-e5a928360c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480107c7-e6ea-434c-828c-ecde1297b2a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_cd640efe-9407-422d-9902-5f1975c63e3c" xlink:href="allo-20210331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480107c7-e6ea-434c-828c-ecde1297b2a1" xlink:to="loc_allo_TwoThousandEighteenPlanMember_cd640efe-9407-422d-9902-5f1975c63e3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended" id="iaf25e508dc13459fbf3fa7ca2fff6df8_StockBasedCompensationValuationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aec67154-f6e2-4e8e-9d7a-83f3f402a61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aec67154-f6e2-4e8e-9d7a-83f3f402a61c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1cf903d1-023e-4b6e-9604-c5496a7a9cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1cf903d1-023e-4b6e-9604-c5496a7a9cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_148e4949-f543-49ae-a157-7fb973d38b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_148e4949-f543-49ae-a157-7fb973d38b80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8eefa227-0672-4b1d-a4a7-935842c17b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8eefa227-0672-4b1d-a4a7-935842c17b0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd1ab919-b502-4daf-b97e-0981e8e24254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd1ab919-b502-4daf-b97e-0981e8e24254" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5484f68b-e756-4c46-8a65-f682b72f19c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:to="loc_us-gaap_AwardTypeAxis_5484f68b-e756-4c46-8a65-f682b72f19c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5484f68b-e756-4c46-8a65-f682b72f19c9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5484f68b-e756-4c46-8a65-f682b72f19c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5484f68b-e756-4c46-8a65-f682b72f19c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb05bc6-3915-4ee6-b83b-3e855b5a263c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5484f68b-e756-4c46-8a65-f682b72f19c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb05bc6-3915-4ee6-b83b-3e855b5a263c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_564034e7-7034-4060-984c-7e2f6b35ef2c" xlink:href="allo-20210331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb05bc6-3915-4ee6-b83b-3e855b5a263c" xlink:to="loc_allo_TwoThousandEighteenPlanMember_564034e7-7034-4060-984c-7e2f6b35ef2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b3819a09-fc8c-4026-bf65-ccc0c5e112eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:to="loc_srt_RangeAxis_b3819a09-fc8c-4026-bf65-ccc0c5e112eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b3819a09-fc8c-4026-bf65-ccc0c5e112eb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b3819a09-fc8c-4026-bf65-ccc0c5e112eb" xlink:to="loc_srt_RangeMember_b3819a09-fc8c-4026-bf65-ccc0c5e112eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b3819a09-fc8c-4026-bf65-ccc0c5e112eb" xlink:to="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_076f5a65-ae7d-4a4a-9d5d-08518a49f140" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:to="loc_srt_MinimumMember_076f5a65-ae7d-4a4a-9d5d-08518a49f140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dbb84b63-5fbc-49fb-a846-ba3a615b02ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:to="loc_srt_MaximumMember_dbb84b63-5fbc-49fb-a846-ba3a615b02ad" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i429cbb6c0eb040e9944e3e8eb22abdf4_StockBasedCompensationRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9a36b6-a3e6-4805-8271-70457ed0e165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9a36b6-a3e6-4805-8271-70457ed0e165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6aa2247-2d58-49f4-9905-25c57e0ff928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6aa2247-2d58-49f4-9905-25c57e0ff928" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f67e2d5-f183-4f6d-a1d9-4ea016c94466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f67e2d5-f183-4f6d-a1d9-4ea016c94466" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_70104504-8060-43c6-a452-cc1c4fa89b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_70104504-8060-43c6-a452-cc1c4fa89b42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_726d9923-645d-4274-86d3-9af639e73775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_3bb5afc0-178e-4fd6-9b90-fba0ff69035f" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_3bb5afc0-178e-4fd6-9b90-fba0ff69035f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1c06445-c4b2-4db0-b2df-00d4b1bd2500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1c06445-c4b2-4db0-b2df-00d4b1bd2500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2090d660-b747-4fb2-b2e0-889d201c48a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2090d660-b747-4fb2-b2e0-889d201c48a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd3c1bbb-da3d-4d4a-8255-be5f65299f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd3c1bbb-da3d-4d4a-8255-be5f65299f2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_f23272b0-96eb-43af-974e-245ad373bd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_f23272b0-96eb-43af-974e-245ad373bd62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74fb4e1d-3e3b-48d5-a17b-be393d0738e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_fa84bc9a-9639-40a8-a328-8dbf256ebd0f" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_fa84bc9a-9639-40a8-a328-8dbf256ebd0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7e90d727-3606-4a00-9378-2958aba7837b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7e90d727-3606-4a00-9378-2958aba7837b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_556818a7-a255-4c31-a0c2-527d96fc247b" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_556818a7-a255-4c31-a0c2-527d96fc247b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_82c5f315-1b26-472d-ba26-4f345108f077" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_82c5f315-1b26-472d-ba26-4f345108f077" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_edbfdb2c-6136-4606-9072-ecd16f9678cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_edbfdb2c-6136-4606-9072-ecd16f9678cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_1daea7b5-b210-45d0-a14b-fa3b2dc8ce03" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_1daea7b5-b210-45d0-a14b-fa3b2dc8ce03" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9eb5e7d9-e487-40fb-9a16-7d9fee7b3844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9eb5e7d9-e487-40fb-9a16-7d9fee7b3844" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c35dbab-3428-4cb2-b0a6-1b196e0d132f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9eb5e7d9-e487-40fb-9a16-7d9fee7b3844" xlink:to="loc_us-gaap_AwardTypeAxis_0c35dbab-3428-4cb2-b0a6-1b196e0d132f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c35dbab-3428-4cb2-b0a6-1b196e0d132f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0c35dbab-3428-4cb2-b0a6-1b196e0d132f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0c35dbab-3428-4cb2-b0a6-1b196e0d132f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f11bb02-4f63-4dbb-9576-bd5e39a0869f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0c35dbab-3428-4cb2-b0a6-1b196e0d132f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f11bb02-4f63-4dbb-9576-bd5e39a0869f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9da87836-9ba5-4187-b9e8-c9a0f18ed1ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f11bb02-4f63-4dbb-9576-bd5e39a0869f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9da87836-9ba5-4187-b9e8-c9a0f18ed1ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended" id="ie0249b17710c453e9be2872d24a2ff24_StockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bceab623-4377-4ad9-aff1-e4a506521c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e44c6a-0df6-4fe1-861d-4a898b3a3e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bceab623-4377-4ad9-aff1-e4a506521c7d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e44c6a-0df6-4fe1-861d-4a898b3a3e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92974cc2-2267-4c7b-96ec-293fe3e7ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bceab623-4377-4ad9-aff1-e4a506521c7d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92974cc2-2267-4c7b-96ec-293fe3e7ebb7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc5485fe-08bb-4141-a1fd-552c07e3c64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92974cc2-2267-4c7b-96ec-293fe3e7ebb7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc5485fe-08bb-4141-a1fd-552c07e3c64c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fc5485fe-08bb-4141-a1fd-552c07e3c64c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc5485fe-08bb-4141-a1fd-552c07e3c64c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fc5485fe-08bb-4141-a1fd-552c07e3c64c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc5485fe-08bb-4141-a1fd-552c07e3c64c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b63e2b57-5d23-41bf-9a30-701c59a049b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b63e2b57-5d23-41bf-9a30-701c59a049b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43e48def-2ea4-4210-9fb6-cd5004c61757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43e48def-2ea4-4210-9fb6-cd5004c61757" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20210331.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended" id="i2057070b419e49c7a1b865719e6e9722_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i8020bd2fd93e4084aee3b3bac84e8d9d_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_122ecd63-bd1e-406c-85d3-f8a549d0442c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_122ecd63-bd1e-406c-85d3-f8a549d0442c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice_4d5ba355-3958-4fdd-ad59-9c534f2a3050" xlink:href="allo-20210331.xsd#allo_AreaOfOffice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_allo_AreaOfOffice_4d5ba355-3958-4fdd-ad59-9c534f2a3050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_ee6635dc-b7cd-4507-8dd3-03ba9d9048ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_ee6635dc-b7cd-4507-8dd3-03ba9d9048ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_55169c6a-5c63-4189-aad7-fdc8b2e961d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_55169c6a-5c63-4189-aad7-fdc8b2e961d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2510605e-712e-4f43-a87a-90f198222ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_OperatingLeaseLiability_2510605e-712e-4f43-a87a-90f198222ce3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_59d2e4e7-7b6e-4616-918a-86c9590820ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_RelatedPartyCosts_59d2e4e7-7b6e-4616-918a-86c9590820ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_205ea644-a1ac-43e1-aeca-5cb085b91de2" xlink:href="allo-20210331.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_205ea644-a1ac-43e1-aeca-5cb085b91de2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_95c26a13-ebd8-4012-8134-34224d3f0d0d" xlink:href="allo-20210331.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_95c26a13-ebd8-4012-8134-34224d3f0d0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e51928a6-4678-4e8d-b9ba-c13b9b0189c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e51928a6-4678-4e8d-b9ba-c13b9b0189c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e51928a6-4678-4e8d-b9ba-c13b9b0189c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e51928a6-4678-4e8d-b9ba-c13b9b0189c8" xlink:to="loc_us-gaap_RelatedPartyDomain_e51928a6-4678-4e8d-b9ba-c13b9b0189c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e51928a6-4678-4e8d-b9ba-c13b9b0189c8" xlink:to="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_17178284-6e36-4d04-8509-d827d86afd6c" xlink:href="allo-20210331.xsd#allo_BellcoCapitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:to="loc_allo_BellcoCapitalLLCMember_17178284-6e36-4d04-8509-d827d86afd6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember_62c796ca-0265-40ba-88f4-f42a13bf1d0e" xlink:href="allo-20210331.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:to="loc_allo_TwoRiverConsultingLLCMember_62c796ca-0265-40ba-88f4-f42a13bf1d0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ead0b16e-91ed-4396-89a6-1f696e54f57e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ead0b16e-91ed-4396-89a6-1f696e54f57e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ead0b16e-91ed-4396-89a6-1f696e54f57e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ead0b16e-91ed-4396-89a6-1f696e54f57e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ead0b16e-91ed-4396-89a6-1f696e54f57e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ead0b16e-91ed-4396-89a6-1f696e54f57e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember_0380d4e4-ad29-4042-aef8-8cdaabc12a1c" xlink:href="allo-20210331.xsd#allo_SubleaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:to="loc_allo_SubleaseAgreementMember_0380d4e4-ad29-4042-aef8-8cdaabc12a1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_e87409a6-f02a-4256-9dff-e0acac2d152c" xlink:href="allo-20210331.xsd#allo_ConsultingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:to="loc_allo_ConsultingAgreementsMember_e87409a6-f02a-4256-9dff-e0acac2d152c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a2156003-ee9d-4b9b-8a1e-f9128f47fccd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_srt_RangeAxis_a2156003-ee9d-4b9b-8a1e-f9128f47fccd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2156003-ee9d-4b9b-8a1e-f9128f47fccd_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a2156003-ee9d-4b9b-8a1e-f9128f47fccd" xlink:to="loc_srt_RangeMember_a2156003-ee9d-4b9b-8a1e-f9128f47fccd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca40c4b6-a91e-4c21-8615-7d4afb23b8d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a2156003-ee9d-4b9b-8a1e-f9128f47fccd" xlink:to="loc_srt_RangeMember_ca40c4b6-a91e-4c21-8615-7d4afb23b8d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c0ff3bc5-99e2-4ef1-b345-6ccef3121de4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ca40c4b6-a91e-4c21-8615-7d4afb23b8d0" xlink:to="loc_srt_MaximumMember_c0ff3bc5-99e2-4ef1-b345-6ccef3121de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis_5cd99ad5-96ec-4975-a92d-3915ab570c5d" xlink:href="allo-20210331.xsd#allo_PaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_allo_PaymentTermsAxis_5cd99ad5-96ec-4975-a92d-3915ab570c5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_5cd99ad5-96ec-4975-a92d-3915ab570c5d_default" xlink:href="allo-20210331.xsd#allo_PaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_allo_PaymentTermsAxis_5cd99ad5-96ec-4975-a92d-3915ab570c5d" xlink:to="loc_allo_PaymentTermsDomain_5cd99ad5-96ec-4975-a92d-3915ab570c5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:href="allo-20210331.xsd#allo_PaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_allo_PaymentTermsAxis_5cd99ad5-96ec-4975-a92d-3915ab570c5d" xlink:to="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2019Member_f8b6171e-2250-4b83-9d65-9a48d6a76195" xlink:href="allo-20210331.xsd#allo_PaymentsCommencingJanuary2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:to="loc_allo_PaymentsCommencingJanuary2019Member_f8b6171e-2250-4b83-9d65-9a48d6a76195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2020Member_ba646c57-9010-4e8d-b28c-dd8763506a69" xlink:href="allo-20210331.xsd#allo_PaymentsCommencingJanuary2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:to="loc_allo_PaymentsCommencingJanuary2020Member_ba646c57-9010-4e8d-b28c-dd8763506a69" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended" id="i472df57799e146788ffffa14c3a83982_IncomeTaxes"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShare"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended" id="i9d2979f88aa4410ca1fe457a58eb7791_NetLossPerShare"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShareTables"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended" id="ib9d7762a00d542519c83b1f92e3872e5_NetLossPerShareTables"/>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended" id="i7f663ff60c414a1f96e59b77bf23f6dc_NetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ed16da3f-12d4-4f2e-8404-daffce182924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d8356334-9db4-43c5-a2a0-3cdb518f4f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ed16da3f-12d4-4f2e-8404-daffce182924" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d8356334-9db4-43c5-a2a0-3cdb518f4f87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050fed6d-b76d-4002-9fa9-d707da876893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ed16da3f-12d4-4f2e-8404-daffce182924" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050fed6d-b76d-4002-9fa9-d707da876893" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1fbd3317-f47d-4375-bc5c-d2fc2023e5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050fed6d-b76d-4002-9fa9-d707da876893" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1fbd3317-f47d-4375-bc5c-d2fc2023e5be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fbd3317-f47d-4375-bc5c-d2fc2023e5be_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1fbd3317-f47d-4375-bc5c-d2fc2023e5be" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1fbd3317-f47d-4375-bc5c-d2fc2023e5be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1fbd3317-f47d-4375-bc5c-d2fc2023e5be" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20c58b4b-ed03-4ee1-965e-a931053bcc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20c58b4b-ed03-4ee1-965e-a931053bcc6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_04a99c86-5844-4adb-accb-cbaf7f6174bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_04a99c86-5844-4adb-accb-cbaf7f6174bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ed0591c1-c997-4066-9e7d-0583cfa79df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_us-gaap_EmployeeStockMember_ed0591c1-c997-4066-9e7d-0583cfa79df5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_28b6f98d-7a22-4e9a-9507-cc65aef0e36d" xlink:href="allo-20210331.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_allo_FounderSharesOfCommonStockMember_28b6f98d-7a22-4e9a-9507-cc65aef0e36d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_8d9fe52a-bef0-4200-b8dc-7166ae8f4291" xlink:href="allo-20210331.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_8d9fe52a-bef0-4200-b8dc-7166ae8f4291" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20210331.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended" id="i446bcd986cbf474cb8ed782f90712750_SubsequentEvents"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>allo-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d318bd7c-046b-4e7c-95c7-84b602262a02,g:436096e2-f446-4eef-a0b1-f01b7434d186-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fef6bc0-8a90-489a-89f6-9dabf5341532_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_c95120a5-bb61-4e2a-86ee-ec76e30ea816_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_95642edc-d452-4e68-8d21-b7ac04bd5c8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8dbf3b83-56d7-4533-bd3c-9640547688fd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b26c721a-94d2-473f-966d-9db516d78ba9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4a90400a-11d2-4620-9b9e-3c9217f85890_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_cb25b95f-8717-42a6-a8ac-505eeaf5bd79_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a05fe0a8-3deb-4fad-81bc-762e70ba4499_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3af6b196-db01-4cb2-a72d-d4ce66e3856a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestoneTypeAxis_aaa54751-e6bb-40b4-a562-a787fab7c5e6_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_label_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:label id="lab_allo_MilestoneTypeAxis_documentation_en-US" xlink:label="lab_allo_MilestoneTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis" xlink:href="allo-20210331.xsd#allo_MilestoneTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeAxis" xlink:to="lab_allo_MilestoneTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PfizerIncMember_961eca07-96e1-4c79-8acf-46d5e9cc9ff5_terseLabel_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_allo_PfizerIncMember_label_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc [Member]</link:label>
    <link:label id="lab_allo_PfizerIncMember_documentation_en-US" xlink:label="lab_allo_PfizerIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember" xlink:href="allo-20210331.xsd#allo_PfizerIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PfizerIncMember" xlink:to="lab_allo_PfizerIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_fc44459b-1740-4111-b043-82209b7dc0d9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_55ec9237-1d9f-45dc-a4e0-21895c9cb2b7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9dab69e2-67a2-410c-8d06-0fe21622cf74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_0ea28d0c-37f2-41f4-aa33-3a6d4a824710_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire interest in Notch</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_8cd3405f-c627-485f-af40-73fb1882cdd3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6f011a83-5afd-4d7d-a496-1bae490438e7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c0f77fc7-41ce-4669-83ce-2c9158844552_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_9a974b0e-912e-4302-af56-cee06b43a11d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_7e2a1bd3-7101-4d62-8444-7b8bdf27892b_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_f89ebf9e-dc5e-4932-a030-7083134c331c_terseLabel_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercised stock options subject to future vesting</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_label_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Of Stock Options [Member]</link:label>
    <link:label id="lab_allo_EarlyExerciseOfStockOptionsMember_documentation_en-US" xlink:label="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:href="allo-20210331.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EarlyExerciseOfStockOptionsMember" xlink:to="lab_allo_EarlyExerciseOfStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2c27e080-0344-4ea9-b394-e8d45789967e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_94a42106-7dff-452d-b6dd-4e99f24c4040_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6181308e-8b6f-44ce-94fe-54796aab4445_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_db448444-4f9d-4dbc-aabc-d7f8dd034996_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a1eef682-a313-450c-9ef1-e0629cf7f648_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Notes 6 and 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_3555f0b0-ba05-425d-9365-884b614d22d7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e7b8e30a-7c8b-4baa-b28b-e1cf26da0ab1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bbf062bb-8ea3-4b9d-93ba-3c53c58ae4d9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_69584183-e9b6-411d-b463-3e69fdae9f47_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_42ba6412-9863-4b68-8351-cdc7abc2af5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_be8e7c92-38ef-4857-a692-753c57be8ae8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_70a7fced-dfb0-4455-99d8-10e2cdbf5e52_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_82694082-4ea8-48e1-9420-94d9e31b370d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a90bb648-c85f-46ee-8d24-092ce48346cf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b824aff4-23af-46c8-adc0-e08d4bf01421_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_9ed2c275-377a-44a4-aa47-70a0466df08a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_98fdff25-3d66-4d78-b264-cc6f275ba709_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_77f39905-d320-4294-8bda-a5e925506c8a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d3db8aa7-7dce-486f-9c5e-210e8bf1444b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_542ba307-5888-441e-88bc-ee9832b9e4d1_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_6ad8e43b-abf2-4001-8434-5f3d7f858149_terseLabel_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_allo_ResearchCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:href="allo-20210331.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:to="lab_allo_ResearchCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_395c66ea-0fc6-4638-862b-ec30f7883bc3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_8611698e-daf2-4299-b15b-256499d65c6b_terseLabel_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers equipment and purchased software</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_label_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Purchased Software [Member]</link:label>
    <link:label id="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember_documentation_en-US" xlink:label="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and purchased software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:href="allo-20210331.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:to="lab_allo_ComputerEquipmentAndPurchasedSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_985ecac6-77d3-4aed-ae7b-3410f393a79d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_80523c2a-e257-4b5b-8379-1e03704ec0aa_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_857f1388-c855-45ba-86c2-4e55cd9983d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_1bd1d990-b810-4740-97f4-8c10a48476ee_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, upfront payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_label_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:label id="lab_allo_CollaborationAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementUpfrontPayment" xlink:to="lab_allo_CollaborationAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_acd27d04-a5cb-438e-905b-7a9c28f4101f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f5cee00e-aef9-474c-8a28-85478bbfdfaf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_StockOptionGrantedPeriod_2823205c-d54b-4c1b-a06f-1a6434f2115b_terseLabel_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option grant period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_label_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Granted Period</link:label>
    <link:label id="lab_allo_StockOptionGrantedPeriod_documentation_en-US" xlink:label="lab_allo_StockOptionGrantedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option granted period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod" xlink:href="allo-20210331.xsd#allo_StockOptionGrantedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_StockOptionGrantedPeriod" xlink:to="lab_allo_StockOptionGrantedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a666d849-ed51-49d5-b584-3aec90ecf4e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares were issued and outstanding as of March 31, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_9585045c-d41f-44e2-b748-3259d4e11837_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_70a5691f-116a-41db-94e9-0246372de09e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of stock in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_8e95d223-b95d-4ca6-b5d8-e096e997b727_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of stock in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_3f610d30-dd47-49da-8d0f-1ffb3b6e0df0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d007fe76-fc8a-4764-9377-44532033b957_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_6405c206-fa7d-41b6-8e9d-e3947aecfd43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8d9f45c4-7c12-4019-90f2-0051f01cc1c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_42ab6629-f95f-4e20-8ee5-d39619cf60c7_terseLabel_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label id="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="allo-20210331.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_95c60c6c-4736-4d8a-b8cf-22b8d30af139_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_74e90e3c-d873-4449-b4ab-f63a29ff4ef0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercised common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f24022c2-9a72-4e65-b57f-d5da6731288a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c794f995-12b2-48e5-85e7-fff37982f59e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue - related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f52b9ebe-81c8-4a22-ae9c-22fe450b055e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_BellcoCapitalLLCMember_17957fac-f689-47ac-a05e-dfba4bc3b31c_terseLabel_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_label_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital L L C [Member]</link:label>
    <link:label id="lab_allo_BellcoCapitalLLCMember_documentation_en-US" xlink:label="lab_allo_BellcoCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bellco Capital LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember" xlink:href="allo-20210331.xsd#allo_BellcoCapitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_BellcoCapitalLLCMember" xlink:to="lab_allo_BellcoCapitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentsCommencingJanuary2019Member_49f20d31-bc3f-4b8d-929e-20833731ed6a_terseLabel_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2019</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2019Member_label_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2019 [Member]</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2019Member_documentation_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2019Member" xlink:href="allo-20210331.xsd#allo_PaymentsCommencingJanuary2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentsCommencingJanuary2019Member" xlink:to="lab_allo_PaymentsCommencingJanuary2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0345e772-e855-4233-819e-9d775c52e42e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_5964ed2b-756e-4ee2-8cab-d94ac730fcc9_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, vested and expected to vest (in years)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_19bb14c3-dcff-47a7-98eb-e592eeebc0ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_1120f15a-cd47-44ef-bc85-148f9e353237_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Leasing Costs, Commissions, and Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:to="lab_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentTermsDomain_65e17f55-d186-48a6-abd2-3d4cb4ac7715_terseLabel_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Domain]</link:label>
    <link:label id="lab_allo_PaymentTermsDomain_label_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Domain]</link:label>
    <link:label id="lab_allo_PaymentTermsDomain_documentation_en-US" xlink:label="lab_allo_PaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain" xlink:href="allo-20210331.xsd#allo_PaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentTermsDomain" xlink:to="lab_allo_PaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_371fde73-2fee-4db2-a01d-551fbc2dba77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Shares</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_279d6b66-f5c1-4c3b-aac4-1c674eeede6c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_c0344474-2b99-4ab1-a27e-e7801268c196_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayable_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayable" xlink:to="lab_allo_AggregatePotentialMilestonePayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c2fe6213-4e44-4b81-a434-5fc2b4a1b8ff_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_5052d69d-a1f3-4691-a9bc-eb6a5dc547f2_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationArrangementExpense_c7baaabb-1c9d-4227-a2f4-5debc0941a4d_terseLabel_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration arrangement, expense</link:label>
    <link:label id="lab_allo_CollaborationArrangementExpense_label_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Expense</link:label>
    <link:label id="lab_allo_CollaborationArrangementExpense_documentation_en-US" xlink:label="lab_allo_CollaborationArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense" xlink:href="allo-20210331.xsd#allo_CollaborationArrangementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationArrangementExpense" xlink:to="lab_allo_CollaborationArrangementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3483d51f-66e8-400e-aaa7-fa813ccbeb12_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_7b787aa6-8950-4ced-8b32-87825f4ae017_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum remaining contractual maturities of available-for-sale securities (in years)</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_b1e98a31-3b8a-4e65-99ff-0aaee6fa81dd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_93763d6f-9390-43d0-8e02-22c65ca2c5ba_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0cae4dc7-8eb2-4630-9f53-42686c2ec13f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7acb4fa6-c60b-4ef0-b4c4-2daaadd1f12c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6f5c8d86-dafe-450d-bf04-f6e233078d33_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LesseeFinanceLeasePaymentUponContractTermination_3a84a719-a7cf-4fd4-844d-243ec8179a16_terseLabel_en-US" xlink:label="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination payment</link:label>
    <link:label id="lab_allo_LesseeFinanceLeasePaymentUponContractTermination_label_en-US" xlink:label="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Payment Upon Contract Termination</link:label>
    <link:label id="lab_allo_LesseeFinanceLeasePaymentUponContractTermination_documentation_en-US" xlink:label="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Payment Upon Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:href="allo-20210331.xsd#allo_LesseeFinanceLeasePaymentUponContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:to="lab_allo_LesseeFinanceLeasePaymentUponContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6f31b263-5bed-47f0-a9f4-1884a1a1f663_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_92536a40-6ab8-4b6e-ba9b-b866f8dda126_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Payments</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestonePayments_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestonePayments" xlink:to="lab_allo_AggregatePotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_148df8fd-2abe-44c7-b669-66d499c7e512_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ce2fb1f9-24b8-42de-95db-d41f7c528726_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_762808ac-97cc-4f58-8f5e-f2ec8d91c546_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancellable purchase commitments</link:label>
    <link:label id="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_label_en-US" xlink:label="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Commitment, Remaining Minimum Amount Committed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="lab_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestoneTypeDomain_8ca73354-74b4-4a17-ab54-c3b50510c70a_terseLabel_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_label_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Type [Domain]</link:label>
    <link:label id="lab_allo_MilestoneTypeDomain_documentation_en-US" xlink:label="lab_allo_MilestoneTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Milestone Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain" xlink:href="allo-20210331.xsd#allo_MilestoneTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestoneTypeDomain" xlink:to="lab_allo_MilestoneTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_324035d7-dcf6-4101-8f87-29f49670355d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_934cb262-b18a-4246-b49f-2a5653a92842_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9260de3b-be69-4c25-a006-ef9eaa10e86b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_304fa108-a4c3-48ed-bb71-c31f2fa12148_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0bedc6ce-40ac-4417-b5be-ac5aec0ce2e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_142d890b-99ef-4efd-91a4-526c5233ea24_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dd71d818-7253-46ef-aabc-33bafa228086_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b23c2c4a-8095-499d-a131-28be569c16e1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_ae701109-b299-4988-b1a2-824659e1ad00_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_e95532bc-c09d-4aca-beae-5ef4aac19c2c_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_3f99d4e2-93c2-431b-a4f8-85c71929d85d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a97e1ae9-863b-479b-a2e4-a6bcf821921c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchases in accounts payable and accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_1b8ffae9-6cf4-4cf7-8f1e-4787903fb2dc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_d83371c8-1f77-4ca6-af59-3bcbdda5b9a9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_f37ae35e-7b2f-4040-a5ef-8d297340bc03_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Compensation Percentage</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionCompensationPercentage_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction compensation percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:href="allo-20210331.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionCompensationPercentage" xlink:to="lab_allo_RelatedPartyTransactionCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_32cf1375-8d54-4bc8-9543-85075654208e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_01009032-2787-4658-aef2-6f45dc259413_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, option to extend term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab8101c6-9504-47db-9611-0e852cf1615a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160;Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_19881069-ea4f-401b-aaf1-83eea41b1c52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ec2402fa-a526-4cc8-8262-eebb0af4da12_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_7f2f030c-cc48-4901-8720-c32c8056ad7c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected shares to be purchased under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_783788b2-21a5-4c2c-9e45-37b1705fa1c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_f1318a70-8e70-4ab5-b0d9-5441eed2891d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts related to tenant improvement allowances</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_b0f01bbf-b52d-44c9-bb13-5e33dd817c07_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5521a275-2c2e-41ad-9149-1db941b623f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_82ecdccf-508b-4ce0-9bd3-d2fa16e5da2e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dd3bb0aa-0af8-4663-8f9d-f7b2b4ec3e44_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_2bf0bfa1-c1e9-4aef-b8dc-4727fa95edfa_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of other intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_4ddbecca-91c4-4f80-9985-fc7cd21ef032_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f2377cdb-23d0-4ed6-aa94-0ed9b6366134_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a8545090-9491-46db-9557-8d5441281ccb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_073f45d2-185d-47f6-a642-6b5599ed82f9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_59b18b3a-fbd9-4d29-8d33-7740f3840389_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_07bfd144-ca7a-47b5-b373-80ebb1e5e395_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_37cf08ab-acd0-4214-8c40-9b6c98e045ef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_441b61cf-77c4-4d52-9811-e94a5cec0223_terseLabel_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Liabilities</link:label>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_allo_LiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LiabilitiesLesseeTableTextBlock" xlink:href="allo-20210331.xsd#allo_LiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LiabilitiesLesseeTableTextBlock" xlink:to="lab_allo_LiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EquityInvestmentBasisAxis_e2fd5d9f-62e0-41b1-8ccf-af18a0ec086a_terseLabel_en-US" xlink:label="lab_allo_EquityInvestmentBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Axis]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisAxis_label_en-US" xlink:label="lab_allo_EquityInvestmentBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Axis]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisAxis_documentation_en-US" xlink:label="lab_allo_EquityInvestmentBasisAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EquityInvestmentBasisAxis" xlink:to="lab_allo_EquityInvestmentBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_604014df-a108-4074-8055-160322d5bf29_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_331638ae-8138-49a8-b33a-4650e280987a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_df0cc1d9-5155-4fc1-beff-79d6817242cf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TenantImprovementAllowanceUtilizedToDate_f3182a3e-a3b6-4013-b898-10c42fb44521_terseLabel_en-US" xlink:label="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance utilized to date</link:label>
    <link:label id="lab_allo_TenantImprovementAllowanceUtilizedToDate_label_en-US" xlink:label="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Utilized To Date</link:label>
    <link:label id="lab_allo_TenantImprovementAllowanceUtilizedToDate_documentation_en-US" xlink:label="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Utilized To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowanceUtilizedToDate" xlink:href="allo-20210331.xsd#allo_TenantImprovementAllowanceUtilizedToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TenantImprovementAllowanceUtilizedToDate" xlink:to="lab_allo_TenantImprovementAllowanceUtilizedToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_bd0066e0-a077-41cc-a77b-cb32560b01d4_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d2f694c3-7012-4fee-b2f6-c8affbe86f52_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_21997077-6c4f-40f2-bd6e-0a977e02f0d4_terseLabel_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_label_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_allo_NotchTherapeuticsIncMember_documentation_en-US" xlink:label="lab_allo_NotchTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notch Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember" xlink:href="allo-20210331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NotchTherapeuticsIncMember" xlink:to="lab_allo_NotchTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_107e3022-de98-4b90-a586-3d0087de385f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3fa0316b-44e3-40d3-903f-d88bb5784f4a_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_c6b61903-bc82-46d6-a5a4-2f8bb95552f2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_56da82e6-944a-4680-a131-576e6f7a29be_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization/accretion on investment securities</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35a1436b-5df0-49e9-97cc-cdd4fe5d2f6d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock based compensation expense, weighted average recognition period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_99a3f34e-15b0-48fd-97ac-0b053f49ef9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_83dd7af9-9d45-4894-9970-9bfa3a0c7601_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d072f672-170e-4a20-b218-ae606a9315dc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_e883d800-4ba4-418c-b3c5-9aef39d5d4ca_terseLabel_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office and laboratory (in square feet)</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_label_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of New Office Building</link:label>
    <link:label id="lab_allo_AreaOfNewOfficeBuilding_documentation_en-US" xlink:label="lab_allo_AreaOfNewOfficeBuilding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of new office building.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding" xlink:href="allo-20210331.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfNewOfficeBuilding" xlink:to="lab_allo_AreaOfNewOfficeBuilding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_2b05c794-d064-4f86-b7c2-e53596421e0c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AllogeneOverlandMember_033ef657-babe-4885-9680-f38a1cbd7170_terseLabel_en-US" xlink:label="lab_allo_AllogeneOverlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland</link:label>
    <link:label id="lab_allo_AllogeneOverlandMember_label_en-US" xlink:label="lab_allo_AllogeneOverlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland [Member]</link:label>
    <link:label id="lab_allo_AllogeneOverlandMember_documentation_en-US" xlink:label="lab_allo_AllogeneOverlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allogene Overland</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember" xlink:href="allo-20210331.xsd#allo_AllogeneOverlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AllogeneOverlandMember" xlink:to="lab_allo_AllogeneOverlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3c68c3d6-b90e-45a3-bdfb-403be6777965_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0c96808c-45fd-490b-8339-516af56e948f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_f0e4ec74-e569-423c-8158-3f5aa1baf472_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_ed088861-40c8-4864-8167-c5b366b66edf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cf462efc-dd59-4e4c-adf7-bbde6ad354b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6485e2ac-3698-409d-ab12-e5eedf9b75c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_302ba510-d1aa-4a27-9cf2-a4e765aa229b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_39a2b236-b8c6-45dc-aabc-da0e467fec7b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6775f33f-3b3c-4f57-8022-a7e4dbb4cf63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_04d787c6-aeb6-466e-94e9-22bbfcc19056_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_2e8bc058-b709-4db7-b5b5-ceab81016445_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development cost payable by collaboration partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By Collaboration Partner</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:href="allo-20210331.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_154d8150-76c7-4238-809e-5015192491d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_d20dec42-3ff0-495e-a661-9613805cdacc_terseLabel_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Liabilities Current</link:label>
    <link:label id="lab_allo_AccruedAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:href="allo-20210331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AccruedAndOtherLiabilitiesCurrent" xlink:to="lab_allo_AccruedAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_14d84b41-3fd5-42c0-b839-793f39a17ab2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_14b712ec-83ad-4988-b857-4190eb6a5d69_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f791edb0-fa50-43d3-bb9a-514711e0428c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_fb0b4022-d12f-47da-8eab-db26fd3591cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_32015899-4751-4ad0-9884-3fd9d2b2d2b4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8a1cefc5-1893-4f0a-b6f0-2b02b19c05c9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dbf4fd6a-da8e-4848-94c3-c563b64617d2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0fc469c9-be08-487c-be3c-1893140dc6ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_894e93c4-b9b3-434b-848f-a5896990a14f_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6d4e6601-7447-48d2-89d1-5d7e86c23a15_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_4a1e4f6b-764d-4ee8-b81b-a91c0ebf0b65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_1d046f73-35bf-4038-8720-f2e97c9ce466_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AssetContributionAgreementMember_2aa0cde4-d069-463f-bb00-69fe103e6cc8_verboseLabel_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_label_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Contribution Agreement [Member]</link:label>
    <link:label id="lab_allo_AssetContributionAgreementMember_documentation_en-US" xlink:label="lab_allo_AssetContributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset contribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember" xlink:href="allo-20210331.xsd#allo_AssetContributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AssetContributionAgreementMember" xlink:to="lab_allo_AssetContributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_56cce2ba-5c73-45ab-96a0-fb137088aaa2_terseLabel_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_label_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements [Text Block]</link:label>
    <link:label id="lab_allo_LicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_allo_LicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreements text block.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAgreementsTextBlock" xlink:href="allo-20210331.xsd#allo_LicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAgreementsTextBlock" xlink:to="lab_allo_LicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_84eac4f1-e865-4cf1-8e95-ababd27ae84c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5e09d8fd-10c8-45a9-9e63-3b8522b77e36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0de4ea78-9e1e-4f84-a12c-234b56f3ab0e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_da65cecf-8b88-4580-8024-0614f2906600_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_2b44d2b9-2f3b-4287-9c9a-3a1056e02a4d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6f267cbd-fd1c-4a15-83ac-7ce1811e1a0a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementCommittedFunding_d4e6ad9a-5e46-4524-bc90-1e0515932897_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed funding</link:label>
    <link:label id="lab_allo_CollaborationAgreementCommittedFunding_label_en-US" xlink:label="lab_allo_CollaborationAgreementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Committed Funding</link:label>
    <link:label id="lab_allo_CollaborationAgreementCommittedFunding_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementCommittedFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Committed Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementCommittedFunding" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementCommittedFunding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementCommittedFunding" xlink:to="lab_allo_CollaborationAgreementCommittedFunding" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentsCommencingJanuary2020Member_76824811-4733-45a3-9357-3e9944538653_terseLabel_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2020</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2020Member_label_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2020 [Member]</link:label>
    <link:label id="lab_allo_PaymentsCommencingJanuary2020Member_documentation_en-US" xlink:label="lab_allo_PaymentsCommencingJanuary2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Commencing January 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2020Member" xlink:href="allo-20210331.xsd#allo_PaymentsCommencingJanuary2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentsCommencingJanuary2020Member" xlink:to="lab_allo_PaymentsCommencingJanuary2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_EquityInvestmentBasisDomain_d4056ca9-6381-4410-bfcb-ac912a4bbf2f_terseLabel_en-US" xlink:label="lab_allo_EquityInvestmentBasisDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Domain]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisDomain_label_en-US" xlink:label="lab_allo_EquityInvestmentBasisDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Domain]</link:label>
    <link:label id="lab_allo_EquityInvestmentBasisDomain_documentation_en-US" xlink:label="lab_allo_EquityInvestmentBasisDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment Basis [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_EquityInvestmentBasisDomain" xlink:to="lab_allo_EquityInvestmentBasisDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a33dc314-6721-42d9-b4d3-eabbcfe44602_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_7a51dcee-3e34-43f3-8a6b-092a409920fd_terseLabel_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payment in arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_label_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction Monthly Payments In Arrears</link:label>
    <link:label id="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_documentation_en-US" xlink:label="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transaction monthly payments in arrears.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:href="allo-20210331.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:to="lab_allo_RelatedPartyTransactionMonthlyPaymentsInArrears" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_UpfrontAndQuarterlyCashPayments_b5f90056-767a-4cb2-bb32-e67a5b6eed97_terseLabel_en-US" xlink:label="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and quarterly cash payments</link:label>
    <link:label id="lab_allo_UpfrontAndQuarterlyCashPayments_label_en-US" xlink:label="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Quarterly Cash Payments</link:label>
    <link:label id="lab_allo_UpfrontAndQuarterlyCashPayments_documentation_en-US" xlink:label="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and Quarterly Cash Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UpfrontAndQuarterlyCashPayments" xlink:href="allo-20210331.xsd#allo_UpfrontAndQuarterlyCashPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_UpfrontAndQuarterlyCashPayments" xlink:to="lab_allo_UpfrontAndQuarterlyCashPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_091aa18b-f2f7-4640-a87c-769ba5044349_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ae1e1783-02ef-41c8-afb6-8b0551b86e4c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenses_af843c8f-2082-4b82-99cc-cf4fdf558220_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_us-gaap_OtherExpenses_label_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_9d71f0d7-2777-4650-8cd2-021adf9de31c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_497cf19b-8301-4383-aaf9-e7f932c79b2e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_19b58e42-48ad-4d6a-98bd-befc74b6456a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c3b7bff6-2c1a-44d2-802d-dd1d538a5c14_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_2ca585c3-bdfc-4aa2-9310-b3c03b1faed1_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfOffice_e072116c-16ce-4821-9e10-360fdbd2789a_terseLabel_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space (in square feet)</link:label>
    <link:label id="lab_allo_AreaOfOffice_label_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Office</link:label>
    <link:label id="lab_allo_AreaOfOffice_documentation_en-US" xlink:label="lab_allo_AreaOfOffice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice" xlink:href="allo-20210331.xsd#allo_AreaOfOffice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOffice" xlink:to="lab_allo_AreaOfOffice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_22276b96-5322-4e22-8eac-8a017dabb0b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_JointVentureCapitalSupportPayments_76dcd383-b630-49a8-816d-df98f499bea8_terseLabel_en-US" xlink:label="lab_allo_JointVentureCapitalSupportPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture capital support payments</link:label>
    <link:label id="lab_allo_JointVentureCapitalSupportPayments_label_en-US" xlink:label="lab_allo_JointVentureCapitalSupportPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture Capital Support Payments</link:label>
    <link:label id="lab_allo_JointVentureCapitalSupportPayments_documentation_en-US" xlink:label="lab_allo_JointVentureCapitalSupportPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint Venture Capital Support Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_JointVentureCapitalSupportPayments" xlink:href="allo-20210331.xsd#allo_JointVentureCapitalSupportPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_JointVentureCapitalSupportPayments" xlink:to="lab_allo_JointVentureCapitalSupportPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_90bd9d4e-8fd5-408d-afa7-bb8970aca9c7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_fd5fcbd9-de1d-4859-8ef4-9bb621a94eb7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_e656d152-1d23-4d96-b47f-3459c2e44ec8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CollaborationAgreementTerm_12667002-10f8-42e4-809e-a04e4d43cc50_terseLabel_en-US" xlink:label="lab_allo_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_allo_CollaborationAgreementTerm_label_en-US" xlink:label="lab_allo_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:label id="lab_allo_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_allo_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementTerm" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CollaborationAgreementTerm" xlink:to="lab_allo_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_9a5c1bfa-2623-41a6-ac93-33aff366d60d_verboseLabel_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_label_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreement [Member]</link:label>
    <link:label id="lab_allo_LicenseAndCollaborationAgreementMember_documentation_en-US" xlink:label="lab_allo_LicenseAndCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember" xlink:href="allo-20210331.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LicenseAndCollaborationAgreementMember" xlink:to="lab_allo_LicenseAndCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ConsultingAgreementsMember_b3b169f4-1cb3-4586-9af5-6fcdb1628f09_terseLabel_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreements</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_label_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreements [Member]</link:label>
    <link:label id="lab_allo_ConsultingAgreementsMember_documentation_en-US" xlink:label="lab_allo_ConsultingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember" xlink:href="allo-20210331.xsd#allo_ConsultingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ConsultingAgreementsMember" xlink:to="lab_allo_ConsultingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8ea259de-34b1-4e3c-bbc8-5108f1f821c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_a38d9b50-6a13-4b18-85d8-5b024655f86b_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SalesMilestoneMember_0b2b5403-9ef8-466f-90f1-7cadc8f6b65b_terseLabel_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_label_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Milestone [Member]</link:label>
    <link:label id="lab_allo_SalesMilestoneMember_documentation_en-US" xlink:label="lab_allo_SalesMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember" xlink:href="allo-20210331.xsd#allo_SalesMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SalesMilestoneMember" xlink:to="lab_allo_SalesMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_23e07536-9138-4367-8dcd-9696f809cb25_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_5cd89c51-49f8-4dc3-ba51-632bd92c8765_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_37ecf016-b1d4-470d-8c1f-cce0327635a1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_aa2131a1-2fd2-42ed-b7de-03ba93ac1a5c_terseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6258b4ad-e523-4545-9bf5-83d5fa6b06c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_ab881db4-cd27-4937-bbb8-e11ce86e16fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_0c33e748-aae0-46ad-8fbd-066722479e55_terseLabel_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_label_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]</link:label>
    <link:label id="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements not yet adopted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:href="allo-20210331.xsd#allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:to="lab_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyCosts_533b2827-0c5f-4c2b-8db9-d2e5c34da66f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party costs</link:label>
    <link:label id="lab_us-gaap_RelatedPartyCosts_label_en-US" xlink:label="lab_us-gaap_RelatedPartyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyCosts" xlink:to="lab_us-gaap_RelatedPartyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AreaOfOperatingLease_759d7189-8f66-4584-ab8c-1e998599199d_terseLabel_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of operating lease (in square feet)</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_label_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area Of Operating Lease</link:label>
    <link:label id="lab_allo_AreaOfOperatingLease_documentation_en-US" xlink:label="lab_allo_AreaOfOperatingLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of operating lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease" xlink:href="allo-20210331.xsd#allo_AreaOfOperatingLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AreaOfOperatingLease" xlink:to="lab_allo_AreaOfOperatingLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dbef977a-563b-4cfd-aa88-bb0a9e937057_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_55121d24-ce6c-474d-9577-1c50f0687cfc_terseLabel_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_label_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Payments Required Per Product Against Selected Target</link:label>
    <link:label id="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_documentation_en-US" xlink:label="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payments required per product against selected target.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:href="allo-20210331.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:to="lab_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b027e25d-ba1f-449b-87c3-5da0a2db32a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1f96781b-9cf5-4352-8825-a95dad3af3f5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_94ca7549-a942-456c-a69e-dc0ce12f95dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cef5ece9-9a40-4479-b15f-4b140c3b2b8a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_29d91dbf-3193-477b-9f1a-ad19b0a7987a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_ecbe1092-22e6-4cb4-8806-0584692b0f52_negatedTerseLabel_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of losses from equity method investments</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_label_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:label id="lab_allo_IncomeLossFromCostMethodInvestment_documentation_en-US" xlink:label="lab_allo_IncomeLossFromCostMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Cost Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment" xlink:href="allo-20210331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_IncomeLossFromCostMethodInvestment" xlink:to="lab_allo_IncomeLossFromCostMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_87548517-a506-4355-99de-597220e0602d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Stock Option Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ed7a2837-2501-477d-a4d2-78f41ce37085_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_e602462f-6029-41a5-8d81-f366f514a672_terseLabel_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_label_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date</link:label>
    <link:label id="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_documentation_en-US" xlink:label="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option exercise price as percentage of fair value of common stock on grate date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:href="allo-20210331.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:to="lab_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_260ed77a-5e1e-4917-9e39-0c1099681af6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2ac23313-9dc1-415f-be1e-714f522a6442_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4e6dba1b-a93a-4bde-b79a-2337c0e11bfa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7c6cbc76-9851-40cc-a2d1-ff7257fca1e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_59b3448f-27c9-4716-a946-bf3cc9001d0e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d58665aa-d1e2-4306-88f7-597c63170819_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_8eed6a9d-633f-4917-a6ed-cd296380dc47_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_ecbde3a1-373f-4e22-a941-1dd29a03a93d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0ff6ed36-02aa-4610-91a7-d5682dee4a7f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e49e0fc9-83ab-4836-a88b-78cb94fdfa95_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_999737c7-0384-474d-a283-f09eb3130b5d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_35f6ae00-61c4-41ce-8597-bcbbcd69ace3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TenantImprovementAllowance_e777f542-6107-4362-ae14-096165944cdd_terseLabel_en-US" xlink:label="lab_allo_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements</link:label>
    <link:label id="lab_allo_TenantImprovementAllowance_48723dc4-aa23-40b1-bc37-f2fb8b2dba6e_negatedLabel_en-US" xlink:label="lab_allo_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance</link:label>
    <link:label id="lab_allo_TenantImprovementAllowance_label_en-US" xlink:label="lab_allo_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance</link:label>
    <link:label id="lab_allo_TenantImprovementAllowance_documentation_en-US" xlink:label="lab_allo_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for tenant improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowance" xlink:href="allo-20210331.xsd#allo_TenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TenantImprovementAllowance" xlink:to="lab_allo_TenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c96e4f91-3bda-4c53-8526-efb0b2cd901a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_721aa941-ac6b-4c0f-9fb5-864a1f8aedf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ca326302-582a-456b-a29a-32c5fbd84978_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0538c633-74c1-4243-8ce8-4e37555d854a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aaced99e-17e8-47f3-a9ae-88dcc676920d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CapitalizedSoftwareCostsIncurredNotYetPaid_6ff985a4-4876-430f-9c98-fe92076df65a_terseLabel_en-US" xlink:label="lab_allo_CapitalizedSoftwareCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized cloud computing costs included in accounts payable and accrued and other current liabilities</link:label>
    <link:label id="lab_allo_CapitalizedSoftwareCostsIncurredNotYetPaid_label_en-US" xlink:label="lab_allo_CapitalizedSoftwareCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software Costs Incurred Not Yet Paid</link:label>
    <link:label id="lab_allo_CapitalizedSoftwareCostsIncurredNotYetPaid_documentation_en-US" xlink:label="lab_allo_CapitalizedSoftwareCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Software Costs Incurred Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CapitalizedSoftwareCostsIncurredNotYetPaid" xlink:href="allo-20210331.xsd#allo_CapitalizedSoftwareCostsIncurredNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CapitalizedSoftwareCostsIncurredNotYetPaid" xlink:to="lab_allo_CapitalizedSoftwareCostsIncurredNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_db6c8cad-9f41-4ee7-9d5f-fccc57c1103e_terseLabel_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder's shares of common stock subject to future vesting</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_label_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder Shares Of Common Stock [Member]</link:label>
    <link:label id="lab_allo_FounderSharesOfCommonStockMember_documentation_en-US" xlink:label="lab_allo_FounderSharesOfCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Founder shares of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember" xlink:href="allo-20210331.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_FounderSharesOfCommonStockMember" xlink:to="lab_allo_FounderSharesOfCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_c508fc6b-aa30-4c26-98b9-2b2ef46c3c81_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_c2b17da8-961a-4ccf-86b0-49ea1730b207_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_accfd6d6-f6d2-499c-a72c-b8406ed45263_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6052dd04-ec5b-42fc-b061-ae7f61578b59_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized&#160;Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_d396377e-db88-411a-aeee-8728683fea0b_terseLabel_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_label_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone [Member]</link:label>
    <link:label id="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember_documentation_en-US" xlink:label="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Regulatory, and Commercial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:href="allo-20210331.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:to="lab_allo_ClinicalRegulatoryAndCommercialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_4efd5df3-c1e4-4086-8c6b-96ddb8bf3ec7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_87356753-2f3e-49de-94a0-bca410448ea1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_887c1a27-7791-4d90-9172-5f8c0345bfc8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_VotingInterestMember_a17a8f91-0609-4425-9fc9-fc9183a4186f_terseLabel_en-US" xlink:label="lab_allo_VotingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Interest</link:label>
    <link:label id="lab_allo_VotingInterestMember_label_en-US" xlink:label="lab_allo_VotingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Interest [Member]</link:label>
    <link:label id="lab_allo_VotingInterestMember_documentation_en-US" xlink:label="lab_allo_VotingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember" xlink:href="allo-20210331.xsd#allo_VotingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_VotingInterestMember" xlink:to="lab_allo_VotingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_4df1f4ee-73fb-42e6-9dea-ce506fe2445f_terseLabel_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Significant Accounting Policies Policy [Policy Text Block]</link:label>
    <link:label id="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:href="allo-20210331.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:to="lab_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f9fb99bd-74be-42df-919f-c2a78fefdd7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_OverlandPharmaceuticalsIncMember_85a6a9db-b5c0-4558-8e2b-b9e7f618620d_terseLabel_en-US" xlink:label="lab_allo_OverlandPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland Pharmaceuticals Inc.</link:label>
    <link:label id="lab_allo_OverlandPharmaceuticalsIncMember_label_en-US" xlink:label="lab_allo_OverlandPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_allo_OverlandPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_allo_OverlandPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overland Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember" xlink:href="allo-20210331.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_OverlandPharmaceuticalsIncMember" xlink:to="lab_allo_OverlandPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_69f0f2d8-9e94-4ae4-a476-82b58f80dfba_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_df69eaa9-0348-4f5e-881c-c3eaaa9c3082_terseLabel_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_allo_PreClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Clinical Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:href="allo-20210331.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PreClinicalDevelopmentMilestoneMember" xlink:to="lab_allo_PreClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_d71554a6-fa2d-4b52-8297-d514d12309db_terseLabel_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of development costs payable by the Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_label_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:label id="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany_documentation_en-US" xlink:label="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Development Cost Payable By The Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:href="allo-20210331.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:to="lab_allo_PercentageOfDevelopmentCostPayableByTheCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5c7320e7-9618-4e69-b4bf-d2f00f9f3c75_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7460b81e-e31e-448c-967c-ff20ce8bdef0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_12979568-a01f-4ae0-80e4-6a3814b4cbbd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fdab1238-53a7-41c4-87c3-cee57c560859_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ed7b6d36-651d-47bf-a98a-d7a1cd4c2525_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e257854c-f2dc-4b4b-9285-7adac3b06ea6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_b94411d1-080b-495f-89b5-f56ce98c2f66_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_75de5eab-5d32-4e64-b98d-97cd84ce3e89_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3cb23227-6664-4bdf-b6a7-36529f33fb7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_35e52784-8d1f-4135-bfdb-aeb4fa3aa139_terseLabel_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_label_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Lease</link:label>
    <link:label id="lab_allo_NumberOfOptionsToExtendLease_documentation_en-US" xlink:label="lab_allo_NumberOfOptionsToExtendLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease" xlink:href="allo-20210331.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfOptionsToExtendLease" xlink:to="lab_allo_NumberOfOptionsToExtendLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_44961210-d1a7-4eea-bf8f-40223303160a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4dcbde22-6954-4564-a861-5468894e7856_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_4fea5a19-b1f6-48f8-87f8-0b95ccc2d4ad_terseLabel_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_label_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting L L C [Member]</link:label>
    <link:label id="lab_allo_TwoRiverConsultingLLCMember_documentation_en-US" xlink:label="lab_allo_TwoRiverConsultingLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two River Consulting LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember" xlink:href="allo-20210331.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoRiverConsultingLLCMember" xlink:to="lab_allo_TwoRiverConsultingLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_72b95ab5-2e56-4cd3-8e4a-99820dfff188_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_8ff36bbf-e758-499d-ae99-3b189da49c59_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_4d22aeb4-9a93-4ae5-92e0-c699bb893d49_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_896433a2-601e-4cb9-9010-1fc43110f83a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dabdde9f-ddbe-4ada-8d27-ccb6a58351c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a7e7af71-914f-4f0f-8b6a-09ef5a9b1e60_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d2f45f0-3b9a-4aa3-ab60-6393d429bb12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_32c4d6a5-846d-4319-9511-7a8f9aab0e33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c162609-3d08-4d46-8bf2-8902d18f7a00_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_00e2f9db-3300-46a6-923d-b2daeb8d749b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_27c318d7-68f5-47ef-aa2f-f16a4ddffebe_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5ac787ca-aa4c-4d35-945f-2e8478078040_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_08cfa412-8e87-41ba-8b09-0b18c2f266cf_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2a92247a-0096-477a-95bf-288e88662292_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 141,470,075 and 140,474,305 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AtTheMarketOfferingMember_5295f983-bf02-4784-bdd3-3be64da4a785_terseLabel_en-US" xlink:label="lab_allo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM offering</link:label>
    <link:label id="lab_allo_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_allo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_allo_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_allo_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AtTheMarketOfferingMember" xlink:href="allo-20210331.xsd#allo_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AtTheMarketOfferingMember" xlink:to="lab_allo_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_80cc3bd7-44f8-44c1-9814-9a03a738d1dd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_53363b26-f567-404a-b957-992dc42dacc8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c7a8a002-22de-4824-829d-e78e9254563b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0a866ced-5fdc-475c-83a0-e3f6fc43f700_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NewarkMember_c55636bc-1673-4921-9c26-cd4d8353f77a_terseLabel_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark</link:label>
    <link:label id="lab_allo_NewarkMember_label_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark [Member]</link:label>
    <link:label id="lab_allo_NewarkMember_documentation_en-US" xlink:label="lab_allo_NewarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Newark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember" xlink:href="allo-20210331.xsd#allo_NewarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NewarkMember" xlink:to="lab_allo_NewarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_LaboratoryEquipmentMember_25345242-7c3b-4c0b-b2cf-6c9a6602feb8_terseLabel_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_allo_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_allo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember" xlink:href="allo-20210331.xsd#allo_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_LaboratoryEquipmentMember" xlink:to="lab_allo_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PublicOfferingMember_80def4d3-1c8d-4791-8d09-7e1bdf0eb76e_terseLabel_en-US" xlink:label="lab_allo_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_allo_PublicOfferingMember_label_en-US" xlink:label="lab_allo_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_allo_PublicOfferingMember_documentation_en-US" xlink:label="lab_allo_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PublicOfferingMember" xlink:href="allo-20210331.xsd#allo_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PublicOfferingMember" xlink:to="lab_allo_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_7c284721-35c7-4617-924e-32b561d744c1_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_401d7361-ef92-4c90-af2e-2027856eddb4_terseLabel_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction cost</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_label_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:label id="lab_allo_CostMethodInvestmentTransactionCosts_documentation_en-US" xlink:label="lab_allo_CostMethodInvestmentTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Method Investment, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts" xlink:href="allo-20210331.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CostMethodInvestmentTransactionCosts" xlink:to="lab_allo_CostMethodInvestmentTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c77f0a86-8c6f-4570-b173-58e91494cd79_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at date of grant per share, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_47f85648-18fe-485c-ab92-481979538d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_9619677d-3093-4551-972e-be7508cf5632_totalLabel_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments</link:label>
    <link:label id="lab_allo_CashEquivalentsAndShortTermInvestments_documentation_en-US" xlink:label="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:href="allo-20210331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CashEquivalentsAndShortTermInvestments" xlink:to="lab_allo_CashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_852d77ab-ef20-4ff4-8962-712f8e500a50_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_219e3b7f-5fed-48bf-a4ee-c348cb8f8b4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_439dca01-1d51-42e8-82af-e2d6a4bfa0d8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6e6c1fb1-9600-426a-a278-2f6b9391d032_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ec8827db-8bb9-4b2a-bc4e-4cc793a96398_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_78b6e245-f481-4700-a48a-a27bbf6d095e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_3c6f1921-fb2e-42d1-9d20-c9dd3215e2d7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b98d4e1c-3e90-4b84-b0e1-b2c367b16d07_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_68074cb3-3093-4cdb-b561-586b3cc4af29_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_DevelopmentAndSalesMember_0f379daf-8bb8-4a09-9923-01c4dbdb4068_terseLabel_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and Sales</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_label_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:label id="lab_allo_DevelopmentAndSalesMember_documentation_en-US" xlink:label="lab_allo_DevelopmentAndSalesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember" xlink:href="allo-20210331.xsd#allo_DevelopmentAndSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_DevelopmentAndSalesMember" xlink:to="lab_allo_DevelopmentAndSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_23aa7d65-91fe-45bf-bbdd-69bbb6671373_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5acb217b-befa-4db8-aaf4-b198c768465e_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0e390a2d-8f84-4ea4-8394-e44b7337333c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_192475b9-f8e2-4483-b755-9f42d0c49d05_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_54b3b8ab-de06-4874-92d3-b3379daf9971_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e915c341-664c-4534-96d8-aa8822721169_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e70724c1-4420-4faa-a635-ca2d9c41aab5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_be2fc4a9-11db-48a2-9837-1cdb16cb4ebb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_87a99df8-229e-4d80-8590-d2f7ddadfa5f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units subject to vesting</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_ac632dde-b810-4ba9-abda-9f687e209bdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_94cd72b1-436a-4676-a9c2-4fa0aad13ae3_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b6f80036-4ed6-489f-a182-a924ad22e3b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8cb4a75a-6c52-4573-84dc-b8614fd37cc0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_1ae1aa0b-86ff-413b-8857-61c12e643d65_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_42f04c6e-74cf-4244-806d-67c56b7efec0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_a1aa62c5-9cc7-4473-9e6b-d2cdcf7ea146_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_06683d5e-3df3-4c1a-bed5-1a1a06de58cc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e94b90b6-91bc-490b-9693-2b7bccd94b74_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a0f9ab24-73d8-4844-bb3f-8002fd897c80_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_0ac5b187-1253-47e9-840d-8f1cc0a721c4_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_6912c4c6-1a18-49b1-ae3a-2d785ab8989a_terseLabel_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_label_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Plan [Member]</link:label>
    <link:label id="lab_allo_TwoThousandEighteenPlanMember_documentation_en-US" xlink:label="lab_allo_TwoThousandEighteenPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember" xlink:href="allo-20210331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_TwoThousandEighteenPlanMember" xlink:to="lab_allo_TwoThousandEighteenPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_faecbc20-d117-42f0-85ed-3e5161f62cf3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bc8f527d-8683-4e53-9eb6-0c49ae557b75_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b6b1d85e-55af-419c-9b5b-8f20564b59da_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_92b42606-8fe6-413f-9a9e-22139e4c82e4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6d45796f-f0e9-44aa-b81a-7bba18716f54_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_dd0f0385-3332-4da0-aa42-57fcc31f905a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining 9 months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_c86c98cd-0975-4bfb-ab15-3d2fb9832f42_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_42f506be-23e5-4a72-9596-ebfbdbe4f83d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e99749f5-d43d-44af-80cb-e6f059af4e72_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_1a9893b5-45d9-4059-80ca-8aeb14fc6f76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_CellectisSAMember_7e8c1919-2c2f-416d-a5e5-014b313b84ef_terseLabel_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis</link:label>
    <link:label id="lab_allo_CellectisSAMember_label_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S A [Member]</link:label>
    <link:label id="lab_allo_CellectisSAMember_documentation_en-US" xlink:label="lab_allo_CellectisSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cellectis S.A..</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember" xlink:href="allo-20210331.xsd#allo_CellectisSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_CellectisSAMember" xlink:to="lab_allo_CellectisSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_7ea229eb-38fd-4fe6-b0bc-ad6163ac99a2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1f2578a4-95a0-4e37-b06e-8d39ff80f2d0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4ba75bdd-6033-4848-b2b2-39da7a1dd047_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e2fa41e1-a8b8-4a80-8c53-560b5671410e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_de108717-49e8-4fb8-beb2-5a9092e0acc0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_fb7dbc2e-59f9-4d6b-a8f8-a8fcc5e82b84_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_PaymentTermsAxis_b8694792-24e9-41b7-adda-46c67a8d74bb_terseLabel_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Axis]</link:label>
    <link:label id="lab_allo_PaymentTermsAxis_label_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms [Axis]</link:label>
    <link:label id="lab_allo_PaymentTermsAxis_documentation_en-US" xlink:label="lab_allo_PaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis" xlink:href="allo-20210331.xsd#allo_PaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_PaymentTermsAxis" xlink:to="lab_allo_PaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4b38850b-5b21-4a59-8f4a-4045bbe2b2b0_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_c620617b-0547-439e-a309-569bd5cd53f2_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_680c9568-4194-4efe-9199-2f79c6cf5e22_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_574124c5-f7ce-4883-aa8d-7946d08ca126_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_79d24717-0b22-4107-9123-7c8f3a5ca713_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3a6a5a49-fa74-4a9b-97ed-b541f77f5d27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7044c22c-2ffb-4e56-b26a-54e30915b0da_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d59c55b5-34bb-4f56-ba13-c90672c31ec9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b03e1554-d22f-4f58-b4bf-24b64da5d98b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8db0ed1d-4568-49d1-88a3-938112a0da93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_372817ec-d893-4e96-9504-94592551499f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_db8802d9-708a-4ddc-88e0-6fce473108ac_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_12170cdc-ad21-4897-9117-feb14f1757fb_terseLabel_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements Policy [Policy Text Block]</link:label>
    <link:label id="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently adopted accounting pronouncements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="allo-20210331.xsd#allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb3f6747-9d37-4f04-b393-0aa5d2241168_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock from public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_1af46f16-2138-4a26-b4e4-1f3650d80ab9_terseLabel_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, granted (in years)</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_documentation_en-US" xlink:label="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:to="lab_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_ad6645d0-46d0-4f5a-93e2-4f226cc756f7_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_a77e6c4b-7716-4aec-bdf3-5ba5d4779f06_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_57d25731-bf71-45e3-9b6e-ab81c84b73a3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_70861fbb-f298-4485-a445-d40b520becc3_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_SubleaseAgreementMember_b26d9080-e357-40a4-8854-797e27330643_terseLabel_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_label_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:label id="lab_allo_SubleaseAgreementMember_documentation_en-US" xlink:label="lab_allo_SubleaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember" xlink:href="allo-20210331.xsd#allo_SubleaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_SubleaseAgreementMember" xlink:to="lab_allo_SubleaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_58cc86d7-a9cf-4218-8311-24aad8e802d6_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_66119b3a-f7a9-41e4-8d3d-380f2c127161_terseLabel_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty obligation period from date of first sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_label_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:label id="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale_documentation_en-US" xlink:label="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Obligation Period From Date Of First Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:href="allo-20210331.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:to="lab_allo_RoyaltyObligationPeriodFromDateOfFirstSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_50d6576e-4378-4a83-b9e3-f8ebf0e15006_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9ed78c9d-554c-4da9-a787-87242763a43d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of RSU's (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e211c34c-8d56-46a7-861c-fa54e8e01ceb_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options, options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_136de7ba-96ac-420a-bd93-2ff4408079bc_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9915deb8-717b-4bce-88d7-e5b97affa5d8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_2e251f49-4a11-4198-8b0e-5d82c9e8791c_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8ad2cc87-12ad-4bbc-82c1-e629f8396969_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Lease Payments Under Lease Liability</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7b4d6e00-601c-436f-b65d-b91346df94ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_df846776-27f8-4d70-bcd9-f81b6444e6c2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f58355ee-5837-4e1f-8931-5fff3ef4369d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_b6329051-bf11-4d6c-84fe-3d42a406bfe1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f2539554-ddb4-4b5d-aaf8-d858003403f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_e5d6d320-855b-48ca-8ef1-6311f70c80ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember_00d32565-5acb-430e-9c77-06617f4150df_terseLabel_en-US" xlink:label="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Texas MD Anderson Cancer Center</link:label>
    <link:label id="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember_label_en-US" xlink:label="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Texas MD Anderson Cancer Center [Member]</link:label>
    <link:label id="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember_documentation_en-US" xlink:label="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University Of Texas MD Anderson Cancer Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:href="allo-20210331.xsd#allo_UniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:to="lab_allo_UniversityOfTexasMDAndersonCancerCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b0068adc-f884-4e69-9480-a54b79c72ffd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_MilestonePayments_d4ebd75f-d2c1-4054-bb94-795ed06f146d_terseLabel_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone payments</link:label>
    <link:label id="lab_allo_MilestonePayments_label_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_allo_MilestonePayments_documentation_en-US" xlink:label="lab_allo_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments" xlink:href="allo-20210331.xsd#allo_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_MilestonePayments" xlink:to="lab_allo_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_5f725edb-2120-4782-9edc-7778156fa5c4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_7e80098d-e2a4-428d-b5da-b5b133648cc5_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_efd0a8dd-a562-43f2-9b94-55d833e69603_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_4e98895b-79aa-4040-8a1a-2625db16324d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity Under Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1be8f926-93e8-4bdc-8e58-bb702dd04029_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edde8606-cc36-43b3-b867-8928993b9be4_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash &#8212; end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_d64f704a-fdd2-4949-88cf-8f28043d6cf8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_815f1757-4300-4584-9d47-5cae414cbb2a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_6c3d0621-bb83-4728-a986-2afd6f81a1a5_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_label_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Milestone Receivable</link:label>
    <link:label id="lab_allo_AggregatePotentialMilestoneReceivable_documentation_en-US" xlink:label="lab_allo_AggregatePotentialMilestoneReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential milestone receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialMilestoneReceivable" xlink:to="lab_allo_AggregatePotentialMilestoneReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_eec3afd9-e822-4f09-8d26-532aaa131d0b_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_0104a572-bfd6-4d6a-abfa-3109e0fb1c7f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8233bd07-67a9-4f83-a6ae-04134596c873_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5d9a86ef-e408-4716-af25-db1e0f0b0a61_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_d41cf285-bdde-4279-9171-892598e4777b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1727b46c-b960-4c28-be68-dce85f11a6f5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4823f969-4c1b-4667-b48b-fa06d365007f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and vesting of RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e3def159-7e63-4249-aef2-ee766d5fd57f_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a84881c8-9c3f-4a82-acf5-7fabad298d4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Fair Value at Date of Grant per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_72e75fb4-46e1-4aa9-b896-053422d48927_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3c4b1089-d66e-4bcb-9ebb-26cfbc061b90_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_e798f6d9-cf42-4c29-8781-4e9c8dabb38e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ba877c56-ec8d-44f8-8ba2-1a80ea4595be_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_678c4cc6-2776-4d2f-bd58-f9da00bfaeac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f4599a9f-807d-4b35-b20c-9f10c8a749ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_e8f00aaf-e1d1-4139-8261-134369b53407_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_345a3111-c728-47bb-b3fe-a77798e47170_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_47e648cb-9949-4f28-bae8-2daca607bfba_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_8081dc2d-d43d-48cb-8014-9ae95222c40b_terseLabel_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_label_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares As Percentage Of Common Shares Outstanding</link:label>
    <link:label id="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_documentation_en-US" xlink:label="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares as percentage of common shares outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:href="allo-20210331.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:to="lab_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_67e01549-66b8-4d55-891c-6baa5a9c6118_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contract term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_201c1503-8887-4090-ab5c-023068772038_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3301347b-a6f8-489e-9b56-4ffc88a290cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_f32c9838-2d48-433c-8a8d-2745330787a3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c265954f-8a26-427d-a055-67255de64e25_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_ServierMember_d261a7ee-c227-4508-9dc3-feb640f3f600_verboseLabel_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_allo_ServierMember_label_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_allo_ServierMember_documentation_en-US" xlink:label="lab_allo_ServierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Servier.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember" xlink:href="allo-20210331.xsd#allo_ServierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_ServierMember" xlink:to="lab_allo_ServierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0fc5a099-dfcb-4bf5-b1cf-2310818cb8e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_b9282c56-d843-4ec1-bc47-afb38cf4fe19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining vesting life, unvested (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_7fcb1b80-9bae-4280-a4a4-2c861a943788_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_728bee43-bbf7-483c-a0b6-71fad4a94684_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c32184bc-2511-4519-a2e3-10e4f906185a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_96cbd638-5904-420b-94af-3bb5e81a925c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7794abd4-60bd-4284-a3ce-c42281741531_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_42d5f867-ba4d-495c-8787-22c9744eef73_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_069810ed-2981-46ef-b497-7827da47e3c9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Quoted Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:to="lab_us-gaap_EquityMethodInvestmentQuotedMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9c87bfbf-d15c-44b9-9dee-0b12464d4737_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5a3968a8-aa39-4115-9c5d-5b71023d4cc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fb1c510d-27f4-4b07-a6a4-85faaaaa987b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_780fcf99-5fc9-4e51-ae00-cf4f6b1fff15_terseLabel_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential regulatory and development milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_label_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Potential Regulatory And Development Milestones</link:label>
    <link:label id="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_documentation_en-US" xlink:label="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate potential regulatory and development milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:href="allo-20210331.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:to="lab_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_allo_RegulatoryMilestoneMember_1ec5dc45-b9f9-4284-a451-2f944f05f23f_terseLabel_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_label_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone [Member]</link:label>
    <link:label id="lab_allo_RegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_allo_RegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember" xlink:href="allo-20210331.xsd#allo_RegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_allo_RegulatoryMilestoneMember" xlink:to="lab_allo_RegulatoryMilestoneMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>allo-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:d318bd7c-046b-4e7c-95c7-84b602262a02,g:436096e2-f446-4eef-a0b1-f01b7434d186-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://allogene.com/role/CoverPage" xlink:type="simple" xlink:href="allo-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e19c6f04-dbb3-4ef9-865c-75d01537c15c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_DocumentType_e19c6f04-dbb3-4ef9-865c-75d01537c15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_f0462f2e-3204-4bad-9eac-33277d8da5ce" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_DocumentQuarterlyReport_f0462f2e-3204-4bad-9eac-33277d8da5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fbd6091a-d59d-4db1-8910-b7ac62136c94" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_DocumentPeriodEndDate_fbd6091a-d59d-4db1-8910-b7ac62136c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_548a2094-0d4e-49ba-a351-0d2252b7455d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_DocumentTransitionReport_548a2094-0d4e-49ba-a351-0d2252b7455d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_59864f90-99e8-4cd8-9604-401fd6773f24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityFileNumber_59864f90-99e8-4cd8-9604-401fd6773f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_037a7747-008e-4db3-b057-03291d273912" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityRegistrantName_037a7747-008e-4db3-b057-03291d273912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_769e534a-30ac-4f48-88c2-6311bfb5364f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_769e534a-30ac-4f48-88c2-6311bfb5364f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f64d3d98-5c98-4b09-b3a5-f6f7de527f0b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityTaxIdentificationNumber_f64d3d98-5c98-4b09-b3a5-f6f7de527f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_514024d4-267d-481b-881b-0019ee075243" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityAddressAddressLine1_514024d4-267d-481b-881b-0019ee075243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d7ea3570-60d1-48f4-892b-44286702911a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityAddressCityOrTown_d7ea3570-60d1-48f4-892b-44286702911a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_348cb8d3-0140-47c4-b3c5-8b94ca74cf24" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityAddressStateOrProvince_348cb8d3-0140-47c4-b3c5-8b94ca74cf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1fe34ed5-d78a-45fc-a51f-d998eb79e636" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityAddressPostalZipCode_1fe34ed5-d78a-45fc-a51f-d998eb79e636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_91e0be38-53ee-44eb-b7f0-4220d1fbb10b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_CityAreaCode_91e0be38-53ee-44eb-b7f0-4220d1fbb10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_61850c86-a224-4c0f-bdb8-f44b8dc32152" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_LocalPhoneNumber_61850c86-a224-4c0f-bdb8-f44b8dc32152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c36216b3-a3ad-478d-a870-5e4ae69a6b9f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_Security12bTitle_c36216b3-a3ad-478d-a870-5e4ae69a6b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_db335c12-b1f8-4461-b6ac-cd78eaf9c3fa" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_TradingSymbol_db335c12-b1f8-4461-b6ac-cd78eaf9c3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_df5ba399-0145-4ecd-8646-24297689fc9c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_SecurityExchangeName_df5ba399-0145-4ecd-8646-24297689fc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_11f07b7c-1e83-4908-91cc-5047dc8e87d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityCurrentReportingStatus_11f07b7c-1e83-4908-91cc-5047dc8e87d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_db4d3d5b-7abd-404d-b1c2-d20416782e0e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityInteractiveDataCurrent_db4d3d5b-7abd-404d-b1c2-d20416782e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7020641c-a307-4909-89e6-b71653e8cc23" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityFilerCategory_7020641c-a307-4909-89e6-b71653e8cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ba12613d-c0b4-408b-a334-2e1b26cb24ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityEmergingGrowthCompany_ba12613d-c0b4-408b-a334-2e1b26cb24ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7c7e9bc9-28a9-4db6-a8d3-3682b199f644" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntitySmallBusiness_7c7e9bc9-28a9-4db6-a8d3-3682b199f644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d991d106-0832-4f42-97ea-bfde1ab59c07" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityShellCompany_d991d106-0832-4f42-97ea-bfde1ab59c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e329ac3b-d0f9-4b4d-9cbd-b0040ab05429" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e329ac3b-d0f9-4b4d-9cbd-b0040ab05429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c4f16263-c436-4618-bba2-de12e2b71ced" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_CurrentFiscalYearEndDate_c4f16263-c436-4618-bba2-de12e2b71ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_34acd40b-20b2-41e7-9a8b-c482dfa0fe2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_AmendmentFlag_34acd40b-20b2-41e7-9a8b-c482dfa0fe2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_31375b4b-b2eb-41c8-8e00-51fe2e0d222a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_EntityCentralIndexKey_31375b4b-b2eb-41c8-8e00-51fe2e0d222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b89b1159-a49f-4fe2-beee-0b0745517b2e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_DocumentFiscalYearFocus_b89b1159-a49f-4fe2-beee-0b0745517b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5dcf42aa-05d2-48c2-8bc7-fdffdaa64065" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_316c23a0-f1cf-4b08-8c3e-ef535e970ca7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5dcf42aa-05d2-48c2-8bc7-fdffdaa64065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_600ba74a-531a-4619-9165-ef988a28b5d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_600ba74a-531a-4619-9165-ef988a28b5d2" xlink:to="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_64be69a4-b1c4-45c8-af2b-cbf8205b43ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_64be69a4-b1c4-45c8-af2b-cbf8205b43ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_053c709c-d0e6-4a7e-a1af-b273720682d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64be69a4-b1c4-45c8-af2b-cbf8205b43ad" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_053c709c-d0e6-4a7e-a1af-b273720682d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f673eae3-6b8e-4524-9583-ba99e32af44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64be69a4-b1c4-45c8-af2b-cbf8205b43ad" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f673eae3-6b8e-4524-9583-ba99e32af44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e4a28fdf-992d-4311-9963-8fffe59aabb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64be69a4-b1c4-45c8-af2b-cbf8205b43ad" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e4a28fdf-992d-4311-9963-8fffe59aabb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5590e517-c126-4b78-9a23-c4bf9cb19594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_64be69a4-b1c4-45c8-af2b-cbf8205b43ad" xlink:to="loc_us-gaap_AssetsCurrent_5590e517-c126-4b78-9a23-c4bf9cb19594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c741474f-916f-40b7-991f-57220ad61424" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c741474f-916f-40b7-991f-57220ad61424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e44afa7d-dcc8-43ea-b417-108ac0da0f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e44afa7d-dcc8-43ea-b417-108ac0da0f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fe650de1-0656-4b52-9d3f-8dfbdad00a65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fe650de1-0656-4b52-9d3f-8dfbdad00a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_a36620fe-dee3-4126-8165-d9c46b29be0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_a36620fe-dee3-4126-8165-d9c46b29be0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3227a192-d5eb-4044-ada9-46d4e8e03dfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3227a192-d5eb-4044-ada9-46d4e8e03dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_be10e0d5-1e4b-49b3-bb89-66b39305b8d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_be10e0d5-1e4b-49b3-bb89-66b39305b8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b2efe55e-687f-45bb-8a8b-d1d882bd76b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_44efde3d-7dac-472c-b728-c53206e843d8" xlink:to="loc_us-gaap_Assets_b2efe55e-687f-45bb-8a8b-d1d882bd76b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_600ba74a-531a-4619-9165-ef988a28b5d2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_904d2a09-5143-4979-ab1f-c8d35efc024e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_904d2a09-5143-4979-ab1f-c8d35efc024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a0a867d0-f0a9-4c0f-a59c-011baebcd291" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_904d2a09-5143-4979-ab1f-c8d35efc024e" xlink:to="loc_us-gaap_AccountsPayableCurrent_a0a867d0-f0a9-4c0f-a59c-011baebcd291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AccruedAndOtherLiabilitiesCurrent_4f475143-b272-45d0-8b68-2cace7abd23e" xlink:href="allo-20210331.xsd#allo_AccruedAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_904d2a09-5143-4979-ab1f-c8d35efc024e" xlink:to="loc_allo_AccruedAndOtherLiabilitiesCurrent_4f475143-b272-45d0-8b68-2cace7abd23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_89fd4ea6-90f7-405e-b67a-509f2b9a2bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_904d2a09-5143-4979-ab1f-c8d35efc024e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_89fd4ea6-90f7-405e-b67a-509f2b9a2bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c2875f5d-c018-4ef4-a208-33eb3fe25dcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_904d2a09-5143-4979-ab1f-c8d35efc024e" xlink:to="loc_us-gaap_LiabilitiesCurrent_c2875f5d-c018-4ef4-a208-33eb3fe25dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_269fec25-a332-4137-b150-66fa6d65754f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_269fec25-a332-4137-b150-66fa6d65754f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2744538a-4087-4f5d-9a4c-5feca58cc53f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2744538a-4087-4f5d-9a4c-5feca58cc53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a2fa59c-828e-4b63-ae16-dcb9b653f934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:to="loc_us-gaap_Liabilities_1a2fa59c-828e-4b63-ae16-dcb9b653f934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b61c5805-32dd-4b71-862b-06fc56d12abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b61c5805-32dd-4b71-862b-06fc56d12abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a1f4cd37-2346-4e78-b4bb-5affa124e495" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:to="loc_us-gaap_PreferredStockValue_a1f4cd37-2346-4e78-b4bb-5affa124e495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ccf79ec3-7434-46ac-b0c7-c1eee28e4d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:to="loc_us-gaap_CommonStockValue_ccf79ec3-7434-46ac-b0c7-c1eee28e4d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f50832fc-e4ed-485c-a0fe-885ccdd241f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f50832fc-e4ed-485c-a0fe-885ccdd241f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4e2fcafe-cba6-4df2-85da-b70fed652f8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4e2fcafe-cba6-4df2-85da-b70fed652f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44fdd8a5-cffc-47bf-a460-4344f02074f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44fdd8a5-cffc-47bf-a460-4344f02074f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_53925607-bfb0-4818-86fa-56319f6ef5a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0144f84e-475d-4fc2-bd57-10951aa002f6" xlink:to="loc_us-gaap_StockholdersEquity_53925607-bfb0-4818-86fa-56319f6ef5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cefba703-cc56-4376-bdb3-20b89daaaa28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24fa5492-2e43-459b-b64c-a27173725533" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cefba703-cc56-4376-bdb3-20b89daaaa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26717043-4f3a-4d91-90f1-7ed8d0a8261d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_26717043-4f3a-4d91-90f1-7ed8d0a8261d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c2c8157c-f793-4d04-b9fd-3c97ea065e14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c2c8157c-f793-4d04-b9fd-3c97ea065e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ba4073bb-3eb7-4486-92c2-69bab538eac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ba4073bb-3eb7-4486-92c2-69bab538eac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6f1648ee-10a6-43ef-885c-177b77459bb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6f1648ee-10a6-43ef-885c-177b77459bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_34b40f1c-f37c-4520-9ffc-7eee952efbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_34b40f1c-f37c-4520-9ffc-7eee952efbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c90add25-a1cf-4ca2-b5d9-c36e5eef7719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c90add25-a1cf-4ca2-b5d9-c36e5eef7719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_879b3b4a-6aca-4e63-8964-8ec699fd8089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_CommonStockSharesIssued_879b3b4a-6aca-4e63-8964-8ec699fd8089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c2778b9f-eaa7-45ec-b99e-c2dcef0376fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2570d506-b81d-496d-adc2-8650592774c7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c2778b9f-eaa7-45ec-b99e-c2dcef0376fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a5132df3-4f95-4575-852c-5ca85a14b540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_RevenuesAbstract_a5132df3-4f95-4575-852c-5ca85a14b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4360cfdb-f2a6-4e82-bd2f-94ca470eedac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a5132df3-4f95-4575-852c-5ca85a14b540" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4360cfdb-f2a6-4e82-bd2f-94ca470eedac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bc799c9e-49ec-4f69-bbc8-1e00c9cbc484" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bc799c9e-49ec-4f69-bbc8-1e00c9cbc484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_fdf3cb24-c68f-48ba-8266-de69edf00d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc799c9e-49ec-4f69-bbc8-1e00c9cbc484" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_fdf3cb24-c68f-48ba-8266-de69edf00d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_29e8cad0-5d41-419b-9663-0da74e37f8a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc799c9e-49ec-4f69-bbc8-1e00c9cbc484" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_29e8cad0-5d41-419b-9663-0da74e37f8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a38c0230-2edb-4568-9022-55cd47448d6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bc799c9e-49ec-4f69-bbc8-1e00c9cbc484" xlink:to="loc_us-gaap_OperatingExpenses_a38c0230-2edb-4568-9022-55cd47448d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1260d634-f0bc-4ec1-b612-107e64112760" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_OperatingIncomeLoss_1260d634-f0bc-4ec1-b612-107e64112760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_173d54b5-b543-47d8-940a-5722664898d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_173d54b5-b543-47d8-940a-5722664898d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2e7443d2-5d98-44c1-8396-30bd89b8c324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_173d54b5-b543-47d8-940a-5722664898d6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2e7443d2-5d98-44c1-8396-30bd89b8c324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_b277fa78-c311-4ad9-9051-62a158532d8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_173d54b5-b543-47d8-940a-5722664898d6" xlink:to="loc_us-gaap_OtherExpenses_b277fa78-c311-4ad9-9051-62a158532d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4c155721-519c-4308-9802-d6bef8de4f60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_173d54b5-b543-47d8-940a-5722664898d6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4c155721-519c-4308-9802-d6bef8de4f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_afb6ac7d-9687-44f1-8c94-48e2c6773f32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_NetIncomeLoss_afb6ac7d-9687-44f1-8c94-48e2c6773f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_951bcbc5-f5e5-43f2-a4fe-c0820e416edd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_951bcbc5-f5e5-43f2-a4fe-c0820e416edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c225fefe-5870-46f3-b952-ad50823959b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_951bcbc5-f5e5-43f2-a4fe-c0820e416edd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c225fefe-5870-46f3-b952-ad50823959b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_97de11d0-b835-40a5-a5bd-497b3db28886" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_951bcbc5-f5e5-43f2-a4fe-c0820e416edd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_97de11d0-b835-40a5-a5bd-497b3db28886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_356bea30-60c2-4c2d-922a-1f64107e1705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_356bea30-60c2-4c2d-922a-1f64107e1705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1b809737-9682-4d94-885f-e37bd8f56719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_f5ee3692-0832-4842-aec5-10279c1890c7" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1b809737-9682-4d94-885f-e37bd8f56719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_14e9bd82-32a7-4efd-b5fd-d1b2b2612519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_26cd98f1-6ffd-412b-8fef-fc19ef5231d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_14e9bd82-32a7-4efd-b5fd-d1b2b2612519" xlink:to="loc_us-gaap_StatementTable_26cd98f1-6ffd-412b-8fef-fc19ef5231d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_58acf216-9990-4c25-a989-c983b9140057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26cd98f1-6ffd-412b-8fef-fc19ef5231d8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_58acf216-9990-4c25-a989-c983b9140057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_58acf216-9990-4c25-a989-c983b9140057" xlink:to="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e4103dcf-3bbc-40e6-8b62-fb9c3fd0c485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_CommonStockMember_e4103dcf-3bbc-40e6-8b62-fb9c3fd0c485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a94a0e21-88f5-4df8-ba7c-203305b52f9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a94a0e21-88f5-4df8-ba7c-203305b52f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_46501c1f-8bc0-4351-9ad5-48bd19c2e2f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_RetainedEarningsMember_46501c1f-8bc0-4351-9ad5-48bd19c2e2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e123bd84-6def-4ebc-9141-b0cb6ce2b805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_205999fe-e7ba-41fb-a813-176d6a8300d4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e123bd84-6def-4ebc-9141-b0cb6ce2b805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8dd1849-5022-4a1b-bf24-0567c7ddf4c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_26cd98f1-6ffd-412b-8fef-fc19ef5231d8" xlink:to="loc_us-gaap_StatementLineItems_c8dd1849-5022-4a1b-bf24-0567c7ddf4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8dd1849-5022-4a1b-bf24-0567c7ddf4c7" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bcd57e76-3a82-4e73-91f1-fb7f0f866284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bcd57e76-3a82-4e73-91f1-fb7f0f866284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b91f773b-d89c-43e2-9a5a-5e5fae44085f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockholdersEquity_b91f773b-d89c-43e2-9a5a-5e5fae44085f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4f0c9650-ffcd-4473-9b15-98a7f84d1e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4f0c9650-ffcd-4473-9b15-98a7f84d1e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a5b09925-8155-44be-b54d-639b0448cb05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a5b09925-8155-44be-b54d-639b0448cb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6067b7b4-ba94-4f86-81d8-f161ed875e71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_6067b7b4-ba94-4f86-81d8-f161ed875e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_da17b32c-fb09-48d2-80e9-d0ce2946bbad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_da17b32c-fb09-48d2-80e9-d0ce2946bbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_317040ca-9984-4a10-96ab-4c4c7237a177" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_317040ca-9984-4a10-96ab-4c4c7237a177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_627a87f7-cec2-40a9-8c1a-6537a109bc70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_627a87f7-cec2-40a9-8c1a-6537a109bc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7b0c215-823e-460d-a978-c6da86d79cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c7b0c215-823e-460d-a978-c6da86d79cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72c5a01c-210b-40d7-88a7-48e759b62e04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_72c5a01c-210b-40d7-88a7-48e759b62e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_703b6cde-a23a-40b3-8cc6-c4bc7487c9ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_NetIncomeLoss_703b6cde-a23a-40b3-8cc6-c4bc7487c9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_16e8c9f6-4fab-4676-9048-c24d125cb694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_16e8c9f6-4fab-4676-9048-c24d125cb694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ac83154d-2288-4016-8fbb-5d4240752ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ac83154d-2288-4016-8fbb-5d4240752ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1aed2397-46b3-455b-8af9-c30bd819f500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_57f35f70-081e-401a-83fc-4a49049f800c" xlink:to="loc_us-gaap_StockholdersEquity_1aed2397-46b3-455b-8af9-c30bd819f500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b4bd3ebd-3f36-4846-9fa5-7e277047a2d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_62068877-476d-449f-82bb-f77e3f3d1f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b4bd3ebd-3f36-4846-9fa5-7e277047a2d7" xlink:to="loc_us-gaap_StatementTable_62068877-476d-449f-82bb-f77e3f3d1f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dc4c9456-8eab-4ba5-b63c-63b6ded700a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_62068877-476d-449f-82bb-f77e3f3d1f97" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dc4c9456-8eab-4ba5-b63c-63b6ded700a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3698b717-7e14-4bcc-8c7e-79cb0077b24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dc4c9456-8eab-4ba5-b63c-63b6ded700a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3698b717-7e14-4bcc-8c7e-79cb0077b24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PublicOfferingMember_75963937-0606-4d36-8d95-b2a2136ca173" xlink:href="allo-20210331.xsd#allo_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3698b717-7e14-4bcc-8c7e-79cb0077b24a" xlink:to="loc_allo_PublicOfferingMember_75963937-0606-4d36-8d95-b2a2136ca173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ed593d8-252a-4d76-b9ed-bf1ae9ee27a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_62068877-476d-449f-82bb-f77e3f3d1f97" xlink:to="loc_us-gaap_StatementLineItems_3ed593d8-252a-4d76-b9ed-bf1ae9ee27a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_479fc892-2918-4eea-a851-d087877acd70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ed593d8-252a-4d76-b9ed-bf1ae9ee27a7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_479fc892-2918-4eea-a851-d087877acd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="allo-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a9813e71-d2f8-4253-a068-8891c14ed946" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c332e066-41dd-41e8-bae1-bde7b39c2b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a9813e71-d2f8-4253-a068-8891c14ed946" xlink:to="loc_us-gaap_StatementTable_c332e066-41dd-41e8-bae1-bde7b39c2b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_16707766-ca82-497f-8329-54920182ca73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c332e066-41dd-41e8-bae1-bde7b39c2b8b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_16707766-ca82-497f-8329-54920182ca73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ac7534b-47cf-4d21-9f33-0a4cd6a5cc28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_16707766-ca82-497f-8329-54920182ca73" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ac7534b-47cf-4d21-9f33-0a4cd6a5cc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AtTheMarketOfferingMember_67f26bed-b63c-4d6d-b863-eeba36d3bfd9" xlink:href="allo-20210331.xsd#allo_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5ac7534b-47cf-4d21-9f33-0a4cd6a5cc28" xlink:to="loc_allo_AtTheMarketOfferingMember_67f26bed-b63c-4d6d-b863-eeba36d3bfd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c332e066-41dd-41e8-bae1-bde7b39c2b8b" xlink:to="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c00ded5e-2386-4beb-b003-e71b6f2e950c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_ProfitLoss_c00ded5e-2386-4beb-b003-e71b6f2e950c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_660e1c23-1d34-41aa-b6c8-8c68cccdfb6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_ShareBasedCompensation_660e1c23-1d34-41aa-b6c8-8c68cccdfb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3953d7d9-761d-4836-baa8-3d6b301e8c54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3953d7d9-761d-4836-baa8-3d6b301e8c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_a1a2f616-cfaa-4e2e-9313-c5e79f79e331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_Depreciation_a1a2f616-cfaa-4e2e-9313-c5e79f79e331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d165e9ee-bd40-4679-888f-f6e17a6823f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_d165e9ee-bd40-4679-888f-f6e17a6823f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_63fa8f56-d4ec-48b0-911b-c4f09bd6a876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_us-gaap_OperatingLeaseExpense_63fa8f56-d4ec-48b0-911b-c4f09bd6a876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_IncomeLossFromCostMethodInvestment_573df315-fd68-4400-903f-ef82c540a764" xlink:href="allo-20210331.xsd#allo_IncomeLossFromCostMethodInvestment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_494f4642-89c3-4603-9dba-b97e49261b39" xlink:to="loc_allo_IncomeLossFromCostMethodInvestment_573df315-fd68-4400-903f-ef82c540a764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ddda67ae-8d31-4e7f-96ac-ff84906ea075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ddda67ae-8d31-4e7f-96ac-ff84906ea075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ab3b097b-74ad-4271-b8b9-495a44be8888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_ab3b097b-74ad-4271-b8b9-495a44be8888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f18d776-327d-4d7b-a72d-fb173cf662e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f18d776-327d-4d7b-a72d-fb173cf662e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d4d0c06d-34d7-40d2-a0e9-1c53ee4382f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_d4d0c06d-34d7-40d2-a0e9-1c53ee4382f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_96553124-963d-4c24-8573-b2dd7fdbe188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_96553124-963d-4c24-8573-b2dd7fdbe188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cdf3c3ba-c598-4f32-bda6-a7eba556504a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2744837c-2a33-4183-b1fb-62de23a928ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cdf3c3ba-c598-4f32-bda6-a7eba556504a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_83057f45-82f9-498c-8348-a913f4631ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_28349ac0-dd10-41c0-8d5a-45f274889503" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_83057f45-82f9-498c-8348-a913f4631ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4bd50efa-f173-4569-9d87-e8b0a0e32628" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4bd50efa-f173-4569-9d87-e8b0a0e32628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3f263091-de42-4d2e-8be7-c07f866f204c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3f263091-de42-4d2e-8be7-c07f866f204c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6788e5f6-28cc-427a-8f2f-4f402d58b88b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_6788e5f6-28cc-427a-8f2f-4f402d58b88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_628593db-01b9-4741-adea-2ba22d6fa798" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_628593db-01b9-4741-adea-2ba22d6fa798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b3dc4423-6ade-4197-8376-08c5889ebb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b0c546db-cfea-4220-a4f9-bb9244b7e399" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b3dc4423-6ade-4197-8376-08c5889ebb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51ac13a6-4789-438e-b402-341c5260f8af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_51ac13a6-4789-438e-b402-341c5260f8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dd433d80-d359-48fd-9909-6a720dc1d34f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_dd433d80-d359-48fd-9909-6a720dc1d34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_97ad82d9-331e-4430-aba2-4c35fc15a29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_ProceedsFromStockPlans_97ad82d9-331e-4430-aba2-4c35fc15a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35fdd5b1-3868-4a20-9601-2caeccf2df15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_4df57851-c29b-4ba5-afaa-0d92cb3bc400" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35fdd5b1-3868-4a20-9601-2caeccf2df15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_016cff8b-577c-4e1d-acab-b8dd8f511ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_016cff8b-577c-4e1d-acab-b8dd8f511ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e66fc2b-c008-4816-87d9-86dfa97b2e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7e66fc2b-c008-4816-87d9-86dfa97b2e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbbae4a7-8d30-43a1-a783-c4aa7e57bee6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbbae4a7-8d30-43a1-a783-c4aa7e57bee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_931bade3-ae3e-4436-84bd-e5506d823422" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_931bade3-ae3e-4436-84bd-e5506d823422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CapitalizedSoftwareCostsIncurredNotYetPaid_a1f15d5d-9b33-4d7f-85c3-f23c00029c50" xlink:href="allo-20210331.xsd#allo_CapitalizedSoftwareCostsIncurredNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_43ab52b1-653e-4ddb-87cb-d05b9361e9e0" xlink:to="loc_allo_CapitalizedSoftwareCostsIncurredNotYetPaid_a1f15d5d-9b33-4d7f-85c3-f23c00029c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab411c62-afef-4810-9c98-58b9f599998c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_481c9a48-f279-4c0f-8019-a2b2cf48eae3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:to="loc_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements_481c9a48-f279-4c0f-8019-a2b2cf48eae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_3b6ec3c2-b4c6-40f8-bd5c-16c0dd1691c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6a49836a-adb0-4f77-a1f6-901a8705f9fa" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_3b6ec3c2-b4c6-40f8-bd5c-16c0dd1691c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="allo-20210331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95d4be54-4c7d-455b-b382-eb8fecd6b0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_54947bce-749e-49b5-86be-276b80bd6438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95d4be54-4c7d-455b-b382-eb8fecd6b0d6" xlink:to="loc_us-gaap_NatureOfOperations_54947bce-749e-49b5-86be-276b80bd6438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b05439e1-8168-4df1-840e-fe240b1ce386" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_83a7337d-4f1b-42c2-9a79-0fd3ee574e92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b05439e1-8168-4df1-840e-fe240b1ce386" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_83a7337d-4f1b-42c2-9a79-0fd3ee574e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8cb5e764-7901-4227-85e0-29f827a438e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b05439e1-8168-4df1-840e-fe240b1ce386" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8cb5e764-7901-4227-85e0-29f827a438e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="allo-20210331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_076f6ac1-4843-4737-a40e-1414c8e48481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a9e9097a-5864-4d79-8da7-e2241dd55d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_076f6ac1-4843-4737-a40e-1414c8e48481" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a9e9097a-5864-4d79-8da7-e2241dd55d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="allo-20210331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f6db94a6-885f-4f7a-bcab-5869fcb7b903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_33739f13-4104-45bf-a5de-d7936718109b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6db94a6-885f-4f7a-bcab-5869fcb7b903" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_33739f13-4104-45bf-a5de-d7936718109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_bce555f2-9c80-49e5-b60b-840250e90dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6db94a6-885f-4f7a-bcab-5869fcb7b903" xlink:to="loc_us-gaap_UseOfEstimates_bce555f2-9c80-49e5-b60b-840250e90dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_8b26d672-a18f-416a-8762-f5c715f6b4c0" xlink:href="allo-20210331.xsd#allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6db94a6-885f-4f7a-bcab-5869fcb7b903" xlink:to="loc_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock_8b26d672-a18f-416a-8762-f5c715f6b4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ce06d0e9-5d6d-49b8-a7d1-bd57debc3cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6db94a6-885f-4f7a-bcab-5869fcb7b903" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_ce06d0e9-5d6d-49b8-a7d1-bd57debc3cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_248cb4ab-0d52-4ac7-b012-f1f614607e94" xlink:href="allo-20210331.xsd#allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6db94a6-885f-4f7a-bcab-5869fcb7b903" xlink:to="loc_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock_248cb4ab-0d52-4ac7-b012-f1f614607e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_864fb2f9-26bd-4a79-b66f-021a48bb3b8e" xlink:href="allo-20210331.xsd#allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f6db94a6-885f-4f7a-bcab-5869fcb7b903" xlink:to="loc_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock_864fb2f9-26bd-4a79-b66f-021a48bb3b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2ed95a55-f395-4f58-b1cd-e88f5d7c3d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_51f4e3a6-3203-4c57-b54c-8e5bfa5d1dfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2ed95a55-f395-4f58-b1cd-e88f5d7c3d1e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_51f4e3a6-3203-4c57-b54c-8e5bfa5d1dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ed58c890-b23d-4f68-a15a-e0ce2a8cde48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_234d0270-3235-48a6-8c64-37ac6b5348f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ed58c890-b23d-4f68-a15a-e0ce2a8cde48" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_234d0270-3235-48a6-8c64-37ac6b5348f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b2e573b7-c22f-4a61-bfa5-af29afea79db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b2e573b7-c22f-4a61-bfa5-af29afea79db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a39d659a-ba6d-4ef7-925c-1d700b0827f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a39d659a-ba6d-4ef7-925c-1d700b0827f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb724b00-9432-440c-a5c7-a914fce4515b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a39d659a-ba6d-4ef7-925c-1d700b0827f6" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb724b00-9432-440c-a5c7-a914fce4515b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_5c6c70d9-2ace-49da-8654-02cc867a1e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bb724b00-9432-440c-a5c7-a914fce4515b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_5c6c70d9-2ace-49da-8654-02cc867a1e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_982450ff-7447-496b-9ca7-e669920f46e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_982450ff-7447-496b-9ca7-e669920f46e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7108536-aa90-46bb-b4e6-b909220e9450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_982450ff-7447-496b-9ca7-e669920f46e9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7108536-aa90-46bb-b4e6-b909220e9450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_17b21882-0d8c-4bf4-8864-f22d40feccd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d7108536-aa90-46bb-b4e6-b909220e9450" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_17b21882-0d8c-4bf4-8864-f22d40feccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85c78746-558f-4147-b85d-ece948cd3ec4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_799d8a5e-a763-40f9-bc5a-eb56e2d4f28e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_799d8a5e-a763-40f9-bc5a-eb56e2d4f28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_a52d3582-7594-4eb5-bd64-67ce01b2e634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d4cbfc35-c8ec-4951-88e9-b1b5fc964400" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_a52d3582-7594-4eb5-bd64-67ce01b2e634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="simple" xlink:href="allo-20210331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_11fd48b1-25f6-4671-a929-d1f5351672a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_11fd48b1-25f6-4671-a929-d1f5351672a9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a2cb88e7-ac67-4d15-84ed-56526e5b25bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a2cb88e7-ac67-4d15-84ed-56526e5b25bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_785684ba-8e29-4131-8733-dbc4f8f1b90b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a2cb88e7-ac67-4d15-84ed-56526e5b25bc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_785684ba-8e29-4131-8733-dbc4f8f1b90b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6b9f35a2-cf82-4936-bd31-67814b5040dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_785684ba-8e29-4131-8733-dbc4f8f1b90b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6b9f35a2-cf82-4936-bd31-67814b5040dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_721cc81e-4779-4e0c-887d-d16b71ffcd89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_721cc81e-4779-4e0c-887d-d16b71ffcd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_721cc81e-4779-4e0c-887d-d16b71ffcd89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d02eb711-94cb-4de0-a7e3-69667f32844c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d02eb711-94cb-4de0-a7e3-69667f32844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6c3fc8c7-bb7c-43ca-9966-35111746d595" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6c3fc8c7-bb7c-43ca-9966-35111746d595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ef8e9b17-fb65-44c5-ba54-1580615009e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ffb94b29-3d80-4b00-b9a4-554cdc986aee" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ef8e9b17-fb65-44c5-ba54-1580615009e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_2452a9b8-d705-431d-8d86-80b9eefc1bed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_2452a9b8-d705-431d-8d86-80b9eefc1bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_2452a9b8-d705-431d-8d86-80b9eefc1bed" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_d251a136-fded-4c41-b83c-404e10eeae36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_d251a136-fded-4c41-b83c-404e10eeae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_04c72e35-657f-4785-93ed-12ec1fe5ffdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_CommercialPaperMember_04c72e35-657f-4785-93ed-12ec1fe5ffdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_8e8207aa-d048-4940-8656-0e0f33dc6bf3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_8e8207aa-d048-4940-8656-0e0f33dc6bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_87121086-8bfc-4ecd-8ee5-e83375e999ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_87121086-8bfc-4ecd-8ee5-e83375e999ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_42b1a7ba-6176-4574-99f8-24ea3a8586da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_11451c01-76c9-415c-8c07-418c80bdef4d" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_42b1a7ba-6176-4574-99f8-24ea3a8586da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae572329-236d-4660-8d74-636825355475" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7df1305-beb5-4da6-8e91-500996b97e08" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae572329-236d-4660-8d74-636825355475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_920355c2-b1ee-470f-b6d9-26599464ff71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ae572329-236d-4660-8d74-636825355475" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_920355c2-b1ee-470f-b6d9-26599464ff71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstruments" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cf018275-53c8-4776-8bef-c6dcd9111afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ca3dde20-25bf-495f-97e3-b1f8b2f0cfe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_cf018275-53c8-4776-8bef-c6dcd9111afa" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_ca3dde20-25bf-495f-97e3-b1f8b2f0cfe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_193e5633-21bb-4fce-8450-65951bcf5dd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d5a5fa4d-a838-49cf-bed1-85be742e0b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_193e5633-21bb-4fce-8450-65951bcf5dd9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_d5a5fa4d-a838-49cf-bed1-85be742e0b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_06ec806a-b89f-4b91-8aad-eba1a9af5551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_de2565e5-86e9-4a6a-9fbf-ab7a9b510993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_06ec806a-b89f-4b91-8aad-eba1a9af5551" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_de2565e5-86e9-4a6a-9fbf-ab7a9b510993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_ab03da9f-5205-46eb-8a98-e316c400607a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_de2565e5-86e9-4a6a-9fbf-ab7a9b510993" xlink:to="loc_us-gaap_InvestmentTypeAxis_ab03da9f-5205-46eb-8a98-e316c400607a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_ab03da9f-5205-46eb-8a98-e316c400607a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_c4a13aed-0a67-4738-bb4e-5d9c566daa60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_MoneyMarketFundsMember_c4a13aed-0a67-4738-bb4e-5d9c566daa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_065492eb-6920-43d9-9a0a-30ea9ca02e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_CommercialPaperMember_065492eb-6920-43d9-9a0a-30ea9ca02e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_6391e269-179c-4599-84b0-0dc226b50dba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_6391e269-179c-4599-84b0-0dc226b50dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_db714e09-f4b3-48d3-bdef-f61686a9a183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_db714e09-f4b3-48d3-bdef-f61686a9a183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_317b771f-07c9-4cf7-ba23-2ef5163ed990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d4c17d8-fb65-4e38-9ed8-a4924f274225" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_317b771f-07c9-4cf7-ba23-2ef5163ed990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_de2565e5-86e9-4a6a-9fbf-ab7a9b510993" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5d29abe-d8fe-4411-8afd-4b5c1b577c4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e5d29abe-d8fe-4411-8afd-4b5c1b577c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d6f32951-ac7c-475a-b5bf-a9861fb5d3bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d6f32951-ac7c-475a-b5bf-a9861fb5d3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_858dadf9-60fd-4917-b785-9e2d7d29e706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_858dadf9-60fd-4917-b785-9e2d7d29e706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55457637-379b-4e0a-b915-18b034a56859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_55457637-379b-4e0a-b915-18b034a56859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_0fa44c8d-2a51-421c-98ab-1036aee3dfc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_0fa44c8d-2a51-421c-98ab-1036aee3dfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_27bc62ad-08fe-47ab-b6e5-c633e39baa24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_27bc62ad-08fe-47ab-b6e5-c633e39baa24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8a82668f-2c63-468f-98ab-e6b352423de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_8a82668f-2c63-468f-98ab-e6b352423de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CashEquivalentsAndShortTermInvestments_c483611b-200e-434f-953b-8bde6f9796f4" xlink:href="allo-20210331.xsd#allo_CashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4c1d9b66-80f8-461a-8b8f-b86641185f61" xlink:to="loc_allo_CashEquivalentsAndShortTermInvestments_c483611b-200e-434f-953b-8bde6f9796f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#FinancialInstrumentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_c3f912c3-4b17-47d4-b4d7-bdcc3d46a565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_48b1fb78-0f4e-457e-8789-9aff5ba66689" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_c3f912c3-4b17-47d4-b4d7-bdcc3d46a565" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_48b1fb78-0f4e-457e-8789-9aff5ba66689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_398c5924-05db-4f7c-9e13-9a2157e0900e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_c3f912c3-4b17-47d4-b4d7-bdcc3d46a565" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_398c5924-05db-4f7c-9e13-9a2157e0900e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df5c042a-ba34-48f9-9aa6-38ef7a9e7771" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_03eb0644-2e7d-4281-b6d9-8d1aa8e55687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_df5c042a-ba34-48f9-9aa6-38ef7a9e7771" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_03eb0644-2e7d-4281-b6d9-8d1aa8e55687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c080a4d3-ab45-4a1c-b40a-960c591b9937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bfb7e98e-1617-4d92-9501-1f9f94823700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c080a4d3-ab45-4a1c-b40a-960c591b9937" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_bfb7e98e-1617-4d92-9501-1f9f94823700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#BalanceSheetComponentsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/BalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92ab551d-198f-4ae3-9ced-4c44946ec8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3badc6dc-85f4-457a-b9b8-24bfe58d41e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92ab551d-198f-4ae3-9ced-4c44946ec8b9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3badc6dc-85f4-457a-b9b8-24bfe58d41e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4776690c-03f6-44d0-85be-ced542f59a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3badc6dc-85f4-457a-b9b8-24bfe58d41e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4776690c-03f6-44d0-85be-ced542f59a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4776690c-03f6-44d0-85be-ced542f59a84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_d0c73dc0-9bc0-473c-9e30-3a97d24b98f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_us-gaap_ConstructionInProgressMember_d0c73dc0-9bc0-473c-9e30-3a97d24b98f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_3a9cff22-5887-4330-a371-8c5023daf5e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_3a9cff22-5887-4330-a371-8c5023daf5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LaboratoryEquipmentMember_9d0707eb-1578-4f55-84b4-f00266e22ff0" xlink:href="allo-20210331.xsd#allo_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_allo_LaboratoryEquipmentMember_9d0707eb-1578-4f55-84b4-f00266e22ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_8c70bea4-f30d-492d-b12d-e0c75404cb81" xlink:href="allo-20210331.xsd#allo_ComputerEquipmentAndPurchasedSoftwareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_allo_ComputerEquipmentAndPurchasedSoftwareMember_8c70bea4-f30d-492d-b12d-e0c75404cb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_e88f34b7-4878-49be-8683-be2772789563" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_15b94312-f41c-4841-b138-8480ef187d4d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_e88f34b7-4878-49be-8683-be2772789563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3badc6dc-85f4-457a-b9b8-24bfe58d41e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1d1a78ec-af17-4793-b0d4-85e1039df6c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1d1a78ec-af17-4793-b0d4-85e1039df6c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b145819a-7880-43b9-a632-3958b55a5c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b145819a-7880-43b9-a632-3958b55a5c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5cef12a0-1a78-4aeb-9754-f0df2e8d9ac8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4880f6b-1712-4d3a-8b8c-256626fcbb7f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5cef12a0-1a78-4aeb-9754-f0df2e8d9ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreements" xlink:type="simple" xlink:href="allo-20210331.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_454a42b6-cbd8-4092-9f16-413e86da6299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAgreementsTextBlock_e2c89070-2eec-4983-b7de-de3a25dcbf53" xlink:href="allo-20210331.xsd#allo_LicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_454a42b6-cbd8-4092-9f16-413e86da6299" xlink:to="loc_allo_LicenseAgreementsTextBlock_e2c89070-2eec-4983-b7de-de3a25dcbf53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_410c0feb-aa2a-4f88-8c34-007e8a954dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_410c0feb-aa2a-4f88-8c34-007e8a954dc7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6af6bd3-9975-4932-ba63-1493b6791093" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6af6bd3-9975-4932-ba63-1493b6791093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d6af6bd3-9975-4932-ba63-1493b6791093" xlink:to="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PfizerIncMember_5aa099c2-de1e-4e5f-bb8e-422bcecf2c25" xlink:href="allo-20210331.xsd#allo_PfizerIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_PfizerIncMember_5aa099c2-de1e-4e5f-bb8e-422bcecf2c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CellectisSAMember_c590e001-cf4e-46e1-84a4-c266d2a48a24" xlink:href="allo-20210331.xsd#allo_CellectisSAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_CellectisSAMember_c590e001-cf4e-46e1-84a4-c266d2a48a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ServierMember_1ad4c86c-9254-4417-8701-2336e5f12df9" xlink:href="allo-20210331.xsd#allo_ServierMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_ServierMember_1ad4c86c-9254-4417-8701-2336e5f12df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_b99f45bc-0dba-40c0-87fe-75b363b787d9" xlink:href="allo-20210331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_15726bfc-d2af-4813-9e4a-064f84da396a" xlink:to="loc_allo_NotchTherapeuticsIncMember_b99f45bc-0dba-40c0-87fe-75b363b787d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeAxis_9f2e1333-868f-44e0-b405-486b7784413c" xlink:href="allo-20210331.xsd#allo_MilestoneTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_allo_MilestoneTypeAxis_9f2e1333-868f-44e0-b405-486b7784413c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestoneTypeDomain_f91ae83d-6945-4e34-a498-666534f038eb" xlink:href="allo-20210331.xsd#allo_MilestoneTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeAxis_9f2e1333-868f-44e0-b405-486b7784413c" xlink:to="loc_allo_MilestoneTypeDomain_f91ae83d-6945-4e34-a498-666534f038eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_DevelopmentAndSalesMember_41a2e0f7-da74-4655-893c-a30add606ef0" xlink:href="allo-20210331.xsd#allo_DevelopmentAndSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_MilestoneTypeDomain_f91ae83d-6945-4e34-a498-666534f038eb" xlink:to="loc_allo_DevelopmentAndSalesMember_41a2e0f7-da74-4655-893c-a30add606ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1214c4c8-8da8-4897-b3aa-3db750ca4362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1214c4c8-8da8-4897-b3aa-3db750ca4362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1214c4c8-8da8-4897-b3aa-3db750ca4362" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AssetContributionAgreementMember_8b51aa12-3d2f-4450-8632-4f2312955c1c" xlink:href="allo-20210331.xsd#allo_AssetContributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_AssetContributionAgreementMember_8b51aa12-3d2f-4450-8632-4f2312955c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RegulatoryMilestoneMember_50763141-3169-4d77-8db8-ec2d7c064478" xlink:href="allo-20210331.xsd#allo_RegulatoryMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_RegulatoryMilestoneMember_50763141-3169-4d77-8db8-ec2d7c064478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SalesMilestoneMember_79ed0a2f-8ea1-4b88-a384-343c75a41c1b" xlink:href="allo-20210331.xsd#allo_SalesMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_SalesMilestoneMember_79ed0a2f-8ea1-4b88-a384-343c75a41c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PreClinicalDevelopmentMilestoneMember_368b000e-f9b6-4cc8-9681-b8b65c4649a5" xlink:href="allo-20210331.xsd#allo_PreClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_PreClinicalDevelopmentMilestoneMember_368b000e-f9b6-4cc8-9681-b8b65c4649a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_e1f4f0e0-5e79-4bde-b3da-cd5490edee10" xlink:href="allo-20210331.xsd#allo_ClinicalRegulatoryAndCommercialMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_9881add5-7b81-41e5-a7c6-f2d58372dced" xlink:to="loc_allo_ClinicalRegulatoryAndCommercialMilestoneMember_e1f4f0e0-5e79-4bde-b3da-cd5490edee10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0ec1d97-a1bc-44d8-a697-1b5535ff7053" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_srt_RangeAxis_a0ec1d97-a1bc-44d8-a697-1b5535ff7053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a0ec1d97-a1bc-44d8-a697-1b5535ff7053" xlink:to="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_df994e21-ccef-4de3-b8dc-f4092d43230e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:to="loc_srt_MinimumMember_df994e21-ccef-4de3-b8dc-f4092d43230e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_264d1999-bb07-482e-8797-c1242b04bbb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e1fe541-44d7-4d39-bf93-319f66d3af0a" xlink:to="loc_srt_MaximumMember_264d1999-bb07-482e-8797-c1242b04bbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b7fc3f1c-af86-40f2-bedd-17e3211aac42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b7fc3f1c-af86-40f2-bedd-17e3211aac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b7fc3f1c-af86-40f2-bedd-17e3211aac42" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ResearchCollaborationAndLicenseAgreementMember_48dba038-8304-497f-bb69-0f84fa66667f" xlink:href="allo-20210331.xsd#allo_ResearchCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:to="loc_allo_ResearchCollaborationAndLicenseAgreementMember_48dba038-8304-497f-bb69-0f84fa66667f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LicenseAndCollaborationAgreementMember_d8fa55f9-f998-4e75-9514-8227ccc3fe3f" xlink:href="allo-20210331.xsd#allo_LicenseAndCollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:to="loc_allo_LicenseAndCollaborationAgreementMember_d8fa55f9-f998-4e75-9514-8227ccc3fe3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_a193943e-57c4-4c45-9c78-6eaf9a21f4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35406ff0-b951-4252-9408-6f44788b15ba" xlink:to="loc_us-gaap_CorporateJointVentureMember_a193943e-57c4-4c45-9c78-6eaf9a21f4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_57d946b9-77fb-4251-b2c4-99e9e2827ef3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_57d946b9-77fb-4251-b2c4-99e9e2827ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_57d946b9-77fb-4251-b2c4-99e9e2827ef3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_7434236f-428a-48f4-9caa-af3d8045ed97" xlink:href="allo-20210331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:to="loc_allo_NotchTherapeuticsIncMember_7434236f-428a-48f4-9caa-af3d8045ed97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_00cb4181-ae0e-4158-af5a-f7cc90b6a110" xlink:href="allo-20210331.xsd#allo_AllogeneOverlandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e24da4e6-5c10-4784-88fd-f5e2180475c4" xlink:to="loc_allo_AllogeneOverlandMember_00cb4181-ae0e-4158-af5a-f7cc90b6a110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_018c70f3-9074-488d-a3f1-de95b21d6abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_018c70f3-9074-488d-a3f1-de95b21d6abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b3cb9d07-81d3-45bf-a3d6-d93c17dfdfc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_018c70f3-9074-488d-a3f1-de95b21d6abb" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b3cb9d07-81d3-45bf-a3d6-d93c17dfdfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea2c606e-689f-4f48-bc71-3ceef71a8c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b3cb9d07-81d3-45bf-a3d6-d93c17dfdfc9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ea2c606e-689f-4f48-bc71-3ceef71a8c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_srt_CounterpartyNameAxis_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6a392acd-f6e4-431f-89f3-8dcdf03dd5d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5dd11f58-4a22-47c2-8691-316205ee65ba" xlink:href="allo-20210331.xsd#allo_UniversityOfTexasMDAndersonCancerCenterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:to="loc_allo_UniversityOfTexasMDAndersonCancerCenterMember_5dd11f58-4a22-47c2-8691-316205ee65ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_db34fc03-90c5-44c2-9608-232bb8e50da8" xlink:href="allo-20210331.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_84301459-db64-44c1-b129-fa45ac0dce5d" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_db34fc03-90c5-44c2-9608-232bb8e50da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_014623fa-c687-4813-b902-0f6ba5b94690" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_dei_LegalEntityAxis_014623fa-c687-4813-b902-0f6ba5b94690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_83a93301-9a83-47d6-9340-1de6b59bc19e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_014623fa-c687-4813-b902-0f6ba5b94690" xlink:to="loc_dei_EntityDomain_83a93301-9a83-47d6-9340-1de6b59bc19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OverlandPharmaceuticalsIncMember_cb624de9-a7d3-4c3e-84ed-833fb3c05ad8" xlink:href="allo-20210331.xsd#allo_OverlandPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_83a93301-9a83-47d6-9340-1de6b59bc19e" xlink:to="loc_allo_OverlandPharmaceuticalsIncMember_cb624de9-a7d3-4c3e-84ed-833fb3c05ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_ec618e43-6eaa-4a62-86b7-75e5a793421f" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_allo_EquityInvestmentBasisAxis_ec618e43-6eaa-4a62-86b7-75e5a793421f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_9dfcd326-32da-4143-8a05-90f01d327838" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisAxis_ec618e43-6eaa-4a62-86b7-75e5a793421f" xlink:to="loc_allo_EquityInvestmentBasisDomain_9dfcd326-32da-4143-8a05-90f01d327838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_00299f67-691b-4b5c-b374-51c5bc3943d3" xlink:href="allo-20210331.xsd#allo_VotingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisDomain_9dfcd326-32da-4143-8a05-90f01d327838" xlink:to="loc_allo_VotingInterestMember_00299f67-691b-4b5c-b374-51c5bc3943d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0f5d7af7-37ad-410e-bbe1-0ae6ad0f18dc" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_2dcdf222-5eff-43af-b6f1-822aee24b127" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialMilestonePayments_2dcdf222-5eff-43af-b6f1-822aee24b127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_9b1595b2-f598-473c-8d30-368234d81fb7" xlink:href="allo-20210331.xsd#allo_AggregatePotentialRegulatoryAndDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones_9b1595b2-f598-473c-8d30-368234d81fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MilestonePayments_e9990fd9-a26c-4bd2-9f39-ae612bf82dbb" xlink:href="allo-20210331.xsd#allo_MilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_MilestonePayments_e9990fd9-a26c-4bd2-9f39-ae612bf82dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_8dcd6dfa-ce44-49af-a5c1-8a62a5cc3632" xlink:href="allo-20210331.xsd#allo_RoyaltyObligationPeriodFromDateOfFirstSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_RoyaltyObligationPeriodFromDateOfFirstSale_8dcd6dfa-ce44-49af-a5c1-8a62a5cc3632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_504557fc-2eff-43e4-a937-db990b0a88f4" xlink:href="allo-20210331.xsd#allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget_504557fc-2eff-43e4-a937-db990b0a88f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7402e9c1-772c-4162-bb9b-e969c7dd207c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7402e9c1-772c-4162-bb9b-e969c7dd207c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_7af660ae-3b93-40fa-9550-58b5910635b8" xlink:href="allo-20210331.xsd#allo_PercentageOfDevelopmentCostPayableByTheCompany"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByTheCompany_7af660ae-3b93-40fa-9550-58b5910635b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_786cbf34-f071-47d3-9ffc-f7cc521cd324" xlink:href="allo-20210331.xsd#allo_PercentageOfDevelopmentCostPayableByCollaborationPartner"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner_786cbf34-f071-47d3-9ffc-f7cc521cd324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayments_82eb7901-9a8a-4784-b9ff-2d96fe8762fb" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestoneReceivable_8e6f48e0-dba1-4ffd-a741-21ddf367795f" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestoneReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialMilestoneReceivable_8e6f48e0-dba1-4ffd-a741-21ddf367795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc93d439-b7a5-4ec8-936d-029f4ee38d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cc93d439-b7a5-4ec8-936d-029f4ee38d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_68438af7-a627-436e-9669-7d040d10dd93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_DueFromRelatedParties_68438af7-a627-436e-9669-7d040d10dd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementUpfrontPayment_d8f4dd3c-bd1a-446f-adc7-60822cbdcb32" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementUpfrontPayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationAgreementUpfrontPayment_d8f4dd3c-bd1a-446f-adc7-60822cbdcb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_cd2b9db6-4352-43ba-9338-fcc93f9c6b90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_cd2b9db6-4352-43ba-9338-fcc93f9c6b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0b9167ae-d8ea-410f-9741-79b656de6d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_0b9167ae-d8ea-410f-9741-79b656de6d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_776f95fd-dbed-4860-a25c-87f5a7af8e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_776f95fd-dbed-4860-a25c-87f5a7af8e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AggregatePotentialMilestonePayable_330b5034-4f28-4b48-9e0e-f106bd7c6939" xlink:href="allo-20210331.xsd#allo_AggregatePotentialMilestonePayable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_AggregatePotentialMilestonePayable_330b5034-4f28-4b48-9e0e-f106bd7c6939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationArrangementExpense_39b1f098-c6d9-433f-94bd-1171c2be74bd" xlink:href="allo-20210331.xsd#allo_CollaborationArrangementExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationArrangementExpense_39b1f098-c6d9-433f-94bd-1171c2be74bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementTerm_7aa1f508-8b2c-4aaf-9239-85a08ae591ed" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementTerm"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationAgreementTerm_7aa1f508-8b2c-4aaf-9239-85a08ae591ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CollaborationAgreementCommittedFunding_8a09d8d1-b318-4a4e-b4b5-6f4415d21670" xlink:href="allo-20210331.xsd#allo_CollaborationAgreementCommittedFunding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_CollaborationAgreementCommittedFunding_8a09d8d1-b318-4a4e-b4b5-6f4415d21670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_UpfrontAndQuarterlyCashPayments_351a1d2a-774d-41fd-a32a-0cc94b80e18d" xlink:href="allo-20210331.xsd#allo_UpfrontAndQuarterlyCashPayments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_UpfrontAndQuarterlyCashPayments_351a1d2a-774d-41fd-a32a-0cc94b80e18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_JointVentureCapitalSupportPayments_3e0ff9fe-744c-4a55-8c89-b539940417a3" xlink:href="allo-20210331.xsd#allo_JointVentureCapitalSupportPayments"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_allo_JointVentureCapitalSupportPayments_3e0ff9fe-744c-4a55-8c89-b539940417a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f43d4a0-2de1-4f9c-913d-31f43e5d5100" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e1c5ba7a-54e0-45c2-bbb0-c9048a9bbd45" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f43d4a0-2de1-4f9c-913d-31f43e5d5100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2dd4d232-f3f5-42bf-b6ec-678a0dac8f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9efdaf22-67d2-4e48-89fb-c6d37c4e7f43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2dd4d232-f3f5-42bf-b6ec-678a0dac8f0e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9efdaf22-67d2-4e48-89fb-c6d37c4e7f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1893b36b-1be4-410b-a8c4-a010f46015eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LiabilitiesLesseeTableTextBlock_71a7b1fe-ae5f-4260-b076-1e86e86da916" xlink:href="allo-20210331.xsd#allo_LiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1893b36b-1be4-410b-a8c4-a010f46015eb" xlink:to="loc_allo_LiabilitiesLesseeTableTextBlock_71a7b1fe-ae5f-4260-b076-1e86e86da916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_97d08066-9ffc-4e67-8301-f4e33cf3c773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1893b36b-1be4-410b-a8c4-a010f46015eb" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_97d08066-9ffc-4e67-8301-f4e33cf3c773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_58a31ade-2b72-4425-a2a1-f071407d23e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1893b36b-1be4-410b-a8c4-a010f46015eb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_58a31ade-2b72-4425-a2a1-f071407d23e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910360f8-f252-41cb-84d6-1203b011ca64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_910360f8-f252-41cb-84d6-1203b011ca64" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_17085a3f-c3b5-421f-9bc3-56513cfeb620" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:to="loc_srt_StatementGeographicalAxis_17085a3f-c3b5-421f-9bc3-56513cfeb620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eb2312b1-e1b7-4d60-abd4-98dfa1ffbaed" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_17085a3f-c3b5-421f-9bc3-56513cfeb620" xlink:to="loc_srt_SegmentGeographicalDomain_eb2312b1-e1b7-4d60-abd4-98dfa1ffbaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NewarkMember_5474e327-49bb-4bc2-9d14-0da4fc9dd483" xlink:href="allo-20210331.xsd#allo_NewarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_eb2312b1-e1b7-4d60-abd4-98dfa1ffbaed" xlink:to="loc_allo_NewarkMember_5474e327-49bb-4bc2-9d14-0da4fc9dd483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c908c58e-1807-46d8-8fed-85f5500447bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:to="loc_us-gaap_CreditFacilityAxis_c908c58e-1807-46d8-8fed-85f5500447bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_624eb3bd-2d8e-474b-96a7-dc0c11115e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c908c58e-1807-46d8-8fed-85f5500447bb" xlink:to="loc_us-gaap_CreditFacilityDomain_624eb3bd-2d8e-474b-96a7-dc0c11115e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_258e74c0-6016-4bf0-9987-830baf558966" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_624eb3bd-2d8e-474b-96a7-dc0c11115e54" xlink:to="loc_us-gaap_LetterOfCreditMember_258e74c0-6016-4bf0-9987-830baf558966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_0c77590d-3fa8-426d-96d9-c32206793ea5" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfNewOfficeBuilding_74a07988-c9a4-4e0b-b8e4-ad5b34868bbc" xlink:href="allo-20210331.xsd#allo_AreaOfNewOfficeBuilding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_AreaOfNewOfficeBuilding_74a07988-c9a4-4e0b-b8e4-ad5b34868bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_cec7efc8-5e79-4b08-8ccf-d3bcf6d3feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_cec7efc8-5e79-4b08-8ccf-d3bcf6d3feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c2d399c5-bde9-4237-ad3a-5b7e3eb2b26f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c2d399c5-bde9-4237-ad3a-5b7e3eb2b26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_4498f032-2204-45bd-b94a-3a281102d0ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_TenantImprovements_4498f032-2204-45bd-b94a-3a281102d0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowance_fdaede7e-f9ca-43b1-83d4-2931842a96eb" xlink:href="allo-20210331.xsd#allo_TenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_TenantImprovementAllowance_fdaede7e-f9ca-43b1-83d4-2931842a96eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOperatingLease_9ca3785f-1a79-4e0d-b089-2c06313fb6fe" xlink:href="allo-20210331.xsd#allo_AreaOfOperatingLease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_AreaOfOperatingLease_9ca3785f-1a79-4e0d-b089-2c06313fb6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfOptionsToExtendLease_7934fdca-bb16-46cc-8ab5-5fc6fbb948b2" xlink:href="allo-20210331.xsd#allo_NumberOfOptionsToExtendLease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_NumberOfOptionsToExtendLease_7934fdca-bb16-46cc-8ab5-5fc6fbb948b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowanceUtilizedToDate_3c11e541-9f60-4b75-99fe-0aca842fc406" xlink:href="allo-20210331.xsd#allo_TenantImprovementAllowanceUtilizedToDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_TenantImprovementAllowanceUtilizedToDate_3c11e541-9f60-4b75-99fe-0aca842fc406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_34d272dc-ad55-4bf0-80da-af0e10fa7555" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_34d272dc-ad55-4bf0-80da-af0e10fa7555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_49f7cbd2-eddb-4f4f-89b5-cb51ae9df87d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_OperatingLeasePayments_49f7cbd2-eddb-4f4f-89b5-cb51ae9df87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e035da91-b38b-4765-ae4e-fd5e91eb4692" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_e035da91-b38b-4765-ae4e-fd5e91eb4692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80598219-d517-4669-93c3-8b7bde20453d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_80598219-d517-4669-93c3-8b7bde20453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_928c0d96-7b8e-4f9c-abea-6b0f475fe629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_928c0d96-7b8e-4f9c-abea-6b0f475fe629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_ddac809c-48fd-497b-9388-98f6a1c4ff38" xlink:href="allo-20210331.xsd#allo_LesseeFinanceLeasePaymentUponContractTermination"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_allo_LesseeFinanceLeasePaymentUponContractTermination_ddac809c-48fd-497b-9388-98f6a1c4ff38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_004d51b0-46a2-40ea-b51d-a4de8d9e8fa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_cca7935f-9015-4e6d-9ec9-263f98921a1b" xlink:to="loc_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_004d51b0-46a2-40ea-b51d-a4de8d9e8fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76ef7001-b716-4bc3-a02e-b068b217b76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_37ba2ba1-6984-4b45-9abe-9f0e341df7d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76ef7001-b716-4bc3-a02e-b068b217b76f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_37ba2ba1-6984-4b45-9abe-9f0e341df7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d8ccc9f-ff57-4b49-b443-e562b367d826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76ef7001-b716-4bc3-a02e-b068b217b76f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0d8ccc9f-ff57-4b49-b443-e562b367d826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_46db01e1-bfbd-4a98-9240-19e8758d39d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76ef7001-b716-4bc3-a02e-b068b217b76f" xlink:to="loc_us-gaap_OperatingLeaseLiability_46db01e1-bfbd-4a98-9240-19e8758d39d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_15ae92eb-44f0-4151-ad3f-f39c0d119ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76ef7001-b716-4bc3-a02e-b068b217b76f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_15ae92eb-44f0-4151-ad3f-f39c0d119ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7de16d2-1b99-4e13-a105-9cc08a01dcc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0bd877e4-52f7-4b46-90a2-60689b54b039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7de16d2-1b99-4e13-a105-9cc08a01dcc2" xlink:to="loc_us-gaap_OperatingLeaseCost_0bd877e4-52f7-4b46-90a2-60689b54b039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_84f49a1d-8fb6-498d-a0bf-040be95fb6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7de16d2-1b99-4e13-a105-9cc08a01dcc2" xlink:to="loc_us-gaap_VariableLeaseCost_84f49a1d-8fb6-498d-a0bf-040be95fb6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3eb3c0ac-11c1-4a3e-8769-55d06faf0f44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7de16d2-1b99-4e13-a105-9cc08a01dcc2" xlink:to="loc_us-gaap_LeaseCost_3eb3c0ac-11c1-4a3e-8769-55d06faf0f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_219459f2-e1d8-41a6-84fe-1d6782e40a4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_219459f2-e1d8-41a6-84fe-1d6782e40a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bdbe893b-8019-49b0-b3f4-940722a8a0ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bdbe893b-8019-49b0-b3f4-940722a8a0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_664eb435-d1ab-4701-9115-f62bdc3d7f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_664eb435-d1ab-4701-9115-f62bdc3d7f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3cf78ee8-70bc-4f66-8524-8ec91c9c633c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3cf78ee8-70bc-4f66-8524-8ec91c9c633c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ea96134-a12d-4756-8962-32e76e1c7d8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0ea96134-a12d-4756-8962-32e76e1c7d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c91454e8-dd50-4576-8357-14702a5bef9d" xlink:href="allo-20210331.xsd#allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_c91454e8-dd50-4576-8357-14702a5bef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c2dfafd-e36a-4112-84bd-508e9bd86694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0c2dfafd-e36a-4112-84bd-508e9bd86694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_758881ba-f547-4d89-9e2c-8256824e33bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_758881ba-f547-4d89-9e2c-8256824e33bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TenantImprovementAllowance_8969570a-de32-4670-becd-48e984e85a38" xlink:href="allo-20210331.xsd#allo_TenantImprovementAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_allo_TenantImprovementAllowance_8969570a-de32-4670-becd-48e984e85a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_13e01d64-7dc3-4377-9d5b-88fabc734c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b7c9d496-070a-4494-9772-220911f3aa03" xlink:to="loc_us-gaap_OperatingLeaseLiability_13e01d64-7dc3-4377-9d5b-88fabc734c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestment" xlink:type="simple" xlink:href="allo-20210331.xsd#EquityMethodInvestment"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_80c98f75-66b1-4bcd-8c78-dd6bdf352ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_ebb2e1c2-9584-4792-943b-c82db216deeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_80c98f75-66b1-4bcd-8c78-dd6bdf352ed5" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_ebb2e1c2-9584-4792-943b-c82db216deeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#EquityMethodInvestmentDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/EquityMethodInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_2bf0b16c-30d6-4bed-96b0-c43f1c48501c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_2bf0b16c-30d6-4bed-96b0-c43f1c48501c" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7115884-6b98-4b19-b350-9e8a59800e56" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7115884-6b98-4b19-b350-9e8a59800e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a7115884-6b98-4b19-b350-9e8a59800e56" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NotchTherapeuticsIncMember_fd5a1c29-9ca7-41b0-ae6d-0b229892fd64" xlink:href="allo-20210331.xsd#allo_NotchTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:to="loc_allo_NotchTherapeuticsIncMember_fd5a1c29-9ca7-41b0-ae6d-0b229892fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AllogeneOverlandMember_5f24b940-d09e-4af0-9b82-7ceee382f134" xlink:href="allo-20210331.xsd#allo_AllogeneOverlandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8bc1b430-36b7-482a-967c-3515881b374b" xlink:to="loc_allo_AllogeneOverlandMember_5f24b940-d09e-4af0-9b82-7ceee382f134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisAxis_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:to="loc_allo_EquityInvestmentBasisAxis_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EquityInvestmentBasisDomain_b1ba84fb-1884-49f8-ad14-3c5929a059d2" xlink:href="allo-20210331.xsd#allo_EquityInvestmentBasisDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisAxis_2fdd4b5a-6250-494f-9fbc-c1cf02e1196f" xlink:to="loc_allo_EquityInvestmentBasisDomain_b1ba84fb-1884-49f8-ad14-3c5929a059d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_VotingInterestMember_b1ac76d6-aa65-487d-a349-2f1e015520dc" xlink:href="allo-20210331.xsd#allo_VotingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_EquityInvestmentBasisDomain_b1ba84fb-1884-49f8-ad14-3c5929a059d2" xlink:to="loc_allo_VotingInterestMember_b1ac76d6-aa65-487d-a349-2f1e015520dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_05701ecc-244c-4a40-b780-391b907ca83a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_d9d85536-ef2c-4ef6-808a-a3beeb4b8f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_d9d85536-ef2c-4ef6-808a-a3beeb4b8f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_CostMethodInvestmentTransactionCosts_66306d6e-bbb8-48db-ba5a-25674e0d3b8e" xlink:href="allo-20210331.xsd#allo_CostMethodInvestmentTransactionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_allo_CostMethodInvestmentTransactionCosts_66306d6e-bbb8-48db-ba5a-25674e0d3b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90e2cd9e-8019-4a96-8d8f-eb10a75c55a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_90e2cd9e-8019-4a96-8d8f-eb10a75c55a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f06457c1-1d0c-4c7e-850a-d8b946be77b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f06457c1-1d0c-4c7e-850a-d8b946be77b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491ceff7-ec05-4dce-a1e4-82b9a8fcaa95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_491ceff7-ec05-4dce-a1e4-82b9a8fcaa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bdbdaf16-04ae-4808-991c-2b87af85c574" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentQuotedMarketValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3a20e4e0-a25a-4f50-b96a-7d20819f85bb" xlink:to="loc_us-gaap_EquityMethodInvestmentQuotedMarketValue_bdbdaf16-04ae-4808-991c-2b87af85c574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c32c43d3-4448-4083-9fed-9780df67e1c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aea76eda-06c4-49f1-acc0-24f06b685786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c32c43d3-4448-4083-9fed-9780df67e1c1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_aea76eda-06c4-49f1-acc0-24f06b685786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a5347a2-69e9-4e7e-9b97-9d91949fe530" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_54b75c2e-00e2-4c4f-87cf-72f3e641fd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a5347a2-69e9-4e7e-9b97-9d91949fe530" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_54b75c2e-00e2-4c4f-87cf-72f3e641fd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_10026beb-a8d9-47f3-ad15-50bb217762f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a5347a2-69e9-4e7e-9b97-9d91949fe530" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_10026beb-a8d9-47f3-ad15-50bb217762f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_eaf7dd04-cd35-40a7-b11c-e24b9051282d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a5347a2-69e9-4e7e-9b97-9d91949fe530" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_eaf7dd04-cd35-40a7-b11c-e24b9051282d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7dcef15c-3809-49b8-a615-c516d35fdba1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a5347a2-69e9-4e7e-9b97-9d91949fe530" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7dcef15c-3809-49b8-a615-c516d35fdba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ad50703-c5a2-48c5-bb0b-4a218f7ae4a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8ad50703-c5a2-48c5-bb0b-4a218f7ae4a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f160f767-690c-49c2-8aa0-a8eb9a04815f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:to="loc_srt_RangeAxis_f160f767-690c-49c2-8aa0-a8eb9a04815f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8ff3ca20-da10-4319-b27e-1e4d1cc6e4fc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f160f767-690c-49c2-8aa0-a8eb9a04815f" xlink:to="loc_srt_RangeMember_8ff3ca20-da10-4319-b27e-1e4d1cc6e4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_40b78914-1ab4-4911-b11b-132b53cbecd5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8ff3ca20-da10-4319-b27e-1e4d1cc6e4fc" xlink:to="loc_srt_MaximumMember_40b78914-1ab4-4911-b11b-132b53cbecd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_504def74-190c-467d-98b0-bd7aaa5128bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:to="loc_us-gaap_AwardTypeAxis_504def74-190c-467d-98b0-bd7aaa5128bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_504def74-190c-467d-98b0-bd7aaa5128bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_b2cf2b5e-12ef-4c23-948f-16db90447507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:to="loc_us-gaap_StockOptionMember_b2cf2b5e-12ef-4c23-948f-16db90447507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_31867914-06b5-4443-be35-d79c502d724b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_31867914-06b5-4443-be35-d79c502d724b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2cf43dc9-1354-4740-bf8e-ffdaa4b6ec28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6b0686e2-d6be-42fc-91a4-e86077bb2d0f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2cf43dc9-1354-4740-bf8e-ffdaa4b6ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dc149d17-aced-4d6f-b28e-763e54a33f61" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_5c5b8c46-95f0-4aeb-9ecd-236d189986fe" xlink:href="allo-20210331.xsd#allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding_5c5b8c46-95f0-4aeb-9ecd-236d189986fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_StockOptionGrantedPeriod_80f73494-5212-45c3-93fe-571e70af7603" xlink:href="allo-20210331.xsd#allo_StockOptionGrantedPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_allo_StockOptionGrantedPeriod_80f73494-5212-45c3-93fe-571e70af7603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_2a8606b2-6143-460e-addb-15d22b659469" xlink:href="allo-20210331.xsd#allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate_2a8606b2-6143-460e-addb-15d22b659469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c508fe06-7dfa-4a32-b900-2e7cabc1990b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c508fe06-7dfa-4a32-b900-2e7cabc1990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_49477be7-32e3-46b9-b727-807a2bec4a34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_49477be7-32e3-46b9-b727-807a2bec4a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3b4d85c-f10f-412c-967b-0be4b7f71e05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c3b4d85c-f10f-412c-967b-0be4b7f71e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3a79c9ad-fb18-4ddb-8c1c-9921e6a2924b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3a79c9ad-fb18-4ddb-8c1c-9921e6a2924b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1a373fcb-2160-4930-b2b5-d47a21ef91cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1a373fcb-2160-4930-b2b5-d47a21ef91cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_4a22bc51-9b13-4477-a6df-54abadf86d74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent_4a22bc51-9b13-4477-a6df-54abadf86d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_72d3863b-bc42-4c05-a5b6-f5e7fd0b7223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8b4d99c7-0d85-4468-af6c-32702f77a83f" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent_72d3863b-bc42-4c05-a5b6-f5e7fd0b7223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_127201ba-15b7-433f-8d6b-f5974f7a9650" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740ddeb0-b6de-49e9-ab20-4580ece16377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_127201ba-15b7-433f-8d6b-f5974f7a9650" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740ddeb0-b6de-49e9-ab20-4580ece16377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_55d1186c-7bc9-48d9-a006-e5a928360c7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740ddeb0-b6de-49e9-ab20-4580ece16377" xlink:to="loc_us-gaap_AwardTypeAxis_55d1186c-7bc9-48d9-a006-e5a928360c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480107c7-e6ea-434c-828c-ecde1297b2a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_55d1186c-7bc9-48d9-a006-e5a928360c7f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480107c7-e6ea-434c-828c-ecde1297b2a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_cd640efe-9407-422d-9902-5f1975c63e3c" xlink:href="allo-20210331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_480107c7-e6ea-434c-828c-ecde1297b2a1" xlink:to="loc_allo_TwoThousandEighteenPlanMember_cd640efe-9407-422d-9902-5f1975c63e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_740ddeb0-b6de-49e9-ab20-4580ece16377" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_001805f0-989d-4a9b-9f58-382bcf123999" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_001805f0-989d-4a9b-9f58-382bcf123999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac86c3bc-d653-42f6-91c5-15c50e1a9b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ac86c3bc-d653-42f6-91c5-15c50e1a9b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3caf71bb-7411-4fba-94fb-2a9f2d5435b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3caf71bb-7411-4fba-94fb-2a9f2d5435b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c50c4663-bc04-4670-8250-b053010ca751" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c50c4663-bc04-4670-8250-b053010ca751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cf3ae28b-c9b5-4c55-8af9-fb1c366348f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a190d5f2-35b0-4d53-af3a-7fe7f4b91cda" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cf3ae28b-c9b5-4c55-8af9-fb1c366348f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7326b133-42fb-4b90-aaec-6f107219f69f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7326b133-42fb-4b90-aaec-6f107219f69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9bab7fbc-67e3-4ae2-9efa-95f2c0ce1856" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9bab7fbc-67e3-4ae2-9efa-95f2c0ce1856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d165d68-b1b6-422b-8a4a-e86ac1736155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d165d68-b1b6-422b-8a4a-e86ac1736155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eca74c80-d751-414a-9472-97209bafdf4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eca74c80-d751-414a-9472-97209bafdf4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40117a56-c760-4001-b11b-4b53a9815dbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40117a56-c760-4001-b11b-4b53a9815dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20ad7ce8-51e8-42a3-b7a0-65d13613ff9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20ad7ce8-51e8-42a3-b7a0-65d13613ff9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9cabc6b-2a9f-437c-8606-b7c1bcdec593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8e70939-bf8b-4820-a215-f5e3d4a01903" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9cabc6b-2a9f-437c-8606-b7c1bcdec593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_be1a245a-b3a9-4dc4-b910-0831567967cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_be1a245a-b3a9-4dc4-b910-0831567967cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_667e0644-8a02-4e47-8113-eb1eeee35dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_667e0644-8a02-4e47-8113-eb1eeee35dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f8acf051-c27b-4de1-80f7-ca5671cc8cf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f8acf051-c27b-4de1-80f7-ca5671cc8cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8a66d25f-627a-4cba-967a-5b04ec4eef4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8a66d25f-627a-4cba-967a-5b04ec4eef4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_552d5929-2b5c-4329-ba8d-b3d8ec8d5993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_552d5929-2b5c-4329-ba8d-b3d8ec8d5993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ab1d5f39-4c11-4f88-a0d2-699c8474b37e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ab1d5f39-4c11-4f88-a0d2-699c8474b37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1195acb-98d9-4389-806c-dc6624bfad7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d1195acb-98d9-4389-806c-dc6624bfad7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_247c2e73-5c36-4f87-b1b4-4662bbe3de0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5280d16d-b160-4fca-af19-bf6f08b2760a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_247c2e73-5c36-4f87-b1b4-4662bbe3de0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef773654-8461-415c-bcef-cdfa95d01da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ef773654-8461-415c-bcef-cdfa95d01da0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5484f68b-e756-4c46-8a65-f682b72f19c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:to="loc_us-gaap_AwardTypeAxis_5484f68b-e756-4c46-8a65-f682b72f19c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb05bc6-3915-4ee6-b83b-3e855b5a263c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5484f68b-e756-4c46-8a65-f682b72f19c9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb05bc6-3915-4ee6-b83b-3e855b5a263c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoThousandEighteenPlanMember_564034e7-7034-4060-984c-7e2f6b35ef2c" xlink:href="allo-20210331.xsd#allo_TwoThousandEighteenPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7bb05bc6-3915-4ee6-b83b-3e855b5a263c" xlink:to="loc_allo_TwoThousandEighteenPlanMember_564034e7-7034-4060-984c-7e2f6b35ef2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b3819a09-fc8c-4026-bf65-ccc0c5e112eb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:to="loc_srt_RangeAxis_b3819a09-fc8c-4026-bf65-ccc0c5e112eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b3819a09-fc8c-4026-bf65-ccc0c5e112eb" xlink:to="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_076f5a65-ae7d-4a4a-9d5d-08518a49f140" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:to="loc_srt_MinimumMember_076f5a65-ae7d-4a4a-9d5d-08518a49f140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dbb84b63-5fbc-49fb-a846-ba3a615b02ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ae57e087-6204-403a-a0ac-eac8bc327c1d" xlink:to="loc_srt_MaximumMember_dbb84b63-5fbc-49fb-a846-ba3a615b02ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7e8f77eb-c078-49c0-bde3-ecbb18d23c4c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aec67154-f6e2-4e8e-9d7a-83f3f402a61c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aec67154-f6e2-4e8e-9d7a-83f3f402a61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1cf903d1-023e-4b6e-9604-c5496a7a9cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1cf903d1-023e-4b6e-9604-c5496a7a9cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_148e4949-f543-49ae-a157-7fb973d38b80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_148e4949-f543-49ae-a157-7fb973d38b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8eefa227-0672-4b1d-a4a7-935842c17b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8eefa227-0672-4b1d-a4a7-935842c17b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd1ab919-b502-4daf-b97e-0981e8e24254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b143e886-2629-452a-b7af-cb7c565699ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dd1ab919-b502-4daf-b97e-0981e8e24254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76345d72-50c0-4a14-870f-4ea90a91a06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9eb5e7d9-e487-40fb-9a16-7d9fee7b3844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_76345d72-50c0-4a14-870f-4ea90a91a06d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9eb5e7d9-e487-40fb-9a16-7d9fee7b3844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0c35dbab-3428-4cb2-b0a6-1b196e0d132f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9eb5e7d9-e487-40fb-9a16-7d9fee7b3844" xlink:to="loc_us-gaap_AwardTypeAxis_0c35dbab-3428-4cb2-b0a6-1b196e0d132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f11bb02-4f63-4dbb-9576-bd5e39a0869f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0c35dbab-3428-4cb2-b0a6-1b196e0d132f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f11bb02-4f63-4dbb-9576-bd5e39a0869f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_9da87836-9ba5-4187-b9e8-c9a0f18ed1ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6f11bb02-4f63-4dbb-9576-bd5e39a0869f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_9da87836-9ba5-4187-b9e8-c9a0f18ed1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9eb5e7d9-e487-40fb-9a16-7d9fee7b3844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9a36b6-a3e6-4805-8271-70457ed0e165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9a36b6-a3e6-4805-8271-70457ed0e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6aa2247-2d58-49f4-9905-25c57e0ff928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6aa2247-2d58-49f4-9905-25c57e0ff928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f67e2d5-f183-4f6d-a1d9-4ea016c94466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4f67e2d5-f183-4f6d-a1d9-4ea016c94466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_70104504-8060-43c6-a452-cc1c4fa89b42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_70104504-8060-43c6-a452-cc1c4fa89b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_726d9923-645d-4274-86d3-9af639e73775" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_649f31d8-45cf-4720-90ec-45c4073ea8b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_726d9923-645d-4274-86d3-9af639e73775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_3bb5afc0-178e-4fd6-9b90-fba0ff69035f" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_3bb5afc0-178e-4fd6-9b90-fba0ff69035f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1c06445-c4b2-4db0-b2df-00d4b1bd2500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a1c06445-c4b2-4db0-b2df-00d4b1bd2500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2090d660-b747-4fb2-b2e0-889d201c48a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2090d660-b747-4fb2-b2e0-889d201c48a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd3c1bbb-da3d-4d4a-8255-be5f65299f2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd3c1bbb-da3d-4d4a-8255-be5f65299f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_f23272b0-96eb-43af-974e-245ad373bd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_f23272b0-96eb-43af-974e-245ad373bd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74fb4e1d-3e3b-48d5-a17b-be393d0738e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6082c301-2d4c-432e-a2d6-f719c7101f4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74fb4e1d-3e3b-48d5-a17b-be393d0738e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_fa84bc9a-9639-40a8-a328-8dbf256ebd0f" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_fa84bc9a-9639-40a8-a328-8dbf256ebd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7e90d727-3606-4a00-9378-2958aba7837b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_7e90d727-3606-4a00-9378-2958aba7837b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_556818a7-a255-4c31-a0c2-527d96fc247b" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms_556818a7-a255-4c31-a0c2-527d96fc247b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_82c5f315-1b26-472d-ba26-4f345108f077" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_82c5f315-1b26-472d-ba26-4f345108f077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_edbfdb2c-6136-4606-9072-ecd16f9678cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_edbfdb2c-6136-4606-9072-ecd16f9678cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_1daea7b5-b210-45d0-a14b-fa3b2dc8ce03" xlink:href="allo-20210331.xsd#allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bbf120cc-577f-4596-92c9-449c5a8f36af" xlink:to="loc_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_1daea7b5-b210-45d0-a14b-fa3b2dc8ce03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#StockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/StockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49eb796b-58bd-488e-be30-8a73b3dbd2e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92974cc2-2267-4c7b-96ec-293fe3e7ebb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49eb796b-58bd-488e-be30-8a73b3dbd2e7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92974cc2-2267-4c7b-96ec-293fe3e7ebb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc5485fe-08bb-4141-a1fd-552c07e3c64c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92974cc2-2267-4c7b-96ec-293fe3e7ebb7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc5485fe-08bb-4141-a1fd-552c07e3c64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc5485fe-08bb-4141-a1fd-552c07e3c64c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b63e2b57-5d23-41bf-9a30-701c59a049b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b63e2b57-5d23-41bf-9a30-701c59a049b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43e48def-2ea4-4210-9fb6-cd5004c61757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7616756c-1ce4-4f64-8ba9-a181f205217d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_43e48def-2ea4-4210-9fb6-cd5004c61757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bceab623-4377-4ad9-aff1-e4a506521c7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_92974cc2-2267-4c7b-96ec-293fe3e7ebb7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bceab623-4377-4ad9-aff1-e4a506521c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e44c6a-0df6-4fe1-861d-4a898b3a3e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_bceab623-4377-4ad9-aff1-e4a506521c7d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f6e44c6a-0df6-4fe1-861d-4a898b3a3e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="allo-20210331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c37e42eb-2825-4c00-a78b-6f3db5010166" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81f88fd5-5091-4f7f-bc21-5085b183b5a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c37e42eb-2825-4c00-a78b-6f3db5010166" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81f88fd5-5091-4f7f-bc21-5085b183b5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_12eb5c39-973f-4530-90d5-14b7316ebfa8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_12eb5c39-973f-4530-90d5-14b7316ebfa8" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e51928a6-4678-4e8d-b9ba-c13b9b0189c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e51928a6-4678-4e8d-b9ba-c13b9b0189c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e51928a6-4678-4e8d-b9ba-c13b9b0189c8" xlink:to="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_BellcoCapitalLLCMember_17178284-6e36-4d04-8509-d827d86afd6c" xlink:href="allo-20210331.xsd#allo_BellcoCapitalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:to="loc_allo_BellcoCapitalLLCMember_17178284-6e36-4d04-8509-d827d86afd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_TwoRiverConsultingLLCMember_62c796ca-0265-40ba-88f4-f42a13bf1d0e" xlink:href="allo-20210331.xsd#allo_TwoRiverConsultingLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_68f072e1-a4e4-4a1a-887c-6dcc5d31671b" xlink:to="loc_allo_TwoRiverConsultingLLCMember_62c796ca-0265-40ba-88f4-f42a13bf1d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_ead0b16e-91ed-4396-89a6-1f696e54f57e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_ead0b16e-91ed-4396-89a6-1f696e54f57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_ead0b16e-91ed-4396-89a6-1f696e54f57e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_SubleaseAgreementMember_0380d4e4-ad29-4042-aef8-8cdaabc12a1c" xlink:href="allo-20210331.xsd#allo_SubleaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:to="loc_allo_SubleaseAgreementMember_0380d4e4-ad29-4042-aef8-8cdaabc12a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_ConsultingAgreementsMember_e87409a6-f02a-4256-9dff-e0acac2d152c" xlink:href="allo-20210331.xsd#allo_ConsultingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a1de0048-0c99-4a97-bb2b-4535244f10bf" xlink:to="loc_allo_ConsultingAgreementsMember_e87409a6-f02a-4256-9dff-e0acac2d152c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a2156003-ee9d-4b9b-8a1e-f9128f47fccd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_srt_RangeAxis_a2156003-ee9d-4b9b-8a1e-f9128f47fccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca40c4b6-a91e-4c21-8615-7d4afb23b8d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a2156003-ee9d-4b9b-8a1e-f9128f47fccd" xlink:to="loc_srt_RangeMember_ca40c4b6-a91e-4c21-8615-7d4afb23b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c0ff3bc5-99e2-4ef1-b345-6ccef3121de4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ca40c4b6-a91e-4c21-8615-7d4afb23b8d0" xlink:to="loc_srt_MaximumMember_c0ff3bc5-99e2-4ef1-b345-6ccef3121de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsAxis_5cd99ad5-96ec-4975-a92d-3915ab570c5d" xlink:href="allo-20210331.xsd#allo_PaymentTermsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_allo_PaymentTermsAxis_5cd99ad5-96ec-4975-a92d-3915ab570c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:href="allo-20210331.xsd#allo_PaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsAxis_5cd99ad5-96ec-4975-a92d-3915ab570c5d" xlink:to="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2019Member_f8b6171e-2250-4b83-9d65-9a48d6a76195" xlink:href="allo-20210331.xsd#allo_PaymentsCommencingJanuary2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:to="loc_allo_PaymentsCommencingJanuary2019Member_f8b6171e-2250-4b83-9d65-9a48d6a76195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_PaymentsCommencingJanuary2020Member_ba646c57-9010-4e8d-b28c-dd8763506a69" xlink:href="allo-20210331.xsd#allo_PaymentsCommencingJanuary2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_allo_PaymentTermsDomain_bb2bd5b0-6424-4b23-9004-e47bf6428b97" xlink:to="loc_allo_PaymentsCommencingJanuary2020Member_ba646c57-9010-4e8d-b28c-dd8763506a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1571c3db-2eb2-42cd-8276-cbf3e7edb774" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_122ecd63-bd1e-406c-85d3-f8a549d0442c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_122ecd63-bd1e-406c-85d3-f8a549d0442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_AreaOfOffice_4d5ba355-3958-4fdd-ad59-9c534f2a3050" xlink:href="allo-20210331.xsd#allo_AreaOfOffice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_allo_AreaOfOffice_4d5ba355-3958-4fdd-ad59-9c534f2a3050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_ee6635dc-b7cd-4507-8dd3-03ba9d9048ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_ee6635dc-b7cd-4507-8dd3-03ba9d9048ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_55169c6a-5c63-4189-aad7-fdc8b2e961d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_55169c6a-5c63-4189-aad7-fdc8b2e961d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2510605e-712e-4f43-a87a-90f198222ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_OperatingLeaseLiability_2510605e-712e-4f43-a87a-90f198222ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyCosts_59d2e4e7-7b6e-4616-918a-86c9590820ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_us-gaap_RelatedPartyCosts_59d2e4e7-7b6e-4616-918a-86c9590820ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_205ea644-a1ac-43e1-aeca-5cb085b91de2" xlink:href="allo-20210331.xsd#allo_RelatedPartyTransactionMonthlyPaymentsInArrears"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_allo_RelatedPartyTransactionMonthlyPaymentsInArrears_205ea644-a1ac-43e1-aeca-5cb085b91de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_RelatedPartyTransactionCompensationPercentage_95c26a13-ebd8-4012-8134-34224d3f0d0d" xlink:href="allo-20210331.xsd#allo_RelatedPartyTransactionCompensationPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_c20fb7d0-7ff8-48ff-9b28-cd21e9a3138e" xlink:to="loc_allo_RelatedPartyTransactionCompensationPercentage_95c26a13-ebd8-4012-8134-34224d3f0d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="allo-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://allogene.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13deaa06-828f-4a77-9042-131157ac1a72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_7245b99f-af23-4f45-8d0d-dcd5fed66795" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13deaa06-828f-4a77-9042-131157ac1a72" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_7245b99f-af23-4f45-8d0d-dcd5fed66795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShare" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_31626686-9e8e-46c0-a40e-f90ed295778a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_93a8bb00-9a8d-406d-ad68-9b50c5515338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_31626686-9e8e-46c0-a40e-f90ed295778a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_93a8bb00-9a8d-406d-ad68-9b50c5515338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d8bfd2a3-26d4-4973-90a7-a8952efc87d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a8e5c81c-efc3-45e0-9bee-c2484e7c4297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d8bfd2a3-26d4-4973-90a7-a8952efc87d1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a8e5c81c-efc3-45e0-9bee-c2484e7c4297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/NetLossPerShareDetails" xlink:type="simple" xlink:href="allo-20210331.xsd#NetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://allogene.com/role/NetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a0aedb6c-05a9-46f7-938a-ee66f875eb1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050fed6d-b76d-4002-9fa9-d707da876893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a0aedb6c-05a9-46f7-938a-ee66f875eb1a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050fed6d-b76d-4002-9fa9-d707da876893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1fbd3317-f47d-4375-bc5c-d2fc2023e5be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050fed6d-b76d-4002-9fa9-d707da876893" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1fbd3317-f47d-4375-bc5c-d2fc2023e5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1fbd3317-f47d-4375-bc5c-d2fc2023e5be" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20c58b4b-ed03-4ee1-965e-a931053bcc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20c58b4b-ed03-4ee1-965e-a931053bcc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_04a99c86-5844-4adb-accb-cbaf7f6174bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_04a99c86-5844-4adb-accb-cbaf7f6174bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_ed0591c1-c997-4066-9e7d-0583cfa79df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_us-gaap_EmployeeStockMember_ed0591c1-c997-4066-9e7d-0583cfa79df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_FounderSharesOfCommonStockMember_28b6f98d-7a22-4e9a-9507-cc65aef0e36d" xlink:href="allo-20210331.xsd#allo_FounderSharesOfCommonStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_allo_FounderSharesOfCommonStockMember_28b6f98d-7a22-4e9a-9507-cc65aef0e36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_allo_EarlyExerciseOfStockOptionsMember_8d9fe52a-bef0-4200-b8dc-7166ae8f4291" xlink:href="allo-20210331.xsd#allo_EarlyExerciseOfStockOptionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8c99683e-d967-413c-8313-08f86e9aef72" xlink:to="loc_allo_EarlyExerciseOfStockOptionsMember_8d9fe52a-bef0-4200-b8dc-7166ae8f4291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ed16da3f-12d4-4f2e-8404-daffce182924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_050fed6d-b76d-4002-9fa9-d707da876893" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ed16da3f-12d4-4f2e-8404-daffce182924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d8356334-9db4-43c5-a2a0-3cdb518f4f87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ed16da3f-12d4-4f2e-8404-daffce182924" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d8356334-9db4-43c5-a2a0-3cdb518f4f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://allogene.com/role/SubsequentEvents" xlink:type="simple" xlink:href="allo-20210331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://allogene.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_383e3180-44ac-414c-b077-7957c65dcd6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4fcea92d-74e7-4b5d-b5a8-5556180e93d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_383e3180-44ac-414c-b077-7957c65dcd6b" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4fcea92d-74e7-4b5d-b5a8-5556180e93d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>allo-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:allo="http://allogene.com/20210331"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="allo-20210331.xsd" xlink:type="simple"/>
    <context id="if2e29ff114d54feab704d039fd34576e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8bb0ce173a264ffb98a91df551b8de22_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="ia39d6a89bb844679938131a4168a79f8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0bc1f891fbe4441687ad896e3591b769_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2011b80082724645a7f1440247f631ed_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id5d8d5d7cc5e4b369dc02b51cc31ba63_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if62b8835b5894a97961539f08038f95b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84f14c477d6247bcb8b315bd0a71ca2b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i964ffbd064624356a2ce6298cdba096c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7c89cfc2f1df420e80df10b19bb7045c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8fe5f193450e4e168c14067f2f2d182e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i90d14178c6914d93a889ac3ed04c02a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0e5769ae558548b8b8db13dd5a510d74_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id6562b41725243958717d88b90e4728a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iad89e42e666e4c46b385e97bc6797118_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i01ccf8d124ff499fbbabad09739a47b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic054bea3b59344829df6ae5dc931c60b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i313259e23cfb4a2ab8bd19b643ad78ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8f4a1b7bf0a947fb8b63dca9e112a72b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60c3252db9b543d6a7491e001ef77b45_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iacc623b05c8141db83c3d25a61bcb2cf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib4c2a96affa64584ab33e6e2aa1a077b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i62bda789cb6d4921af13cb46113d49d7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i571a727871624fde93fb27f4e770e678_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i989fb3c13e4c463ca87f71c224b0cb1d_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic3d9397e7db24081a8cb1f7febad8dfb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3ef8c73e705a4baa9efc6f53a2920a77_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i504c57fff4964e769a633e05ed2a8d01_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i344a99f050b64372885525e2c3a160e8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4d1b5c9589324b51a5ac5e3aa31ea60e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">allo:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id12fb68b0dae4f7a91f55375717a8a56_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i165eea287dc54c3585c522f50f626b8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b8935686a9046d6abb1898661b57010_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib0ea4f1b6e1f4122bf000ec2f062663f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib0e44b399f5c47039974adea069751e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i55f0f98344ea41ee89c1226f1ebfb886_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia444669c28534a2f916cca00d9a1084c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia0453ee7dff14085ab6fbbaa87e73917_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b8ebc8cb37b496daa43a0b287fbcb06_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idb31a0895811482e8e0345481a846bb5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1842dec3973f4c7fbaefb4e0b73af312_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8af6adb4d85d4284a8361787ad478d67_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib91dea83a7374424acc07bf7143a9de1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibbf32eb5eb78476fbab5c4d927d70513_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib7e0375da1c3406a99fb9a733a7af9e2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic1db911011e7478f95e414ea628f6000_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i639fb921dad04c38b75ac3f84cea54ce_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i78c77fed04674b399c499733307337a2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id39b02d830004ca0ae7768a7ab1cfb0a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i58b8541c2de84111941a459c4cca9e41_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2b1f946978604abd96aacdf6511485f5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib77f8b7841b54c16b57577533fef2ad5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i73b87df3539b4602a0cb77a894476522_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i190755c884ba4407a67755b5981209fb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i425ece1b06434afbbb883c90e17bdb61_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3619adf51ab94510807b3324a8c3fb3e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if31b6a89951d44f89dbabea0393f7de8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0aa4add5f0548b1bbcfbe54905115be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib345026090ae4d7aaf20623437eda88e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb40fd0c453149bf89e2575d7dfd1a8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8693ce8adb3e4f87894764efa1dc1be6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27ee0888939a402dbc25013b3f240b0f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34403b8da4544edeb9bcf602d09ea7e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i925a07a2a5da4c4a954ec447c21627d9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94dd7dacb51143a7be602182537411c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id36ca55f6d2d4f6e82521817fdfb9e12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22b516ddd68d487c9dc9976d12bdb980_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31a51a763aa048458e78d279f2649278_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i89b7be258eff4efa93d6f7841ab564b8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3a8e946c7364e21ad7e16db6b94a4a4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98c4ad06e92445fdb0c7c1102056f114_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i24de2ec1a8294b05a3fad113a1acd836_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5e4e73bf01548db85151208211a884f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic62115cf799f465eb2f3b2b3d65a0c40_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ab2e4c6e7c24bac8d2935a6b6c36a9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fc6467fc7c44ae18600b20b5a30e83e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d8d696029864336acfec926937a4a09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie501860c6b9a4e07a7bb38b17e7be2b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i087dace4c72a4178aadef0c41c9bb356_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i007c67785640431a9ade0b3cbec093e5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6376740830184eaa825958505c990d48_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7f300d7009234b3da0340504d7e659a9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i81538cf0c097486badfa1786facbcdff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f071d9be3e64ae7909bb18979e547ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a1941e2894148b696f50b001c993d68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icba50cbc018a4f96b6da7385f98c25c9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6758881023d4b35b0388e05d5360ed4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie50601403e82462a993279d9571f8647_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2c98ae4709454667a0750d6459d7ac91_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c63d34d1bfe495ea11be0647eed83c7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib2ac0012f0854969a20a692346460384_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d90dd4d682d4d36a32874f3b745fcb9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1d87e6eccd34d439d8a2297c843c8df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6974fc646add4195bfcc6857939ed0d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia10370fc5f7e4e4e8a0c23adbcbc6922_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">allo:ComputerEquipmentAndPurchasedSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieed9ef18264f4d15aa5462978b00b3bf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0fc7cbd26add4fff8fe2bc2d9c90f90d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i407ac8a1e41242c9be72213ac2a23645_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1278a0a51b1640cdbb03fe0a13675240_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i48368b1762a44efd868c61b94c87d3b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5cf55e9cbdb241bda666ae71bf9b4636_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:AssetContributionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7c01076628f14533a22a6ed1bf7f645f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2d3809bdb24e4487867ca711c35faed6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5979e4ee83f743c18eb44a9e12a96a76_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:MilestoneTypeAxis">allo:DevelopmentAndSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0d63cc5b557e4a7781a31dbcd492270b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i62d689d0f8bd4b609f81b32837461df5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:CellectisSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieb0b77194500411893671236498c869e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie804f754091d4ee08b0012cf286c45ee_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i94890323746341f2b456015e6973a164_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9bcc3e59ff0414e9e68d09f328231d1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6ce30503f7e4dcb8b48f3209ba957d1_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i88109eef01694d5087c4d4045520c227_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iedead71724684d8c9198e3945bc63aad_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i93e629aa48694adaba119d9561912c43_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:ServierMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i076cc18b50ba412ca3242c4341c20664_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="ie316218928294928a89e52d1606777a9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-01</instant>
        </period>
    </context>
    <context id="i63935ec464224be99ddd75ab04bfdab1_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i2d8539bb2dda47de90067bfbe0969f59_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:EquityInvestmentBasisAxis">allo:VotingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i11005bc5a44b4d80a0ea4954488ea86b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:ResearchCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifac376ffe9ed4e7b99c011fd45a31021_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:PreClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7b8687e0cabd401c931e5f274bdb2016_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ClinicalRegulatoryAndCommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">allo:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2f77c63a834a4681b022dff5f2da6fe7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i019720c47c404ba483f76b9fc6e614e2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia54b21b65ef24f6cbdcf06ec5a9d9dd0_D20201006-20201006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-06</endDate>
        </period>
    </context>
    <context id="i08db9380997d4d1b9f4e44201d651df9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:UniversityOfTexasMDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i9f26d67082094c649f56c52d8b485753_I20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">allo:OverlandPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="i0af7e5161e0e4accbc495ed05d1832d0_I20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i087b1f988f50425c88274e63ae23612e_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i9c1ff3e19d184af39773c955bf6f264f_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i741a26ced88a4be9b88be81d60e87b12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">allo:NewarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6f0049318f88420fb355203ab4e399b1_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="i413a4f8e6e7e4ee28ed209070c2b4426_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b1c66efc41f41b3a6ae07c79e88874c_D20191101-20191101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:NotchTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-01</endDate>
        </period>
    </context>
    <context id="i6e523f02887b4694813dc952ebe2a83d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie55d9fe72329461caf14cd949cf5f9f0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">allo:AllogeneOverlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14bbb500f25447d69b2babcd02fb2d40_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic2b360877fd0487881046b793d288efa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie9606d98985d4a4aa8219e4759fe5755_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib97658ccecf0407bb53a0ff5d41930f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i15371b2572eb4bbab0588d744217e7b9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i4e50cc94898c4c38af402cdd90cb3431_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7851275aa1884775b7054b0238c07f90_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5060d1ddf0ff4c76a3852cdb609b01d6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id0f00168a0e94cdcb56ab6e3ec5a5938_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i25c39330288e480a82e92430adf135a6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i14661dcd7bd04b018bb9677c345a8f5c_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia0618c69e39949038145e2a090838f1f_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">allo:TwoThousandEighteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i769dd97badbb4b2f80e2f2bbbb9b5946_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i231088853bd94ca78694266c68e382cd_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i51e3200cd5ee4aec98b75df42cbd8a19_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i701ddf49607b425c93a8f1bcc7064cec_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if95eb4b787c74543b5067fc4b0661d0f_D20181201-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0ebc3e0c018541f4b70cf9419d86dfa9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2f6335266109450ca23eec174e7cdcab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6c6f84593b7d463c9ff60c7ca46e93bb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:SubleaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i722789689fd9475695feac4a92e9226f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i158e95b9cb1646beabf8dfd28baec0fc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:TwoRiverConsultingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i986898a7e34741d7954f86f9c33d1968_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="i5a1c8fe00fa14644bd319487f70e9221_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="allo:PaymentTermsAxis">allo:PaymentsCommencingJanuary2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="ia418d380ade7488fa285afa3617ce316_D20180801-20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="iea9e93b01c9d476194a141c6b0fef19e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if0bf2b2e4cd04570b9e804413fe277cb_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">allo:ConsultingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">allo:BellcoCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6e4b9c96e43a4d7e97a39037a134b7e1_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie2ea6b4be1364df5a17f2f871d780f18_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i18038f78c8f7485c88a47821af555ffa_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i787d6c72d2aa4f58916999e0c3306ea9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ieec840582431407c876320ad99849824_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i64ffc5ac698f42a59f37c79159d75b55_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i855de4b72ebc4f219d2f0aba2723cefd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i04ba8e4cb94c47d6b333c42599e31017_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:FounderSharesOfCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i41eacec9267f4e78b154a165573c48bc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iadaf0078bc664e608b63092936b79aaf_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001737287</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">allo:EarlyExerciseOfStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="renewal">
        <measure>allo:renewal</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8yLTEtMS0xLTA_00d45b22-f53d-4aa0-803f-e8a4c537a591">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8yLTEtMS0xLTA_94131f6d-e9da-41a9-bce1-3f28dd05012d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8zLTEtMS0xLTA_92a95488-ee28-4273-af91-fa7190cf50f2">false</dei:AmendmentFlag>
    <dei:AmendmentFlag
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF8zLTEtMS0xLTA_ddd3edfd-facd-4945-b691-9519e416b2b5">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF80LTEtMS0xLTA_c114de0c-1602-4a81-bed2-463b7bf9aa23">0001737287</dei:EntityCentralIndexKey>
    <dei:EntityCentralIndexKey
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF80LTEtMS0xLTA_c802cef4-c995-4e5d-ae20-df6094565f90">0001737287</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF81LTEtMS0xLTA_27b9d347-209a-4aeb-af2a-1967013d8464">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF81LTEtMS0xLTA_89c67530-abb5-4d24-827d-a57bfb62153d">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF82LTEtMS0xLTA_2f4120d1-b81a-4520-b677-442399bb581f">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180L2ZyYWc6MGVkMmI3ZThlYzIwNDJhZmEzMTY0ZTkxNzZlODY2YjUvdGFibGU6NWRjMGMxYTI5NmRjNDk0MGJjYzFjNjljNjAxOGE1ZGQvdGFibGVyYW5nZTo1ZGMwYzFhMjk2ZGM0OTQwYmNjMWM2OWM2MDE4YTVkZF82LTEtMS0xLTA_fd84fb26-42c8-4809-8680-880a4a306736">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181NS9mcmFnOjE3ZDY1M2Q3YzUxOTQyN2Q5YzY3ZTkzNjJmZmE0MjAwL3RhYmxlOmEzODUyMmE0YzNkOTRjZWFhYzY5M2U2ZTE4NzJmM2M5L3RhYmxlcmFuZ2U6YTM4NTIyYTRjM2Q5NGNlYWFjNjkzZTZlMTg3MmYzYzlfMC0wLTEtMS0w_0047954c-8fd9-4279-a19c-74e76903725e">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181NS9mcmFnOjE3ZDY1M2Q3YzUxOTQyN2Q5YzY3ZTkzNjJmZmE0MjAwL3RhYmxlOmEzODUyMmE0YzNkOTRjZWFhYzY5M2U2ZTE4NzJmM2M5L3RhYmxlcmFuZ2U6YTM4NTIyYTRjM2Q5NGNlYWFjNjkzZTZlMTg3MmYzYzlfMC0wLTEtMS0w_328b8780-37a1-4bd6-a6a6-cc1a590a826d">allo:AccruedAndOtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzMx_2d4c9d01-7ac3-4851-a63c-2e7d69651fdd">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6NDcyZjFlMzFkMTQzNGM3ZjlhM2NlYmI2NjE1NWEwYTUvdGFibGVyYW5nZTo0NzJmMWUzMWQxNDM0YzdmOWEzY2ViYjY2MTU1YTBhNV8wLTAtMS0xLTA_685d2a33-4b7d-44f3-92be-24240afd608e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8zODQ4MjkwNjk5NzI1_e7fdcb96-4996-4937-8e5e-3daa8551d0d5">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6YTY5ZmU1ODZkYzYyNGIzNWFlNjFiNWNhNGQ0ZTY0OTQvdGFibGVyYW5nZTphNjlmZTU4NmRjNjI0YjM1YWU2MWI1Y2E0ZDRlNjQ5NF8wLTAtMS0xLTA_c738fe35-ee1f-44ad-8d49-6c414d2bab81">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI1_ec87dae7-30b2-4706-970c-455d7787a150">001-38693</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV80MjQ_982cd335-1bce-47c4-a856-dcc8da534d1d">Allogene Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6YTEwMWU1ZmRkOGFmNDMyYjkwNjk4ZmI2ZDJmZGMzYzkvdGFibGVyYW5nZTphMTAxZTVmZGQ4YWY0MzJiOTA2OThmYjZkMmZkYzNjOV8wLTAtMS0xLTA_7954a52c-97eb-41c3-88d3-36ea939b9ad7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6YTEwMWU1ZmRkOGFmNDMyYjkwNjk4ZmI2ZDJmZGMzYzkvdGFibGVyYW5nZTphMTAxZTVmZGQ4YWY0MzJiOTA2OThmYjZkMmZkYzNjOV8wLTItMS0xLTA_d6172f5c-ef3c-4e30-b536-d2173c1858ff">82-3562771</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzIw_c1d90a5d-2c73-4783-86b2-ccc2ed5c8f19">210 East Grand Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzIy_9cc132a9-ed03-41d1-b073-afbd08fea6cd">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI5_3ce45342-4c04-4e4a-8acd-743824d61d4d">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI0_3e4dd881-d982-4906-9c65-6b16b9755a37">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV83MTY_c12fbe58-5833-4406-a85b-61061607d4de">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzMy_3ebffd2d-387a-43c9-8bf7-7303252f78ee">457-2700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6ODI3ZjMyNzRiNjQxNDUzODg1MWY0OTYxNDFhNjUwODUvdGFibGVyYW5nZTo4MjdmMzI3NGI2NDE0NTM4ODUxZjQ5NjE0MWE2NTA4NV8xLTAtMS0xLTA_3e266546-b179-4980-8ef7-bfebcdf91ae7">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6ODI3ZjMyNzRiNjQxNDUzODg1MWY0OTYxNDFhNjUwODUvdGFibGVyYW5nZTo4MjdmMzI3NGI2NDE0NTM4ODUxZjQ5NjE0MWE2NTA4NV8xLTItMS0xLTA_ddf50e0c-45d7-4611-b31b-2a1822bf10dd">ALLO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6ODI3ZjMyNzRiNjQxNDUzODg1MWY0OTYxNDFhNjUwODUvdGFibGVyYW5nZTo4MjdmMzI3NGI2NDE0NTM4ODUxZjQ5NjE0MWE2NTA4NV8xLTQtMS0xLTA_063c10a7-83cc-4a40-bc63-bd2fbb5d05dc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI3_1c9a9b1c-7236-440f-9e69-f8240374cced">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzMw_89f2255e-3d57-488f-923f-98eb3cc3e587">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6OGQzNjljYmVmYWVlNDFkMTkzZjU4MzMzYjc5MWI2N2EvdGFibGVyYW5nZTo4ZDM2OWNiZWZhZWU0MWQxOTNmNTgzMzNiNzkxYjY3YV8wLTAtMS0xLTA_ab8c192d-6220-41c5-ab6d-1a9b70772d96">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6OGQzNjljYmVmYWVlNDFkMTkzZjU4MzMzYjc5MWI2N2EvdGFibGVyYW5nZTo4ZDM2OWNiZWZhZWU0MWQxOTNmNTgzMzNiNzkxYjY3YV8xLTQtMS0xLTA_a7272428-5fed-4ced-aaa7-64f0f2026c1f">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGFibGU6OGQzNjljYmVmYWVlNDFkMTkzZjU4MzMzYjc5MWI2N2EvdGFibGVyYW5nZTo4ZDM2OWNiZWZhZWU0MWQxOTNmNTgzMzNiNzkxYjY3YV8yLTEtMS0xLTA_bd166d0b-0dfd-49d9-b80f-c04930e093f9">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMzI4_66179782-fe55-4e4c-b7b3-06c22f954132">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8bb0ce173a264ffb98a91df551b8de22_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xL2ZyYWc6MDdmM2E2YzhiMTUzNGYzYmIxYmY4NzVkMGEyODI3OWUvdGV4dHJlZ2lvbjowN2YzYTZjOGIxNTM0ZjNiYjFiZjg3NWQwYTI4Mjc5ZV8yMjUw_0895831c-acda-4aa7-8aa1-3d022a66ea8a"
      unitRef="shares">141538421</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0xLTEtMS0w_be087a82-1132-4ead-93bc-7652a27e21bc"
      unitRef="usd">236865000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0zLTEtMS0w_47b966a1-77f8-47e2-92a3-b44c18d3761b"
      unitRef="usd">183351000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0xLTEtMS0w_129330e8-e857-4c1b-9f78-401588f654c1"
      unitRef="usd">462716000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0zLTEtMS0w_35f3d49f-37b9-44b1-81b0-54756833a5c9"
      unitRef="usd">644559000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0xLTEtMS0w_4967502f-b4f9-438e-9084-0e2f86feaf90"
      unitRef="usd">16480000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0zLTEtMS0w_22241486-a7e9-49f8-a1f8-19cd00a4baa6"
      unitRef="usd">17220000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0xLTEtMS0w_bcbcfd92-b310-4e25-b002-36ddd85cc3ec"
      unitRef="usd">716061000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0zLTEtMS0w_f954bfd9-3ec4-49a1-8ed4-3603eb6c4420"
      unitRef="usd">845130000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0xLTEtMS0w_6e281a81-c073-4e69-bc01-f47874174bba"
      unitRef="usd">264573000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0zLTEtMS0w_bc524264-0ca4-4835-99e7-d6ea5ec1348d"
      unitRef="usd">204208000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0xLTEtMS0w_7da97dc1-8517-4f00-b967-882fc98662fc"
      unitRef="usd">40189000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0zLTEtMS0w_86b80932-6046-4e43-b786-e789b1c5c394"
      unitRef="usd">41295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0xLTEtMS0w_b224e7f8-d03b-4352-804b-af37d3c84df6"
      unitRef="usd">123146000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0zLTEtMS0w_0912a133-4ef3-43bb-b0a1-210618ffe1fd"
      unitRef="usd">118840000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMS0xLTEtMA_0d5f9d4d-3c92-454d-916e-197ee1ed990c"
      unitRef="usd">9449000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMy0xLTEtMA_c57dc54d-b37a-4a7f-adfa-57966c63a2de"
      unitRef="usd">9449000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMS0xLTEtMA_deace675-1d36-4423-896a-ab86d07ac2b1"
      unitRef="usd">6275000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMy0xLTEtMA_2ed3d9e1-6c63-413c-bb02-093ff5201ac8"
      unitRef="usd">5169000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMS0xLTEtMA_31ba4057-b60e-4732-9645-32aa30930cfe"
      unitRef="usd">19351000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMy0xLTEtMA_307edecc-1f63-4284-9b6f-669b07cf0d86"
      unitRef="usd">3738000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:Assets
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMS0xLTEtMA_15ed111c-8129-433d-a337-6971a98e9bd0"
      unitRef="usd">1179044000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMy0xLTEtMA_4270382f-5182-4bc8-9df9-42838675b91c"
      unitRef="usd">1227829000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMS0xLTEtMA_d62a88a2-fc86-467e-9537-658ebce6baa8"
      unitRef="usd">14875000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMy0xLTEtMA_858375b0-b7e6-44d0-aee2-5433ebd4d75e"
      unitRef="usd">10390000</us-gaap:AccountsPayableCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMS0xLTEtMA_0b4454cc-9fbe-41a8-9690-09e06a5f60e7"
      unitRef="usd">39735000</allo:AccruedAndOtherLiabilitiesCurrent>
    <allo:AccruedAndOtherLiabilitiesCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMy0xLTEtMA_05d265ff-76ea-4f8b-a25a-bc8590153428"
      unitRef="usd">44938000</allo:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMS0xLTEtMjI_91417940-b86f-49dd-8820-655b3817ff48"
      unitRef="usd">239000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMjI_13761176-f72a-483a-b335-8ff7963fdc1d"
      unitRef="usd">38992000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMS0xLTEtMA_3152015f-e64b-4215-afe4-4a73938b069c"
      unitRef="usd">54849000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMA_6dcd5482-5ea0-4e1a-9ece-14a8ed6ab7d8"
      unitRef="usd">94320000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMS0xLTEtMA_c44acc97-b8f2-4e08-add5-2a7488c7fc26"
      unitRef="usd">51625000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMy0xLTEtMA_f86ec844-b092-466f-875d-31a225500c6d"
      unitRef="usd">50809000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMS0xLTEtMA_aa36f01b-006a-4d9c-acfb-d96183609b39"
      unitRef="usd">2791000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMy0xLTEtMA_7d1df015-883b-43a9-bdf2-99712365fcd0"
      unitRef="usd">3083000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMS0xLTEtMA_55918b96-bbe1-4bba-897f-dc26a9331d89"
      unitRef="usd">109265000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMy0xLTEtMA_032c8e48-834a-4336-8f3e-c82f3e031e8c"
      unitRef="usd">148212000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMS0xLTEtMA_a430e1be-0e29-4ba6-9210-f02c7620ee80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMy0xLTEtMA_641c80ef-eff9-4b78-8e4a-43867ef01b17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzIx_833aba23-2810-4b96-b241-cf6b427db633"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzIx_b6a62c7c-ec87-4075-9cd4-d003b04dc85c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzM1_9f8fc5e6-f8a6-4ce7-88c9-edcd54b1e0fd"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzM1_afd80ab3-0ead-4839-829f-ea506aa148bb"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_2b6fc218-8500-4435-b1b4-7634de09d431"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_623c74b7-360c-4477-b02f-cb5b34b4d9a8"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_747f8b54-9f5a-49fc-a212-4b45f47317e1"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMC0xLTEtMC90ZXh0cmVnaW9uOjU5NjQ2ZTEyODBiMTRhNzJhYTg2MTZhYmRkMDExMjgwXzEwNA_abfc9e2f-b077-44e3-8df3-96193f1c7058"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMS0xLTEtMA_6174f0f6-27b0-4ef0-a149-8d7daf08cd4a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMy0xLTEtMA_fc257be9-08cb-46b2-8838-a02f1641ffe1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzE4_9eec1364-e641-43ba-aed4-966963fd48bd"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzE4_c004c48a-ea4c-4bc8-8a9f-fa69a923b8cf"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzMy_21e08519-fb7d-42d2-8ac6-9c1a3259a2b5"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzMy_f05483b5-b015-4c2b-8b46-8ea10651765d"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwMQ_4c27f3da-31d4-40be-9ef5-1c2de5218e04"
      unitRef="shares">141470075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwMQ_8c2490ad-c78c-418e-b3f9-c613330ba089"
      unitRef="shares">141470075</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwOA_9d93cedb-7927-42d4-b1e8-b27f1a4282bd"
      unitRef="shares">140474305</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMC0xLTEtMC90ZXh0cmVnaW9uOjZiZjA5OGVlNmE2MDQ4OGU5NTBhYjRiNjNlY2E1ZTlmXzEwOA_d74f9f1c-552a-40da-9339-a8489f2a4cb0"
      unitRef="shares">140474305</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMS0xLTEtMA_20fad735-1b84-4b6b-8208-61bcd43715d2"
      unitRef="usd">141000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMy0xLTEtMA_0195fc54-fdd9-4a59-ac0c-b5d33857f0c7"
      unitRef="usd">140000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMS0xLTEtMA_8225d449-4b8c-4a01-88c4-c5456d05f7f2"
      unitRef="usd">1749097000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMy0xLTEtMA_10341c22-77ed-49b5-81b9-e3fe143b6963"
      unitRef="usd">1725552000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMS0xLTEtMA_691a9365-60a1-4981-968e-dca9fdcd81de"
      unitRef="usd">-679358000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMy0xLTEtMA_8aad1752-7abe-41ca-9395-682a129acf01"
      unitRef="usd">-646343000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMS0xLTEtMA_e543b0d7-5cf1-4da4-834b-fee5c8102d3b"
      unitRef="usd">-101000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMy0xLTEtMA_5e9f9b98-da28-4e8c-a81c-8427db4456b5"
      unitRef="usd">268000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMS0xLTEtMA_e7e57667-9380-43db-8bdd-28c9248f894c"
      unitRef="usd">1069779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMy0xLTEtMA_8309ea67-a578-46de-b7fb-90ba2e3014f6"
      unitRef="usd">1079617000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMS0xLTEtMA_590a7cbe-5a77-437e-b0bb-7586315931f4"
      unitRef="usd">1179044000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMy0xLTEtMA_8a4279c2-3924-4726-9d6e-3ecc7f9022ce"
      unitRef="usd">1227829000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMi0xLTEtMS02Njg_bc1263b4-915a-42e7-9991-640aeab390d6"
      unitRef="usd">38345000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMi0zLTEtMS02Njg_c797f4c5-318e-403a-baa1-788dd2afde92"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMy0xLTEtMS0w_18a48833-7d61-4b95-bee0-d6e270f92c39"
      unitRef="usd">55183000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMy0zLTEtMS0w_ae2688d4-bc4e-433e-acff-3db254dd3e7a"
      unitRef="usd">42042000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNC0xLTEtMS0w_f6b29deb-dbb6-49f8-bf86-e3d3d14d2369"
      unitRef="usd">16363000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNC0zLTEtMS0w_5ee45197-edd3-4507-961f-c5ec24c4b055"
      unitRef="usd">15641000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNS0xLTEtMS0w_05b11ead-eaed-4ca5-81a3-ea19550a143e"
      unitRef="usd">71546000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNS0zLTEtMS0w_b7f39df8-3db4-4325-9485-cddcd509d3d2"
      unitRef="usd">57683000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNi0xLTEtMS0w_22c06c38-9f52-46c2-986a-c470ced837dc"
      unitRef="usd">-33201000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfNi0zLTEtMS0w_e4e4363b-25da-4a79-b969-13aef829c6b2"
      unitRef="usd">-57683000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOC0xLTEtMS0w_a8d39c8e-7715-49f1-8279-dee8777cb30c"
      unitRef="usd">511000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOC0zLTEtMS0w_d8b94d3b-6dbd-49a0-8c18-07c8c7936fbc"
      unitRef="usd">3261000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherExpenses
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOS0xLTEtMS0w_5d4616aa-08a2-4039-b731-3f79e1174219"
      unitRef="usd">325000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfOS0zLTEtMS0w_d5b04d7b-1c07-4116-b3a8-6f87ddbad897"
      unitRef="usd">58000</us-gaap:OtherExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTAtMS0xLTEtMA_9edc69a3-fa3f-4380-aa15-3425a34436b0"
      unitRef="usd">186000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTAtMy0xLTEtMA_38a16bfb-2ce5-4d5c-9d69-770f187300a0"
      unitRef="usd">3203000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTMtMS0xLTEtMA_3f4e7362-4bfc-4b88-ab0a-80761c0f9fb0"
      unitRef="usd">-33015000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTMtMy0xLTEtMA_c64f04de-4d1b-45bd-8402-104151931228"
      unitRef="usd">-54480000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTUtMS0xLTEtMA_140ed417-fcb2-4d99-939b-46e0a9b57c42"
      unitRef="usd">-369000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTUtMy0xLTEtMA_ceab7f73-dab0-447e-90b9-92f02eec2f41"
      unitRef="usd">465000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTYtMS0xLTEtMA_39392653-2a30-46a8-ae9a-e301c1141f16"
      unitRef="usd">-33384000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTYtMy0xLTEtMA_6cc071d2-0cf4-4c77-ba8b-75202c1c1bcb"
      unitRef="usd">-54015000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTctMS0xLTEtMA_156734ee-6c5c-449b-acd2-d34233b0241d"
      unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTctMy0xLTEtMA_563ed89b-d947-4b1c-97af-754e873071b6"
      unitRef="usdPerShare">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTgtMS0xLTEtMA_654b6994-2979-4559-b9ce-873606fe74d0"
      unitRef="shares">132165014</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xOS9mcmFnOjg0YzE0NGYxZDA2MDQ3OThhZmRmYzdjMGM4NzY1ZmNiL3RhYmxlOjM0NGI3ODI5NTBlMzQwNjNiNWM2OTY0MGYyNWMyNDQyL3RhYmxlcmFuZ2U6MzQ0Yjc4Mjk1MGUzNDA2M2I1YzY5NjQwZjI1YzI0NDJfMTgtMy0xLTEtMA_47e5b9cd-0df7-43e1-9495-0ed0c4f6cde8"
      unitRef="shares">108963522</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5d8d5d7cc5e4b369dc02b51cc31ba63_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi0xLTEtMS0w_f1b34b7f-884f-4bc3-8d7c-ac24f7934484"
      unitRef="shares">140474305</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id5d8d5d7cc5e4b369dc02b51cc31ba63_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi0zLTEtMS0w_68e95bbd-329c-4526-9fba-6072cd6754d7"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if62b8835b5894a97961539f08038f95b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi01LTEtMS0w_c1cb4b49-594a-43c1-9b3f-55b40674ada8"
      unitRef="usd">1725552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84f14c477d6247bcb8b315bd0a71ca2b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi03LTEtMS0w_47c76a32-03a6-4500-b50b-32b64c6e71e2"
      unitRef="usd">-646343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i964ffbd064624356a2ce6298cdba096c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi05LTEtMS0w_77c3bbb3-7525-407a-84be-8e3c992fb20c"
      unitRef="usd">268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMi0xMS0xLTEtMA_7141eaef-87f7-4eb3-a8bf-907cc6686a82"
      unitRef="usd">1079617000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy0xLTEtMS0w_2c940ee3-9a7c-4444-aad4-025ee22551c1"
      unitRef="shares">897744</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy0zLTEtMS0w_20241d2e-b542-493c-9fee-528c83ada373"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy01LTEtMS0w_a8662677-4f95-4b6e-8861-efabf708fb63"
      unitRef="usd">4059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfMy0xMS0xLTEtMA_5aabc9a0-165c-4dba-be3c-e0e8dc1a094e"
      unitRef="usd">4060000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNC01LTEtMS0w_52f522ec-6add-4fa0-afad-7acc7923b4b0"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNC0xMS0xLTEtMA_5506827d-fd49-4b08-aff8-763a84e24dba"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNS01LTEtMS0w_4101fd15-c09a-4d8a-b069-a0939062a121"
      unitRef="usd">16792000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNS0xMS0xLTEtMA_1577d938-b26c-4631-a29c-497a00ed9b63"
      unitRef="usd">16792000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i06a9f4891bdd4050aeec96b59a7bcbaf_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNi0xLTEtMS0w_a8f503df-af8a-4ce4-9d3e-dd4847d2e218"
      unitRef="shares">98026</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5664ad576e32462c8cc209b069f458e7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNi01LTEtMS0w_b861dfcf-27e8-4467-bd1d-a040c4f3b116"
      unitRef="usd">1984000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNi0xMS0xLTEtMA_aac38992-9a4e-43a5-8481-f1543f0d1237"
      unitRef="usd">1984000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="i7c89cfc2f1df420e80df10b19bb7045c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNy03LTEtMS0w_c699ced9-52e0-474a-bff2-9b3aab59c868"
      unitRef="usd">-33015000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfNy0xMS0xLTEtMA_b9873f65-8b5f-4326-bc69-d64c020c5848"
      unitRef="usd">-33015000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8fe5f193450e4e168c14067f2f2d182e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOC05LTEtMS0w_f49de07a-2e00-41fb-bc3f-8c94eb33e026"
      unitRef="usd">-369000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOC0xMS0xLTEtMA_1070e1e9-f4fb-43f5-a96a-1e6e1f348a56"
      unitRef="usd">-369000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i90d14178c6914d93a889ac3ed04c02a9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS0xLTEtMS0w_a55da04e-48b1-4e79-9bf7-855f607ec315"
      unitRef="shares">141470075</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i90d14178c6914d93a889ac3ed04c02a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS0zLTEtMS0w_9ce88efb-6dca-4dd1-a438-4550a6a9010e"
      unitRef="usd">141000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e5769ae558548b8b8db13dd5a510d74_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS01LTEtMS0w_b4c6037e-0408-491e-b50b-ccaec4d19748"
      unitRef="usd">1749097000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6562b41725243958717d88b90e4728a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS03LTEtMS0w_312da796-aa49-476a-ba67-2f727b4b3817"
      unitRef="usd">-679358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad89e42e666e4c46b385e97bc6797118_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS05LTEtMS0w_5bad1bf3-2816-4198-9104-14abc7ecd7c5"
      unitRef="usd">-101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjczNWY4YTU2NzE5YTQ3ZjE4M2YzYzUxYzJjY2I0NjlkL3RhYmxlcmFuZ2U6NzM1ZjhhNTY3MTlhNDdmMTgzZjNjNTFjMmNjYjQ2OWRfOS0xMS0xLTEtMA_a7f8327e-ceca-4e14-bfc4-e99e6f9b5514"
      unitRef="usd">1069779000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i01ccf8d124ff499fbbabad09739a47b4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi0xLTEtMS0w_45994a9e-70b7-42b0-a99a-f6fd1d42afa6"
      unitRef="shares">124267358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i01ccf8d124ff499fbbabad09739a47b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi0zLTEtMS0w_1c24a76f-a7f0-4c2e-97b7-74152a19af5c"
      unitRef="usd">124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic054bea3b59344829df6ae5dc931c60b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi01LTEtMS0w_36fa0d8c-1e0b-4a0c-9d8d-33d2bae9eaec"
      unitRef="usd">1023876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i313259e23cfb4a2ab8bd19b643ad78ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi03LTEtMS0w_2304e56f-8dd6-4407-8e9f-0078eaebcefc"
      unitRef="usd">-396122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8f4a1b7bf0a947fb8b63dca9e112a72b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi05LTEtMS0w_93d3f98a-fb4f-472f-99d5-baa42458c50d"
      unitRef="usd">1145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60c3252db9b543d6a7491e001ef77b45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMi0xMS0xLTEtMA_b221a4e1-29c0-443e-a252-1c0117ed6ded"
      unitRef="usd">629023000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMy0xLTEtMS0w_0391318e-8880-4a8f-8537-05a3a99d669f"
      unitRef="shares">339775</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMy01LTEtMS0w_ddd65c42-4406-4a92-8cfe-a6b12d936cf5"
      unitRef="usd">303000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMy0xMS0xLTEtMA_d14aa182-d00b-4cd3-9ff7-5844f8d0177e"
      unitRef="usd">303000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNC01LTEtMS0w_466a8939-a865-4311-96bf-afcebfb7861c"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNC0xMS0xLTEtMA_5f610947-d0c2-4dc1-9efb-fa1f759a7730"
      unitRef="usd">710000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNS01LTEtMS0w_b05aa790-5854-42dc-9fe0-463516c47344"
      unitRef="usd">14215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNS0xMS0xLTEtMA_a09287a2-da7f-47e7-a685-f8e4f51b96eb"
      unitRef="usd">14215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNi0xLTEtMS0w_16279507-0a9e-4e90-9982-85b3342dc2f8"
      unitRef="shares">84565</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNi01LTEtMS0w_eadff80c-17e3-4712-9de8-a49a2aa361d5"
      unitRef="usd">1438000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNi0xMS0xLTEtMA_ec4c4c99-88bf-4b5a-9a8c-49a03e7c09c9"
      unitRef="usd">1438000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="iacc623b05c8141db83c3d25a61bcb2cf_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0wLTEtMS0zNDEvdGV4dHJlZ2lvbjplYzdjNDRjZDkzYmY0MTdiYmY5YWNlYzgyNDllYTI0NF8zODQ4MjkwNjk3NDQ4_5ef1c35f-28b1-4506-ab5c-ded0cac9164f"
      unitRef="usd">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0xLTEtMS0xMjc_580d48c1-bd53-47ea-8210-9937c9046eae"
      unitRef="shares">570839</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic28fedf5a6bf418881ad7e8abd2131bf_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0zLTEtMS0xMjc_3a927305-6462-4e45-904a-252b508d5bca"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3faea87c6f8d4ef09a68d0b1f49346ad_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy01LTEtMS0xMjc_0fdc7287-8d48-4662-a5a7-b7cb7574851a"
      unitRef="usd">14844000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfNy0xMS0xLTEtMTI3_8ebc563b-bce1-41c2-9b7d-256e039eab3a"
      unitRef="usd">14845000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="ib4c2a96affa64584ab33e6e2aa1a077b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfOS03LTEtMS0w_51811127-4cc4-41ae-a55c-4725a7d1bd71"
      unitRef="usd">-54480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfOS0xMS0xLTEtMA_f97ddd10-7f39-4695-9592-486eb9d794bc"
      unitRef="usd">-54480000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i62bda789cb6d4921af13cb46113d49d7_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTAtOS0xLTEtMA_233c58a3-290e-426b-bb79-593335a5819c"
      unitRef="usd">465000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTAtMTEtMS0xLTA_5716df9b-7a26-4ada-8513-5e9519f66eaa"
      unitRef="usd">465000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i571a727871624fde93fb27f4e770e678_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtMS0xLTEtMA_db64fc4c-1da9-4cd8-92ca-2658cd0e5cb5"
      unitRef="shares">125262537</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i571a727871624fde93fb27f4e770e678_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtMy0xLTEtMA_6060fb4e-f62e-419f-98dc-4cd1b6d4c7df"
      unitRef="usd">125000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i989fb3c13e4c463ca87f71c224b0cb1d_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtNS0xLTEtMA_322ae224-1131-4d22-80d1-39d97c395daa"
      unitRef="usd">1055386000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3d9397e7db24081a8cb1f7febad8dfb_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtNy0xLTEtMA_ed5bc21b-122f-4551-9c4e-7889fa0f2a5d"
      unitRef="usd">-450602000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3ef8c73e705a4baa9efc6f53a2920a77_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtOS0xLTEtMA_bb5b1814-0aeb-45d4-9e89-3ac5c6dcf452"
      unitRef="usd">1610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i504c57fff4964e769a633e05ed2a8d01_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yMi9mcmFnOjJjMWM4ODUzZDY2YjQ2ZTI5YzFlYWZlODU1NzM3MWIwL3RhYmxlOjdhZDFlNGM2ZjI0ZjRkYTE4NGQzZjk2MDk3ZGVmNTBkL3RhYmxlcmFuZ2U6N2FkMWU0YzZmMjRmNGRhMTg0ZDNmOTYwOTdkZWY1MGRfMTEtMTEtMS0xLTA_9fc031b4-f354-4347-b411-bfb0095dd1c8"
      unitRef="usd">606519000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMy0xLTEtMS0w_30a095a5-90d2-459d-afbc-5970af3bfad3"
      unitRef="usd">-33015000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMy0zLTEtMS0w_986dd8ed-616d-4405-9b94-88b907cc0647"
      unitRef="usd">-54480000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNS0xLTEtMS0w_eab6f617-0175-442a-99f5-3322e8184bfd"
      unitRef="usd">16792000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNS0zLTEtMS0w_63cb026a-348c-4c05-ac74-96db72080a3f"
      unitRef="usd">14215000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNi0xLTEtMS0w_aba5c1ae-a0de-48ef-a34c-acbb2c433988"
      unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNi0zLTEtMS0w_70d63f55-493e-46dd-b0ac-e9ce3229f3f4"
      unitRef="usd">151000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNy0xLTEtMS0w_feb71e16-b658-41de-ba57-caf867425ed2"
      unitRef="usd">1918000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfNy0zLTEtMS0w_71ca78a3-2a23-45fd-863c-7e856139a0ef"
      unitRef="usd">1893000</us-gaap:Depreciation>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOC0xLTEtMS0w_62f34e43-e864-4955-b7b9-50f9ecbf1ff8"
      unitRef="usd">-1911000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOC0zLTEtMS0w_d38557b4-d1df-40d4-a5fc-7220f7c0c7cf"
      unitRef="usd">207000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:OperatingLeaseExpense
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOS0xLTEtMS0w_dd489e89-faad-46cc-a8c1-9e4a0a26dd89"
      unitRef="usd">2007000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfOS0zLTEtMS0w_6ba4468c-f7f9-4000-a674-63688bbc7a21"
      unitRef="usd">718000</us-gaap:OperatingLeaseExpense>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTEtMS0xLTEtMA_fc82a76a-d675-418e-aafa-f9b0e868c890"
      unitRef="usd">-325000</allo:IncomeLossFromCostMethodInvestment>
    <allo:IncomeLossFromCostMethodInvestment
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTEtMy0xLTEtMA_b6bce23d-1bfe-4637-99a3-0186ec0b6fc2"
      unitRef="usd">-64000</allo:IncomeLossFromCostMethodInvestment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTMtMS0xLTEtMA_4294117e-8e8e-4ec2-a810-d22d2555dea0"
      unitRef="usd">-740000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTMtMy0xLTEtMA_b7bcfb4f-0dfd-425d-bce7-09942c7987ec"
      unitRef="usd">-2552000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTQtMS0xLTEtMA_97882fdf-b802-4cda-aa7e-42ce47d9691d"
      unitRef="usd">799000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTQtMy0xLTEtMA_1f2c12a8-c62b-4d7a-af40-f7ae643c29d7"
      unitRef="usd">57000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTUtMS0xLTEtMA_7fb22bf0-8987-4a95-a241-957449c33630"
      unitRef="usd">4152000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTUtMy0xLTEtMA_6d2008fc-0a04-44eb-9118-2deffb46f03b"
      unitRef="usd">-1044000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMS0xLTEtMA_9253d575-7c12-4332-abeb-6551bda498ab"
      unitRef="usd">-4314000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMy0xLTEtMA_69bbca01-a9b4-4b73-9860-9b0f8587d5a4"
      unitRef="usd">-3913000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMS0xLTEtNzE2_ff9a05bd-19ea-4a68-acdb-5de7d99c7fc0"
      unitRef="usd">-38753000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTYtMy0xLTEtNzE2_52dacf49-ac22-4e01-82a9-1758f52eacfb"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTctMS0xLTEtMA_6e1b0f3b-2ede-4a22-8fff-01535dd5f3c5"
      unitRef="usd">-292000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTctMy0xLTEtMA_145fabbe-a4b9-4810-921c-70ad32a15f1f"
      unitRef="usd">-701000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTgtMS0xLTEtMA_0b8c3810-e283-49db-93ed-3eeec3b63c68"
      unitRef="usd">-49328000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMTgtMy0xLTEtMA_cee101c3-e824-4989-825b-8ea26e11caa4"
      unitRef="usd">-40809000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjAtMS0xLTEtMA_8545f65c-8966-488f-84c0-91a7761763a8"
      unitRef="usd">6461000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjAtMy0xLTEtMA_2886d68a-5de9-4a22-bc0b-c363077da46e"
      unitRef="usd">12253000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjEtMS0xLTEtNzIx_4071eaf8-3f36-4a8c-b9e6-ce2d7b600f44"
      unitRef="usd">15938000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjEtMy0xLTEtNzIx_ea167afd-6f62-49dd-888d-84451b223b34"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjItMS0xLTEtMA_4da6cb0c-9c7a-4f24-ad98-82112c63d824"
      unitRef="usd">268249000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjItMy0xLTEtMA_d5bab684-d8d4-456b-9c30-65693da2e8e2"
      unitRef="usd">120261000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjMtMS0xLTEtMA_59636cea-0d35-44fa-a839-bd6f1720cec6"
      unitRef="usd">149052000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjMtMy0xLTEtMA_9308b5cf-cfc3-42a9-8416-1a7ff3de902d"
      unitRef="usd">123015000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjQtMS0xLTEtMA_700c7988-c355-49a0-a63a-48e2982b1a1d"
      unitRef="usd">96798000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjQtMy0xLTEtMA_8bc41eda-d5c4-4c74-8908-7c1751fa7cc6"
      unitRef="usd">-15007000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i344a99f050b64372885525e2c3a160e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjYtMS0xLTEtMA_66160138-b13c-4bad-a33f-c48c5f643484"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4d1b5c9589324b51a5ac5e3aa31ea60e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjYtMy0xLTEtMA_08f16fb6-8b60-4091-97d2-647670b10405"
      unitRef="usd">14845000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjgtMS0xLTEtMA_30e6becc-843d-4fb4-84bc-bb5314d3349b"
      unitRef="usd">4060000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjgtMy0xLTEtMA_81355331-3a34-43ee-9897-5858cab421da"
      unitRef="usd">303000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromStockPlans
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjktMS0xLTEtMA_62d31cfe-1209-43c2-9888-c1e7d429367b"
      unitRef="usd">1984000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMjktMy0xLTEtMA_a1e46ed7-05b6-46a2-ad68-90219d9bbef8"
      unitRef="usd">1438000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzAtMS0xLTEtMA_0f0c8867-28d1-4ad6-9f74-a67f372407ae"
      unitRef="usd">6044000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzAtMy0xLTEtMA_a46d8e1c-3509-4788-af9e-3eba6a897924"
      unitRef="usd">16586000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzEtMS0xLTEtMA_e8075b15-d032-49b5-ac09-18aca8c87525"
      unitRef="usd">53514000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzEtMy0xLTEtMA_b21519b8-0566-4f2c-839a-a50d59d46d73"
      unitRef="usd">-39230000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzItMS0xLTEtMA_c5cdd762-dbd1-4bf6-af31-f1c3b41ce341"
      unitRef="usd">192800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60c3252db9b543d6a7491e001ef77b45_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzItMy0xLTEtMA_803062cf-ae32-4ae0-985b-eb74021d6091"
      unitRef="usd">179425000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzMtMS0xLTEtMA_9fd08174-e2b1-4327-aec0-b88db64fe74b"
      unitRef="usd">246314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i504c57fff4964e769a633e05ed2a8d01_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzMtMy0xLTEtMA_7dd00fe4-93f9-4a90-89a0-21ba4c51ab3a"
      unitRef="usd">140195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzUtMS0xLTEtMA_c0938901-8874-4007-991a-58f941781ff0"
      unitRef="usd">8299000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzUtMy0xLTEtMA_2e536578-0e26-4254-bd95-0bdc0930f7c7"
      unitRef="usd">4208000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <allo:CapitalizedSoftwareCostsIncurredNotYetPaid
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzYtMS0xLTEtNzMy_ff3fb11b-d2f2-4722-b0b3-d93afe25d7a8"
      unitRef="usd">277000</allo:CapitalizedSoftwareCostsIncurredNotYetPaid>
    <allo:CapitalizedSoftwareCostsIncurredNotYetPaid
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzYtMy0xLTEtNzMy_ed526169-8861-4818-b39d-58c849c133ae"
      unitRef="usd">0</allo:CapitalizedSoftwareCostsIncurredNotYetPaid>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzctMS0xLTEtMA_6d744925-b437-4d0f-9817-0eac98bc8cd3"
      unitRef="usd">966000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzctMy0xLTEtMA_c496da22-2ac9-4967-b2e8-ff2133d2a3bf"
      unitRef="usd">1396000</us-gaap:PaymentsForLeasingCostsCommissionsAndTenantImprovements>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzgtMS0xLTEtMA_36339926-c23b-4f2b-8704-e9dbef33fb18"
      unitRef="usd">-1111000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:PaymentsForProceedsFromTenantAllowance
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18yNS9mcmFnOmExODFiNDk3MWY0MTRlNmNiNjFkNDMyZTgwN2JmZjRkL3RhYmxlOjViNDI3NDIyMDU5ZDRmYjhhZjZhZGZmYzIyN2E0NDAwL3RhYmxlcmFuZ2U6NWI0Mjc0MjIwNTlkNGZiOGFmNmFkZmZjMjI3YTQ0MDBfMzgtMy0xLTEtMA_b7549fc9-13c8-4a31-9a34-d115e216dc2f"
      unitRef="usd">-532000</us-gaap:PaymentsForProceedsFromTenantAllowance>
    <us-gaap:NatureOfOperations
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zMS9mcmFnOjU5MjdkNWUxYmI1ZjRjY2I4NTIwOWIwYTkzZmEwYzIyL3RleHRyZWdpb246NTkyN2Q1ZTFiYjVmNGNjYjg1MjA5YjBhOTNmYTBjMjJfMzY2Nw_81f72516-7b53-4e04-a255-de54201c09d9">Description of Business&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Need for Additional Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#x2019;s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. The Company had cash and cash equivalents and investments of $964.2 million as of March&#160;31, 2021. Since inception through March&#160;31, 2021, the Company has incurred cumulative net losses of $679.4 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). &lt;/span&gt;&lt;/div&gt;The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company&#x2019;s results may be adversely affected.</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zMS9mcmFnOjU5MjdkNWUxYmI1ZjRjY2I4NTIwOWIwYTkzZmEwYzIyL3RleHRyZWdpb246NTkyN2Q1ZTFiYjVmNGNjYjg1MjA5YjBhOTNmYTBjMjJfMTg1Mw_2f7c8aea-5eb8-4c42-8d68-df6c00891b82"
      unitRef="usd">964200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zMS9mcmFnOjU5MjdkNWUxYmI1ZjRjY2I4NTIwOWIwYTkzZmEwYzIyL3RleHRyZWdpb246NTkyN2Q1ZTFiYjVmNGNjYjg1MjA5YjBhOTNmYTBjMjJfMTk0NA_c9135747-0be9-405e-8805-3a23d46b83f7"
      unitRef="usd">-679400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAzMQ_038a4e64-55d4-4792-b547-9f827442ae7c">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#x2019;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2021 and 2020, the condensed consolidated statements of stockholders&#x2019; equity as of March&#160;31, 2021 and 2020, the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2021 and 2020, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and related notes for the year ended December&#160;31, 2020, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 25, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2021, as compared to the significant accounting policies described in Note 1 of the &#x201c;Notes to Financial Statements&#x201d; in the Company&#x2019;s audited financial statements included in its Annual Report, with the exception of revenue recognition related to the collaboration revenue recognized in the three months ended March 31, 2021 and the recently adopted accounting pronouncements in the section below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue may be generated through collaboration research and license agreements. The terms of these agreements may contain multiple deliverables which may include (i) grant of licenses, (ii) transfer of know-how, (iii) research and development activities, (iii) clinical manufacturing and, (iv) product supply. The payment terms of these agreements may include nonrefundable upfront fees, payments for research and development activities, payments based upon the achievement of certain milestones, royalty payments based on product sales derived from the collaboration, and payments for supplying product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606, Revenue from Contracts with Customers (ASC 606). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that the Company determines should be accounted for under ASC 606, the Company assesses which activities in the collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. A performance obligation represents a promise in a contract to transfer a distinct good or service to a customer, which represents a unit of accounting in accordance with ASC 606. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once the Company has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. A portion of the consideration should be allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The total consideration which the Company expects to collect in exchange for the Company&#x2019;s products is an estimate and may be fixed or variable. The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The transaction price is re-evaluated, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately. Revenue is recognized when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers. Funds received in advance are recorded as deferred revenue and are recognized as the related performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued Accounting Standard Update No. 2020-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Equity Securities (Topic 321), Investments &#x2013; Equity Method and Joint Ventures (Topic 323)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which clarifies the interactions between Topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company adopted this standard on January 1, 2021 on a prospective basis. Adoption of the new guidance had no significant impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAzMg_f3f3150a-b48a-4078-a89d-b0258db7dd49">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#x2019;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2021 and 2020, the condensed consolidated statements of stockholders&#x2019; equity as of March&#160;31, 2021 and 2020, the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2021 and 2020, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited financial statements and related notes for the year ended December&#160;31, 2020, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February 25, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAyNw_4d987479-e83d-47b0-b586-3071a5573a17">Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <allo:ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAyOA_8c9cbf15-751f-4fb2-84ae-dabce6afcf34">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2021, as compared to the significant accounting policies described in Note 1 of the &#x201c;Notes to Financial Statements&#x201d; in the Company&#x2019;s audited financial statements included in its Annual Report, with the exception of revenue recognition related to the collaboration revenue recognized in the three months ended March 31, 2021 and the recently adopted accounting pronouncements in the section below.&lt;/span&gt;&lt;/div&gt;</allo:ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfMzg0ODI5MDcyOTk2NA_92eb5568-b070-48e8-90da-fb4817bcdc11">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue may be generated through collaboration research and license agreements. The terms of these agreements may contain multiple deliverables which may include (i) grant of licenses, (ii) transfer of know-how, (iii) research and development activities, (iii) clinical manufacturing and, (iv) product supply. The payment terms of these agreements may include nonrefundable upfront fees, payments for research and development activities, payments based upon the achievement of certain milestones, royalty payments based on product sales derived from the collaboration, and payments for supplying product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606, Revenue from Contracts with Customers (ASC 606). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For elements of those arrangements that the Company determines should be accounted for under ASC 606, the Company assesses which activities in the collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. A performance obligation represents a promise in a contract to transfer a distinct good or service to a customer, which represents a unit of accounting in accordance with ASC 606. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once the Company has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. A portion of the consideration should be allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The total consideration which the Company expects to collect in exchange for the Company&#x2019;s products is an estimate and may be fixed or variable. The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The transaction price is re-evaluated, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately. Revenue is recognized when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers. Funds received in advance are recorded as deferred revenue and are recognized as the related performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <allo:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAzNA_79fbecfa-0bd2-49dd-95ad-e9191768a9b4">Recently Adopted Accounting Pronouncements&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued Accounting Standard Update No. 2020-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Equity Securities (Topic 321), Investments &#x2013; Equity Method and Joint Ventures (Topic 323)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which clarifies the interactions between Topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company adopted this standard on January 1, 2021 on a prospective basis. Adoption of the new guidance had no significant impact on the Company's condensed consolidated financial statements.&lt;/span&gt;</allo:RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock>
    <allo:RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNC9mcmFnOmFmZGY3NDRkYTU3ZjRlNDM5NzBhZDExNmU3MjkwMTY1L3RleHRyZWdpb246YWZkZjc0NGRhNTdmNGU0Mzk3MGFkMTE2ZTcyOTAxNjVfODAyNA_a4e8741e-6b25-45fc-9c69-affb29326791">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</allo:RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfOTA0_bca82606-799a-4dd7-9feb-c3df967a3c3a">Fair Value Measurements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets or liabilities as of March&#160;31, 2021 and as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Included within cash and cash equivalents on the Company&#x2019;s condensed consolidated balance sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id12fb68b0dae4f7a91f55375717a8a56_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_31780b62-1e2d-432b-b991-af70f905a0e0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i165eea287dc54c3585c522f50f626b8b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_b51faa19-39db-4d5d-b1d3-5a84fed659a0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i165eea287dc54c3585c522f50f626b8b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_ca49c28c-570a-40c8-8dd0-af2cc2be7953"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id12fb68b0dae4f7a91f55375717a8a56_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfNTE3_e8783496-2c08-4d66-b48b-8391860c5ba9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RleHRyZWdpb246ZGE0MTFmZTY3N2ZlNDNlN2E2NDBhY2I5YTY5MDQ1ODNfOTAw_55ebb18f-4c4a-4b5c-a639-b65a73e31012">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;566,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;549,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Included within cash and cash equivalents on the Company&#x2019;s condensed consolidated balance sheets&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b8935686a9046d6abb1898661b57010_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC0xLTEtMS0w_40148f24-673d-4597-bf88-921eae637c60"
      unitRef="usd">176627000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0ea4f1b6e1f4122bf000ec2f062663f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC0zLTEtMS0w_b2c66fcd-8398-4080-84fb-176f627475a9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0e44b399f5c47039974adea069751e0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC01LTEtMS0w_04b6e2b3-3b64-444f-a219-e7e624c3ffa8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i55f0f98344ea41ee89c1226f1ebfb886_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNC03LTEtMS0w_abc1eba8-75a9-44a0-8b47-e5fba09eb7f0"
      unitRef="usd">176627000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia444669c28534a2f916cca00d9a1084c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS0xLTEtMS0w_0785b18c-8d94-4933-b567-e93613bd3fb9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia0453ee7dff14085ab6fbbaa87e73917_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS0zLTEtMS0w_8c278e94-b197-48ab-aae1-a6f15e3dd67c"
      unitRef="usd">39993000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b8ebc8cb37b496daa43a0b287fbcb06_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS01LTEtMS0w_e3535208-e0d1-490b-a4b1-9208f0c7d8f5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idb31a0895811482e8e0345481a846bb5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNS03LTEtMS0w_30ed9b75-4201-4249-965f-9413f9095200"
      unitRef="usd">39993000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1842dec3973f4c7fbaefb4e0b73af312_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi0xLTEtMS0w_4f19b281-3995-4399-ad91-310a6c0a869d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8af6adb4d85d4284a8361787ad478d67_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi0zLTEtMS0w_091642f1-71ec-493a-89cb-09d0572f626e"
      unitRef="usd">221891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib91dea83a7374424acc07bf7143a9de1_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi01LTEtMS0w_ca95f857-c1ac-4ac2-8cc8-1250d91f2b8f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibbf32eb5eb78476fbab5c4d927d70513_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNi03LTEtMS0w_3d68f87a-b80c-4a98-937d-93bfbc2b4eb2"
      unitRef="usd">221891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib7e0375da1c3406a99fb9a733a7af9e2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy0xLTEtMS0w_19a77c47-5e71-4ab3-89ff-3a95c0b53b2d"
      unitRef="usd">390318000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic1db911011e7478f95e414ea628f6000_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy0zLTEtMS0w_26bd603e-5043-4551-b6b0-1882ac8abebf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i639fb921dad04c38b75ac3f84cea54ce_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy01LTEtMS0w_c1964722-6569-4060-b5eb-f2750ac7dfdf"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i78c77fed04674b399c499733307337a2_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfNy03LTEtMS0w_b5c08525-e78f-40a6-90b1-08d674871109"
      unitRef="usd">390318000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id39b02d830004ca0ae7768a7ab1cfb0a_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC0xLTEtMS0w_9087849f-e638-4ff6-ad71-cec0d816dc2e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i58b8541c2de84111941a459c4cca9e41_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC0zLTEtMS0w_7d9bd9ce-d3f4-42f2-93c0-f6c197cff171"
      unitRef="usd">75087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b1f946978604abd96aacdf6511485f5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC01LTEtMS0w_543717c0-e6c8-4b37-a49d-8aabbfaa6f15"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib77f8b7841b54c16b57577533fef2ad5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOC03LTEtMS0w_76e3340f-c928-4d8f-97cc-93d6aed51395"
      unitRef="usd">75087000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i73b87df3539b4602a0cb77a894476522_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS0xLTEtMS0w_152f9cf4-20ca-4f69-9bb4-36bdb66b5bdc"
      unitRef="usd">566945000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i190755c884ba4407a67755b5981209fb_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS0zLTEtMS0w_9e13d493-7fbb-4145-b9b6-8fedb69bbac7"
      unitRef="usd">336971000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id12fb68b0dae4f7a91f55375717a8a56_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS01LTEtMS0w_92d0af24-5608-4050-8913-f20415595fa1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i425ece1b06434afbbb883c90e17bdb61_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjdlMzBmYmRmMmIyMjQyNTVhNTNlMDU4ZWYxNmZhODlhL3RhYmxlcmFuZ2U6N2UzMGZiZGYyYjIyNDI1NWE1M2UwNThlZjE2ZmE4OWFfOS03LTEtMS0w_13a33d09-59f4-43ce-9f0b-581ff763b429"
      unitRef="usd">903916000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3619adf51ab94510807b3324a8c3fb3e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC0xLTEtMS0w_782a952c-be0e-4c7f-8925-b2cba4120e22"
      unitRef="usd">102039000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if31b6a89951d44f89dbabea0393f7de8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC0zLTEtMS0w_d224e4be-ec32-4aa3-8b65-792f113ffdc5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib0aa4add5f0548b1bbcfbe54905115be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC01LTEtMS0w_a5927c79-084c-4297-a87d-15516ca50f41"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib345026090ae4d7aaf20623437eda88e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNC03LTEtMS0w_dc6004db-2a39-4bcf-923c-f4aff69c8621"
      unitRef="usd">102039000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ieb40fd0c453149bf89e2575d7dfd1a8b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS0xLTEtMS0w_8fd397f6-e7c6-4b68-bf00-8c0ebdbb3a45"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8693ce8adb3e4f87894764efa1dc1be6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS0zLTEtMS0w_3b8bd89b-6773-4dd8-88c6-61f554ec3522"
      unitRef="usd">58975000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i27ee0888939a402dbc25013b3f240b0f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS01LTEtMS0w_1f249d47-c763-448a-af05-2f8ab436a073"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i34403b8da4544edeb9bcf602d09ea7e4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNS03LTEtMS0w_1bfea288-b15e-4ef6-8e25-b4ac2807fe14"
      unitRef="usd">58975000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i925a07a2a5da4c4a954ec447c21627d9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi0xLTEtMS0w_4543ecf0-429f-49a6-bd35-01d634d2ee43"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i94dd7dacb51143a7be602182537411c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi0zLTEtMS0w_e316203c-8f57-4d27-8770-de85246e8f8a"
      unitRef="usd">262757000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id36ca55f6d2d4f6e82521817fdfb9e12_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi01LTEtMS0w_b9f77dcf-1f5a-4cf5-a10c-f02ce5522269"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i22b516ddd68d487c9dc9976d12bdb980_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNi03LTEtMS0w_088b10b5-5766-4fc3-b490-8e4b99052ec8"
      unitRef="usd">262757000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31a51a763aa048458e78d279f2649278_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy0xLTEtMS0w_c524ca80-c00e-4089-9b27-64a3ab885416"
      unitRef="usd">446996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i89b7be258eff4efa93d6f7841ab564b8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy0zLTEtMS0w_1eb676bd-16e6-47c0-be5b-ad852d1ba7a4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if3a8e946c7364e21ad7e16db6b94a4a4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy01LTEtMS0w_36e3f7e1-eea4-4488-96d4-6fbf830d10fb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i98c4ad06e92445fdb0c7c1102056f114_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfNy03LTEtMS0w_ce8c64b8-aebf-40c9-bbd0-1fd5502dcdc3"
      unitRef="usd">446996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i24de2ec1a8294b05a3fad113a1acd836_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC0xLTEtMS0w_01aef45d-1bfb-4410-9000-fa2369df9491"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if5e4e73bf01548db85151208211a884f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC0zLTEtMS0w_85bbbe0e-2a6d-48e5-a184-181cfb05d87b"
      unitRef="usd">80039000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic62115cf799f465eb2f3b2b3d65a0c40_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC01LTEtMS0w_67d5488d-3252-4e99-91ec-656d957787a5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1ab2e4c6e7c24bac8d2935a6b6c36a9d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOC03LTEtMS0w_8edebc8c-1447-43e0-846e-2e118451674c"
      unitRef="usd">80039000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9fc6467fc7c44ae18600b20b5a30e83e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS0xLTEtMS0w_98880587-f40f-430f-8bff-89f9b18238d6"
      unitRef="usd">549035000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d8d696029864336acfec926937a4a09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS0zLTEtMS0w_762017b6-119b-461f-858e-95924d57ecf1"
      unitRef="usd">401771000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i165eea287dc54c3585c522f50f626b8b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS01LTEtMS0w_26dee2c0-6886-4e2a-ac8b-fe6b6f2fca82"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie501860c6b9a4e07a7bb38b17e7be2b3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18zNy9mcmFnOmRhNDExZmU2NzdmZTQzZTdhNjQwYWNiOWE2OTA0NTgzL3RhYmxlOjAwNDhhN2I0YmVkNTQ4NmE4MjJiZGYzOGFlMmJhYWQ5L3RhYmxlcmFuZ2U6MDA0OGE3YjRiZWQ1NDg2YTgyMmJkZjM4YWUyYmFhZDlfOS03LTEtMS0w_9770c2ac-d202-4a66-b87e-bc76ee59bb4b"
      unitRef="usd">950806000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfOTYx_3e0b525e-c1ab-4d45-b248-b832c120f124">Financial Instruments&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021,&#160;the remaining contractual maturities of available-for-sale securities were less than 3 years. There have been no significant realized losses on available-for-sale securities for the periods presented. As of March&#160;31, 2021, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more likely than not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#x2019;s marketable securities are due to market factors. As of March 31, 2021 and December 31, 2020, securities with a fair value of zero and $5.0&#160;million respectively, were in a net unrealized loss position for more than 12 months. To date, the Company has not recorded any impairment charges on marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfOTYy_5acf2024-bf73-499b-9f66-862428b27f90">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&#160;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Classified as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy0xLTEtMS0w_f3b23c9d-557a-4e4d-b5f8-fcaa72020505"
      unitRef="usd">176627000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy0zLTEtMS0w_a9865f7b-aabd-4dff-9284-67415ae90e54"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy01LTEtMS0w_2282b06e-d551-40dc-a9bf-016c8d6738e7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i087dace4c72a4178aadef0c41c9bb356_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMy03LTEtMS0w_2d4c569f-fbc7-4752-a5ce-3d8984e80e15"
      unitRef="usd">176627000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC0xLTEtMS0w_4534be32-f531-4c3e-8451-e4116d1b0052"
      unitRef="usd">39986000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC0zLTEtMS0w_b1a05efe-291b-492a-80b1-700e5768d783"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC01LTEtMS0w_0ea6fece-3192-4e3b-94fc-a29ced34e47e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i007c67785640431a9ade0b3cbec093e5_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNC03LTEtMS0w_5578cd3f-31f1-43b3-9dae-142f7007c4ae"
      unitRef="usd">39993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6376740830184eaa825958505c990d48_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS0xLTEtMS0w_cb394716-9cbd-47df-9536-32310a750872"
      unitRef="usd">221738000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6376740830184eaa825958505c990d48_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS0zLTEtMS0w_423af8dc-27e3-4b2d-968b-aeb568eec155"
      unitRef="usd">184000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6376740830184eaa825958505c990d48_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS01LTEtMS0w_11022ea9-8de8-40fb-b27a-da94c319b95c"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6376740830184eaa825958505c990d48_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNS03LTEtMS0w_b1473272-2ed2-4e1c-a354-27be486650bf"
      unitRef="usd">221891000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi0xLTEtMS0w_9275b49a-2235-49eb-baec-f9f3013a143f"
      unitRef="usd">390132000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi0zLTEtMS0w_1cef983e-5f6e-4b9d-9b71-5d06b64438a5"
      unitRef="usd">194000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi01LTEtMS0w_8ac7d32f-4c0d-4802-b5f6-7679e983e291"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f300d7009234b3da0340504d7e659a9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNi03LTEtMS0w_71845a1c-3dc0-464d-bd88-c6003b97420e"
      unitRef="usd">390318000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy0xLTEtMS0w_17d99b63-7653-4321-874f-c696c330c275"
      unitRef="usd">75092000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy0zLTEtMS0w_7eb39815-3d56-425f-8d34-ca0bba09a100"
      unitRef="usd">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy01LTEtMS0w_3fb1561e-3a79-4915-8928-f59994151490"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i020d13f6e1c44d089ffa8eee1c97beb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfNy03LTEtMS0w_2ce24be0-f5fc-4584-aebf-4471ba745a14"
      unitRef="usd">75087000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC0xLTEtMS0w_a91f95b0-b32d-4d17-a8a9-818734799c46"
      unitRef="usd">903575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC0zLTEtMS0w_6d55251d-d56e-48bf-aaa0-8efa1e26bcb2"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC01LTEtMS0w_8e852753-145c-47e5-bae3-101537533e52"
      unitRef="usd">59000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfOC03LTEtMS0w_46f89f19-2fae-4d53-b69b-00885a53f605"
      unitRef="usd">903916000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTEtNy0xLTEtMA_fc700a7d-b288-4ebd-ab10-b840a0ae7373"
      unitRef="usd">176627000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTItNy0xLTEtMA_5f9b5ecb-0154-4ba5-af72-bfafeb3fbba6"
      unitRef="usd">462716000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTMtNy0xLTEtMA_8482b0a3-a0e8-41d1-b7ac-20f372831a46"
      unitRef="usd">264573000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjAwNzMwNDFlZDUyODQzMjJhZTdkZDAzY2RjNjdkZjFhL3RhYmxlcmFuZ2U6MDA3MzA0MWVkNTI4NDMyMmFlN2RkMDNjZGM2N2RmMWFfMTQtNy0xLTEtMA_e3e7ff18-b46c-415d-9a94-0db032bd6d88"
      unitRef="usd">903916000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i81538cf0c097486badfa1786facbcdff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy0xLTEtMS0w_e923addf-3fed-462e-a868-9a7ff76b6fce"
      unitRef="usd">102039000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i81538cf0c097486badfa1786facbcdff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy0zLTEtMS0w_b6338e17-3d8a-433e-bfcb-df3f306684e2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i81538cf0c097486badfa1786facbcdff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy01LTEtMS0w_101640d8-7cce-44b9-8454-05992bb8af23"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i81538cf0c097486badfa1786facbcdff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMy03LTEtMS0w_a4c25374-47be-4351-bc46-4700d247e8fe"
      unitRef="usd">102039000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC0xLTEtMS0w_008b3780-1115-45e7-adfd-c54043d45c50"
      unitRef="usd">58969000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC0zLTEtMS0w_ea36360f-a170-49e5-85ef-51a70de5659f"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC01LTEtMS0w_03fea637-77fe-4652-bd80-70fbb53ab0f6"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f071d9be3e64ae7909bb18979e547ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNC03LTEtMS0w_594e321a-a062-4384-bc76-74330ec6f721"
      unitRef="usd">58975000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7a1941e2894148b696f50b001c993d68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS0xLTEtMS0w_c1a60420-e543-42b8-a2ff-bf2c7fbc109e"
      unitRef="usd">262349000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7a1941e2894148b696f50b001c993d68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS0zLTEtMS0w_8443d7d6-347d-40dd-8c21-15699cecd1c9"
      unitRef="usd">444000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7a1941e2894148b696f50b001c993d68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS01LTEtMS0w_614735a5-6cb6-43e1-b38d-fe988e89eade"
      unitRef="usd">36000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a1941e2894148b696f50b001c993d68_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNS03LTEtMS0w_a23d3d19-2767-41ed-a9b4-ee6da62844fc"
      unitRef="usd">262757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi0xLTEtMS0w_f02487b7-b051-4ea3-8910-cb54679e58df"
      unitRef="usd">446726000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi0zLTEtMS0w_17c857d7-426f-4076-8701-4ce3f7eb05b6"
      unitRef="usd">282000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi01LTEtMS0w_1ee744fa-9042-434d-8517-19089bc2af9d"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icba50cbc018a4f96b6da7385f98c25c9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNi03LTEtMS0w_beea2117-70d5-4d0d-94f5-6c97c5dd359a"
      unitRef="usd">446996000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy0xLTEtMS0w_1bd7d35d-3be2-4203-8574-90277733aaa4"
      unitRef="usd">80012000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy0zLTEtMS0w_5f865957-6c25-4ff8-a50f-3dc591b059eb"
      unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy01LTEtMS0w_afa42d45-e092-46fc-baaf-b97cc3d804a7"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6758881023d4b35b0388e05d5360ed4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfNy03LTEtMS0w_bcbd8213-2703-4e8b-985a-10cc524ba971"
      unitRef="usd">80039000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC0xLTEtMS0w_5d5caafd-09b6-40ee-a310-ae50d0e5ddf3"
      unitRef="usd">950095000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC0zLTEtMS0w_d9ee5276-b1c3-4100-b50e-8a436e524153"
      unitRef="usd">764000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC01LTEtMS0w_0fd89903-2b50-4c24-8215-dc4b0cb579b3"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfOC03LTEtMS0w_62ec0906-e010-4da1-b21a-08f4daa85fbb"
      unitRef="usd">950806000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTEtNy0xLTEtMA_23a3035b-5974-4cec-9741-effe5c9ec4b0"
      unitRef="usd">102039000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTItNy0xLTEtMA_00fb7216-3913-4ecb-b6be-2cc55b9d2e23"
      unitRef="usd">644559000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTMtNy0xLTEtMA_c93224dd-254d-44c1-9566-d976a8db4d93"
      unitRef="usd">204208000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <allo:CashEquivalentsAndShortTermInvestments
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RhYmxlOjQ2MWUyOTZhMjg5NjQ3NzRhNTNkMTI4ZDU2Y2NiMzljL3RhYmxlcmFuZ2U6NDYxZTI5NmEyODk2NDc3NGE1M2QxMjhkNTZjY2IzOWNfMTQtNy0xLTEtMA_b338f5fc-71e3-4d9b-a042-840db249bd9a"
      unitRef="usd">950806000</allo:CashEquivalentsAndShortTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfMzEw_c0ae7875-5f1a-4c3b-9676-b8f83914bb59">P3Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfMzg0ODI5MDY5ODgwMw_32e6d37d-dd62-4b5c-824d-9abd0b2b899e"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180My9mcmFnOjU2NzJmM2M2ZjQzZTQ2ZWY5OGJmNmM2Yjk5MDBjZjBkL3RleHRyZWdpb246NTY3MmYzYzZmNDNlNDZlZjk4YmY2YzZiOTkwMGNmMGRfMzg0ODI5MDY5ODc5MA_b04c1633-f1eb-44f5-bcc8-5fbabb5ac95c"
      unitRef="usd">5000000.0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RleHRyZWdpb246M2E0NmI0OTlmYjU0NGJkYzgyMTU3M2UyMDk3YTc4ODdfMTE1_00d9b715-8859-43f4-a98c-b8d59beed7ae">Balance Sheet Components&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and Equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RleHRyZWdpb246M2E0NmI0OTlmYjU0NGJkYzgyMTU3M2UyMDk3YTc4ODdfMTE2_44004e0a-52c8-4c57-ba88-a8b7204b532e">Property and Equipment consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.014%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers equipment and purchased software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie50601403e82462a993279d9571f8647_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMi0xLTEtMS0w_b899e155-127a-4c96-800d-94abd964a1c3"
      unitRef="usd">73339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2c98ae4709454667a0750d6459d7ac91_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMi0zLTEtMS0w_66d8133b-0db0-4a69-8039-0bd9e6cfada8"
      unitRef="usd">68944000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6c63d34d1bfe495ea11be0647eed83c7_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMy0xLTEtMS0w_bec31451-dc1d-4eb2-ab18-4230c76ae6ee"
      unitRef="usd">31518000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib2ac0012f0854969a20a692346460384_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfMy0zLTEtMS0w_253b3441-aa5b-47ec-bcd1-17d641596216"
      unitRef="usd">31518000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8d90dd4d682d4d36a32874f3b745fcb9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNC0xLTEtMS0w_78b2d7ba-b253-426a-9e18-dc86b40777d6"
      unitRef="usd">25112000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie1d87e6eccd34d439d8a2297c843c8df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNC0zLTEtMS0w_63a1f621-69d8-4422-9f85-0d5c2ae3838d"
      unitRef="usd">23810000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6974fc646add4195bfcc6857939ed0d3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNS0xLTEtMS0w_c9ea5b0c-73dd-499c-b298-8cade2c43425"
      unitRef="usd">4271000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia10370fc5f7e4e4e8a0c23adbcbc6922_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNS0zLTEtMS0w_fc0b4f33-0c93-44e3-bb96-23786f4eb36c"
      unitRef="usd">4088000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieed9ef18264f4d15aa5462978b00b3bf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNi0xLTEtMS0w_aaf66043-707c-4c7a-b492-8d366b65d168"
      unitRef="usd">3731000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0fc7cbd26add4fff8fe2bc2d9c90f90d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNi0zLTEtMS0w_8388c069-6939-46b2-b1e7-ab96b733e132"
      unitRef="usd">3388000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNy0xLTEtMS0w_d0c7245b-d3b0-41a9-b39c-291dffc640ca"
      unitRef="usd">137971000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfNy0zLTEtMS0w_8ecd4aef-1aec-4461-a3a9-7a4c35456ad1"
      unitRef="usd">131748000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOC0xLTEtMS0w_d0c32d29-358c-4b2c-86f5-9bfb72d4b2d2"
      unitRef="usd">14825000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOC0zLTEtMS0w_8558a214-3bda-4833-bef3-2ff382fc4fca"
      unitRef="usd">12908000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOS0xLTEtMS0w_b12f7ad7-dd5a-4907-9101-2d64a4a5258a"
      unitRef="usd">123146000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180Ni9mcmFnOjNhNDZiNDk5ZmI1NDRiZGM4MjE1NzNlMjA5N2E3ODg3L3RhYmxlOmFmNjJlNGExNTI2YzQwNGJhODFjMDMzYTQ0ZTI2MzBlL3RhYmxlcmFuZ2U6YWY2MmU0YTE1MjZjNDA0YmE4MWMwMzNhNDRlMjYzMGVfOS0zLTEtMS0w_afc3eaf7-1b1b-4292-af72-912eb286b4b7"
      unitRef="usd">118840000</us-gaap:PropertyPlantAndEquipmentNet>
    <allo:LicenseAgreementsTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTg4ODY_70170465-015f-41d1-bd54-25e6a46677a3">License Agreements&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Asset Contribution Agreement with Pfizer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three months ended March&#160;31, 2021 and 2020 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#x2019;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Collaboration and License Agreement with Cellectis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#x2019;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#x2019;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#x2019; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#x2019; prior written notice in the event of the other party&#x2019;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs the Company incurred in connection with this agreement were recognized as research and development expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and March&#160;31, 2020, $5.0 million and zero costs were incurred related to the achievement of a clinical development milestone under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License and Collaboration Agreement with Servier&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19, ALLO-501 and ALLO-501A in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#x2019;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#x2019;s sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42.0 million and &#x20ac;70.5 million ($82.7 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#x2019;s election not to pursue such rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#x2019;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#x2019;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2021 and 2020, the Company recorded $3.9 million  and $1.0 million, respectively,&#160;of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. As of March&#160;31, 2021 and December&#160;31, 2020, amounts due from Servier of $4.5 million and $3.8 million, respectively, were recorded in other current assets in the accompanying condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research Collaboration and License Agreement with Notch&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#x2019;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#x2019;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#x2019;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#x2019;s election, following the joint development committee&#x2019;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#x2019;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $10&#160;million during the year ended December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $5.0&#160;million investment in Notch&#x2019;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#x2019;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#x2019;s Board of Directors. In February 2021, the Company made an additional $15.9 million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was 20.7% on a voting interest basis. The Company did not have a controlling interest in Notch as of March 31, 2021, and continued to account for its investment in Notch as an equity method investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Notch Agreement, Notch will be eligible to receive up to $7.25&#160;million upon achieving certain agreed research milestones, up to $4.0&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#x2019;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#x2019;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#x2019;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#x2019; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#x2019;s insolvency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the three months ended March&#160;31, 2021 and 2020, the Company recorded $1.2 million and $0.3 million, respectively, in collaboration costs as research and development expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Strategic Alliance with The University of Texas MD Anderson Cancer Center&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 6, 2020, the Company entered into a strategic five-year collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The Company and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the Company has committed up to $15.0&#160;million of funding for the duration of the agreement. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. The Company made an upfront payment of $3.0&#160;million to MD Anderson in the year ended December 31, 2020. The Company is obligated to make further payments to MD Anderson each year upon the anniversary of the agreement effective date through the duration of the agreement term. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, among other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Joint Venture and License Agreement with Allogene Overland Biopharm (CY) Limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2020, the Company entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by the Company and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Share Purchase Agreement, the Company acquired Seed Preferred Shares in Allogene Overland representing 49% of Allogene Overland's outstanding stock as partial consideration for the License Agreement, and Overland acquired Seed Preferred Shares representing 51% of Allogene Overland's outstanding stock for $117.0&#160;million in upfront and certain quarterly cash payments, to support operations of Allogene Overland. As of December 31, 2020, the Company and Overland are the sole equity holders in Allogene Overland. The Company received $40&#160;million from Allogene Overland as partial consideration for the License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the License Agreement, the Company granted Allogene Overland an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell candidates directed at four targets, BCMA, CD70, FLT3, and DLL3, in the JV Territory. As consideration, the Company would also be entitled to additional regulatory milestone payments of up to $40.0&#160;million and, subject to certain conditions, tiered low-to-mid single-digit sales royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promises that the Company concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and delivery of know-how, (2) the manufacturing license, related know-how and support, (3) if and when available know-how developed in future periods, and (4) participation in the joint steering committee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Fixed consideration exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. Milestone fees were constrained and not included in the transaction price due to the uncertainties of research and development. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The shares of Series Seed Preferred Stock were accounted for as part of the Company&#x2019;s joint venture and equity method accounting upon formation of the joint venture, and as such, were excluded from the transaction price. The Company determined that the initial transaction price consists of the upfront payment of $40.0&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The transaction price allocated to the license of intellectual property and delivery of know-how will be recognized upon grant of license and delivery of know-how. The transaction price allocated to (i) the manufacturing license, related know-how and support services, (ii) if and when available know-how developed in future periods, and (iii) participation in the joint steering committee, will be recognized over time as the services are delivered. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that Allogene Overland is a variable interest entity as of March 31, 2021 and December 31, 2020, respectively. The Company does not have the power to independently direct the activities which most significantly affect Allogene Overland's economic performance. Accordingly the Company did not consolidate Allogene Overland because the Company determined that it was not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2021 the Company recognized $38.3 million of collaboration revenue, primarily related to the license of intellectual property and delivery of the know-how performance obligation which was delivered in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;</allo:LicenseAgreementsTextBlock>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i407ac8a1e41242c9be72213ac2a23645_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNzk3_46d77fa3-5fb6-4d41-b065-19cd8ba9c437"
      unitRef="usd">30000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i1278a0a51b1640cdbb03fe0a13675240_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfODAz_38a2e1f2-acc7-4134-9f75-66250bb20059"
      unitRef="usd">60000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialRegulatoryAndDevelopmentMilestones
      contextRef="i1278a0a51b1640cdbb03fe0a13675240_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfOTA0_255f63c6-0a16-418d-a449-c81122707eb4"
      unitRef="usd">840000000.0</allo:AggregatePotentialRegulatoryAndDevelopmentMilestones>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i48368b1762a44efd868c61b94c87d3b4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTM1OA_673d0a72-692e-4a46-a041-27af1de27752"
      unitRef="usd">325000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:MilestonePayments
      contextRef="i5cf55e9cbdb241bda666ae71bf9b4636_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY2MA_3e1963c1-2924-4518-aaec-2e05e09d8e7c"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:MilestonePayments
      contextRef="i48368b1762a44efd868c61b94c87d3b4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY2MA_b46d6f31-bd13-4c25-ba93-261a62df11ec"
      unitRef="usd">0</allo:MilestonePayments>
    <allo:RoyaltyObligationPeriodFromDateOfFirstSale
      contextRef="i7c01076628f14533a22a6ed1bf7f645f_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjMzMg_574d96eb-796e-4df4-aa03-6df386a00122">P12Y</allo:RoyaltyObligationPeriodFromDateOfFirstSale>
    <allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget
      contextRef="i2d3809bdb24e4487867ca711c35faed6_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDYxMA_b0e2c895-7646-48b3-a4fe-20b274a61677"
      unitRef="usd">185000000.0</allo:MaximumPaymentsRequiredPerProductAgainstSelectedTarget>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i5979e4ee83f743c18eb44a9e12a96a76_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDc1MQ_5085354f-2c35-48c1-bb84-be9ed679a184"
      unitRef="usd">2800000000</allo:AggregatePotentialMilestonePayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0d63cc5b557e4a7781a31dbcd492270b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfODM0MQ_686ddb1c-a9c4-4cef-a934-c4ceff0ccf3f"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i62d689d0f8bd4b609f81b32837461df5_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjc0ODc3OTA5NzAyMA_1adacbbd-3c4f-4159-afd2-0b00eed88398"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentExpense>
    <allo:PercentageOfDevelopmentCostPayableByTheCompany
      contextRef="ieb0b77194500411893671236498c869e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5MDQ_29eca72e-2310-4d6d-a8cd-6edd0ccf861c"
      unitRef="number">0.60</allo:PercentageOfDevelopmentCostPayableByTheCompany>
    <allo:PercentageOfDevelopmentCostPayableByCollaborationPartner
      contextRef="ieb0b77194500411893671236498c869e_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5ODc_e575909f-bd36-4b3c-990a-1fc50b32548f"
      unitRef="number">0.40</allo:PercentageOfDevelopmentCostPayableByCollaborationPartner>
    <allo:AggregatePotentialMilestonePayments
      contextRef="ie804f754091d4ee08b0012cf286c45ee_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTE2Mjg_764662f9-6eb6-42ef-9ef1-2e35051d4ad0"
      unitRef="usd">137500000</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i94890323746341f2b456015e6973a164_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTE3NjA_9b4ba7c7-a754-483c-8462-1fda4b93b090"
      unitRef="usd">78000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="ib9bcc3e59ff0414e9e68d09f328231d1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTIyMjA_4090d77a-e1f8-41dd-a2a7-8ca51d802431"
      unitRef="usd">42000000.0</allo:AggregatePotentialMilestoneReceivable>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="ie6ce30503f7e4dcb8b48f3209ba957d1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTIyMjc_713dc3c8-e8e8-4aeb-9bdf-589f4b734727"
      unitRef="eur">70500000</allo:AggregatePotentialMilestoneReceivable>
    <allo:AggregatePotentialMilestoneReceivable
      contextRef="ie6ce30503f7e4dcb8b48f3209ba957d1_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTIyMzE_0701789f-3f7d-4447-9d88-4536184e7498"
      unitRef="usd">82700000</allo:AggregatePotentialMilestoneReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i88109eef01694d5087c4d4045520c227_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjc0ODc3OTA5NzE3Nw_331a9104-636f-4e70-b6e0-8f38d3564167"
      unitRef="usd">3900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iedead71724684d8c9198e3945bc63aad_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMjc0ODc3OTA5NzE4Mg_388d0742-51b4-43e8-9a04-a94e6dfeb16b"
      unitRef="usd">1000000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:DueFromRelatedParties
      contextRef="i88109eef01694d5087c4d4045520c227_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY2MTIyOA_dfbf0daa-0793-4bb6-9a0c-4ba689016cbc"
      unitRef="usd">4500000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i93e629aa48694adaba119d9561912c43_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTcxOQ_eb552932-aed1-4fee-a5a7-e5531179563c"
      unitRef="usd">3800000</us-gaap:DueFromRelatedParties>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="i076cc18b50ba412ca3242c4341c20664_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTU5NDQ_88628b99-b778-4d96-ac76-1a27e9927f6f"
      unitRef="usd">10000000.0</allo:CollaborationAgreementUpfrontPayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie316218928294928a89e52d1606777a9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTYxMjM_b1cd8145-6055-442e-b948-31f1aa51c62e"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTYyNTM_fc0053a3-e62d-4efc-abd8-cb94f945168c"
      unitRef="usd">5000000.0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTYzNTA_51583b07-fb98-4e34-98f8-c9764b82acad"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i63935ec464224be99ddd75ab04bfdab1_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTk4OQ_8b245ad8-9e85-4bbc-a14d-4eeaba073bb6"
      unitRef="usd">15900000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2d8539bb2dda47de90067bfbe0969f59_I20210228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTk4MQ_dea8c621-a876-419d-9b18-30da2e67a0c3"
      unitRef="number">0.207</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <allo:AggregatePotentialMilestonePayable
      contextRef="i11005bc5a44b4d80a0ea4954488ea86b_I20210331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY3MTM_0c8ac0e1-8cb8-44f7-bc26-77c70eef83b7"
      unitRef="usd">7250000</allo:AggregatePotentialMilestonePayable>
    <allo:AggregatePotentialMilestonePayments
      contextRef="ifac376ffe9ed4e7b99c011fd45a31021_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY3NzM_58571966-c1ec-490f-944f-de35ff978cd7"
      unitRef="usd">4000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:AggregatePotentialMilestonePayments
      contextRef="i7b8687e0cabd401c931e5f274bdb2016_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTY4Njc_34f81b1d-2bb7-4614-83a1-6cb623847dd7"
      unitRef="usd">283000000.0</allo:AggregatePotentialMilestonePayments>
    <allo:CollaborationArrangementExpense
      contextRef="i2f77c63a834a4681b022dff5f2da6fe7_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTg3OTk_d4671c9b-5d4e-4203-b863-1135ced57091"
      unitRef="usd">1200000</allo:CollaborationArrangementExpense>
    <allo:CollaborationArrangementExpense
      contextRef="i019720c47c404ba483f76b9fc6e614e2_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY1OTI2Nw_011a77c4-044f-4feb-ba59-362cee0612b5"
      unitRef="usd">300000</allo:CollaborationArrangementExpense>
    <allo:CollaborationAgreementTerm
      contextRef="ia54b21b65ef24f6cbdcf06ec5a9d9dd0_D20201006-20201006"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQwOA_3337902f-99ed-4e28-ae19-bacd9f8f50c3">P5Y</allo:CollaborationAgreementTerm>
    <allo:CollaborationAgreementCommittedFunding
      contextRef="ia54b21b65ef24f6cbdcf06ec5a9d9dd0_D20201006-20201006"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQxMA_020bbf8b-4261-43f4-b6ce-b3e84c8738ac"
      unitRef="usd">15000000.0</allo:CollaborationAgreementCommittedFunding>
    <allo:CollaborationAgreementUpfrontPayment
      contextRef="i08db9380997d4d1b9f4e44201d651df9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQyNQ_5fdd29b1-005d-4bfd-b515-a11085af0202"
      unitRef="usd">3000000.0</allo:CollaborationAgreementUpfrontPayment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ0Nw_2e96f81d-f6a8-4cea-8f40-9e341a56056f"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i9f26d67082094c649f56c52d8b485753_I20201214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ2OA_17b4a9ec-5123-467a-84e2-3b6519a4f63b"
      unitRef="number">0.51</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <allo:UpfrontAndQuarterlyCashPayments
      contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ1Mg_d6faeda1-fa33-430c-bf83-a71712a207da"
      unitRef="usd">117000000.0</allo:UpfrontAndQuarterlyCashPayments>
    <allo:JointVentureCapitalSupportPayments
      contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ3Mw_0b09187f-31c7-413f-8bda-96901b6fad72"
      unitRef="usd">40000000</allo:JointVentureCapitalSupportPayments>
    <allo:MilestonePayments
      contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjQ4Ng_ee4d9952-9a8b-457b-bfe1-8a7b34f6161b"
      unitRef="usd">40000000.0</allo:MilestonePayments>
    <allo:JointVentureCapitalSupportPayments
      contextRef="i33761b24c37a4775bcdb7380a34c6b85_D20201214-20201214"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfNDk0NzgwMjM1MjUwMQ_392784ad-2984-4d6f-9755-6c6755976519"
      unitRef="usd">40000000.0</allo:JointVentureCapitalSupportPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY180OS9mcmFnOjM2Nzk5YjA5YmMyMjQyNjNhOWJlZTYzNGQ0YTIzOTNiL3RleHRyZWdpb246MzY3OTliMDliYzIyNDI2M2E5YmVlNjM0ZDRhMjM5M2JfMTA5OTUxMTY2MDE1Ng_fe8dd224-5c98-486e-b851-b29b68939bbc"
      unitRef="usd">38300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY4OQ_20f1af12-5d9b-46cc-8baf-0d9dc4235a85">Commitments and Contingencies&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term is 127 months beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $5.0 million of tenant improvement allowances. The rent payments began on March 1, 2019 after an abatement period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of 14,943 square feet located in South San Francisco, California. The lease term is 124 months beginning November 2018 through February 2029, with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $0.8 million. Rent payments began in November 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of 188 months and commenced in November 2020. Upon certain conditions, the Company has two ten-year options to extend the lease, both of which are not reasonably assured of exercise. The Company is entitled to a tenant improvement allowance of&#160;$2.9 million for costs related to the design and construction of certain Company improvements and has received $2.7&#160;million of tenant improvement allowances up to March 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains letters of credit for the benefit of landlords which is disclosed as restricted cash in the condensed consolidated balance sheets. Restricted cash related to letters of credit due to landlords was $5.2&#160;million and $4.3&#160;million as of March&#160;31, 2021 and December&#160;31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities for the three months ended March&#160;31, 2021 was $1.0 million and was included in net cash used in operating activities in our condensed consolidated statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The undiscounted future lease payments under the lease agreements as of March&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;2021 (remaining 9 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discount rate used to determine the operating lease liability was&#160;8.40%. As of&#160;March&#160;31, 2021, the weighted average remaining lease term for our operating leases is&#160;10.22 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In July 2020, the Company entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at the Company's cell therapy manufacturing facility in Newark, California. The agreement has a term of 20 years and is expected to commence in the second quarter of 2021. The Company is obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by the Company will result in a termination payment due of approximately $4.3&#160;million. In connection with the agreement, the Company maintains a letter of credit for the benefit of the service provider in the amount of $4.3&#160;million which is disclosed as restricted cash in the condensed consolidated balance sheet as of March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of March&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of March&#160;31, 2021, the Company had non-cancellable purchase commitments of $4.1&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i0af7e5161e0e4accbc495ed05d1832d0_I20180831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTkx_0aaf9bd2-6efc-42e1-bf67-7f3d004aedac"
      unitRef="sqft">68000</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i0af7e5161e0e4accbc495ed05d1832d0_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMjY4_eeb09f85-8d60-4859-b127-ac1fdbfd0136">P127M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i0af7e5161e0e4accbc495ed05d1832d0_I20180831"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzYx_abaf5f5a-2788-4696-aab8-e6a7b72bdbd8">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:TenantImprovements
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNTIw_227ae940-24b8-4c18-8ff4-d453dab68d29"
      unitRef="usd">5000000.0</us-gaap:TenantImprovements>
    <allo:AreaOfNewOfficeBuilding
      contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNzYw_24e3d701-7cf6-4ec4-912d-a0e7e20c99da"
      unitRef="sqft">14943</allo:AreaOfNewOfficeBuilding>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfODM3_c8be7649-6ac2-43ac-a1b2-d0db997cd7a8">P124M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfOTMz_c9cb49cd-5d69-47a5-89ba-92a2b62d2ba4">P7Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:TenantImprovementAllowance
      contextRef="i738bb7afc6e4444b8295b50d0d40c0a4_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTEzMA_e16a8cea-d308-4f7e-b830-b5c6afce8d32"
      unitRef="usd">800000</allo:TenantImprovementAllowance>
    <allo:AreaOfOperatingLease
      contextRef="i087b1f988f50425c88274e63ae23612e_D20190201-20190228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTI2MA_68cd4165-1f4a-4d8c-9796-eafbd2581c79"
      unitRef="sqft">118000</allo:AreaOfOperatingLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i9c1ff3e19d184af39773c955bf6f264f_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTM4MA_934eb55e-702f-4ba8-9187-c80e59ab70bb">P188M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <allo:NumberOfOptionsToExtendLease
      contextRef="i087b1f988f50425c88274e63ae23612e_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTQ3MA_fd20772a-e7f3-420f-9f80-2395a9f10ee3"
      unitRef="renewal">2</allo:NumberOfOptionsToExtendLease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i9c1ff3e19d184af39773c955bf6f264f_I20190228"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5Nw_37b21459-745e-4665-997b-d1edb252decc">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <allo:TenantImprovementAllowance
      contextRef="i9c1ff3e19d184af39773c955bf6f264f_I20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTYxNg_08f73df9-edc2-4bb0-9a62-8c56aeb59926"
      unitRef="usd">2900000</allo:TenantImprovementAllowance>
    <allo:TenantImprovementAllowanceUtilizedToDate
      contextRef="i741a26ced88a4be9b88be81d60e87b12_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzg0ODI5MDcwMjM3OA_236b53b5-eae4-4e9f-ba5e-40bb0a57b52d"
      unitRef="usd">2700000</allo:TenantImprovementAllowanceUtilizedToDate>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTkyOQ_f01aaa02-8de1-4c22-8063-278027f65f57"
      unitRef="usd">5200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMTkzNg_9a383dd1-38a5-4e24-a6a7-912a44e5f5c2"
      unitRef="usd">4300000</us-gaap:LettersOfCreditOutstandingAmount>
    <allo:LiabilitiesLesseeTableTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5Ng_044acca2-784f-4a6e-bae8-13a065bdb148">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</allo:LiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMi0yLTEtMS0w_95f2efe8-a4e6-40d6-babe-fa900fd07000"
      unitRef="usd">3061000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMi00LTEtMS0w_d7096567-c4dd-420e-aebe-995bb0e6b830"
      unitRef="usd">2974000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMy0yLTEtMS0w_c77a2e80-5c94-4246-8766-fe6ad1026ce1"
      unitRef="usd">51625000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfMy00LTEtMS0w_ba573571-8796-44ee-ae2e-96fbca8f9c17"
      unitRef="usd">50809000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfNC0yLTEtMS0w_c401927c-5750-4cc1-83a7-35dc3f4347a7"
      unitRef="usd">54686000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjE4Y2RiMWMxNDQzNjQxYmZhZDY1ZjE2YzE3NDhlNGMyL3RhYmxlcmFuZ2U6MThjZGIxYzE0NDM2NDFiZmFkNjVmMTZjMTc0OGU0YzJfNC00LTEtMS0w_d005770c-4761-448d-9be1-53e102eae088"
      unitRef="usd">53783000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5Mw_25904f3a-f3ca-4cc7-b30f-6fba46096f0d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.806%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMi0yLTEtMS0w_b2b4acba-e875-4f48-98c5-70795a16d67d"
      unitRef="usd">1862000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMi00LTEtMS0w_0f98ad67-0353-40c6-943f-8b8947dc5bcb"
      unitRef="usd">1868000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMy0yLTEtMS0w_593008ce-5bc8-40ac-8c39-f196ea8b35f2"
      unitRef="usd">327000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfMy00LTEtMS0w_b7247ae1-983c-49ae-b825-355384af7ca7"
      unitRef="usd">210000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfNC0yLTEtMS0w_a95b983d-b692-4299-bbe9-0e44e46bed2a"
      unitRef="usd">2189000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjFkZTc4OWNmNTdkNjQ5OGJhZWQwMTNlNmRhYzM5NWM5L3RhYmxlcmFuZ2U6MWRlNzg5Y2Y1N2Q2NDk4YmFlZDAxM2U2ZGFjMzk1YzlfNC00LTEtMS0w_01288f1c-1e57-4816-b468-3511012e2612"
      unitRef="usd">2078000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMjI5Nw_e77130f6-cc86-481a-afd5-a40b78eaf797"
      unitRef="usd">1000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY5OA_e42508ec-baa4-4c43-8d7a-73bc1d02fe4e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The undiscounted future lease payments under the lease agreements as of March&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;2021 (remaining 9 months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(325)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMS0yLTEtMS0w_05dcc7ae-e759-4d27-b82a-a5290e8fb1ca"
      unitRef="usd">5044000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMi0yLTEtMS0w_d5810666-7b9b-4e6e-a7a6-86afc1848a24"
      unitRef="usd">7917000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMy0yLTEtMS0w_cec51cdf-5481-44a0-a6a5-ccb9e66fe83c"
      unitRef="usd">8168000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNC0yLTEtMS0w_643aa75b-14aa-42dc-9deb-1cddf45bd28b"
      unitRef="usd">8430000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNS0yLTEtMS0w_ddf88de3-da45-4564-abc1-26e88985a929"
      unitRef="usd">8509000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <allo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNi0yLTEtMS0w_90bf574f-c924-477b-9529-3e490c52e40d"
      unitRef="usd">48143000</allo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfNy0yLTEtMS0w_2fb36098-c487-4ea9-ae19-e0f729a14ae8"
      unitRef="usd">86211000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfOC0yLTEtMS0w_26273cc2-9c52-4ee2-a608-85a5c0372d66"
      unitRef="usd">31200000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <allo:TenantImprovementAllowance
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfOS0yLTEtMS0w_1c8c57b8-80b1-4028-8c94-f7c9c7515b24"
      unitRef="usd">325000</allo:TenantImprovementAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RhYmxlOjI5NzJiZjhkY2RkZjRjZWU5Y2Y3YjA2YmEyNDI1OWM4L3RhYmxlcmFuZ2U6Mjk3MmJmOGRjZGRmNGNlZTljZjdiMDZiYTI0MjU5YzhfMTAtMi0xLTEtMA_61eb93a5-1892-4dee-a555-dde09bcfe242"
      unitRef="usd">54686000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMjgzOA_e1744f99-38d8-4f85-ac70-0e8de89cf055"
      unitRef="number">0.0840</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfOTM0NTg0ODg0MDg1Mw_3c41a5b6-572c-45c8-8802-48b9fa30f6fc">P10Y2M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i6f0049318f88420fb355203ab4e399b1_I20200731"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzI5MA_73d246f0-4ce1-49a7-a19d-1e9457d367cd">P20Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <allo:LesseeFinanceLeasePaymentUponContractTermination
      contextRef="i6f0049318f88420fb355203ab4e399b1_I20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzU4NQ_58cc8fd6-4637-4b7d-adb6-25fd8c215e7d"
      unitRef="usd">4300000</allo:LesseeFinanceLeasePaymentUponContractTermination>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i413a4f8e6e7e4ee28ed209070c2b4426_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfMzcwNQ_5e26b1fb-c53b-4b66-869a-5580c101a3f6"
      unitRef="usd">4300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181Mi9mcmFnOjEwMDk2MDkyMDc2NDQwZGRiYzI3YTZhNmFmYTFiNzMyL3RleHRyZWdpb246MTAwOTYwOTIwNzY0NDBkZGJjMjdhNmE2YWZhMWI3MzJfNDY4Nw_f47537b0-a09f-4605-99d1-c651e350df91"
      unitRef="usd">4100000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNTUx_91a81bf6-2667-4a32-ad57-e6e7e668b60d">Equity Method Investment&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Notch Therapeutics&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement with the Company acquiring shares of Notch&#x2019;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1&#160;million, resulting in a 25% ownership interest in Notch. In February 2021, the Company made a $15.9 million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was 20.7% on a voting interest basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s total equity investment in Notch as of March&#160;31, 2021 and December&#160;31, 2020 was $19.4 million and $3.7 million, respectively, and the Company accounted for the investment using the equity method of accounting. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allogene Overland Biopharm (CY) Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the execution of the License Agreement with Allogene Overland (see Note 6), the Company also entered into a Share Purchase Agreement and Shareholders' Agreement with the joint venture company under which it acquired shares of Allogene Overland&#x2019;s Seed Preferred Shares representing a 49% ownership interest as partial consideration for entering into a License Agreement which had a carrying value of zero. The Company accounts for its investment in Allogene Overland as an equity method investment at carrying value. The Company's total equity investment in Allogene Overland was zero as of March 31, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The  Company&#x2019;s equity investment in Allogene Overland as of March&#160;31, 2021 and December&#160;31, 2020 had a zero carryover basis. Therefore, the Company did not account for its share of losses incurred by Allogene Overland. See Note 6 for further details.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i6b1c66efc41f41b3a6ae07c79e88874c_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMjg1_ae5eec99-e032-46fb-83a6-a2ddb911af30"
      unitRef="usd">5100000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <allo:CostMethodInvestmentTransactionCosts
      contextRef="i6b1c66efc41f41b3a6ae07c79e88874c_D20191101-20191101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzI0_40e0f98c-057e-498d-a29b-1709b30bad88"
      unitRef="usd">100000</allo:CostMethodInvestmentTransactionCosts>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3c84986557334acb9bdbc8bfba9cd4f1_I20191101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzQz_2b14c934-7f77-472e-a75c-cb5804326378"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i63935ec464224be99ddd75ab04bfdab1_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5OTUzNQ_82610b38-2016-428f-97e5-4a9d361dd14b"
      unitRef="usd">15900000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2d8539bb2dda47de90067bfbe0969f59_I20210228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5OTcyMw_9bbba1d9-3571-4c53-a03f-c0b18e517c7d"
      unitRef="number">0.207</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMTA5OTUxMTYzMDMzNQ_3dc256eb-b576-4783-b48a-5e05d4cefc40"
      unitRef="usd">19400000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMTA5OTUxMTYzMDM1MA_db38dcc0-574d-4b1d-9b76-b308c0ba0b2b"
      unitRef="usd">3700000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNDk0NzgwMjMyNjU5Mg_077441ae-53a3-4ed3-9464-7fde735a6f53"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="idbebe1fc87f140f6ac1a8780693c3a2b_I20201214"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5ODgyOQ_499db0d7-5cec-42e3-9065-be872d8c2958"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i6e523f02887b4694813dc952ebe2a83d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNDk0NzgwMjMyNjU5Ng_01fc0b96-5f2e-45a6-a40c-4e02f5217b73"
      unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ie55d9fe72329461caf14cd949cf5f9f0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfNDk0NzgwMjMyNjU5Ng_0d46ce28-a856-4231-b24e-9b8a77f3db32"
      unitRef="usd">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="i6e523f02887b4694813dc952ebe2a83d_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5ODgzOA_8867cdd4-a60a-4d20-9e9a-4abfd6b034f9"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:EquityMethodInvestmentQuotedMarketValue
      contextRef="ie55d9fe72329461caf14cd949cf5f9f0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY181OC9mcmFnOjYzNWI5YTdlM2Y5YjQ5MWE4NTAwM2Y5ZjJlYzAzYWZkL3RleHRyZWdpb246NjM1YjlhN2UzZjliNDkxYTg1MDAzZjlmMmVjMDNhZmRfMzg0ODI5MDY5ODgzOA_d908d159-8a5b-4f20-a0d0-db21687ca21c"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentQuotedMarketValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyMQ_e79fe5b8-5554-414c-93e8-27745c47d538">Stock-Based Compensation&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company adopted its 2018 Equity Incentive Plan (Prior 2018 Plan). The Prior 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#x2019;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#x2019;s Board of Directors. In September 2018, the Board of Directors adopted a new amended and restated 2018 Equity Incentive Plan as a successor to and continuation of the Prior 2018 Plan, which became effective in October 2018 (the 2018 Plan), which authorized additional shares for issuance and provided for an automatic annual increase to the number of shares issuable under the 2018 Plan by an amount equal to 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than 100% of the fair market value of the Company&#x2019;s common stock on the grant date. Options granted typically vest over a four-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, there were 17,212,410 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes option activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contract&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,434,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(496,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,423,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#x2019;s common stock on the Nasdaq Global Select Market on March&#160;31, 2021. For the three months ended March&#160;31, 2021, the estimated weighted-average grant-date fair value of employee options granted was $21.41 per share. As of March&#160;31, 2021, there was $102.9&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 2 years, 332 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07 - 6.09&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.42%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 1.16%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80% - 1.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Unit Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value at Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;of Grant per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,493,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$107,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$107,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2021, there was $82.0&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 3 years, 88 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#x2019; common stock was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Early Exercised Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows certain of its employees and its directors to exercise options granted under the Prior 2018 Plan and the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#x2019;s lapsing repurchase right upon termination of employment or service on the Company&#x2019;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of March&#160;31, 2021 and December 31, 2020 there was $2.8 million and $2.8 million recorded in accrued and other liabilities and $0.4 million and $1.1 million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed consolidated financial statements since the exercise date but the shares which are subject to future vesting conditions are not included in the calculation of earnings per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNzYz_6ddd5c12-11d7-4bc6-b52c-08e6dbe33cf4"
      unitRef="number">0.05</allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding>
    <allo:StockOptionGrantedPeriod
      contextRef="i14bbb500f25447d69b2babcd02fb2d40_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfOTQy_fd418ff8-0f11-4fe5-8766-5ac7c00c2503">P10Y</allo:StockOptionGrantedPeriod>
    <allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate
      contextRef="i14bbb500f25447d69b2babcd02fb2d40_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTA3NQ_c6463d25-87ac-4551-97e1-48dd1644de89"
      unitRef="number">1</allo:OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic2b360877fd0487881046b793d288efa_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyMg_831e34f3-9bf7-4aab-9c0a-bde04fe03fc3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyNQ_d805b16a-301c-4ec6-95bc-e32171a24d46">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTQwMQ_31426d0f-c8e3-416e-afb4-1cdb8c30245b"
      unitRef="shares">17212410</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyMw_d96f35a6-774b-41bf-88e7-62d0cfac1a20">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes option activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contract&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,434,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(447,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(496,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,423,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie9606d98985d4a4aa8219e4759fe5755_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy0xLTEtMS0w_35f5602d-3387-4c9b-8ba5-da3ece833703"
      unitRef="shares">10434034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie9606d98985d4a4aa8219e4759fe5755_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy0zLTEtMS0w_92df33ca-a716-4bc8-9700-95e9fb2d7ac3"
      unitRef="usdPerShare">17.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ib97658ccecf0407bb53a0ff5d41930f1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy01LTEtMS0w_700e025d-a226-4b05-8915-0f80f59bd466">P8Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ie9606d98985d4a4aa8219e4759fe5755_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfMy03LTEtMS0w_28b0b7f0-24da-411e-832c-995fac0f564b"
      unitRef="usd">93149000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNC0xLTEtMS0w_f08511c1-e695-43b0-a3ac-4270dfb01377"
      unitRef="shares">1617078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNC0zLTEtMS0w_b7bf0cc6-0491-4249-a462-96868ddbd2c9"
      unitRef="usdPerShare">34.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNS0xLTEtMS0w_ef3fdf46-b926-476f-b19a-0e135f12ae74"
      unitRef="shares">447880</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNS0zLTEtMS0w_154ca88f-046a-400c-b626-ee07c770f0f1"
      unitRef="usdPerShare">8.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNi0xLTEtMS0w_caa880a8-fae4-4872-8115-9c28cc24acfe"
      unitRef="shares">496070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNi0zLTEtMS0w_1018bdb0-9a30-4261-80c6-e99b2111e10e"
      unitRef="usdPerShare">15.36</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy0xLTEtMS0w_632a0fbf-4925-44ec-b8ac-2bc8c3f60055"
      unitRef="shares">11107162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy0zLTEtMS0w_1e08903e-5396-4bea-87fd-5c1d57c28754"
      unitRef="usdPerShare">20.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy01LTEtMS0w_2299a786-eefd-43bf-b219-ec29b0f51129">P8Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfNy03LTEtMS0w_ab303b4a-8a7d-4461-a314-b94976af518b"
      unitRef="usd">166162000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0xLTEtMS0w_56ffaf4a-8a6c-4e2e-bb72-cd690d0f482f"
      unitRef="shares">7423034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0xLTEtMS0w_7b8dd709-71fa-4bd3-9d70-c8068a683afa"
      unitRef="shares">7423034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0zLTEtMS0w_3abec557-0e02-42cd-9756-f30b15e07bb7"
      unitRef="usdPerShare">19.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC0zLTEtMS0w_6cd3e5c4-9d99-4c74-b44a-603c37e11254"
      unitRef="usdPerShare">19.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC01LTEtMS0w_fb7cf964-96a7-432c-8d8e-84c5eafa9f68">P8Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOC03LTEtMS0w_fb332fad-8ba3-465a-baad-b40b73a9515f"
      unitRef="usd">120201000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS0xLTEtMS0w_79296f64-f68f-4e29-883d-3c2b4bb24364"
      unitRef="shares">11107162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS0zLTEtMS0w_1b6cb5eb-e73c-4255-a1ac-9a11a68c9375"
      unitRef="usdPerShare">20.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS01LTEtMS0w_6776f4ed-4241-4471-a58e-9da6584b158f">P8Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i15371b2572eb4bbab0588d744217e7b9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOmJmZTJjZDM1MWZmMzRhYTdiYjYyMjk1Yzg0NjZmMjg4L3RhYmxlcmFuZ2U6YmZlMmNkMzUxZmYzNGFhN2JiNjIyOTVjODQ2NmYyODhfOS03LTEtMS0w_706c1772-1bc4-4fd0-84b7-1490218b4c05"
      unitRef="usd">166162000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4e50cc94898c4c38af402cdd90cb3431_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTk2Mg_13ca98fd-73a6-475d-a7c9-5d5715bb96d1"
      unitRef="usdPerShare">21.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7851275aa1884775b7054b0238c07f90_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMTk5Ng_388381b6-7d6b-4b59-8f64-c9bfabd2df1f"
      unitRef="usd">102900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i4e50cc94898c4c38af402cdd90cb3431_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMjE0NA_dcc77090-5766-40fd-813b-90a42ca98a62">P2Y332D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIxOA_86fdbd7d-d877-4aee-988d-4b8a710beb6e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.194%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06 - 6.08&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.07 - 6.09&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.42%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.60% - 1.16%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.80% - 1.65%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5060d1ddf0ff4c76a3852cdb609b01d6_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0xLTEtMS0wL3RleHRyZWdpb246M2Q4YTNkMzRiMGUzNGViMDk1MDhiMGJlZmJiMWU2YTVfNA_2f771285-af4d-4d86-9d46-b9e5a8689dbe">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id0f00168a0e94cdcb56ab6e3ec5a5938_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0xLTEtMS0wL3RleHRyZWdpb246M2Q4YTNkMzRiMGUzNGViMDk1MDhiMGJlZmJiMWU2YTVfOQ_1c8fe72a-3c42-4b5e-beaa-f306113c5f70">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i25c39330288e480a82e92430adf135a6_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0zLTEtMS0wL3RleHRyZWdpb246MDJhYjVjMGFiYjc3NDViNGExZGFiZTljNzU5MWE2NTlfNA_a0c34740-bd09-494d-9751-e7e960a0ef05">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i14661dcd7bd04b018bb9677c345a8f5c_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMi0zLTEtMS0wL3RleHRyZWdpb246MDJhYjVjMGFiYjc3NDViNGExZGFiZTljNzU5MWE2NTlfOQ_58c3fa10-5a03-40cb-8fe2-641aa038776a">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMy0xLTEtMS0wL3RleHRyZWdpb246YTgzNTA4NzczZTZiNDIyMzkzNDliN2QyZTdlOGVlM2JfNA_e29a7b5d-59cf-4566-8f28-2b94f8464146"
      unitRef="number">0.7080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfMy0zLTEtMS0w_f07081b0-8e37-4667-85fb-77de83b3a34a"
      unitRef="number">0.7142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0xLTEtMS0wL3RleHRyZWdpb246NDc4ODMzZDVmYTgxNDM0NjlkNTA1MjA4NGZiMGY5NTBfNA_2351e3aa-e4a8-477c-b7a9-fbb892b53eed"
      unitRef="number">0.0060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0xLTEtMS0wL3RleHRyZWdpb246NDc4ODMzZDVmYTgxNDM0NjlkNTA1MjA4NGZiMGY5NTBfOQ_a4edba89-42db-4eab-a19e-967d2f19d6c1"
      unitRef="number">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0zLTEtMS0wL3RleHRyZWdpb246MDBjYmE5OTliM2M4NDg5ODk3NWEyN2MzYzQ1OGYxYjZfNA_fc772c8f-66e7-40d3-83c7-f14b822cea75"
      unitRef="number">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNC0zLTEtMS0wL3RleHRyZWdpb246MDBjYmE5OTliM2M4NDg5ODk3NWEyN2MzYzQ1OGYxYjZfOQ_f5c0ebfe-36ca-4fdb-9ec7-7cd83fb91443"
      unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNS0xLTEtMS0w_803ab3e5-11e3-45d7-bbdb-d5d1856e6f4a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia0618c69e39949038145e2a090838f1f_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjdiOGNmYmIxZTQzYzQ0YmZhNzcyNDI1N2U1YzcwNmQwL3RhYmxlcmFuZ2U6N2I4Y2ZiYjFlNDNjNDRiZmE3NzI0MjU3ZTVjNzA2ZDBfNS0zLTEtMS0w_b4ea430b-213a-4170-9326-3584d7db74a9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNzY5NjU4MTM5OTcwOQ_58fbf565-f4bd-4efb-bc07-3ab94c028497"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIxOQ_1f6f5dfe-ad6f-43c9-b0fa-008e7a6cc6c9">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes restricted stock unit activity under the 2018 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value at Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;of Grant per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Vesting Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,493,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,139,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140,218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$107,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$107,785&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy0xLTEtMS0w_25dcd22e-5f76-469b-b39c-d146b4669aa7"
      unitRef="shares">2493920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy0zLTEtMS0w_4ffc3200-a0a7-44a3-9844-78a57a25a907"
      unitRef="usdPerShare">26.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i769dd97badbb4b2f80e2f2bbbb9b5946_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy01LTEtMS0w_807ce759-4907-4d75-9df7-34f94d898d11">P1Y7M28D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i988626a8ccaf4d1cb7b3374deed4d98a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfMy03LTEtMS0w_55bbc5d3-6b87-4373-b237-d60ea64c2566"
      unitRef="usd">62947000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNC0xLTEtMS0w_07cafc7f-9ab5-40b7-afdb-389af001b55c"
      unitRef="shares">1139363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNC0zLTEtMS0w_900c5091-d208-4558-ace2-c31023e0e9c7"
      unitRef="usdPerShare">33.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNC01LTEtMS0w_251904ed-38de-4b0e-a206-3224eb04f94a">P2Y5M12D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNS0xLTEtMS0w_ea8c1713-4a79-4b9d-a013-53c64a44b11c"
      unitRef="shares">439652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNS0zLTEtMS0w_073ff20f-0967-44f8-94c3-02b7a7721672"
      unitRef="usdPerShare">23.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNi0xLTEtMS0w_91d7d9a0-a40a-4366-8315-82ff5bb03128"
      unitRef="shares">140218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNi0zLTEtMS0w_9adabadf-439e-4262-b9bd-3aed9b348bde"
      unitRef="usdPerShare">25.53</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i231088853bd94ca78694266c68e382cd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy0xLTEtMS0w_27dcde55-6d68-4369-b1ec-b9bde5f9e812"
      unitRef="shares">3053413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i231088853bd94ca78694266c68e382cd_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy0zLTEtMS0w_338f4e3f-9fb4-4646-88b6-69ea425001d6"
      unitRef="usdPerShare">29.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy01LTEtMS0w_3714a88b-e329-4047-8259-3a325c4e7d6a">P2Y3D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i231088853bd94ca78694266c68e382cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfNy03LTEtMS0w_de12f607-a20e-4ef1-9dab-b1574c3b2c46"
      unitRef="usd">107785000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i231088853bd94ca78694266c68e382cd_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC0xLTEtMS0w_27118ad5-6251-419a-9cc0-a2a43d52427c"
      unitRef="shares">3053413</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i231088853bd94ca78694266c68e382cd_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC0zLTEtMS0w_641213f0-26f5-480a-8713-9c03992987b9"
      unitRef="usdPerShare">29.47</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC01LTEtMS0w_eb90490a-7a2a-4306-93d0-314260cb97d9">P2Y3D</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm>
    <allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="i231088853bd94ca78694266c68e382cd_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjQ2YjFjNjQyMzU0NjQ5MzBiMWI0OTNmMzBlNDcxNWU2L3RhYmxlcmFuZ2U6NDZiMWM2NDIzNTQ2NDkzMGIxYjQ5M2YzMGU0NzE1ZTZfOC03LTEtMS0w_ff1d1248-e916-421a-926e-7ce919bc3264"
      unitRef="usd">107785000</allo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i231088853bd94ca78694266c68e382cd_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMzY0Nw_744c056a-da00-47ac-a424-7894880301c8"
      unitRef="usd">82000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie454e25a92304e9c925d7d248ce95679_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMzgwNA_975a8c5f-28dd-448f-b30b-eeec099510d1">P3Y88D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNTIyNA_76bf6ea7-7dc1-420f-9f7b-812f0e5e7df8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#x2019; common stock was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2f77c63a834a4681b022dff5f2da6fe7_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMi0xLTEtMS0w_3f50f097-f461-45a1-87e2-cb1ba3664696"
      unitRef="usd">7920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i019720c47c404ba483f76b9fc6e614e2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMi0zLTEtMS0w_9e7ee6c2-c499-4bf9-9dcb-c76167989421"
      unitRef="usd">6657000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i51e3200cd5ee4aec98b75df42cbd8a19_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMy0xLTEtMS0w_8270b588-504c-4006-9fdd-4379f5a53f28"
      unitRef="usd">8872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i701ddf49607b425c93a8f1bcc7064cec_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfMy0zLTEtMS0w_3d808b63-9960-4140-be5d-71f153f319ab"
      unitRef="usd">7558000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfNC0xLTEtMS0w_a131fb76-4a77-430d-81cf-60efa9df2bb4"
      unitRef="usd">16792000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RhYmxlOjllNGJjM2NjY2RiYzRjNDhhOWQ4NzM5ZTdhNmI1Y2Y2L3RhYmxlcmFuZ2U6OWU0YmMzY2NjZGJjNGM0OGE5ZDg3MzllN2E2YjVjZjZfNC0zLTEtMS0w_b4e99c70-8320-4515-8d64-de5e6bea0163"
      unitRef="usd">14215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNDc4Nw_21872964-5d53-4831-948e-92bba3cb7caa"
      unitRef="usd">2800000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNDc5NA_0419d91a-f897-44c7-a978-cbc92d0dd30e"
      unitRef="usd">2800000</us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="ia39d6a89bb844679938131a4168a79f8_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfNDg0Mw_0947e532-4298-43d5-9111-7e9a4ca46e8e"
      unitRef="usd">400000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="i0bc1f891fbe4441687ad896e3591b769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182MS9mcmFnOjIwNjUwMTYxYTU2MTRhYzFhN2U0MTQ1OGY5YzNiM2JjL3RleHRyZWdpb246MjA2NTAxNjFhNTYxNGFjMWE3ZTQxNDU4ZjljM2IzYmNfMjc0ODc3OTA3NjMwNg_0bbea527-4782-4bb0-b01d-d1dcf4b46ec5"
      unitRef="usd">1100000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfNDIxNA_168a8ef5-900c-43eb-a302-a894e8b7888d">Related Party Transactions&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company entered into a license agreement with Allogene Overland, a corporate joint venture entity and related party (see Note 6). During the three months ending March 31, 2021, the Company recognized $38.3 million of collaboration revenue from Allogene Overland under this arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sublease Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for 1,293 square feet of office space in Los Angeles, California for a three year term. On April 1, 2020, Bellco Capital Advisors Inc. assumed all rights, title, interests and obligations under the sublease from Bellco Capital LLC. The Company&#x2019;s executive chairman, Arie Belldegrun, M.D., FACS, is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc. The total right of use asset and associated liability recorded related to this related party lease was $0.1 million and $0.1 million for the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consulting Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#x2019;s President and Chief Executive Officer, the Company&#x2019;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.1 million and $0.1 million for the three months ended March&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#x2019;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $37,500 per month in arrears commencing January 2020 and $38,583 per month in arrears commencing January 2021. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million and $0.2 million for the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMjc0ODc3OTA3ODc2NA_fe8dd224-5c98-486e-b851-b29b68939bbc"
      unitRef="usd">38300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <allo:AreaOfOffice
      contextRef="if95eb4b787c74543b5067fc4b0661d0f_D20181201-20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMTMwOA_cc3d3aea-f86c-453e-abea-e32a94f37f51"
      unitRef="sqft">1293</allo:AreaOfOffice>
    <us-gaap:LessorOperatingLeaseTermOfContract
      contextRef="i0ebc3e0c018541f4b70cf9419d86dfa9_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfNDIxNQ_907c0f87-da3a-4a9e-bac2-5b49db0a6231">P3Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2f6335266109450ca23eec174e7cdcab_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMTc4NQ_330b200d-72da-4939-af66-cf6a248c95b2"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2f6335266109450ca23eec174e7cdcab_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMTc4NQ_8272f28e-bdbe-418d-a83c-4bbbc4faa55c"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6c6f84593b7d463c9ff60c7ca46e93bb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0Mzc5Ng_ab5487f4-2b2e-4939-b7b1-4784635ff9e0"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6c6f84593b7d463c9ff60c7ca46e93bb_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0Mzc5Ng_c8017c14-7733-410b-87c2-dbcd0ea7d046"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RelatedPartyCosts
      contextRef="i722789689fd9475695feac4a92e9226f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMjk3Mg_17f425c5-d267-404f-ae88-37e285f6440c"
      unitRef="usd">100000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="i158e95b9cb1646beabf8dfd28baec0fc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0NDU4MQ_9179ac35-3728-4add-8d29-20156481dc9e"
      unitRef="usd">100000</us-gaap:RelatedPartyCosts>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="i986898a7e34741d7954f86f9c33d1968_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMzYyMQ_a70c0847-bdea-4c5f-ba0c-61ed9fa1e77b"
      unitRef="usd">37500</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionMonthlyPaymentsInArrears
      contextRef="i5a1c8fe00fa14644bd319487f70e9221_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMzY3Mw_80f87820-5388-446e-8b18-12b0451ccf9d"
      unitRef="usd">38583</allo:RelatedPartyTransactionMonthlyPaymentsInArrears>
    <allo:RelatedPartyTransactionCompensationPercentage
      contextRef="ia418d380ade7488fa285afa3617ce316_D20180801-20180831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfMzgyMQ_a6a53196-10a9-4cfc-ab46-32633dfcb4c0"
      unitRef="number">0.60</allo:RelatedPartyTransactionCompensationPercentage>
    <us-gaap:RelatedPartyCosts
      contextRef="iea9e93b01c9d476194a141c6b0fef19e_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfNDEwNA_9f23b98a-ea8e-4865-a1bd-17fc2be242b0"
      unitRef="usd">200000</us-gaap:RelatedPartyCosts>
    <us-gaap:RelatedPartyCosts
      contextRef="if0bf2b2e4cd04570b9e804413fe277cb_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182NC9mcmFnOmIyZDdlODc0ZmRiMjQ3M2Q4M2RkMjQxNThhMjBiNWEzL3RleHRyZWdpb246YjJkN2U4NzRmZGIyNDczZDgzZGQyNDE1OGEyMGI1YTNfOTM0NTg0ODg0NDU4Ng_fdba8feb-1fc9-48fa-af33-7e0eece10f05"
      unitRef="usd">200000</us-gaap:RelatedPartyCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY182Ny9mcmFnOmJkMTNmMWI5ODllMDRmZTJiOWM2ODkxYmNhMmYyNjc1L3RleHRyZWdpb246YmQxM2YxYjk4OWUwNGZlMmI5YzY4OTFiY2EyZjI2NzVfMjAw_13aa7775-a362-46ac-855d-0a6bca94e6e1">Income TaxesThe Company has a history of losses, and expects to record a loss in 2021. The Company continues to maintain a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RleHRyZWdpb246NTIxZjNjMjgxMTZlNDhjMDk2MGUxZGMwODRkNDNmMTVfMjIx_219bb92b-69f0-40e8-935e-7f9a219e3dd3">Net Loss Per Share&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected shares to be purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Founder's shares of common stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,057,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,115,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,678,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,900,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,182,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RleHRyZWdpb246NTIxZjNjMjgxMTZlNDhjMDk2MGUxZGMwODRkNDNmMTVfMjIy_28ba6190-a155-4f10-823a-19bcd99988d5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,107,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,627,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units subject to vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,053,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,534,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected shares to be purchased under Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Founder's shares of common stock subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,057,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,115,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Early exercised stock options subject to future vesting&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,423,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,678,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,900,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,182,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6e4b9c96e43a4d7e97a39037a134b7e1_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMi0xLTEtMS0w_254e8757-d2a8-442a-b896-8ee7897446b2"
      unitRef="shares">11107162</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie2ea6b4be1364df5a17f2f871d780f18_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMi0zLTEtMS0w_c1702964-49ef-4305-bf94-65d0188fcbdb"
      unitRef="shares">11627389</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i18038f78c8f7485c88a47821af555ffa_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMy0xLTEtMS0w_2357c602-67f1-4489-a0e3-d6d4b2626a99"
      unitRef="shares">3053413</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i787d6c72d2aa4f58916999e0c3306ea9_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfMy0zLTEtMS0w_3cd32f6d-0f36-4ca7-a531-96aaad7e344c"
      unitRef="shares">2534671</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieec840582431407c876320ad99849824_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNC0xLTEtMS0w_44086156-96d3-4862-83be-f4c6898c496b"
      unitRef="shares">258986</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i64ffc5ac698f42a59f37c79159d75b55_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNC0zLTEtMS0w_9de13edc-b9ce-46db-97c9-9259cc27885f"
      unitRef="shares">226459</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i855de4b72ebc4f219d2f0aba2723cefd_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNS0xLTEtMS0w_44bd39b7-4518-47ef-850a-5a685238f338"
      unitRef="shares">6057696</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i04ba8e4cb94c47d6b333c42599e31017_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNS0zLTEtMS0w_17adabaa-b0f6-4399-b776-76a6b9807b55"
      unitRef="shares">12115382</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41eacec9267f4e78b154a165573c48bc_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNi0xLTEtMS0w_3dc3a1c6-f9ef-4fe5-b89c-a868e799d677"
      unitRef="shares">1423350</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iadaf0078bc664e608b63092936b79aaf_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNi0zLTEtMS0w_d2c1dacb-e2e4-4742-9a11-fc310c8cf6dd"
      unitRef="shares">2678501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNy0xLTEtMS0w_eb743a7f-65c9-466c-8639-51e15c04ac1a"
      unitRef="shares">21900607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2011b80082724645a7f1440247f631ed_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183MC9mcmFnOjUyMWYzYzI4MTE2ZTQ4YzA5NjBlMWRjMDg0ZDQzZjE1L3RhYmxlOjczOGQ0NWI3YTQ2NDQ0Nzg5NGFiZTc5NjRlM2IxM2E2L3RhYmxlcmFuZ2U6NzM4ZDQ1YjdhNDY0NDQ3ODk0YWJlNzk2NGUzYjEzYTZfNy0zLTEtMS0w_c242bb41-d7dc-45b7-a95a-24b5cf60c23f"
      unitRef="shares">29182402</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if2e29ff114d54feab704d039fd34576e_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY183My9mcmFnOmNiODYzYTM1NWU4ODRlZWVhMmRkOTUxYmNkMjUwMzVmL3RleHRyZWdpb246Y2I4NjNhMzU1ZTg4NGVlZWEyZGQ5NTFiY2QyNTAzNWZfNTY1_8ff0ed93-3867-46b8-a6fa-3d7aad61eb30">Subsequent EventsNone.</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0zLTEtMS0w_47b966a1-77f8-47e2-92a3-b44c18d3761b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0zLTEtMS0w_47b966a1-77f8-47e2-92a3-b44c18d3761b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMy0xLTEtMA_0195fc54-fdd9-4a59-ac0c-b5d33857f0c7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMy0xLTEtMA_0195fc54-fdd9-4a59-ac0c-b5d33857f0c7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0zLTEtMS0w_35f3d49f-37b9-44b1-81b0-54756833a5c9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0zLTEtMS0w_35f3d49f-37b9-44b1-81b0-54756833a5c9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMy0xLTEtMA_307edecc-1f63-4284-9b6f-669b07cf0d86"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMy0xLTEtMA_307edecc-1f63-4284-9b6f-669b07cf0d86"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMy0xLTEtMA_858375b0-b7e6-44d0-aee2-5433ebd4d75e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMy0xLTEtMA_858375b0-b7e6-44d0-aee2-5433ebd4d75e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMy0xLTEtMA_2ed3d9e1-6c63-413c-bb02-093ff5201ac8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMy0xLTEtMA_2ed3d9e1-6c63-413c-bb02-093ff5201ac8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMy0xLTEtMA_c57dc54d-b37a-4a7f-adfa-57966c63a2de"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMy0xLTEtMA_c57dc54d-b37a-4a7f-adfa-57966c63a2de"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMy0xLTEtMA_10341c22-77ed-49b5-81b9-e3fe143b6963"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMy0xLTEtMA_10341c22-77ed-49b5-81b9-e3fe143b6963"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMy0xLTEtMA_4270382f-5182-4bc8-9df9-42838675b91c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMy0xLTEtMA_4270382f-5182-4bc8-9df9-42838675b91c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMy0xLTEtMA_7d1df015-883b-43a9-bdf2-99712365fcd0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMy0xLTEtMA_7d1df015-883b-43a9-bdf2-99712365fcd0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0zLTEtMS0w_0912a133-4ef3-43bb-b0a1-210618ffe1fd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0zLTEtMS0w_0912a133-4ef3-43bb-b0a1-210618ffe1fd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0zLTEtMS0w_bc524264-0ca4-4835-99e7-d6ea5ec1348d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0zLTEtMS0w_bc524264-0ca4-4835-99e7-d6ea5ec1348d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0zLTEtMS0w_f954bfd9-3ec4-49a1-8ed4-3603eb6c4420"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0zLTEtMS0w_f954bfd9-3ec4-49a1-8ed4-3603eb6c4420"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMy0xLTEtMA_8a4279c2-3924-4726-9d6e-3ecc7f9022ce"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMy0xLTEtMA_8a4279c2-3924-4726-9d6e-3ecc7f9022ce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMy0xLTEtMA_05d265ff-76ea-4f8b-a25a-bc8590153428"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMy0xLTEtMA_05d265ff-76ea-4f8b-a25a-bc8590153428"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0zLTEtMS0w_22241486-a7e9-49f8-a1f8-19cd00a4baa6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0zLTEtMS0w_22241486-a7e9-49f8-a1f8-19cd00a4baa6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMA_6dcd5482-5ea0-4e1a-9ece-14a8ed6ab7d8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMA_6dcd5482-5ea0-4e1a-9ece-14a8ed6ab7d8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMy0xLTEtMA_f86ec844-b092-466f-875d-31a225500c6d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMy0xLTEtMA_f86ec844-b092-466f-875d-31a225500c6d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0zLTEtMS0w_86b80932-6046-4e43-b786-e789b1c5c394"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0zLTEtMS0w_86b80932-6046-4e43-b786-e789b1c5c394"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMy0xLTEtMA_fc257be9-08cb-46b2-8838-a02f1641ffe1"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMy0xLTEtMA_fc257be9-08cb-46b2-8838-a02f1641ffe1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMy0xLTEtMA_8aad1752-7abe-41ca-9395-682a129acf01"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMy0xLTEtMA_8aad1752-7abe-41ca-9395-682a129acf01"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMy0xLTEtMA_641c80ef-eff9-4b78-8e4a-43867ef01b17"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMy0xLTEtMA_641c80ef-eff9-4b78-8e4a-43867ef01b17"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMy0xLTEtMA_5e9f9b98-da28-4e8c-a81c-8427db4456b5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMy0xLTEtMA_5e9f9b98-da28-4e8c-a81c-8427db4456b5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMy0xLTEtMA_8309ea67-a578-46de-b7fb-90ba2e3014f6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMy0xLTEtMA_8309ea67-a578-46de-b7fb-90ba2e3014f6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMy0xLTEtMA_032c8e48-834a-4336-8f3e-c82f3e031e8c"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMy0xLTEtMA_032c8e48-834a-4336-8f3e-c82f3e031e8c"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMy0zLTEtMS0w_47b966a1-77f8-47e2-92a3-b44c18d3761b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjYtMy0xLTEtMA_0195fc54-fdd9-4a59-ac0c-b5d33857f0c7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNC0zLTEtMS0w_35f3d49f-37b9-44b1-81b0-54756833a5c9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTMtMy0xLTEtMA_307edecc-1f63-4284-9b6f-669b07cf0d86"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTctMy0xLTEtMA_858375b0-b7e6-44d0-aee2-5433ebd4d75e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTItMy0xLTEtMA_2ed3d9e1-6c63-413c-bb02-093ff5201ac8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTEtMy0xLTEtMA_c57dc54d-b37a-4a7f-adfa-57966c63a2de"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjctMy0xLTEtMA_10341c22-77ed-49b5-81b9-e3fe143b6963"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTQtMy0xLTEtMA_4270382f-5182-4bc8-9df9-42838675b91c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjEtMy0xLTEtMA_7d1df015-883b-43a9-bdf2-99712365fcd0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOS0zLTEtMS0w_0912a133-4ef3-43bb-b0a1-210618ffe1fd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNy0zLTEtMS0w_bc524264-0ca4-4835-99e7-d6ea5ec1348d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNi0zLTEtMS0w_f954bfd9-3ec4-49a1-8ed4-3603eb6c4420"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzEtMy0xLTEtMA_8a4279c2-3924-4726-9d6e-3ecc7f9022ce"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTgtMy0xLTEtMA_05d265ff-76ea-4f8b-a25a-bc8590153428"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfNS0zLTEtMS0w_22241486-a7e9-49f8-a1f8-19cd00a4baa6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMTktMy0xLTEtMA_6dcd5482-5ea0-4e1a-9ece-14a8ed6ab7d8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjAtMy0xLTEtMA_f86ec844-b092-466f-875d-31a225500c6d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfOC0zLTEtMS0w_86b80932-6046-4e43-b786-e789b1c5c394"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjUtMy0xLTEtMA_fc257be9-08cb-46b2-8838-a02f1641ffe1"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjgtMy0xLTEtMA_8aad1752-7abe-41ca-9395-682a129acf01"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjMtMy0xLTEtMA_641c80ef-eff9-4b78-8e4a-43867ef01b17"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjktMy0xLTEtMA_5e9f9b98-da28-4e8c-a81c-8427db4456b5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMzAtMy0xLTEtMA_8309ea67-a578-46de-b7fb-90ba2e3014f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RhYmxlOjdjMzgzOTU3NmM0ZDQ0OTQ5OWFiYmExNDdmZTU2Y2QxL3RhYmxlcmFuZ2U6N2MzODM5NTc2YzRkNDQ5NDk5YWJiYTE0N2ZlNTZjZDFfMjItMy0xLTEtMA_032c8e48-834a-4336-8f3e-c82f3e031e8c"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjgyYzQ5YWZkNGJjYjRhMmE4ZGE3NGVkY2YxNWJjMGFjL3NlYzo4MmM0OWFmZDRiY2I0YTJhOGRhNzRlZGNmMTViYzBhY18xNi9mcmFnOmQ0ZGY0N2U5M2NiYTQ3YWZhYzQxZjYwYzc2NjY3ODcyL3RleHRyZWdpb246ZDRkZjQ3ZTkzY2JhNDdhZmFjNDFmNjBjNzY2Njc4NzJfMzM2_8f28c01a-8031-406e-b799-43a66fa4d504"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291501807592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Allogene Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-3562771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 East Grand Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">457-2700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALLO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141,538,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001737287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291576550584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 236,865<span></span>
</td>
<td class="nump">$ 183,351<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">462,716<span></span>
</td>
<td class="nump">644,559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,480<span></span>
</td>
<td class="nump">17,220<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">716,061<span></span>
</td>
<td class="nump">845,130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">264,573<span></span>
</td>
<td class="nump">204,208<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">40,189<span></span>
</td>
<td class="nump">41,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">123,146<span></span>
</td>
<td class="nump">118,840<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">9,449<span></span>
</td>
<td class="nump">9,449<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">6,275<span></span>
</td>
<td class="nump">5,169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">19,351<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,179,044<span></span>
</td>
<td class="nump">1,227,829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">14,875<span></span>
</td>
<td class="nump">10,390<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">39,735<span></span>
</td>
<td class="nump">44,938<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">38,992<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">54,849<span></span>
</td>
<td class="nump">94,320<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, non-current</a></td>
<td class="nump">51,625<span></span>
</td>
<td class="nump">50,809<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">2,791<span></span>
</td>
<td class="nump">3,083<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">109,265<span></span>
</td>
<td class="nump">148,212<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Notes 6 and 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares were issued and outstanding as of March 31, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 141,470,075 and 140,474,305 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,749,097<span></span>
</td>
<td class="nump">1,725,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(679,358)<span></span>
</td>
<td class="num">(646,343)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(101)<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,069,779<span></span>
</td>
<td class="nump">1,079,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,179,044<span></span>
</td>
<td class="nump">$ 1,227,829<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291577162328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">141,470,075<span></span>
</td>
<td class="nump">140,474,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">141,470,075<span></span>
</td>
<td class="nump">140,474,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291501531656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="nump">$ 38,345<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">55,183<span></span>
</td>
<td class="nump">42,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,363<span></span>
</td>
<td class="nump">15,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">71,546<span></span>
</td>
<td class="nump">57,683<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(33,201)<span></span>
</td>
<td class="num">(57,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="num">(325)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">3,203<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,015)<span></span>
</td>
<td class="num">(54,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">(369)<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (33,384)<span></span>
</td>
<td class="num">$ (54,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)</a></td>
<td class="nump">132,165,014<span></span>
</td>
<td class="nump">108,963,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291501980040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">124,267,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 629,023<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 1,023,876<span></span>
</td>
<td class="num">$ (396,122)<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">339,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">84,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">570,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from public offering</a></td>
<td class="nump">14,845<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">14,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,480)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="nump">465<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,262,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 606,519<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 125<span></span>
</td>
<td class="nump">1,055,386<span></span>
</td>
<td class="num">(450,602)<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">140,474,305<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">140,474,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,079,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">1,725,552<span></span>
</td>
<td class="num">(646,343)<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">897,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and vesting of RSUs</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Vesting of early exercised common stock</a></td>
<td class="nump">710<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,792<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">98,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(33,015)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized gain (loss) on available-for-sale investments</a></td>
<td class="num">$ (369)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(369)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">141,470,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">141,470,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">$ 1,069,779<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 1,749,097<span></span>
</td>
<td class="num">$ (679,358)<span></span>
</td>
<td class="num">$ (101)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496378040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=allo_PublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=allo_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=allo_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291497309128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (33,015)<span></span>
</td>
<td class="num">$ (54,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">16,792<span></span>
</td>
<td class="nump">14,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of other intangible assets acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">1,918<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Net amortization/accretion on investment securities</a></td>
<td class="nump">1,911<span></span>
</td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash rent expense</a></td>
<td class="nump">2,007<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_IncomeLossFromCostMethodInvestment', window );">Share of losses from equity method investments</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(799)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,152<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="num">(4,314)<span></span>
</td>
<td class="num">(3,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(38,753)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="num">(292)<span></span>
</td>
<td class="num">(701)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(49,328)<span></span>
</td>
<td class="num">(40,809)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,461)<span></span>
</td>
<td class="num">(12,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of stock in equity method investment</a></td>
<td class="num">(15,938)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">268,249<span></span>
</td>
<td class="nump">120,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="num">(149,052)<span></span>
</td>
<td class="num">(123,015)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">96,798<span></span>
</td>
<td class="num">(15,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">1,438<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,044<span></span>
</td>
<td class="nump">16,586<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">53,514<span></span>
</td>
<td class="num">(39,230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; beginning of period</a></td>
<td class="nump">192,800<span></span>
</td>
<td class="nump">179,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash &#8212; end of period</a></td>
<td class="nump">246,314<span></span>
</td>
<td class="nump">140,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases in accounts payable and accrued and other current liabilities</a></td>
<td class="nump">8,299<span></span>
</td>
<td class="nump">4,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CapitalizedSoftwareCostsIncurredNotYetPaid', window );">Capitalized cloud computing costs included in accounts payable and accrued and other current liabilities</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="num">(966)<span></span>
</td>
<td class="num">(1,396)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Cash received for amounts related to tenant improvement allowances</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=allo_AtTheMarketOfferingMember', window );">ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CapitalizedSoftwareCostsIncurredNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitalized Software Costs Incurred Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CapitalizedSoftwareCostsIncurredNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_IncomeLossFromCostMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Cost Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_IncomeLossFromCostMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=allo_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=allo_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291495112872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Allogene Therapeutics, Inc. (the Company or Allogene) was incorporated on November&#160;30, 2017 in the State of Delaware and is headquartered in South San Francisco, California. Allogene is a clinical-stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T&#160;cell therapies for the treatment of cancer. The Company is developing a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Need for Additional Capital</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained operating losses and expects to continue to generate operating losses for the foreseeable future. The Company&#8217;s ultimate success depends on the outcome of its research and development activities as well as the ability to commercialize the Company's product candidates. The Company had cash and cash equivalents and investments of $964.2 million as of March&#160;31, 2021. Since inception through March&#160;31, 2021, the Company has incurred cumulative net losses of $679.4 million. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available when needed and at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents and investments will be sufficient to fund its operations for a period of at least one year from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC). </span></div>The Company cannot at this time predict the specific extent, duration, or full impact that the ongoing COVID-19 pandemic will have on its financial condition and operations, including ongoing and planned clinical trials. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the pandemic and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain. If business conditions, financial markets and/or the overall economy are impacted for an extended period, the Company&#8217;s results may be adversely affected.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496512632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2021 and 2020, the condensed consolidated statements of stockholders&#8217; equity as of March&#160;31, 2021 and 2020, the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2021 and 2020, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2020, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 25, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2021, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report, with the exception of revenue recognition related to the collaboration revenue recognized in the three months ended March 31, 2021 and the recently adopted accounting pronouncements in the section below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue may be generated through collaboration research and license agreements. The terms of these agreements may contain multiple deliverables which may include (i) grant of licenses, (ii) transfer of know-how, (iii) research and development activities, (iii) clinical manufacturing and, (iv) product supply. The payment terms of these agreements may include nonrefundable upfront fees, payments for research and development activities, payments based upon the achievement of certain milestones, royalty payments based on product sales derived from the collaboration, and payments for supplying product.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606, Revenue from Contracts with Customers (ASC 606). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that the Company determines should be accounted for under ASC 606, the Company assesses which activities in the collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. A performance obligation represents a promise in a contract to transfer a distinct good or service to a customer, which represents a unit of accounting in accordance with ASC 606. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once the Company has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. A portion of the consideration should be allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The total consideration which the Company expects to collect in exchange for the Company&#8217;s products is an estimate and may be fixed or variable. The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The transaction price is re-evaluated, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately. Revenue is recognized when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers. Funds received in advance are recorded as deferred revenue and are recognized as the related performance obligation is satisfied.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standard Update No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarifies the interactions between Topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company adopted this standard on January 1, 2021 on a prospective basis. Adoption of the new guidance had no significant impact on the Company's condensed consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291497075416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports its cash equivalents, restricted cash, and investments at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds are measured at fair value on a recurring basis using quoted prices and are classified as Level&#160;1. Investments are measured at fair value based on inputs other than quoted prices that are derived from observable market data and are classified as Level 2 inputs, except for investments in U.S. treasury securities which are classified as Level 1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets or liabilities as of March&#160;31, 2021 and as of December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included within cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496617144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,806&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021,&#160;the remaining contractual maturities of available-for-sale securities were less than 3 years. There have been no significant realized losses on available-for-sale securities for the periods presented. As of March&#160;31, 2021, unrealized losses on available-for-sale investments are not attributed to credit risk. The Company believes that it is more likely than not that investments in an unrealized loss position will be held until maturity and all interest and principal will be received. The Company believes that an allowance for credit losses is unnecessary because the unrealized losses on certain of the Company&#8217;s marketable securities are due to market factors. As of March 31, 2021 and December 31, 2020, securities with a fair value of zero and $5.0&#160;million respectively, were in a net unrealized loss position for more than 12 months. To date, the Company has not recorded any impairment charges on marketable securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291495177464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment consist of the following:</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,112&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,810&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers equipment and purchased software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,825)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,908)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496726664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LicenseAgreementsTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset Contribution Agreement with Pfizer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into an Asset Contribution Agreement (the Pfizer Agreement) with Pfizer pursuant to which the Company acquired certain assets, including certain contracts and intellectual property for the development and administration of chimeric antigen receptor (CAR) T&#160;cells for the treatment of cancer. The Company is required to make milestone payments upon successful completion of regulatory and sales milestones on a target-by-target basis for the targets including CD19 and B-cell maturation antigen (BCMA), covered by the Pfizer Agreement. The aggregate potential milestone payments upon successful completion of various regulatory milestones in the United States and the European Union are $30.0 million or $60.0 million, depending on the target, with aggregate potential regulatory and development milestones of up to $840.0 million, provided that the Company is not obligated to pay a milestone for regulatory approval in the European Union for an anti-CD19 allogeneic CAR T cell product, to the extent Servier has commercial rights to such territory. The aggregate potential milestone payments upon reaching certain annual net sales thresholds in North America, Europe, Asia, Australia and Oceania (the Territory) for a certain number of targets covered by the Pfizer Agreement are $325.0 million per target. The sales milestones in the foregoing sentence are payable on a country-by-country basis until the last to expire of any Pfizer Royalty Term, as described below, for any product in such country in the Territory. In October 2019, the Territory was expanded to all countries in the world. No milestone or royalty payments were made in the three months ended March&#160;31, 2021 and 2020 respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer is also eligible to receive, on a product-by-product and country-by-country basis, royalties in single-digit percentages on annual net sales for products covered by the Pfizer Agreement or that use certain Pfizer intellectual property and for which an investigational new drug application (IND) is first filed on or before April&#160;6, 2023. The Company&#8217;s royalty obligation with respect to a given product in a given country begins upon the first sale of such product in such country and ends on the later of (i)&#160;expiration of the last claim of any applicable patent or (ii) 12 years from the first sale of such product in such country.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Cellectis</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company a Research Collaboration and License Agreement (the Original Cellectis Agreement) with Cellectis S.A. (Cellectis). On March 8, 2019, the Company entered into a License Agreement (the Cellectis Agreement) with Cellectis.&#160;&#160;In connection with the execution of the Cellectis Agreement, on March 8, 2019, the Company and Cellectis also entered into a letter agreement (the Letter Agreement), pursuant to which the Company and Cellectis agreed to terminate the Original Cellectis Agreement.&#160;The Original Cellectis Agreement included a research collaboration to conduct discovery and pre-clinical development activities to generate CAR T cells directed at targets selected by each party, which was completed in June 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, Cellectis granted to the Company an exclusive, worldwide, royalty-bearing license, on a target-by-target basis, with sublicensing rights under certain conditions, under certain of Cellectis&#8217;s intellectual property, including its TALEN and electroporation technology, to make, use, sell, import, and otherwise exploit and commercialize CAR T products directed at certain targets, including BCMA, FLT3, DLL3 and CD70 (the Allogene Targets), for human oncologic therapeutic, diagnostic, prophylactic and prognostic purposes. In addition, certain Cellectis intellectual property rights granted by Cellectis to the Company and to Servier pursuant to the Exclusive License and Collaboration Agreement by and between </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Cellectis Agreement, the Company granted Cellectis a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license, with sublicensing rights under certain conditions, under certain of the Company's intellectual property, to make, use, sell, import and otherwise commercialize CAR T products directed at certain targets (the Cellectis Targets).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cellectis Agreement provides for development and sales milestone payments by the Company of up to $185.0 million per product that is directed&#160;against an&#160;Allogene Target, with aggregate potential development and sales milestone payments totaling up to $2.8 billion. Cellectis is&#160;also eligible to receive tiered royalties on annual worldwide net sales of any products that are commercialized by the Company that contain or incorporate, are made using or are claimed or covered by, Cellectis intellectual property licensed to the Company under the Cellectis Agreement (the Allogene Products), at rates in the high single-digit percentages. Such royalties may be reduced, on a licensed product-by-licensed product and country-by-country basis, for generic entry and for payments due under licenses of third party&#160;patents. Pursuant to the Cellectis Agreement, and subject to certain exceptions, the Company is required to indemnify Cellectis against all third party claims related to the development, manufacturing, commercialization or use of any Allogene Product or arising out of the Company&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement, and Cellectis is required, subject to certain exceptions, to indemnify the Company against all third party claims related to the development, manufacturing, commercialization or use of CAR T products directed at Cellectis Targets or arising out of Cellectis&#8217;s material breach of the representations, warranties or covenants set forth in the Cellectis Agreement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalties are payable, on a licensed product-by-licensed product and country-by-country basis, until the later of (i)&#160;the expiration of the last to expire of the licensed patents covering such product; (ii)&#160;the loss of regulatory exclusivity afforded such product in such country, and (iii)&#160;the tenth anniversary of the date of the first commercial sale of such product in such country; however, in no event shall such royalties be payable, with respect to a particular licensed product, past the twentieth anniversary of the first commercial sale for such product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the Cellectis Target, the Company has a right of first refusal or right of first negotiation to purchase or license from Cellectis rights to develop and commercialize products against such Cellectis Targets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cellectis Agreement, the Company has certain diligence obligations to progress the development of CAR T product candidates and to commercialize one CAR T product per Allogene Target in one major market country where the Company has received regulatory approval. If the Company materially breaches any of its diligence obligations and fails to cure within 90 days, then with respect to certain targets, such target will cease to be an Allogene Target and instead will become a Cellectis Target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the Cellectis Agreement will expire on a product-by-product and country-by-country basis, upon expiration of all royalty payment obligations with respect to such licensed product in such country. The Company has the right to terminate the Cellectis Agreement at will upon 60 days&#8217; prior written notice, either in its entirety or on a target-by-target basis. Either party may terminate the Cellectis Agreement, in its entirety or on a target-by-target basis, upon 90 days&#8217; prior written notice in the event of the other party&#8217;s uncured material breach. The Cellectis Agreement may also be terminated by the Company upon written notice at any time in the event that Cellectis becomes bankrupt or insolvent or upon written notice within 60 days of a consummation of a change of control of Cellectis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs the Company incurred in connection with this agreement were recognized as research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and March&#160;31, 2020, $5.0 million and zero costs were incurred related to the achievement of a clinical development milestone under this agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Collaboration Agreement with Servier</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Pfizer Agreement, Pfizer assigned to the Company an Exclusive License and Collaboration Agreement (the Servier Agreement), with Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, Servier) to develop, manufacture and commercialize certain allogeneic anti-CD19 CAR T cell product candidates, including UCART19, in the United States with the option to obtain the rights over additional anti-CD19 product candidates and for allogeneic CAR T cell product candidates directed against one additional target.  In October 2019, the Company agreed to waive its rights to the one additional target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company has an exclusive license to develop, manufacture and commercialize UCART19, ALLO-501 and ALLO-501A in the field of anti-tumor adoptive immunotherapy in the United States, with an exclusive option to obtain the same rights for additional product candidates in the United States and, if Servier does not elect to pursue development or commercialization of those product candidates in certain markets outside of the United States pursuant to its license, outside of the United States as well. The Company is not required to make any additional payments to Servier to exercise an option. If the Company opts-in to another product candidate, Servier has the right to obtain rights to such product candidate outside the United States and to share development costs for such product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Servier Agreement, the Company is required to use commercially reasonable efforts to develop and obtain marketing approval in the United States in the field of anti-tumor adoptive immunotherapy for at least one product directed against CD19, and Servier is required to use commercially reasonable efforts to develop and obtain marketing approval in the European Union, and one other country in a group of specified countries outside of the European Union and the United States, in the field of anti-tumor adoptive immunotherapy for at least one allogeneic adaptive T cell product directed against a certain Company-selected target.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product candidates that the Company is co-developing with Servier, including UCART19, ALLO-501 and ALLO-501A, the Company is responsible for 60% of the specified development costs and Servier is responsible for the remaining 40% of the specified development costs under the applicable global research and development plan. Subject to certain restrictions, each party has the right to conduct activities that are specific to its territory outside the global research and development plan at such party&#8217;s sole expense. In addition, each party is solely responsible for commercialization activities in its territory at such party&#8217;s sole expense.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to make milestone payments to Servier upon successful completion of regulatory and sales milestones. The Servier Agreement provides for aggregate potential payments by the Company to Servier of up to $137.5 million upon successful completion of various regulatory milestones, and aggregate potential payments by the Company to Servier of up to $78.0 million upon successful completion of various sales milestones. Similarly, Servier is required to make milestone payments upon successful completion of regulatory and sales milestones for products directed at the Allogene-target covered by the Servier Agreement that achieves such milestones. The total potential payments that Servier is obligated to make to the Company under the Servier Agreement upon successful completion of regulatory and sales milestones are $42.0 million and &#8364;70.5 million ($82.7 million), respectively. The foregoing milestones are subject to certain adjustments if the Company obtains rights for certain products outside of the United States upon Servier&#8217;s election not to pursue such rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each party is also eligible to receive tiered royalties on annual net sales in countries within the paying party&#8217;s respective territory of any licensed products that are commercialized by such party that are directed at the targets licensed by such party under the Servier Agreement. The royalty rates are in a range from the low tens to the high teen percentages. Such royalties may be reduced for interchangeable drug entry, expiration of patent rights and amounts paid pursuant to licenses of third-party patents. The royalty obligation for each party with respect to a given licensed product in a given country in each party&#8217;s respective territory (the Servier Royalty Term) begins upon the first commercial sale of such product in such country and ends after a defined number of years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with the Servier Agreement, the Servier Agreement will continue, on a licensed product-by-licensed product and country-by-country basis, until the Servier Royalty Term with respect to the sale of such licensed product in such country expires.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2021 and 2020, the Company recorded $3.9 million  and $1.0 million, respectively,&#160;of net cost recoveries under the cost-sharing terms of the Servier Agreement as a reduction to research and development expenses. As of March&#160;31, 2021 and December&#160;31, 2020, amounts due from Servier of $4.5 million and $3.8 million, respectively, were recorded in other current assets in the accompanying condensed consolidated balance sheets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research Collaboration and License Agreement with Notch</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2019, the Company entered into a Collaboration and License Agreement (the Notch Agreement) with Notch Therapeutics Inc. (Notch), pursuant to which Notch granted to Allogene an exclusive, worldwide, royalty-bearing, sublicensable license under certain of Notch&#8217;s intellectual property to develop, make, use, sell, import, and otherwise commercialize therapeutic gene-edited T cell and/or natural killer (NK) cell products from induced pluripotent stem cells directed at certain CAR targets for initial application in non-Hodgkin lymphoma, acute lymphoblastic leukemia and multiple myeloma. In addition, Notch has granted Allogene an option to add certain specified targets to its exclusive license in exchange for an agreed per-target option fee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notch Agreement includes a research collaboration to conduct research and pre-clinical development activities to generate engineered cells directed to Allogene&#8217;s exclusive targets, which will be conducted in accordance with an agreed research plan and budget under the oversight of a joint development committee. Allogene will reimburse Notch&#8217;s costs incurred in accordance with such plan and budget. The term of the research collaboration will expire upon the earlier of (i) the fifth anniversary of the date of the Notch Agreement, (ii) at Allogene&#8217;s election, following the joint development committee&#8217;s determination that for each exclusive target, Notch has met certain success criteria, or (iii) the joint development committee&#8217;s determination that the research collaboration cannot be reasonably pursued against any exclusive target due to technical infeasibility or safety issues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Notch Agreement, Allogene made an upfront payment to Notch of $10.0&#160;million in return for a license to access Notch's technology in order to conduct research pursuant to the Notch Agreement. The Company recognized a research and development expense of $10&#160;million during the year ended December 31, 2019 as the license had no foreseeable alternative future use. In addition, Allogene made a $5.0&#160;million investment in Notch&#8217;s series seed convertible preferred stock, resulting in Allogene having a 25% ownership interest in Notch&#8217;s outstanding capital stock on a fully diluted basis immediately following the investment. In connection with this investment, David Chang, M.D., Ph.D., the Company's President, Chief Executive Officer and Board member, was appointed to Notch&#8217;s Board of Directors. In February 2021, the Company made an additional $15.9 million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was 20.7% on a voting interest basis. The Company did not have a controlling interest in Notch as of March 31, 2021, and continued to account for its investment in Notch as an equity method investment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Notch Agreement, Notch will be eligible to receive up to $7.25&#160;million upon achieving certain agreed research milestones, up to $4.0&#160;million per exclusive target upon achieving certain pre-clinical development milestones, and up to $283.0&#160;million per exclusive target and cell type (i.e., T cell or NK cell) upon achieving certain clinical, regulatory and commercial milestones. Notch is also entitled to receive tiered royalties in the mid to high single digit range on Allogene&#8217;s sales of licensed products, subject to certain reductions, for a term, on a country-by-country and product-by-product basis, commencing on first commercial sale of such product in such country and continuing until the latest of (i) the date upon which there is no valid claim of the licensed patents in such country of sale that covers such product, (ii) the expiration of applicable data or other regulatory exclusivity in such country of sale or (iii) a defined period from the first commercial sale of such product in such country.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the Notch Agreement will continue on a product-by-product and country-by-country basis until Allogene&#8217;s payment obligations with respect to such product in such country have expired. Following such expiration, Allogene&#8217;s license with respect to such product and country shall be perpetual, irrevocable, fully paid up and royalty-free. Allogene may terminate the Collaboration Agreement in whole or on a product-by-product basis upon ninety days&#8217; prior written notice to Notch. Either party may also terminate the Collaboration Agreement with written notice upon material breach by the other party, if such breach has not been cured within a defined period of receiving such notice, or in the event of the other party&#8217;s insolvency.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March&#160;31, 2021 and 2020, the Company recorded $1.2 million and $0.3 million, respectively, in collaboration costs as research and development expenses.  </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Strategic Alliance with The University of Texas MD Anderson Cancer Center</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2020, the Company entered into a strategic five-year collaboration agreement with The University of Texas MD Anderson Cancer Center (MD Anderson) for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The Company and MD Anderson are collaborating on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company has committed up to $15.0&#160;million of funding for the duration of the agreement. Payment of this funding is contingent on mutual agreement to study orders in order for any study to be included under the alliance. The Company made an upfront payment of $3.0&#160;million to MD Anderson in the year ended December 31, 2020. The Company is obligated to make further payments to MD Anderson each year upon the anniversary of the agreement effective date through the duration of the agreement term. These costs are expensed to research and development as MD Anderson renders the services under the strategic alliance. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by either party for material breach by the other party. Individual studies may be terminated for, among other things, material breach, health and safety concerns or where the institutional review board, the review board at the clinical site with oversight of the clinical study, requests termination of any study. Where any legal or regulatory authorization is finally withdrawn or terminated, the relevant study will also terminate automatically.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Joint Venture and License Agreement with Allogene Overland Biopharm (CY) Limited </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, the Company entered into a License Agreement with Allogene Overland Biopharm (CY) Limited (Allogene Overland), a joint venture established by the Company and Overland Pharmaceuticals (CY) Inc. (Overland), pursuant to a Share Purchase Agreement, dated December 14, 2020, for the purpose of developing, manufacturing and commercializing certain allogeneic CAR T cell therapies for patients in greater China, Taiwan, South Korea and Singapore (the JV Territory). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Share Purchase Agreement, the Company acquired Seed Preferred Shares in Allogene Overland representing 49% of Allogene Overland's outstanding stock as partial consideration for the License Agreement, and Overland acquired Seed Preferred Shares representing 51% of Allogene Overland's outstanding stock for $117.0&#160;million in upfront and certain quarterly cash payments, to support operations of Allogene Overland. As of December 31, 2020, the Company and Overland are the sole equity holders in Allogene Overland. The Company received $40&#160;million from Allogene Overland as partial consideration for the License Agreement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the License Agreement, the Company granted Allogene Overland an exclusive license to develop, manufacture and commercialize certain allogeneic CAR T cell candidates directed at four targets, BCMA, CD70, FLT3, and DLL3, in the JV Territory. As consideration, the Company would also be entitled to additional regulatory milestone payments of up to $40.0&#160;million and, subject to certain conditions, tiered low-to-mid single-digit sales royalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promises that the Company concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and delivery of know-how, (2) the manufacturing license, related know-how and support, (3) if and when available know-how developed in future periods, and (4) participation in the joint steering committee.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Fixed consideration exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. Milestone fees were constrained and not included in the transaction price due to the uncertainties of research and development. The Company re-evaluates the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The shares of Series Seed Preferred Stock were accounted for as part of the Company&#8217;s joint venture and equity method accounting upon formation of the joint venture, and as such, were excluded from the transaction price. The Company determined that the initial transaction price consists of the upfront payment of $40.0&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The transaction price allocated to the license of intellectual property and delivery of know-how will be recognized upon grant of license and delivery of know-how. The transaction price allocated to (i) the manufacturing license, related know-how and support services, (ii) if and when available know-how developed in future periods, and (iii) participation in the joint steering committee, will be recognized over time as the services are delivered. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received in advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that Allogene Overland is a variable interest entity as of March 31, 2021 and December 31, 2020, respectively. The Company does not have the power to independently direct the activities which most significantly affect Allogene Overland's economic performance. Accordingly the Company did not consolidate Allogene Overland because the Company determined that it was not the primary beneficiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 the Company recognized $38.3 million of collaboration revenue, primarily related to the license of intellectual property and delivery of the know-how performance obligation which was delivered in the first quarter of 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreements text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291495177464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of approximately 68,000 square feet located in South San Francisco, California. The lease term is 127 months beginning August 2018 through February 2029 with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the addition of laboratory space, and has received $5.0 million of tenant improvement allowances. The rent payments began on March 1, 2019 after an abatement period. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an operating lease agreement for new office and laboratory space which consists of 14,943 square feet located in South San Francisco, California. The lease term is 124 months beginning November 2018 through February 2029, with an option to extend the term for another seven years which is not reasonably assured of exercise. The Company has made certain tenant improvements, including the upgrading of current office and laboratory space with a lease incentive allowance of $0.8 million. Rent payments began in November 2018. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company entered into a lease agreement for approximately 118,000 square feet of space to develop a cell therapy manufacturing facility in Newark, California. The lease has a term of 188 months and commenced in November 2020. Upon certain conditions, the Company has two ten-year options to extend the lease, both of which are not reasonably assured of exercise. The Company is entitled to a tenant improvement allowance of&#160;$2.9 million for costs related to the design and construction of certain Company improvements and has received $2.7&#160;million of tenant improvement allowances up to March 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains letters of credit for the benefit of landlords which is disclosed as restricted cash in the condensed consolidated balance sheets. Restricted cash related to letters of credit due to landlords was $5.2&#160;million and $4.3&#160;million as of March&#160;31, 2021 and December&#160;31, 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,686&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,783&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities for the three months ended March&#160;31, 2021 was $1.0 million and was included in net cash used in operating activities in our condensed consolidated statements of cash flows. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undiscounted future lease payments under the lease agreements as of March&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2021 (remaining 9 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,686&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our estimated incremental borrowing rate. The weighted average </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discount rate used to determine the operating lease liability was&#160;8.40%. As of&#160;March&#160;31, 2021, the weighted average remaining lease term for our operating leases is&#160;10.22 years.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In July 2020, the Company entered into a Solar Power Purchase and Energy Services Agreement for the installation and operation of a solar photovoltaic generating system and battery energy storage system at the Company's cell therapy manufacturing facility in Newark, California. The agreement has a term of 20 years and is expected to commence in the second quarter of 2021. The Company is obligated to pay for electricity generated from the system at an agreed rate for the duration of the agreement term. Termination of the agreement by the Company will result in a termination payment due of approximately $4.3&#160;million. In connection with the agreement, the Company maintains a letter of credit for the benefit of the service provider in the amount of $4.3&#160;million which is disclosed as restricted cash in the condensed consolidated balance sheet as of March&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into certain license agreements for intellectual property which is used as part of our development and manufacturing processes. Each of these respective agreements are generally cancellable by the Company. These agreements require payment of annual license fees and may include conditional milestone payments for achievement of specific research, clinical and commercial events, and royalty payments. The timing and likelihood of any significant conditional milestone payments or royalty payments becoming due was not probable as of March&#160;31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into contracts in the normal course of business that includes arrangements with clinical research organizations, vendors for preclinical research and vendors for manufacturing. These agreements generally allow for cancellation with notice. As of March&#160;31, 2021, the Company had non-cancellable purchase commitments of $4.1&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496395288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investment</a></td>
<td class="text">Equity Method Investment<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Notch Therapeutics</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the Notch Agreement (see Note 6), the Company also entered into a Share Purchase Agreement with the Company acquiring shares of Notch&#8217;s Series Seed convertible preferred stock for a total investment cost of $5.1&#160;million which includes transaction costs of $0.1&#160;million, resulting in a 25% ownership interest in Notch. In February 2021, the Company made a $15.9 million investment in Notch's Series A preferred stock. Immediately following this transaction, the Company's share in Notch was 20.7% on a voting interest basis. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s total equity investment in Notch as of March&#160;31, 2021 and December&#160;31, 2020 was $19.4 million and $3.7 million, respectively, and the Company accounted for the investment using the equity method of accounting. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allogene Overland Biopharm (CY) Limited</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the execution of the License Agreement with Allogene Overland (see Note 6), the Company also entered into a Share Purchase Agreement and Shareholders' Agreement with the joint venture company under which it acquired shares of Allogene Overland&#8217;s Seed Preferred Shares representing a 49% ownership interest as partial consideration for entering into a License Agreement which had a carrying value of zero. The Company accounts for its investment in Allogene Overland as an equity method investment at carrying value. The Company's total equity investment in Allogene Overland was zero as of March 31, 2021 and December 31, 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The  Company&#8217;s equity investment in Allogene Overland as of March&#160;31, 2021 and December&#160;31, 2020 had a zero carryover basis. Therefore, the Company did not account for its share of losses incurred by Allogene Overland. See Note 6 for further details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291495177464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company adopted its 2018 Equity Incentive Plan (Prior 2018 Plan). The Prior 2018 Plan provided for the Company to sell or issue common stock or restricted common stock, or to grant incentive stock options or nonqualified stock options for the purchase of common stock, to employees, members of the Company&#8217;s Board of Directors and consultants of the Company under terms and provisions established by the Company&#8217;s Board of Directors. In September 2018, the Board of Directors adopted a new amended and restated 2018 Equity Incentive Plan as a successor to and continuation of the Prior 2018 Plan, which became effective in October 2018 (the 2018 Plan), which authorized additional shares for issuance and provided for an automatic annual increase to the number of shares issuable under the 2018 Plan by an amount equal to 5% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year. The term of any stock option granted under the 2018 Plan cannot exceed 10 years. The Company generally grants stock-based awards with service conditions only. Options shall not have an exercise price less than 100% of the fair market value of the Company&#8217;s common stock on the grant date. Options granted typically vest over a four-year period but may be granted with different vesting terms. Restricted Stock Units granted typically vest annually over a four-year period but may be granted with different vesting terms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, there were 17,212,410 shares reserved by the Company under the 2018 Plan for the future issuance of equity awards.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:42.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,434,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,423,034&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the closing price of the Company&#8217;s common stock on the Nasdaq Global Select Market on March&#160;31, 2021. For the three months ended March&#160;31, 2021, the estimated weighted-average grant-date fair value of employee options granted was $21.41 per share. As of March&#160;31, 2021, there was $102.9&#160;million of unrecognized stock-based compensation related to unvested stock options, which is expected to be recognized over a weighted-average period of 2 years, 332 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:67.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.195%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06 - 6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 - 6.09</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.80%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.42%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 1.16%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80% - 1.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The expected term represents the period that stock-based awards are expected to be outstanding. The expected term for option grants is determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the stock-based awards.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses an average historical stock price volatility of comparable public companies within the biotechnology and pharmaceutical industry that were deemed to be representative of future stock price trends as the Company does not have sufficient trading history for its common stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Unit Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes restricted stock unit activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value at Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Grant per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$107,785</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$107,785</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2021, there was $82.0&#160;million of unrecognized stock-based compensation related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 3 years, 88 days.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercised Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows certain of its employees and its directors to exercise options granted under the Prior 2018 Plan and the 2018 Plan prior to vesting. The shares related to early exercised stock options are subject to the Company&#8217;s lapsing repurchase right upon termination of employment or service on the Company&#8217;s board of directors at the lesser of the original purchase price or fair market value at the time of repurchase. In order to vest, the holders are required to provide continued service to the Company. The proceeds are initially recorded in accrued and other liabilities for the current portion, and other long-term liabilities for the non-current portion. The proceeds are reclassified to paid-in capital as the repurchase right lapses. As of March&#160;31, 2021 and December 31, 2020 there was $2.8 million and $2.8 million recorded in accrued and other liabilities and $0.4 million and $1.1 million recorded in other long-term liabilities related to shares held by employees and directors that were subject to repurchase. The underlying shares are shown as outstanding in the condensed consolidated financial statements since the exercise date but the shares which are subject to future vesting conditions are not included in the calculation of earnings per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496435256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company entered into a license agreement with Allogene Overland, a corporate joint venture entity and related party (see Note 6). During the three months ending March 31, 2021, the Company recognized $38.3 million of collaboration revenue from Allogene Overland under this arrangement.</span></div><div style="margin-top:18pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sublease Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, the Company entered into a sublease with Bellco Capital LLC (Bellco) for 1,293 square feet of office space in Los Angeles, California for a three year term. On April 1, 2020, Bellco Capital Advisors Inc. assumed all rights, title, interests and obligations under the sublease from Bellco Capital LLC. The Company&#8217;s executive chairman, Arie Belldegrun, M.D., FACS, is a trustee of the Belldegrun Family Trust, which controls Bellco Capital Advisors Inc. The total right of use asset and associated liability recorded related to this related party lease was $0.1 million and $0.1 million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consulting Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into a services agreement with Two River Consulting LLC (Two River) a firm affiliated with the Company&#8217;s President and Chief Executive Officer, the Company&#8217;s Executive Chairman of the board of directors, and a director of the Company to provide various managerial, administrative, accounting and financial services to the Company. The costs incurred for services provided under this agreement were $0.1 million and $0.1 million for the three months ended March&#160;31, 2021 and 2020, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Company entered into a consulting agreement with Bellco. Pursuant to the consulting agreement, Bellco provides certain services for the Company, which are performed by Dr. Belldegrun and include without limitation, providing advice and analysis with respect to the Company&#8217;s business, business strategy and potential opportunities in the field of allogeneic CAR T cell therapy and any other aspect of the CAR T cell therapy business as the Company may agree. In consideration for these services, the Company paid Bellco $37,500 per month in arrears commencing January 2020 and $38,583 per month in arrears commencing January 2021. The Company may also, at its discretion, pay Bellco an annual performance award in an amount up to 60% of the aggregate compensation payable to Bellco in a calendar year. The Company also reimburses Bellco for out of pocket expenses incurred in performing the services. The cost incurred for services provided and out-of-pocket expenses incurred under this consulting agreement were $0.2 million and $0.2 million for the three months ended March&#160;31, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496979992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThe Company has a history of losses, and expects to record a loss in 2021. The Company continues to maintain a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496435256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,627,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units subject to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Founder's shares of common stock subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,057,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,115,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,678,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,900,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,182,402&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496693496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsNone.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291493081736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete consolidated financial statements. In the Company&#8217;s opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All material intercompany balances and transactions have been eliminated during consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of March&#160;31, 2021, the condensed consolidated statements of operations and comprehensive loss for the three months ended March&#160;31, 2021 and 2020, the condensed consolidated statements of stockholders&#8217; equity as of March&#160;31, 2021 and 2020, the condensed consolidated statements of cash flows for the three months ended March&#160;31, 2021 and 2020, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. The results of operations for the three months ended March&#160;31, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021, or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited financial statements and related notes for the year ended December&#160;31, 2020, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February 25, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, fair value of investments, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the accounting policies during the three months ended March&#160;31, 2021, as compared to the significant accounting policies described in Note 1 of the &#8220;Notes to Financial Statements&#8221; in the Company&#8217;s audited financial statements included in its Annual Report, with the exception of revenue recognition related to the collaboration revenue recognized in the three months ended March 31, 2021 and the recently adopted accounting pronouncements in the section below.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue may be generated through collaboration research and license agreements. The terms of these agreements may contain multiple deliverables which may include (i) grant of licenses, (ii) transfer of know-how, (iii) research and development activities, (iii) clinical manufacturing and, (iv) product supply. The payment terms of these agreements may include nonrefundable upfront fees, payments for research and development activities, payments based upon the achievement of certain milestones, royalty payments based on product sales derived from the collaboration, and payments for supplying product.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, Collaborative Arrangements (ASC 808) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and, therefore, within the scope of Topic 606, Revenue from Contracts with Customers (ASC 606). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, generally by analogy to Topic 606.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For elements of those arrangements that the Company determines should be accounted for under ASC 606, the Company assesses which activities in the collaboration agreements are performance obligations that should be accounted for separately and determine the transaction price of the arrangement, which includes the assessment of the probability of achievement of future milestones and other potential consideration. A performance obligation represents a promise in a contract to transfer a distinct good or service to a customer, which represents a unit of accounting in accordance with ASC 606. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once the Company has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. A portion of the consideration should be allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The total consideration which the Company expects to collect in exchange for the Company&#8217;s products is an estimate and may be fixed or variable. The Company constrains the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The transaction price is re-evaluated, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The allocation of the transaction price is performed based on standalone selling prices, which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately. Revenue is recognized when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers. Funds received in advance are recorded as deferred revenue and are recognized as the related performance obligation is satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">Recently Adopted Accounting Pronouncements<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued Accounting Standard Update No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Securities (Topic 321), Investments &#8211; Equity Method and Joint Ventures (Topic 323)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarifies the interactions between Topics 321 and 323 in applying or discontinuing the equity method of accounting for investments. This guidance is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. The Company adopted this standard on January 1, 2021 on a prospective basis. Adoption of the new guidance had no significant impact on the Company's condensed consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently adopted accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291495112872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:&#160;</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">566,945&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds (1)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,771&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,806&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included within cash and cash equivalents on the Company&#8217;s condensed consolidated balance sheets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291495135816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Fair Value and Amortized Cost</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value and amortized cost of cash equivalents and available-for-sale securities by major security type as of March&#160;31, 2021 and as of December&#160;31, 2020 are presented in the following tables:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,916&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462,716&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Gains</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized&#160;Losses</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,095&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,806&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496714424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Property and Equipment consist of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,112&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,810&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers equipment and purchased software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,825)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,908)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,146&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,840&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291495173960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LiabilitiesLesseeTableTextBlock', window );">Schedule of Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Current portion included in accrued and other current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,974&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Long-term portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,686&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,783&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs for operating leases, which were recognized in operating expenses, were as follows (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Lease Payments Under Lease Liability</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undiscounted future lease payments under the lease agreements as of March&#160;31, 2021 were as follows:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2021 (remaining 9 months)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,686&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496431688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under Plan</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes option activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:42.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Options</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contract<br/>Term</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,434,034&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(496,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,423,034&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Stock Option Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of employee, consultant and director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:67.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.195%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06 - 6.08</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.07 - 6.09</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.80%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.42%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk-free interest rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60% - 1.16%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80% - 1.65%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity Under Plan</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes restricted stock unit activity under the 2018 Plan:</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Stock Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Units</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value at Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">of Grant per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Vesting Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,493,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$107,785</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$107,785</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation related to stock options, restricted stock units, employee stock purchase plan and vesting of the founders&#8217; common stock was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,215&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291494809656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Shares</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the period presented due to their anti-dilutive effect:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,107,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,627,389&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units subject to vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,053,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,534,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected shares to be purchased under Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Founder's shares of common stock subject to future vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,057,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,115,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Early exercised stock options subject to future vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,423,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,678,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,900,607&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,182,402&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496539240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="nump">$ 964,200<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 679,358<span></span>
</td>
<td colspan="2" class="nump">$ 646,343<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291497164584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 903,916,000<span></span>
</td>
<td class="nump">$ 950,806,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291580746232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities (Detail) - Fair Value, Measurements, Recurring - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 903,916,000<span></span>
</td>
<td class="nump">$ 950,806,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">176,627,000<span></span>
</td>
<td class="nump">102,039,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">39,993,000<span></span>
</td>
<td class="nump">58,975,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">221,891,000<span></span>
</td>
<td class="nump">262,757,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">390,318,000<span></span>
</td>
<td class="nump">446,996,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">75,087,000<span></span>
</td>
<td class="nump">80,039,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">566,945,000<span></span>
</td>
<td class="nump">549,035,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">176,627,000<span></span>
</td>
<td class="nump">102,039,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">390,318,000<span></span>
</td>
<td class="nump">446,996,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">336,971,000<span></span>
</td>
<td class="nump">401,771,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">39,993,000<span></span>
</td>
<td class="nump">58,975,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">221,891,000<span></span>
</td>
<td class="nump">262,757,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">75,087,000<span></span>
</td>
<td class="nump">80,039,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291497308584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 903,575<span></span>
</td>
<td class="nump">$ 950,095<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(59)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">176,627<span></span>
</td>
<td class="nump">102,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">462,716<span></span>
</td>
<td class="nump">644,559<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investments</a></td>
<td class="nump">264,573<span></span>
</td>
<td class="nump">204,208<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CashEquivalentsAndShortTermInvestments', window );">Total cash equivalents and investments</a></td>
<td class="nump">903,916<span></span>
</td>
<td class="nump">950,806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">176,627<span></span>
</td>
<td class="nump">102,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">176,627<span></span>
</td>
<td class="nump">102,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">39,986<span></span>
</td>
<td class="nump">58,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">39,993<span></span>
</td>
<td class="nump">58,975<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">221,738<span></span>
</td>
<td class="nump">262,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">444<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">221,891<span></span>
</td>
<td class="nump">262,757<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">390,132<span></span>
</td>
<td class="nump">446,726<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">390,318<span></span>
</td>
<td class="nump">446,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">75,092<span></span>
</td>
<td class="nump">80,012<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized&#160;Gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized&#160;Losses</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 75,087<span></span>
</td>
<td class="nump">$ 80,039<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291496674152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Maximum remaining contractual maturities of available-for-sale securities (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Net unrealized loss position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291502037944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 137,971<span></span>
</td>
<td class="nump">$ 131,748<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(14,825)<span></span>
</td>
<td class="num">(12,908)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">123,146<span></span>
</td>
<td class="nump">118,840<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">73,339<span></span>
</td>
<td class="nump">68,944<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">31,518<span></span>
</td>
<td class="nump">31,518<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">25,112<span></span>
</td>
<td class="nump">23,810<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember', window );">Computers equipment and purchased software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">4,271<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment, gross</a></td>
<td class="nump">$ 3,731<span></span>
</td>
<td class="nump">$ 3,388<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=allo_ComputerEquipmentAndPurchasedSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291487473576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 14, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,183,000<span></span>
</td>
<td class="nump">$ 42,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,220,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,738,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of stock in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,938,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,345,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=allo_UniversityOfTexasMDAndersonCancerCenterMember', window );">University Of Texas MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationAgreementCommittedFunding', window );">Committed funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationArrangementExpense', window );">Collaboration arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of stock in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Voting Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember', window );">Allogene Overland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember', window );">Allogene Overland | Overland Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture | Allogene Overland | Overland Pharmaceuticals Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_UpfrontAndQuarterlyCashPayments', window );">Upfront and quarterly cash payments</a></td>
<td class="nump">117,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_JointVentureCapitalSupportPayments', window );">Joint venture capital support payments</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale', window );">Royalty obligation period from date of first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember', window );">Pfizer | Asset Contribution Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones', window );">Aggregate potential regulatory and development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget', window );">Maximum payments required per product against selected target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Pre-Clinical Development Milestone | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember', window );">Cellectis | Development and Sales | Maximum | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByTheCompany', window );">Percentage of development costs payable by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner', window );">Percentage of development cost payable by collaboration partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Regulatory Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestoneReceivable', window );">Aggregate potential milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 70.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember', window );">Servier | Sales Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Research Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayable', window );">Aggregate potential milestone payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CollaborationAgreementUpfrontPayment', window );">Collaboration agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Pre-Clinical Development Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Clinical, Regulatory, and Commercial Milestone | Maximum | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AggregatePotentialMilestonePayments', window );">Aggregate potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialMilestoneReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential milestone receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialMilestoneReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AggregatePotentialRegulatoryAndDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory and development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AggregatePotentialRegulatoryAndDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementCommittedFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Committed Funding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementCommittedFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CollaborationArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CollaborationArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_JointVentureCapitalSupportPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint Venture Capital Support Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_JointVentureCapitalSupportPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum payments required per product against selected target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PercentageOfDevelopmentCostPayableByTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Development Cost Payable By The Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PercentageOfDevelopmentCostPayableByTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RoyaltyObligationPeriodFromDateOfFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Obligation Period From Date Of First Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RoyaltyObligationPeriodFromDateOfFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_UpfrontAndQuarterlyCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront and Quarterly Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_UpfrontAndQuarterlyCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=allo_UniversityOfTexasMDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=allo_UniversityOfTexasMDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_EquityInvestmentBasisAxis=allo_VotingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_EquityInvestmentBasisAxis=allo_VotingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=allo_OverlandPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=allo_OverlandPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=allo_OverlandPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=allo_OverlandPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_AssetContributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_CellectisSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_ResearchCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_PreClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_MilestoneTypeAxis=allo_DevelopmentAndSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=allo_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ClinicalRegulatoryAndCommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291487463416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfNewOfficeBuilding', window );">Area of office and laboratory (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,943<span></span>
</td>
<td class="nump">68,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">124 months<span></span>
</td>
<td class="text">127 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_TenantImprovementAllowance', window );">Allowance for tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 2 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LesseeFinanceLeasePaymentUponContractTermination', window );">Termination payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Non-cancellable purchase commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=allo_NewarkMember', window );">Newark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">188 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, option to extend term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_TenantImprovementAllowance', window );">Allowance for tenant improvements</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfOperatingLease', window );">Area of operating lease (in square feet) | ft&#178;</a></td>
<td class="nump">118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfOptionsToExtendLease', window );">Number of options to extend lease | renewal</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_TenantImprovementAllowanceUtilizedToDate', window );">Tenant improvement allowance utilized to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfNewOfficeBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of new office building.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfNewOfficeBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LesseeFinanceLeasePaymentUponContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Payment Upon Contract Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LesseeFinanceLeasePaymentUponContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfOptionsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfOptionsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_TenantImprovementAllowanceUtilizedToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance, Utilized To Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_TenantImprovementAllowanceUtilizedToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=allo_NewarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=allo_NewarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291497289736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in accrued and other current liabilities</a></td>
<td class="nump">$ 3,061<span></span>
</td>
<td class="nump">$ 2,974<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">51,625<span></span>
</td>
<td class="nump">50,809<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 54,686<span></span>
</td>
<td class="nump">$ 53,783<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291583063960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="nump">$ 1,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">327<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 2,189<span></span>
</td>
<td class="nump">$ 2,078<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291576656792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Undiscounted Future Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining 9 months)</a></td>
<td class="nump">$ 5,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">7,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">8,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">8,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">8,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">48,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">86,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustment</a></td>
<td class="num">(31,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_TenantImprovementAllowance', window );">Less: Tenant improvement allowance</a></td>
<td class="num">(325)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 54,686<span></span>
</td>
<td class="nump">$ 53,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291501503576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2019</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 14, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of stock in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,938,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,738,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire interest in Notch</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_CostMethodInvestmentTransactionCosts', window );">Transaction cost</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchase of stock in equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember', window );">Notch Therapeutics, Inc. | Voting Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember', window );">Allogene Overland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentQuotedMarketValue', window );">Carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_CostMethodInvestmentTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost Method Investment, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_CostMethodInvestmentTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentQuotedMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentQuotedMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_NotchTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_EquityInvestmentBasisAxis=allo_VotingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_EquityInvestmentBasisAxis=allo_VotingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=allo_AllogeneOverlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291501853496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding', window );">Number of shares as percentage of common shares outstanding</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance (in shares)</a></td>
<td class="nump">17,212,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent', window );">Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent', window );">Other long term liabilities, related to shares held by employees and directors that were subject to repurchase</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="nump">$ 82.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation expense, weighted average recognition period (in years)</a></td>
<td class="text">3 years 88 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 21.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock based compensation expense</a></td>
<td class="nump">$ 102.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock based compensation expense, weighted average recognition period (in years)</a></td>
<td class="text">2 years 332 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_StockOptionGrantedPeriod', window );">Stock option grant period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate', window );">Option exercise price as percentage of fair value of common stock on grate date</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares as percentage of common shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise price as percentage of fair value of common stock on grate date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_StockOptionGrantedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option granted period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_StockOptionGrantedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291501795672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - 2018 Plan - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance (in shares)</a></td>
<td class="nump">10,434,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, options granted (in shares)</a></td>
<td class="nump">1,617,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, options exercised (in shares)</a></td>
<td class="num">(447,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, options forfeited (in shares)</a></td>
<td class="num">(496,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance (in shares)</a></td>
<td class="nump">11,107,162<span></span>
</td>
<td class="nump">10,434,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable (in shares)</a></td>
<td class="nump">7,423,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of options, vested and expected to vest (in shares)</a></td>
<td class="nump">11,107,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 17.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options granted (in dollars per share)</a></td>
<td class="nump">34.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercised (in dollars per share)</a></td>
<td class="nump">8.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options forfeited (in dollars per share)</a></td>
<td class="nump">15.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">20.57<span></span>
</td>
<td class="nump">$ 17.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">19.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 20.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contract term, outstanding (in years)</a></td>
<td class="text">8 years 2 months 23 days<span></span>
</td>
<td class="text">8 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, exercisable (in years)</a></td>
<td class="text">8 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contract term, vested and expected to vest (in years)</a></td>
<td class="text">8 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, balance</a></td>
<td class="nump">$ 166,162<span></span>
</td>
<td class="nump">$ 93,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">120,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 166,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291501909096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.80%<span></span>
</td>
<td class="nump">71.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Expected risk-free interest rate, minimum</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Expected risk-free interest rate, maximum</a></td>
<td class="nump">1.16%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember', window );">2018 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=allo_TwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291493651528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Unit - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, beginning balance (in shares)</a></td>
<td class="nump">2,493,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units, granted (in shares)</a></td>
<td class="nump">1,139,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock units, vested (in shares)</a></td>
<td class="num">(439,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units, forfeited (in shares)</a></td>
<td class="num">(140,218)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units, unvested, ending balance (in shares)</a></td>
<td class="nump">3,053,413<span></span>
</td>
<td class="nump">2,493,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">Restricted stock units, vested and expected to vest (in shares)</a></td>
<td class="nump">3,053,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Fair Value at Date of Grant per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 26.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, granted (in dollars per share)</a></td>
<td class="nump">33.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, vested (in dollars per share)</a></td>
<td class="nump">23.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, forfeited (in dollars per share)</a></td>
<td class="nump">25.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at date of grant per share, ending balance (in dollars per share)</a></td>
<td class="nump">29.47<span></span>
</td>
<td class="nump">$ 26.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 29.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining vesting life, unvested (in years)</a></td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms', window );">Weighted average remaining vesting life, granted (in years)</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted average remaining vesting life, vested and expected to vest (in years)</a></td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value, unvested</a></td>
<td class="nump">$ 107,785<span></span>
</td>
<td class="nump">$ 62,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 107,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291494866776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 16,792<span></span>
</td>
<td class="nump">$ 14,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">7,920<span></span>
</td>
<td class="nump">6,657<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 8,872<span></span>
</td>
<td class="nump">$ 7,558<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291500828152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,345,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,295,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,686,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,783,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_AreaOfOffice', window );">Area of office space (in square feet) | ft&#178;</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Sublease, term of contract (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Payments Commencing January 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Payments Commencing January 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears', window );">Related party transaction monthly payment in arrears</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember', window );">Bellco | Consulting Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_allo_RelatedPartyTransactionCompensationPercentage', window );">Related party transaction compensation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember', window );">Two River | Consulting Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyCosts', window );">Related party costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The balance sheet as of December&#160;31, 2020 is derived from the audited financial statements as of that date.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_AreaOfOffice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_AreaOfOffice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction compensation percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_RelatedPartyTransactionMonthlyPaymentsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction monthly payments in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_RelatedPartyTransactionMonthlyPaymentsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>allo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_BellcoCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=allo_ConsultingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">allo_PaymentTermsAxis=allo_PaymentsCommencingJanuary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=allo_TwoRiverConsultingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140291576476472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">21,900,607<span></span>
</td>
<td class="nump">29,182,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">11,107,162<span></span>
</td>
<td class="nump">11,627,389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units subject to vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">3,053,413<span></span>
</td>
<td class="nump">2,534,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Expected shares to be purchased under Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">258,986<span></span>
</td>
<td class="nump">226,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember', window );">Founder's shares of common stock subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">6,057,696<span></span>
</td>
<td class="nump">12,115,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember', window );">Early exercised stock options subject to future vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">1,423,350<span></span>
</td>
<td class="nump">2,678,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_FounderSharesOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=allo_EarlyExerciseOfStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<)2[80ZW+:IL .POI30O$WN>-_>WR5]02P,$%     @  H.E4FLH3UMD!
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M1/A\*<T/T;7I(KAR$=?*M.0#F3P;X'OI7-P^L(/Q/X/S?P!02P,$%     @
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MT-A7U$4-X?=R[GHBU,LGT:>GU4?/P7D-CFZYR!$88@DM'/LP(J1%!%I*.%:
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M<X\6:#+'0":'Y-$"36-_-IF]H(\6:#S&1*73%P4:]G]2H'GHO#\@CQ=HG**
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ML<;W#=?N /:72MG]PCD8OI@N_@%02P,$%     @  H.E4ECJYK8- P  :P8
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M <YP(.XBOR"NR8UL[A0P>24TL@BT(B/\T4=I?!98"$HKFT8A, \7 = <T+9
MDT55H=96(+HLX>VJD7I5%SDQ_GW= $^N2#U%:I!-P1 I^.NJ0RTNE""N?,B
M"O"9[-"M!?&0*>+.J[IR#@@"KZQNW"/F1J3.G@0R!0;&+&<*#'33\ :.ELL:
MT=5H2L%0T&Y $C$O)&MP5G=@R[:HPN:CT6'X#$89MRF$)I,IOZS!I"#L*#L&
MT$_U5A1@[@#C,@63"=*I,S#/B!'&3JD1B:WE.0)';+3'&6!O/5?!)7S(VAH)
M!4[A>1K_GFS@%(!%5#E++(B8V4QYW"&J*O(9,#"0!91D ZX3BPT0'ZQ0+NU"
M% #XAD,#26>\(R]L/3MQ&SZ<@#3IM:3XK "H#4& =*+00"W0*85D!@C1H,-3
M*9/<$ ));FF"6TYQ(C5 &^0T\+.01SGLWJ(D@.=M(0YE@]R79J2].>-^22.C
M#1:B T]NY=4B->KB$&H\@7TIJ+VJ[H#4:$M 3 F039(WW1*M1@$:1 ;WX.W[
MUX=(IH5J0+ 6P)X\84LYERBR)AYX2N0^CUS;?__7Y=GILQ^TXZ,Q7;@OF4_#
M$A*+9 DTKT*YLU\Y^LJEJHQI((4AB)!T*.4DI5-2B[B#=&AKQ,$\LEX?J$/6
M%.??G0YEA5"EU1]#$I20M6@-_0\4K#X]2[80^ &!FKI\(%RSQ$6-$/$78EX[
M[YHG@S"-:?:*6:LP: -8FM8"W9>0U'X#D9%:5JQ]40CUL-/)5'X ZZY06 (P
M>N&;_^5F=C6#J,C^?3A+/E1&/2_3P%B,1Y!3(.QQ,ADE"/LJDY;1K^RY9-:%
MG![9C/1^!Y1(';^,K4<,.,0J*%XBAON:O_5 I_>%N/%!N(YY",8;>-#*Y#Z.
ML#;N>L($>["Q0&UD:<@B:8 3@90DOKG29)88-DC0CS)(+D OBCAP1BNKR 3"
M8HPG&H361Q3@=\ W91C#8(QC?"NGT6SRT/.3=&]30YD-1QD8"!*EDU\Z<!*8
MAH Q#^@XR57_Y;*!9T?TH0+Y &IH,O[DDB!/EM:B@ZT'\J!_+E@PTUU1M0D0
M=3?GIW&=B8PZ<%--F)WD"@D-2^)?0$0=S,Z4CMKV,.M1<,+MU?6;]VST\%%X
MRC%39JNJAB!OF]ID(T47DB+U"]BGA$>!6+BV!N(T&Z51;=9%K:SCLY$>&!?#
M4^>T0K9:- Q[0Q@Q9TB3GZ]OS]/D]?7U.8OZZV<GK"E7)@I-;GGI(8<EJZX$
M%M55AO!#A(K@B;4$?<X@3E=B6=6:/B-95ML"Q3 SDEJ;'U'EUK66;")$SJ1/
M';!>2,:=J&&AE2"05+]B($XD839*7O=D](T5-6?GB B1ZGDUG?-^<]EN)+A$
MNRE^QU8>*$ Y@0W%SD_(=CVUZG./+U!Q7K^!V!5D%PZY8RMC;4Y@.G<;GKU4
M,H3 DC2P>)#N5$>[57(!>Z486*TE,8HR_*:1=S4[:Z>J?X4V!N!^/ZF)TUK5
M4ZJO5:2^%[1*8D*O$1MO4DH.,/L5CEXZXF-M$WA:_OB$]?2RG][8\(8"4A5"
MOP3 =4OEH%BI=R30>T/8UBT0#UAI #N;729S!FL6:O)TC)^ DT+'[6-V'Y<[
M:0LB=!,-.C81PIBE1<S,^[2CQ[ ,18*$ 7I6-V23042$36DZ$DO,OW!#C#XQ
MU&Z"3""]USX9>1_H-\ORA"+VK.Y'@QV870"[H0J*2;=6H#.3.<TLN<'8UM.R
M%!BT ZUA.YD;=^D@#!*K_G?W9%@HQA15@#V7+KZG[,F*1MY)@[/96[,"JR;G
ML,*$\7I/2T5RV,W_,-F*54DP3G)MS$6O5!/6]!1 4E9JL8WB.:,:11'!18S'
MY84(8I1 )U*@:]4MP+MU&(VDD>P9"]U06FBDM<]8%C'%TM:U/<OF(HT2<R34
MQSG58>QCC5QCH @L-WAO1(.FFY2'A;42%85S+?($E-P(SR1A(U6U=$OOI7=(
MU\CQ_BV4W6&P![9YA.+#R.[OH#?["*^A08'IKU//L!85I-F<?XVFVE&YBKYU
M)[*6L@VDVEB03O_ &3@MJ+7NU<%MX*"P]K$ RF"6LRL;9V&$+<V>>#(62BIP
M%(T6S=9"AY&6_<S)?E#^W"?O_R%9U1N0NP:#8HAR$O@,!DBO!(5=D1&=!QP:
M%DU0LE4&*#<#SD%81+1%3#;H6N4X-N,8H#4-49@EK_N5\+Z8QR80J\*"@RP\
MB4]IY**#[:FV%_]2R64-WM]FG! M9[ #50$-8EQ@\8?Z.K-1X9'TQ*FGM0F$
MTD _9\EON_SC$#%KCW)58!<DDT%IBT#"C ,8I0=-I;[EP)90KG+?IJA[*&#$
M$Z_ B*L73:$8X8.E^ ,(5HKFLVQ=\6NSPJII'P43 >5C[0)(CB*?X&Q3L376
MB: E$5)D_,;(0$Y9J(((DG4  \HO0/K\!%1HRRYS6 D<Y(W<1F \*3'))$H&
M/#J7(Y&EZ?+I5HJ<GY]+("D\.F \\KU +D%B7V ^Y4HK5&$0&81I.;;L&$A$
M%9^PSGXDDJ+SK"W[JO(QE3=C.XE6H5<*CPC=IR 1;&"T![7'VYY$D+<AK1P4
MF<90%09; O@IL]0X,SA38:6Y42T84>Q: 3!I(A4F/P@(4A)-4B.Q*MSL*J3,
MDC>\C)TXQI3WPI8^\ Q#]>?W(V%]*QML8T%K#Y_SYEV%$I_WO?ITDH:(49HR
MEZ$8]C()@K,'$J8@F&1 OA"#1VF'/XO5 /XKJL]-MVXY$]%U<6?JV6.;&Y4U
M_"5IQ$R&YFN<?"9@JZLEN3UJMM=%%.+,4$7A%]WJ7M$!:,1UTY%JK:UYLEZA
M"0.352\K2K#(@ 4#%Z&)!>6AB'^6_&P[VWMUB:*O3M+D<9CFX@/_EDUMT"!X
M'/R]D!*[E@"/M?= GK$JJ4]H;7(68CS;JRQ$I++%H&_N!U0/+$I1VNA.#^K:
M!-8UB-HU+ZM!";5[\N;JAK9]"S9:M1 .0^[[28)/:<BOO,5B>F6:4KUE!UB:
MMDV\U/YT& 0!80PO1R("UTKVG6[?_A[VO /W'!8P?X,G;[$Q,#INX-H-]=K&
M,_6<?9HUL:!)=\@*4X"DRI6%8B(RH,[LKOY\N&!0@4$Y"TZS#>G1YJU/I&S+
M82-0)M"B^JB+$!S?U4=3 ^D8"1*#LKN+]?9GJ&/%U?7UAZ,G)ZS+]H\KUUU7
MLL@Y(P8ZMUV)U,R108A86795S?7D[2A/;;DJA'64NUJ4CL7$,4^=$39-3:N
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M$=]:L'^T]9K^X91YW;9U21]74D!D@0_ [XNZ;NT?>(#[EW1^^@]02P,$%
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MI0HRP\,L&2W3>0]%QY/E:#*;H*!'RY0E43H- /59BJ79-'G.DDF4IGT@':>
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M1V?K:([<)R[MT[YA@@KT:#08=UP5M7L+DLG[J@&*]HLAB=9)16)*3H/,; 8
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MZYL3=FK7@&^]FM#=5=78RMB LVK=-U"AUGG#YO$S:P.60@ G?^T5J6:ZJD@
MYI]4KV607U;R2?5#5,M-M-:?_W1U<?[T&133*8/3)LR%:'Y![$>K'!)-Y5GA
MUFB.54/,:?!2]\[1@]&&(V9"-9*8-+*6WE.$$YNBF@GER+J#[R2!<0M QO8!
MXCM^YEGT6OA%-0-Z>Z9!B[% V<9G0CAG<)VDS.:$O?(A[I?-$)(W]R;R,](6
M,Z1P>[FP\+5CNS2@YOLIY%60$D:&]F W,,A.A(L4%@!O34X<A4)<&R_J*.7
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M?#6?!:"'Q34<K.K\LM@K2ZO'BPWM>M3.@+[72MG3P068_A[K?P%02P,$%
M  @  H.E4L;CO-K] P  P@D  !D   !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&ULG5;;;N,V$/V5@; /":!&=]LQ; .)TT4+9+'&)KM%4?2!EL86NQ*IDE2<
M].L[I&3%<1T7[8LXI.9^>$C.=E)]UR6B@>>Z$GKNE<8TTR#0>8DUTU>R04%_
M-E+5S-!4;0/=*&2%,ZJK( [#45 S+KS%S*VMU&(F6U-Q@2L%NJUKIEYNL9*[
MN1=Y^X4O?%L:NQ L9@W;X@.:K\U*T2P8O!2\1J&Y%*!P,_=NHNGMR.H[A6\<
M=_I !EO)6LKO=O)S,?="FQ!6F!OK@='PA$NL*NN(TOBS]^D-(:WAH;SW_M'5
M3K6LF<:EK'[AA2GGWL2# C>LK<P7N?L)^WHRZR^7E79?V'6Z6>9!WFHCZ]Z8
M,JBYZ$;VW/?AP& 2OF,0]P:QR[L+Y+*\8X8M9DKN0%EM\F8%5ZJSIN2XL* \
M&$5_.=F9Q5+6-3?49:.!B0*64A@NMBARCAHN'MFZ0GTY"PS%LA9!WON][?S&
M[_A-X!-Y*C7\* HLWMH'E..0:+Q/]#8^Z_ 34U>01#[$81R=\9<,A2?.7_*_
M"K_C.J^D;A7";S=K;13MGM_/1$V'J*F+FKX3]8%(5;05@MS /=)N@GO.UKSB
MAJ*>ZO)9=Y:Q4]VP'.<>45*C>D)O\5@B;=2*B1RA(W9>,:WYAN?,,8%BRU9!
MY>)7K_%AAU0OT["1%9&5X.<"3"E;30W2EU,@#/)R  'N,,=ZC6J_$L+G!A6S
M;3SA?-DJ1=V&1BJ7!1=YU=+>((&XF:N61 N$-"6YS'OM0P\?(/'#441C[%^/
M4[B78ON#054//JFR?P;.(G\49Y"%_B2\AD=I6 7R3*(?($O]T61DA<0?3Q(X
M WPV )_]1^"74IN3D)]U]#[DN:P;*=Q^'MJ0VQ@$ISHN6/NP*SF!Z2!7F,NM
MX']U8+RJXC.=_9WRO^R,QU(AOJ%\MT5.[@J;%34W\B>CN!\G\(TI;@^;0YTD
M'D,<A3UFAR79+1!-KMT8CB?G$!H-"(W.(]1=2[9Y'UMCF=_AM&(OW2GQE<I2
M1ZQ].07@V3CO ]B*@DX=V0I#W=MT*70U-_L46I<"$:3_P;;4]OX,<[ ?,?0(
MMBG\BDP!4B "XX"^TR- .^L+A?9:M[K74#ML+RTI_#!-K48,8_\Z&ELQ@8D?
M$8HDIB2F26C%C,2,.$?BR'';4AO9AC@+*1FD20_MF]*/:IZ,_#B*J.^:\E_9
MCM&Q\,2JEBHK_J ;TJK!!=5,#Y'+7N\1!:-57C=*/KD. ;,M<(?B11)GEWWD
M@>RG=E!P<*_6J+;N]:#!)=I=L</J\$"YZ>[E5_7N=4/ ;+G05-R&3,.K,;%<
M=2^&;F)DXV[IM31TYSNQI$<6*JM _S=2FOW$!AB>;8N_ 5!+ P04    "  "
M@Z52?>*AL'$%  "J#0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R=
M5UMOVS84_BL'7C,D@"R+NCM+#-B]; 76-4B;[&'8 RT=VT(D42-I.]FOWR$E
MRVX;N^F (.;EW/F=C]355L@'M4+4\%B5M;H>K+1N+D<CE:VPXLH5#=:TLQ"R
MXIJF<CE2C42>6Z6J'/F>%X\J7M2#R95=NY&3*['695'CC02UKBHNGV98BNWU
M@ UV"[?%<J7-PFARU? E?D)]U]Q(FHUZ*WE18:T*48/$Q?5@RBYGB9&W O<%
M;M7!&$PF<R$>S.1]?CWP3$!88J:-!4X_&WR-96D,41C_=#8'O4NC>#C>67]G
M<Z=<YESA:U'^6>1Z=3U(!Y#C@J]+?2NVOV&73V3L9:)4]C]L6]DH&D"V5EI4
MG3)%4!5U^\L?NSH<**3>$06_4_!MW*TC&^4;KOGD2HHM2"--ULS IFJU*;BB
M-H?R24O:+4A/3SYID3T,9Y17#J]%16>MN"W7^6<^+U%=7(TTN3'"HZPS.6M-
M^D=,!O!!U'JEX&V=8_ZE_HC"ZV/T=S'._),&/W#I0L <\#V?G; 7]#D'UEYP
M+.<5ESB<VYQO^!-!3,-42EXOT8[_FLZ5EH27OT\X"WMGH746'G/6HAW$ FRM
MX6-CZSLU<"ST$]Q1E23<E+Q^KM0GC9N.O50-S_!Z0"VI4&YP,/F\0EB(DMJM
MJ)==MQ7_H@+1[!O!>%Y;SYK$?8^E-H1+^+C62O,Z-[IMJ K^6%=SDJ04=BM_
M6K1C/H3I!B5U+[Q]1)D5"N%&%AD>"BR7$I=<(Q2UE@6U<P8;7JX1SHL:GI!+
M=6&'>B76BCS3=,8IE@P=>(,96M_=\7O /"<,0L<+0G@%+'&3 %+7']-D'#@L
M',.O=)#D&)@3L\3QDA2"T/7"/L <SL,P<=+4NR#-<034W0LLM-T8QZ1!&RQR
M@W@?!B$P6_40!,8<YB4.BWURZWMNE)@8 A-0'-OESIEIH6^T$R?T@UT"8Y=%
MI,Q, LSW'#H)N$=EHJ%2 #XV1%\TT0(VM/P_0CF!X:C'<'0:PW05Y.L2OT3P
M/1UBRQ5312AKD?$<AD\;MW#EA>Q 02##JBG%$U+E,K)(]$H':JN1%Y*J(>A.
ML7'L\+SE,E>PY0JH0@4QM2F>ML#.#>[(Y-*  M;*H)K#K.1$>I25*/NV&#:$
M6[-=B1P-"^N5M;#O)+[/\A(^KR3B%T3W]<E8M+[MSP]E!3N\0^QZ,0S-3VK^
M)>UXO!??B))*6YHN33PW]<X@86[HG^TE9*$>A@L3!+454O-KD"99SXU)>@C,
M9?$9M+IF%D<'RCD10(Y44=KTSDX@).X1$K\,(53K6XJ%:FG\M'BYJPNM7DIX
MI_T<Y3:Y=]J"8TU.?X#JC@1]9/E;^GMG$'QO$4S0>]/!SG(1-.3:WCF]7J]V
MB^;A9 (P36]^?R\6>,"9[WO.O/\.9][5FY8WON5,WPF)',<T(HZ(718:/,0T
MB7UG'"8'E,F"L1/$ 02!.P[!=\-HQT;G(6W%D7\!?N"&X2%KLI!XBZ6T$[E1
ML _DJX8@SHL")V2&G/RQ2WY]E]CNE>&O)(U^B/:^8^L$HI,>T<F+$7WTD60:
MJE;X'(Y/6C]R<0O-RQ:^W>LD.W0FL>1=30[Y3SG/@Y_6=T3:K39KJB'9A8;@
M;^N\Z4!'.;9<9_M$_?Q3ZK/D%^.^(L>MMN%7^FN[3WV%OA<3(C44VF7+Y[BA
MKX+&/KI>T;W8(C0FF!$FL:86*:T<S^GE6Y@WF7G"0^JDB4_B493"=VIFKD$G
M&9O+D84$TNC9ZW!T\'ZN4"[M5X(B2^M:MT_I?K7_$)FV[^^]>/L50SDOJ5^A
MQ 6I>FY"EY]LOPS:B1:-?8W/A::WO1VNZ&,*I1&@_840>C<Q#OK/L\E_4$L#
M!!0    (  *#I5(JWB*F20,  ,<&   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;'U536_C-A#]*P-=V@)J)%&R; >V@60WBQ;8+8PXVQZ*'FAI9+&A
M2)6D8N??=TC96B^PR<7FQ\R;]V8XH]51FV?;(CHX=5+9==0ZU]\FB:U:[+B]
MT3TJNFFTZ;BCK3DDMC?(Z^#4R82E:9ET7*AHLPIG6[-9Z<%)H7!KP Y=Q\WK
M/4I]7$=9=#EX%(?6^8-DL^KY 7?HOO9;0[MD0JE%A\H*K<!@LX[NLMO[PML'
M@S\%'NW5&KR2O=;/?O-[O8Y23P@E5LXC</I[P0\HI0<B&O^=,:,II'>\7E_0
M/P7MI&7/+7[0\B]1NW8=+2*HL>&#=(_Z^!N>]<P\7J6E#;]P'&V+-()JL$YW
M9V=BT DU_O/3.0]7#HNW'-C9@07>8Z# \B-W?+,R^@C&6Q.:7P2IP9O(">6+
MLG.&;@7YN<T?5/?/VEK8HH%=RPW"ST]\+]'^LDH<!?!F274&NQ_!V!M@.7S1
MRK46'E2-]??^"1&;V+$+NWOV+N 7;FX@SV)@*<O>P<LGM7G R]_ >^!&"76X
M5OOWW=XZ0X_CGW?PBPF_"/C%&_@[ZIEZD BZ@:UVJ)S@4K["1R$'__K&F/9'
MF7T7V+?FK>UYA>N(>L^B><%H\]0B-%I27Y$FH(ZSCJO:K_NKV/4EM@VQH>6T
MWB,JP%,E!RH4-$9WX BMXK(:) _]0A*"*]TK>B32/Y*>TA9@**X)'G0B= V!
ME/*V]8#@M+\3!CB1^'4B@$U#O7@+5-6JG<KJ?U+8.5T]@^Y]:.L!^H&,J-V@
MTEU'=&PPR+(X2^=Q5C*_+-D\SA=+>$0JH:A\^-%L4,)9&C3[?RF@1WLA"Y^8
M/$YG>5QD.;!XEA=Q.<_@X=3CZ#LFB,SW.,6O":PFV0]=+_4KXIGI]D)O*[D"
M-EO$RT4)C)5Q,5O")QV<?K(73$KF=SJNJ#6#&RBA%X8E,9S'Y;*$C,59-B.!
M#.C=4B7QA*82=E)YR=;;8%E<L#S.9RG)+>>+>)9F\*0=E\"R>)FF<9G.@2WC
M;,'B(F7PHQ9(KH9+A^801J@E.8-RXYR93J<I?3<.IV_FXXBGPA\$$9;8D&MZ
M,Y]%8,:Q.6Z<[L.HVFM'@R\L6_K2H/$&=-]H>MCGC0\P?;LV_P-02P,$%
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M6Q>J[RS'@)ULE)X" R"SX9X":SL%NSRZKE"W1\< S:R/JT ^-MMQP"H?I>'
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MR2/@.L,,IK88W>A1+8H"(;VS6,?S(%ZVZF,T:6BCIE$[C_X66\^V<+53Z-;
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M5G)#E'T;T>Q%'M_<&B,B4IN*'XS";P7:F<E,)HDPF%M&$YY&9"93(](EI*$
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MT%JZJ5N[C]%#NJ_5CCC62DS=4OP.AVCUQ36KU[+)_)_I+E9+'G-+TI&CT?0
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MBL['=-9-,Z2;#>J-'UM+C30$_;*D=PT8IT#?5UKC;N,<="^EV3=02P,$%
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M>5;^LN_506P!ANX!@%<!O&< VCL \"N ?RJ@5P%ZIP*""A"<"NA7@/YS@'\
M,*@ @U,M#"O L(AN&8XBEC.FV60LQ89(LQK9S$.1$ 4:0\@SD[MW6N);CC@]
MN?J6<_U(WH&.141NLC4HC:FIR:L9:,83]9K\1C[?S<BKGU^/'8T6#<X)*_;+
MDMT[P/Y>K+O$I6^(Y])1"WQJA\_AODN\H8%[M 4^L\/?,=DE/CT(OSH=[K;
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M92?@^$I*<WBP"]3?=^9_ 5!+ P04    "  "@Z52W0CL!94$  !S$P  &0
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M=W;W8:2JW<X\NW!"4,'.VDXR_?=K&P*D 2?;:EX2;,[E^\ZQS[&9[;AXE2L
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M+#/\I "A#?#Y@G.UWV@'S4=*_ ]02P,$%     @  H.E4GLF0P_Y!   "A4
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M'Z;2&,#[G1#Z-# +=!WV\E]02P,$%     @  H.E4@WJ7V@R P  ,!,   T
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M1S %H %#HJC:!W?VHW"U3X7K_\B&OP%02P,$%     @  H.E4I>*NQS
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MO8U ;T.]C4!O0[V-0&^/>GL"O3WJ[0GT]JBW)]#;H]Z>0&_?V>PFT-NCWIY
M;X]Z^W?J'=.U"O'9\UCC\]])=;K=&YZ/OR\?)SOO^!UG!W_L%K]02P,$%
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M@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M (:M
M(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"ED3%+(F
M*&1-4,B:_"=9W[5>_?7_IG:-:U4V1W_6_=2;?P)02P$"% ,4    "  "@Z52
M!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    (  *#I5*,A9/A[@   "L"   1              "  :\
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M2P$"% ,4    "  "@Z52DBH>V=P"  #+"0  &               @(' %
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @  H.E4FLH3UMD
M!   O@X  !@              ("!TA<  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    (  *#I5)Y%[8[= 8  "@<   8              "
M@6P<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  "@Z52
M,\BELR,"  !T!   &               @($6(P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @  H.E4C6ZS0IA!P  7AX  !@
M     ("!;R4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M  *#I5('H=JW6@4  "4,   8              " @08M  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  "@Z52; \JK/(,  #P)0  &
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M970Q,RYX;6Q02P$"% ,4    "  "@Z52$(02IG8)  !1&@  &0
M    @(%2:@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M  *#I5(Z7BJL:@0  '0+   9              " @?]S  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @  H.E4E<S)>EY"P  61\  !D
M             ("!H'@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  "@Z52H[77& L&   7#P  &0              @(%0A   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  *#I5+ONR95/P(
M /$$   9              " @9**  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @  H.E4D*KYETQ P  O 8  !D              ("!
M"(T  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  "@Z52
M(YU\1]L!  !5!   &0              @(%PD   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    (  *#I5*Z!)U(2@T  )HH   9
M      " @8*2  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @  H.E4EF[I+G2 P  < D  !D              ("! Z   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  "@Z52"8:W6_<#  "<"0
M&0              @($,I   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    (  *#I5)0ER^)& ,  $D&   9              " @3JH  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @  H.E4L;CO-K]
M P  P@D  !D              ("!B:L  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  "@Z52?>*AL'$%  "J#0  &0
M@(&]KP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (  *#
MI5(JWB*F20,  ,<&   9              " @66U  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @  H.E4HBW*L;O @  - <  !D
M         ("!Y;@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  "@Z52)AW)W'@"  #X!@  &0              @($+O   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  *#I5*MY!G@IP4  $TJ
M   9              " @;J^  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @  H.E4D9[LIKG!0  8QL  !D              ("!F,0
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  "@Z5213IX
ME5@"  !8!0  &0              @(&VR@  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    (  *#I5+8:5'N$ 0  $,/   9
M  " @47-  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M H.E4C:Z=7J>"0  W#<  !D              ("!C-$  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  "@Z52A@3]VR0%   Q%   &0
M            @(%AVP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    (  *#I5+)X4/)70,  #4)   9              " @;S@  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @  H.E4N\?52"  @
M<@8  !D              ("!4.0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  "@Z52""*&+"T#  "B"0  &0              @($'
MYP  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  *#I5)>
MX,_),@0  (D0   9              " @6OJ  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @  H.E4N[SF3>G!   ZQ$  !D
M     ("!U.X  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M"  "@Z52W0CL!94$  !S$P  &0              @(&R\P  >&PO=V]R:W-H
M965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  *#I5(V_DW*/0,  . ,   9
M              " @7[X  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L!
M A0#%     @  H.E4MO1> %:!   (Q(  !D              ("!\OL  'AL
M+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  "@Z52VI#\B<X"
M  "P"   &0              @(&#  $ >&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;%!+ 0(4 Q0    (  *#I5)[)D,/^00   H5   9              "
M@8@# 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @  H.E
M4K\\2(FZ P  ;0\  !D              ("!N @! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    "  "@Z52#>I?:#(#   P$P  #0
M        @ &I# $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  *#I5*7BKL<
MP    !,"   +              "  080 0!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   (  *#I5*/5,I<[@,  /8>   /              "  >\0 0!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    "  "@Z52_2S5I:X!  #!&P  &@
M    @ $*%0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M"  "@Z52)OJ'I[4!  #<&P  $P              @ 'P%@$ 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     -@ V +$.  #6& $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>184</ContextCount>
  <ElementCount>327</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2118107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124108 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2133110 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2135111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2136112 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2139113 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://allogene.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/FinancialInstruments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/BalanceSheetComponents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/CommitmentsandContingencies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2327305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/DescriptionofBusiness</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Balance Sheet Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/BalanceSheetComponentsDetails</Role>
      <ShortName>Balance Sheet Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/BalanceSheetComponentsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/LicenseAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Commitments and Contingencies - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Undiscounted Future Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/EquityMethodInvestmentDetails</Role>
      <ShortName>Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/EquityMethodInvestment</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2428413 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Compensation - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/StockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/RelatedPartyTransactions</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="allo-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2438419 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://allogene.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://allogene.com/role/NetLossPerShareTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="allo-20210331.htm">allo-20210331.htm</File>
    <File>allo-20210331.xsd</File>
    <File>allo-20210331_cal.xml</File>
    <File>allo-20210331_def.xml</File>
    <File>allo-20210331_lab.xml</File>
    <File>allo-20210331_pre.xml</File>
    <File>allo-20210331xex311.htm</File>
    <File>allo-20210331xex312.htm</File>
    <File>allo-20210331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "allo-20210331.htm": {
   "axisCustom": 3,
   "axisStandard": 19,
   "contextCount": 184,
   "dts": {
    "calculationLink": {
     "local": [
      "allo-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "allo-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "allo-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "allo-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "allo-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "allo-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 418,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 10,
    "total": 12
   },
   "keyCustom": 43,
   "keyStandard": 284,
   "memberCustom": 30,
   "memberStandard": 26,
   "nsprefix": "allo",
   "nsuri": "http://allogene.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://allogene.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Fair Value Measurements",
     "role": "http://allogene.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Financial Instruments",
     "role": "http://allogene.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Balance Sheet Components",
     "role": "http://allogene.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - License Agreements",
     "role": "http://allogene.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118107 - Disclosure - Commitments and Contingencies",
     "role": "http://allogene.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124108 - Disclosure - Equity Method Investment",
     "role": "http://allogene.com/role/EquityMethodInvestment",
     "shortName": "Equity Method Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126109 - Disclosure - Stock-Based Compensation",
     "role": "http://allogene.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133110 - Disclosure - Related Party Transactions",
     "role": "http://allogene.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135111 - Disclosure - Income Taxes",
     "role": "http://allogene.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136112 - Disclosure - Net Loss Per Share",
     "role": "http://allogene.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139113 - Disclosure - Subsequent Events",
     "role": "http://allogene.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://allogene.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Financial Instruments (Tables)",
     "role": "http://allogene.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://allogene.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "allo:LiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://allogene.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://allogene.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://allogene.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i425ece1b06434afbbb883c90e17bdb61_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "id12fb68b0dae4f7a91f55375717a8a56_I20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i425ece1b06434afbbb883c90e17bdb61_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities (Detail)",
     "role": "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i55f0f98344ea41ee89c1226f1ebfb886_I20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "role": "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails",
     "shortName": "Financial Instruments - Cash Equivalents, Restricted Cash and Investments, Classified as Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Financial Instruments - Additional Information (Details)",
     "role": "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Financial Instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Balance Sheet Components (Details)",
     "role": "http://allogene.com/role/BalanceSheetComponentsDetails",
     "shortName": "Balance Sheet Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - License Agreements (Details)",
     "role": "http://allogene.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i08db9380997d4d1b9f4e44201d651df9_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "allo:CollaborationAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i738bb7afc6e4444b8295b50d0d40c0a4_I20181031",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "allo:AreaOfNewOfficeBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i738bb7afc6e4444b8295b50d0d40c0a4_I20181031",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "allo:AreaOfNewOfficeBuilding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "allo:LiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Commitments and Contingencies - Lease Liabilities (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "allo:LiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Commitments and Contingencies - Lease Costs (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails",
     "shortName": "Commitments and Contingencies - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Commitments and Contingencies - Undiscounted Future Lease Payments (Details)",
     "role": "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Undiscounted Future Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ia39d6a89bb844679938131a4168a79f8_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Equity Method Investment (Details)",
     "role": "http://allogene.com/role/EquityMethodInvestmentDetails",
     "shortName": "Equity Method Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i6b1c66efc41f41b3a6ae07c79e88874c_D20191101-20191101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428413 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "allo:NumberOfSharesAsPercentageOfCommonSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ie9606d98985d4a4aa8219e4759fe5755_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i9f2d41ee9a5c4897b54cff41e3ae41c2_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Stock-Based Compensation - Valuation Assumptions (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i988626a8ccaf4d1cb7b3374deed4d98a_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "ie454e25a92304e9c925d7d248ce95679_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Compensation - Expense (Details)",
     "role": "http://allogene.com/role/StockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Related Party Transactions (Details)",
     "role": "http://allogene.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if95eb4b787c74543b5067fc4b0661d0f_D20181201-20181231",
      "decimals": "0",
      "lang": "en-US",
      "name": "allo:AreaOfOffice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438419 - Disclosure - Net Loss Per Share (Details)",
     "role": "http://allogene.com/role/NetLossPerShareDetails",
     "shortName": "Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i01ccf8d124ff499fbbabad09739a47b4_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "i01ccf8d124ff499fbbabad09739a47b4_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "iacc623b05c8141db83c3d25a61bcb2cf_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "role": "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "iacc623b05c8141db83c3d25a61bcb2cf_D20200101-20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://allogene.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://allogene.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "allo-20210331.htm",
      "contextRef": "if2e29ff114d54feab704d039fd34576e_D20210101-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "allo_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential milestone payable",
        "label": "Aggregate Potential Milestone Payable",
        "terseLabel": "Aggregate potential milestone payable"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayable",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential milestone payments.",
        "label": "Aggregate Potential Milestone Payments",
        "terseLabel": "Aggregate potential milestone payments"
       }
      }
     },
     "localname": "AggregatePotentialMilestonePayments",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialMilestoneReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential milestone receivable.",
        "label": "Aggregate Potential Milestone Receivable",
        "terseLabel": "Aggregate potential milestone receivable"
       }
      }
     },
     "localname": "AggregatePotentialMilestoneReceivable",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AggregatePotentialRegulatoryAndDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate potential regulatory and development milestones.",
        "label": "Aggregate Potential Regulatory And Development Milestones",
        "terseLabel": "Aggregate potential regulatory and development milestones"
       }
      }
     },
     "localname": "AggregatePotentialRegulatoryAndDevelopmentMilestones",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_AllogeneOverlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allogene Overland",
        "label": "Allogene Overland [Member]",
        "terseLabel": "Allogene Overland"
       }
      }
     },
     "localname": "AllogeneOverlandMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AreaOfNewOfficeBuilding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of new office building.",
        "label": "Area Of New Office Building",
        "terseLabel": "Area of office and laboratory (in square feet)"
       }
      }
     },
     "localname": "AreaOfNewOfficeBuilding",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AreaOfOffice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office.",
        "label": "Area Of Office",
        "terseLabel": "Area of office space (in square feet)"
       }
      }
     },
     "localname": "AreaOfOffice",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AreaOfOperatingLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of operating lease.",
        "label": "Area Of Operating Lease",
        "terseLabel": "Area of operating lease (in square feet)"
       }
      }
     },
     "localname": "AreaOfOperatingLease",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "allo_AssetContributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset contribution agreement.",
        "label": "Asset Contribution Agreement [Member]",
        "verboseLabel": "Asset Contribution Agreement"
       }
      }
     },
     "localname": "AssetContributionAgreementMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "terseLabel": "ATM offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_BellcoCapitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bellco Capital LLC.",
        "label": "Bellco Capital L L C [Member]",
        "terseLabel": "Bellco"
       }
      }
     },
     "localname": "BellcoCapitalLLCMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CapitalizedSoftwareCostsIncurredNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Software Costs Incurred Not Yet Paid",
        "label": "Capitalized Software Costs Incurred Not Yet Paid",
        "terseLabel": "Capitalized cloud computing costs included in accounts payable and accrued and other current liabilities"
       }
      }
     },
     "localname": "CapitalizedSoftwareCostsIncurredNotYetPaid",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CashEquivalentsAndShortTermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments",
        "totalLabel": "Total cash equivalents and investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestments",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CellectisSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cellectis S.A..",
        "label": "Cellectis S A [Member]",
        "terseLabel": "Cellectis"
       }
      }
     },
     "localname": "CellectisSAMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in significant accounting policies.",
        "label": "Changes In Significant Accounting Policies Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "ChangesInSignificantAccountingPoliciesPolicyPolicyTextBlock",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_ClinicalRegulatoryAndCommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical, Regulatory, and Commercial Milestone",
        "label": "Clinical, Regulatory, and Commercial Milestone [Member]",
        "terseLabel": "Clinical, Regulatory, and Commercial Milestone"
       }
      }
     },
     "localname": "ClinicalRegulatoryAndCommercialMilestoneMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CollaborationAgreementCommittedFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Committed Funding",
        "label": "Collaboration Agreement, Committed Funding",
        "terseLabel": "Committed funding"
       }
      }
     },
     "localname": "CollaborationAgreementCommittedFunding",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Term",
        "label": "Collaboration Agreement, Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_CollaborationAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Upfront Payment",
        "label": "Collaboration Agreement, Upfront Payment",
        "terseLabel": "Collaboration agreement, upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPayment",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_CollaborationArrangementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Expense",
        "label": "Collaboration Arrangement, Expense",
        "terseLabel": "Collaboration arrangement, expense"
       }
      }
     },
     "localname": "CollaborationArrangementExpense",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ComputerEquipmentAndPurchasedSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and purchased software.",
        "label": "Computer Equipment And Purchased Software [Member]",
        "terseLabel": "Computers equipment and purchased software"
       }
      }
     },
     "localname": "ComputerEquipmentAndPurchasedSoftwareMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ConsultingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting agreements.",
        "label": "Consulting Agreements [Member]",
        "terseLabel": "Consulting Agreements"
       }
      }
     },
     "localname": "ConsultingAgreementsMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_CostMethodInvestmentTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Method Investment, Transaction Costs",
        "label": "Cost Method Investment, Transaction Costs",
        "terseLabel": "Transaction cost"
       }
      }
     },
     "localname": "CostMethodInvestmentTransactionCosts",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_DevelopmentAndSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development And Sales [Member]",
        "label": "Development And Sales [Member]",
        "terseLabel": "Development and Sales"
       }
      }
     },
     "localname": "DevelopmentAndSalesMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_EarlyExerciseOfStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercise of stock options.",
        "label": "Early Exercise Of Stock Options [Member]",
        "terseLabel": "Early exercised stock options subject to future vesting"
       }
      }
     },
     "localname": "EarlyExerciseOfStockOptionsMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_EquityInvestmentBasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment Basis",
        "label": "Equity Investment Basis [Axis]",
        "terseLabel": "Equity Investment Basis [Axis]"
       }
      }
     },
     "localname": "EquityInvestmentBasisAxis",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_EquityInvestmentBasisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment Basis [Domain]",
        "label": "Equity Investment Basis [Domain]",
        "terseLabel": "Equity Investment Basis [Domain]"
       }
      }
     },
     "localname": "EquityInvestmentBasisDomain",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_FounderSharesOfCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder shares of common stock.",
        "label": "Founder Shares Of Common Stock [Member]",
        "terseLabel": "Founder's shares of common stock subject to future vesting"
       }
      }
     },
     "localname": "FounderSharesOfCommonStockMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_IncomeLossFromCostMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Cost Method Investment",
        "label": "Income (Loss) from Cost Method Investment",
        "negatedTerseLabel": "Share of losses from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromCostMethodInvestment",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_JointVentureCapitalSupportPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint Venture Capital Support Payments",
        "label": "Joint Venture Capital Support Payments",
        "terseLabel": "Joint venture capital support payments"
       }
      }
     },
     "localname": "JointVentureCapitalSupportPayments",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment member.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_LesseeFinanceLeasePaymentUponContractTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Payment Upon Contract Termination",
        "label": "Lessee, Finance Lease, Payment Upon Contract Termination",
        "terseLabel": "Termination payment"
       }
      }
     },
     "localname": "LesseeFinanceLeasePaymentUponContractTermination",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Payments Due After Year Four",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_LiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, Lessee",
        "label": "Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Lease Liabilities"
       }
      }
     },
     "localname": "LiabilitiesLesseeTableTextBlock",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreements text block.",
        "label": "License Agreements [Text Block]",
        "terseLabel": "License Agreements"
       }
      }
     },
     "localname": "LicenseAgreementsTextBlock",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration agreement.",
        "label": "License And Collaboration Agreement [Member]",
        "verboseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_MaximumPaymentsRequiredPerProductAgainstSelectedTarget": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payments required per product against selected target.",
        "label": "Maximum Payments Required Per Product Against Selected Target",
        "terseLabel": "Maximum payments required per product against selected target"
       }
      }
     },
     "localname": "MaximumPaymentsRequiredPerProductAgainstSelectedTarget",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Aggregate potential milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_MilestoneTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Type [Axis]",
        "label": "Milestone Type [Axis]",
        "terseLabel": "Milestone Type [Axis]"
       }
      }
     },
     "localname": "MilestoneTypeAxis",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_MilestoneTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Milestone Type [Axis]",
        "label": "Milestone Type [Domain]",
        "terseLabel": "Milestone Type [Domain]"
       }
      }
     },
     "localname": "MilestoneTypeDomain",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NewarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Newark [Member]",
        "label": "Newark [Member]",
        "terseLabel": "Newark"
       }
      }
     },
     "localname": "NewarkMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NotchTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notch Therapeutics, Inc.",
        "label": "Notch Therapeutics, Inc. [Member]",
        "terseLabel": "Notch Therapeutics, Inc."
       }
      }
     },
     "localname": "NotchTherapeuticsIncMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_NumberOfOptionsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Number Of Options To Extend Lease",
        "terseLabel": "Number of options to extend lease"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendLease",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "allo_NumberOfSharesAsPercentageOfCommonSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares as percentage of common shares outstanding.",
        "label": "Number Of Shares As Percentage Of Common Shares Outstanding",
        "terseLabel": "Number of shares as percentage of common shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesAsPercentageOfCommonSharesOutstanding",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise price as percentage of fair value of common stock on grate date.",
        "label": "Option Exercise Price As Percentage Of Fair Value Of Common Stock On Grate Date",
        "terseLabel": "Option exercise price as percentage of fair value of common stock on grate date"
       }
      }
     },
     "localname": "OptionExercisePriceAsPercentageOfFairValueOfCommonStockOnGrateDate",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_OverlandPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Overland Pharmaceuticals Inc.",
        "label": "Overland Pharmaceuticals Inc. [Member]",
        "terseLabel": "Overland Pharmaceuticals Inc."
       }
      }
     },
     "localname": "OverlandPharmaceuticalsIncMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentTermsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Terms",
        "label": "Payment Terms [Axis]",
        "terseLabel": "Payment Terms [Axis]"
       }
      }
     },
     "localname": "PaymentTermsAxis",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "allo_PaymentTermsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Terms",
        "label": "Payment Terms [Domain]",
        "terseLabel": "Payment Terms [Domain]"
       }
      }
     },
     "localname": "PaymentTermsDomain",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentsCommencingJanuary2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Commencing January 2019",
        "label": "Payments Commencing January 2019 [Member]",
        "terseLabel": "Payments Commencing January 2019"
       }
      }
     },
     "localname": "PaymentsCommencingJanuary2019Member",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PaymentsCommencingJanuary2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Commencing January 2020",
        "label": "Payments Commencing January 2020 [Member]",
        "terseLabel": "Payments Commencing January 2020"
       }
      }
     },
     "localname": "PaymentsCommencingJanuary2020Member",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PercentageOfDevelopmentCostPayableByCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Development Cost Payable By Related Party",
        "label": "Percentage Of Development Cost Payable By Collaboration Partner",
        "terseLabel": "Percentage of development cost payable by collaboration partner"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostPayableByCollaborationPartner",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PercentageOfDevelopmentCostPayableByTheCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Development Cost Payable By The Company",
        "label": "Percentage Of Development Cost Payable By The Company",
        "terseLabel": "Percentage of development costs payable by the Company"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostPayableByTheCompany",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PreClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Clinical Development Milestone [Member]",
        "label": "Pre-Clinical Development Milestone [Member]",
        "terseLabel": "Pre-Clinical Development Milestone"
       }
      }
     },
     "localname": "PreClinicalDevelopmentMilestoneMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering",
        "label": "Public Offering [Member]",
        "terseLabel": "Public offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent accounting pronouncements not yet adopted.",
        "label": "Recent Accounting Pronouncements Not Yet Adopted Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsNotYetAdoptedPolicyPolicyTextBlock",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recently adopted accounting pronouncements.",
        "label": "Recently Adopted Accounting Pronouncements Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "allo_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone member.",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RelatedPartyTransactionCompensationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction compensation percentage.",
        "label": "Related Party Transaction Compensation Percentage",
        "terseLabel": "Related party transaction compensation percentage"
       }
      }
     },
     "localname": "RelatedPartyTransactionCompensationPercentage",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "allo_RelatedPartyTransactionMonthlyPaymentsInArrears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction monthly payments in arrears.",
        "label": "Related Party Transaction Monthly Payments In Arrears",
        "terseLabel": "Related party transaction monthly payment in arrears"
       }
      }
     },
     "localname": "RelatedPartyTransactionMonthlyPaymentsInArrears",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ResearchCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreement.",
        "label": "Research Collaboration And License Agreement [Member]",
        "terseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_RoyaltyObligationPeriodFromDateOfFirstSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Obligation Period From Date Of First Sale",
        "label": "Royalty Obligation Period From Date Of First Sale",
        "terseLabel": "Royalty obligation period from date of first sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodFromDateOfFirstSale",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_SalesMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone member.",
        "label": "Sales Milestone [Member]",
        "terseLabel": "Sales Milestone"
       }
      }
     },
     "localname": "SalesMilestoneMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ServierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Servier.",
        "label": "Servier [Member]",
        "verboseLabel": "Servier"
       }
      }
     },
     "localname": "ServierMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Granted, Weighted Average Remaining Contractual Terms",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining vesting life, granted (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under equity instruments other than options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Restricted stock units, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "allo_ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement By Share-based Payment Awards Other Than Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining vesting life, vested and expected to vest (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_StockOptionGrantedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option granted period.",
        "label": "Stock Option Granted Period",
        "terseLabel": "Stock option grant period"
       }
      }
     },
     "localname": "StockOptionGrantedPeriod",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "allo_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Agreement [Member]",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sublease Agreement"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for tenant improvements.",
        "label": "Tenant Improvement Allowance",
        "negatedLabel": "Less: Tenant improvement allowance",
        "terseLabel": "Allowance for tenant improvements"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_TenantImprovementAllowanceUtilizedToDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Allowance, Utilized To Date",
        "label": "Tenant Improvement Allowance, Utilized To Date",
        "terseLabel": "Tenant improvement allowance utilized to date"
       }
      }
     },
     "localname": "TenantImprovementAllowanceUtilizedToDate",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_TwoRiverConsultingLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two River Consulting LLC [Member]",
        "label": "Two River Consulting L L C [Member]",
        "terseLabel": "Two River"
       }
      }
     },
     "localname": "TwoRiverConsultingLLCMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_TwoThousandEighteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen plan.",
        "label": "Two Thousand Eighteen Plan [Member]",
        "terseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenPlanMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_UniversityOfTexasMDAndersonCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University Of Texas MD Anderson Cancer Center",
        "label": "University Of Texas MD Anderson Cancer Center [Member]",
        "terseLabel": "University Of Texas MD Anderson Cancer Center"
       }
      }
     },
     "localname": "UniversityOfTexasMDAndersonCancerCenterMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "allo_UpfrontAndQuarterlyCashPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront and Quarterly Cash Payments",
        "label": "Upfront and Quarterly Cash Payments",
        "terseLabel": "Upfront and quarterly cash payments"
       }
      }
     },
     "localname": "UpfrontAndQuarterlyCashPayments",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "allo_VotingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Voting Interest",
        "label": "Voting Interest [Member]",
        "terseLabel": "Voting Interest"
       }
      }
     },
     "localname": "VotingInterestMember",
     "nsuri": "http://allogene.com/20210331",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r33",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r183",
      "r184",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r183",
      "r184",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r173",
      "r183",
      "r184",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r173",
      "r183",
      "r184",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r337",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r124",
      "r125",
      "r170",
      "r172",
      "r338",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r170",
      "r172",
      "r338",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r22",
      "r156"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r13",
      "r38",
      "r39",
      "r40",
      "r327",
      "r344",
      "r345"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r37",
      "r40",
      "r41",
      "r82",
      "r83",
      "r84",
      "r243",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r185",
      "r187",
      "r223",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r187",
      "r213",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r68",
      "r152",
      "r153"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of other intangible assets acquired"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r77",
      "r112",
      "r115",
      "r121",
      "r146",
      "r239",
      "r244",
      "r257",
      "r313",
      "r325"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r32",
      "r77",
      "r146",
      "r239",
      "r244",
      "r257"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized\u00a0Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized\u00a0Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r131",
      "r149"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r128",
      "r132",
      "r149",
      "r316"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r130",
      "r149"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r130",
      "r149"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term investments",
        "verboseLabel": "Long-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r188",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases in accounts payable and accrued and other current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r19",
      "r70"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r65",
      "r70",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash \u2014 end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash \u2014 beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r258"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "allo_CashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r29",
      "r162",
      "r318",
      "r331"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Notes 6 and 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r10",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value: 200,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 141,470,075 and 140,474,305 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r43",
      "r45",
      "r46",
      "r48",
      "r320",
      "r335"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r167",
      "r168",
      "r171"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Maximum remaining contractual maturities of available-for-sale securities (in years)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r137",
      "r150",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Net unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current",
        "terseLabel": "Accrued and other liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent",
        "terseLabel": "Other long term liabilities, related to shares held by employees and directors that were subject to repurchase"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r68",
      "r154"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r80",
      "r283",
      "r317",
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock based compensation expense, weighted average recognition period (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Expected shares to be purchased under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r86",
      "r91",
      "r93",
      "r100",
      "r148",
      "r165",
      "r166",
      "r217",
      "r218",
      "r219",
      "r230",
      "r231",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentQuotedMarketValue": {
     "auth_ref": [
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.",
        "label": "Equity Method Investment, Quoted Market Value",
        "terseLabel": "Carrying value"
       }
      }
     },
     "localname": "EquityMethodInvestmentQuotedMarketValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets And Liabilities Subject To Fair Value Measurements On Recurring Basis And Level Of Inputs Used In Such Measurements By Major Security Type"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r248",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r249",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r251",
      "r252",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r174",
      "r175",
      "r180",
      "r182",
      "r249",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r174",
      "r175",
      "r180",
      "r182",
      "r249",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r249",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r254",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedLabel": "Net amortization/accretion on investment securities"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Equity method investment"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r276",
      "r278"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Lease Payments Under Lease Liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining 9 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, option to extend term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Sublease, term of contract (in years)"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r77",
      "r116",
      "r146",
      "r240",
      "r244",
      "r245",
      "r257"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r16",
      "r77",
      "r146",
      "r257",
      "r315",
      "r329"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r77",
      "r146",
      "r240",
      "r244",
      "r245",
      "r257"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r101",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r66",
      "r69"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r42",
      "r44",
      "r47",
      "r69",
      "r77",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r112",
      "r114",
      "r117",
      "r120",
      "r122",
      "r146",
      "r257",
      "r319",
      "r334"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r112",
      "r114",
      "r117",
      "r120",
      "r122"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r271",
      "r278"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
      "http://allogene.com/role/CommitmentsandContingenciesUndiscountedFutureLeasePaymentsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, non-current",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseLiabilitiesDetails",
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r269",
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r275",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r274",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r35",
      "r36",
      "r38"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Net unrealized gain (loss) on available-for-sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r52",
      "r336"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLeasingCostsCommissionsAndTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy; for costs that are essential to originating the lease and would not otherwise have been incurred without the lease agreement, including but not limited to, evaluating the lessee's credit condition, guarantees, and collateral and costs incurred in negotiating, processing, and executing the lease agreement; and for any commission(s) incurred.",
        "label": "Payments for Leasing Costs, Commissions, and Tenant Improvements",
        "negatedTerseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "PaymentsForLeasingCostsCommissionsAndTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromTenantAllowance": {
     "auth_ref": [
      "r58",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.",
        "label": "Payments for (Proceeds from) Tenant Allowance",
        "negatedTerseLabel": "Cash received for amounts related to tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsForProceedsFromTenantAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchase of stock in equity method investment",
        "terseLabel": "Purchase of stock in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://allogene.com/role/EquityMethodInvestmentDetails",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to acquire interest in Notch"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2021 and December 31, 2020; no shares were issued and outstanding as of March 31, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r17",
      "r18"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock from ATM offering, net of commissions and issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r62",
      "r216"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r56",
      "r57",
      "r129"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r42",
      "r44",
      "r64",
      "r77",
      "r85",
      "r92",
      "r93",
      "r112",
      "r114",
      "r117",
      "r120",
      "r122",
      "r146",
      "r238",
      "r241",
      "r242",
      "r246",
      "r247",
      "r257",
      "r321"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r22",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r21",
      "r155"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r6",
      "r157",
      "r330"
     ],
     "calculation": {
      "http://allogene.com/role/BalanceSheetComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails",
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r5",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r5",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r8",
      "r314",
      "r326"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Non-cancellable purchase commitments"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyCosts": {
     "auth_ref": [
      "r50",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.",
        "label": "Related Party Costs",
        "terseLabel": "Related party costs"
       }
      }
     },
     "localname": "RelatedPartyCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r181",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r181",
      "r282",
      "r283",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "verboseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r181",
      "r282",
      "r285",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "verboseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r283",
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r226",
      "r372"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r4",
      "r7",
      "r74",
      "r362"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Unit",
        "verboseLabel": "Restricted stock units subject to vesting"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails",
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r12",
      "r166",
      "r220",
      "r328",
      "r343",
      "r345"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r86",
      "r91",
      "r93",
      "r148",
      "r217",
      "r218",
      "r219",
      "r230",
      "r231",
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r110",
      "r111",
      "r113",
      "r118",
      "r119",
      "r123",
      "r124",
      "r126",
      "r169",
      "r170",
      "r300"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue - related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Shares"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r139",
      "r140",
      "r141",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r187",
      "r212",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r187",
      "r212",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r77",
      "r144",
      "r146",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/EquityMethodInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r22",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r78",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails",
      "http://allogene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r188",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r192",
      "r202",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity Under Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule Stock Option Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Restricted stock units, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Restricted stock units, unvested, ending balance (in shares)",
        "periodStartLabel": "Restricted stock units, unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-average fair value at date of grant per share, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average fair value at date of grant per share, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Fair Value at Date of Grant per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining vesting life, unvested (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Restricted stock units, vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Expected risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Expected risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of options, options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grants in period, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r194",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, ending balance (in shares)",
        "periodStartLabel": "Number of options, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted-average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r186",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails",
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average exercise price, options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average exercise price, options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value, unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r208",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value at date of grant per share, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contract term, vested and expected to vest (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Vesting of early exercised common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r31",
      "r82",
      "r83",
      "r84",
      "r86",
      "r91",
      "r93",
      "r100",
      "r148",
      "r165",
      "r166",
      "r217",
      "r218",
      "r219",
      "r230",
      "r231",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Other Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r100",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r9",
      "r10",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock from public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r9",
      "r10",
      "r165",
      "r166",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, options exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSU's (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://allogene.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r9",
      "r10",
      "r165",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r9",
      "r10",
      "r165",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r165",
      "r166"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options and vesting of RSUs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r10",
      "r14",
      "r15",
      "r77",
      "r127",
      "r146",
      "r257"
     ],
     "calculation": {
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://allogene.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r174",
      "r182",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesDetail",
      "http://allogene.com/role/FinancialInstrumentsCashEquivalentsRestrictedCashandInvestmentsClassifiedasAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r272",
      "r278"
     ],
     "calculation": {
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CommitmentsandContingenciesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://allogene.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919359-209981"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r373": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r375": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r376": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r377": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r378": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001737287-21-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001737287-21-000022-xbrl.zip
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MMP![NL\:4:7MGWHRTQ53#\/O:7JSWV4$R]6M@[W'\W3A D4<T91ZZ)U5EBF
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MXE))+YPDGAC#(E<:"ZUU0(Y2),)H$\C28LP:&C.Q&B$XQ1!7A%',D'1*"DK
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MN\9__PL+] ?%RY74^_-+RAX(U-V]DJ:4-&4^:4I>)JZ9 H2%YRF']4-^U#[
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M@']$?DC^_IPEY \2U<1(O@P9..\W5SO-UE]+@]XP?)_:==41ZQU_JQM*6_
M6W"KR*1A% 5L0X9"JHUDC<@T2"&+B#@I" I!H:1BWQB!F=45>"%P/F;P*L'Y
MLN"\,:G/L%,HQ PDG\ I8<@*^9"EA PI\(7E#\&Y\%[J_@^+R#RM@L@4R[R\
MV#U>:92_HA:^^65R[_$MLG3^JLZ;- NIO^]-%H7D1826*_]UGYE['WK[#=,+
M4W',=VK;W^^%-VY-#L;WIK?;VQ^80? ?36L8KI\^)NNHM($/L($'@^IDC^P-
MC8[^IX%<^V/'?-+#W9,#7COY0([J6Q>[FW\WJ_7TGO\T#NO'I%J']K?W3JN;
M6^?5D^.O_W.Y<_Y946JL(30C"@9UEGOXA.',16$9D=X*2N\?*'^ H*=Y>R6"
M"H<@*XP *NBRX)3,&)(\T\ZSS"-$+6+>*0[.(EI!Z/LIIN^^J)R97N5+$NQJ
MY8>@ZR>!]Z>'MT=L['D3BCGN^NO#0:/; _OL2PC.!()5_!D&I.AX$%E4X)XP
M%V2FE--9R',^+0XH;0WZ.#P]8P0L\51P/)GH%3*6@L]K?%JZI#-%-'@9AB-A
M#&;*VKR^"C"Y]/<!=FV$L8JYDF[%]"O=6*F:GFM4*%ZN)#CEP9G_G[T_;6HK
MR=9 X;^BX)QX;U6$DLIY<'400=FXFKX%N&S<=>TOCAQ!6$@<#<;XU[\K<VMD
M,F*48$=WV9@M[9T[5ZXGGS7D6F^BC\<N]L:_Q;\O"(7WLW2!?_J\?$_!H.['
MSDW6[MYPT!_ *P +KA?ODRS>K=/=S2_4R>0I 5M88.!TG GDB.-(2<9#Q"9P
MD/R3P.$MUM1VOS^LL? IEY.DS"ON%&(2>UA.2B&':4+>"<>XX\'DRG=/P=;J
MY;2"RTEQE;03')DD+.(F>60IR96JN4A<,:+BPNCT9,NIWO&68DU9E[R)@$D.
M SIQ'AG2(3%D)#$L$:^P (CJ='].U&Y.Y4YC+S9:!4ZJ(F_3I;  MYLX8D/K
M6YVY^% 90C]BKQML__!ZE2X.I3IO8%$UGL8*)5$\X20152Z?L4P8@;$$QE-0
MP2:L?>!V;:.$(NCO2Y2O6.<;+V6J3ZVU#ZBU,R>5/!7*18- 01WBTM&<;:R1
M!9)/)"<I94*V?%K[2/';)0[UY5R";F<IXGS54.H0S?WIZ*=K"/+GUN>C3;'W
MYW_;N\=;=.?-WWSO3R#-^_!^1^];NT<P)W2+?-YO'P-!YE],C)XPR7.A$X(X
M<Q;9&, "D[)48N+:7><??X0@7[U\EGCY>(RYY]JB:+FO.DII:Q)@FC364.:T
M3X\0X7N,B,S,.JS#,4NQ_G;.OE 2L1;$H.140)P&("C62V0\L8P*8ZD33^,Q
MJA?3RBVFA 77S GD\K$Z[JE#VG&)=+0$2T&4%+ 74OR\@WL++MS:S?G4*W?K
M=.?O+[!:56+!(D: O7'L(C(Q"40\#5%0HB/FRYCG<&$]U5&8IUY*VE-NL 7;
M6&G@=+!TD&/)("\)8PP[B\MY/DZ:7 $,7M+3ZB(,9GQ;@5VX!K.G7X%[FU],
M,,S'X) R5&56QY$C42,'& ?X0S6]UBA=GO54@]E3+Z6@>#*)>"1$+C6-88<T
MC!ED-=<F4;!:7>[?SC& &6\R?!,P&W&Z.P?XF@VXS4F$NWZ+[;,[A/M>1-6S
M^VO3,%'2.CYP*^V<1O4H3C8H!C03A(*XDV Q4:R1),X'SA01@1:JL$1ES.IR
MA$L3T:L5\WX5<^:8/C$B><%1"L$@;@7L>!Y[Y$1@3 N5L%=EVULBQ7Q9/2!A
MS'F^;;MQ8EL!M3H-;T]: ]NN2PT^97/LB5C>@52V.Z\KF<Q 4XU*"Z'27*-L
M3:D(G.?CV-FS8#')AW$X J 2,F"15,ITH:FX:6*CEBBAH$X#6AK24.OR$^KR
ME&$ SG+B*45*Q8"X<0)IX@R*+$7"F<OI T67J6B"[;U$NORBVD!N>C\\'K9S
MR@3H46KYUDMKD/#+HS",/KPG_+0 /+V/ PN##5NVUX$I[<](ZDTEJ!J>%H*G
MN3[3TA!KF!1(8DL GC1!1NJ(@K<F!1\T"7%M T3<9.)BC]H+-;!JQ\0JJO/M
M24:MSLN@SE.VH:T-1 E@&[:TC??9C6] NS6UA!KK$R:@SEPV&;]8[OA)U/EE
MN3-F:$:WM%'PW>.37CR,G7[K6VS\TN[V^[\V6AWX]>U:4:^N5?3(!.2<$305
M3"G#_GI6+-M%''^!:';C8"_MV^\U1BV$47,](Z, LP<'A81/0#F"Y;E(JD,I
M1N$UP32P4AKB8C#DYOA4NS2>HTNC5ME'5=DIK1#1)..,1L%2C7C4'EE-/-*E
MOAGG0N;T82HO6@BU^^(1NRGTKZQ663=76-9(RFR%T:TBJQJH%@&J'W.M'Z.*
M0DFIP.K1&'$6<FIZ"(AJ;RC7L.WP7':]B:5I*G5?7>/J+@O/2NL?(>92:_W=
MM7[&Z\&PB1:TW@H%]$2&B)Q*#AGL+(T,$YYDT7IEFI+<.5Y:MUMXJ!Y0)?_S
MYBSFAH7LJUE]Q4 ,H3MT[3B1TMU [MJC[D\QG__[A!/T;-#_<1MJ;79"O1?<
M<2^8:]<I#+;*NXB$S76LF(*] #N'E-"2$6$823SO!03V LSY/1FL]Z=(3^RF
MJB&UAM15)-0UI-XWI,X&%3E5QE/$P(9&7%&)8(N,B$7O53*84A\SI%*JFIK>
MV:A>&D@M_/NW@86'CH\;S10P.K:]@U:G/%[.@YB/L/9[#Z>6Y8ZO<HY>RU^O
MJ+2P[,/8L#['&6WG+)^\ZI0V9K8'O^XT6C#6@UY)K^X-\HFLP6'L1]!F.PRM
M'*8$30ZQTZ]^*I-<HI>IU;$=WRI>1_A%Z<:T/G\VZ^K)FBO^)-7ZQ+?:RL\:
MO$),/D5%J#)=OY!)F.GQ'S\_,Y2O,S[NLI6ZW4&6W$K"5SO^^_W9YW_"B:-<
MPG.^?C[ZFWW>__KC$_W/(<#6X>?CMT>[;]X>[Q[]<;0+O]T]\GSWQW\ BG;H
M%YVH]IA8I#$CB&.9[7MC<C-G*9/E06">]XIJ@MYWL[P.!X.35[_]=GIZNO[=
M]=KKW=[!;Q1C]EL/+O\V_FRE'<ZV82W'1O\PQL'H8.+X%&(%7N.CB(U6'W:H
M7NM;UH!>]SAK2V.L*9>IQ.AN@T,+^ 6_7"_H.'[\QI4*,UH3G*ZKK!PGW7[)
MT7W5BVV;ST'^?MH*@\/Q5CSSQ1%>XNE7K .M'0ZN_LHC0M>UFD?.'>V<^3./
MMJQ[33TW-@7NO..66AVLXC'X1(3SV/HOQ*R-OW38FQ:;.X ETXOV*[()7O"5
M;9_:L_[:;_,@!0AU;M[/3]F5$Y/2PV%"D0_PGF[/%H'"7AE[^5,P)KLT8VD<
M]C+9^Y^?BTB!UN5--2M&[MZ7]>1?O]F-R\1_^1Y"Z./NN*,949<NV\V__MK[
M<VMWJ['_[ZWWF^^V/NYOO_[0;&SOOKYZ/UR6L;^>;.ZO9S?W#U/\ AGMG<1*
MVN.FJ+,92SG$O@RON2 I^N7CF.#\NHJCW^[ EM(=PEU#O]F(WWW,#/BPXG2A
M 0(;_^L8J/6@?_5+CK1JM&U<Q60+"9YN,85XP^NW[4D_OAK_\'MH]4_:]NQ5
MJU.&7+YTB;=YA*I&KTO-,[".?-RCVX\P=[U@[CEKH;JF^+K!5U_&Z^3*:]?=
MEF  _:N_>MUMK[\F^(,,EF%ST]M>XAH:"PLLM;@<G_Q)O..G44USX:.7>)BJ
M)?TXGA3],PRNHB"P<<;&#GSNL-_8 CP.TZH8-V@R^K1S/N-J7, <7VZ!9/_^
M3;J[+M(F^:5,''[P%?L$6K#ZD=;7>8MV(]+>Z,5OL3.,#=0HYB0 3G;^W#:\
M^M)=_2_)DY]HI"8E0G@0/$7K%.8!,Y,"XT+)^.5-"8["_]"=HZ3OJU7ZMM<]
MSE9B'MT_K<'AZV$?IBKVMK[[]C!/\6:_'^'_89ER?/<^C-QD1P?XTX\MO/OG
MI^^?WVSF2EQL;__P\//Q^^-//P+<?X?O_OA$/A_OMJ9>_AWX_#;;>[.=*W:U
M=W[\?;I[M-O:_6>'[NU_PCM_?CJ#G\]VW_Q]=M[+#Y_%GXX\WSGZ2G;^_/AC
M-S^3;I-//S[EAD"GGX_RS]MX]\U_TDYKY.'_@.GNT<$7YPF5S'%D2.XJ1:-"
MQAB"),<6),T,#G)M@^DFB/I^??S/)2IZ\3U>- P^4PRDF!"G,=9442ZYL"H1
MSC'E*DE&8B@8B,<8B&_;6*F&OP>'OQ^S\.>548E[@5BNY,HQL\A92Y#2.@1J
M4XB&WG</EYNISOV"WS-@W[?K0O-T['OD0.T<-.+WD^QN[;^ZB7UYZ_3NY;O'
M,UATUQQ-HJ**%BWM GP?^[&XE+)S.,#&TNZ>9/?^"SMAO+2&3B6=S4YX,Y7-
M5@45]9Z^R)Y^-C%I3K\0;;G6C"$5)$'<&8%<C!@%&:G"R5#/S-J&$$VB+Y9"
MJ$NH/1M5OF>^7JOR8ZGRCXDJVT@ET'".G.? S1F+R/J4$ N."AX"B\JN;7#:
MQ'R9*J@]6RYTS5'II>="?\9.S/F.F0K9<-SJM/J#7LFI>F$%WY:4#8WD PBZ
M.2>=&D07!]'=US-\*$E'38@.!><DXB9IY)*6*++  DB6,IG[U<@FDW?F0W6Y
MM^55YL?D0[4RWZLR3QF1B)$+8A2*P'X0%U@A(TE"7D1/N><."P'*+)IR!9I*
M/ -&M&H) =71Z^X%Q^1=/$(ON&3$8Q*DB3=Y!*+]&D470=$/,Y0("T=(M %%
MFXMS>YN+<UL&_R1&"&P)9P )BC0%ER\LY%TK_M*1J5KQ[ZCX4_KD5&(F@ 7$
M@N.(,RJ0X5H@'X(/ ANPB.C:AE!->6^^X2=2_&? K58MW)N/Q%2G [N3DS-U
M ;[;%?J]!V*U>(WR"=!.JXC64+L(U+9F.!:E'DO/-#))4,2EI\AH:9'G"OL8
M-%/!KVTPUJ1WJOA;E^)[EOI_#_RJUO\GT/\IU8H\<B:90U0$B[A5!CDC#2+,
MQJ2I\=)=3;561?^? <M:-0]6J?D]ZI30^&7DO_JUV>C$P>VRZVYJ$"_?/9[!
MZELUCE_9@!?_W,YG\F)_4+4[GUFB96'6$>8'Y/GG]O \][O=3G=^+Z\#3XMO
MYWNS462K S->1Z04$3F*3!!P,X-"C%HIY1W#0.<%6?ZH4QU"7@VO9ZW(]ZC(
M4UX>M#,\ "^7P>7&I!8C[8E&6'GME6$RN6R7-ZE<?E5^!@1HU>CW502HHN7W
M$4Y>00A]9,_F)4!9AX9N@XNS,6$1N"326H2UI?D<H$%.,8)84B82HCC-)>88
MO7@&NFY/]BP4\Q[(3:V8]Z:8,X1%.$!(Y1#Q6"%.B$2.68UDTBH$ETM**[ \
M[M*EN,[]?WZ>FE&FV]7>P@<)S:XB2#XE>:D-O'LY-+4_UPW-Q."EL0R6"TN(
MYY9HUA*!&*?",LZ9='AM@^@[Y[8MI TKY,5YJ>K]F/Z=6O/O3?.G+1N8MD2Z
MY!#U42  :9];-ABD%$Y$*X:QQ<6Y@^_KJ$]=RN1%N'UVXZ#1GBWY?)_IPJN(
MJDN?S 82J]-8;HFI.[-LBB4>%9,4<9<\_*$UL@[GIA1*@DF:3,ILBK$F)O?@
M&UH.+O48AP2>N]8_20I;K?5WTOHID_*2)T#I""2*.,2%"TB#\!#!G AB&*%4
MKVT(WN0:KZ;6/P,6M6H^J2I(YN<::52^J;HPW%-_\CX+PQ&Z3I>Z&$JF\\-.
M+\(X?L30.+"M3N.7S.]_;<"F9K_95CLW\4"P[Z ^;"&P2K_%_N"X:ME3QW8?
M@>A?$DN:Z\ SW>8WQ^)ZV^U] &%]B'[8JUIBAJ-A)340^%ZJ2\4N2@D^SAH"
MA.,8.%$H>0?60# &&6: ',B(K7%">4[!$) 7.V$N422JCA _I7>T5NKE4.H9
MGI]1.BF& ACUB',5D<$.-)LF3&/T-'&RML'E?96^K_G\,^+SF4;-L_G+?*0/
M>\YOA1L)+/S^R[V5++U+^)*MIMY";K6%?)IS$ ,+I%(P1"V#+41:C6PT%D6&
MB0<)DT1D<1 SS5?VI./"1G^->C7J+85+O$:]>T2]*7&6WF-% D78)XZX5PHY
MJQU2 D3G ?B<=\5!?K>P6'V^^X5F&DR;&3<;SO9;OFIBT<HM[<,=XBL,%DCH
M#G-?XY>PVRP^ 2N\W;R+O0]YQ=POV:97>F6W;*\#\]8?/_>/O$YS#X!JE4ZV
M%UQO+S?87OR<LU5(Q7B,2'KA$>?&(>MAMP&14<8<< 82UC;P^GV<Q[FY<JQ.
M/\(:YEX<S-V17=<P]V@P-V710K(8-(!;,%PA[HA'1MD$+)K'G*^KB),9YL3]
M)ID\*LP] Q)].\?TDR+(/^4?,2 +H[('L0%&L@-*W4T5J^XWAOT8&JU.\6 /
M2S7PSFVX]RT.5E03<]DJO.,.MGQ ?B6.5T*X7Z:*%W"+C-?'9K4\=LOJV$L%
MX/>&@_X 1 YS76/]7;#^8);22L&=-(8C:I1!7(A<$<]'!#@OL4Q1@:C7-@BC
M32)%$Y.+SN(['=&X#Z5;O3-<-=1< 35W9(LUU"P?U$QI)5=1 +8$A$,"6LDB
M088;@7 ,V/,D?8@:H ;KII&L*>B=N^<M.]0L*0?];9!3?.#OT/JV\2_X8_R-
M8]L[:'4J?S>=!QX?<ZW!A\.8<L=7K0$\S5^/.K2<LS^,#>LSA[2=LT(BNP-X
M'J@VD$:@EX-XD-ONG=C>('//P6'L1X F.PPM4/*,22&?^BP_%;>^S;].K8[M
M^!9\$=!A$$OBZ?ID-9Z?K=& .*UZ$)YT^ZV\B%_U8KNTG?K]M!4&AV.8G/GB
M:*'BZ5>L@T$ _%SYE4>4Q+7S3N=G8_;//-J"F)IZ;FP*W'G'+;4Z6,5C\(D(
MY['U7RA=&W_IL#=^@Q/ :.1ZT7Y%-L$+OK+M4WO67_MM?H7"\CPW[^>G[,J)
M2>G!)J;2%-B(NE4%_E< 4K&7/P5CLDLSEL9A+^_"__-S$2E0L0P267E>YPV\
MI&#;C<O$OQP ,IH1=>FRW?SKK[T_MW:W&OO_WGJ_^6[KX_[VZP_-QO;NZZO5
M>UG&_GJ"5:]GL>K#!*&RC#X,NO[K8;<-DN[___Y'4Z)^;VS]W[ U.%N&]UL0
MW'_Y. ;J7U=Q]-L=V&^Z0[AKZ#<;\;N/.79\6/:F8Z O@_[BK[7Q+]?[;>.)
MOP9$HV#"9!LKK IFNFU/^O'5^(??Q\2CU2FS4[YT2:AWBMSKN$+OD7-L=/_1
MY?5RZ1P7K*Y1LZX-N?(R7K_ZVG6W->M*W^ZNUU_C6M_[6-4ZIG)%QJK7-5$K
M,E:"UQFCJS)8NDXH6Y7!8E#:JR_/WG;D,3]'N!DN[IG+C9Z?.G',A8]>XF:I
MT/")_"P7: "N:,#Q<;=3;?37'=OL=4_/>ZMN<D+RFJ^MQOQLPF SW07C[9UM
M!=3J-%[;D[QKU[-UR6QY/SP>M@N3?!-3R[>NKDQ73U.9INH8]5Q>9V-[5.*O
M'&*M)_"J>H@WL$ZNAGO"[P+W,W[_FU8[6/(I+0[LJ\]#+_+"+VC6-HOE==ER
M>^BDUB=][3]LVW9\;"! >1]+*)Z19B/'5NJB6K>*8 41-/RGO!>1.R9-\)@Z
M0;QGQ%G)OFSGR04Z/A>XVMY]N]CA >!Z!34K;9^)5RU+@.ILIS4.4,$]_MGA
M>V\^_OC\!NYZ]#?]O+\M/OUXVX9GM^'W9/?'#MOY9_MT&J#R/W;_^<0_[7^D
MNS^VQ*?]O]GGHRV^0S_]^/3CX_=//V"\\/S=H_;7\P$JN!?Y?'1XN+L/;[O?
M/MQ]$V!<!S\^'^T>[>Z_/=HYWCW*8]C[YWW:F>T-F8ACW*F$M.8)<><9TB!'
M9#WE21G&N>9K&X3C)E>\R?!]';Y=B>):#ZCQ2Y>D=)<$S^M>?D5A[N*)J=MA
MW,52 [.\K^)[RW+V:570:UJ07NIHA',!,6H\XH)*9)*S2&)%?9!*\* *>M6H
M5:/6BT2M)*G3F@DGM.'6*".)8"9AC9E.H#M7H]:-B5D-:'<%-#(!-$^\XXX;
M)$!:B#-/D'$L(2$<QU)Q&VS.%FHJ*II"W#E7J(:U&M:6YZT7.;\.U@KAGBL5
M).7*>:<=(\(%;!7QEEZ#:XL?6Z\![JX QR8 QY57TC**,+,2&!O&R GL@, Y
MR;V,BD2ZMB&Y;#)^EV;D-;+5R+8\;[T L!G)4P(< Q6@G EIJ8^2&NV#L]A(
M7YN9CP5:8@):2GGFG&.YHH9 '"N+-'<1Z<B\,30YFCLN4WFQ\5G-QVK4>@FH
MA9TG21N27.2<$ZE5;@8H(Q.&."5-;68N :!]GSD!IP@GT<:$M,K'4B* F]4N
M(8.5]U)J:37-AB96IBF)6@E@>^RSQ#-)HZ-;H/SY5V9\CU9.4AZ\0J8 YU.H
M\':_/RRQSF[*AXMSLE0_ZU%C> (_QN^QYUO]<K7Z=?<D2[=?#AGG,N/Y% E<
M?/_A8_]<EOLMS@$^^S HEM8D#C#H0N!88!NC-]()8[.%:M-/S@PO%@\M>)CE
M&\.;80_F]1V\8C=4L=%R<:\2YM9(RDMSC&\U\/)L)DI*O>$X1H9 DKD$#N?(
MVL 1IB)&2H4@GJQM:*.:BM_76>$5/>S[G)3\$IYS-PV_PDR[J,7_M>UAO%Z)
M:])S(R6>!@MIJ51%(W*"4\0-\\BD&)&@VFMF@V6* >6IU??YJJ^0DMN0RW<P
MRB7UVGN*C<,2E%KHJ&Z@OG?=GVO-OB_-GD;-K):22@5V3#("<2<CTEH2%)-U
M26&=G 3-YDTL+C8$J;5[N;6[I$;3WVLQU6*JQ?2HF2-W[XM0[Y7+LE?.NOZ$
MM<X;BQ&1N9YK<!:Y"&0XXJB#)Q8;'LMN*>^<-G>/^OW8!Q-6P+GWWZF#+MI>
M^VSBSPMSOKX[..Y6MYG8[?:CNN=;+:9:3$]M8I_C!MFA[2R@6CYF&CO]4L!G
ML]>SG8-2Z^6/L^E'WMFS_*O-4]L+(\Z043*&[4Y%*=[:5J_0"E)3B 4HQ.[K
M&7-;T"0HC1Y)6,E@<P.5L,D&I*SWRE#FN,-K&XK<5]9]K><U'-=BJL6T:F)Z
M7&.[WC67<=><,[P%EIJJ@%+@!L$FJ6'?3!HIR:SFD693?-GVS9=0G[]XF%#1
MA%*!?ZPM=RFOOX)P5;MP:S'58EI-D_G&GO9IR_K^?G=:'BQ7!]ONC&J#7<X=
MWL?_&[;ZK4'\$'O?6CY6S.!]]-V#3KE+(0@U/UB$'WR8L:HYR#<%(I#'QB(>
MM$5Y"2"+#3-84DLH6=L@L@DF]A+YY6LTJ$&[%E,MIB7=6Q\SBEWOK<NUMWZ?
M:V*J5#!,(T>E1UPR@FRI&6.4Q3@&4U+$EFYWK:/>%Y1_Z_BDW3V+<71BY638
M\X>@3XV3MNV\R%#WJIY1&0NR?.C=2(SO0(K]^J#*(D W6\[/ZB0P"PG9!/8#
M]Y$C$UA$(&O-58#-D.BU#:.;F,HE\C+6\80Z[/-LQ+2DGI_K<BROA.*:<BZ&
MQ%-WCM.2A.03HBIJQ+E4R 42D,4\]_UCCA"9#U@;?><#@[6&UT!<BZD6TXJ*
M:4F].?5^^1B6RXR+QEK/M#$4&<LCXLP*I+DF*!'!6<*!4*:6;\=\"0D2NW'0
MR-U<ZH2(.AI0BZD64RVFYRNF18KP*J^-3YXFL'0YQ5'CD AVQ+A,S(2_ 1U;
MO!HO;$95A[&_8$>J^=8B?.MLIA"OE\;X& P2-&+$%;?(I41SN7%KG3!>2[VV
MP5@3DXL]7VY>A[?6WQIF:S'=#6;OP>JM8?9187;6K'5&*Y8D&+-.)#!KJ40.
MP!<%R3VFV LP<I<+:.ND@TLMX&&G%V'D/V(HQG #E-9^LZUV[N2.0*]0'U2D
MT>KDNIDE">A%9B/43M=:3+68:C'58JK%M&QB6JC!4(HB$0,,&T<>B=2>Y Y<
MB28:B*8+D>YY9EUZIL^U3)\2[<TQH7C;[7T .O$A^F&O-6C%_C2Y&+C(7MJW
MWVM2O@ IWWL]T\\C<1-B[N)!(\:(D^2 DK.$M#>Y$CZ+F$J@Y/)BM<B%&Q#5
MRKV,RGV?%G6MW,N@W'.Y_ECA2*)!B8-F<Y8$LD9:1**,)#&NK5@F]7Y>$61U
MJ7+^8=NE#05J[-B>/VPPTFQDS;I+1'G43*1ZKU<,9C]TAZ!=54.1.[0?6CYL
M6RS%W^! .%':2P, 9YC5VEC/8L#9XV2K9CQWS.Q_70H,EOR7*IM_;SCH#VPG
MSVR=OK\(=GV83=\7(EB<LU^T(XA'99!Q22$M1))81<^(R/VL29,KW,3JHL/P
M=G[_^U"E)XX7/!E:+%VVSLV;E=WGU*PH@%[2@/%6Z%DW8+Q_7)RV[C ^:AV!
MS,G@<VV$0)#E3",N!+;2&F#JL>!BC8<U'M9X>*]XB"-8Q,9&(;0 6@+_"XZP
M$(05! ?%K\;#NK7CHT'ES+DC[B5F*B+,,0"D(;%JL.V]C9X'8E0.-Y.FXJ:)
MS9T;.]: 60/F2P#,1;R+00I)'7!(*BAG1FA%5-#:&1RYHMI>C9B+I^G4T'E7
MZ)RF1#)"@U5&(FMS?4XE+7)6*D23HLIQQS11:QM2F283%UM]+YRJ4V-FC9DU
M9HXP,[<+CYQ&*67DGDM0-A&-<A[431&B;X"9-3#>+S!.XZ7"V4!<8HAJ(A$G
M1B-#,$>$6^=5]$'Y[);$%\WO&A1K4*Q!\9:6MV4F2*N-<SK7CS &" @CEA.I
M@::D:S"QIH^/%[R9/<&LDF84;&\?LYLR$HY<\AQ%8Z),Q@E!>+:]L31-I>ZK
M%^E30F:)7?\VR$D-XSSGF6SNF7OY" N[-]*YC7^YWF\;\^G1=__:L>T=M#KC
M>9#SV#BY41GK9$ZKR8'Y;-N3?GPU_N'WT.J?M.W9JU:G:'#YTOF9@"G]_;05
M!H=9L]=QI=VC./[H_J/+Z^72.7E6UZA9UX9<>1FO7WWMNMN:=:5O=]?KKW&M
M[WVL:AU3N2)CU>M@ Z[(6 E>9XRNRF#I.J%L50:+06FOOCQ[VU%RS_@#(RK
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MXD1K3<!XC=JZ0 DCKFJ[C,<5Y_ #METN%_<J86Z-I!SJ@.LB@'DV$W#%S(
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M'*O9S*K+PHMW\;$\LS2*):4@5R1/O!T+LTZ>N!VD_9BKWH,3]EI+A:@.!'&
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MP)-'%.!G&_5DT6=BFK]P\UV[C-QE+I(R(.6'7J$1)0M@5*(M#PP>E1-&89#
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M>]L"B(1(.!G-. ?-B,2HC0>]2"8277):;T@@:NVSQT C-D,CZSQ<D-4HZS^
M1A;4(L<5BB(YBTUT*C72/KLGI^[WX?EZ.6\B>&$OXFBC?Y=N=P!K\?6[!B$+
M\E3*G!DI&+<T&2*]MQ@'8PG6W+?:4 /PY\^:?P@K+1S1'NE@0!LRC"$G)."/
M89(P%UAR]V>678,!WTH;NFT$H.5<S 6+4864"%CGPCJ9G+-6JZB8(:I5'YK#
MOG.OBO94Z0B<ZXA1B&OKD+61( MZGX@L!*G\SAXS76-8R[U/EWNET]%Y[1U3
MCAL9K.7,8D>U2LX[?$OEOY6[WYAQYUZ(R 03%&L4<2 @=S$P+G<$&?A;PEX%
MG40K=Y\!YP;'B,7:"$T(US3JB!D77!.KN71.M'*W.>P[-]L9CL$X)1"G&-B7
M<H.,% D93E@RV !KXP;*W6>5K_)R.+K(W=?RM(%!&'^5T7Y;I^AW#4%$<PK0
MP8QBB7O0&&Q,CD?L%+.)$=HJ#PU GUX]J2,1 [H=0<P8@"#X%]E@X%>"K?38
M:FG"$PYAM)P[Y5QMD[3!\:!%X%1SJYDD2BL;N-)@^[7*0W/8=VZT8T,DIXD@
M1:+//C>+M/$.81.P4#17[\>=/4I)5QO2LN_395]G2(C LU8QQ4&)M-YCY9(B
M8+R;$$DK>!O!N7.KW5LCDA8*>6*!<ZVG2'NO$:$"@P!.U.G4"M[GP+DNL3QN
M,CJEN9*@,COA>3!4!84%8:W@;0[[UJSV('4"[0@YC3/[&HT,4P'^<<EY"C:/
MHTT4O,\JV+ZI#UL;=-\(1BIBID2PQ#..I34F.0,Z!>@5-IEX2_N]!:-O#T97
M-2.>P!4ISQ4241$ (\? "D@)@>HG/':".1JR"Q%W&=$-\B&V$8![9E]/ A@"
M!!,2%9CMR8C("8]64ITDK+*U AK!N7/[G4H7)&81"<P9XD(0Y*3#B&A-K=?6
M17=_5D#+N<WE7,FRI*4DV("Y9]HI83U+FOMH!?S3<FXC.+=FOQ,CN:(422$-
M ET)HVS#H425P-:KD$++N<^!<Y7V2J4(;"M54;WCN3&@,3,,_RC;JLP-8M^Y
M_>Y ,=:""A15;JN(K40&.X)PCG5PK4"),DU4F9]5V+VPW^V'./!WMMZ?A2LQ
M,.,P#9K!BKBWV$:51RDJZXA/#MM6B7A\%#JNMU0P6"O-34)1,HUX2A+9 ":\
MCQX'363P-+9!@&? N4([+3CQ-$3-"2&&$\L%J!+>6P,V?*M$-(=]Y]:["L8%
MXR,*+''$::+(,(]1DF =*)\2461G3XDNL'G+O4^7>ZDCR7!IE):86R )::T/
M28J<ARO2+1-O6[G[C1EW;KP+SA11P*E1>I"[CBEDN0E(6^M<LD7)2RMWGP'G
M.C#==0Z\$R>X)]())902C*68J UMRGR#V'=NO"L9&>,X(6]H'K(!%CR(6P_"
M-T@;@R#,B ;*W?N,O5-1#DMOK.U^,IS8?FT$9SGR85N7R6*/8 :;#\/+/ (A
M;V!SA^ GW7KD/H_FR0"Y8DZKD)A@QG&)J<4>L-UJP[F2@K9>V,8 >;UE !$T
M&0^V$\7>(IZD0<8YCIATP4F0QB[XG3TA9==P<4]>V/O@FT<.OK2HV:+F_91K
M&:R$\%IS9SG'RDI0?H431A.*37(M:C8'->=N)Q,)"]PPI))SB!,ND#-.(ITB
MH"8 J/5J9X\Q0$UUY]S3%C5;U&Q1\Q[F:[;NO@<&S+F[S]" ;>Y<+F0>RHD%
M1MH0AA+%G AA1++DOG-U6L!L ;,%S!(P.1711^*PY(Q;4%J<ULP;'(G*=EX;
MW6P0:LZ]K(19Q@(V2)@<W60^(I.P0T*3E)1DCE.SLV<PZQHBGP!J%N[9?Q7#
M4O=6I[&NS,S:^;HAKJO#M^!!WVBL*Y7F*\>Z"GF[P9O;SO/47_?8FX:/RG:Q
MW]=B>3O6];HQ<-.9T]/)KKB=['K3D;6371_]\-O)KNUDU^=V^.UDUW:R:SO9
MM7U&.]FUG>SZ]5M\,IX^)HFQ(0EBG>&"8(V58XQRJSU+CI5ES)C0UM.WT=.W
M__GHX/3T*'_'^7]_/#IYPX]@;8=G_\D>O"_'O_[2/SS_S^G;O]^(94_?X<$^
M/H8]P'YZ[_Y^0XX./M"W)Q^NX/T?WYT=\K=__W7U]OR7TW<'_<7)KDI3:P3U
MR$4<4>[;BK2A CGJG>6$XDCISA[!M(N9:5!"93O'K$6CZ] H,>*DU<8($CA/
MV@1G7;1 Q"RI$/7MT.BY!FH?#(CFF2V!4AZYBRAZ1A&WEB'MI$#*T$0(2RGX
MIUR7T0+1$P4BAZWEL#.1L.#:$>=\<E%P@P4APMU2+6J!Z!L#T3QCQ I#E5<&
MY4ESB%.CD-4J("($D=X*G/C]98RT0-0"T4,!$>,"4XD-MI$'96VB6%+&F8K!
M:MW:9PU"HWDF1O 28QX<HI89Q$%X($.91XG;E*3Q6E+21/OL636;;2>[WA:$
MHN,X!>RY8(0;!W99I$*)D'NF$:M=JPTU '_J95HZ!694DB@J+P%_I$8N88RT
MQ]$%YYCE[82YY\"Y6AKFH[;!L<B35MIP)7E,E@1/7)2M^M <]IU[59C3+FCC
MD%2*(1Z"1EH#(\M<M\"C9R*[=X7N&G5?198M]S:0>ZF*$6NM#3.68QJ<IP(3
MYEBB'#N<6KG;",:=>R$(7(P)7"&O)# NUQ;9A 6B25O'F;18L5;N/@/.99QC
M0/$ >A;G,41GP :4P,+81*LB;^5N<]BW5D#A4K14@[),1$2@)DFD8PZKYFE/
M&JL4"6^@W'U6^2KM9-=;0I"A L2-I58 "GEN3=8<.5>>$DE5,*WRT #T69CL
M*CB+/N$<O4B(&RN1"TP@3()D/- 8^?TI#\T+8;2<.^-<L/A4L-[E=I3,*K#3
M,26:"J8X(9ZTRD-SV'=NM$<&N(J91SH)!48[54@KA5&(6E NHP8;8&>/2MI5
MHDE-[EKVO?>F[CG@+)(,-/ $%T\%<"]1*21G8C52O16\C\VY<ZO=F:14\ F1
M)"SB/@ED"?8H8>JC$)12:5K!^PPXEU(0N3*$('7@6GD3O#%*!D)=<$;C5O V
MAWWG5CO6VA'L!!)*2L239V"P&PRF.W?&8$&CUTT4O,\JV-Y.=MW:A4BL(%9)
M9BWFF@L=E0:ETB0JN:'JEKG0+1A]>S"J3W;UH.M[JS'R.%=F8)T;I((I(+EE
MUND\,T3N['$NN\;<5P^6-@+00/;5QH'A3H%M4\H!]]SJ/.6^]=8)R5U;RM ,
MSIW;[R0ZJ:0+B,@(:D0>-N&B<,@&L-\#<599WL;NG@'G)F9U-%QZQ22/E-B@
M(E@%3CK#+?R_Y=Q&<.[<?F<RL@1WA&*T/$?=-3(R<"232YKA0'!R+><^ \XU
MVG,;L(R&<BY2<-@K3PAPJY")D#;JWB#VG=OO/FJ?-2)DH\N37;U!S@6,2 I"
M8!I\\*R)*O.S"KNWDUVW="7R$&GTQ&IJN,/"LF0#(<P2ZX-FMTR\;96(;XE"
M"Y-=,;$Q<0'JOTL.E B"D0%J D*B3)J0##=/N8"PY=R9^B\BCXJYA(G@.C@M
MB" 4P[T#,VM^RZ3;5HEX"/:=6^]:.%<T0Z%6!L1US#$\S1'1Q21M$;0"&T#C
MAA7<M=Q[S]SK)?"I\$D9D[@4T='$''4L2&&QY[<,X;5R]QLS[MQXERH S.J
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M(U2]@051P1@G&6@5@B'.*$%:\00(9:1G#'NJP&)0H@MRJ$%.RC;DT!BF;AT
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M2V&$ @V#@L*1DD:@1B;$@A>&."Q,=#M[#+>L_)VQ\C8.@,?FY=8!< =>GCL
M;+*<!BY0Q 9$LTP>.6L3<F [>!8TYE8!+[=) -\/%S=;RV[M__MAX9K][UW0
ME#!$%2C6/&J'C!86$>R]H-Q9HTBI73_9NO_&3TG[NJ$W-QU%.SOEV8U&P<Z3
MI U)+G*>!Z(H&[21D67-6\DV-:+AR'U<;XL <M:#LA40-CD%$\>(+",8V2AP
MP%&$D-C.GA$ W>:^2K>^^1"4AQTLU6)?BWTW8U_K/GITU)N[CX*)45 ED2,>
M]%4@ ^0$CDA;SB2\PHD U%/RSE4D+>*UB-= Q-O&R_;8D-=ZV>X >;4N&PEN
MS8!U3@'I$/>4([#8!0J>.^R=4,8!Y(F[N-E:L&O!KH%@UPS3]OE-_7PPD)O[
M(26-'ALL4<1@P_)@"7*Y+0G6"7ZQ6B3G2FM6XWN>^?F-1WI.1M.%3&E;%&!V
MW_&(6SRCMN$U$T[OXQO:57[WJWSR,^1?]NUXW$N]&#IV_**=%?],GG&?&:.-
M#QF]7 H6?165WR,.M<^XW3/NG%'P'1LO3WI*P@.$WI9-E,E+.QI=P5$6LSU;
MTV2;V0A@ELR2D/??4V899L(A8?*(!!\]@A\( G*-PIN8'3%/?3I"XT5>88^C
M"1CDUV5%-$(5:9_1EM4U*4EC4UK=R\O1")BH%1U;B8[7==&!<7**$HF8(3F_
MSCODI(N(>B^$,X'&//5+<MX5HDG3*YZ5M?3;</#A?B3'=V)F/,EG//N$[ 9)
MCJ/AP+?"XRN$QV%=>'C#*.4A("IX0)Q[@HR0$@6CI-7!\6! >%#,NQ3?>6!*
M\^R.Y@J,K\O(;IRNW3YCFSAA2>/KXBAMOL&]'5 KC-N$A,>3OF_JTM<QII-(
M'BD2P70+QB&;&QUICH.CW+B06Z-\DY2$>^"D.\GN?TVRC@?_#;U/>].M'5V>
M ]?XO7_#'Z<;.;>C#[U!N1Q:@.H#LR7-;+D_[@Q3Y]"._&EY[(QT.\!>I%O^
M.CF-G5$\M[T!G$[!IOF6+D&$ Z-5&FM^@IUJMPAX$(V!<6KM5CJ?XRAV^G$\
M[DQ.88__7CB51>:WS 30T(QSFN<^E89IPHC-,&"5265_9()99OX:N\/^_8MP
M.;J*=K2L>2\E72[IX9GMOT\.[\?_^\?5N[_#!;"4/#J!%9^__?+VR[OSHX.C
M_M'!N_Z[LX_\[3FL[LN[WO')Q\^'^7M__2,=?GGU^;W'-BJM!!*)6,0]<\C(
MG!VNDV:&<.>$J54@3TFXDT]XO-LY.<UW>FH_Q8Z+<= 9##MC8(E> O883#K3
M1-9.?S@>9Q(9W$ B\+=.)K8+^)9A&'<N1G$,,!S#;F<SC8(4N=T7U53+CH5U
M#X:3CIU,1CUW"5_1F0P[?A1##];=&W\L-M=Y.3P'?KR"W?5[$3Z=27?2@;?T
MQIWS8:;GWL?8ORHI.C^O?+WV13U8RF!YB9V+X;A72,#/O7X?GMXYC?T [YKT
M9CQU5:C#(*O@$1,XYO&D^,/%J#?PO0O@O>E'1]''WJ=\1IM7#$O(4N^S'?A8
MG'*UT^J\8#>7@P$\9SRVH_Q9;R_'L;B*M8?K 0$!#?*-3.;?^?_]+TV)^@E.
MQHX^Q@("ZY>;CSQ<QGS.Y1LZ"5!DF.FH=KF=Z;T6NSV -9V[.)K^%7<7$*4W
M.>U8>$QOU/F4@W3Y*5OH&-O S%S'>'WTRRKJ@*+Q&40+4.MVP+.8[?U[118S
MM0,_.U#Z@(\/7L.SX-D''SX??G[/:)2!J8!"R!/6G/!(@U&/C'4!.^JTR7.,
MOL31<$6'*$CH?W][I5-LX0&Z$SG(9TT.7F2M$G-/)&,HD>@0S[WVG/<:!)BS
M(*VL-\+O[(G=30UP0'WJ9RH 0+V(\,(G@.]NJ9MDJ.X, )<VHG5&S@+V"[PG
M%'X93$ZS(!QV@IW$;AT.02Z."YD  )VU3@!S^&,/7NN-LFSH^%/0_DI 78N8
MNS/M=Z9&9FKM#2YML:%"D2SH05//C4V!.^^XI58'JW@,/A'A0,3[]USN3!^S
M0?O4H"E6^B_*%O4+)J=F=F\08+DO4/[+-]=0U5H-5>R6M[?MO]<IF8E&:E(B
MA ?!4[1.81XP,RDP+I2,[P\*](?_H[D86&3F/R\O+OHQ7Z;M_VS[6;K^>1KC
MY* W]D YET!D)_!]/_>'_N,CL^Y1;\JZ1Z? <KVC@X_BW?EK<@2????K(3\\
M>T6.OASU#\_VQ1%]Q0!]V3+K'M)7^.C\-3X^Z9^_/?L+PSH_OOWRX>KPY"]V
M2/^Z.CSXR-Z>>'Y\$'(*"'F/,5A]B@BDM3"(L\21-=J#>AF$ 8TQ*!M+" :B
MCF$_ RCH'II)SK4BB2=EX+\A,<*PU\EP >^/@(87< N3T24@?W7NG>+@"]X;
M#DKOX9+9M<!,2[Q4WLW-7[VXU$2P$$I9&4+@!E,G562,196;N%@'FO,&;ONF
MC%0\\44/2++G;\%:OX^&H&Y7ZF;VB%QD>N["%TX6C^P1MG*MU?J->7MZ+K\#
M>4WV!V%V-,^8H^E[#G?!([9(4!"ZW N%G-4:6>T4Q:"=@;JVS"86[L)RS+2B
M@DOB7;22&AJUBP$>9Y<Y>CU%YH>.>V %549'&F:#)KMKKN?T]6)SL:2$TS+"
M/A7T+T:Q;[-N\-/G7IB<3KV7M0]6'B8\_XAUXV$?#,F-'ZGYD7PV:D>/Q#=Z
MZ7QJ_Y[.:FTN[(>('*A!'Y%-L-87MO_97HUW_K6( P "2T>XO/N->TSIF^VQ
M5%M"5KN**W]Q"1K,*+\+UF0;LY;.Z2B#U?^Z67U3.WLGA7((M/\RXUPAW^PR
MI6^ Z8I62Z1>*_AN(<C6?NY&SM[[=Z743KFF\+["R??MQ3B^F/[P4^B-+_KV
MZD5O4)Q?\:$UX<J*NHS955AE JN"I-7C*]K;+6AOR65<OJ;P+B9\X\MXEVQ\
M[;K'$KIKE/RJQU[_FF#LVRQ6W>JQ-P2BMP@J7A.:+L'PD>)4*SI1 5PS3]2_
MW>A?>UE#N$4L>IL0ZT*8XL9 1,-/J^ZDFQX87CBPN]*163ZY6\5O&GYL/[P>
M@"(SO(1GA/&/VYS7;9-/FIL  D)L#,I>Z9#K#3H7H^$',)9OWX2OK>?YOL/[
M46 )DABSJ,$,H=881I4)1H#IK257ZUWO6^7:;33@BC8KC8GL?Z495T;VSW\Y
M/SK[3__HUU?_')V\IK#.S[#&T^.#7\X.#PZ_O#UY@]_!WP^__-Q?CNR__?LM
M/3S_"];VBAR>O3L[.MC';V%?AW\??C[\DM?R!WSGVR^'O_YW.JS/%"P\[D0(
M1*C*,4,CD<;%W!/K@I'<$I];2+$N:U0Q3UMAV"+2=8A$O=$V<H4-!UM&*HN5
MP$%R88*RWI![R/YM$>D^$6G>U$[*H EC#N'@,.)6&D D9A &/(K2)QNLWMF3
MNFOXG?O:M6F^6]2%1#N.I\-^R%&OT?!3O#ZM]]F7KDDO66 \$)<B-R):0ES$
MH W%&#3SK5+4+ BJ3UERT3/"!4'!DX!X=!191S3BE&&OI(TRQIT],) %N7.E
MP3V6J;75I_?,PHY:CT%+2%@+;J2Q%(,XHHQ++C'3]S'4H67A^V3AN19!!7.,
M<X*L%0X!Z'KD?""(*- "B3"2$ME %M[>5Y023OX[TB*LR[&3X>BJ*!8J2/WK
M9C>N;OSI 9 .!H? @]04_F72,JH53\PI+I)WIM4AF@1 1_6)!$H[&I2SR $4
MY0GO%ID(.D3P6CJ.E0(@VMFCHDON85+C6A#XMHZ5Q:_\NCKDY\#"D02M0&'T
M/AL#G)F@+:5&><V9UR&U.D3#6+CFB6"6)% 4D(1+0YQ3BDS2 N$@/+61::8#
ML##K:G+W"8WWQ\)/WA.1TP(O)W$TGJL0937%Y<B?VG&$8QZFR6<[BJUW8J-W
MPH >X<&.@5UR8H1+WDLME&$F!AQ8JUDT"I;^K&D6WD2P:;!'BH6 N#%@VE"C
MD?8V1.HYXU3L[/$N5:1!EDWKG+AG#K; G0IDAD@J<OB_MMA39H/SSDM#::M8
M-(R#YXI%\MB!%<<0]@9L QX9<LY(1)G2,O'HF/29@['^OGT3WUD>RR^7(V"W
MRU$LM(D$[)%K/K[.._$<6BS%&$Q,1%/)$P]$6"NX!--&.XP=<ZG5(1J%0/6T
M#VN3E)@SI+#RB'MED>.&(AV8E$Z*0*3>V6-=Q>ZL0S0OZZ/EX%F);/+*NT +
M*P#DA$Z1.D^#\08G@T.K0S2,@^<ZA&9:>RP-DF"R(2X=18Y$A2PH$DXQ%@FC
MF8/9W76(YF5)E(Q(=VFC.VD6C='NXH+8F!_]Q&'IZUHYM+#T2+!43YT(V"O*
MA4.!Y>PM8@URS'A$#0DI.YRPMSM[A*FNN3?WQ.W8Y#MR7#Q7OG^ GJTMW]\G
MW]?4D>@#MS$A8B,8%%P29!DPO[+<,\$%:)@D\SWI*GY?3HUOR_=//Q4CCL<O
M.G8^L19XZF($;%/4A#ZSI(QM1@D_@'I2FR-\4+L4^+D?\P^ 7/OG0SB^+\7?
M-Z):"VA; -KQRT5%AM% #6)" Z YZI&622#C\@R# '\(8%\1WM54W&'8<)NZ
MT6!&?X@>\BVC/PJCUS07(;2EA"/F@D5<,X9<3 S1E)BFR?-46"RT:]:TE7\4
M1G]^3I1<4CSO(A/G?8T&<25[])9:8]O O&U@WBB5;R.T'\46W;="]WJRC",T
M@=16* 0!Z&ZP0J9H%!8DM]P*"N"?T9UU"7\Z?<O;61 ME#852A_3R=="Z=90
M.E>4;?(LVJ00<<0A3@U%\!L%/*71T5S5X!1 *=%=S>^<#]T8*%T< ;'2?G#-
M7V[57W.OZ*VTVI/SEAV S??= 5@VJP-P,4/FMYZ/@W'<_S"*96E[4UJ#'O\Y
M!8I#>O3EHW@+@/#V_/#J\.S-U1& Q_'?_^F_.WG[Y>C7-_"<UU^.3XYZ*ZU!
MO[QEQR?]WN%!'Y[[^NKH ,"!OH+G_'?_Z.P0PSI.#\\.Q2']3SH\^<"/#]Z^
M5YC $4J!,!$)<1((<G"TB(HH;6ZJH2Q;[@ZJ<2!1)&^$8CPDKW6*A# @8<&\
ML'BY.VAUZ)WYJ7]%I]^;OW1QD4PSYZEP0!Z$^^"M8DY:'!,GUM/$OXM.O_OC
M<=$A>5".O,B',3O$<I;"[PF^8-3LMK^O8=47HUZ_ Q)?+S9<+WJ\Q3Q#;C+,
M(R^NW? /^9/EAN=__;%^#KDZ9'R9!YG XSZ?]OSIPK=9#SI"_KKI- R;OV[<
MA:_W_<M0C,JI7IF.S)F.N)O$?C^6$W1F;HKI[),0/\7^<%ZB8L-Y;] ;3\KV
MH;D#J#_ME6 &2^M]B(-B LC%!#[_P\O]/W[LG)3(Y^%+YB-5)J-HBY$DQ1-R
MQ^S1XL"0WAB>4^VH&-'Q,7;@^N)X,AS$SH6]*N>97%[ (L:7/L\*29=]V-IY
MY7?,#Q[%#]DSF6MU\]KSV)7Q_"GE8);.)+>]GR!WA<J?.LZ.>[65%G\<UX[Q
MY0$QQ?-^1GE3Y824\CBF1_##SR\/]W_LPG(^%23@KCKK[K?<LOT OW^P$]C6
M,/=2[>5)1MMN]9,=]8:7X_J6:QOM#8KO_PN46EC-GQ/XLO+R\U]?7>9+!P*%
ME_,>1G&K*14<*^NU)9$3RJDW+BI*"0,@LI1)+M:*K<WS2ZX9DK8_/:C?I^=T
M.-WB[]4I-68VQ4/+//@.]I[+H%2R+(^?D(@'#@(/@_PCQ@?MK/&<@8++\)IQ
M%)WI) H@^VUNGU"E+;8"5.J<&A.<PRQ%; F32E".V]M_B-L_/MC_\IYI2R-)
M8-1XKT#=81R9I 22D@KL',4X3\^2U]U^-T?0XZ" N>&@AG_=:KK1&JA: MFZ
MP*A#;0( RTC^O1#7'[-M@?U],-_4C.B>,;6=[./W5(@DF9<(K@.PANB +.<&
M>4T(I0JKZ$ /!4/Z6G++?;AZ>1A-,1=LLJ@ Y&DU0P<FK:T&HH$L!($]EXU9
M1M?)[R(_SO:GXFY)L.5WVU)&HU*&P\V#M(Z@NX"FTCGI%.(<GA$N/5 \?&%^
M"E!CIN4_X^A3#X1W'J,#HA=4'E]0?]8%Q_F]()I!(XNC42\O9GO1#AH1J%(U
M-<T.!EDERR. 2LUE<CJ*X]S K!#H1\,1<.1^H7O9;K79+FB9/?AM_S*K:/V>
M+7CRV,,IP,^%DGDR7>*/Y8G,O@^X([=-S@,-*IWG!O5E>U5!,ZD=49("J<04
MM-1>$F>XURHPQUMA\3#F\2$YWG\O%0O8*HJDH1%Q,(CS0%0X>643"9$J@%A0
M%NBZX54S;0&,A8I:2H)?4;$K5H1;BQ^&F;J+"8IY0DXF'N" <I! 5L3]\!+L
MDJNLB5<_5JIX.8@P/Z9OQX7Y$_^Y ,N@&/()4%'1Y1_#*]L'TR5/S^R"^0.4
M,_9@:F4"!O3^W*T0X&K*XGEQ!==.OZY:[,F<B<&\._:38>8+,/!,=_'USF?X
M%E@+\%@)4'D^8OFPWGSOGX>C?MC=9A*@\$F(:+S+DVF)"U9*::,B+AG')9,%
MG^ IG^"O' E8,,IFMGCL87\/SQ9OZ>'^>Q:) ;D&)VLH1UP0C6S."*41BXA-
MT%'YK<(%]PQZ[65N<9G +4$FEOU^A"'NJ4!@!C%$);&2AD1(A,L\6IW5N!;Q
M*K&=E8X*:F82O)C8=VY#G#)]EM6Q&LC7B04^K)D66TCGS,(+ P!W;^/R>L0!
MS17> C(#A0(8@X;6RR@. %A-?^V6B%[A;$;T*>3F#6\"^FYUKA5VCD%<]",*
M\/1)%C1Y:(*M)A2NZ$89VJOON%EO*5P[H&_FJ;)3[6>ZJ;7>L**<&CY5NMWL
MH)JIFS53((YB(9\[873Y(>N@?=#'"E#XX?71P8_YF%)O!'(K 06%3FEBNY@E
M8NDZ+$E"%A3!%KQ@LQ&V4WJKM.%R5"]H?Q75%**G\P$.?E"7;=,_S0XY O%4
MVF8AE(ME%<.(09(6DG"39"RRE@9A/+4*<[Y?H2K^T/NQ7'\ADF=.P9FP]GW;
M.Y\*ZNIP,JU<V$EU$S_T>C]>.WY;>0!'!5:L3H0+QBRE5L;<EE8ER45:"Z W
MS.$NX+)2&(YGA_I[,>CYE]'P_ "6=YQ^R0>4!Z$^-_0\._QR^.&]4#P8&1U2
M\"_B(<]+M)@A&1+3TN;&HCF#F*Z?Q]U)<(Y;TMGMD$\W*(KQ1QS'8CS/RSP\
MR@UGCN#060D-E3S[LL27WKC9@8W],?#H:#;?;AE#N]._V'&>L5ZJOPOQB,Y6
M1U.8IL=@3?<RG,[.:"46,G_ES]W]W<X/L]]_W.T<#ZJAW;I;T];7AV,V+>$6
MW[P0^GU=A%,&T<]!N70:1']9!\,USRV$Y#4+S@<U_U@I:A?WT(^3#,-V<0N_
ME7^=K[][4^AH\8ORY\KK!$,*KF-2CEZ_[G*J(SFYX6U5$"7/'LZBJZ0.OT =
M>>S]<%!@0^B-"T%^54V:C\@#F>8\A\6H5-::R@GL\.'LSQGE)<\].F (@K'H
MLP\I^Y@JW\8X]LN_@9*0/2\%M>?9R\7Q?"Z]/#G 4AQWYS^7H/GE&%_CE;/:
M56\DO/D?/XS@O6NX=P D#'<U+I2YPH+]W MQJJ&![@:7E\WY?LE&W>MB:97S
M>'SIRG?GSU5^LV+\8#TP&8KQE?"1Q5?RI,'IFF=:T5I=K1[P[,$WG.S_]NJH
MU%_R6^%=,U*+_G0 M_+AJCL-,7:S2MC-M-'OYBD!PQ$<5O[L$ YG]+DWSIQ]
MT1_VIHKLU \(%U11W$P)K1/==!L5\=77F".%W<XOOYVP;N?@M]]8R8T'"I?,
MO%_Y*#LGY4=_++T8IY= *'#FF:H^@,*4EV<O(D".[\(WVP^#X;CX.1_+Z54_
M,XFO^&A8O9A1X6(XCN/"S9%3;2:%3W:ZV#F1K%>*JRN<4A#PT?P3*^144-C4
MAWJQ1*.OIJ0V0^7B$!: 80XBKGR>BY//$;3;=K[JM7A@VOFJS5C+MYFONC:?
MZ,;\H.7)X4%J80+V,F&./76.419PC!H+KB+>F$_TB')NBB49"DI5%("O"!1-
M';8,%UJ5G,KT&Q36WF(FS^=>OP\B"[[D4ZG_3+6AFE)WK4KT%/2$^OE,<;ZF
M*7; Z$/7ZPD)GM7-WIN+6$B/(N-H-(J?AJ4?8*8_W(>*4%ON?VU4#S:+^B5)
M_[72?=F0F$KNIE/$R7HJF,9H2Q_;<C[84L!G[A&M?&]3ZOFJ^#\-3&-31$$B
MYUIIJ0#+"/%,)!N#O+]XX:']IW=^>3[UF_]1I9[]'D>_ES>^_P%N>#SYL[(:
MRCM]MB'$HX.W_V3W.H[4:R.0DEPBKAU#EJ<(E^&HXE82J7)"O;XQA#AU!Q5>
MV=Z<NTJSTI9G#_16_KZD$U^3FW)K:IWD(LT,.ML3J3#*1 ZRDB7%F2<Z.LZM
MB81:(ZVZ1R+=)JAMGAU%>G+XYKW 6C#!$Z* $4"1GJ!<\0CFJ@&\4,82S7?V
MZ.YJ(73'E?2X6[=[QA4!;@AS=":]PATS#UO,0Q,S65@+4E1N\)D0*<@]Q\$7
M1$U8QL[B;9GF"C&78Q2@7A9F+ @P.PT\719",T>X\P.SVSU'&T:U8$CW1I.N
MDL8KNE$I:3>H"4N&:@68V5*%98^*5-,J*'8*TF9C6&>W\V?V!,_/\MSFD 6<
M-3PNALK#,%MA+;:T_+<;@DQ9C!5N(C"!XRRZ4020IG 0+F.UY^K9XU*]Z(U"
MZ2<JZ:(,8L#*;Z5,%0!TZ<ZJ@,U4:P#]*5Y4&LU2 E0] SH7O9P/>NEJP557
M 6._7U]<>?OYXWU;\^W4P+ +ASNX3$#ZE]F+TUT@P$K%'17AL8IDEV^WI+->
M27*7DR7E:^:A.<]AH@S$KLANFKYME!M%Y$006^W[LQUE[;+@H))B!W90..DF
M^6( W2L*VGBP=::=G5OWQO.NG^N"P^)!3O8:G7)%?5QSXJL>L8<X[^]!C9V#
M2"W+Z/X0I)Z0M!P'+;W_:V.A"XE+Q5]G7UL"28G51994+4CV4Q$BG3^]/QR/
MEZH;IC98+\>J4\HEA>':0%O)-/#<^H/S&G)T>P"B;32VHZOI.K-=/?VY#.;5
M,B!O$]?[J7,Z_ Q,,LJ>3[ :._ SH.7XU!9&]@+LN]J%K0:Y,QOV/.Q[M'*1
M8&86IYQW\CGK1W'];M;O(.-_?0M-)_.#Y43M9<18E"8Y;=66)G4^A_(,1C%=
MPN:+C);%5P;QPW#2FX5DIH-I\CNK8R_#N_,OG2?"5FBXQD,^0[HIO!8'O@)U
M33_ZOZ[3AE:/?2IX0J^?BX-\K*5Q% >67?) Y..5@JME$9$KI4(OS*MWADL'
MG&V:Q4]DZVK)7LHLF-]X;L_@.N%(/\;)+-'C\VG.9%K>0J7OAG79UKN=UPO"
M?R:$^E>5&"I66[!?KY!RZXZA4,%LKU\<B,\C##+OPTH-!OBY*G6CU:R7E<!*
MF85=[K-PX?D\]3F_U<6B"&_I+,H*N/$DVE"^WT4X4GCK"EDVGRK[F8:B'?6S
M7W06O"W"E]:#R1!RG5UYA/DB\CNF.N<:K;XXC:F\^JILKB+1:%$69KQ?2IY;
M((/E^RVN<T4Z+V>-+%0.9GHME)X"T5;"V.NV:JO=%@N6)<%5.A5\9R\G?HUZ
M$Q"/N20!%M/MQ%YV$^:%Y)/,PF84<W[6Z+HXZ&[G5?FQ4I?,]LV-:^MN^1W5
MJ9N;-S%5\4I17,G&X7Q],Z7R<I#Y,2PKE]6IKSG.O+'"9':Q3H9+5FVQSJ4E
M97,X&[S %XO+*TS@^7>53 K_M8./H\N+26D5CX?]3U52V;J'5X!2W6]!C=FJ
M'E^>G\_ILP-R;O"A4&B*,MEA?T'3;CH([!<)Z./)>"FT 3=8YHVLR5:9YGR4
M7)_A'^!^^&%0N"(*\*\R-9;+NX"U"]MX=BCWNV-ZJQTOMN5XC#/_95HI?/N4
MW]6_X^Y63D<<)/->."%4Y%8I32PCP?G 32Z^<C<X'9'8HAG--(]KL0[N57GY
MS]8%?GQPB _?O)=:AN"(1[FZ%G$?$_S$./+YQX2]3RSM[%WK ,\$L<W@0QJD
M-@$G[0)W$INDB6-4,\4E"4G<3W%(>_G7)\AZ?'S@X?W[XNC+_M7A_GMB@_7.
M!<0\S\U&A$$V!8JPPSC&H#4S>F?O2QRM%AM4B%U [PRJEUQ,N380SG]J%H"<
M6I<+-X]L3#VV=7#__K)K;Y,.5$BQ*AO@B:?4#K;,E"H<\]-$B7H^:'%FO\'.
MIM/L0;4<S][YY_Z?Q6-?@UW4FUQ.@,0Z?T2PXT:%+?<Z9S,-JLJ'I8_]D+,Y
MIW4LW>E+/];< G4':5SC(YA5O\Z+<^<5NZMENC63N)Y5]Q>\\R0GU*[M?#%+
MTQU>3#T<0U?:D5/# ?3#3_DJJJRX(G-ANHH-UGA177A=27'] W-?;^4*R4Q;
M^[9I4>7Z"L2YFWJ:J_O99J+(AL+<$5/L<.UCVYRY:QDU3\-ND^::L)8'3)J[
M,0EN*6F.".8T)@P+D/A"!0/"G_F 0XC6A&N:<#7"<[DB%=:XBVLYX#.O[^V!
M? ;!^[_]=HP$+BV?Z2_[L\KP7NR',LP(^#JY/,\H&C(P9SP[/[\<#,ODYJNU
M6#Y-_JBO=2VJCT&MG6)C@=1S4%P#SYL:)H% 2;.S"\-8-JDHDH(J/_GX<LF'
M.UH7 LP:P' <-WSU5 :6OMEQCO>-<R9!I3@LKJJ>3)WQ?YZ1?]VG;-8W^_V5
MIEMY.RN-MPI14SNO>=;,["R*V%;>9*&25%>PXAJ&/X]1K[@:.ZA\3<LGT%UH
MM;'@R:NN<ZGGQLH39CO?T/-JF -/H\5K*E7PY2#0_)E-=_S<FK.7T@HN%Q(=
M^U>Y#<D8;CDC:<R1Q-683G4+)7%F96NY[\KBD6_/YP5[3CK]:"N]:'H;*TI3
M5L?*4.9TUP^PO<6V,E5]R&#J.ZWUDK"=W!+VH@B.7H !#D<P=9<7D?=%_EQN
MPU9U9UM"NWLXS;IF'6SYD25%=>6@YUUB*CI"L_JIM2IEX_CCE^$:J!FO;3OD
MAZBBAWS[=?-RK86Q7KRM8;KQQ7 P+C+(\I5L]/B4;7B6)U4[[)0BA@N,.2':
M,*E(;J]GM-?2K.\-.W?ZT(4\PM]G25?'J>;4>0D0^'L9>?_Y"L1"M?B9DP?1
MY^;E.=D7AP=OWE,3O54T(LH(1CS(@*SV <D80O;P:4E\;JRVXMCY/U/>GK/_
MJLQ90:]%.BGS=\Z!]3+5-9QJ%AP1O]O19)#7])SIY_C OX]""8--0F @2,0=
M\\@8;!%)7F"P,@37:6=O3<OQ6]'//#>SUE[A0W_HBMY\&T(W%WT[R F7*]EQ
M\ F03K[*$YL7QJXJ8],RW7K][32?M5JOG^JDL[9H"ZK9;1:915>ID2W$),?#
M?IS&GY;*%VMK[I5O+,3^(E>MJN2U;501U_FB;[&&AHN_D\T:X*;6NC7E_DY=
M=DL38T4K72PK69>\OZF4I+:PKZHJ 8.>)R4X-B3P&+%VN9.%3U1+,.3C3:C8
M=J&[)W!\10_//KS/I2.2)@/2-/>LI3$A$Q,<?60""[@A&W Q;WEW=4KA+(1V
MA][(I?[^D/1GN#:8T1RO8YPDZKB0F(@HC6*6R+8+XD/1'SLZVW]O''=6>84L
M0$*>GN>1YI*"< Z6.\,<-D!_2E\7P;T=^:T"XY\]^,V.:I&2A^E[OM L:Z$Y
M1JV08YI6M-1,:Q7(2ZE?QB?'I:!<1O]).0-OE;6*S];VOM#NM=C\QDJ4U87<
M[5"V;6;JC/.>16%2 N6:1Q.E#J#E,:K!3@ADPT2UVV1>W,2\?Q3IF%G1>\;L
M^QJ>O?\>I#@.2ED42=)YQ@?89M0JI+T%X:$QY7#^>YS>E( !6AW813]MO/]X
MN6)<21\9%I@E%7GP3CM0XQG%QEDC5'O_#W'__KTB+'CF-8HZPOW;Z)!Q(2&A
M3>).,:ZH OC&UVD//VRE/;;7_MC7_N75>YQG^\ 5([B&@#CG"IF@@0 $DT3S
MJ'C.MM%T5VV\]A^[BTTW"T$U[U.\)!G6%)+9<'8YGI1RK+<4YRA\R.-ZO&GZ
MJ9G<O38\4XBR2L+-#,["XYK),P=IYM&FLGZF^*:FFZ&O%FSSKRFKG1?3]@8U
M7WJ5VYL/$G2+?'^+MOK\INN^B+*V<3F]_-JZW+D?8/ZN90UJV@=B]N#%SUVC
MPI1$.$V0+VMG;9$5EHMWBL3D65?%_O!SKMB:97H4Q;63W!'I]D6U!67F4N!1
MF?9<^(Z*/J:QK!);S-ZOFG965%W83>?Y"G)>4R\L1")7ZF91N?E9R6Q]H[6V
MIGE!-0_.IBZGZTH"EMN=YEI/N^*U64L)"XE2]3[B/VYHFKIE_=N\?VJ1*0)+
M#3'U<HK7O.E^T32SZ0R\59')-='(5>6]+-:I,BR^1:GFNNM=H:\R4Z!VH3?5
MGE05,HV_N*](4B^STNMB+=<%%*6EVRA,6A-L8DR82,.#P%IY'CCF0E#L*55W
M4)CFXU)C!J J*WE_$(YS\+.8MS9^F=-I!\^W5<MBJC+LX?-[.&IK".9(,ID0
M*$L8.1DQ CU6!R8D)S*/B=HUFU7F@D"V4IM#M$$1!:O7/&AOB-&1&2Z<E\S:
M4 [-;:G@8:B 'WYXS[0.6'&*!'$<<0;FD[% %-;P*$.*CDBWLT>N'=]35Z"[
M)80 < YB&9LJ\"(7M,=ZE"J_@G("3M;2BAK$J0J\*A3*HN6LJTPSNFXN1NKL
M%P_<A&H'H&-FD;M<?3/59'+KCT+'JOEX&P9W!Y<Q]RC_HZP0R&'6WC.>1E5$
M64_^^J<8^0#FX?'^^Y!<PL%:A)5AB#LG,VE[^,E*;>!FO/,[>_PZG\"V^&98
ME-18RS5<NPW664),,$(20ZCG;,-0\/;:[^':R?&)_^?XS?OH@,D,H\C&0!!/
M,2(KK$)1"$:(@LM@/LNU-<V?UB/:O!JRT'IRW7R9XU5*DVK$ZC0G*ZN_A9Y4
M#/$:YB'5XR+A:U ,]2YK8&V_T(_'I_'6C0Z:5)"S?;O[H^'$GS:[+N<X#U/[
M5$B%#KE%Z_A;][,O]K[22+[\Z\F\8W,NJ?&[G1^*%]9V:R\_4NO5/6MC<-M&
MW=UY;\UZW\W5'IK%5UW?8GLI"?Q6;;,7<\,G\\T7K;A0#(7WJTI#A(_^"^R5
M03%8M]_Y",P)B_SAZ/_]N)"F6(V8Z U*7\9%_W+4*V-,0$'Q?$WS]UD2X_X?
M,R]-Z0+I%7&I^O26HE'- /W?8?CP$7[N7YU?G *MP<;\Y216O[O<V <VT8^7
M'^-Y-6[O_+(_Z5W (9]?P1F=VZ4$E?(R<S[-]$+KMSE/7H=/S!8\3P":+KO*
MK%G-T"];7)55[-.1AV69$%S>-*A7?0M 9%L+=$,M$&EK@9JQE@>L!;JQMF>I
M%HAB@4'SB,Z1R+$7-L"G4C26RN0D9DVL!3I9%5#3^1SC6\WG6##%MAW/$0=P
M!#&6 ^L78+HFW>:1CQG*S1K]5',ZRI8]TS6M]T/.$7"VY#*U,$\1N P9#^?F
M:398Q]-F6+9S-@01N)1U>7Z>^XK$W3EN%\L8Q=ZY ]$=EV1HF:99[\&QO,#2
M=;RXI"IQ(CLI9UW\UMY(O4_/S$L]=="6G>DJQW6ZN;O;$D%TR^E<(#E7KZ0*
M1N5^FO#:Y\*:AR=<<V"SSX98;Z9>Q%%F?O_EJZ[+R_,X%^%5GD?'CWI%6YIN
M-4NLVNU7+N.:<_9P=,-)&3RI:DBNJA!<K4YB<+6R@\*E4/0A\J<E?_0&"1[1
M<[U^KVSH,[8I%C$Q>%CC7<FW'7FT0DLS=BGZU=J<-P4*7$X%K3I!P2&5']K2
MYX*5])YH)["S',QMRRC/1C<GGF(I>3:^P0XG^"MC\@L*_VQ#?Y6KKS+IGK$A
M_I<X.GCS7FM)M3,&.:4TRI/CD/5*(F*IBL90E63*I=5K'(JE+V[J>BFRT$'S
MKR9VUTM/;<GS!9'\U[@VP:>PS4>A+$1<$5#+\V:6*'.Q"++>_.A&=^.VE!H9
MD91H0S4U'/ZUVD1! VQ?*J6LR;F?Q%2YG]EUM.0ODFW?GKM/AOT'?G[OB ^:
M<($D%@)Q3D%_-UPC1A*Q5A O:2P[ 5Q+K.%R-)5\.8!;A=2F3N8.J_P)G:IZ
M8DK+IS;D-J@YW60<R[ [6.ME6PT0'.FR**J^7"EN6(+0K6B/><V-ED(HQKCU
M+@]6\-HE9XT//)$[H.24Y%X78U&+E)C7@_V40,#E'(8_+]VX%WHV1P+VQ^.A
M+_X*=/F?+*7_&]X.NWW.KLRW5T<GA^^3QV!P6(:BI 'QF#RR+F@$5\63X8)(
M[=?WDEH&T.DM9%A<5$;'93AF'$O/)*B"DR+[!O3W% O]=#P9^H^%(S2[,?(4
MM5K7S%/[J2B)W;(0[>M(CRZ3UZO_N02%Z3!.3H=A3FK'G\&F&)_V+N85:L^Y
MY@R>=;+_7A"AF<,*)6= &D?&D=$):,DHR9VFUMNPLT=7(R#_IS.<GF>9&02G
MO$I&.7EM8LO^P]Y>9/]Q23AEXD:ZS+76H9<]/*%,Q<A5R3%DQN]?+9D,<WHM
MT&YMA\+Y>[J= R#"T'F975S=SN'NP6ZW\_MI\9^:TQ;4@]]A[;U0#CP\[<74
M>56JJ "PQX!-OIH>]?/0C@+8%IENN\7D1WMQD8&I-$87-UZ^&:3^06&O#D?E
M]+Q?HAM=9ILJ!_<6G<=39;?60&$;U);,,!$]EYQ2[D"1"B$H81WF+@7K2%4M
M0J?5(I3JKX^@5VGY)\-]7]0@K&>XYXS4]:#31WX,:B\\0UA :1.UR+%& &W"
M,WR#6+=8,><DZ!'BNFR*-8#]7T5?K0S5^\O8# 2W@97RX,416':VLLP7V:%L
M>C']@H+0MT-Q&K1@QCD:@N4J1(-!:P40C]A(DX2I0MM+%,A:%+\SG1V^>1^B
MU:"3$F0U&%6<F(",(Z"OXF!IE,IBSP#0\9J,Y_]3@O*G827.*U"O>A+7;9_0
M"T5R,8CY6';'S1UP^PL?FQ&0G>=9=*8I%MTJ':]RCE8V6\ZL*.,LD_$Z8N]4
MW88*PLA>'J",NE1HN$-DWGMEQ>51L5KEI5R7Z[Q]_2"H25@X+RSGC@>-+8Z6
M&\&YUD CTFW(,.'W4S7XS,L/8'>@J6.OK<>1(.T=:%<\*>0\E4@IKW","52O
M7'6RNT:_6E35"X=M63M7J%+3TH(E=W6]7'5[@DG6,R53RC.P>%3.&(\)20'D
M%@.X)O?1++BM-[T%Z1Q].7POM%#$2(D\B1YQ@Q,R0$ H1"92,DK[H')NTDU&
M7A[LL.)IWD!.&X,SRV70V].6<EIJ%;$'2Y5CX@TC422J>)[:B,E-T^]:VKHG
MVN)'9_X]X[D7- F(.J<0EX0CS2Q!TCM)F0:=+=,6U>SKJ*L0[3G_8G)U$3L_
M]'8CF%Q5R@8(]Z/_5_SXXR8JG%)@=[D4MU9,42\<+F7GK$X([GS2+U6*C75"
M52;6>:]X6VW<7*<<-U>6T P'J^&LV8"^E6J@M4/$9CFIU3PY6T3JJK*%-=4(
MU>3UY?D959%"<0 #7PWS^?H*DTKO*N98+HRH&D_JD< BX/?_L_?N36WDVMKX
M5W'EG/V>F2K$EM122\J<-U5,2/)C?F,SR9!)P3^4KF!B;+8O(?#IWR5UVV[?
M ',UX*ESL@&WN]72TK.>M;0N18>$=(C:3SU?4O&_V@_=@LE+;<X6=JF:?G0<
M6AQBV:<P'B].C+4\1>S/=,:J%*R!,>G4VB(%V"UH;;7HP:.3OW%>#0AP$TCD
M*%OJ5I.ZZL1S>$+<6W#D-IE4<ZLN+J4@S>R7&S=O622OR<0HCJW=9NWCR(I-
M%XW%9&/VT4,?^I6/J[Q3V68L]A4;MJ'>J/:@WBC=52F';5 4 :RVK]ZL>MUG
M6K8L*+W=C)NK4\CFHGDO)SANQ#:L+0CXM3U;AOZH.:UD$DK>;'!IYJ;NG(8Q
MW3^PK/E0Z0J3"J"FF2XOB>?RQ;EX3+U+C6+*9,R9S9B*,$3D'JWSL)U."L&[
M63>:89L7N\J[D_ G3;FB 0R1/-,R8YKE0 DPI2X$X&5.Y\&+>R-EDP?CW:1>
MUX>,D9 =P;7?#QW+!7!B@S@87HA1G"'@RQDB)./6.RZP(C''AMY?(@(F2E!L
MF; ,,Z-9;$N=&Q5L[H$/>GI->Y#UVM^O[VZ'-LX/P=K6L",9PM'28\$;9#17
M*,NI]1[GA!K^YAW>S&Z<F)"2WR>BDXI:DC?IUE2K/:>T@P2E?_=CT.!1TT95
MW!P'SNT5A1-2R%X_\<$]_Q,FH;Y=VXI.N1[,S/MX>;?V/@41KWPBPK#70[XQ
M1QE,Y2'T1K-2XD-C<)JZ6D\ @N;,4&)R[@-E 4Q!9P/.O>5:.>4<+@"!8)RC
MX0^S#8+<H#O5(.B*P*B86?W*-GUC^SMN7!Z=P^\$GG&^NW6899E0F :DE(_'
M050B[8F"G6^="C+PY+ /(+PH1HX,MWZYAN^F]K>>)&]+"W[ME\I'OXXJRYX!
MOQ@ZAA)E'OY2>-^'51F*SHTWZFPR>:"0FIU5QE04U1B]V+A[K?.QY\W0BBU:
MC(?%P^OU!VY8]Z,2LIO,O6'0;J_OBV;*E8C=U:6,4R<)$V:=/EK8I&'X;K?Q
MW=T*&>XO?O+]<.@?!RF0X-4RABGP^%G?.H3I-B9( YPQ)XAE@2&36X],YB6S
M4F12VW2J?)TC+W9T+J9WM.<!RR=ZDX_[@]7^&EKUH3A-'GXU546/7H2C]"D8
MBH.4$39&I6A_PYZ\**(P>^-XS"(%Z:+\M.C#6Z89N&KMXE*O3\+'HD#A9>.#
MI3,JDU@IX9@CP(:99\#&B<LY<4'=(3EW'1^\I'1?-#X?\N <588@C#FH1A,<
M,IQPI G!DNL BT%CHNYUP@W25%4NI0MA<1PFQ3/]3F8+3H9!MW0[C LA5Y^2
MO![I&:-LBSE)%>.=X4,HZPVYPB_3[0R.CJ_>B0G^TUA[?DCMNZ-BT^[*0@A3
M+*#KTT]%99M8TL!.5&,8<\CQ#EQQ);DW,5-E0:O)/L.^ZAP+J<OY=8ZM&,8%
MK]IT@PJ]F+TYW"S5BHC,)7TYNKJ.>AO33]BH'7O=ZA^7M493>@=@$A"R=B^Z
MN\9]UIMEE[TB-*SK?S1AFDP,,]LHTU'&?QE6&!OSH&;?3Y.@4I@FN-+%1BHK
MZWMEW^]ATDM9 BU=LEG[E@:5:J+Y(YT.=:I'-8/^<:<[K)<>M0/<)3I.X_-=
M5Y]'R*_,U7#X+?]#)SH6%4#R2$^Y*N'&G=B"V<:[K?-1K\E'I>M\U-48RR/F
MH]X^OW1%O#A)=%.T?ZT,][^J9L3HO&470*V58G2;G;-CW3VM_?)^_U?XVFDJ
M%[#RWIP1_R#L!OZ<.\[&+S,7_KHQ,H9_E+,.&@ DL=D['E?TKMKJHT?\%>^O
M;2K1 '!=/*DH4U&Y>S6Q2M?^3@&F?PUB,<GJ:VS4BN(G<V9CY(<8=,\Z13K5
MN/=2M<-@RCJ8ZC$X$3$UUSU1U)EH#DN>PXX:'F##V*+"CH'A;;U1V]/-<]W>
MJ/W= 257^_\[\&G1F >>H<_@UZ*@QQ__Q+*!1='(7U>>*/TUE?:V>'TFQ,"6
MY>?_CB%H?XUBC].W>Q/9("-IZ?JSR$>3A;AD4+$SWG@2P*8-A.&0:TNT%!+G
M*K.9IF9HFQ&V3@VY5T,,-\X/J5=YD,0AF'<9N]=K) /#2/F,$<USS&/.)IL-
M74^=B6;DX'\F$T.*A!!==+V.U#B60FHZWQV7>HV"-P-[&Y-0=(U WD'V5*"Y
MRP66%"MF<Z8"SRVG+M;TYH)G:]E[(-FCNUN'1 !94MXB3FB&6"Y ]IBG*#,Y
M)TJSD&?FS3M.[B)[4<262I',1$[@W6PF-!,"Z)LS(I-89R >1O+2(PH"@>9)
MQLT]1J5O"*STSP/8'/ *%^]U[_C51S).R0FI'QVZ/&CO- $=F8&<9-@B$V2&
MM"""4$VQ<#J6Z1$W22P?.A*+4,:".OQGN (U"TLP\OML%#%%9[&:52T6OBJC
MG.8)W[#HY(R_:6,QP]*E_5^T$2M2'XX[K:'W=,XSIK+48PCD<K$!=Q7OFV2?
M)_&NYO6^+](#_RYF<BWADQ*>U<\/L<&* /]!&;$",9(%)(W32.4*$P/B[P2=
MVQ]P4KS3X=<L-UM>_SX[8CN'052WW4R9M?'<W*W%^=7&1Z7-;+4&7>@,NN,R
M1K^_KV]MU-YO"X"*CW_N907WV?[SSVS4Z[=J="2@F5C&R5<][PQ:KO"OQ7RC
M2LQT)?UT7A^TL;O[5CW-'DUQKH/^%P ):QP=>L^<4IPBI>/1(1<&5&7,4M+"
M9$"H"*Q1!))K-67J=#\G[#T>S3?+L/<R^+[5.0<X0#'DO@BU1T6H?1%0/PK-
M7QRLF1QLS5@MM?\V&WMKWOVOZ?[[W<RWG@AP %J;O7G]HJ-/OSC+3+5B7;,'
M=@A,&O"%)- Q5*D:(UWNZ5E7S_!,]&WM%_+K1*T0V)#SRW 6)S^M>/24SIV^
MMV$MCCOG&[5?:'&+2?])><-X%)!*"(^^4!Q2% H:OIS]&H-\X]_.CST(PP_=
M;"7WY>CZ$A^+:F9EL9(BR+=,)/J%_5IH'=L\&Y73'-?EFA.:L>(J9Z=27VA8
M-ZS@;Y6,ZQBS'<.9)WQ\/W1KD&9;%PZIB8/%5$VL9'*54C+3!X,I$1>>L5G[
MV/Q9UA0>*W+_L]D;ER&.8C?\WM2Y^6;MR[P6F)6(]Q13XU.03O$$>%CL7YB6
M?^*IHP6[W]6@-UJ-VL,\?/E>NG%*8&5BAY@4O0Z[_S0M]OQ)*S94LZ@<'?\O
M_MSLQ2UMTM5%3Z%:C(6*_9,CQ^GZ=+3<&I693H7JXPK;P>F@..A*%\44CTKQ
MJGAVV;%VT)W=HYNUD1J-)6 K2Y[>)<IJNT@$'T5JE ^?$?91<;LH;>U23Q0]
MF\+",^II4P8--TEOT8XJQC'<'M=.\_7#3NRO2(X9OW31 F!CU#FHZR,BIFY2
M109#R:='+UJD*Q2'\_"R,3'!C;.8BB*\1:>J9A=6*WHGXO%[6I9B$GJ%$PLF
MJRSW,.WD2GZ,M#YE(GW9M:FD]<.=7D[F*$UBTNN?V@]-9->7-TNI8F>%,7 Z
M 3D3-]@8OGG,VBC+HB?B'.=XE&,U,\M3Q06&L.G&:G18>'EV@=*"]OJ]!5"V
M; C0VO1=-<;Z];S^^3!35$BF':)*,L1<'I 2G*/<YO _2D17X$T8Z^9<C6"T
M_7[4!3EWJ%0.(?WWVZ.&JH!4V(FM-2OL4044A+$HEQ11)+X%[#K=BB@=2ZLG
M'(J7CZK?1M@973T&Q6$KDQFR6EB' $O=86WP!3PU\C_03&F? ZH!.?0 -JG@
MS%-JWK(F[BR8%U-<&+IWHLZC4AT519KP,?D0*OG!"^]PHS$.,W%OP<]'05QE
M5NV=F7I*G%V*JV_,FZ48?P0VX:D?ECH<!9NE%HG%3,54SY7<J#$$N3>FXJF[
MYX^T*72U XB.18-+S3RD7&GV9^>CG(5%=F#J*0H_]V)1_U4W?JI:_%CW9C3Y
MK&,M9NV/R=FH=E!R2%W,K1PTT9RIXC^?[=$ZXA,=WQM7*TJ3W3DO++3H3CCS
MR:>0ZM!UDQ\C]6@952,O(/0T]JFJT&VX7*> S;DG3+"\[<YITU:7=;.VE<IY
M1^?'9$#%L)I2I0/,G*DRWNI!ST]^<VJ"(Q:7>;9%U@8@?<S0AAO!L)MZ]5/5
MKTN&'<O!=/9KN9^6*GA#/54A$,(<9\%K(S!S.%/!98R+W-]'_NNXRFZ"@=B9
MZ7UII7]K]H_?#\"\.O7=#S]+PV6KL/C<GO[Y:@G@1*NN[0^D<708O'2.4H:X
MC74J9>X1L'&"#%4FERJ6FXL]F^05N9')%)Y(EBJA>:/<*"#-(Y5Z6X(0OS12
MJ@M(4]F2( %DJ>Y&3IE4?J(\:8SWBW)WHU#7)"#71AAR^N;Z=,[?SN(A0/L(
MM7PH?*V_59VO*'N,6+GYH8%BLZ#SR_Y[5>+CK5!@<G,7*4K):MMJN_?#%!@+
M^F.[V;.M3@_XU!X\\7<@=]^?=C>3>G.XFS^<U[>_PP[[?E'?MK2Q_?G\X-.7
MN#NS_;V#X\;IQ]/]O8_-QF7]8F8W[VV=[^[MP__OG#<N]W%C^_?O!S#6^HF#
M[WV@,/;C^K>=K'X9S;G]6 "3XD!T(!1QIPQBN;5(&AT0=LI91C.N)9_NE^(S
M*D!Z-?%,,L&(])[@W#L3RT9)E[T!:\;JLW@ZT!WX-^\JZY!VYL1*3&=.3NZJ
MN?&TUS]_<KRYC'W]<NZ,<<S"EY33F!!K95 99G9A_&W^U+MNR1#=/SV8D[W5
MCJO=:=>V!D>@7V-E=7E51&U[&+<1C:OX9I6\D6C^MF% G50).$E5J4&B<QS>
M*^:8)T"O>J+T&6B(G\G.!J6RD)+T_A/ZTSEH.@C/24X\]DQ;:P#1N7>8.R(S
MZG J@2VQG*(BV8WKHW6]W@TPQ45IX]\'S=9$4B5^9>A4W_O^\Q!K'91Q%.6Q
MF#JC'HA%R 42(7,8LQA7!'LWEQL@L;/\HA?U=?*0]VM#XQWT>1$C_#=(%UP*
M"-2SG8W:>]A@L%#MIBZ,E$+<4ON>9N_*_/QE!&-.6GZBTM-ZZ\](-?WN4/C3
MKHY9^;MAR%%?FS2<[+-#[PU607(D78Z!:W*%#*$":4N",\%ADL52S53,Y.*7
M]HKQ@'[MB"85 !IE]%5K@*M1YZEQ/S]8<3!X1MG=969L<53P@ (R5;?A*A'Y
M O;DN6X]??V&QY>/R_V?AQIH"P]<(RHDV")Y[&"CC40^U\(("M3 R3?O>M&X
M2 F@,\RC5!C-PE*OM(G2O5ZJC 4:Q/^,\4.]J;.1U-TJ)CL/#Y9 5*+#L7D*
M^N:'+P,2)T_!AA$]R2LYI;H*W]ZQ[MTN4%!GRN5:@O$E&<N%4IDD&=&,Y%(+
MV$+WT,1Z+[W@3N7]5L4L?GPB#=<<4BJT5PPCRF))84LDDB$PY!C/G 9;V%$U
MO_E'U0Z>%9OD>#Y/YXZ%R*7.Q:,8!("T"%+MT@LS:E<3DP93UP(#:B_=I_ :
M3\<&KO,SI_,SLW5^YFJ,Y1'S,Z^U#Z?L2<(UUAS^@;W.G-"&>#"A"<V]%BZG
M>!7[A>Z,BU,]OMVUC*4E,FF,T+'B'8/_C*2*&XX==@S#<A?= "5HKPGEA=>&
MUBVUU^4^:"_F,R<P0<*&'#%O&5*$.J2Q%YYBJU1*TF ;BLUQY#Z.H;6,7*P-
MK5M*P^YV/3NTTGB1,X5R;2EBF8X]<0Q%,-5&*6$!\60TM-CUAE8CTI@AYLPW
MM3;NT=:ZHXRL;:V;B,A>_?+0*M#%RCK$7:X0$QJL<F4T4E13DU-'C68K9&L-
MSHZZ.OV6XBZ[W2($[0H5ED2R1">X5SSY_N''9'S9^+7;*;5HD554UXS-M34<
MSJNUO>I['R[K6X>>@+D;TY]=AL'Z"B(>0V88&6YSF'0O749CA5:YT/J*L=6S
MAE7J<%1!L)5/K9KL94?4E04KYG&[.WC(I3 D*!E+8S+*K904:'J>:4^SG%!?
M]L:E96_<F4YW2[K*)^'XU=*W^MX.A0V02^L8R3DB@6G$G+1("94CL$N,HUP2
M*U3,LKV!JSPV54@8.$ZDBTTQQO4X+J;BWN"GHA-ZW"V@%+O?%]&\"-U%JXV*
M43!7D2M+0L@\48Y(ID.FA,BLXMR$/-"<A:+C:"%#:[)W:]FI,Y =E3%O./=(
MQ'*WS&B)8CXKLA)[KN*YNS$@.U(NHGNCS$K01&X*,V/-OJ\Q G-N#MJ46E\(
M-]V";=TOXNPT/LX*#\#.O$K)C51_(J).&OI>YT-BJ*\=>SYG(#_!42P$U<B+
MD,4J^0&I(#&BF>):!8*]S]Z\ZY]W9G'G 2%@S>5O%@/"&^>'F3"4,*Z08  #
M+ <] G:>08YX9RBGL&<LK*!OSR]U7=AMO2G#+4'^1LUT8G7#4 EY7Y;P-WN3
MF=!7>LGA-D5HT3+L?!E16[/S90 "QGMTB&40F0L*>1?]"<9@I'1.D;0\UZ!Z
ME*+YFW?TJA:[D9H6A52G(@$G"X_W^MVBKU>R\TJ-,Y*CBH%XM_,UP8BF.2@[
M*75LZFRD-%X2EV,?51*]P_G:-:+TM=^,I0O<7F<;9N'U"M;E$=[=WN'PC)B.
ME.UN'8+*-SPS'"BO9XAY%6*3#D S8"]8<V$ QJ*0S?;7G:FX?>4I7%E=83+J
M>>7MPLFJW&#_I9S7EN_W8[V:N%D @IO]45&1(C2]R)B!K=**RG3LLG%%\&21
M)A$S T -Q#V9"O"4(;.1YQ75CBOQ\S$[JI5@NG<,MD8O6MV3WZYL[]G1E<FJ
ME1'!\U?L8/S/8M1@5*0Q[XZ+6FVEO*[7NV?WOE_L?CX,F&BM,:"_\P0Q2^$G
MG&<Q: -3$7(>N(@'Y;,]E69J7"Q71-Z DI>*!!,]<+#@0CNI<I]Q18S([U)$
M?KWTUR_])?  I3.9.4=0)C6/+548TKD6\:A),^9AY6TLE#0G5V!JZ<?Y1W.:
ML V3D"8^FLY$F@DR?H H]*3*_VQJ$[TC3=\K3(]T4OV*8\YY)(0L!L)IBH2,
M#;5TS!K17B*2:9QSXPQA<CJ&?#5UZH0ZBWU7>[V4B3;DH+%85.'[:HT%H:P'
M$*O:1EK1J_V2=&9G *-QO5_?+L$E^BGN811V$TN<H)1,<];S;X<__ ;Z^JRE
M+]XVV^DMTI=^^^&[J3AP&74#-QU'IVSB(D*EWX7_=\/[EQ]OIH_^W7>SGW&Y
MR9E:^#'>)+?\+)/L5M^\:K!$;8+F>2Z#%9M$B!O=]M]IU8J5 Q&(LO1_WV1O
MQK%+*9_A+:Z1)$+#^]W/I?3L9[SXMYEXKFEY*V+$'C]?*0GV)'L?[;=7.!,S
M*;L3DW&-*,WF?5OK?0B_73$',8UF#O8\/H:GU]^="G2JH/0-I.+:][^!N"R\
M1XGF">S/^K5D0M7BC-S+W9]@A#?$I967F9LD-KXO8PQ2 :*IBD9 ?8#1%-6(
MRDI#Y=7+2=^B)9PSG[AVPUE])"R:/['_/?W2\]ZD^@;=^.65>H6']T7<Y)A\
M:)!.'G,,39&+4CA'YFCV/*V0X_W3GRWX#MNG7YKU;_6?</UEX^3SS_W3@^.#
M[7UR< +6QR6,<?NXU?@T_@X\:W! OX+E<GQR\&GG)UP#5DL=GO>Q>7#Z\7OC
MY!\8W\%)?<_BW4]?\7XT89OXXL^]#_WZW_C\4'$P"P,8+)KY'#'L<K!?C >1
M4A@'AT'5XC?OL@V<SY8_+Q.?KY?T"*E+2OP:+%XJ6-S2>[4&BZ<""SP""R>P
MRGDND&7.Q>-QC[0'L%"*&X-]'@/5WKRC&TJPQP>+%T_P;T+6_NRTCU"*2AK2
MM7CL\:CV %UNRN="]+,&N*=C0XU.VZXQ;GF,NZ@0(BN$IE[B6 :( <:Q'$F1
MYRCX7#N"XUDYB<U@-G+*EP.YFR+0/5*E]2Y^AC1EO8MONXO'3,5H+C(N".Q=
M!68-\Y&I4& J>3!6RZ LB4>S>$/BV5"=I]O%K\FOM.C?O4X_-OR]DS?S&A.Q
M]/:5N=T9+);K#.+I4_+X7>\+?/ZFY;W,P(O!^J=C;&N$7P+A&^^K/(UAHJBP
MB N.$;,6L#[3 F7<V2RPC D=$9YMY#)?$N'O86\\JL=K#6=K.%L-ZKJ&L^7@
MK.):PY@+@2UB(B= 6*5#RGB">.;!Z/3:8RD!SK(-(1?%E*T@G"4^^^\4I%,M
MTU,MD?FP95.3>+[O]/JO/E:M?GY(N<(L9!J%S.JH,@4R&0X(;"+-<@RV$7;/
M(U;-=D[/.NUAD\#"0BAR*F+4]Y3M,&I2D6+5*H6\F]7J,/[G68SQ[FVL0]I6
M(TIL'=)VUY V]4P#N?929?YZD9'[(5;F3QT81Y%NR\1U/4R(X$*M.4=QKOAD
MWS!J\$9O_.IF[I6'&$:5^Q!GB;>.UGMA5NW=W__%V+1W;:1R>^,V6@\OQ*[]
M^/U@S[+=;XW3QIX#F_0SW_WTQ_'!M\_G];U&JW$*UUW6>>-;G<_8M=^^M!J7
M1QS&3QKT,SSO.]L__=@ZV-[Z6:=?Z0&\3_WR.]F_;$W&EQEJF+9&(R\%1RPP
MB92T' DL%-<D=[EP;]Z1#9DORI)[L,WQQ$>M:Y!;@]P4R%%,B)$82RK PF=<
MBT 8PY2)D&?$NZ(UZ!#D\!KDGA3DQLX[')34@&0(9SQ##-L<*98%)(U43#C+
MC34%R,U6;5M1D'LI)]'_##O_+<58EPB/>=E1,/= NR9A9[@>:]2Y%>I4(]6X
MRD!56(\ 7B2@CK9(VDRA0%3NM309#_3-NXPN*A.R,H'[KVY7W8.>7^^J>]U5
ME<@Q6!*A/0$S);.(*1WKKU*.,LZS6%%+V!A7 %"WCG!?D;"Q(F"L<@CTA"ZI
MUQR#\:!3\V*P_S$=66MU<!MU,!%FIA4WH D<,KFBB%&ED#%>(>P9\RPWWE$=
M4YZ(O*\XXM4+/UN#Y1HLGRU17H/E0X-EQ0]&J)2!6$0\%XA)DB/#<@G<F< 2
M@>++"8U@B<4]^\%6-;AMY8*GWL?"E&<:IB%U2$BU_'H3)3UBP<M3V J#;E$N
M=%[^Z*BV9C]%:I2UTWV,U)A;RV[9VI9WY4C+5#J<](/_53;->+WU#4]V8AEM
M+P3)<,B1M3*/.UDC'1Q'FF$CI <S6($53*[J 1EKPL2%KPI7.U:6BR(XZ$W'
MW\6O_RBD*_Y]T%U4=K77+_M %N54X]U"C-.;+ES[T(&EL\771V'0=1W[2?0O
M7GW0Z>[6H6>48^DM,EHSQ"S+D'1"(Y$92QRFP3/_/().0?O$QF^ F""%80!+
M/#Q5&+7:22T?QR7CQPUI>E=4^IR*-[TVP+14=CD,?.5#3B7;%$0^0!0GSQ8_
M]-91G'0SX_0^HSA7RT29'\:V[W4WZNX(PI42>F_OXYCL[C.R& EFHP.?: *+
M[3P9)3[5K_55>V\3R/T"=%(W4R-%51+&7Y_"3_L*7 @OTQ7P"#FZ5W*ZH67P
M)<FQBQV4/C:CD1#Q\X6X#(#Z7_[1/#@YAG%\^7YP\N7DX-O7Z ;(]D^VZ/[I
MAXO&]@[9_59G,RZ#D^]9_?2/4QC7"3SGM/&IT3K8:YT<G+AF??N@N;^W@^LG
M<*_+XU#_N^)?Q=Q9*[1'7G"%F*,B'K>!M<&IPEX&0ZQ^\XYO8+9D2:FGK-,P
M^^R0_IO[;& =E*\RKL.^HK>"ZJF7OE6MF3D3]_+B 58%V[8'O@&#VCOWK1^^
MR+]9(]LRR%:-?'9<$ISG.1)&&<1\[I$6.D<RMG$EDDE-V9MW8D.1)0-TED*7
M)XHQ>#;(EJUKX;T29(L\;>^\LP:T90!MHC*>MYQ8%Q!G,I8HT#CVO.'(6J-\
MG@<O,_OFG=P@]Q;EO*9JRP,:6U.UUP1H\0!N#6E+0-I$=$_.,JT%-X@PK1&C
MSB+E//QJG0N,&T>EB9#&LB7#/=<<[1XAC:\YVBN"M(^=P=J?MA2B5?UI@%M2
M.I\AIQE'C.<,:6,)HKF74DFN%541T?ASJGOZXDA:GJ(C8L,<KT/?=VMKTO9,
M$:[HC'E#>-N*:[W&N-M@W$3/&FP"%RP@JRA#3 B#%*<*99XI;#GU#+LW[QA8
MHFS96GG/A;:)3;'2&%?DY$Q$S$R&RCPUI;M#D/D:"N^'[*T!<!D K'KB:#!9
MCI5$EDF!F-<*:4\4\C@(JC08LUX"R<LW*%FR:]<=]\N:_]U@M\;]\;;V5]?W
M8GSU#]T:^)IV)X->/^Z,-1-<>D)_>4;X][6B$C_\M'#I5@K"7X/A$F"X6_7A
MT9R*S%J*%% _ $-/D<ZQ1&#K<HLS05V>OWF7D0V*9YUX,S%HSXT(/A.TV_-M
M#6#7/#WK=GX4B271<CJ/'>>?F@JN$>_*RBW)PBW6;V>\?%O#U5L#US+ 5775
M$2LM%P:0"AN"&*;P4^PY%H155G#"30P0R>:T&;LY:JVHC^Y9F*\/P<2N^]Z5
M^8Q7IC2^]/SH^Y^@U8;XU>*T+[O?QR,%T^QM]>M-_#,I@*W#G'BC,LT1D;&R
MA(LMZCCGR#F/E;'!4T9OV<#HX3?/:\J9GJYZ74V$UEU?,SKFJ':*U.F8X7HV
M8=IW0OI@G/\RE3,(A*H[]XK8QG>SMM.&/1M_+#Z*%\[<?_*.L8-%3+!-2;2^
MUX?]W$_9MK9(Z=:M&JQSMW,>[P=OYC=K,;VQF .X4,. ])&?2J>-RQ11I]D>
MZ"2"U84JYXO10J^?=7K->,W;KF_!Q3_\.)'P7Y,Y7:4HXO%7M &I&_07?^7Q
MT[[FBP5A4Q-4^?>X.\Y[._+(=+W^CM))WUO=.M<7O3?_GA1TD/*I.9Q^_84O
M&<*#O62QN4$E=+IIS=^F_-9X%8Q)K\Q8:L?=J ?_JRFI94H'QXPU3%,MG1;,
M.QN 2UNL[:$ :I<29&'3O(\J-)U$Z'?S5G)*W@O]1KC&@-(:,]"U3FA#O Z$
MT-QKX7**5S%W>>AP2GN]R+SO=T:@XA.D+&JW>1%3^$MELXB0 '$PL OO@Y.P
MJWG'MQ*BM@J$VBY?[ N\UU^^:ZL=<Q%]GHSD#H4;CBYCNCT1C 6E4":=1"Q(
MCK05&&$OG9?*!LSYFW=RD\WZPOZU6=N*2>K%<L_)5-](HC*C)^;IK:(/TV"V
M%U.M.2E.<^LS+",\%0H+&\2^=8/N1<K(6T*0O@S?('VX!^,GKTQZ=O?JN+%W
MA'>WCW!]^XC4SP\SRXCF)D=<4(L8MQ))B8&I2J."CL5!@@4MB#<IG>9PM;@"
MO<T;=<J2D2\4S!)%\_1ME@]MUIAFV>Z_1?$O#X>=Z8YOFT"+FO;J;.^"#<:H
M'5 >IZ?-_N1)]A5O^: OL C\"8?A GW\8]"ZB/L7%_L7A@[CN*@E[I1X(6@#
M7?N[T]+=VE^=<WB[OP:P]U/]BK:K?6C[[M%%[6_?_=&T,+"M84V+416@9KL'
ML]<JU&3\2KGIX3?0LSJ:$7#KL^-.O_.CT^IKV.Y'OCW$A=Y%K^]/T_>,[L.8
MXM#2(WO]3@*8X17]ZOC_IU>SOM5*053Z[*(&,S4(@&2#;KPI_%2HKV8[SJ3N
M?M^HO8<5AB&WF[H@O*/B'#5X5QAFPBT8\%7(E >,F<J(#%(RBH/).*<XTX;Y
M3"E#BM::6"R!3,5QT<=F.WI31P"T&R(_B=#\VJ"H?KG#P3P6F8,OAMC:UY-8
MAU<@391#Q"O&A<MR85V,I9N//4F<FKW4U<_V"\9C8<]ZF.-AE2M8DPY<]9^!
M[L80/%CYJ%4*V1AN$KA%QX"MH<M[@(V5Q-ZWX+;PN"ABI2S'HC#=SFEQZY'$
MPHY/<N8*]C7<,B +HPW2GY#%PNK;2]QLP27F8F(CGS=A&X!).&CUXZL5@CS\
M<FD4P@,3Z=5G9]W.SV01 B@L4Y-K&<E?LA17)8:NN@W*4)&O9YWV<"]4IN7U
M5NBZ_,H:GP^YM%8&ER.69P(Q(QS2#K0UY<%)2PGWL;$.VUP4 5>6Z4H.!ECH
MMB\DX+S9/YX4MTFM$8D2('@[ F;+]\N-8T&1-,<*P<".",W^4')[A>JHQ<.C
M9BR05&[ HOQ<O&H9060DT\!K?>Z%CZ>]TCN*%1;84L,8S1=X.Y>I"?=G>K$>
M8'!ZK]U!'Q1<JI S=5C_^F3/GD?9\S0W)!AD>69 ]O*8U:PTXEQB2S#16<AO
M('ME6U; V&BBMCK1,@5-#% 6H34":JKN5DK+@G)P1K<B8M1ZQ][W%U?9NAD9
M?1(C/?&TJM*)=&2"G5G?C7L.K'(;9Z!:5BQN.;@&F!!LX(%NQ4T&["L:[L/)
M'93S>@9Z+LY.-,N<_^%;G;/B(!Z4X"1[@GO$R!3?VZQ]T'"38A_WHJG7B_JT
M^6.RM%G7ETJP!4K%QN4 -AC=+).:*JG6R>%W_7\&S>[(=YE45+L=WV/XKL'[
M7CG$BV$MP20+R5T(%\)B@,!TVA67:JIM:8^;_L>HAF4<=S, G8N^TR@>&S4+
MJQ =U>GNB1QT;1-^A6\E+VK\<[=SH5LPF<-;%^R@WSQ-)0OA@E;SNV\UCSL=
M5XP=6&OSJ!V?%.,=KADG#'/Z 8"=,)1X]ZBQ8_W$=B=ZE#LF3>AB^:X](P%/
MPMTK9;M4[;WA/F]'E&[!WP?=7N(L9M"#N_5Z\*GN#T4@2EU7MX]*.4IJ:[2@
MPS6&"3[2[>9E(@RPHK"PKM,MY..LZV>OCRM:O6AB6\P1W['4IVB6])VA_(_5
M*:P@"'/I79FW>),J]E@[^$H;53?2V= BLV/#<UG%><MCPF44Y]!P')O'(]=*
M'?X]'9P6"K3X'.#[U6K2QO8^:YP?!B9X)@Q&&JL 5 YSI)0CR.:<^(QC%Q2)
MFG11&.^0Q=WDK";-[[4N<B[?K+K'YDK_C-R\71>1!ZX7^P'T7/^B[OO'';?3
M_N&+8-_>=D%\!MV5*1.[^WZX$?8O&]]V^/Z>:]7I/M\_^<SKWSZP!@AY_/W@
MY ^X]]9E',?T1FB<U,G^2>NX0;]>'IRTFHWM[S_W]XY(?7LK_GY:/_WGI+[=
M.#XX_1(:>U]_'BJB)3$!K)<\!V-&9Q2,&2Y0(OEY+DV.2S0#D?9N*V*1 K*O
M<VFEX8()3[7!8!%YG%$)OS(V752V6(%:L02U\1K,'$!/5Q&>/06Z]M%/X@=<
MTI'9Z/1!X^TE]YD?@(9:74]F&F]AIYX,VE.&JO_I[:#J*"E>;.RF_*7GTQ]]
M+?]U4M."@NO,^$&/(YT=>4#'MQD]</1M&[EK<F'&[R1]G)[]?_Y+4B)^ZT6?
M:0P2^-L71DN*C$C:O.N#[W93,6O8\05?K?53SE1S))BIF=&R2A[L,IOG/EA&
M B,FT[GV6%BAO)12,!NABBA20%7QP^VU?<E9]SI;:2K\3IK*7G^G_?? ])JN
MJ>/[;[7=5@C-5A/LM=4IK/[8.%<_.2*'VG/OK8J9.@!Q+ <36L(2(4V=,[ 8
M.F3XS3M^G;H?VG9#*@P$NMTK92-UP%I%J4E>OMA?8UH)[HU''S]^Q2)RN8,/
M&?:QG:Q%F N/F)(.I$,91 16)L-&.PD,#5\G(ANE1SC"4W(*+W=\GUD)C\XY
M%UD6^W<KXPRHNV"TLHZ%Y.V=E0-Z,]:S>PY64^^X>58>VNLCOSKG]H^_Z)\O
M#ZDAS*J,(1$$\!]!8ZU ;I$U7&*6T3P3L.AS(L'_5>L,)S.Y@2+ZIC.OJ(>2
M;_>C-]V![E[,,31/M0-K=CF@R%3&O64YHY09#[:*<X(#_V$F.&U(R83ID E3
M*N]/O2S@T*\8+^*!_0ZOQTX+>U\O&Y\/)<T)-IF,,)TC1F5 2G@.E%JY+"?.
M$18[4?/-V>H?H\8=%08RE*3_&7&9K6GR D)V>NI=LSA1*GH8%(&*S0G%M#%U
M>)LXT^@!R=.U'$11)WFFC '5J9EP7F&<"T HCU6N E>E.V-* F=:IZXA:DDY
MLQ?U\T.8=Z.)4RCC@B!F>88TS@*RV!#I.0'ND$YG-V=KF_XKALKJVH].J9M*
MT#*ZUYSIX;)*7LQ1'Y!2AD<LO^#MOC OYVR>*UI_1'_CL.?"Q$=XZ9Y)C^#=
MJV#N3GM,Z2>X?J_7L>FOP/K_Z,#J_@.7#[JOF?CO;45T_EG?V[^L;]<C2F?.
M4IY[@PP7@-)"9L@PJ1'WF#MF(P\',X"HS=F:YQ/ME9:1#VPL"5(1 $C&HE0(
M8)(J]QE7Q(B\@$M,Z%H^GE8^2'WKT($&=]9BQ 5SB!GBD((U0L#_)2"LQH:"
M%L_F@&NM2O_+H[K6Q<:PW%3%=S%J9#0*XAH!5SQO*3(-2E [+7QF\8"K^%XZ
M#;EI>-_*>+QBSFH\L:GM_O#=5IR2WYN=,^ AI[5?WN__6ONS>=J$*7DA;K _
MRP/4*0_6["3<DW\LWBI]>-QI.2!/_S//=W82MWP\8DO=LVSYG*)M5NG4Z)>.
MM4@P1WZUF5%7?&QPX5\C3OIW\96N+Y-DTCGMDLS2&6\\"5;&;J,XY-H2+87$
MN<ILIJD90B5A:^/WCL[_[>^X<7ET7C^I7S1.OO+ZT2$6 M23]HAG.D/,NPPI
M,#?!,G9>9%SG@6=OWK%9^V6N*5R&/333@7*[%Z./"C]^"N*+5Y4D-(KVG!V3
M1#(>R.J:U=WN1;QZE':UA/:]G4CM-#[.AI&"R)YWN@Z$^V8"]WD 6]L!^_SN
M^__$H8_$#;\R:9NP8[:/+G8_'S*EG,%.(&Z]!7O9@[3AG"/CI: QCD[%\]!+
MW^W,R-MDH&BI&,N G!3-4#4$9E$WAARWIQ1LY3NZ/R5P$X_[GRNMCMF'76E=
MS_'R>$ZS@*F4PK!<,; DG%6<@@Q3+3,WWY984EKOARV^-AF>1LP&(";@"C8J
M1SQ0CQB/YPD,@S1[3 ,'+6E$ME0^N>?<J> %S2A +[$:,,LZQ90-/*B YYL*
MZ^5_HN5W++>>2J0ECRZ_C""XJP>+ 0Q_$3(P)N@"")LU'RJNBMI<+\7PKWC2
MPECA\,J1WV;&<7-#\+R5^Z;@#*N&N6N&L!1#B F54L9,$\=B43$=&]1AI+R"
MG[0)+C<X8T&M'KJN%WKIA78*2T>X0E)S@UB@,2C/8>0,C=XRJRFQ-\;1Q-U2
M98?2KQWC;#RLGY^TL%W3I0#?DCZ.V&-Q.A)+.W1Z*6NV;0?)OC47LPBU&8W@
MTH)/=PB#;LI2=+ZOFZWI1,QU)8?I2@Y\<26'FP=.YN3-NOS#RRG_\"R#7]5J
M!K^.HUQC6NOIF6_WTB)^B:#B78KZ28Z[WV,IG=&Y_VI$Q-+ZWT/=M',.G/N\
MOK</>N4KK>]].=Z__!CU#:[O?2:[GT!?73::=?K'R4QH^,D6!1WVLW$"U\/W
M&S 6T&O9P=[GGXWMKPSTTTF=[ESNGS9"8V_GHO[YT M@"=Q(Q#EGB %)0"KS
M$E$A&+=,.)[)Z9A88JDR6L"_3#,>ZY2XG!H7-&4QD$=,Q\3^'4_P49KU6G5A
M;A$3>_VCI\)WE>$YJ%9I<PI&B]/*&^N)\IEVUO'P-#&TU[G>_QB W@5V)J<<
MY:YSEFHL@>J.G];*8..==E1L,5WJ+U#4M5_^ZC9!/:<KXA]^+9PZ4W\=YDF.
MSV:&C^EW:KV8\QY)0J\W*+)!.NTRBC1F$U52YRH?;<3/X,M'W52$=32H\GMG
M*3TF7@-+_I]!3)-OCF)3AY\.QS+*1(EIGQ//@ ?XT[-6Y\+[WD;M-%E%O>%I
MQ+3M]7M'=].)TG:S"T9DITS9CD[:0:NOR_26ZLL7AP0QM[FX-,U2+XT-WAI@
MO=D[+@C2S9Z7HJ/^]K!NR:X=+^J\H97KJVMM$"7 MG9<GI0@%I\=/[IBV5-U
M@=[ QIRZ8B'*5QUOH?)=IR1AHW1 &V_AF34?0IE\!W;J+HQL..[:+_'+8[$:
M?D\/@/]W0<)AK&Z4B%:>JH12BE+VY&A"AV(7AST 0@?#L\.4O%1!+%5XZ129
M6NGP)&77%;=,MXOZM5RKZJ#BPL2;%CF_/HI9O,]R)S.WTD531E0E&K61GK$;
MBD.CK=[X2";I*9#MXI-* O#*G-4\OEJZW+\\S)USW!**"'$QZ]SFR'!J$98^
M=\9GF0WLS;NY<8J%A!=NZQG)F0*36F<\XS%<J.)]&MXHYN_Y]'E<C[;3W53Y
MH4S0+$MYI'S,"HP5" @B/D] +8@YF&+^IXU'BE=1(L*,,1SX+N4,%'&N##7:
M6(=I,-0Q/%<,KRD'D@0RZ>/=--1/Q4A!))L=]\I$;7?O\\4A\'@B0Y (PWX'
M>]QS)$6>(ZZML!A;RG$6ZP\M*#XT<3HSSM-, M KA (5E1OU.>!]F4(Z+%4P
M2MP%T6RW+C9KNZ4:!'D%!1SEY%C'+.AV/'COVF:LO]B-WVR5F:KM):'M5C*U
M&-J*\7XHQ_97'-HDOGW4S6[R 8V@+LE>E+N^WX;_?[U(5]_;RAJ?#VW.\LS1
M*'8Z%L#B),;2@BA*YTC.6*RG%@5P3B6U(4@%F.3::?*W358#G:8GD^!7)$(7
M;,VE IU#\1OB5__B+&8N@T!'WUY10U1?B5F6QIXQ4HC@,)-"2H)9;H2"-Y32
M!WU3S%K@<!R;;U4[8FN<H_W[Q8R%MQ4W7OKGGUBFM'U4@-T3%SQZ&GOOZ%!F
MQ&<L9$B9$',@M4'*8HV,\QC0#V?! MZ%SJ"+(L+-P-Y9FKR:&?13J03C1\*2
MD,TU@3UV4]G88K(+*KU9^S*V&1($U+ZVHQFS0-(**@B_W4#D/./,T]AR,L/,
M*ZLH=\)1)JU7/!=J+7)/*7* <$YB;DBN489)/"\&-J>XL<AG@$H$+'?'\@<0
MN14_*[RZ3$,W5L"$?Q9J]X+1WDMT]O2AS]7AMQ4U_EZ?Q:C(PGJ!#0ZLQKN/
MG>['03P^WRFMOE4Y_7D"!?_YO/[Y,".,Y@X'9*7/$*R%1SH8%KM_&VDS3!F/
MR3)B@Q*ZP<BLGA]:+]URAJ<KL\VS,H9^E)"68FR!@\B5Y]$%'[UQ]<R5":\M
MM$?!5&I;T5$!;S/C.7Q -_/?]MB[0<N7!OV,:JA85[WA^-)YP*OV-)\?.I6'
M&%F)A& &]H$)""BA0#EUV(88JDCQM.=XY9RST=P;9Y_U!J<P*OAZ;VCYZW+!
MYVW*M]?MM?)PLWB[U+U@?.R9.B; 6[;T6<^_'?[PFVOVSEKZXFVSG<::OC2G
MP4UYT*?4)LU5/.LK.^R4MR^/ 3?3,>!4FX?B,T8W,2<+/\:;BS^[ZK:$;G*5
MW^JV5W_&L]O==3W8ZS[+I'J(P>9X\<?5VU[3'^KZ3FUDYMHY'8R*0($GZM0S
MH_?2U%2\PT,[?:(QRUTGIM)NZJ9-6&_<\^E)HS'F3V?AE%^(R*LRS$Y8^2%.
M"V,1W7 7\5K+:#&SP_X!:.5EH.QPL/+C''JJ5WZ@R97^#+;4"BK*\:XQW7^/
M)#/^/*H2F7X;5OM.O\22WS?IQ+B>Z,JF/SKJ^EBS/F:V=9OM'AC;Z?CAL7G)
MDO/_ A[Y/ 3DEV:[.":=Z22[GJ+*%/6/.P.XAYN:IGOJW[VZ[6]_+VJJ;\QF
M_2P4EY?99WLY)[]7.<Z=DDIRQS336E*B/!,\!G(*SF^6V7&UD__6AUZE,5 Q
M5AME&,+S/@0H6KB>_G%ZL/?'R4&LG_'MX+1^"7_?<\W]D_V+^LEWLG]YA!LG
M\/>3HYD6KONG!ZWZ:>-[_?+KSX-3N/.G^*P_FHV3G8O=O7].=K<_T\;I_L7N
M]G&H7Y3M6V/_[HP'GF/J4)9)@9A5!DFC.7(Z@VTCLTP4 2H;+&,;.)NMY;)D
M$]=[[.5]2^"Z<3?KF^[X9]R/>MXK/E,P&_1BF%F"C7M!M)E*&/<(6E.=^R8"
MG-90MAR478Z@3%$7LLQJI$4L&VBL1 IH$5+<JQA^)G2,/2%B4RQJZ?*,4>R>
M*-S*;OBYQZU&B3RVD/(V8(:%,3S3. 38YD1E.!2%//'PN+7<XC?L:)?VLKE^
MNYNEM_O(3S!T$0QT*SH(GFF$XF-O>#+:\+"Y/:8\UA:F<<-CCJ0B'.$@<>#*
M.);GL9<"50M3@=8\8LTCKLUUOQ5_0-G3&$0[0V?99&Y\M@:7FX!+-@(7*@TV
M(F!$F=.($>*1S*A%2O&@+>!+'HL0JVR#S"GC]71T8FFW3DC_S7TVH9N4K[*+
MITPON94_9\Y[OTA_C@H4Z)#W2G/+I!*&,QL"_"73GA%+;Y*2\6@XEA:TM],N
M IH_=3N]E:F2]"P0K/&^XMH)6')"+$$^5QRQ+#;HRF(2"!78!8-))@380QLY
M$1M8R+N"V!5 \E VT=0C%T?EO"X<6.P*N2,8+.\3Z2VUX==^D?O#@;%?Q @3
ML+4YPDP1V/U,(<URBE0N<^F<<=2J-^\RMHGO[-U=80QX[O>XI_.ZYT'LACO_
M=M3N^1[5_;+*W"XF'L2L&^^V4RO9 K.+])QJ5L)H\=:0O0QD_UVA;CYDP066
M(Z.B9TOD 1FB-,*>9#P0JKU@;]XQ)C:DG,WHF8F'>(Y^[)>YP5\"9QON[S5M
M>P ,&-,V NNLI0Q VW*-0)PL,CF@@4]-#04..)#HW5:SA4I>Y6G62M[C5;GC
M/G:ZP3=?GT-NI5G;'3URY9K&>N5#N%]#^C*0WJS0.JL!T+&6((:>(28%19(0
MCI2ETEK*M T^M@7)-["X"ZU;83/\92+ 2Z!U<W;ZFMC='PI4B!TFTCB#D=(9
M1HSF!$EL@=@I92@AQ!/L4WO3+%_[XU;V'J\G?GZRD<9=/'(WSJQX[K _E_<1
MG@EB*!?4&V:,-IA+Z01CE @OC+J/\CGKR/HGA?EJ9'V>48V#"8@IRA%C'NQW
MJ2VBQDJ;A1QCS@'FR0;!8H/D])ZL^&6RE]9A]^MPN0<CN+>#NW78_?/ N0J=
M]5@JG,5>ERI&X7J-I @.<4L<%V#9"LY2%W4^V^GW53HJGQ.UF1MV?RO3=1UV
M_[PW_#CLGE*EM)#Q) *V.<N XH#=JI"/S3-PX(10E<+NLW78_9I'W#KL_G;\
M81UV_QS!91QVKTV&,\. 0V@!X,)R@G1&&#***9%K0!<9RYGF^3V:3"L4=[^Z
M[J"2+<<*D/?B$BK?OV*N9C#UKC.(=2G7/J$5\@E55G[M$UH:W7:K(?D\#T&'
MA&YYK%5./3)&4&1=KK##@4D:UB*T%J$K1$@8Z9S "@D2-)C;+D,*?D=6XARD
M2F8ZZ#?OQ :CV=QZ'?=TI'1SW'[B Z<[GS8_8_M@WBL^4^VY\G[&"L2M_8SW
M!WQC/V.FC;><"Q23_A&CUB$E>(Y"A@WA/I9_$&L!6@O00@'*K<L\MPSTI5*(
M60%6)0,NEN/,9L(30J.CFJA-,AM1NP[$6'NN']ASO7C_+_)</].&3X^- &//
M=3#"!I4# N1:(!;+.4@G/9+,<@^\685<1L\UN9^",6MF^DJ8Z1-YKN\';"8]
MUV3MNEX.7;(*NF09#=K% IH98CG7R&CXU3!L1*85)[$A/*%X@V*R0H3BQ4<R
MQBZ)9:=S__/,IRZ1_4[JY_< T8UEFZ4Y7I&UKWOE'96%J&RUW8=24/8Z\4_K
ML,@[H60UM5DHJO( ' RX5H@N<(6DS!S*+(U205F6LX<+B[R/S;D.G%P'/+P"
MA^;U4+AV4]T?0%;B*4UN#?<&>9'%8EV<(TVT14H3HG-I52;X.IYR[95Z'*_4
MTBBP=E;="0?&SJI<B#PP[V+%+H(8$P1I+CU23N=<,D.X#.LPRS7K>";.JOMG
M(A4?UJA7V#H,\R[@DU5*J^>6"$$1,98A%AQ& #D"$:9 &J1A%O.5#</\=^I3
M/6IL. 6."YK0TTFX.AGT^LUP\?C[=]0'7"_J?]>K=4+9$!Q^'"OBC9JOQFC^
M6.SUJIW[KJ_!'-I!2Z>+>JF7N&N& )^TK:\9WS_WOIW^7-[6U\XBLX]/CW\=
MCB ^(/YN6YT>C&+RHKCA=?OB__R7!#CYK0?0<WK:B=/9L=]KG>+V#=US^C^U
M3ZV.T:W:W[X%8XUNN>^^'R])#KI"HH9>NLW:QT[1_;Q_W/6^!K?L'_=JONW@
M7>9<OU&\!JSH:7K=\V$/1UUPEMI1+$.*7)SLH)O=8I[C._C3LU;GPH_?]J@H
M.5T[ARG[[UL8=\QS;*T"FB<MLYG4@6%JG5/8FHQEY-[+/MRE &OZ<!MFY2-,
MRB2B/E.SKN7_OR\7!]_<F:$LKY]LT<;>UL_&"5P/WP=T/*E_^Y =['W^V=C^
MR@Y.6B=UNG.Y?]H(];WOM'YT2#*KE0P.B4S'PGRQ^82P"G''!>'&J-P1,,[(
M)IOU\-?.?+>6/*.;M:VTB1>)*FS.:^5K2JZ$Y(0*KC61D@G!C<"<&4PS:;$(
M"B]0XWP)-?ZAW M_^^X/V.+S):_1:1? DX2LM]?IZU;U\_>=7K_1Z>][&+?M
M'+4!%,<%A?+7)U2\<72829E),/N1<+E!S'"%9/206F6"-HZZ0.+!$::;BSH-
M@ IJ10$!F1JTNZ.)+7 6)=LN0N]H%6I=7P _*(1!N6!#4"YP8:-V?MRTQ[5F
M;T)[&%^KW+X#,%'3LW!ZEL DCN8JL_=64#C'[#WO@*#Y]J.):P&5H('*/\7K
MGJEU>WO)/?F &UN'SL9*A HC+G* 0PS *$EFD,*:T8B4.J< AT6;UHU:EM&:
MTQ>]:4ZV.=F*^@J9"=13%0(AS'$6O :88PYG*KB,P1C\7)F9TICVV+M!R^^&
M^8JQ6LHVZKQ"H?9Z@]/B;WN17NW!B'YOP86O;-T;>SL_=[<.91Z<<<(A)X5
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M^/LKM<;9ZL7&9,DQ4W"4H7<F-3?K^MJY[M4>81/R)7RH'T[/6IT+[__VW1_
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MAR1'-6#KD:3"MT:&1KRZ9@8%-2X?660 3AD 8= ?P%^&^2OQL<VQI=#N]&%
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M +^2<#LKQ,+IM9USZBJ!\)@:W!N!U,H\5P"*)PH8'&CCA6XL 5021(5ZYK5
MM$UZ1+:\29-\IP8J=8'_E9J0-M/17VGIY/.TC+%9G!<P=KE&70G,/F'GQC*S
M^F[XE>W)S/:D>GL0$0P>>ULF;*L0[CJ.4B9>"2^+@$9!C%/ZB91#:EYBM?<
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MSDVI;K>FEAD=]EMYFC[8I/ $$'$,+(MV("5.6H!TYG^BYX!IBE0%[QT, ,2
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MB8ZU$2)U950"W#'6;<>Z)\=8]W[,Y=LHLB8NV,"4VLZ?<U1W3 \H8&34YZH
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M7*@&$RNG**/L=DG\RI9=M&OL@R140G0MNBJ.D,D&B_(U:;[*L;2$56D]*N
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M0'6AR*1;QBOT'[GSJP)P5MYKNY1@F;&Z5<H<,\EJU;&L16\J3<)D0Q?#&*I
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M4$?-9;;C,['/%[&.#D>?QWI$TT&^'&ZG^ D, @DQ65=2Q-0)#;.IPDL%/3P
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MP1^>SN.%KD(PL\IBD_M/(<YL"97/>GC$V+HIRO"!]UEQFY7SV;NJ"S?X7^&
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M=EX)W./$95$+=)ZRAYVR.E?P0S#)"7+[/-(/O3G K<(C[5(&P!1P)7C9::>
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M$8R,/DAU!6[;AV'B>_Y1Y>C6R(^RVM#!07 S9UI>WM\N94!F,3S&33C'V$W
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M9!(YZL:CS*)"80VBD02L'.7@ &/O!%!+<L754A%WYJBA2C4Q3$=BXO)V"+)
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M4VXU;\CM:*,2T'P4NA;F 5\25[,2[/NL =216LD&)QLB$&+7?,9?-=J'B<B
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MY=GL,G(/ANO'J=,K_:L'SK\.)GU4Y_O;7.#&M)1><Y-/WN\T.B2,5>H$:P,
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M2NHFB+@<PCY3_4>*=:Y)R0&R =2&J$:P_[N\Y9X]]"<0^MB0?]GH<SP;3IV
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MQ#\RE.GT7R'2D"Q00+8CVK"APGRN-A+R%272CDUKZF9BE?JV_\T;099]R#0
M^/E9<=/N<8=50U;.-8 >F3!H;J&N5;!<NH+:,;*BKN=K'2K=VE7WCPXWYT0\
M?IF3*(P/[U_XKQ(>\F(/#WD<8_F2Y$./JH8@?;'2UFMLE#*(^I1V8"S?D/T+
M998HVM->4#15B8WIZS[EOF^#V9ROE?J>420[6$% 'Q12UTDDE<[\")QH7)4D
MGUFESF-:V8O"5 RB5%^\4K=>#\Z8B\@==+ *M)YD%8K!;ME%&&;="-S$<Y\4
M^8Q5+>4'=9^X2+XH%RJ\3*8_S:4=A1OZI?OK'W4V^4A.1,TB:+B6W$B6":7D
MH]$21%2ZF"4KN[ITKF'J;AB%=D<$.7(1?,:V>60^AZ($@@20"9A5"5<3]Z8
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M^0LG\)TY+?-T78D8%6N\H<"9S><T$/O[0]T45LW4LS"WB<B'&%59K),Y$TR
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MTQ)7J7LHTW0J-IU1,!]:N/FF3AKN2;Y&0H3_,*;;]DKJGRXFI!LU$>7Z[7C
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M/-%=<_O.C+F/6]BWGRXHUB@*+X9=E#$0#O=Q][6 OJSHRYKED+7@NK)?"<8
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MIH6N#?VM8G]?:1TC7A9JEP,U"R5.*WW;4'SWO/E*BMV#,D=/I(#_W8GC/KA
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MU':G8R<ED0_3<&9^((GO+#C[W/?#:3Z!*T5+SF>T!86:4(H*YBSHRHE6";"
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M@ZMIZ^7(CD_V&"Y*YM!MZL02+3-=T\=HP]])R#SMZFMA^0J(OO;"U#67SF0
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MX%Z&[I?1MJ*13F:I)2?615'J @1Q*7@2G 'IN&9!N#JWD-TS<_)8/#@":G0
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MV%9W@-O!_AD-(S[Q-F8V3#>GZ0Q-M^>V\$%Q/%"U*M-!<>M W<9 $E7!"<W
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M]/B[3@0"-22[0O,M&YW?,]#&R/L9W(U]"Q=8ILZ2B#M8R7/&?4V&1!@S+/(
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MVO*F.YO+')@0HO2Y0 Z+JQIDF8MG=3#&(N)$;*3)!X\^?6>H Y%VO6;O4;,
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MG U539*6\*%W#';\;ME8O_?6TW?]=Q=R#4TO ->$C"W<^>8Z[WZ=/^ZPM]#
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M#'/7Q E)"4N@@W(A,K>B:.0(-;G&A*NFR&T$U[6!]N@Q$8/F,H$CWI3H1Q1
MK(1$K! YB$B57XX&'/T)W$X!6QVRVTBO:^-J?N=V>V7^BY_T)S/40M3,@A0E
M/\NCW:>+R1<,,0J4-\@Z9\WR*->^XO3/U@Y%O&)-5]#\]55K \*V:FBYX64'
M:&S9D48>57(+:7:]A6^BSZ4<D^":")[*4%ZDU'JJT.;/E.$/C!7-=N^]:WE3
MX\L]*WD;(7:MW'^.IOWAV;OB&B)E-^D-W+FL#4$_/1 95"1!&$E4F9H32R9N
M:C;%;-73]]S^LC/!C[J4VMJS^#]_6A++>_QV]H/9YX7M3Y!_*/__QZ=W-R+R
MBSR5O\71Q4\SV<QG)<XRMWW)PA\6BF$8^S"Y3\2D?W$Y@,?4N>EQ/]W2=Y_N
MQ3/O*;,%I?!M"L-4^H_TT\\_]JFTTE@=4;Y6*DU],F 852PXHX46O88T=R+3
MV4'?M607#ZTGWU54+TDY"*>$$-&4,00@D@L\YP#<J:2SX7*3E!_2WXFL7Z4T
M$X$?O!OF$1K&L\M4F/K^H&L-;'Q5/;TTYW!)6TFAW5]N=VGFTF3J-20*DG$7
M7/"0-VEKXTO;90Q\0!/;ES>]!S^!-.ON-WE_,XTMQG)VJHP;+ROMB'4B#J(C
M7(OLK./,+S=8ZR998#-9[9(NQ^ _Y-_AKP\Y]R/\<M4?S";6&NFI<=:2Z+Q$
M5FD@ 0T*XI,*0EIM47O-LBY7OV#_R0T=ZO9^ZF4'$JS0:/I]F1<)]YDN$ZD_
MY.M!D[T(T4".]KJW59E2'6,F2828=1(9@JD!Y\=).PET5-)$A42I511^PC/@
M+S^8#3&// GGHB*AA' D%P91+#Q1P8" P /7>5] N4/7R:-D5QUT6%IX4\,/
M0S^<OKNX'(^^SNLL>U(ZFZG@A/-2**U"(L%)3X3GEC'*\4"O@HJ'I)P4$%I*
MNNOVE _(*:4&?Y7K\UY.'A*8TC4SHELJ B-6)$FX$\Q*[IUN.$5D_3M.0K-=
MRK'#SH-WK)?[3/>0#&$L,LE\.8Z (MZH128CU8*AY:[SH\[*VJ>?CDI;RZ[#
MKDCSPJZK(HA"TBS$_V7TZ\SKFA-6HGXY(<!"8)I('2.Q/BBB<M3HBSEI V^D
MU$UO.1WE=B;+#HNL']E(_ICV!_U_0_HR>N.GT!.1L5D?.)<U1:.R-*UP&0CU
MT>.VDJ.DNN7V?/^-IZ/\*C*N4"SU'J93&$_0DQA#ZD\_7$TG4S\L[N>KBY)'
MU1,R\=(,N7B=*(&0*;$TE7I."HQF;Y12=2SWS82=!%2J:*'#=/;5K'_TWQ=6
MI<LFAL0)I!1*O47)N,5-+):1%>!2MJ;**)C5Y)P4(CJ0>(<Y9ZNI^A?TS\ZG
MR/=7_/0,WO0GL8#U$VYK'V$<D> >4*&2=XP$89%>HQ7Q(-%.30H<@R"UJ])N
M<UM"3Q@['6NIRQ2+1@1_@B+/NV$OUK-4.<N9(TDQ@]:3=L2)*(@-)B1 %U>)
M/6P\CQ/Z?&#55DLK8-514/)M?UC,KA5!4]9SW$::G"XS( "W4X<'; !/=*!9
M&I5!\RKEO8]2=E+ Z58/*Y#2;GK.0_(6Q^T?EZ/A-8V%8OR-HH->2CY:BC3*
MTEE#.A,0U]829[/V+,J<&Z8";?OFDT!%?9FO0$CK"9H?%U4FM[?*-SO>HF_]
MW%*?_QSWQ1ZE$O>]@#Z=]IQ(BG!&(RT1+Q/8Y,!FWZ3EU-9[R]:4G@2J]J.G
M%<C:.7CZ,-%VI5@6>;71&.5H(B*7<9*\B$0G1Z+@G&J4%BS/[NH&3$V(ZQ _
MN#<<!#6=ZV#5%>L/A>TT_7L<C/#)/_\X'5_![8>XY\&WZ:^#6;#HYQ\G<';Q
MP"]I#JY9X[?K+@S_@-'9V%^>EXSZ^7!20ZWR(B/IZ#N63$[B AIF2BLF8H:@
M^8HJL1V;=:ZCXO")[5WI>M2US#NN+O\\Q])=DJX'#C<@JNL&!&NI.4 OS6ZT
M-:HEZKWA $*9)1L8 1;*P!=-T?Y.$JVKE#W+.?A&,YV/4?^;.F/N4?W;2+CS
MCI?PEQ__>5VD+HT$P9$&%TKN=BE63DP2FKS,T:4D;;.,][M/W6_-=T=2'G4A
MH@IY=_,[@+<^]@?7Q9'141L5NL;,EE%*.EEB<RE^4UDI-&"EJ=/J\"$I)W=J
M=R3U"@E3]RE:(+P)337;%ZXBZC!="]LJ;*/^6TB[QO2&5;1I+B&(D A/)69F
M9$"P>T-2I)'A?Q2H*O&%_2'@D8Z$^P# -D*NDE9;[H6OKX6OY^HA@T9&2C0M
MJ2/E+M@Y:\JTF>"13^NTKJ'X5<3L/W;47DTK[]Y;R/B@%6ZS0_!]WX<B#OR^
M3G'0NK?4JPMJQ-=221#@XD_&6B]-E&B[N1Q,,#I*YR!RS3>5!#7@L#M]O1Y-
MIC4U=>_YE76TGI<E[1@-F4&TB@8F53#.N=+PDT=( :+<6+"UD:M.]/+',"TN
MQB&]O2H#>>XE7M115L.7UM/@+EPOJ36:D&VV*2E#I6'>*5&*\41R7*N<-ZIU
M>_Z;ZWKUL(M=%+CF22VUTH2^Y0)5RB 9T-D(/)LRMT$F:L$J)YTQG*V8#;!,
M:5OYM5@'FQ]819J-\)N3URHPX[25%DUYQWP2&E32(28GUPBUFVK1QV:SW+G>
M$)Y3D$")Y\H3F549/:8],8E3RURVJDX(H#F)K:]8%\O^R^A5Q%>-X;KKP+OA
MYZLPZ:>^'Y?BW6%ZE3,>TWX*DUYRR2HE-(',(Y&0-;'4>N)%  @RV+P\R+"C
M6]8=B-V_L5P)7P\N76MKKNN&3L646);%G=9&,TNCI[6@.NG2P2A84H9ZDN!1
M-EQI4ZHR1+#-:EB:O.WDL%%'SA5\[-7<?_AK"./)>?]RD2/ISZ#G*' \$@!Q
MRAR1WB%BD\T$ J/>J*B4K^)X-Z;PY$!45T<58K8/=L(U8NEEJJ4RD1&6*.Y^
MT2#%BGJ2;&EU&,"8T&1>9OMS:PV!)PNE*AKJL&3V=I+&#2GOAK?'YKWS=#(9
MQ=FG>++>G25;Z@18A)P-@4@5D2D"\0S*N.'@O,W1HY]6 UZMJ#Y9S.U/EQT6
M]V[>>__7U0B=]M_\^$^8_M,/KJ 74D@^,TVH](#'.+7$(>6$!VL\BB<J4^4^
MHB%])PNN&OKIL*RXL3065[C*4 81R9(2=UTO41+&4B(<"XZ:Z*WP!W%S]YKJ
MN"?H5-#)420^MIEXZPUCREI)='#HC02T(H- H3JP7CE+*:@F1OXS&&3>'6:Z
MFER^C>[V.W^Z"64OD\N[4FWS0=2[Z&6_R+$ALB %KIS2?5=:[HG3)A*A"N&L
M]%UM$O<]6L34FEQ>"3#;J&./D\MS4IY%[LJL;22KE+/X4@%! ^>E^"$GO61\
M/^W)Y5NIH>'D\FUDN*?)Y2IS&1R>G8DZM-E]24,)EA,3 4!8GIEHIM8G,+E\
M9Y5V(+N]-)*?;4N(HB0#6NJ:XV8DG<S$Y1!)9#%3#HRYY4:(3V]@1.>&88<R
M[3#F^VC3]29TG>2 B*T4TG1VP"[2W.> B,""MS('PHK5(='S)KY4#8BH''>>
M*I>:=4=[(@,BJBAY&R'N94!$8#X:G33Q7BL\E4P9;2X=P>,#*%.*T]N!-D]Y
M0,16@G]T0,0V4JN?/OMY.HI__E**15Z/+LJ\\'DSA1URF-8\J67R4A/ZEKO?
M4R54#E8J7'B>)>>EHBFCEJ3U4KC>XY2VE=_N<R V/J^*+!M,?XA6H$$B)<O:
M20C:40\T<I71?^0\ZS42;3/X8?43NY[YL,-;JNA@YTD/+EGPV4/R-DB6A'?&
M1ZU+?P8N-#5K-%-QR,/G<S^&AR\<C_WP;!;&_N7[[:\L+IQ?_>7'Z39L7W(W
MG8N&T&3+S%B-^VW6Z.UP0WDV!LW@*GEK[4GOI+_L[!V35Y/;S(W2#NCB8C2<
M_^1.!\2>BBK8*#5Q"GTXZ2&4Q@Z)H/(3L\[9IKV$=WCY 6X-]XNME1UK:VFG
MZZC);.'/V^O^ ^531A'"N#]*/4NS07M#$L49)U)%09S(0)1A8*C/1M-F1<[K
MWO"\<-&)G#N?MSJCY]=OB-'^!#Z.^Q'N(_:M[X]G5]\WX)VQ45B8PJSW+O=6
M4QTXT64@FM04T.A-: .KQ'G0J@R=;023]K0\+T#M67<5$OUVEM[LGW^BJX2;
MYWP5L5Y4U&:@FIB4RZQ%P<OL8THXF.C+S%Q'Z^3V=\C$LP'PP1%0(=GPSAI[
M[2_[4S^8'_2?8 +CKY#>CL;S^JQWD\G5;.($;OK&!# H*BC++S@2##?$4N-Y
MJ>?SRS<3'56?;TOIL\-E75U62##<65Z+P0HSDV3R;CA?2TM]:6<_+ ?&S8G2
MBP*E:U4DF=%,)..Q7#0%0@/(8#*:+K1.+[W]\OGL@'_,.*J04/GKQ>5@]!W@
M,ZYJM)]6<__[:'[1.C]T)E]&N!W<_7FIP/E]-/T_,/T$<70V+(,I>L(;%YU/
M) =FB2Q6E8T,N7.<@?;<\48I)]MG\M;BZ-DMA>/ 1H=S:ZHS-E_T>#8N/BJ_
MQWK,"R-R#(2S,IS%"4H"#XHDB2<C@^Q8K!*EVR^;+\OC>%!48<3/&\@P'M]G
M[I;E.T*?7/<_^?[Z"O]@..U)C[YT5(RXP- R1#.1>)TR4=('G[+5J4Y-Q^XD
M/SLL[TF[%88*K:4\K*=\X">3?NY#PM49%VP8GH35(I 0)2>R%$EY%33)"DQ.
M%%T97J64LB/Z7Q"[![U7F(5TF^_VJ#PGZP0Z3XE+D4F7&*Z^"*ET+<UX/E@@
M1@O M2A$UJQNS5-+#O96%G5@!_,@&C^&BJI/A:]9UE=&$R8;;8AVI2K:14ZL
M]Y1X"\%Y*BU332SB1N4(-V\]?$KK7A4^:BOXCBM49D1<)\DW(*/K0J8[[]]_
MU=*.&EC680OQ5=2FS5E$CP)/GJ%G(DJ1##= &,C$8M0@<WPR6MQ02=2M$K>1
M6L?*^\U_*S-L%H1(-'*L8Y(P'TK2)F,D,!8($^A>BA@@IB:1[$;JN_?F_1:.
M["S[41>"J]#A?7XPX"_/(*FH1 D:)&8&26T2<390$I+QWBO&;6BR"+<V_^Y1
M\3R/V/8*.41JP5I!W+(Q3!\'?GBGNJH)3S7[QM=@ZC!]YUM@9=L+JWTIND)7
MM2J\Z4"UU<!)TKB[E.'HQ#$O"5A-C0F!)WJ8I-FC >\C+?./'+O;Z+<&9F_3
M'*_K6'C,:!&@><$A$QFY($[:3)A.P95Q HJ:*H!;IN0(@X35%;R,N%;:J6#%
M?8+)=-R/4T@STOY C4P^??YC09Q@5IMB8E)=1DA)*4@ H4@R+BK*DZETB;Z1
MJA<8=:BU&KU(KR\F'V =H2Y%B@Y=%"7+A O<IC-:MSDG[V70$+FM :>U%+U
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MYH3.%_-J+O1Y\E>=K/RP6JC[R]H1<TO+JB"LFB6)8'D49S#DN;(+$LX@02*
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M%\MXE>9[@8[7/>D*S_6';2>FCTKCIJ6*+DX;L)1!E,6ZF14FD&(F8111S..
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M_D6<&GFV&FHK\?.J4A,\5[/]#-XTNM9..D=[<8"9M=S7ONA\#;TOWIFJ7?7
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MH9Y1OOW[6HWW12V(RD[1F<*S@!&!.,O4YZP+SZ=Q '.9Q!!%*4Y9)%@86QT
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M*-2R?@.6HFHO:\IK&1_*YA%,%]]RC7>\-%]VNQJOLS#P0K(_ >]W)J"6MW;
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M;O0'K[H=,:\:1TQSW9XCYKP?YF['#P-JP,"M[AC4OJ-J,=,_WBM5V\(&&MQ
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M=*0:2/U> ,L@L,E.ZQC'!]>E%)]UU%8[CMJ=\H'JKVM]!JH#UK[6371_T^"
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MHH"S5$A7M]ADWY?A/6P7WQ9Q[(+[45X5NY5X@I,_\)KNLWUQ=X?B%@%@()A
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M"J>Y08:I+1JU%KM.#V!=ZP&>;49(I0E@E2J@J'4!FU(9#PNUYXPY&/?#S\/
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M%54LSM.()Y%?>,I(@D^-[>QQF; NU+61&6HC-)C74I?I6W?@J1)\I$!-W_?
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M*VD4@"T-0%L%\-O;U1.;+ST/C7RGR.W8:$#@!UY%WJP69H2R[\,/=5 YR4Y
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M9G6,-W+GK.N:G[;/<KBG1RWE[[^OOC^NMH59)M[-'QXW2BTM/]7O-J9Q(I#
M=K=I+!#*8\A4RF B<Y(Q3BBA3EWVK@\U->)(HIB4*ZA'=>!N++MY(BQ" [.$
MD1,T@H)&TA*M/D65NV'S**P<#+Z1BBM;&#<-C*J!\=E<$ZJALQ,BG=65NY\P
M7H5E)TT.JBR[W=&W4L=W]L<':5Z1N9Z+\C7Y95N^KIHIP859@&0<Y] >+D.2
M*0E3E<4XUC@1VBD?X^I(4R/,NB:%K5AS*"ZHY/6MW'$)X&X:#0K;P"S:&[$>
ME3RNH'%S/8]+SQ^YJL<5-4]K>UR[H=]V;%\:Z+.VYZ9J690/_ZK*XF-E)=<R
ML/=G5BC9U'O=E[+B@N@LR<T6#1.S8U.9/;_D&-HZB$QE6<YSKU"\&^69&M64
M*;2PE!6TU?';U-TZ26[[OA&A'_J@TTH)>8EZ+2>X7Z_-):K\>9CB9('P"[F1
MO%6D4?>:@? [WHZ&>FS/1A=JLX] F7',8VF,+)AES 8N4P$ISS@D.HDRC'A&
M)?-QDQ\\?6I^\5_JG##/?A8'@-&$HP1'V""DL(WTUI RJF"2Q"E52)!$>3D$
M^P,VPF(1 C WJN\-P\#$;1$X*&([>/NSLT@$;?QQ,,"X/3_.Z7;2[N/L1<$"
M19HB V_8\]Q0SCVWN<%B,\,293G%&NI(48@08[8 "(,YYRPF>8QUYO5ANP\]
MM:_^S:.U2PKKPMZW1Z[B1<H3L5:%_[_='$!R:3K<:&,8D ?FE$MA)#NL:]'!
M;XWP80O6>B(V<#C)I=%?.Z+D"BH.0277GM"S#8DR7Z*ZT+&X,1:_*IO_9A[Z
M6;\WUB9;_+=BZYF4D8Y2DL$T31.()(L@8RB!6:Z%2&--H\SI1.)V4:9&>=9W
M"WY:EZ+:+Y""I]5R\^A;*."&N7'CNW$0'YC_*B7NP$EYI9TF=]:PXLK85G-Y
M!W;ZV##A2B-@50K8">5F6(/V2.DOS;C=4VY&[:2ORNU/]"/58KVI4X<_J<WC
M2E8Y=DK]8E[?.C==$"PH$1)&-,\@XII#QF/#H3+1G)(TT2AQ(<WK0TV-%/<)
MAW? 2GD]G]T7VV[2"XO8X$:=+UC.+.6.0P<+F8>T&,C\[9A]'$89A5W<M6W8
MP^..GO6>RKW/FRHXV":]9A'F"B:I,H3 \@32C&*H##5(KI FJ?1QF1T\?6HN
MLRJ4M EL[Y,T< B>FYG3&Y*!/_)*KCM02Q:P&-$YA8,6%3H88-SB0.=T.RGR
M<_8B_P"#^@E[P^#=4KYE&S53E.:(Z@Q*E$KKWK&AX()#A7644::1RIV6\:Y!
MIK: UW*V;69@1 565O>0@HN0=G_+H8 :^)/NA9%7$,$U$&Z('[CXZ-%"!ZXI
MUXX:N'KMC26<Z^*.Q<Z'&#-*:,K-(IU)"I'YSNTWSR!ABL=("ZQSKU3FBR--
M[</?[ZQ5+:FGH_8RIFX+>!"D!O[R]R U0@[B<+T*Q2#%GD\&>YV:SY=TOECZ
M^>(-/<*SWZC%0HG-O/AV7\?#YHJ(F,84)B*QI]U80I89(SZ*$4_CE!.DM'-(
M]LGCI\8".P$]XHE/,>O^X&]'8NCUO9$-? /W?2*L3Q'QB*J^"9F1(JE;"/WU
M_J^AHJ<O:MX9,7UZUWA1TA<E/HB,OGQ5S\JBQ^5*FX4V5\PVM>$P)=IL6&RT
M"8^X@$SB&*=,4,J<-BS7!IH::YW6_G59EOVP=3-B0B V,+OU \N_[.@5)()6
M'KTTUKC%1Z]H?%)_]-KUKU)I_N-\J3YLU%,QBW62Y80A2#,60:32W+ )5I#(
ME&I-(IU(KU+%H02;&OL$*E<.?K,:@E)%3](*-N6.KM97F,BAO;1CSN'8=>=/
M )]0Z?F];'^FZO,GB 8N0'_Z_)XE_&SFQN-J8>XHJN.NG3V#.,LS+B7$QIRV
MQ4X(Y E/8$HERUDL981RKYI]%X>:&E^W)?WW?R-)G/]G6>MD\^+I\>I UXU(
MPV V,#6VA?P/4!>L/Q_1/(@A>1VDH&7V+H\V;EV]JUJ?%-*[?D=/$MGEE;0S
M3UJI2#^_G*2>W/_.UO+SL[VP^+S=%!NVE(;@OJX6B_>KM?W'F4HT0[&*(2.<
M0,1L'U:1I3##$<]P'J,X4EX$-(B84R.O*E_26A^UV)Z4-<Q<.M+=J\_0T%39
M2MEKJWB0M\=?P-G4/JO+73.KYH>]LN WJRZH]0U)K8-.2%!:'D;2<2E]4+1/
MEH-A1_,/LWA;NZ:KLUQCZ<Y7\KWY76'^-8Y(;LLW4&56 FV6 ZZ,*9HQ&M%$
M1<RQ)U+G*%,C\D;0)HJ@$A64LKH'6EP&M9N2@T$U,*/V0LDKU.(J"C?$6EQ^
M]FC!%E?5:T=;7+^XGP7YZ[>_KWZH]=(^^\UJ_;Q:EV1D6Y7</ZBE,%OC_2:Y
M/C'3/)=<) IF5%.().;&4-3$_B%$IDC"B5=N70\9ID89O_[UVU\!L\*^]&Z%
MU&<JW*R[@0$>F&A^_0;VXH.V_%7/WEJ#@_KRP4OTW0!A2&.KCQBC6E(WX'1L
M)MWRJ![Q);6A97LS%?=_S(L9)YBBG"8P03:%..8Y9%+:SN("YXS('''N'%YR
M_/2I$5BSURD%!+]9$7W"*D[ ZR:FFR$9F')"H^$18W(+*B.%F!R@$RC Y)+:
MG?$E)S>-%UYR2=Z#Z)*+%_7T]FV?GQ?E!I$M;&>Y]XO5[Q^6>K5^JC:0^_.#
ME) LXC#C20P1LX&R&AGBBE#&N4IXPKU.AQW'G1JEM<4&<E>EQ_<DP1%T1S];
M>"B'=IRU42P[5%J904OH88X6_( *ZM!R''I<#Y4?'B<N)\_;^Q<S6*T/$WXM
M^=G"6,OJ,Q$XB7"<<QAE*(<HI0JR-*(PPY3+3,@LU5YQ<->'G!XM\465(%]V
M[EEI(&I)P4_S)7A1;-VG4,$5W-WH*2R: S-3)>R9P@/?:UP;F<-6%G##)W0%
M@2NCCEXIP V%<Q4!'.^\(:KB0U%LE7QK=H;+A\I35KK3BW=/SXO5BU+E15_,
M:_AHAK>%D(L9)I&@&2:V9AZ"2&D%J7D!8:)S*K#0F4J\:*FG'%/CJD924%A1
MP7,M:UF8NV2KHE3(DZ[Z3I*CB34\]$.;7"78E0J@TJ'VKM]5YY/%'=C-3'5Q
MHTI9>3Y@K[(;P0P>_M%#E/%C0_KC=39PY(;']6VA4SG;U/]:S9>;?QBCT6R;
M:H=SEJ,X02*#.A<*(D)2R!B1,*<(RX@(%B=>29@=8TV-#'>B@E)64 OKVS_G
M,K9N_!8(L8$Y[ )8@S3/N8I'V-XYEX<;N77.5;U/.^=<OZ5O%XCW\X5:OS'/
M?EBM7V8YE0FR<0,13Q)C5$6YL:>2%.:"Z)1E@N6Q9^^'@^=/C1KJ_@6EC* 1
MTK?-PR&"W600 )>!"< /DAY]',XJ?G/WAL.GCMRSX:Q*IYT:SE]V:R?YG3FA
MUC_F0ET(4EJ44U-&QG]58O6PG/]+R<HJ*2N=[YL"I RSC"$*-<O-EHI1#FFN
M).09BG6>ZTPF?E'L0TDZ-3)IMU&_U-^A*7+0MTE]Z,EVW)I-80J'WKQU]X:X
M:V9.EL$+=3%9J]<=N']:;<ON$67H_B ]) :?@: [OL&$'7=/.#3F)[O&P0?L
MNZ]\>EHM2TIK*GA$"(DD$3#1FMON/ACR!#.8(95&-,YX)+U*&)^,,#5NKP2L
M:-UWXW@,GNMV\09(!M\D[M$89&=X0?6P^\'C04;>!5[0\73O=^G"?A_SQ1;.
M'W<IRS*C(LMX!E/$S=>M[=?-XA0*&N$\$6FL!/7YNJ\/.;7/O;,#^0U9Y0[@
MN[%#6$@'IHL :(;KZWX"T"C=W3^^3DZV.PK.G=Y/[PS,0]_-\^K"U#Q*59QE
M",K$%@K3&8$<<0T3Q#&2+).4.$5R>HSYIV*B.V %#T1!+=QOY*!^: X==;!:
M/L"/\Q]F _?=_'YNMVIEN=N )<)[(#,*^[2&G0;]G.+@S#]G;ATY!_L]FZ__
MP19;95Z?[5.5VO=U7OSS_5JI#TM#"JK8?&4;]8G],7_:/LV(Y)&2L82H#%2@
M,H:$L!32E,1QPLQ6B3KYU,<6?&I4:!TP8F.^W[61&6HC-)C74@-[.'('GBK!
M1\K?]GT/''UM$YS=$5UO/7.\K?*@U!ZTU+\#%@!@$0 -!.!K^:I\NO*JC)?X
MW7/>)I$*[BO[GR,YO.>,!$L7[SM^:$-\?R24)R3.E8"24-O,FV)(LPA!BC*:
M9%F,*'4JV.L^Y-36GO;93B/]H2T>R@KW/)H)"^7K.@(&/#]QAVD<@_QU3C3<
M47 WQP.=,?SZ[;MMV+A=OYSD2DM.2)1("O.(,(BD%,9^5A'$6BB4I['YK?!+
M6[\TU-18I\Q.W]3"WI"??A%:-XX) ]C W/+K-]!(.71&^34TPB:.7QQMY/SP
M:UJ?IH%?O:-'MO=7)0SK+%[NY>K9[ 7OA;!G[S;"=KU:FA]%:5D57U:+N7BI
M_MPOJ7$2YY&0MGJW3; DU$:WQ3G492.2.,]R[9X9?HLD4R.:1A=0*P/VVH!#
M=3RRJ6^:JFYF&G4"!B8N=^Q!I03XK?ZOBZ44>%H\$N+'FIZ1DN=WT\3J:6+[
M:7H^T"A4[X80 ':FX=\TP'@I^R%P.$CO#_+  ?+<?E&_E_]4S#1/-<Z169YD
MFD.DS5Z;IV;K'3&6R21!<8S)[(=:\U60Q+;=P#[?77OXX3X[*Q<S,U+EVY9A
M)U5.6UD]_'G+S>R8?].JS+8:)K5M/R^.+MS@6 _M@'5(7#-R5U>,E:5V M1H
M26G[D:>3@W:"AE?*V>G=/4SOWO[,JG3RAV6Q69<K=?%Y\ZC6WQ_9LBZ,^7?S
M"$/$_Z7F#X^6D VUL =5=1@WFC0YQENV*$NRS&*F$=8QADF<VCK'"88<*01C
MG>(LDB1BW"E :5IJ36U3T,@-6"4X6#>2 ]O9V?YW,=?J#CQ4>GJ709@6_"Y;
MCLD(.Z7%H^S2<2;5H7UZ]W-]>E=?=W!ZUQ3 ;Z$#2GB Q:<IWPQJA,#NM:PQ
M CN00 NE*T6NIOP>>NRQ)B/T!#=L-[^7=VXOYEWS9MZ%>37]-HF3>P,Z=YS3
MD7:\[>MT=#ZW%YZ>='U+6!D!;:N.#T_/Z]6/:@=?GW(PB3'*9 1MJ0,;1LH@
M355B?DH2+$2>8>V5T=@QUM1LN)VH8-Z2U;=*U65HW3;$@0 ;V)#98]46<X 3
M) <XPI:ANCS<R/6GKNI]6GCJ^BTW)U"73/9);1Y7\L/2;FW*43[N4C)8GBLL
M$(=Y;O:<B"D!N=0IS#C+),ISJB.OVBGN0T^-3MIA,+5Q5 D/6M+?D!_C,2F.
MKKA!H!YZ1Q4.Y5L2C1T!&RAS^-KHKY4*[(A*1VZOZQ/Z\=I;I=5Z?6C.[2VX
MEF%G1F1\OC"RO-FN;:NY69;+),O3&'*=QQ!E*H648P49)[$@B.<I\PI4[R_*
MU'CO7HCUMD[]7Y4[P$4M\=SZQM=JP>RV;[.J3Q_ HS)F!'\!JD[DKEH>R/E:
M"?/]%6#SR#;@=V4VGL66_X_YI;UWK9I"?7ZL><.4N['H.!,Y,*LV2APZ ]HQ
MY6U%[L!.E3M0*Q..96\'-"3KWB#-J"Q\.VK'K!S@B?U8^M-JJ5X^L?4_U>;]
M=BF+75T%@F/-.=0))1 ADD&&4 8EBGB61%P)X<7 YX>9&KN64H*G4DR@K9Q^
M_'<!3#=NNQVB@7FK0J>2$)0B#K E[48A)-E<&&E4(NG6]I@DKES=YR2U+B5^
M_[!6);W4;RQ/L*01B:!*LQRBB"%(2(9@3G.5Y&D:8>3T^7<-,K6/OQ$3[.3T
M.;2Y *3+4=[M\ R]#3Q!YOJ'[PZ1SRG3[5"-=>;3 S+/\Y9N++I//R[<.^)9
M1+?TAR<#5Z[M9_B8G=3V:5MNE]ZJ9[,=FI>OA/EYH<J3AZ6\?UJM-_-_E;^_
MF'<RRX@0!,L<,BHT1$E,($GC&":(,4F4S1C!LZ5ZL".Y&4NA1'/Z+FCU7;0%
M'-*S711_LP&KC7Y MA3T,[:"3:";>3;JI(S#ZRV50%NG.[#3JFJ0V-+K;I=U
M6.?.W3EF'WI;@J$!#VD[!I-M5&LS-*+']FGPY_=)RUF]L,7FY3-?S!^J4:I.
MMP:,MT:PS_K]?%ULOK&%FF$<QY2G#.J<V?:,RABY,I4P)9%.1)SD,8[=DW"<
MQYV:W5M+#E8[T<%SU8FYC&R6M@3[2@-MY0>%4< GQ<-]-APLY6$P'IAD&WCW
M4N\:75MXK>#@LP:EZ.#;8/#ZY,L, O-8V3'!X/;,D?$&K3LCQOUQ(^:_>.MX
MF.WB?WL_T_X7HPLK'JLSK?GRP:PM[^=+MA3FY_)D:]=S,8LDSG*L($IS&[]-
M4LBI2J$FBNM(Q5GD=Z#N//+4%@$C.+22@WDCNK'2-_,?Y;F29\-+=_C=+.]!
M0!V8]6N9P8<]G,9*WHE=G98/TO?2&ZV0=K'[X*,:OMZ8'%NV_@\8("NO_,<Z
MIO'='VHMYH62,ZID3@25,,N0@$@:4Y;E)(<D3U"2XY2A5 9K/'=6A*EQV<5,
MO>VS^5'58MM_K7Z]JN/Z[1?:?*WF'[]^^_4_BH$2^<Y/I4KB6*1F%HG,,$28
MF5G$L8":94@1%<5"<3]/TD"3.:K/Z)>M]?;9&5DU<>[-C#5S*4>=)K=5:]CO
M:&B/_^V%\'9)"8U^A;$M:EM\I,3-3I1'2^(\+\5T$CH[4?)*[NQ^4K\5\6L5
MT?2%K3<OW\V[5UBSU#Q_9T/&*98JYPQ2S,SZET0,<DE3VQ "H8A$.>5>19FN
M#3BUU:Z6%Y0"@[;$+N9E/\S=&# DDD,[:6X"T9NU7)$)R5%7QQR5D5P1..8?
MY_MZ-I@Q1K[]GW5%_V +&V_UU5B$Z[DM]VO_P1C^A[]H75E1X8>EL-6FU%M5
M_=?\?;&5ABG?_2$>[=II"V:^TUJ9[XC2.).*$YC;AO:("P4)D3E4&:<YT\;N
MDV2V66W8PHV[QA7?BPEW2@QH**H-J&2TEH;=K]V5?P*U5[(T\M<[",I_]VRC
M,^XKXD:UTYWX@8G[33G+]D_0TN@.[)6M_M%.^_'O#FZHG<0-"N"G!H>_W($=
M%*#!HJS=#"HT K8;>I59#-K+:%P-QFV4]"JS<]*%Z76DZ.V(MT>\S+I4S"BK
M)U7W+IPE*LEBC2A$+(XABBF!A$<*F@4O$521G,;"9^6[.-+4%JGO=HPZ=6->
M"@I^4I6HAFF6RK-\\V6$G7WKM^,VO"]])R/X4&-6BWG9V]/'<=X-16!'^87!
MQG:,=^M\QA%^Y8:^6?-%H=3GYM%EMNTNT^$3V]BRK2]E6>Y]"4C"9"($R6&<
M,&FL9RZ@(8\8*IQ035**S?_Y9=-[RS U9\"W[=,36[]89^G[K>W-#DHM&M]<
M 7Y=FCFI?[G3S3<+WW^JW,AHX D8F*8JZ:WCL^&J4H&#_*U&B4%+S-\ 8]AL
M?W\Q1JX"T!NGT^H _1_5CS!WC7GW/M<F=8LCB54401S% J(4:\AQ)B&G<8JP
MU!0IY4.+%T>:'/D=G.9M5J!)8CTX!?0CN\LPNU%:$/!&/.PYVW"\DGN 9*^K
MZ(3DH\N#C<HZ5W4^YI;K-_1CD)]9,2\^ZU;1X?.%MC5!.,\Q3')-())Y!+F0
M%&H2<XP04E@D/G3B-NS4N*64NNJYHXHFBM&/2ASQ=N.5\"@.3#([ /<BW_4I
M(^_-,7Y(A20<QY%'91\_-(ZIR//N?KS4*D7R87FOM;&AV$85W[:\F,LY6\]5
M<5\4*U'^]GXI_]=JOMS\PUQNMCO%3&<DS3*EH/EO#I&*-20TC6&FM4Z5-N80
M]0J'NDF:J;%87</GJ:KA,]^IYD=DMTV0&[^-!OO M->NDS2OLZGDCS(ZS1BH
M>\7N0%NU.[!7KLJO*O4#C8+AV#$(SB%)\S:!1N72(-@=4VR8A_:,/C6#J/^]
M-0][]\,*L(OWX#A-:)39>DS66R^Q@ 1I!5.)$H8BS+5RRI2Z-M#4^'(O)Z@$
M[1U2<Q%:-SH, =C0N\@^6/G'^UT!(FA4WZ6QQHW=NZ+Q283>M>L':E)>7*K/
M6P<$OE^MM9J7-/6ASOPYJLC;A Q^6<^%FNDD2VF6(2@E1Q#Q3$+&S Y4DHP8
M&%&4:B_O_M@*3(W+&EEATT1A%PC_;,7=!U7K2L\ZJ%JN%@NV+FQ*:!5@[1M?
M/?9[XTBH$WX;1G3W78KM+ER#NULP[,.[S]2?;\  )1HC-CL?:!Y';7H>6H=I
M-3\?:(:\FZ /)4=?+\AQD$Y=^O/COMZG,?_+6O?[<Z?]O\U4)K%,S0M'LHQ#
M1 2#1.D8XC2.=1X)$FFO5NFW"C2U]?"TDJJH"BJV*ZKZ.D9NG#-7W\AX,S&X
M>^0DW-(N(\W<M(0NYZGJ>=(Z8'>8J1XND3#PAO6*W"C3R(Z1, B>^D8"/;='
M79E?EW-#\L5\\_)9?U=_L.+3VWL;2U.LEF^L.V_]QE"'6M>'PU%DJ#?#&<R8
M,.2;1@I2D><PPCC.-8JS2#J1K__04Z/9O?"V[$8I/OCT%C0*@$H#4*G@4?K$
M;SZZB758E >F4"^ ^]1M]$/:H\[,8(B/5&HFS*OM5V:F%V:=E6;\GCA>L9E>
MFA[4F^GWA)[N,68[*I0A&K^85\8,N$].>[NRG:9F/(HP85) 30B"2&$**2(1
M9!GBN5D=$JW]"C5<'7)J:X&5V(8 ?/./PW+ U]'Q$Q2UH5TU;<# ;Y5\(;WI
MSF $]7=<'W5<#X4S"B<^!?<[>YB<G^8+56Q62]5$;\\D4ESFF8;2QKFC*$.0
M<VK+<F=*1EC'"#M1R/G'3XTN[A\>UF6%$?"\VA@!YVP!GAJAP7,MM8<E<PJH
M@UUX$TP#\\-.MEV _TUH>-AN-Z$RDGWVZ>1=^6L@*^RB]IV6UNE=XUE3%R4^
ML)@N7]4S2/ULAZG/OR\->SS.G[\H,]/F-7A0LTSGB>$P#I/8K!DH)PFDRMA*
M>9Z3.,.:90)Y!:V[CCPUTMN):$_<:AD]0]:=07>SF :!<F!BO-2L[@[L\?UR
M'5__@'9?K((&N#L//F[ NR\F)P'PW@^XH?C>82J-(E%$B80J86;+EIB?>":9
M^8/':8H1$2+SKJTW_12:2L(>==1Z),A,.3&F9I'!TE]&27MYY707YS27T.DM
MWXQY69[K?M;E@8 ]]5VK1[4LYC]4E;J\"\)36D:,2 E9AA.(4FVL#[NORC))
MTE1ABB.O;F<>8T^/ 6K1K=^A.F\[D+Y)P.\=".DQ+:X,,@C80[MVPN'<@W>\
M$0O+2.[#C\Q5WKB<LIC_(VYM&_[+JC2*5*ON2TFFOR[GF^*^JN)]G)"/%"6$
M9ASFE#&((A1!PF(&$YQDDL<X39"?,_H6:2;'@:VVUZVB495Q5.H!&D7J@@JV
MA4G?!N-]IL^1&<>:E*&YLC4?.TVNSLR0)1:"(#M,O_(^ KU2"_,;L+O<U?R6
MA[Y"T<A9S!71-,&0IHI Q*6 1&4$<IY'B92&F1,ZJQKRF,5EO7'CXYMD\OGT
MCR4;C@7>.!=T!/_^;R2)D_\$7#W,E\NZGOMS=^GI :962:D(CC 4(L5F6\%3
MR G.(:$)H33EE"M43^V[I6-%]Y$GMI%K4M.J;,CF:TRHV[([VA0-O.P&JJTY
MD?J80ZRZMPGTYZE>>6G5#?/0GA7C]G&=[]E\_0^VV*JW\T(L5L5VK682(YU'
MB$$M90(11102(C0D.B$12B46FG@5A^L<;FH[F+HY#5OT#V:_@J\;%89#;6"N
MVP-FV<S8D'KWBY8.=\!J 4HUP%Z/@*7;G/ *6J6M>\1Q"[(Y:7]2>\WM+C^6
MD6H^^VBF:_'E<;5450N:&8DS'>=9;@.Z(X@R@B"5*(>98 K%2'">,!=..??P
MJ3%(*1\H!025A&[T<1:X;K*X%8Z!J<$#">?OO4OE_===-)]WH<1?'U8__F]S
M6_5EFQ^./^BSCQSE\^U2IOE8.Z_I$1NWBPW[TH2&[6)7OBJAC(W!;8=?D<H(
M)['93),4HCPAD%&"8<*TQ)K$+&9.Y[?N0T[M,^Z.H5OOY/:(&W.#OON3'P;0
M@8E@C^5.8+"/,?LZ')8><7G!,1TI5L_U/0T5P>>%4V=4G]N3QHOT\]+L(/K/
M[\Y^N[;OYK;/NI5U??_'O)@I)5)#R10JDIC-FH[,9DTF&&9IPAB+TUA&?/9#
MK?G*=;MV=AR?][X]VG"OO16S+(K8:JM7;T @:_WNJ".5T<7SV/T\[FZ;N)NQ
M'-I/94N4\)5-]_RA3J!L_[TZ9]\\LB4XO.D*I-[[N$[(0F[?S@\TZJZM4]?C
MS5KWQ?TXY:UZ-@O$O%H=HSA"+,L3R(V)9TN5,<BX9@:WB*I(\UCD7F4/V@^?
MFG'7EJU\U]G3:KV9_ZM'<=H##-UHH2\R [-!6ZQP'_0Y94-^QP?/'_7S/:?9
M\5=[]AI_A\H[8U1L7NZE-/-=U/_Y.%^J>$:2-.4RRB'.&34&@-FM,<P4C%"<
MHHQB07*G +S.4:;V^5:"@EK$N^8'8(4%GY>.^XAN8*][7H+ -? WW1LI+X?,
M521N\,Q<?O9H+IJKZK5]-=<OOKFX\_UB4=IC[5\UD9^9I(Q@I:%"$8$HCS%D
M.LF@Y+%9Q",>,>Q5<-1MV*D11$M$\\XO%K7]VJXIW#<,UW$>W"R!\.@.S"=A
M@+VEV+(#3@-55>X:^;7*)SN@T5$GV>7NH,W'ZX(#$L5")R2#7$H%49)32.,\
MMN$]&24*Y7G. W0>GV8MAXL=LZ^7*>@!M1L/!0-P8/JY ;M0K<:'J^[0/> 4
MFHQWUW1PNZGOYN?=DUH_S)</?U^O?M\\VNP MGR9Q7F2<X0%Y!1'$(F$0*XP
M@5(HDNDX9E@[G5-=&6=J'%*;]8VLH!(6U-+Z;G_.0^NZ ;H9L'&V0+Y8]=@
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MFI85$!P;:F!$VKZ6%<ASR2J,E=*54X'4^=//C0[V%F:-B5EKHWO%PQGXKE/
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M^<-E1VO!H0<Y-I Z10S/SN!Z5,C[\@^NZBDI*RU<LR".EKIM:Q/Q(C.2P*G
M6=(^A!H.^A,TM3)T_EAIU+[4TR[2-LLPB!A*#VIB61)$JI"1F:1)<B(RDW+*
ML4J[IR>I&GHT<T^Z[X:I/131 *H>[]WRRX_SDDZYJF_Q/)9;)D1;AUMTEI:$
M:! *$2 ;YFU451(-'6AK$F'[(.%!.7V_:ADX6GL]NYCBD\Z+4;\.,;07CON(
MKH(&7(."98*,"(+F/&4J4E*IMY/FQPCHA!W[\O?"7A0P=%T2G&^ZY%^G=.^S
MM%EU5@K*I'(D!5TNU<?2-YT[DKU4/M(4076Y\].M:JDK5<,%<X<K?E9;"T,'
M=+]-QQB"+##(^9B_P@^_^/4-FEW\9#9]7>9ESE]#8?'J%D)*C&55^J5RCO%.
MY,1JM[J4P*D"T ].J+?$>3N]=L#2J#HZGQU% 4-#ZRJV_?3-S\]\7*4]_.16
MXB,%(7.DQ0^-JLB,E^&ZEG#!2YL?19/O=DGHN3<-6%U5'T"]BGE S"08C][#
MJ9_\,EV.-]W#4"*:B^Q)U&7J5.DS$ASEI'2$]F5&B':/3+A>7&UH"XA_/IU]
M_QD?O=[/\(O[6]DCK^T$%_?R?:-#)3XP6-947RT?X9W %42<MQAO& PUG)"4
ML 0Z*!<B<X_4[>Z,E-OO'&9;.EAILQXDV/S6$H/F,H$CWI3P,PH@5D(B5HB,
MH2E5_GYX57-KJ0*"_96WT^ZQBR2'AL4Z6W]SR/?*+\:+U0J!J)D%*4H9@D?G
M21>_*1AB%"AO4%2<=2L\VOJ*;D"@+W_7Z%'23>+EZOY<RC$)KHG@"?E@R)'U
M5*$3E2G#'Q@KNEF0)UXR8/>>GA3X+";VD.;0J/C;;#F>GKXK3CIR<GTRQYW+
MVA",M@*10442A)%$L:A"+!5/J=N,A<>>WAH.]E':K$\)-G$V\*@9?7\]F08*
MW=YXHDJK,ZDPK HA4!(=E=:[$))4#SW.:OUUWN\T>(_]\9N0[Z>IH8W/R>GI
M?#60ZM-LB=*^?>'ZD[]<57>.>,E4\C*+&7(F4OA,@LZL%/)Z "X#X]T*<#J\
MK,DV/'NJ=E91SNWAYL[]_<?:0BQ&+C!5CGQ)5J4BO R+MZD,B]>6"YDLRV%?
M(#W_]B8;^%1!5L^:&!IJ#Q<*.(<^0<(8D>M8>D"4 4P"OP7->,B6I_NU/L_U
M.-W)_!R[L4\/(#E,AD,CX//LTD^6EQ_#9'RZ'N$(\_$LO44!OD&!?<QOQ_/%
MLO0O&I53-9U*:@IDN<2$-M2KB#84XPK\(@HM>"=H=']GDRU^>L!,):D/#:;-
MY?&KA? 9,")!$I"Y3_-9NHC+DU,,1I Q*),"('WU\],ROY%*I4R.A*\W9Y#$
M.V%("KB. O76YF[3%?9[?Y.M?_HP3/6UT41P]T2%T<A(RL'A<C&&HREFN@C/
M!0).NVA2XM0<O^1KV'L\50#7OS:&MF6X3&)1RRE:XUNLO)XMEKBB2J3[ZO+K
M-W@].SOWT\L11KQ:8XA+1'"BW%KWQ"E%29EN[!C50MUO-[*M]=U.[QVV#KJ>
M[:HH_9< K#N7?XMXI^5RB=4Q9%'F&AM6#H8$NI5HI\N- L59R>]UVR;WI6#8
M0L-AP7:P1H:&79<LB>40C%L?/?KU'9B #!&>G,Y@C>:Y6_"W<S:J/V8^0X3Q
M]U4FTH+.TB(64B@-5G-.Q!O)"&<I9:&-<:K;26&GUPU\:CA(?FU/83?@-GZ:
MP[D?IXUG@N[*Q^4WF*^:>B]>7\R+Q$<Q.I%DZ9QE?!F!4;JL"IT(Y2Y+ &&3
MK#)&N -M Y\,5/4A^U9- VA[<P$EMK\EMC$L1MI*8<M)"8;R!B,M#<1I[8A)
M5-+$:$IUAN ^2DTW1+VL)&Y_XA]Z]WZ\&\QOYRC(Z7*SI9:N,#(E$4E(#+=O
MJ3/Q*1JBJ>4\AA1#QP1=E[=UP\L+S.?V+NH&[,]-4<#BW?0DY_%DC-);?+D(
MBW$:^SDN![2OL[CZ%"WN[68PBU%,/+A4&HT+Q?&/@-&5$);D8H6SBSH\5KK;
MQYW, ZCNAL^7E3L^OCH;P.[C33\^_HX!V.+;^/PF>!O1X)@V'DBR4(I<:":N
MN*#&!:UT IWJX+0SA=TP^;)2S775U #^K@+6K[.3N,J@/\[I8F2,SACD)(R
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M9FV,(K,F91$MB!G70SH"6YO>]=B"[@'LMP?^WXKE1"IDZVGC$%A )2'!*U>
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MD2A6VC%,R(VT;3)-_ZE+W!.][>H2]\% !Y[)1O*YSIP[VL]L3+XV.*?%,V8
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M'TF/UDBE,QENS1(#%;@"9UFAD#YX%CP/S#1I/_%<DAX]1HTV>T#E+"A6(OC
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MNE6A7\,G7"?SNN2]<1(A^]I>F,L$3G()S!5GT <L;4XIGUK8N&#N!D$[(?M
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M:7AP]RA3_O)5QQ]Z3OG6;:15^!PWUE==Z!ABF-OM+E^YP%1\^NM4[F+7^?\
M4$L#!!0    (  *#I5(%+!C4[P4  $8;   7    86QL;RTR,#(Q,#,S,7AE
M>#,R,2YH=&WM6>MOVS80_[Z_XNI@:0)83]MQ_&@ UW;0 &V<Q2ZZ?AIHB;*X
M2J)*47'<OWY'2G*45^=AZR-KB\*Q=;SC/7X\WIV&SR:S\>+]Q11"&4=P\?;E
MZ[,Q- S+>M<:6]9D,8%7BS>OH6W:#BP$23(F&4](9%G3\P8T0BG3OF6MUVMS
MW3*Y6%F+2TN):EL1YQDU?>DW3H;J"7Y2XI_\,GQF&##A7A[31((G*)'4ASQC
MR0K>^33[ (91KAKS="/8*I3@VJX#[[CXP*Y(09=,1O2DDC.TBM]#2V\R7')_
M<S+TV14P_T6#.82XCMWKN'Z;MEMV;^ET_,#S@F67=KN=KO.'@TI:N+S@R>0F
MHB\:,4N,D*K]^VW7['92.5@S7X9]Q[9_;>BE)\. )Q+W$\A??"W$W!,FZ;4T
M2,1625^;U"A8*[+'(R[Z>[;^-U 4(R QBS;]YPL6TPS.Z1HN>4R2Y\T,PV!D
M5+"@6)BQ3Q1U0O7TSW6A<A?E1"RAE0F.JY2>7H=LR22T7-.YK7'=<")6:+OD
M:2&VIKN'SJ;B&RD_GEXNSD[/QJ/%V>P<P7HY?SLZ7\!B!LXQO#7GYMB$^72L
MJ4ZK8S<?M?![L6@TA]%D=K&83NKF?/=J5T[NV4<P.X7%JRG,1Y<O1^?3N3'[
M_?7T/8S&"T5Q;=O=WW..[,%.8',KL+'$1_OZ[:[IXK'[XE:V'[3R+ &/)PGU
M5,J#-9,AR)#"QYP(='VT 4%3+B3P $91Q%<TH; (J2 IS27SLB:<)9X)!XII
M?^_8=>W!F,<I23;ZES,X!)1[RD4,CFW\!@$7]0V HA-\>$.$%Q8^;#G-(A.2
M# (6(7&KU)QZN<#<C-:3Q(?IM1>29$4QA<8QRS)E /Y7*WW,MX!:4E2[KMJE
M-J;2#'5OPH1<,1_&2E(3WI@3LPD78?%'T(RI$.G=QB&C >Z).DAV16$6!,Q#
M W 'M4%I=%.O1;%3P3R8>V&,R70KL9!QRA*2>(Q$C\K 9Y(%^"7-1983U$#R
M^O$OHE7X2^< Y2SB\U3=,G6>6RL5D,N=YD0L24(S8W8=T0V,/!U@!>0FT@EJ
MC,SQ!CXD?(TA6-']O<[QX!^"/"6^CQ>>$=% ]H]:=V!O.,??#/0'SF%EQ=??
M_HY?S%9;^0'/%!3HA""/\-QY"(9(07T+?T$_YDQ050ID*EQW8'! \*@)<#H'
M_F$!B!0%>&09T>8V[C<G:'MZRN [O5:[8(N+,UD_-_7%U>E!2/0&"N[_'UBX
MWR4L6()),R8Z06.NE@0Y?7RJ(UIAAC"5K%-,60H>344F403(ALI@JD%"BGC)
MFIHKV*8@%.CK<E<G+ER51P6Z>(I)7A&R.^G)W"W>2RXEC_M':/H=!&!TI4)E
MQ;#DPJ?"0#='),UHO_HR\%F61F339XEVEF8:7*G<Z)&H+!%0:%FP]GKF<:>E
M:E:)A:KT*_%E.6OJ<M:2_GU:Y\AT>ZU'R;;I/$K[G-BV8W;L[DYB+:URH3::
MGZ&?7S1:C8JAA$;?3:_!N5VK*K0\X).O?X)TNS!!N.FK F_T#72*FWR+E-(+
M_][  EM?SD8ML<\D[N;M8/7^7KL[R/1GO9RX9?>.$;:5^8W/^JH\+OHTI6@]
MCW##RNPGA)2'RZXOY+0GXY>=BLX?W4D'%X+A]97B_77/-X</.:=2L)+2+FZA
M_\IAMY9^NRV??%Q_7A_UMO'G_?$9ISW07__H6?&1Z<*/[I;:97'C&W6YCCR/
MYXE4,_G'[PY+=QU/:J2W"%E6CI P +JWRT+5#"9<PI*"3VF,#639VNL96]G3
MZ^E<FHN49_2!$<-QU0G>GAT(X/A0K%F&+5V^_!-YU/A(+8P86;*(R<V.PDR8
MYUZX@_(H?ZDZ8X^CLD*_75FJ665 !4T\1<$5V*RJ$:(*<(Z!$7='(#>3CU9]
M\M&$<D99UZP)]-JCZ=8RC+8JTM2PK-X<@^JRM>IJAE/3+P,F;ZEH/MI WWD=
M@\'0#7I?T(BH2N?>"YJ;S*Y;;ON&A2PQO>?R/LO?O-,I/XLW3/I=U\E?4$L!
M A0#%     @  H.E4@S@29<Z>@( UO84 !$              ( !     &%L
M;&\M,C R,3 S,S$N:'1M4$L! A0#%     @  H.E4O$$HG+1#P  BZ0  !$
M             ( !:7H" &%L;&\M,C R,3 S,S$N>'-D4$L! A0#%     @
M H.E4JLOZI"9&   I/@  !4              ( !:8H" &%L;&\M,C R,3 S
M,S%?8V%L+GAM;%!+ 0(4 Q0    (  *#I5+WX$"3<58  $C% P 5
M      "  36C @!A;&QO+3(P,C$P,S,Q7V1E9BYX;6Q02P$"% ,4    "  "
M@Z52K@='G/[%   /90@ %0              @ '9^0( 86QL;RTR,#(Q,#,S
M,5]L86(N>&UL4$L! A0#%     @  H.E4CDR[Y<Q<P  W$L% !4
M     ( !"L # &%L;&\M,C R,3 S,S%?<')E+GAM;%!+ 0(4 Q0    (  *#
MI5)*X M[:@@  !TF   7              "  6XS! !A;&QO+3(P,C$P,S,Q
M>&5X,S$Q+FAT;5!+ 0(4 Q0    (  *#I5+D#8R\9@@  #,F   7
M      "  0T\! !A;&QO+3(P,C$P,S,Q>&5X,S$R+FAT;5!+ 0(4 Q0    (
M  *#I5(%+!C4[P4  $8;   7              "  :A$! !A;&QO+3(P,C$P
C,S,Q>&5X,S(Q+FAT;5!+!08     "0 ) %D"  #,2@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
